Industria y Comercio

SUPERINTENDENCIA

Delegatura de propiedad Industrial

División de Nuevas Creaciones

PCT

SOLICITUD

PATENTE DE INVENCIÓN

21. **EXPEDIENTE No.** 06.7787

54. **TÍTULO** Compuestos de sulfonamidas derivadas de Benzoxazinona, su preparación y uso como medicamentos.

51. **CLASIFICACIÓN INTERNACIONAL** C07D 413/04, A61K. 31/535, A61P 25/00

71. **SOLICITANTE** Laboratorios del Este S.A.

DOMICILIO Barcelona, España.

74. **APODERADO** Dilia Maria Rodriguez D'Alemán

22. **BOGOTÁ, D. C.,** Enero 27/06

(FORMA P-10)

PETITORIO

SUPERINDUSTRIA Y COMERCIO
Radicacion : 06007787 00000000
Fecha (DMA): 2006-01-27 17:51:45 Folios: 623
Tramite : 811 PCT-PATENT 379 FORM NRCI 411 PRESENTA
Dependencia: 8000 DIVISION DE NUEVAS CREACIONES

Industria y Comercio
SUPERINTENDENCIA

FORMULARIO ÚNICO DE SOLICITUD DE PATENTE
PCT
ENTRADA EN FASE NACIONAL 28-02-2006.

1) SOLICITUD DE:		
☒ Patente de invención	☐ Patente de Modelo de Utilidad	
☐ Capitulo I.	☒ Capitulo II.	
2) SOLICITANTE (71)	**Nombre: LABORATORIOS DEL DR. ESTEVE S.A.** **Dirección: Avenida Mare de Deu de Montserrat 221, E-08041 Barcelona, España** **Nacionalidad o domicilio: Barcelona, España** **Lugar de constitución: España**	**IDENTIFICACIÓN** **C.C.** ☐ **NIT:** ☐ **C.E.** ☐ **OTRO** ☐ **Cual** _____ **NÚMERO** _____
	Teléfono: **Fax:** **E. Mail:**	
3) REPRESENTANTE APODERADO	Nombre: DILIA MARÍA RODRIGUEZ D´ALEMAN Dirección: Carrera 11 N°. 86-53 Piso 6 Bogotá D.C. Teléfono: 6181088 Fax: 6350824 E. Mail: info@clarkemodet.com.co	**IDENTIFICACIÓN** **C.C.** ☒ **NIT:** ☐ **C.E.** ☐ **OTRO** ☐ **NÚMERO:** 41.654.882 **TP:** 20824 CSJ
4) INVENTOR (ES) (72)	**Nombre: 1. TORRENS JOVER, Antoni; 2. MAS PRIÓ, Joseph; 3. DORDAL ZUERAS, Alberto; 4. FISAS ESCASANY, María Angeles.** **Dirección: 1. C/Racó, 8, 2° 2 a, E-08221 Terrase, España; 2. CCal Princep, 39, E-08191 Rubi, España; 3. C/Maladeta 26, 3° 3 a, E-08016 Barcelona, España; 4. C/Hipólito Lázaro 19 3° 1 a Izq., B-08025 Barcelona, España** **Nacionalidad o Domicilio: Todos lo anteriores, Españoles**	
5) PCT (86) Solicitud Internacional No. PCT/EP2004/008507 Fecha: Julio 29, 2004 Publicación Internacional No. WO2005/014589 A1 Fecha: Febrero 17, 2005		
6)Título (54) COMPUESTOS DE SUFONAMIDAS DERIVADOS DE BENZOXAZINONA, SU PREPARACIÓN Y USO COMO MEDICAMENTOS		
A61K31/366, 31/4412, 31/427		
7) Clasificación Internacional: C07D 413/04, A61K 31/535, A61P 25/00 A61P3/04		

8) PRIORIDAD	**33) País de Origen**	**(32) Fecha**	**(31) Número de Solicitud**
SI ☒ **N** ☐	**ESPAÑA**	**JULIO 30, 2003**	**P200301812**

9) Comprobante de pago N°. 06-7291 **Fecha: Enero 25, 2006**

Instrucciones para el diligenciamiento del presente formulario. Ver reverso de esta pagina

2

SUPERINDUSTRIA Y COMERCIO
Radicacion : 06007787 00000000 Folios: 623
Fecha (AMD): 2006-01-27 17:51:45
Tramite : 011 PCT-PATENT 379 FASE NACI 411 PRESENTA
Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

RECIBO OFICIAL DE CAJA : 06 - 7,291
FECHA : ENERO 27 DE 2006

***** C O N S I G N A C I O N *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PGO	Vr. PAGO
CLARKE MODET Y CO. COLOMBCONSIGNACION		BANCO POPULAR	050-00110-6	49044331	27/01/2006	3,364,000.00

***** C O N C E P T O *****

CANT.	REMTISTICO	CONCEPTO	TOTAL CONCEPTO
1	50005-01-01 SOLICITUDES	1 TRAMITES DE SOL. DE PATENTE DE IN	463,000.00
		TOTAL : $	463,000.00

SON: CUATROCIENTOS SESENTA Y TRES MIL PESOS

RESPONSABLE : _____

RECIBO DE CAJA APLICADO AL EXPEDIENTE No._____

10) ANEXOS

- [X] Comprobante de pago de la tasa de presentación de la solicitud
- [ ] Comprobante de pago por reivindicación de prioridad
- [ ] Documento que acredita la existencia y representación legal cuando el solicitante sea persona Jurídica
- [X] Poderes, si fuera el caso
- [ ] Documento de cesión del inventor al solicitante o a su causante
- [ ] Declaraciones
- [X] Copia de la solicitud internacional. (Resumen, descripción, reivindicación, Dibujos).
- [X] Traducción de la solicitud internacional al castellano. (Resumen, descripción, reivindicación, Dibujos)
- [X] Copia del examen preliminar efectuado por la IPEA
- [ ] De ser el caso, copia del contrato de acceso
- [ ] De ser el caso, documento que acredite la licencia o autorización de uso de conocimientos tradicionales de las comunidades indígenas
- [ ] De ser el caso, certificado de depósito del material biológico
- [ ] Arte final 12 x 12 y 6 x 6 cm
- [ ] De ser el caso, información sobre otras solicitudes de patente o títulos obtenidos en el extranjero por el mismo titular o su causante, relacionados parcial o totalmente con la invención de esta solicitud.
- [X] Otros:
  1. Reporte internacional de búsqueda
  2. Solicitud PCT

11) FIGURA CARACTERÍSTICA:

12) Solicitud concesión de la patente,

NOMBRE: DILIA RODRÍGUEZ D'ALEMAN

FIRMA: _____

C.C. 41.654.882 de Bogota TP 20824 CSJ

Instrucciones para el diligenciamiento del presente formulario. Ver reverso de esta pagina

P 588

EP 1 0011 CO

COLOMBIA

Carrera 11 nº 93-43, Of. 404 Bogotá Colombia Tel: (57 1) 6350813-Fax: (57 1) 6350824-Email:clarksmodet@clarksmodet.com.co

PODER

Yo (nosotros), abajo firmante(s)

en mi (nuestro) carácter de representante(s) legales de

una sociedad organizada y existente de acuerdo con las leyes de

y en actual cumplimiento de su objeto social, con domicilio en

por el presente instrumento confiero (conferimos) poder especial a favor de DILIA MARIA RODRIGUEZ D'ALEMAN, con Cédula de Ciudadanía No. 41.654.882 de Bogotá, y tp. 20824 y CLAUDIA LUCIA CARO RAMIREZ, con Cédula de Ciudadanía No. 40.017.374 de Tunja, y tp. 36448, con domicilio en Bogotá, Colombia, para que actuando en su orden en nombre del (de la) otorgante le (la) representen ante cualquier entidad, autoridad y/o persona, especialmente ante las del orden Administrativo, Contencioso Administrativo, Judicial, Tribunales de Arbitramento y/o cualquier otro en lo referente a los siguientes asuntos:

1) Solicitar, tramitar, obtener y/o registrar cualquiera de las modalidades de Propiedad Industrial, tales como: patentes de invención, modelos de utilidad; diseños industriales, variedades vegetales; marcas, lemas, nombres y enseñas comerciales y denominaciones de origen; así como sus renovaciones, prórrogas, transferencias, cambios de nombre y/o domicilio, contratos y licencias.
2) Solicitar, tramitar, obtener y/o registrar derechos de autor, en cualquiera de sus presentaciones así como la protección de secretos industriales y know-how.
3) Solicitar, tramitar, obtener y/o registrar registros sanitarios, permisos y/o licencias de funcionamiento; así como sus renovaciones o prórrogas, transferencias, cambios de nombre y/o domicilio, contratos y licencias.
4) Ejercer acciones de oposición, observación, reclamos, reconsideración, reposición, apelación, cancelación administrativa o judicial, nulidad, protección al consumidor, concesión de licencias, protección de secretos industriales y demás acciones y recursos relacionados con derechos derivados de los asuntos arriba indicados y en contra de la competencia desleal, acciones derivadas de la obtención o explotación de licencias, acciones de indemnización de perjuicios. También podrá(n) intervenir en juicios civiles, comerciales, penales, contencioso-administrativos, tutelas y de policía; en acciones o juicios promovidos por el (la) mandante o en contra el (ella).
5) Registrar nombres de dominio ante la entidad competente.
6) En el ejercicio de este mandato los mandatarios arriba mencionados quedan facultados para: conciliar, cancelar, transigir, comprometer en árbitros, desistir, recibir y tomar posesión de la cosa objeto de litigio y renunciar o desistir a derechos concedidos o en curso de concesión, admitir los hechos del proceso.
7) Ratificar o no la agencia oficiosa.
8) Así mismo faculto (facultamos) a los mencionados apoderados para recibir notificaciones y designar apoderados judiciales o extrajudiciales, sustituir el presente poder y revocar las sustituciones que hicieren.

Dado y firmado en

a los días de

POWER OF ATTORNEY

I (we), Jose Maria RAFOLS FERRER the undersigned legal representative(s) of

Laboratorios del Dr. Esteve S. A.

an organization existing under the laws of

SPAIN

and in present execution of its business activity, domiciled at Av. Mare de Déu de Montserrat, E-08041, SPAIN

do hereby grant POWER OF ATTORNEY to DILIA MARIA RODRIGUEZ D'ALEMAN, identification card No. 41.654.882 of Bogotá, and tp. 20824 and CLAUDIA LUCIA CARO RAMIREZ, tp. 36448, identification card No. 40.017.374 of Tunja, residing in Bogotá, Colombia, to act in the order of their appointment in behalf of grantor before any entity, authority and/or natural or juridical person, specially before those Administrative, Administrative-Contentious, Judicial, arbitration courts, and/or any other, in all matters concerning the following:

PCT/EP03/03629

1) To apply, process, obtain and/or register any of the modalities of Industrial Property, such as: Patents of Invention, Utility Models; Designs, plant varieties; Marks, Slogans, Trade Names and emblems and appellations of Origin; as well as their renewals, assignments, changes of name and/or domicile, agreements and licenses.
2) To apply, process, obtain and/or register copyrights of any kind as well as protection of industrial secrets or know-how.
3) To apply, process, obtain and/or register sanitary registrations, operating authorizations and/or licenses; as well as their renewals or assignments, changes of name and/or domicile, agreements and licenses.
4) To bring actions of opposition, observations, claims, reconsideration, appeal or legal remedies, cancellations, nullity, protection to the consumer, granting of licenses, protection of trade secrets and other actions related with rights derived from the above- mentioned matters and against the unfair competition, actions resulting from the obtaining or exploitation of licenses, recovering damages actions. They can also intervene or participate in Civil, Commercial, Criminal or Contentious-Administrative Trials; the actions for writ mandamus, police actions; in actions, lawsuits or litigations instituted by the grantor or against him.
5) To register domain names before the competent entity.
6) To the effect of this mandate the above-named proxy are empowered to: conciliate, cancel, settle, submit to arbitration, withdraw and to receive and take possession of the litigation related objet and waive or renounce the rights granted or in process of granting, admit the facts of the case.
7) To ratify or not the officious agency.
8) I (we) hereby appoint the afore mentioned attorneys with powers to receive notifications and to designate judicial and extrajudicial attorneys, substitute this Power of Attorney and to revoke such sustitutions.

Granted and signed at Barcelona

on this day of 31 ENE. 2005 of 2005

Firma y Huella

José María RAFOLS FERRER
Attorney

DILI

NOTARIA 36 BOGOTA D.C.
Como Notaria 36 de este Circulo hago constar que este copia coincide con el documento original presentado para su autenticación
27 ENE 2006
NOTARIO TREINTA Y SEIS DE BOGOTA
ENCARGADO

-GENCIA.- La extiendo yo, TOMÁS GIMÉNEZ DUART, Notario del Ilustre Colegio de Notarios de Cataluña, para hacer constar que la firma que antecede de DON JOSÉ MARÍA RAFOLS FERRER, como apoderado de la entidad "LABORATORIOS DEL DR. ESTEVE, S.A.", la considero legítima por haber sido puesta en mi presencia. Hago constar que tiene concedido un poder otorgado a su favor, mediante escritura autorizada ante mí el día 1 de febrero de 2.000, bajo el número 480 de protocolo, que causó la inscripción 90ª en la hoja número B-19079, folio 190 del tomo 21254, en el Registro Mercantil de Barcelona, cuyo poder le faculta para este acto.----------

Igualmente hago constar que la sociedad LABORATORIOS DEL DR. ESTEVE, S.A., es una compañía mercantil de nacionalidad española, que se rige por las leyes de España, debidamente inscrita en el Registro Mercantil de Barcelona, al tomo 21254 , folio 190, hoja número B-19079 , inscripción 76ª y con número de identificación fiscal A-08-037236.----------

Y para que así conste y surta efecto en Colombia, la extiendo en Barcelona, a 31 de enero de 2005.----------

Asiento número 131, Libro Indicador número 8 .----------

SELLO DE LEGITIMACIONES Y LEGALIZACIONES

0,15 0,05 0,10

NOTARIA DE TOMAS GIMENEZ DUART

CONSEJO GENERAL DEL NOTARIADO ESPAÑOL

NOTARIADO EUROPA

0063326390

NOTARÍA 36 - BOGOTÁ D.C.
Como Notaría 36 de este Círculo hago constar que esta copia coincide con el documento original presentado para su autenticación.
27 ENE 2006
WILLIAM QUIROZ VELÁSQUEZ
NOTARIO TREINTA Y SEIS DE BOGOTÁ
ENCARGADO

PAPEL EXCLUSIVO para documentos NOTARIALES

5Y0174010 5

10/2004

APOSTILLE (o legalización única)
(Convention de la Haye du 5 de octobre, 1961-Real Decreto/1978, de 2 de octubre)

1. Pais ESPAÑA

El presente documento público

2. ha sido firmado por D. Tomás Giménez Duart----------

3. Actuando en calidad de Notario, en legitimación de firma-- de D. José María Ràfols Ferrer, puesta al pie de un Poder, en representación de "LABORATORIOS DEL DR. ESTEVE, S.A.",- libro indicador nº. 131, de fecha 31 de enero de 2005.----

4. Se halla sellado/timbrado con el de su Notaría.

C E R T I F I C A D O

5. En BARCELONA 6. El 01 de Febrero de 2005.

7. Por DON RAFAEL MARTÍNEZ DIE, Secretario.

8. Con el Nº : -6155-

9. Sello/timbre: 10. Firma:

SELLO DE LEGITIMACIONES Y LEGALIZACIONES
NIHIL PRIUS FIDE
A 23488059
FE PÚBLICA NOTARIAL

Rafael Martínez Die
Secretario

CONSEJO GENERAL DEL NOTARIADO ESPAÑOL
NOTARIADO EUROPA
0073259051

NOTARIA DE BOGOTA D.C.
Como Notario 36 de este Circulo hago constar que esta copia coincide con el documento original presentado para su autenticación
27 ENE 2006
WILSON OSMEDO VELASQUEZ
NOTARIO TREINTA Y SEIS DE BOGOTA D.C.
ENCARGADO

P-751.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number
WO 2005/014589 A1

(51) International Patent Classification⁷: C07D 413/04, A61K 31/535, A61P 25/00

(21) International Application Number: PCT/EP2004/008507

(22) International Filing Date: 29 July 2004 (29.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
P 200301812 30 July 2003 (30.07.2003) ES

(71) Applicant (*for all designated States except US*): LABORATORIOS DEL DR. ESTEVE S.A. [ES/ES]; Av. Mare de Déu de Montserrat, 221, E-08041 Barcelona (ES).

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): TORRENS JOVER, Antoni [ES/ES]; C/Rec6, 8, 2° 2a, E-08221 Terrasa (ES). MAS PRIÓ, Josep [ES/ES]; C/Cal Princep, 39, E-08191 Rubí (ES). DORIDAL ZUERAS, Alberto [ES/ES]; C/Maladeta, 26 5° 3a, E-08016 Barcelona (ES). FIBAS ESCASANY, Maria Angeles [ES/ES]; C/Hipólito Lázaro 19 5° 1a Isq., E-08025 Barcelona (ES).


(74) Agent: DAVILA BAZ, A.; Clarke, Modet & Co., C/Goya, 11, E-28001 Madrid (ES).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM).

[Continued on next page]

(54) Title: BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS



(I)

(57) Abstract: The present invention relates to benzoxazinone-derived sulphonamide compounds of general formula (I), a process for their preparation, a medicament comprising these compounds and the use of benzoxazinone-derived sulphonamide compounds for the preparation of medicaments for 5-HT_6 receptor regulation as well as for the treatment of disorders related thereto.

WO 2005/014589 A1

European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *with international search report*

Benzoxazinone-derived sulphonamide compounds, their preparation and use as medicaments

The present invention relates to benzoxazinone-derived sulphonamide compounds of general formula (I),



(I)

a process for their preparation, a medicament comprising these compounds and the use of benzoxazinone-derived sulphonamide compounds for the preparation of medicaments for 5-HT_6 receptor regulation as well as for the treatment of disorders related thereto.

The superfamily of serotonin receptors (5-HT) includes 7 classes (5-HT_1-5-HT_7) encompassing 14 human subclasses [D. Hoyer, et al., Neuropharmacology, 1997, 36, 419]. The 5-HT_6 receptor is the latest serotonin receptor identified by molecular cloning both in rats [F.J. Monsma, et al., Mol. Pharmacol., 1993, 43, 320; M. Rust, et al., Biochem. Biophys. Res. Commun., 1993, 193, 268] and in humans [R. Kohen, et al., J. Neurochem., 1996, 66, 47]. Compounds with 5-HT_6 receptor affinity are useful for the treatment of various disorders of the Central Nervous System and of the gastrointestinal tract, such as irritable intestine syndrome. Compounds with 5-HT_6 receptor affinity are also useful in the treatment of anxiety, depression and cognitive


memory disorders [M. Yoshioka, et al., Ann. NY Acad. Sci., 1998, 861, 244; A. Bourson, et al., Br. J. Pharmacol. , 1998, 125, 1562; D.C. Rogers, et al., Br. J. Pharmacol. Suppl., 1999, 127, 22P; A. Bourson, et al., J. Pharmacol. Exp. Ther. , 1995, 274, 173; A.J. Sleight, et al., Behav. Brain Res. , 1996, 73, 245; T.A. Branchek, et al., Annu. Rev. Pharmacol. Toxicol. , 2000, 40, 319; C. Routledge, et al., Br. J. Pharmacol. , 2000, 130, 1606]. It has been shown that typical and atypical antipsychotic drugs for treating schizophrenia have a high affinity for 5-HT_6 receptors [B.L. Roth, et al., J. Pharmacol. Exp. Ther. , 1994, 268, 1403; C.E. Glatt, et al., Mol. Med. , 1995, 1, 398; F.J. Moerna, et al., Mol. Pharmacol. , 1993, 43, 320; T. Shinkai, et al., Am. J. Med. Genet. , 1999, 88, 120]. Compounds with 5-HT_6 receptor affinity are useful for treating infant hyperkinesis (ADHD, attention deficit / hyperactivity disorder) [W.D. Hirst, et al., Br. J. Pharmacol. , 2000, 130, 1597; C. Gérard, et al., Brain Research , 1997, 746, 207; M.R. Pranzatelli, Drugs of Today , 1997, 33, 379].

Moreover, it has been shown that the 5-HT_6 receptor also plays a role in food ingestion [Neuropharmacology, 41, 2001, 210-219].
Food ingestion disorders, particularly obesity, are a serious, fast growing threat to the health of humans of all age groups, since they increase the risk of developing other serious, even life-threatening diseases such as diabetes or coronary diseases.

Thus, it was an object of the present invention to provide novel compounds that are suitable in particular as active substances in medicaments, preferably in medicaments for the regulation of 5-HT_6 receptors, for cognitive enhancement, for the prophylaxis and/or treatment of food-intake related disorders, disorders of the central nervous system, disorders of the gastrointestinal tract, such as irritable intestine syndrom, anxiety, panic, depression, cognitive memory disorders, senile dementia disorders, such as Morbus Alzheimer, Morbus Parkinson and Morbus Huntington, schizophrenia, psychosis, infantile hyperkinesis, ADHC (attention deficit, hyperactivity disorders) and other 5-HT_6 mediated disorders particularly in mammals, including humans.

It has been found that the benzoxazinone-derived sulphonamide compounds of general formulae (I), (Ia) and (Ib) given below show affinity for the 5-HT_6-receptor. These compounds are therefore also suitable for the manufacture of a medicament for cognitive enhancement, for the prophylaxis and/or treatment of food ingestion (food intake) disorders, particularly for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (Non-Insulin Dependent Diabetes Mellitus), preferably type II diabetes, which is caused by obesity, disorders of the central nervous system, disorders of the gastrointestinal tract, such as irritable intestine syndrom, anxiety, panic, depression, cognitive memory disorders, senile dementia disorders, such as Morbus Alzheimer, Morbus Parkinson and Morbus Huntington, schizophrenia, psychosis, infantile hyperkinesis, ADHC (attention deficit, hyperactivity disorders) and other 5-HT_6 mediated disorders particularly in mammals, including man.

Thus, one aspect of the present invention are benzoxazinone-derived sulfonamide compounds of general formula (I),



(I)

wherein

R^1, R^2, R^3, R^4 are each independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano group, -OR^{10}, -OC(=O)R^{11}, -(C=O)-O-R^{11}, -SR^{12}, -SOR^{12}, -SO_2R^{12}, -NH-SO_2R^{12}, -SO_2NH_2 and a -$NR^{13}R^{14}$ moiety,

R^5 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical,

R^6, R^7, R^8, R^9 are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano group and a -$COOR^{15}$ moiety,

W represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

an optionally at least mono-substituted heteroaryl radical, which may be bonded via an optionally mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

an optionally at least mono-substituted, monocyclic aryl radical, which is condensed with an optionally at least mono-substituted mono- or polycyclic ring-system and which may be bonded via an optionally at least mono-substituted alkylene group,

a $NR^{16}R^{17}$-moiety,

a COR^{16}-moiety,

or a phenyl radical, which is at least mono-substituted with one of the substituents selected from the group consisting of:

2,2,2,-Trifluoroethoxy-, C_{2-6}-Alkenyl-, 1,3-Dihydro-1-oxo-2H-isoindol-2-yl-, N-Phthalimidinyl-, [(2-chloro-1,3-thiazolyl-5-yl)-methoxy, Ethyl-5-yl-2-methyl-3-furoate, C_{11-20}-alkyl-, 1,3-Dioxo-2-azaspiro[4,4]non-2-yl-, pyrazolyl-, (1,3-oxazol-5-yl)-, (5-Methyl-1,3,4-oxadiazol-2-yl)-, difluoromethoxy, dichloromethoxy, 1-pyrrolidinylsulfonyl, morpholinosulfonyl, 2-methyl-4-pyrimidinyl-, a phenoxy group, which is at least mono-substituted with C_{1-6}-alkoxy, a phenyl group, which is at least mono-substituted with one of the substituents selected from the group consisting of nitro, C_{1-6}-alkoxy, F, Cl, Br, at least partially fluorinated C_{1-6}-alkyl, at least partially chlorinated C_{1-6}-alkyl, [(2-Chloro-1,3-thiazol-5-yl)-methoxy]-, -(C=O)-H and -(C=O)-C_{1-6}-alkyl, a pyridinyl group, which is at least mono-substituted with C_{1-6}-alkoxy, a pyridinyloxy group, which is at least mono-substituted with C_{1-6}-alkoxy, a phenoxy group, which is at least di-substituted and a pyridinyloxy group, which is at least di-substituted,

with the proviso that W does not represent unsubstituted furyl-, unsubstituted thienyl- or thienyl substituted with a substituent selected from the group consisting of C_{1-6}-alkoxycarbonyl, C_{1-6}-alkylcarbonyl, carboxyl and pyridyl, unsubstituted pyrrolyl-, unsubstituted naphthyl, unsubstituted indolyl, unsubstituted tetrahydronaphthyl, substituted or unsubstituted pyridyl, unsubstituted pyrazinyl, unsubstituted quinolinyl-,

C_{1-6}-alkylsubstituted pyrrolyl-, and unsubstituted cyclohexyl or cyclohexyl substituted with one or two members selected from the group consisting of oxo, hydroxyl, C_{1-6}-alkoxyl, C_{1-6}-alkoxy-carbonylamino-C_{1-6} alkyl and amino-C_{1-6} alkyl,

R^{10} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{11} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{12} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{13} and R^{14} each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

or R^{13} and R^{14} together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member,

R^{16} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{15} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

R^{17} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, and

R^{18} represents an optionally at least mono-substituted aryl radical,

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate.

A mono- or polycyclic ring-system according to the present invention means a mono- or polycyclic hydrocarbon ring-system that may be saturated, unsaturated or aromatic. If the ring system is polycyclic, each of its different rings may show a different degree of saturation, i.e. it may be saturated, unsaturated or aromatic. Optionally each of the rings of the mono- or polycyclic ring system may contain one or more heteroatoms as ring members, which may be identical or different and which can preferably be selected from the group consisting of N, O, S and P, more preferably be selected from the group consisting of N, O and S. Preferably the polycyclic ring-system may comprise two rings that are condensed. The rings of the mono- or polycyclic ring-system are preferably 5- or 6-membered.

If one or more of the residues R^1-R^{17} and W represents an aliphatic radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkoxy, branched or unbranched C_{1-4}-perfluoroalkoxy, branched or unbranched C_{1-4}-perfluoroalkyl, amino, carboxy, amido, cyano, nitro, $-SO_2NH_2$, $-CO-C_{1-4}$-alkyl, $-SO-C_{1-4}$-alkyl, $-SO_2-C_{1-4}$-alkyl, $-NH-SO_2-C_{1-4}$-alkyl , wherein the C_{1-4}-alkyl may in each case be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and an unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methoxy, ethoxy, CF_3 and an unsubstituted phenyl radical. If any one of the above mentioned substituents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy.

If one or more of the residues R^1-R^{15} represents or comprises a cycloaliphatic radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkyl, branched or unbranched C_{1-4}-alkoxy, branched or unbranched C_{1-4}-perfluoroalkoxy, phenoxy, benzoyl, cyclohexyl, branched or unbranched C_{1-4}-perfluoroalkyl, $-NR^AR^B$ wherein R^A, R^B are each independently selected from the group consisting of H, a branched or unbranched C_{1-4}-alkyl-radical, $-CH_2-CH_2-OH$ and phenyl, carboxy, amido, cyano, nitro, $-SO_2NH_2$, $-CO-C_{1-4}$-alkyl, $-CO-OC_{1-4}$-alkyl, $-SO-C_{1-4}$-alkyl, $-SO_2-C_{1-4}$-alkyl, $-NH-SO_2-C_{1-4}$-alkyl, wherein C_{1-4}-alkyl may in each case be branched or unbranched, unsubstituted or at least mono-substituted phenyl or naphthyl and unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, methoxy, ethoxy, benzoyl, phenoxy, cyclohexyl, $-CF_3$, $-CO-CH_3$, $-CO-OCH_3$, $-NR^AR^B$ wherein R^A, R^B are each independently selected from the group consisting of H, a branched or unbranched C_{1-4}-alkyl-radical, $-CH_2-CH_2-OH$ and phenyl, and an unsubstituted phenyl radical. If any one of the above mentioned substituents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy.

If one or more of the residues R^1-R^4, R^{10}-R^{15} and W comprises an alkylene group, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkoxy, branched or unbranched C_{1-4}-perfluoroalkoxy, branched or unbranched C_{1-4}-perfluoroalkyl, amino, carboxy, amido, cyano, nitro, $-SO_2NH_2$, $-CO-C_{1-4}$-alkyl, $-SO-C_{1-4}$-alkyl, $-SO_2-C_{1-4}$-alkyl, $-NH-SO_2-C_{1-4}$-alkyl, wherein C_{1-4}-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and an unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methoxy, ethoxy, CF_3 and unsubstituted phenyl. If any one of the above mentioned

substituents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy.

If one or more of the residues R^1-R^4 and R^{10}-R^{15} comprises a mono- or polycyclic ringsystem, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkyl, branched or unbranched C_{1-4}-alkoxy, branched or unbranched C_{1-4}-perfluoroalkoxy, branched or unbranched C_{1-4}-perfluoroalkyl, amino, carboxy, amido, cyano, keto, nitro, $-SO_2NH_2$, $-CO-C_{1-4}$-alkyl, $-SO-C_{1-4}$-alkyl, $-SO_2-C_{1-4}$-alkyl, $-NH-SO_2-C_{1-4}$-alkyl, wherein C_{1-4}-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl, more preferably from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, methoxy, ethoxy, CF_3, keto, cyano and an unsubstituted phenyl radical. If any one of the above mentioned substituents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy.

If one or more of the residues R^1-R^4, R^{10}-R^{15} and R^{15} represents or comprises an aryl radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkoxy, branched or unbranched C_{1-4}-alkyl, branched or unbranched C_{1-4}-perfluoroalkoxy, unsubstituted or at least mono-substituted phenoxy, unsubstituted or at least mono-substituted benzoyl, cyclohexyl, branched or unbranched C_{1-4}-perfluoroalkyl, NR^AR^B wherein R^A, R^B are each independently selected from the group consisting of H, a branched or unbranched C_{1-4}-alkyl-radical, $-CH_2-CH_2-OH$ and phenyl, carboxy, amido, cyano, -CH(OH)(phenyl), nitro, $-SO_2NH_2$, $-CO-C_{1-4}$-alkyl, $-CO-OC_{1-4}$-alkyl, $-SO-C_{1-4}$-alkyl, $-SO_2-C_{1-4}$-alkyl, $-NH-SO_2-C_{1-4}$-alkyl, wherein C_{1-4}-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl,

cyano, -CH(OH)(phenyl), methoxy, ethoxy, unsubstituted or at least mono-substituted benzoyl, unsubstituted or at least mono-substituted phenoxy, cyclohexyl, CF_3, -CO-CH_3, -CO-OCH_3, -NR^AR^B wherein R^A, R^B are each independently selected from the group consisting of H, a branched or unbranched C_{1-4}-alkyl-radical, -CH_2-CH_2-OH and phenyl, and an unsubstituted phenyl radical. If any of the above mentioned substituents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy.

If one or more of the residues R^1-R^4 and R^{10}-R^{15} represents or comprises a heteroaryl radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkoxy, branched or unbranched C_{1-4}-alkyl, branched or unbranched C_{1-4}-perfluoroalkoxy, unsubstituted or at least mono-substituted phenoxy, unsubstituted or at least mono-substituted benzoyl, cyclohexyl, branched or unbranched C_{1-4}-perfluoroalkyl, NR^AR^B wherein R^A, R^B are each independently selected from the group consisting of H, a branched or unbranched C_{1-4}-alkyl-radical, -CH_2-CH_2-OH and phenyl, carboxy, amido, cyano, nitro, -CH(OH)(phenyl), -SO_2NH_2, -CO-C_{1-4}-alkyl, -CO-OC_{1-4}-alkyl, SO-C_{1-4}-alkyl, SO_2-C_{1-4}-alkyl, -NH-SO_2-C_{1-4}-alkyl, wherein C_{1-4}-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and an unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, cyano, methoxy, ethoxy, unsubstituted or at least mono-substituted benzoyl, unsubstituted or at least mono-substituted phenoxy, cyclohexyl, CF_3, -CH(OH)(phenyl), -CO-CH_3, -CO-OCH_3, -NR^AR^B wherein R^A, R^B are each independently selected from the group consisting of H, a branched or unbranched C_{1-4}-alkyl-radical, -CH_2-CH_2-OH and phenyl, and an unsubstituted phenyl radical. If any one of the above mentioned substituents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy.

If R^{13} and R^{14} form a heterocyclic ring, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkoxy, branched or unbranched C_{1-4}-alkyl, branched or unbranched C_{1-4}-perfluoroalkoxy, brainched or unbranched C_{1-4}-perfluoroalkyl, amino, carboxy, amido, cyano, nitro, $-SO_2NH_2$, $-CO-C_{1-4}$-alkyl, $-SO-C_{1-4}$-alkyl, $-SO_2-C_{1-4}$-alkyl, $-NH-SO_2-C_{1-4}$-alkyl, wherein C_{1-4}-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and an unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methoxy, ethoxy, methyl, CF_3 and an unsubstituted phenyl radical. If any of the above mentioned substituents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy.

If R^{13} and R^{14} form a heterocyclic ring, which contains one or more further heteroatoms as ring members, unless defined otherwise, each of these heteroatoms may preferably be selected from the group consisting of N, O and S, more preferably from the group consisting of N and O.

If one or more of the residues R^1-R^{15} and W represents or comprises a cycloaliphatic radical, which contains one or more heteroatoms as ring members, unless defined otherwise, each of these heteroatoms may preferably be selected from the group consisting of N, O, S and P, more preferably from the group consisting of N, O and S.

If one or more of the residues R^1-R^4, R^{10}-R^{15} and W represents or comprises an heteroaryl radical, which contains one or more heteroatoms as ring members, unless defined otherwise, each of these heteroatoms may preferably be selected from the group consisting of N, O, S and P, more preferably from the group consisting of N, O and S.

If W represents or comprises a cycloaliphatic radical, a heteroaryl radical, an aryl radical and/or a mono- or polycyclic ring system, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, nitro, carboxy, cyano, keto, halogen, C_{1-20}-alkyl, partially fluorinated C_{1-4} alkyl, partially chlorinated C_{1-4} alkyl, partially brominated C_{1-4} alkyl, C_{1-6}-alkoxy, partially fluorinated C_{1-4} alkoxy, partially chlorinated C_{1-4} alkoxy, partially brominated C_{1-4} alkoxy, C_{2-6}-alkenyl, SO_2-C_{1-4}-alkyl, -(C=O)-C_{1-6}-alkyl, -(C=O)-O-C_{1-6}-alkyl, -(C=O)-Cl, -S-C_{1-4}-alkyl-, -(C=O)-H, -NH-(C=O)-NH-C_{1-6}-alkyl, -(C=O)-C_{1-4}-perfluoroalkyl, -NR^AR^B, wherein R^A and R^B are independently selected from the group consisting of H, C_{1-4}-alkyl and phenyl, NH-(C=O)-C_{1-6}-alkyl, -C_{1-6}-alkylen-(C=O)-C_{1-6}-alkyl, (1,3-Dihydro-1-oxo-2H-isoindol-2-yl), N-Phthalimidinyl-, (1,3-Dioxo-2-azaspiro[4,4]-non-2-yl, substituted or unsubstituted phenyl, -SO_2-phenyl, phenoxy, pyridinyl, pyridinyloxy, pyrazolyl, pyrimidinyl, pyrrolidinyl-, -SO_2-pyrrolidinyl, morpholinyl, SO_2-morpholinyl-, thiadiazolyl, oxadiazolyl, oxazolyl, thiazolyl, isoxazolyl, O-CH_2-thiazolyl,-, NH-phenyl, and -C_{1-4}-Alkylen-NH-(C=O)-phenyl, more preferably from the group consisting of hydroxy, nitro, carboxy, cyano, keto, F, Cl, Br, I, C_{1-12}-alkyl, CH_2F, CHF_2, CF_3, CH_2Cl, CH_2Cl_2, CCl_3, CH_2Br, $CHBr_2$, CBr_3, OCF_3, $OCHF_2$, OCH_2F, O-CH_2-CF_3, vinyl, SO_2-CH_3, -(C=O)-CH_3, -(C=O)-C_2H_5, -(C=O)-O-CH_3, -(C=O)-O-C_2CH_5, -(C=O)-Cl, -S-CH_3-, -(C=O)-H, -NH-(C=O)-NH-CH_3, -(C=O)-CF_3, dimethylamino, diethylamino, di-n-propylamino, di-iso-propylamino, di-n-butylamino, di-tert-butyamino, NH-(C=O)-CH_3, -CH_2-(C=O)-CH_3, -CH_2-(C=O)-C_2H_5, (1,3-Dihydro-1-oxo-2H-isoindol-2-yl), N-Phthalimidinyl-, (1,3-Dioxo-2-azaspiro[4,4]-non-2-yl, substituted or unsubstituted phenyl, -SO_2-phenyl, phenoxy, pyridinyl, pyridinyloxy, pyrazolyl, pyrimidinyl, pyrrolidinyl-, -SO_2-pyrrolidinyl, morpholinyl, SO_2-morpholinyl-, thiadiazolyl, oxadiazolyl, oxazolyl, thiazolyl, isoxazolyl, O-CH_2-thiazolyl,-, NH-phenyl, and -CH_2-NH-(C=O)-phenyl.

If any of the afore mentioned substituents itself is substituted by one or more substituents, said substituents may preferably be selected from the group consisting of halogen, nitro, cyano, hydroxy, -(C=O)-C_{1-4}-alkyl, C_{1-4}-alkyl, at least partially fluorinated C_{1-4}-alkyl, at least partially chlorinated C_{1-4}-alkyl, at least partially brominated C_{1-4}-alkyl, -S-C_{1-4}-alkyl, -C(=O)-O-C_{1-6}-alkyl, -(C=O)-CH_2-F, -(C=O)-CH_2-Cl, -(C=O)-CH_2-Br, preferably from the group consisting of F, Cl, Br, CH_2F, CHF_2,

CF_3, CH_2Cl, $CHCl_2$, CCl_3, CH_2Br, $CHBr_2$, CBr_3, nitro, cyano, hydroxy, -(C=O)-CH_3, CH_3, C_2H_5, -S-CH_3, -C(=O)-O-CH_3, -C(=O)-O-C_2H_5, -(C=O)-CH_2-F, -(C=O)-CH_2-Cl and -(C=O)-CH_2-Br.

Preferred compounds of general formula (I) are those, wherein R^1, R^2, R^3, R^4 are each independently selected from the group consisting of H, F, Cl, Br, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano group, $-OR^{10}$, $-OC(=O)R^{11}$, $-SR^{12}$, $-SOR^{12}$, $-SO_2R^{12}$, $-NH-SO_2R^{12}$, $-SO_2NH_2$ and a $-NR^{13}R^{14}$ moiety,

preferably selected from the group consisting of H, F, Cl, Br, a saturated, branched or unbranched, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_5- or C_6- cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_1- or C_2-alkylene group, a nitro group, a cyano group, $-OR^{10}$, $-OC(=O)R^{11}$, $-SR^{12}$ and $-NR^{13}R^{14}$ moiety,

more preferably selected from the group consisting of H, F, Cl, $-CH_3$, $-CH_2CH_3$, $-CF_3$, $-CF_2CF_3$, cyclopentyl, cyclohexyl, a nitro group, a cyano group and $-OR^{10}$,

and R^5-R^{16} and W have the meaning as defined above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred are compounds of general formula (I), wherein R^5 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical,

preferably represents H or a branched or unbranched C_{1-3}-alkyl radical,

more preferably H, CH_3 or CH_2CH_3,

and R^1-R^4, R^6-R^{15} and W have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Preferred compounds of general formula (I) are also those, wherein R^6, R^7, R^8, R^9 are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, a cyano group and a $-COOR^{15}$ moiety,

preferably selected from the group consisting of H, a branched or unbranched C_{1-3}-alkyl radical, a cyano group and a $-COOR^{15}$ group,

more preferably from the group consisting of H, $-CH_3$, $-CH_2CH_3$ and a cyano moiety,

and R^1-R^5, R^{10}-R^{15} and W have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred are compounds of general formula (I), wherein W represents an unbranched or branched, optionally at least mono-substituted C_{11-30}-alkyl radical, a napthyl group, which is at least mono substituted, a quinolinyl group, which is at least mono-substituted, a pyrrolyl group, which is at least mono-substituted by a substituent other than C_{1-5}-alkyl, an optionally at least mono-substituted thiazolyl-, benzo[b]-thiophenyl-, benzo[b]-furanyl-, isoquinolinyl-, tetrahydroisoquinolinyl-, pyrazolyl-, isoazolyl-, chromanyl-, benzothiadiazolyl-, imidazolyl-, benzofurazanyl-, dibenzo[b,d]-furanyl-, benzoxadiazolyl-, Imidazo[2,1-b]-thiazolyl-, anthracenyl-, coumarinyl-, 2,3-Dihydro-1,4-benzodioxinyl-, 2,3-Dihydrobenzo[b]furanyl-, 3,4-Dihydro-2H-1,4-Benzoxazinyl-, 3,4-Dihydro-2H-1,5-Benzodioxepinyl-, Benzothiazolyl-, Imidazo[1,2-a]-pyridinyl-, a chromonyl- group, an isatinyl group, a pentamethyldihydrobenzofuranyl group, an optionally at least mono-substituted cyclopropyl- or cyclopentyl-group, a 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl-)-ethyl, a thienyl group, which is at least mono-substituted by one or more substituents independently selected from the group consisting of F, Cl, Br, C_{1-5}-alkoxy-, CF_3, $-SO_2-C_{1-5}$-alkyl and optionally at least mono substituted benzoylaminomethyl-, phenylsulfonyl-, isoxazolyl-, benzamidomethyl-, pyrimidyl-, thiazolyl-, pyrazolyl-, phenyl-, 1,2,4-thiadiazolyl-, 1,3-oxazolyl- or 1,2,4-oxadiazolyl-, a furyl group, which is at least mono-substituted by one or more substituents independently selected from the group consisting of a C_{1-5}-alkyl radical, which may be at least partially fluorinated or chlorinated, an optionally at least mono-substituted phenyl and a $-(C=O)-O-C_{1-5}$-alkyl group,

a $NR^{16}R^{17}$-moiety,

a COR^{16}-moiety,

or a phenyl radical, which is at least mono-substituted with one of the substituents selected from the group consisting of:

2,2,2,-Trifluoroethoxy-, C_{2-5}-Alkenyl-, 1,3-Dihydro-1-oxo-2H-isoindol-2-yl-, N-Phthalimidinyl-, [(2-chloro-1,3-thiazolyl-5-yl)-methoxy, Ethyl-5-yl-2-methyl-3-furoate, C_{11-20}-alkyl-, 1,3-Dioxo-2-azaspiro[4,4]non-2-yl-, pyrazolyl-, (1,3-oxazol-5-yl)-, (5-Methyl-1,3,4-oxadiazol-2-yl)-, difluoromethoxy, dichloromethoxy, 1-

pyrrolidinylsulfonyl, morpholinosulfonyl, 2-methyl-4-pyrimidinyl-, a phenoxy group, which is at least mono-substituted with C_{1-8}-alkoxy, a phenyl group, which is at least mono-substituted with one of the substituents selected from the group consisting of nitro, C_{1-8}-alkoxy, F, Cl, Br, at least partially fluorinated C_{1-8}-alkyl, at least partially chlorinated C_{1-8}-alkyl, [(2-Chloro-1,3-thiazol-5-yl)-methoxy]-, -(C=O)-H and -(C=O)-C_{1-8}-alkyl, a pyridinyl group, which is at least mono-substituted with C_{1-8}-alkoxy, a pyridinyloxy group, which is at least mono-substituted with C_{1-8}-alkoxy, a phenoxy group, which is at least di-substituted and a pyridinyloxy group, which is at least di-substituted,

more preferably W represents a moiety selected from the group consisting of 5-Dimethylamino-napth-1-yl, 2-Acetamido-4-methyl-5-thiazolyl-, Trifluoromethyl-, Trichloromethyl-, Isopropyl-, Methyl-, 2,2,2-Trifluoroethyl-, Ethyl-, Hexadecyl-, 2-Chloroethyl-, n-Propyl-, 3-Chloro-propyl-, n-Butyl-, Dichloromethyl-, Chloromethyl-, Dodecyl-, 1-Octyl-, 6-(p-toluidino)-naphth-2-yl-, 4,5-Dibromo-thiophene-2-yl-, Benzoylchloride-2-yl-, 1-Octadecyl-, 4-Bromo-2,5-dichloro-thiophene-3-yl-, 2,5-Dichloro-thiophene-3-yl-, 5-Chloro-thiophene-2-yl-, 1-Decyl-, 3,5-Dichloro-4-(2-chloro-4-nitrophenoxy)-phenyl-, 2,3-Dichlorothiophene-5-yl-, 3-Bromo-2-chloro-thiophene-5-yl-, 3-Bromo-5-chloro-thiophene-2-yl-, 2-(Benzoylaminomethyl)-thiophene-5-yl-, 4-(Phenyl-sulphonyl)-thiophene-2-yl-, 2-Phenyl-sulphonyl-thiophene-5-yl-, 2-[1-Methyl-5-(trifluoromethyl)pyrazol-3-yl]-thiophene-5-yl-, 5-Chloro-1,3-dimethylpyrazole-4-yl-, 3,5-Dimethylisoxazole-4-yl-, 2-(2,4-Dichlorophenoxy)-phenyl, 4-(2-Chloro-6-nitro-phenoxy)-phenyl-, 4-(3-chloro-2-cyanophenoxy)-phenyl, 2,4-Dimethyl-1,3-thiazole-5-yl-, Methyl-methane-sulfonyl-, 2,5-Bis-(2,2,2-Trifluoroethoxy)-phenyl-, 5-(Di-n-propylamino)-naphth-1-yl-, 2,2,5,7,8-Pentamethyl-chroman-6-yl-, 5-Chloro-4-nitro-thiophene-2-yl-, 2,1,3-Benzothiadiazole-4-yl-, 1-Methyl-Imidazole-4-yl-, Benzofurazan-4-yl-, 5-(Isoxazol-3-yl)-thiophene-2-yl-, Vinyl-phenyl-4-yl-, 5-Dichloro-methyl-furan-2-yl-, 5-Bromo-thiophene-2-yl-, 5-(4-Chlorobenzamidomethyl)-thiophene-2-yl-, Dibenzo[b,d]-furan-2-yl-, 5-Chloro-3-methylbenzo[b]-thiophene-2-yl-, 3-Methoxy-4-(methoxycarbonyl)-thiophene-2-yl-, 5-[2-(Methylthio)-pyrimidin-4-yl-]-thiophene-2-yl-, 4-Chloro-2,1,3-Benzoxadiazole-7-yl-, 5-Chloro-2,1,3-Benzoxadiazole-4-yl-, 6-Chloro-Imidazo(2,1-B)-thiazole-5-yl-, 3-Methyl-benzo[b]-thiophene-2-yl-, 4-[[3-Chloro-5-(Trifluoromethyl)-2-pyridyl]oxy-phenyl-, 5-Chloro-naphth-1-yl-, 5-Chloro-naphth-2-yl-, 9,10-Dibromoanthracene-2-yl-, Isoquinoline-5-yl-,

4-Methoxy-2,3,6-trimethylbenzoyl-, 4'-Nitro-biphenyl-4-yl-, (1,3-Dihydro-1-oxo-2H-isoindol-2-yl-)-4-phenyl-, 5-(2-Methyl-1,3-thiazole-4-yl)-thiophene-2-yl-, 5-(1-Methyl-3-(trifluoromethyl)pyrazol-5-yl-]-thiophene-2-yl-, 5-[5-Trifluoromethyl)-isoxazol-3-yl]-thiophene-2-yl-, p-Dodecyl-phenyl-, 4-[(3-Cyano-4-methoxy-2-pyridinyl)oxy]-phenyl-, 4-(N-phthalimidinyl)-phenyl-, 1,2,3,4-Tetrahydro-2-(trifluoroacetyl)-isoquinoline-7-yl-, 1,2-Dimethylimidazole-4-yl-, 2,2,4,6,7-Pentamethyldihydrobenzofuran-5-yl-, 4-Chloro-naphth-1-yl-, 2,5-Dichloro-4-nitro-thiophene-3-yl-, 4-(4-Methoxy-phenoxy)-phenyl-, [4-(3,5-Dichlorophenoxy)phenyl]-, [4-(3,4-Dichlorophenoxy)phenyl]-, [4-(3,5)-Bis(trifluoromethylphenoxy)phenyl]-, 3-(2-Methoxy-phenoxy)-phenyl, 3-(4-Methoxy-phenyl)-phenyl-, 3-(4-Chloro-phenyl)-phenyl-, 3-(3,5-Dichloro-phenyl)-phenyl-, 3-(3,4-Dichloro-phenyl)-phenyl-, 3-(4-Fluorophenyl)-phenyl-, 3-[4-(Trifluoromethyl)-phenyl]-phenyl-, 3-[3,5-Bis-(Trifluoromethyl)-phenyl]-phenyl-, 4-(2-Methoxy-phenoxy)-phenyl-, 4-(2-Methyl-phenoxy)-phenyl-, 4-(4-Methoxy-phenoxy)-phenyl-, 4-(4-Chlorophenyl)-phenyl-, 4-(3,5-Dichlorophenyl)-phenyl-, 4-(3,4-Dichlorophenyl)-phenyl-, 4-(4-Fluorophenyl)-phenyl-, 4-[4-(Trifluormethyl)-phenyl]-phenyl-, 4-[3,5-Bis-(Trifluoromethyl)-phenyl]-phenyl-, Cyclopropyl-, 2-(2-Chlorophenyl)-2-Phenylethyl-, 2-(2-Trifluoromethylphenyl)-2-phenylethyl-, 5-[4-Cyano-1-methyl-5-(methylthio)-1H-pyrazol-3-yl-thiophene-2-yl-, 3-Cyano-2,4-bis-(2,2,2-Trifluorothoxy)-phenyl-, 4-[(2-Chloro-1,3-Thiazol-5-yl)-methoxy]-phenyl-, 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethyl-, 5-Iodo-naphth-1-yl-, Ethyl-2,5-dimethyl-1-phenylpyrrole-4-carboxylate-3-yl-, Ethyl-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxylate-4-yl-, Ethyl-5-(4-chlorophenyl)-2-methyl-3-furoate-4-yl, Ethyl-5-(4-chlorophenyl)-2-methyl-1-phenyl-3-carboxylate-4-yl-, Ethyl-2,5-dimethyl-3-furoate-4-yl-, 3-Chloro-4-(1,3-dioxo-2-Azaspiro[4,4]non-2-yl)-phenyl-, Coumarin-6-yl, 3-(4-Methoxy-phenoxy)-phenyl-, [3-(3,5-Dichlorophenoxy)]-phenyl-, [3-(3,4 Dichlorophenoxy)]-phenyl-, 3,5-Bis(Trifluoromethyl)phenoxyphenyl-, 2,2-Diphenylethyl-, 4-Phenyl-5-(trifluoromethyl)-thiophene-3-yl-, Methyl-4-Phenyl-5-(Trifluoromethyl)-thiophene-2-carboxylate-3-yl-, Methyl-1,2,5-trimethylpyrrole-3-Carboxylate-4-yl-, 4-Fluoro-naphth-1-yl-, 5-Fluoro-3-methylbenzo[b]-thiophene-2-yl-, Methyl-2,5-dimethyl-3-furoate-4-yl-, Methyl-2-furoate-5-yl-, Methyl-2-methyl-3-furoate-5-yl-, Methyl-1-methyl-1H-pyrrole-2-Carboxylate-5-yl-, 2-(5-Chloro-1,2,4-Thiadiazol-3-yl)-thiophene-5-yl-, 1,3,5-Trimethyl-1H-pyrazole-4-yl-, Pentafluoroethoxytetrafluoroethyl-, 5-(5-Isoxazyl)-thiophene-2-yl-, 5-(5-Isoxazol-yl)-2-furyl-, 5-Methyl-2,1,3-benzothiadiazole-4-yl-, 2,3-Dihydro-1,4-benzodioxine-6-yl-, 4-Methyl-Naphth-1-yl-, 5-Methyl-2-(Trifluormethyl)-3-Furyl-, 2,3-Dihydrobenzo[b]furan-

5-yl-, 1-Benzothiophene-3-yl-, 4-Methyl-3,4-dihydro-2H-1,4-Benzoxazine-7-yl-, 5-Methyl-1-phenyl-1H-pyrazole-4-yl-, 6-Morpholino-3-Pyridinyl-, 4-(1H-Pyrazol-1-yl)-phenyl-, 6-Phenoxy-3-Pyridyl-, 3,4-Dihydro-2H-1,5-benzodioxepine-7-yl-, 5-(1,3-Oxazol-5-yl)-2-thienyl-, 4-(1,3-Oxazol-5-yl)-phenyl-, 5-Methyl-4-isoxazolyl, 2,1,3-Benzothiadiazole-5-yl-, 5-Acetamido-naphth-1-yl-, 3-Methyl-8-Quinolinyl-, 1,3-Benzothiazole-6-yl-, 2-Morpholino-3-Pyridyl-, 2,5-Dimethyl-3-thienyl-, 5-[5-(Chloromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl-, Ethyl-3-[5-yl-2-thienyl-]1,2,4-oxadiazole-5-carboxylate-, 3-(5-Methyl-1,3,4-oxadiazol-2-yl)-phenyl-, 4-(Difluoromethoxy)-phenyl-, 3-(Difluoromethoxy)-phenyl-, 2,2-Dimethyl-6-Chromanyl-, Ethyl-3,5-dimethyl-1H-pyrrole-2-carboxylate-4-yl-, Imidazo[1,2-A]pyridine-3-yl-, 3-(1,3-Oxazol-5-yl)-phenyl-, Ethyl-5-[4-yl)-phenyl]-2-methyl-3-furoate, 1-Pyrrolidinylphenylsulfonyl-, Methyl-5-yl-4-methyl-2-thiophene-carboxylate, Methyl-3-yl-4-(isopropylsulfonyl)-2-thiophene, 7-Chlorochromone-3-yl-, 4'-Bromobiphenyl-4-yl-, 4'-Acetyl-biphenyl-4-yl-, 4'-Bromo-2'-fluoro-biphenyl-4-yl-, 1-Methyl-5-isatinyl-, 2-Chloro-3-thiophenecarboxylic-acid-5-yl-, 2-Methoxy-5-(N-phthalimidinyl)-phenyl-, 1-Benzothiophene-2-yl-, Morpholinophenylsulfonyl- and 3-(2-Methyl-4-pyrimidinyl)-phenyl- and R^1-R^{18} have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Furthermore, compounds of general formula (I) are preferred, wherein R^{10} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

preferably H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical,

more preferably H, $-CH_3$, $-C_2H_5$ or phenyl,

and R^1-R^9, R^{12}-R^{18} and W have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Moreover, compounds of general formula (I) are preferred, wherein R^{11} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

preferably H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl,

and R^1-R^{10}, R^{12}-R^{18} and W have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Preference is also given to compounds of general formula (I), wherein R^{12} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

preferably represents H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical,

more preferably H, $-CH_3$, $-C_2H_5$ or phenyl,

and R^1-R^{11}, R^{13}-R^{19} and W have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred are compounds of general formula (I), wherein R^{13} and R^{14} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

preferably are each independently selected from the group consisting of H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical and a phenyl radical,

more preferably are each independently selected from the group consisting of H, CH_3, C_2H_5 and phenyl,

and R^1-R^{12}, R^{15}-R^{18} and W have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Furthermore, compounds of general formula I are preferred, wherein R^{13} and R^{14} together with the bridging nitrogen atom form a saturated, unsaturated or aromatic, 5- or 6-membered heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member,

preferably form an unsubstituted piperidin or morpholine group,

and R^1-R^{12}, R^{15}-R^{18} and W have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred are compounds of general formula (I), wherein R^{15} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

preferably represents H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical,

more preferably represents H, $-CH_3$, $-C_2H_5$ or phenyl,

and R^1-R^{14}, R^{16}, R^{17}, R^{18} and W have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred are compounds of general formula (I), wherein R^{16} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6} aliphatic radical,

preferably an unbranched or branched, saturated, unsubstituted C_{1-3} alkyl radical,

more preferably a methyl radical,

and R^1-R^{15}, R^{17}, R^{18} and W have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred are compounds of general formula (I), wherein R^{17} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6} aliphatic radical,

preferably an unbranched or branched, saturated, unsubstituted C_{1-3} alkyl radical,

more preferably a methyl radical,


and R^1-R^{16}, R^{18} and W have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred are compounds of general formula (I), wherein R^{18} represents a phenyl radical, which is optionally at least mono-substituted by a C_{1-5} aliphatic radical, more preferably a phenyl radical, which is optionally at least mono-substituted by a methyl group,


and R^1-R^{17} and W have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Particularly preferred are compounds of general formula (I) selected from the following list A:


List A:




1-[1-(Naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(Toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-(1-Phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-(1-Benzenesulfonyl-piperidin-4-yl)-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-(1-phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




2-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile




1-[1-(2,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonic acid dimethylamide




1-[1-(2-Naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




8-Methyl-1-[1-(thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




2-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile




1-[1-(2,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Methoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonic acid dimethylamide




8-Methyl-1-[1-(2-naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonic acid dimethylamide




2-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid methyl ester




1-[1-(3-Trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




2-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid methyl ester




8-Methyl-1-[1-(3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one




2-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile




6-Chloro-1-[1-(4-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




2-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid methyl ester




6-Chloro-1-[1-(2,4-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




8-Methyl-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




8-Methyl-1-(1-phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(4-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(Butane-1-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Bromo-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(Butane-1-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(2-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one




8-Methyl-1-[1-(2-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




8-Methyl-1-[1-(3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




8-Methyl-1-[1-(4-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(4-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-(1-Ethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(Propane-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(Propane-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-(1-ethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(propane-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(propane-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Methyl-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Methyl-1-[1-(2-naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Methyl-1-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Methyl-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Methyl-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Methyl-1-[1-(4-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one



1-(1-Benzenesulfonyl-piperidin-4-yl)-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(5-Dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one


43




1-[1-(4-Chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(4-chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(5-dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2-Bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2-Bromo-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(2,3-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2,3-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2,4,5-Trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




8-Methyl-1-[1-(2,4,5-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(2,4,5-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Methyl-1-[1-(2,4,5-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(5-Bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(5-Bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(5-Bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(5-Bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2,6-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2,6-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(2,6-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one



1-[1-(2,6-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-(1-Pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one




8-Methyl-1-(1-pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one


47




6-Chloro-1-(1-pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Methyl-1-(1-pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-[2-(2,2,2-Trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Methyl-1-(1-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one



6-Chloro-1-(1-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Methyl-1-(1-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2-Methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one


48




6-Methyl-1-[1-(2-methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(2-methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Methyl-1-[1-(2-methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(4-chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one



1-[1-(4-Methoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Isopropyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Isopropyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one


50




6-Chloro-1-[1-(4-isopropyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Isopropyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(3-chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Methyl-1-[1-(3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Methyl-1-[1-(3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2-Nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one



1-[1-(3-Fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2,4,6-Trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one


52




1-[1-(2-Trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




8-Methyl-1-[1-(4-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




8-Methyl-1-[1-(2-nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(3-Fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




8-Methyl-1-[1-(2,4,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




8-Methyl-1-[1-(2-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(3-Nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-{1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl}-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(3-Methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2-Nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




8-Methyl-1-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-(1-Benzenesulfonyl-piperidin-4-yl)-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(3-Methoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




8-Methyl-1-[1-(thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(Toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(5-Fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Isopropoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(3-Chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(3,4-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-(1-Pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one




8-Methyl-1-[1-(toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(5-Fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Isopropoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(3-Chloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(3,4-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




8-Methyl-1-(1-pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one




8-Methyl-1-[1-(toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(5-Fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Isopropoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(3-Chloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(3,4-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Methyl-1-(1-pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Methyl-1-[1-(4-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Methyl-1-[1-(2-nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one



1-[1-(3-Fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Methyl-1-[1-(2,4,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one


S8
S9




6-Methyl-1-[1-(2-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(3-Methoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Methyl-1-[1-(2-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one



1-[1-(4-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Methyl-1-(1-phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one




2-[4-(6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid methyl ester


59
60




6-Methyl-1-[1-(2-oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(3,5-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(3-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(2-oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(5-fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(4-isopropoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(3-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one



6-Chloro-1-[1-(3,4-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-(1-pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(4-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one


61




6-Chloro-1-[1-(2-nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin




6-Chloro-1-[1-(3-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(2,4-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(2,4,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one



6-Chloro-1-[1-(2-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2-Oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(3,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one


62




1-[1-(2,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(6-Bromo-5-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2,6-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




8-Methyl-1-[1-(2-oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(3,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Chloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2,6-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one



6-Chloro-1-[1-(2,5-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(4-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one


05
64




6-Chloro-1-[1-(2,6-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




2-[4-(6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile




1-[1-(2,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one



1-[1-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Chloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2,6-Dichloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one


66
65




1-[1-(3,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




8-Methyl-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(5-Bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one



1-[1-(1-Methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(5-Bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(6-Chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one


67
66




1-[1-(4-Ethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(6-Chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Ethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(6-chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(4-ethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(6-Chloro-Imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Ethyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(7-Chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2-Methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




3-[4-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl]-propionic acid methyl ester




1-[1-(2,4-Dinitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(7-Chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2-Methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




3-[4-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl]-propionic acid methyl ester




1-[1-(2,4-Dinitro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(7-Chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2-Methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




3-{4-[4-(6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl}-propionic acid methyl ester




1-[1-(2,4-Dinitro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(7-chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(2-methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




3-{4-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl}-propionic acid methyl ester




6-Chloro-1-[1-(2,4-dinitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(5-Bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one




8-Methyl-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(5-Bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2,5-Difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2,5-Difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2,5-Difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one



1-[1-(4-Chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(4-Chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(4-chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one


73
72




1-[1-(4-Chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2,4,5-Trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




8-Methyl-1-[1-(2,4,5-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(2,4,5-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one



6-Methyl-1-[1-(2,4,5-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(3,5-Dichloro-2-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2,6-Difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one


44
73




1-[1-(2,6-Difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(2,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2,6-Difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(5-Chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(5-Chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(5-chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(5-Chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2-Chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2-Chloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(2-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(2-Chloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(2-naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(4-bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(2,4-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(2-naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one



6-Bromo-1-[1-(3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one


77
76




1-(1-Benzenesulfonyl-piperidin-4-yl)-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-[4-(4-bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(2-methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(4-bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(5-fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(4-isopropoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(3-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(3,4-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-(1-pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(4-chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(3-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(4-isopropyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(3-chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-(1-pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(2-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one



6-Bromo-1-[1-(4-chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(5-dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(4-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one


80
79




1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(4-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-(1-phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(2,5-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-(1-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(2,3-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(2,4,5-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(5-bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(4-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(2-nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(3-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(2,4-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(2,4,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(2-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(2-bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(3,5-Dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one



1-[1-(3,5-Dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(3,5-dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




1-[1-(3,5-Dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one


83
92




6-Bromo-1-[1-(3,5-dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Chloro-1-[1-(3,5-dichloro-2-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(3,5-dichloro-2-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




2-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile




6-Bromo-1-[1-(4-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




2-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid methyl ester




6-Bromo-1-[1-(2-oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(3,5-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(2,6-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(5-bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one




6-Bromo-1-[1-(4-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one



6-Bromo-1-[1-(2,6-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one



6-Bromo-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one



6-Bromo-1-[1-(5-bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one

More particularly preferred are compounds of general formula (I) selected from the group consisting of


1-[1-(5-Chloro-3-methyl-benzo[b]thiophenyl-2-sulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

1-[1-(5-Dimethylamino-naphthyl-1-sulfonyl)-piperidine-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

1-[1-(5-Dimethylamino-naphthyl-1-sulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,


and corresponding salts thereof, and corresponding solvates.

In a further aspect the present invention also provides a process for the preparation of benzoxazinone-derived sulphonamide compounds of general formula (I), wherein R^1-R^8 and W have the meaning given above, comprising reacting at least one piperidine compound of general formula (II) and/or a corresponding salt thereof, preferably a hydrochloride salt,



(II)

wherein R^1 to R^9 have the meaning given above, with at least one compound of general formula (III),



(III)

wherein W has the meaning given above, in a suitable reaction medium, optionally in the presence of at least one base and/or at least one auxiliary agent, to yield a compound of general formula (I).

Suitable reaction media include e.g. organic solvents, such as ethers, preferably diethyl ether, dioxane, tetrahydrofurane, dimethyl glycol ether, or alcohols, e.g. methanol, ethanol, propanol, isopropanol, butanol, isobutanol, tert-butanol, or hydrocarbons, preferably benzene, toluene, xylene, hexane, cyclohexane, petroleum ether, or halogenated hydrocarbons, e.g. dichloromethane, trichloromethane, tetrachloromethane, dichloroethylene, trichloroethylene, chlorobenzene or/and other solvents, preferably ethyl acetate, triethylamine, pyridine, dimethylsulfoxide, diemthylformamide, hexamethylphosphoramide, acetonitril, acetone or nitromethane, are included. Mixtures based one or more of the afore mentioned solvents may also be used.

Bases that may be used in the processes according to the present invention are generally organic or inorganic bases, preferably alkali metal hydroxides, e.g. sodium hydroxyde or potassium hydroxyde, or obtained from other metals such as barium hydroxyde or different carbonates, preferably potassium carbonate, sodium carbonate, calcium carbonate, or alkoxides, e.g. sodium methoxide, potassium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide or potassium tert-butoxide, or organic amines, preferably triethylamine, diisopropyethylamine or heterocycles, e.g. 1,4-diazabicyclo[2.2.2] octane, 1,8-diazabicyclo[5.4.0]undec-7-ene pyridine, diamino pyridine, dimethylaminopyridine, methylpiperidine or morpholine.

Alkali metals such as sodium or lat hydrides, e.g. sodium hydride, may also be used. Mixtures based one or more of the afore mentioned bases may also be used.

During the synthetic reactions described above or while preparing the compounds of general formulas (II) or (III) the protection of sensitive groups or of reagents may be necessary and/or desirable. This can be performed by using conventional protective groups like those described in the literature [Protective groups in Organic Chemistry, ed. J. F.W. McOmie, Plenum Press, 1973; T.W. Greene & P.G.M.Wuts, Protective Groups in Organic Chemistry, John Wiley & sons, 1991. Said literature description is hereby incorporated by reference as part of the disclosure. The protective groups may also be eliminated as convenient by means well-known to those skilled in the art.


The compounds of general formulas (II) and (III) are either commercially available or can be produced according to methods known to those skilled in the art. The reaction of compounds of general formulas (II) and (III) to yield benzoxazinone-derived sulphonamide compounds of general formula (I) may also be facilitated by conventional methods known to those skilled in the art.

The substituted benzoxazinone compounds of general formula (II), wherein R^5 represents H, are preferably synthesized from substituted anthranilic acid or a corresponding ester via the corresponding substituted benzylalcohol (see scheme 1, method A). By reductive amination with 1-Boc-(tert.-Butylcarbonyloxy)-4-piperidone the Boc-piperidin-moiety is introduced into the substituted benzylalcohol. The benzoxazinone-ring is formed by cyclisation with triphosgene. The elimination of the Boc-protecting group is carried out by treatment in acidic media according to the method described in Williams et al., J. Med. Chem. 1995 38, 4634 and later by Bell et al., J. Med. Chem., 1998, 41, 2148 which are hereby incorporated by reference and form part of the disclosure. By reacting such a substituted benzoxazinone compound of general formula (II) with a substituted sulfuryl chloride of general formula (III) compounds of general formula (I) are obtained.
By reduction of the corresponding ketones via conventional methods known to those skilled in the art, e.g. by reduction with sodium borohydride (see scheme 1, method B, R5=Z) benzoxazinone derived sulphonamide compounds of general formula (I),

wherein R^8 represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical (denoted by Z in method B) can be obtained.

The respective reagents used in said process for the preparation of benzoxazinone derived sulphonamide compounds of general formula (I) are either commercially available or can be obtained by methods well known to those skilled in the art.

Scheme 1:



In a further aspect the present invention also provides a process for the preparation of salts of benzoxazinone-derived sulphonamide compounds of general formula (I), wherein at least one compound of general formula (I) having at least one basic group is reacted with at least one inorganic and/or organic acid, preferably in the presence of a suitable reaction medium. Suitable reaction media are, for example, the ones

given above. Suitable inorganic acids include hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, nitric acid, suitable organic acids are e.g. citric acid, maleic acid, fumaric acid, tartaric acid, or derivatives thereof, p-toluenesulfonic acid, methanesulfonic acid or camphersulfonic acid.

In yet a further aspect the present invention also provides a process for the preparation of salts of benzoxazinone-derived sulphonamide compounds of general formula (I), wherein at least one compound of general formula (I) having at least one acidic group is reacted with one or more suitable bases, preferably in the presence of a suitable reaction medium. Suitable bases are e.g. hydroxides, carbonates or alkoxides, which include suitable cations, derived e.g. from alkaline metals, alkaline earth metals or organic cations, e.g. $[NH_nR_{4-n}]^+$, wherein n is 0, 1, 2, 3 or 4 and R represents a branched or unbranched C_{1-4}-alkyl-radical. Suitable reaction media are, for example, the ones given above.

Solvates, preferably hydrates, of the Benzoxazinone-derived sulphonamide compounds of general formula (I) or of the salts thereof may also be obtained by standard procedures known to those skilled in the art.

If the Benzoxazinone-derived compounds of general formula (I) are obtained in form of a mixture of stereoisomers, particularly enantiomers or diastereomers, said mixtures may be separated by standard procedures known to those skilled in the art, e.g. chromatographic methods or crystallization with chiral reagents.

The purification and isolation of the Benzoxazinone-derived sulphonamide compounds of general formula (I) or a corresponding stereoisomer, or salt, or solvate respectively, if required, may be carried out by conventional methods known to those skilled in the art, e.g. chromatographic methods or recrystallization.

The Benzoxazinone-derived sulphonamide compounds of general formula (I), their stereoisomers, the corresponding salts and the corresponding solvates are toxicologically acceptable and are therefore suitable as pharmaceutical active substances for the preparation of medicaments.

The present invention therefore also provides for a medicament comprising at least one benzoxazinone-derived sulphonamide compound of general formula (I), optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate, and optionally one or more pharmaceutically acceptable adjuvants.

Furthermore, the present invention also provides for a pharmaceutical composition comprising at least one benzoxazinone-derived sulphonamide compound of general formula (I), optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate and optionally one or more pharmaceutically acceptable adjuvants, which is not yet formulated into a medicament.


Preferably the medicament is suitable for 5-HT_6-receptor regulation, for cognitive enhancement, for the prophylaxis and/or treatment of food ingestion (food intake) disorders, particularly for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (Non-Insulin Dependent Diabetes Mellitus), preferably type II diabetes, which is caused by obesity, disorders of the central nervous system, disorders of the gastrointestinal tract, such as irritable intestine syndrom, anxiety, panic, depression, cognitive memory disorders, senile dementia disorders, such as Morbus Alzheimer, Morbus Parkinson and Morbus Huntington, schizophrenia, psychosis, infantile hyperkinesis, ADHC (attention deficit, hyperactivity disorders) and other 5-HT_6 mediated disorders particularly in mammals, including humans.

A further aspect of the present invention is the use of at least one benzoxazinone-derived compound of general formula (I) for the manufacture of a medicament for 5-HT_6-receptor regulation, for cognitive enhancement, for the prophylaxis and/or treatment of food ingestion (food intake) disorders, particularly for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the

94
90

prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (Non-Insulin Dependent Diabetes Mellitus), preferably type II diabetes, which is caused by obesity, disorders of the central nervous system, disorders of the gastrointestinal tract, such as irritable intestine syndrom, anxiety, panic, depression, cognitive memory disorders, senile dementia disorders, such as Morbus Alzheimer, Morbus Parkinson and Morbus Huntington, schizophrenia, psychosis, infantile hyperkinesia, ADHC (attention deficit, hyperactivity disorders) and other 5-HT_6 mediated disorders particularly in mammals, including humans.

In yet a further aspect, the present invention also provides for the use of at least one benzoxazinone-derived sulphonamide compound of general formula (Ia)



(Ia)

wherein

R^{1a}, R^{2a}, R^{3a}, R^{4a} are each independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least

mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano group, -OR^{10a}, -OC(=O)R^{11a}, -C(=O)-OR^{11a}, -SR^{12a}, -SOR^{12a}, -SO_2R^{12a}, -NH-SO_2R^{12a}, -SO_2NH_2 and a -$NR^{13a}R^{14a}$ moiety,

R^{5a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical,

R^{6a}, R^{7a}, R^{8a}, R^{9a} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano group and a -$COOR^{15a}$ moiety,

W^a represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, a $NR^{16a}R^{17a}$-moiety or a -COR^{18a}-moiety,

R^{10a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at

least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{11a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{12a} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{13a} and R^{14a} each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least

94
93

mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

or R^{13a} and R^{14a} together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member,

R^{15a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{16a} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

R^{17a} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

R^{18a} represents an optionally at least mono-substituted aryl radical,

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively,

for the manufacture of a medicament for 5-HT_6-receptor regulation, for cognitive enhancement, for the prophylaxis and/or treatment of food ingestion (food intake) disorders, particularly for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (Non-Insulin Dependent Diabetes Mellitus), preferably type II diabetes, which is caused by obesity, disorders of the

gastrointestinal tract, such as irritable intestine syndrom, anxiety, panic, depression, cognitive memory disorders, senile dementia disorders, such as Morbus Alzheimer, Morbus Parkinson and Morbus Huntington, schizophrenia, psychosis, infantile hyperkinesis, ADHC (attention deficit, hyperactivity disorders) and other 5-HT_6 mediated disorders particularly in mammals, preferably humans.

If one or more of the residues R^{1a}-R^{17a} and W^a represents an aliphatic radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkoxy, branched or unbranched C_{1-4}-perfluoroalkoxy, branched or unbranched C_{1-4}-perfluoroalkyl, amino, carboxy, amido, cyano, nitro, $-SO_2NH_2$, $-CO-C_{1-4}$-alkyl, $-SO-C_{1-4}$-alkyl, $-SO_2-C_{1-4}$-alkyl, $-NH-SO_2-C_{1-4}$-alkyl , wherein the C_{1-4}-alkyl may in each case be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and an unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methoxy, ethoxy, CF_3 and an unsubstituted phenyl radical. If any one of the above mentioned substituents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy.

If one or more of the residues R^{1a}-R^{18a} represents or comprises a cycloaliphatic radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkyl, branched or unbranched C_{1-4}-alkoxy, branched or unbranched C_{1-4}-perfluoroalkoxy, phenoxy, benzoyl, cyclohexyl, branched or unbranched C_{1-4}-perfluoroalkyl, $-NR^AR^B$ wherein R^A, R^B are each independently selected from the group consisting of H, a branched or unbranched C_{1-4}-alkyl-radical, $-CH_2-CH_2-OH$ and phenyl, carboxy, keto, amido, cyano, nitro, $-SO_2NH_2$, $-CO-C_{1-4}$-alkyl, $-CO-OC_{1-4}$-alkyl, $-SO-C_{1-4}$-alkyl, $-SO_2-C_{1-4}$-alkyl, $-NH-SO_2-C_{1-4}$-alkyl, wherein C_{1-4}-alkyl may in each case be branched or unbranched, unsubstituted or at least mono-substituted phenyl or naphthyl and unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from

the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, methoxy, ethoxy, keto, benzoyl, phenoxy, cyclohexyl, $-CF_3$, $-CO-CH_3$, $-CO-OCH_3$, $-NR^AR^B$ wherein R^A, R^B are each independently selected from the group consisting of H, a branched or unbranched C_{1-4}-alkyl-radical, $-CH_2-CH_2-OH$ and phenyl, and an unsubstituted phenyl radical. If any one of the above mentioned substituents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy.

If one or more of the residues R^{1a}-R^{4a} and R^{10a}-R^{16a} and W^a comprises an alkylene group, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkoxy, branched or unbranched C_{1-4}-alkyl, branched or unbranched C_{1-4}-perfluoroalkoxy, branched or unbranched C_{1-4}-perfluoroalkyl, amino, carboxy, amido, cyano, nitro, $-SO_2NH_2$, $-CO-C_{1-4}$-alkyl, $-SO-C_{1-4}$-alkyl, $-SO_2-C_{1-4}$-alkyl, $-NH-SO_2-C_{1-4}$-alkyl, wherein C_{1-4}-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and an unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methyl, methoxy, ethoxy, CF_3 and unsubstituted phenyl. If any one of the above mentioned substituents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy.

If one or more of the residues R^{1a}-R^{4a} and R^{10a}-R^{16a} comprises a mono- or polycyclic ringsystem, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkyl, branched or unbranched C_{1-4}-alkoxy, branched or unbranched C_{1-4}-perfluoroalkoxy, branched or unbranched C_{1-4}-perfluorocarbonyl, branched or unbranched C_{1-4}-perfluoroalkyl, amino, carboxy, amido, cyano, keto, nitro, $-SO_2NH_2$, $-CO-C_{1-4}$-alkyl, $-SO-C_{1-4}$-alkyl, $-SO_2-C_{1-4}$-alkyl, $-NH-SO_2-C_{1-4}$-alkyl, wherein C_{1-4}-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-,

97
96

pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl, more preferably from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, methoxy, ethoxy, CF_3, -(C=O)-CF_3, keto, cyano and an unsubstituted phenyl radical. If any one of the above mentioned substituents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy.

If one or more of the residues R^{1a}-R^{4a}, R^{10a}-R^{15a} and R^{18a} represents or comprises an aryl radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkoxy, branched or unbranched C_{1-4}-alkyl, branched or unbranched C_{1-4}-perfluoroalkoxy, unsubstituted or at least mono-substituted phenoxy, unsubstituted or at least mono-substituted benzoyl, cyclohexyl, branched or unbranched C_{1-4}-perfluoroalkyl, NR^AR^B wherein R^A, R^B are each independently selected from the group consisting of H, a branched or unbranched C_{1-4}-alkyl-radical, -CH_2-CH_2-OH and phenyl, carboxy, amido, cyano, -CH(OH)(phenyl), nitro, -SO_2NH_2, -CO-C_{1-4}-alkyl, -CO-OC_{1-4}-alkyl, -SO-C_{1-4}-alkyl, -SO_2-C_{1-4}-alkyl, -NH-SO_2-C_{1-4}-alkyl, wherein C_{1-4}-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, cyano, nitro, -CH(OH)(phenyl), methoxy, ethoxy, unsubstituted or at least mono-substituted benzoyl, unsubstituted or at least mono-substituted phenoxy, cyclohexyl, CF_3, OCF_3, -CO-CH_3, -CO-OCH_3, SO_2-CH_3, -NR^AR^B wherein R^A, R^B are each independently selected from the group consisting of H, a branched or unbranched C_{1-4}-alkyl-radical, -CH_2-CH_2-OH and phenyl, and an unsubstituted phenyl radical. If any of the above mentioned substituents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, Br, CF_3, OCF_3, methyl and methoxy.

If one or more of the residues R^{1a}-R^{4a} and R^{10a}-R^{15a} represents or comprises a heteroaryl radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkoxy, branched or

unbranched C_{1-4}-alkyl, branched or unbranched C_{1-4}-perfluoroalkoxy, unsubstituted or at least mono-substituted phenoxy, unsubstituted or at least mono-substituted benzoyl, cyclohexyl, branched or unbranched C_{1-4}-perfluoroalkyl, NR^AR^B wherein R^A, R^B are each independently selected from the group consisting of H, a branched or unbranched C_{1-4}-alkyl-radical, $-CH_2-CH_2-OH$ and phenyl, carboxy, amido, cyano, -CH(OH)(phenyl), nitro, $-SO_2NH_2$, $-CO-C_{1-4}$-alkyl, $-CO-OC_{1-4}$-alkyl, $-SO-C_{1-4}$-alkyl, $-SO_2-C_{1-4}$-alkyl, $-NH-SO_2-C_{1-4}$-alkyl, wherein C_{1-4}-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, cyano, nitro, -CH(OH)(phenyl), methoxy, ethoxy, unsubstituted or at least mono-substituted benzoyl, unsubstituted or at least mono-substituted phenoxy, cyclohexyl, CF_3, OCF_3,$-CO-CH_3$, $-CO-OCH_3$, SO_2-CH_3, $-NR^AR^B$ wherein R^A, R^B are each independently selected from the group consisting of H, a branched or unbranched C_{1-4}-alkyl-radical, $-CH_2-CH_2-OH$ and phenyl, and an unsubstituted phenyl radical. If any of the above mentioned substituents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, Br, CF_3, OCF_3, methyl and methoxy.

If R^{13a} and R^{14a} form a heterocyclic ring, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkoxy, branched or unbranched C_{1-4}-alkyl, branched or unbranched C_{1-4}-perfluoroalkoxy, branched or unbranched C_{1-4}-perfluoroalkyl, amino, carboxy, amido, cyano, nitro, $-SO_2NH_2$, $-CO-C_{1-4}$-alkyl, $-SO-C_{1-4}$-alkyl, $-SO_2-C_{1-4}$-alkyl, $-NH-SO_2-C_{1-4}$-alkyl, wherein C_{1-4}-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and an unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methoxy, ethoxy, methyl, CF_3 and an unsubstituted phenyl radical. If any of the above mentioned substituents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy.

If R^{13a} and R^{14a} form a heterocyclic ring, which contains one or more further heteroatoms as ring members, unless defined otherwise, each of these heteroatoms may preferably be selected from the group consisting of N, O and S, more preferably from the group consisting of N and O.

If one or more of the residues R^{1a}-R^{15a} and W^a represents or comprises a cycloaliphatic radical, which contains one or more heteroatoms as ring members, unless defined otherwise, each of these heteroatoms may preferably be selected from the group consisting of N, O, S and P, more preferably from the group consisting of N, O and S.

If one or more of the residues R^{1a}-R^{4a}, R^{10a}-R^{15a} and W^a represents or comprises an heteroaryl radical, which contains one or more heteroatoms as ring members, unless defined otherwise, each of these heteroatoms may preferably be selected from the group consisting of N, O, S and P, more preferably from the group consisting of N, O and S.

If W^a represents or comprises a cycloaliphatic radical, a heteroaryl radical, an aryl radical and/or a mono- or polycyclic ring system, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, nitro, carboxy, cyano, keto, halogen, C_{1-20}-alkyl, partially fluorinated C_{1-4} alkyl, partially chlorinated C_{1-4} alkyl, partially brominated C_{1-4} alkyl, C_{1-8}-alkoxy, partially fluorinated C_{1-4} alkoxy, partially chlorinated C_{1-4} alkoxy, partially brominated C_{1-4} alkoxy, C_{2-8}-alkenyl, SO_2-C_{1-4}-alkyl, -(C=O)-C_{1-8}-alkyl, -(C=O)-O-C_{1-8}-alkyl, -(C=O)-Cl, -S-C_{1-4}-alkyl-, -(C=O)-H, -NH-(C=O)-NH-C_{1-8}-alkyl, -(C=O)-C_{1-4}-perfluoroalkyl, $-NR^AR^B$, wherein R^A and R^B are independently selected from the group consisting of H, C_{1-4}-alkyl and phenyl, NH-(C=O)-C_{1-8}-alkyl, -C_{1-8}-alkylen-(C=O)-C_{1-8}-alkyl, (1,3-Dihydro-1-oxo-2H-isoindol-2-yl), N-Phthalimidinyl-, (1,3-Dioxo-2-azaspiro[4,4]-non-2-yl, substituted or unsubstituted phenyl, -SO_2-phenyl, phenoxy, pyridinyl, pyridinyloxy, pyrazolyl, pyrimidinyl, pyrrolidinyl-, -SO_2-pyrrolidinyl, morpholinyl, SO_2-morpholinyl-, thiadiazolyl, oxadiazolyl, oxazolyl, thiazolyl, isoxazolyl, O-CH_2-thiazolyl,-, NH-phenyl, and -C_{1-4}-Alkylen-NH-(C=O)-phenyl, more preferably from the group consisting of hydroxy,

100
99

nitro, carboxy, cyano, keto, F, Cl, Br, I, C_{1-12}-alkyl, CH_2F, CHF_2, CF_3, CH_2Cl, CH_2Cl_2, CCl_3, CH_2Br, $CHBr_2$, CBr_3, OCF_3, $OCHF_2$, OCH_2F, $O-CH_2-CF_3$, vinyl, SO_2-CH_3, -(C=O)-CH_3, -(C=O)-C_2H_5, -(C=O)-O-CH_3, -(C=O)-O-C_2CH_5, -(C=O)-Cl, -S-CH_3-, -(C=O)-H, -NH-(C=O)-NH-CH_3, -(C=O)-CF_3, dimethylamino, diethylamino, di-n-propylamino, di-iso-propylamino, di-n-butylamino, di-tert-butyamino, NH-(C=O)-CH_3, -CH_2-(C=O)-CH_3, -CH_2-(C=O)-C_2H_5, (1,3-Dihydro-1-oxo-2H-isoindol-2-yl), N-Phthalimidinyl-, (1,3-Dioxo-2-azaspiro[4,4]-non-2-yl, substituted or unsubstituted phenyl, -SO_2-phenyl, phenoxy, pyridinyl, pyridinyloxy, pyrazolyl, pyrimidinyl, pyrrolidinyl-, -SO_2-pyrrolidinyl, morpholinyl, SO_2-morpholinyl-, thiadiazolyl, oxadiazolyl, oxazolyl, thiazolyl, isoxazolyl, O-CH_2-thiazolyl,-, NH-phenyl, and –CH_2-NH-(C=O)-phenyl.

If any of the afore mentioned substituents itself is substituted by one or more substituents, said substituents may preferably be selected from the group consisting of halogen, nitro, cyano, hydroxy, -(C=O)-C_{1-4}-alkyl, C_{1-4}-alkyl, at least partially fluorinated C_{1-4}-alkyl, at least partially chlorinated C_{1-4}-alkyl, at least partially brominated C_{1-4}-alkyl, -S-C_{1-4}-alkyl, -C(=O)-O-C_{1-4}-alkyl, -(C=O)-CH_2-F, -(C=O)-CH_2-Cl, -(C=O)-CH_2-Br, preferably from the group consisting of F, Cl, Br, CH_2F, CHF_2, CF_3, CH_2Cl, $CHCl_2$, CCl_3, CH_2Br, $CHBr_2$, CBr_3, nitro, cyano, hydroxy, -(C=O)-CH_3, CH_3, C_2H_5, -S-CH_3, -C(=O)-O-CH_3, -C(=O)-O-C_2H_5, -(C=O)-CH_2-F, -(C=O)-CH_2-Cl and -(C=O)-CH_2-Br.

Preferred is the use of compounds of general formula (Ia), wherein R^{1a}, R^{2a}, R^{3a}, R^{4a} are each independently selected from the group consisting of H, F, Cl, Br, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro

group, a cyano group, -OR^{10a}, -$OC(=O)R^{11a}$, -SR^{12a}, -SOR^{12a}, -SO_2R^{12a}, -NH-SO_2R^{12a}, -SO_2NH_2 and a -$NR^{13a}R^{14a}$ moiety,

preferably selected from the group consisting of H, F, Cl, Br, a saturated, branched or unbranched, optionally at least mono-substituted C_{1-3}-aliphatic radical, a saturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_5- or C_6- cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_1- or C_2-alkylene group, a nitro, cyano, -OR^{10a}, -$OC(=O)R^{11a}$, -SR^{12a} and -$NR^{13a}R^{14a}$ moiety,

more preferably selected from the group consisting of H, F, Cl, CH_3, CH_2CH_3, CF_3, CF_2CF_3, cyclopentyl, cyclohexyl, a nitro group, a cyano group and -OR^{10a},

and R^{6a}-R^{18a} and W^a have the meaning as defined above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred is the use of compounds of general formula (Ia), wherein R^{6a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical,

preferably represents H or a branched or unbranched C_{1-3}-alkyl radical,

more preferably H, -CH_3 or -CH_2CH_3,

and R^{1a}-R^{4a}, R^{6a}-R^{18a} and W^a have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

182
101

Preference is also given to the use of compounds of general formula (Ia), wherein R^{6a}, R^{7a}, R^{8a}, R^{9a} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, a cyano group and a -$COOR^{15a}$ moiety,

preferably selected from the group consisting of H, a branched or unbranched C_{1-3}-alkyl radical, a cyano group and a -$COOR^{15a}$ group,

more preferably from the group consisting of H, -CH_3, -CH_2CH_3 and a cyano moiety, and R^{1a}-R^{5a}, R^{10a}-R^{15a} and W^a have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred is the use of compounds of general formula (Ia), wherein W^a represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-20} aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8} cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}- alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, a $NR^{16a}R^{17a}$-moiety or a COR^{16a}-moiety,

preferably is selected from the group consisting of 1-Naphthyl-, 5-Dimethylamino-naph-1-yl, 2-Naphthyl-, 2-Acetamido-4-methyl-5-thiazolyl-, 2-Thienyl-, 8-Quinolinyl-,

Phenyl-, Pentafluorophenyl-, 2,4,5-Trichloro-phenyl-, 2,5-Dichloro-phenyl-, 2-Nitrophenyl-, 2,4-Dinitro-phenyl-, 3,5-Dichloro-2-hydroxy-phenyl-, 2,4,6-Triisopropyl-phenyl-, 2-Mesityl-, 3-Nitro-phenyl-, 4-Bromo-phenyl-, 4-Fluoro-phenyl-, 4-Chlorophenyl-, 4-Chloro-3-nitro-phenyl-, 4-Iodo-phenyl-, N-Acetyl-sulfanilyl-, 4-Nitro-phenyl-, 4-Methoxy-phenyl-, Benzoic-acid-4-yl-, 4-tert-Butyl-phenyl-, p-Tolyl-, Trifluoromethyl-, Trichloromethyl-, Isopropyl-, Methyl-,
Benzyl-, trans-styryl-, 2,2,2-Trifluoroethyl-, Ethyl-, Hexadecyl-, 2-Chloroethyl-, n-Propyl-, 3-Chloro-propyl-, n-Butyl-, Methyl-benzoate-2-yl-, 2-Nitro-4-(trifluoromethyl)-phenyl-, Pentamethyl-phenyl-, 2,3,5,6-Tetramethyl-phenyl-, 3-(Trifluoromethyl)-phenyl-, 3,5-Bis-(Trifluoromethyl)-phenyl-, Dichloromethyl-, Chloromethyl-, Dodecyl-, 1-Octyl-, 2,3,4-Trichloro-phenyl-, 2,5-Dimethoxy-phenyl-, o-Tolyl-, p-xylyl-2-yl-, Benzoic-acid-3-yl-, 4-Chloro-3-(trifluoromethyl)-phenyl-, 4-Chloro-5-nitro-benzoic acid-3-yl-, 6-(p-toluidino)-naphth-2-yl-, 4-Methoxy-2,3,6-trimethylphenyl-, 3,4-Dichlorophenyl-, 4,5-Dibromo-thiophene-2-yl-, 3-Chloro-4-fluoro-phenyl-, 4-Ethyl-phenyl-, 4-n-Propyl-phenyl-, 4-(1,1-Dimethylpropyl)-phenyl-, 4-Isopropyl-phenyl-, 4-Bromo-2,5-difluoro-phenyl-, 2-Fluoro-phenyl-, 3-Fluoro-phenyl-, 4-(Trifluoromethoxy)-phenyl-, 4-(Trifluoromethyl)-phenyl-, 2,4-Difluoro-phenyl-, 2,4-Dichloro-5-methyl-phenyl-, 4-Chloro-2,5-dimethyl-phenyl-, 5-Diethylamino-napth-2-yl-, Benzoyl chloride-3-yl-, 2-Chloro-phenyl-, 1-Octadecyl-, 4-Bromo-2,5-dichloro-thiophene-3-yl-, 2,5-Dichloro-thiophene-3-yl-, 5-Chloro-thiophene-2-yl-, 2-Methyl-5-nitro-phenyl-, 2-(Trifluoromethyl)-phenyl-, 3-Chloro-phenyl-, 3,5-Dichloro-phenyl-, 1-Decyl-, 3-Methyl-phenyl-, 2-Chloro-6-methyl-, 5-Bromo-2-methoxy-phenyl-, 3,4-Dimethoxy-phenyl-, 2-3-Dichloro-phenyl-, 2-Bromo-phenyl-, 3,5-Dichloro-4-(2-chloro-4-nitrophenoxy)-phenyl-, 2,3-Dichloro-thiophene-5-yl-, 3-Bromo-2-chloro-thiophene-5-yl-, 3-Bromo-5-chloro-thiophene-2-yl-, 2-(Benzoylaminomethyl)-thiophene-5-yl-, 4-(Phenyl-sulphonyl)-thiophene-2-yl-, 2-Phenyl-sulphonyl-thiophene-5-yl-, 3-Chloro-2-methyl-phenyl-, 2-[1-Methyl-5-(trifluoromethyl)pyrazol-3-yl]-thiophene-5-yl-, 5-Pyrid-2-yl-thiophene-2-yl-, 2-Chloro-5-(trifluoromethyl)-phenyl-, 2,6-Dichloro-phenyl-, 3-Bromo-phenyl-, 2-(Trifluoromethoxy)-phenyl-, 4-Cyano-phenyl-, 2-Cyano-phenyl-, 4-n-Butoxy-phenyl-, 4-Acetamido-3-chloro-phenyl, 2,5-Dibromo-3,6-difluoro-phenyl-, 5-Chloro-1,3-dimethylpyrazole-4-yl-, 3,5-Dimethylisoxazole-4-yl-, 2-(2,4-Dichlorophenoxy)-phenyl-, 4-(2-Chloro-6-nitro-phenoxy)-phenyl-, 4-(3-Chloro-2-cyano-phenoxy)-phenyl-, 2,4-Dichloro-phenyl-, 2,4-Dimethyl-1,3-thiazole-5-yl-, Methyl-methane-sulfonyl-, 2,5-Bis-(2,2,2-Trifluoroethoxy)-phenyl-, 2-Chloro-4-

(trifluoromethyl)-phenyl-, 2-Chloro-4-fluoro-phenyl-, 5-Fluoro-2-methyl-phenyl-, 5-Chloro-2-methoxy-phenyl-, 2,4,6-Trichloro-phenyl-, 2-Hydroxy-benzoic acid-5-yl-, 5-(Di-n-propylamino)-naphth-1-yl-, 6-Methoxy-m-tolyl-, 2,5-Difluoro-phenyl-, 2,4-Dimethoxy-phenyl-, 2,5-Dibromo-phenyl-, 3,4-Dibromo-phenyl-, 2,2,5,7,8-Pentamethyl-chroman-6-yl-, 2-Methoxy-benzoic-acid-5-yl-, 5-Chloro-4-nitro-thiophene-2-yl-, 2,1,3-Benzothiadiazole-4-yl-, 1-Methyl-imidazole-4-yl-, Benzofurazan-4-yl-, 2-(Methoxycarbonyl)-thiophene-3-yl-, 5-(Isoxazol-3-yl)-thiophene-2-yl-, 2,4,5-Trifluoro-phenyl-, Biphenyl-4-yl-, Vinyl-phenyl-4-yl-, 2-Nitro-benzyl-, 5-Dichloro-methyl-furan-2-yl-, 5-Bromo-thiophene-2-yl-, 5-(4-Chlorobenzamidomethyl)-thiophene-2-yl-, 2,6-Difluoro-phenyl-, 2,5-Dimethoxy-4-nitro-phenyl-, Dibenzo[b,d]-furan-2-yl-, 2,3,4-Trifluoro-phenyl-, 3-Nitro-p-tolyl-, 4-Methoxy-2-nitro-phenyl-, 3,4-Difluoro-phenyl-, 4-(Bromoethyl)-phenyl-, 3,5-Dichloro-4-hydroxy-phenyl-, 4-n-Amyl-phenyl-, 5-Chloro-3-methylbenzo[b]-thiophene-2-yl-, 3-Methoxy-4-(methoxycarbonyl)-thiophene-2-yl-, 4-n-Butyl-phenyl-, 2-Chloro-4-cyano-phenyl-, 5-[2-(Methylthio)-pyrimidin-4-yl-]-thiophene-2-yl-, 3,5-Dinitro-4-methoxy-phenyl-, 4-Bromo-2-(trifluoromethoxy)-phenyl-, 4-Chloro-2,1,3-Benzoxadiazole-7-yl-, 2-(1-Naphthyl)-ethyl-, 3-Cyano-phenyl-, 5-Chloro-2,1,3-Benzoxadiazole-4-yl-, 3-Chloro-4-methyl-phenyl-, 4-Bromo-2-ethyl-phenyl-, 2,4-Dichloro-6-methyl-phenyl-, 6-Chloro-Imidazo(2,1-B)-thiazole-5-yl-, 3-Methyl-benzo[b]-thiophene-2-yl-, 4-Methyl-sulphonyl-phenyl-, 2-Methyl-sulphonyl-phenyl-, 4-Bromo-2-methyl-phenyl-, 2,6-Dichloro-4-(trifluoromethyl)-phenyl-, 4-[[3-Chloro-5-(trifluoromethyl)-2-pyridinyl]oxy]-phenyl-, 5-Chloro-naphth-1-yl-, 5-Chloro-naphth-2-yl-, 9,10-Dibromoanthracene-2-yl-, Isoquinoline-5-yl-, 4-Methoxy-2,3,6-trimethyl-phenyl-, 4'-Nitro-biphenyl-4-yl-, [(4-Phenoxy)-phenyl-, (1,3-Dihydro-1-oxo-2H-isoindol-2-yl-)-4-phenyl-, 4-Acetyl-phenyl-, 5-(2-Methyl-1,3-thiazole-4-yl)-thiophene-2-yl-, 5-(1-Methyl-3-(trifluoromethyl)pyrazol-5-yl-]-thiophene-2-yl-, 5-[5-Trifluoromethyl)-Isoxazol-3-yl]-thiophene-2-yl-, 2-Iodo-phenyl-, p-Dodecyl-phenyl-, 4-[(3-Cyano-4-methoxy-2-pyridinyl)oxy]-phenyl-, 4-(N-phthalimidinyl)-phenyl-, 1,2,3,4-Tetrahydro-2-(trifluoroacetyl)-Isoquinoline-7-yl-, 4-Bromo-2-fluoro-phenyl-, 2-Fluoro-5-(trifluoromethyl)-phenyl-, 4-Fluoro-2-(trifluoromethyl)-phenyl-, 4-Fluoro-3-(trifluoromethyl)-phenyl-, 2,4,6-Trifluoro-phenyl-, 3-(Trifluoromethoxy)-phenyl-, 1,2-Dimethylimidazole-4-yl-, Ethyl-4-Carboxylate-3-yl-, 2,2,4,6,7-Pentamethyldihydrobenzofuran-5-yl-, 3-Bromo-2-chloropyridine-5-yl-, 3-Methoxy-phenyl-, 2-Methoxy-4-methyl-phenyl-, 2-Chloro-4-fluorobenzoic-acid-5-yl-,

104
105

4-Chloro-naphth-1-yl-, 2,5-Dichloro-4-nitro-thiophene-3-yl-, 4-(4-Methoxy-phenoxy)-phenyl-, 4-(4-Chloro-phenoxy)-phenyl-, 4-(3,5-Dichloro-phenoxy)-phenyl-, 4-(3,4-Dichloro-phenoxy)-phenyl-, 4-(4-Fluoro-phenoxy)-phenyl-, 4-(4-Methyl-phenoxy)-phenyl-, 4-[4-(Trifluormethyl)-phenoxy-phenyl-, 4-[3,5-Bis-(trifluoromethyl)-phenoxy]-phenyl-, 3-(2-Methoxy-phenoxy)-phenyl-, [3-(2-Chloro-phenoxy)-phenyl-, 3-(2-Methyl-phenoxy)-phenyl-, 4-[2-(Trifluoromethyl)-phenoxy]-phenyl-, 3-Phenyl-phenyl-, 3-(4-Methoxy-phenyl)-phenyl-, 3-(4-Chloro-phenyl)-phenyl-, 3-(3,5-Dichloro-phenyl)-phenyl-, 3-(3,4-Dichloro-phenyl)-phenyl-, 3-(4-Fluorophenyl)-phenyl-, 3-(4-Methylphenyl)-phenyl-, 3-[4-(Trifluoromethyl)-phenyl]-phenyl-, 3-[3,5-Bis-(Trifluoromethyl)-phenyl]-phenyl-, 4-(4-Pyridyloxy)-phenyl)-, 4-(2-Methoxy-phenoxy)-phenyl-, 4-(2-Chloro-phenoxy)-phenyl-, 4-(2-Methyl-phenoxy)-phenyl-, 4-(4-Methoxy-phenoxy)-phenyl-, 4-(4-Chlorophenyl)-phenyl-, 4-(3,5-Dichlorophenyl)-phenyl-, 4-(3,4-Dichlorophenyl)-phenyl-, 4-(4-Fluorophenyl)-phenyl-, 4-(4-Methylphenyl)-phenyl-, 4-[4-(Trifluormethyl)-phenyl]-phenyl-, 4-[3,5-Bis-(Trifluoromethyl)-phenyl]-phenyl-, [3-(Trifluoromethyl)-phenyl]-methyl-, (4-Chlorophenyl)-methyl-, (3,5-Dichlorophenyl)-methyl-, (3,5-Dichlorophenyl)-methyl-, (4-Fluorophenyl)-methyl-, 4-Methylphenylmethyl-, [4-(Trifluoromethyl)-phenyl]-methyl-, Cyclopropyl-, 2-(2-Chlorophenyl)-2-Phenylethyl-, 2-(2-Trifluoromethylphenyl)-2-phenylethyl-, 5-[4-Cyano-1-methyl-5-(methylthio)-1H-pyrazol-3-yl-thiophene-2-yl-, 3-Cyano-2,4-bis-(2,2,2-Trifluorothoxy)-phenyl-, 4-[(2-Chloro-1,3-Thiazol-5-yl)-methoxy]-phenyl-, 3-Nitro-phenylmethyl-, 4-Formylphenyl-, 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethyl-, [3,5-Bis-(Trifluoromethyl)-phenyl]-methyl-, (4-(2-Pyridyloxy)-phenyl)-, (4-(3-Pyridyloxy)-phenyl)-, 5-Iodo-naphth-1-yl-, Ethyl-2,5-dimethyl-1-phenylpyrrole-4-carboxylate-3-yl-, Ethyl-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxylate-4-yl-, Ethyl-5-(4-chlorophenyl)-2-methyl-3-furoate-4-yl, Ethyl-5-(4-chlorophenyl)-2-methyl-1-phenyl-3-carboxylate-4-yl-, Ethyl-2,5-dimethyl-3-furoate-4-yl-, 3-Chloro-4-(1,3-dioxo-2-Azaspiro[4,4]non-2-yl)-phenyl-, 5-Bromo-2,4-difluoro-phenyl-, 5-Chloro-2,4-difluorophenyl-, Coumarin-6-yl, 2-Methoxy-phenyl, (3-Phenoxy)-phenyl-, 3-(4-Methoxy-phenoxy)-phenyl-, 3-(4-Chlorophenoxy)-phenyl-, 3-(3,5-Dichlorophenoxy)-phenyl-, 3-(3,4-Dichlorophenoxy)-phenyl-, 3-(4-Fluorophenoxy)-phenyl-, 3-(4-Methylphenoxy)-phenyl-, 3-[4-(Trifluoromethyl)-phenoxy]-phenyl-, 3-[3,5-(Trifluoromethyl)-phenoxy]-phenyl-, 3-[2-(Trifluoromethyl)-phenoxy]-phenyl-, 2,2-Diphenylethyl-, 4-Phenyl-5-(trifluoromethyl)-thiophene-3-yl-, Methyl-4-Phenyl-5-(Trifluoromethyl)-thiophene-2-carboxylate-3-yl-, Methyl-1,2,5-trimethylpyrrole-3-

Carboxylate-4-yl-, 4-Fluoro-naphth-1-yl-, 3,5-Difluorophenyl-, 3-Fluoro-4-methoxy-phenyl-, 4-Chloro-2,5-difluorophenyl-, 2-Chloro-4,5-difluoro-phenyl-, 5-Fluoro-3-methylbenzo[b]-thiophene-2-yl-, Methyl-3-phenylpropionate-4-yl, Dihydrocinnamic Acid-4-yl-, Methyl-2,5-dimethyl-3-furoate-4-yl-, Methyl-2-furoate-5-yl-, Methyl-2-methyl-3-furoate-5-yl-, Methyl-1-methyl-1H-pyrrole-2-Carboxylate-5-yl-, 2-(5-Chloro-1,2,4-Thiadiazol-3-yl)-thiophene-5-yl-, 1,3,5-Trimethyl-1H-pyrazole-4-yl-, 3-Chloro-5-fluoro-2-methylphenyl-, Pentafluoroethoxytetrafluoroethyl-, 5-(5-Isoxazyl)-thiophene-2-yl-, 5-(5-Isoxazol-yl)-2-furyl-, 5-Methyl-2,1,3-benzothiadiazole-4-yl-, Biphenyl-2-yl-, 2,3-Dihydro-1,4-benzodioxine-6-yl-, 4-Methyl-Naphth-1-yl-, 5-Methyl-2-(Trifluormethyl)-3-Furyl-, 2,3-Dihydrobenzo[b]furan-5-yl-, 1-Benzothiophene-3-yl-, 4-Methyl-3,4-dihydro-2H-1,4-Benzoxazine-7-yl-, 5-Methyl-1-phenyl-1H-pyrazole-4-yl-, 6-Morpholino-3-Pyridinyl-, 4-(1H-Pyrazol-1-yl)-phenyl-, 6-Phenoxy-3-Pyridyl-, 3,4-Dihydro-2H-1,5-benzodioxepine-7-yl-, 5-(1,3-Oxazol-5-yl)-2-thienyl-, 4-(1,3-Oxazol-5-yl)-phenyl-, 5-Methyl-4-Isoxazolyl, 2,1,3-Benzothiadiazole-5-yl-, 3-Thienyl-, 2-Methyl-benzyl-, 3-Chloro-benzyl-, 5-Acetamido-naphth-1-yl-, 3-Methyl-8-Quinolinyl-, 4-Chloro-2-nitrophenyl-, 6-Quinolinyl-, 1,3-Benzothiazole-6-yl-, 2-Morpholino-3-Pyridyl-, 2,5-Dimethyl-3-thienyl-, 5-[5-(Chloromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl-, Ethyl-3-[5-yl-2-thienyl-]1,2,4-oxadiazole-5-carboxylate-, 3-(5-Methyl-1,3,4-oxadiazol-2-yl)-phenyl-, 4-Isopropoxyphenyl-, 2,4-Dibromophenyl-, 3-Cyano-4-fluorophenyl-, 2,5-Bis-(Trifluoromethyl)-phenyl, 2-Bromo-4-fluorophenyl-, 4-Bromo-3-fluorophenyl-, 4-(Difluoromethoxy)-phenyl-, 3-(Difluoromethoxy)-phenyl-, 5-Chloro-2-fluoro-phenyl-, 3-Chloro-2-fluorophenyl-, 2-Fluoro-4-methylphenyl-, 4 Nitro-3-(trifluoromethyl)-phenyl-, 3-Fluoro-4-methylphenyl-, 4-Fluoro-2-methylphenyl-, 4-Bromo-3-(trifluoromethyl)-phenyl-, 4-Bromo-2-(trifluoromethyl)-phenyl-, 3-Bromo-5-(trifluoromethyl)-phenyl-, 2-Bromo-4-(trifluoromethyl)-phenyl-, 2-Bromo-5-(trifluoromethyl)-phenyl-, 2,4-Dichloro-5-fluorophenyl-, 4,5-Dichloro-2-fluorophenyl-, 3,4,5-Trifluorophenyl-, 4-Chloro-2-fluorophenyl-, 2-Bromo-4,6-Difluorophenyl-, 2-Ethylphenyl-, 4-Bromo-2-chlorophenyl-, 4-Bromo-2,6-dichlorophenyl-, 2-Bromo-4,6-dichloro-phenyl-, 4-Bromo-2,6-dimethylphenyl-, 3,5-Dimethylphenyl-, 4-Bromo-3-methylphenyl-, 2-Methoxy-4-nitrophenyl-, 2,2-Dimethyl-6-Chromanyl-, Ethyl-3,5-dimethyl-1H-pyrrole-2-carboxylate-4-yl-, Imidazo[1,2-A]pyridine-3-yl-, 3-(1,3-Oxazol-5-yl)-phenyl-, Ethyl-5-[4-yl)-phenyl]-2-methyl-3-furoate, Methyl-3-(yl)-4-methoxybenzoate, 1-Pyrrolidinylphenylsulfonyl-, Methyl-5-yl-4-methyl-2-thiophene-

carboxylate, Methyl-3-yl-4-(isopropylsulfonyl)-2-thiophene, 2-Pyridyl-, 3-Fluoro-4-nitrophenyl-, 7-Chlorochromone-3-yl-, 4'-Bromobiphenyl-4-yl-, 4'-Acetyl-biphenyl-4-yl-, 4'-Bromo-2'-fluoro-biphenyl-4-yl-, 2-Chloro-4-(3-propyl-Uraido)-phenyl-, 3-(-Bromoacetyl)-phenyl-, 2-Bromo-3-(trifluoromethyl)-phenyl-, 1-Methyl-5-isatinyl-, 4-Isopropyl-benzoic-acid-3-yl-, 2-Chloro-3-thiophenecarboxylic-acid-5-yl-, 3-Pyridyl-, Cyclohexylmethyl-, 2-Methoxy-5-(N-phthalimidinyl)-phenyl-, 1-Benzothiophene-2-yl-, Morpholinophenylsulfonyl-, 3-(2-Methyl-4-pyrimidinyl)-phenyl-, and 2-Cyano-5-methylphenyl-, and R^{1a}-R^{15a} have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Furthermore, the use of compounds of general formula (Ia) is preferred, wherein R^{10a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

preferably H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical,

more preferably H, $-CH_3$, $-C_2H_5$ or phenyl,

and R^{1a}-R^{9a}, R^{12a}-R^{15a} and W^a have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or

diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Moreover, the use of compounds of general formula (Ia) is preferred, wherein R^{11a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

preferably H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl,

and R^{1a}-R^{10a}, R^{12a}-R^{16a} and W^a have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Preference is also given to the use of compounds of general formula (Ia), wherein R^{12a} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

preferably represents H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical,

more preferably H, $-CH_3$, $-C_2H_5$ or phenyl,

and R^{1a}-R^{11a}, R^{13a}-R^{18a} and W^a have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred is the use of compounds of general formula (Ia), wherein R^{13a} and R^{14a} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

preferably are each independently selected from the group consisting of H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical and a phenyl radical,

more preferably are each independently selected from the group consisting of H, $-CH_3$, $-C_2H_5$ and phenyl,

and R^{1a}-R^{12a}, R^{15a}-R^{18a} and W^a have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or

diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Furthermore, the use of compounds of general formula (Ia) is preferred, wherein R^{13a} and R^{14a} together with the bridging nitrogen atom form a saturated, unsaturated or aromatic, 5- or 6-membered heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member,

preferably form an unsubstituted piperidin or morpholine group,

and R^{1a}-R^{12a}, R^{15a}-R^{16a} and W^a have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred are compounds of general formula (Ia), wherein R^{15a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

preferably represents H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical,

more preferably represents H, $-CH_3$, $-C_2H_5$ or phenyl,

and R^{1a}-R^{14a}, R^{16a} - R^{16a} and W^a have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates

or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred is the use of compounds of general formula (Ia), wherein R^{16a} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8} aliphatic radical,

preferably an unbranched or branched, saturated, unsubstituted C_{1-3} alkyl radical,

more preferably a methyl radical,

and R^{1a}-R^{15a}, R^{17a}, R^{18a} and W^a have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred is the use of compounds of general formula (Ia), wherein R^{17a} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8} aliphatic radical,

preferably an unbranched or branched, saturated, unsubstituted C_{1-3} alkyl radical,

more preferably a methyl radical,

and R^{1a}-R^{16a}, R^{18a} and W^a have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred are compounds of general formula (Ia), wherein R^{18a} represents a phenyl radical, which is optionally at least mono-substituted by a C_{1-8} aliphatic

radical, more preferably a phenyl radical, which is optionally at least mono-substituted by a methyl group and R^{1a}-R^{17a} and W^a have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Particularly preferred is the use of one or more benzoxazinone-derived sulfonamide compound of general formula (Ia) selected from the list A given above.

More particularly preferred is the use of one or more benzoxazinone-derived sulfonamide compound of general formula (Ia) selected from the group consisting of

1-[1-(Naphthyl-1-sulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

1-(1-Phenylsulfonyl-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]-oxazin-2-one,

1-[1-(5-Chloro-3-methyl-benzo[b]thiophenyl-2-sulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

8-Methyl-1-[1-naphthyl-1-sulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

1-[1-(Quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

8-Methyl-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

1-[1-(5-Dimethylamino-naphthyl-1-sulfonyl)-piperidine-4-yl]-8-methyl-1,4-dihydrobenzo[d][1,3]oxazin-2-one,

1-[1-(5-Dimethylamino-naphthyl-1-sulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,


1-[1-(2,3-Dichloro-phenylsulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

1-[1-(2,3-Dichloro-phenylsulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, and

corresponding salts thereof, or corresponding solvates thereof.

The compounds of general formula (Ia), their stereoisomers, corresponding salts and corresponding solvates may be obtained analogously by the methods described above for compounds of general formula (I).

In another aspect the present invention relates to benzoxazinone-derived sulfonamide compounds of general formula (Ib),



(Ib)

wherein

R^{1b}, R^{2b}, R^{3b}, R^{4b} are each independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least-one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano group, -OR^{10b}, -$OC(=O)R^{11b}$, -$(C=O)$-OR^{11b}, -SR^{12b}, -SOR^{12b}, -SO_2R^{12b}, -NH-SO_2R^{12b}, -SO_2NH_2 and a -$NR^{13b}R^{14b}$ moiety,

R^{5b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical,

R^{6b}, R^{7b}, R^{8b}, R^{9b} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano group and a -$COOR^{15b}$ moiety,

W^b represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, a $NR^{16b}R^{17b}$-moiety or a COR^{18b}-moiety,

R^{10b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{11b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{12b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{13b} and R^{14b} each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least

HG 15

mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

or R^{13b} and R^{14b} together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member,

R^{15b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{16b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

R^{17b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

R^{18b} represents an optionally at least mono-substituted aryl radical,

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively.

AP 116

If one or more of the residues R^{1b}-R^{17b} and W^b represents an aliphatic radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkoxy, branched or unbranched C_{1-4}-perfluoroalkoxy, branched or unbranched C_{1-4}-perfluoroalkyl, amino, carboxy, amido, cyano, nitro, $-SO_2NH_2$, $-CO-C_{1-4}$-alkyl, $-SO-C_{1-4}$-alkyl, $-SO_2-C_{1-4}$-alkyl, $-NH-SO_2-C_{1-4}$-alkyl , wherein the C_{1-4}-alkyl may in each case be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and an unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methoxy, ethoxy, CF_3 and an unsubstituted phenyl radical. If any one of the above mentioned substituents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy.

If one or more of the residues R^{1b}-R^{15b} represents or comprises a cycloaliphatic radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkyl, branched or unbranched C_{1-4}-alkoxy, branched or unbranched C_{1-4}-perfluoroalkoxy, phenoxy, benzoyl, cyclohexyl, branched or unbranched C_{1-4}-perfluoroalkyl, $-NR^AR^B$ wherein R^A, R^B are each independently selected from the group consisting of H, a branched or unbranched C_{1-4}-alkyl-radical, $-CH_2-CH_2-OH$ and phenyl, carboxy, keto, amido, cyano, nitro, $-SO_2NH_2$, $-CO-C_{1-4}$-alkyl, $-CO-OC_{1-4}$-alkyl, $-SO-C_{1-4}$-alkyl, $-SO_2-C_{1-4}$-alkyl, $-NH-SO_2-C_{1-4}$-alkyl, wherein C_{1-4}-alkyl may in each case be branched or unbranched, unsubstituted or at least mono-substituted phenyl or naphthyl and unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, methoxy, ethoxy, keto, benzoyl, phenoxy, cyclohexyl, $-CF_3$, $-CO-CH_3$, $-CO-OCH_3$, $-NR^AR^B$ wherein R^A, R^B are each independently selected from the group consisting of H, a branched or unbranched C_{1-4}-alkyl-radical, $-CH_2-CH_2-OH$ and phenyl, and an unsubstituted phenyl radical. If any one of the above mentioned substituents itself is at least mono-

substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy.

If one or more of the residues R^{1b}-R^{4b} and R^{10b}-R^{15b} and W^b comprises an alkylene group, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkoxy, branched or unbranched C_{1-4}-alkyl, branched or unbranched C_{1-4}-perfluoroalkoxy, branched or unbranched C_{1-4}-perfluoroalkyl, amino, carboxy, amido, cyano, nitro, $-SO_2NH_2$, $-CO-C_{1-4}$-alkyl, $-SO-C_{1-4}$-alkyl, $-SO_2-C_{1-4}$-alkyl, $-NH-SO_2-C_{1-4}$-alkyl, wherein C_{1-4}-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and an unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methyl, methoxy, ethoxy, CF_3 and unsubstituted phenyl. If any one of the above mentioned substituents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy.

If one or more of the residues R^{1b}-R^{4b} and R^{10b}-R^{15b} comprises a mono- or polycyclic ringsystem, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkyl, branched or unbranched C_{1-4}-alkoxy, branched or unbranched C_{1-4}-perfluoroalkoxy, branched or unbranched C_{1-4}-perfluorocarbonyl, branched or unbranched C_{1-4}-perfluoroalkyl, amino, carboxy, amido, cyano, keto, nitro, $-SO_2NH_2$, $-CO-C_{1-4}$-alkyl, $-SO-C_{1-4}$-alkyl, $-SO_2-C_{1-4}$-alkyl, $-NH-SO_2-C_{1-4}$-alkyl, wherein C_{1-4}-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl, more preferably from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, methoxy, ethoxy, CF_3, $-(C=O)-CF_3$, keto, cyano and an unsubstituted phenyl radical. If any one of the above mentioned substituents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy.

If one or more of the residues R^{1b}-R^{9b}, R^{10b}-R^{18b} and R^{18b} represents or comprises an aryl radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkoxy, branched or unbranched C_{1-4}-alkyl, branched or unbranched C_{1-4}-perfluoroalkoxy, unsubstituted or at least mono-substituted phenoxy, unsubstituted or at least mono-substituted benzoyl, cyclohexyl, branched or unbranched C_{1-4}-perfluoroalkyl, NR^AR^B wherein R^A, R^B are each independently selected from the group consisting of H, a branched or unbranched C_{1-4}-alkyl-radical, $-CH_2-CH_2-OH$ and phenyl, carboxy, amido, cyano, -CH(OH)(phenyl), nitro, $-SO_2NH_2$, $-CO-C_{1-4}$-alkyl, $-CO-OC_{1-4}$-alkyl, $-SO-C_{1-4}$-alkyl, $-SO_2-C_{1-4}$-alkyl, $-NH-SO_2-C_{1-4}$-alkyl, wherein C_{1-4}-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, cyano, nitro, -CH(OH)(phenyl), methoxy, ethoxy, unsubstituted or at least mono-substituted benzoyl, unsubstituted or at least mono-substituted phenoxy, cyclohexyl, CF_3, OCF_3, $-CO-CH_3$, $-CO-OCH_3$, SO_2-CH_3, $-NR^AR^B$ wherein R^A, R^B are each independently selected from the group consisting of H, a branched or unbranched C_{1-4}-alkyl-radical, $-CH_2-CH_2-OH$ and phenyl, and an unsubstituted phenyl radical. If any of the above mentioned substituents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, Br, CF_3, OCF_3, methyl and methoxy.

If one or more of the residues R^{1b}-R^{9b} and R^{10b}-R^{18b} represents or comprises a heteroaryl radical, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkoxy, branched or unbranched C_{1-4}-alkyl, branched or unbranched C_{1-4}-perfluoroalkoxy, unsubstituted or at least mono-substituted phenoxy, unsubstituted or at least mono-substituted benzoyl, cyclohexyl, branched or unbranched C_{1-4}-perfluoroalkyl, NR^AR^B wherein R^A, R^B are each independently selected from the group consisting of H, a branched or unbranched C_{1-4}-alkyl-radical, $-CH_2-CH_2-OH$ and phenyl, carboxy, amido, cyano,

-CH(OH)(phenyl), nitro, $-SO_2NH_2$, $-CO-C_{1-4}$-alkyl, $-CO-OC_{1-4}$-alkyl, $-SO-C_{1-4}$-alkyl, $-SO_2-C_{1-4}$-alkyl, $-NH-SO_2-C_{1-4}$-alkyl, wherein C_{1-4}-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, cyano, nitro, -CH(OH)(phenyl), methoxy, ethoxy, unsubstituted or at least mono-substituted benzoyl, unsubstituted or at least mono-substituted phenoxy, cyclohexyl, CF_3, OCF_3, $-CO-CH_3$, $-CO-OCH_3$, SO_2-CH_3, $-NR^AR^B$ wherein R^A, R^B are each independently selected from the group consisting of H, a branched or unbranched C_{1-4}-alkyl-radical, $-CH_2-CH_2-OH$ and phenyl, and an unsubstituted phenyl radical. If any of the above mentioned substituents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, Br, CF_3, OCF_3, methyl and methoxy.

If R^{13b} and R^{14b} form a heterocyclic ring, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkoxy, branched or unbranched C_{1-4}-alkyl, branched or unbranched C_{1-4}-perfluoroalkoxy, branched or unbranched C_{1-4}-perfluoroalkyl, amino, carboxy, amido, cyano, nitro, $-SO_2NH_2$, $-CO-C_{1-4}$-alkyl, $-SO-C_{1-4}$-alkyl, $-SO_2-C_{1-4}$-alkyl, $-NH-SO_2-C_{1-4}$-alkyl, wherein C_{1-4}-alkyl may be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and an unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methoxy, ethoxy, methyl, CF_3 and an unsubstituted phenyl radical. If any of the above mentioned substituents itself is at least mono-substituted, said substituents may preferably be selected from the group consisting of F, Cl, methyl and methoxy.

If R^{13b} and R^{14b} form a heterocyclic ring, which contains one or more further heteroatoms as ring members, unless defined otherwise, each of these heteroatoms may preferably be selected from the group consisting of N, O and S, more preferably from the group consisting of N and O.

If one or more of the residues R^{1b}-R^{18b} and W^b represents or comprises a cycloaliphatic radical, which contains one or more heteroatoms as ring members, unless defined otherwise, each of these heteroatoms may preferably be selected from the group consisting of N, O, S and P, more preferably from the group consisting of N, O and S.

If one or more of the residues R^{1b}-R^{9b}, R^{10b}-R^{18b} and W^b represents or comprises an heteroaryl radical, which contains one or more heteroatoms as ring members, unless defined otherwise, each of these heteroatoms may preferably be selected from the group consisting of N, O, S and P, more preferably from the group consisting of N, O and S.

If W^b represents or comprises a cycloaliphatic radical, a heteroaryl radical, an aryl radical and/or a mono- or polycyclic ring system, which is substituted by one or more substituents, unless defined otherwise, each of these substituents may preferably be selected from the group consisting of hydroxy, nitro, carboxy, cyano, keto, halogen, C_{1-20}-alkyl, partially fluorinated C_{1-4} alkyl, partially chlorinated C_{1-4} alkyl, partially brominated C_{1-4} alkyl, C_{1-8}-alkoxy, partially fluorinated C_{1-4} alkoxy, partially chlorinated C_{1-4} alkoxy, partially brominated C_{1-4} alkoxy, C_{2-8}-alkenyl, SO_2-C_{1-4}-alkyl, -(C=O)-C_{1-8}-alkyl, -(C=O)-O-C_{1-8}-alkyl, -(C=O)-Cl, -S-C_{1-4}-alkyl-, -(C=O)-H, -NH-(C=O)-NH-C_{1-8}-alkyl, -(C=O)-C_{1-4}-perfluoroalkyl, -NR^AR^B, wherein R^A and R^B are independently selected from the group consisting of H, C_{1-4}-alkyl and phenyl, NH-(C=O)-C_{1-8}-alkyl, -C_{1-8}-alkylen-(C=O)-C_{1-8}-alkyl, (1,3-Dihydro-1-oxo-2H-isoindol-2-yl), N-Phthalimidinyl-, (1,3-Dioxo-2-azaspiro[4,4]-non-2-yl, substituted or unsubstituted phenyl, -SO_2-phenyl, phenoxy, pyridinyl, pyridinyloxy, pyrazolyl, pyrimidinyl, pyrrolidinyl-, -SO_2-pyrrolidinyl, morpholinyl, SO_2-morpholinyl-, thiadiazolyl, oxadiazolyl, oxazolyl, thiazolyl, isoxazolyl, O-CH_2-thiazolyl,-, NH-phenyl, and -C_{1-4}-Alkylen-NH-(C=O)-phenyl, more preferably from the group consisting of hydroxy, nitro, carboxy, cyano, keto, F, Cl, Br, I, C_{1-12}-alkyl, CH_2F, CHF_2, CF_3, CH_2Cl, CH_2Cl_2, CCl_3, CH_2Br, $CHBr_2$, CBr_3, OCF_3, $OCHF_2$, OCH_2F, O-CH_2-CF_3, vinyl, SO_2-CH_3, -(C=O)-CH_3, -(C=O)-C_2H_5, -(C=O)-O-CH_3, -(C=O)-O-C_2CH_5, -(C=O)-Cl, -S-CH_3-, -(C=O)-H, -NH-(C=O)-NH-CH_3, -(C=O)-CF_3, dimethylamino, diethylamino, di-n-propylamino, di-iso-propylamino, di-n-butylamino, di-tert-butyamino, NH-(C=O)-CH_3, -

122
121

CH_2-(C=O)-CH_3, -CH_2-(C=O)-C_2H_5, (1,3-Dihydro-1-oxo-2H-isoindol-2-yl), N-Phthalimidinyl-, (1,3-Dioxo-2-azaspiro[4,4]-non-2-yl, substituted or unsubstituted phenyl, -SO_2-phenyl, phenoxy, pyridinyl, pyridinyloxy, pyrazolyl, pyrimidinyl, pyrrolidinyl-, -SO_2-pyrrolidinyl, morpholinyl, SO_2-morpholinyl-, thiadiazolyl, oxadiazolyl, oxazolyl, thiazolyl, isoxazolyl, O-CH_2-thiazolyl,-, NH-phenyl, and –CH_2-NH-(C=O)-phenyl.

If any of the afore mentioned substituents itself is substituted by one or more substituents, said substituents may preferably be selected from the group consisting of halogen, nitro, cyano, hydroxy, -(C=O)-C_{1-4}-alkyl, C_{1-4}-alkyl, at least partially fluorinated C_{1-4}-alkyl, at least partially chlorinated C_{1-4}-alkyl, at least partially brominated C_{1-4}-alkyl, -S-C_{1-4}-alkyl, -C(=O)-O-C_{1-6}-alkyl, -(C=O)-CH_2-F, -(C=O)-CH_2-Cl, -(C=O)-CH_2-Br, preferably from the group consisting of F, Cl, Br, CH_2F, CHF_2, CF_3, CH_2Cl, $CHCl_2$, CCl_3, CH_2Br, $CHBr_2$, CBr_3, nitro, cyano, hydroxy, -(C=O)-CH_3, CH_3, C_2H_5, -S-CH_3, -C(=O)-O-CH_3, -C(=O)-O-C_2H_5, -(C=O)-CH_2-F, -(C=O)-CH_2-Cl and -(C=O)-CH_2-Br.

Preferred are compounds of general formula (Ib) given above, wherein R^{1b}, R^{2b}, R^{3b}, R^{4b} are each independently selected from the group consisting of H, F, Cl, Br, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-6}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-6}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-6}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano group, -OR^{10b}, -OC(=O)R^{11b}, -SR^{12b}, -SOR^{12b}, -SO_2R^{12b}, -NH-SO_2R^{12b}, -SO_2NH_2 and a -$NR^{13b}R^{14b}$ moiety, preferably selected from the group consisting of H, F, Cl, Br, a saturated, branched or unbranched, optionally at least mono-substituted C_{1-3}-aliphatic radical, a saturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_5- or C_6-cycloaliphatic radical, which may be bonded via an optionally at least mono-

123
122

substituted C_1- or C_2-alkylene group, a nitro group, a cyano group, $-OR^{10b}$, $-OC(=O)R^{11b}$, $-SR^{12b}$ and $-NR^{13b}R^{14b}$ moiety, more preferably selected from the group consisting of H, F, Cl, Br, $-CH_3$, $-CH_2CH_3$, $-CF_3$, $-CF_2CF_3$, cyclopentyl, cyclohexyl, nitro, cyano and $-OR^{10b}$, and R^{5b}-R^{15b} and W^b have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred are compounds of general formula (Ib) given above, wherein R^{4b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, preferably represents H or a branched or unbranched C_{1-3}-alkyl radical, more preferably H, $-CH_3$ or $-CH_2CH_3$, most preferably a hydrogen atom, and R^{1b}-R^{4b}, R^{6b}-R^{15b} and W^b have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred are compounds of general formula (Ib) given above, wherein R^{6b}, R^{7b}, R^{8b}, R^{9b} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, a cyano group and a $-COOR^{15b}$ moiety, preferably selected from the group consisting of H, a branched or unbranched C_{1-3}-alkyl radical, a cyano group and a $COOR^{15b}$ group, more preferably from the group consisting of H, $-CH_3$, $-CH_2CH_3$ and a cyano moiety, most preferably each of R^{6b}, R^{7b}, R^{8b} and R^{9b} represent a hydrogen atom, and R^{1b}-R^{5b}, R^{10b}-R^{15b} and W^b have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its

stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred are compounds of general formula (Ib) given above, wherein W^b represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-20} aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8} cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-6}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-6}- alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, a $NR^{16b}R^{17b}$-moiety or a COR^{18b}-moiety,

preferably W^b represents

a linear or branched C_{1-20}-alkyl radical, preferably an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl and 1,1-dimethyl-propyl; a linear or branched C_{2-20}-alkenyl radical; preferably a vinyl radical; $-CF_3$; $-CHF_2$; $-CH_2F$; $-CCl_3$; $-CHCl_2$; $-CH_2Cl$; $-CH_2-CF_3$; $-CH_2-CH_2-Cl$; $-CH_2-CH_2-CH_2-Cl$; $-CH_2-S(=O)_2-CH_3$; a cyclopropyl radical; a cyclobutyl radical; a cyclopentyl radical; a cyclohexyl radical; $-CH_2$-cyclopropyl; $-CH_2$-cyclobutyl; $-CH_2$-cyclopentyl; $-CH_2$-cyclohexyl; $-N(CH_3)_2$; $-N(C_2H_5)_2$; $-N(n-CH_2-CH_2-CH_3)_2$; phenyl; benzyl; naphthyl; -CH=CH-phenyl; $-(CF_2)-(CF_2)$-O-phenyl; $-(CH_2)$-naphtyl; $-(CH_2)-(CH_2)$-naphthyl; anthracanyl; -(C=O)-phenyl; thiophenyl; benzo[b]thiophenyl; furanyl; 2-oxo-2H-chromenyl; dibenzofuranyl; 2,3-dihydrobenzofuranyl; chromenyl; 2,3-dihydro-benzo[1,4]dioxinyl; 3,4-dihydro-2H-1,5-benzo-dioxepinyl; chromonyl; 1H-Imidazolyl; pyridinyl; pyrrolidine-2,5-dionyl; pyrrolyl; 1H-pyrazolyl; 1H-pyrimidine-2,4-dionyl; quinolinyl; isoquinolinyl; 1H-Benzoimidazolyl; 1,4-dihydro-quinoxaline-2,3-dionyl; 1,2,3,4-tetrahydro-isoquinolinyl; 1,4-dihydro-benzo[b][1,4]diazepine-2,4-dionyl;

125
124

1,3-dihydro-1-oxo-2H-isoindolyl; phthalimidinyl; 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethyl; imidazo[1,2-a]pyridine; isatinyl; thiazolyl; 1,3-thiazolyl; 1,2,4-thiadiazolyl; imidazo[2,1-b]thiazolyl; 1,3-benzothiazolyl; benzo[1,2,5]thiadiazolyl; 2-oxo-2,3-dihydro-benzothiazolyl; 2,1,3-benzothiadiazolyl; imidazo[2,1-b]thiazolyl; isoxazolyl; benzo[1,2,5]oxadiazolyl; benzo[d]isoxazolyl; benzofurazanyl; 2-oxo-2,3-dihydro-benzooxazolyl; 3,4-dihydro-2H-benzo[1,4]oxazinyl; or 2,1,3-benzoxadiazolyl;

whereby each of these afore mentioned cyclic moieties may optionally be substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of methyl; ethyl; n-propyl; iso-propyl; n-butyl; iso-butyl; sec-butyl; tert-butyl; 1,1-dimethyl-propyl; n-pentyl; vinyl; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; morpholino; methoxy; ethoxy; n-propoxy; iso-propoxy; n-propoxy; F; Cl; Br; I; -CN; -OH; $-CF_3$; $-CF_2H$; $-CH_2F$; $-CCl_3$; $-CClH_2$; $-CHCl_2$; $-CH_2-F$; $-CH_2-Cl$; $-CH_2-Br$; $-(C=O)-CH_2-Br$; $-OCF_3$; $-O-CH_2-CF_3$; $-O-CHF_2$; $-NO_2$; $-NH_2$; $-N(CH_3)_2$; $-N(C_2H_5)_2$; $-N(n-CH_2-CH_2-CH_3)_2$; $-N(n-CH_2-CH_2-CH_2-CH_3)_2$; $-NH-(C=O)-CH_3$; -NH-phenyl; $-(C=O)-CF_3$; $-(C=O)-OH$; =O (oxo); $-(C=O)-H$; $-S(=O)_2-CH_3$; $-S(=O)_2$-isopropyl; $-S(=O)_2$-phenyl; $-S(=O)_2$-pyrrolidinyl; $-S(=O)_2$-morpholino; $-(CH_2)-(CH_2)-(C=O)-O-CH_3$; $-NH-(C=O)-NH-CH_2-CH_2-CH_3$; $-(C=O)-CH_3$; $-(C=O)-O-CH_3$; $-(C=O)-O-C_2H_5$; $-(CH_2)-NH-(C=O)-$phenyl; $-CH_2-C(H)(phenyl)(phenyl)$; $-O-CH_2$-thiazolyl; 1,3-dioxo-2-azaspiro[4.4]non-2-yl; phenyl; phenoxy; isoxazolyl; 1,3-oxazolyl; 1,2,4-oxadiazolyl; 1,3,4-oxadiazolyl; pyridinyl; pyridinyloxy; pyrazolyl; pyrimidinyl and phthalimidinyl; and

whereby each of the cyclic moieties of these afore mentioned substituents may optionally be substituted with 1, 2, 3, 4 or 5 substituents that are independently selected from the group consisting of methyl; ethyl; n-propyl; iso-propyl; F; Cl; Br; I; CN; $-CH_2-F$; $-CH_2-Cl$; $-CH_2-Br$; $-CF_3$ and $-S-CH_3$.


more preferably W^b represents

an alkyl radical selected from the group consisting of methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec.butyl; iso-butyl and tert-butyl; vinyl ($CH_2=CH-$); $-N(CH_3)_2$; 1-naphthyl; benzyl; 2-naphtyl; phenyl; 2-methyl-phenyl; 3-methyl-phenyl; 4-methyl-phenyl; 2-ethyl-phenyl; 3-ethyl-phenyl; 4-ethyl-phenyl; 2-n-propyl-phenyl; 3-n-propyl-


126
125

phenyl; 4-n-propyl-phenyl; 2-isopropyl-phenyl; 3-isopropyl-phenyl; 4-isopropyl-phenyl; 2-n-butyl-phenyl; 3-n-butyl-phenyl; 4-n-butyl-phenyl; 2-iso-butyl-phenyl; 3-iso-butyl-phenyl; 4-iso-butyl-phenyl; 2-tert-butyl-phenyl; 3-tert-butyl-phenyl; 4-tert-butyl-phenyl; 1,1-dimethylpropyl-phenyl; 2-cyclopentyl-phenyl; 3-cyclopentyl-phenyl; 4-cyclopentyl-phenyl 2-cyclohexyl-phenyl; 3-cyclohexyl-phenyl; 4-cyclohexyl-phenyl; 2-methoxy-phenyl; 3-methoxy-phenyl; 4-methoxy-phenyl; 2-ethoxy-phenyl; 3-ethoxy-phenyl; 4-ethoxy-phenyl; 2-n-propoxy-phenyl; 3-n-propoxy-phenyl; 4-n-propoxy-phenyl; 2-iso-propoxy-phenyl; 3-iso-propoxy-phenyl; 4-isopropoxy-phenyl;2-fluoro-phenyl; 3-fluoro-phenyl; 4-fluoro-phenyl; 2-chloro-phenyl; 3-chloro-phenyl; 4-chloro-phenyl; 2-bromo-phenyl; 3-bromo-phenyl; 4-bromo-phenyl; 2-trifluoromethyl-phenyl; 3-trifluoromethyl-phenyl; 4-trifluoromethyl-phenyl; 2-trifluoromethoxy-phenyl; 3-trifluoromethoxy-phenyl; 4-trifluoromethoxy-phenyl; 2-carboxy-phenyl; 3-carboxy-phenyl; 4-carboxy-phenyl; 2-acetyl-phenyl; 3-acetyl-phenyl; 4-acetyl-phenyl; 2-(C=O)-O-CH_3-phenyl; 3-(C=O)-O-CH_3-phenyl; 4-(C=O)-O-CH_3-phenyl; 2-(CH_2)-(CH_2)-(C=O)-O-CH_3; 3-(CH_2)-(CH_2)-(C=O)-O-CH_3; 4-(CH_2)-(CH_2)-(C=O)-O-CH_3; 2-cyano-phenyl; 3-cyano-phenyl; 4-cyano-phenyl; 2-nitro-phenyl; 3-nitro-phenyl; 4-nitro-phenyl; 4-(4-bromophenoxy)-phenyl; 2-methylsulfonyl-phenyl; 3-methylsulfonyl-phenyl; 4-methylsulfonyl-phenyl; 2-phenyl-phenyl (biphenyl-2-yl); 3-phenyl-phenyl (biphenyl-3-yl); 4-phenyl-phenyl (biphenyl-4-yl); 2-phenoxy-phenyl; 3-phenoxy-phenyl; 4-phenoxy-phenyl; 2,4-dimethyl-phenyl; 3,4-dimethyl-phenyl; 2,4,6-trimethyl-phenyl; 2,3,5,6-tetramethyl-phenyl; pentamethyl-phenyl; 2,5-dimethoxy-phenyl; 3,4-dimethoxy-phenyl; 2,3-dichloro-phenyl; 2,4-dichloro-phenyl; 2,5-dichloro-phenyl; 3,4-dichloro-phenyl; 3,5-dichloro-phenyl; 2,6-dichloro-phenyl; 2,4-difluoro-phenyl; 3,4-difluoro-phenyl; 2,5-difluoro-phenyl; 2,6-difluoro-phenyl; 3-chloro-2-fluoro-phenyl; 3-chloro-4-fluoro-phenyl; 5-chloro-2-fluoro-phenyl; 2,3,4-trichloro-phenyl; 2,4,5-trichloro-phenyl; 2,4,6-trichloro-phenyl; 2,4,5-trifluoro-phenyl; 2,3,4-trifluoro-phenyl-; 2-chloro-4,5-difluoro-phenyl; 2-bromo-4-fluoro-phenyl; 2-bromo-4,6-difluoro-phenyl; 4-chloro-2,5-difluoro-phenyl; 5-chloro-2,4-difluoro-phenyl; 4-bromo-2,5-difluoro-phenyl; 5-bromo-2,4-difluoro-phenyl; pentafluoro-phenyl; 2,4-dinitro-phenyl; 4-chloro-3-nitro-phenyl; 2-methyl-5-nitro-phenyl; 5-bromo-2-methoxy-phenyl; 3-chloro-2-methyl-phenyl; 4-bromo-3-methyl-phenyl; 4-chloro-2,5-dimethyl-phenyl; 4-fluoro-3-methyl-phenyl; 5-fluoro-2-methyl-phenyl; 2-nitro-4-trifluoromethyl-phenyl; 2-methoxy-4-methyl-phenyl; 3,5-dichloro-2-hydroxy-phenyl; 3,5-dichloro-4-hydroxy-phenyl; 5-chloro-2,4-difluoro-phenyl; 3-chloro-4-(NH)-(C=O)-CH_3-phenyl; 2-chloro-6-methyl-phenyl; 2-chloro-5-


trifluoromethyl-phenyl; 2-chloro-5-trifluoromethoxy-phenyl; 4-bromo-2-trifluoromethoxy-phenyl; 4-bromo-2-trifluoromethyl-phenyl; 4-bromo-3-trifluoromethyl-phenyl; 3-carboxy-4-fluoro-phenyl; 3-carboxy-4-chloro-6-fluoro-phenyl; 4-methoxy-2,3,6-trimethyl-phenyl-; or one of the following groups:





128
127


X
(CH2)1-2X
X
X
F
X
Cl
X
N
X
Cl
X
NH-C(=O)-CH3
X
O
N
O
X
HO
HO
X
H3C-(O=C)-O
H3C-(O=C)-O
X
(CH2)1-2-X
X
X
Cl

129
128




X
O
N
H
Cl
(CH2)—X



whereby in each case X denotes the position by which the respective substituent W^b is bonded to the $-SO_2$ group of formula (Ib),

and R^{1b}-R^{18b} have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred are compounds of general formula (Ib) given above, wherein R^{10b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl, and R^{1b}-R^{9b}, R^{11b}-R^{15b} and W^b have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred are compounds of general formula (Ib) given above, wherein R^{11b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl, and R^{1b}-R^{10b}, R^{12b}-R^{15b} and W^b have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

133
132

Also preferred are compounds of general formula (Ib) given above, wherein R^{12b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched C_{1-6}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl, and R^{1b}-R^{11b}, R^{13b}-R^{18b} and W^b have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred are compounds of general formula (Ib) given above, wherein R^{13b} and R^{14b} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably are each independently selected from the group consisting of H, a linear or branched C_{1-6}-alkyl radical, cyclohexyl and a phenyl radical, more preferably are each independently selected from the group consisting of H, $-CH_3$, $-C_2H_5$ and phenyl, and R^{1b}-R^{12b}, R^{16b}-R^{18b} and W^b have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates

134
133

or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred are compounds of general formula (Ib) given above, wherein R^{13b} and R^{14b} together with the bridging nitrogen atom form a saturated, unsaturated or aromatic, 5- or 6-membered heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member, preferably form an unsubstituted piperidin or morpholine group, and R^{1b}-R^{12b}, R^{15b}-R^{18b} and W^b have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred are compounds of general formula (Ib) given above, wherein R^{15b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably represents H, $-CH_3$, $-C_2H_5$ or phenyl, and R^{1b}-R^{14b}, R^{16b}-R^{18b} and W^b have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

135
134

Also preferred are compounds of general formula (Ib) given above, wherein R^{16b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8} aliphatic radical, preferably an unbranched or branched, saturated, unsubstituted C_{1-3} alkyl radical, more preferably a methyl radical, and R^{1b}-R^{15b}, R^{17b} and R^{18b} and W^b have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred are compounds of general formula (Ib) given above, wherein R^{17b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8} aliphatic radical, preferably an unbranched or branched, saturated, unsubstituted C_{1-3} alkyl radical, more preferably a methyl radical, and R^{1b}-R^{16b}, R^{18b} and W^b have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

Also preferred are compounds of general formula (Ib) given above, wherein R^{18b} represents a phenyl radical, which is optionally at least mono-substituted by a C_{1-8} aliphatic radical, more preferably a phenyl radical, which is optionally at least mono-substituted by a methyl group, and R^{1b}-R^{17b} and W^b have the meaning given above, optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemates or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or corresponding salts thereof, or corresponding solvates.

More preferred are compounds of general formula (Ib) given above, wherein

R^{1b}, R^{2b}, R^{3b}, R^{4b} are each independently selected from the group consisting of a hydrogen atom; a fluorine atom; a chlorine atom; a bromine atom; a methyl group and a methoxy group;

R^{5b} represents a hydrogen atom;


R^{6b}, R^{7b}, R^{8b}, R^{9b} each represent a hydrogen atom;

W^b represents


an alkyl radical selected from the group consisting of methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec.butyl; iso-butyl and tert-butyl; vinyl (CH_2=CH-); -$N(CH_3)_2$; 1-naphthyl; benzyl; 2-naphtyl; phenyl; 2-methyl-phenyl; 3-methyl-phenyl; 4-methyl-phenyl; 2-ethyl-phenyl; 3-ethyl-phenyl; 4-ethyl-phenyl; 2-n-propyl-phenyl; 3-n-propyl-phenyl; 4-n-propyl-phenyl; 2-isopropyl-phenyl; 3-isopropyl-phenyl; 4-isopropyl-phenyl; 2-n-butyl-phenyl; 3-n-butyl-phenyl; 4-n-butyl-phenyl; 2-iso-butyl-phenyl; 3-iso-butyl-phenyl; 4-iso-butyl-phenyl; 2-tert-butyl-phenyl; 3-tert-butyl-phenyl; 4-tert-butyl-phenyl; 1,1-dimethylpropyl-phenyl; 2-cyclopentyl-phenyl; 3-cyclopentyl-phenyl; 4-cyclopentyl-phenyl 2-cyclohexyl-phenyl; 3-cyclohexyl-phenyl; 4-cyclohexyl-phenyl; 2-methoxy-phenyl; 3-methoxy-phenyl; 4-methoxy-phenyl; 2-ethoxy-phenyl; 3-ethoxy-phenyl; 4-ethoxy-phenyl; 2-n-propoxy-phenyl; 3-n-propoxy-phenyl; 4-n-propoxy-phenyl; 2-iso-propoxy-phenyl; 3-iso-propoxy-phenyl; 4-isopropoxy-phenyl;2-fluoro-phenyl; 3-fluoro-phenyl; 4-fluoro-phenyl; 2-chloro-phenyl; 3-chloro-phenyl; 4-chloro-phenyl; 2-bromo-phenyl; 3-bromo-phenyl; 4-bromo-phenyl; 2-trifluoromethyl-phenyl; 3-trifluoromethyl-phenyl; 4-trifluoromethyl-phenyl; 2-trifluoromethoxy-phenyl; 3-trifluoromethoxy-phenyl; 4-trifluoromethoxy-phenyl; 2-carboxy-phenyl; 3-carboxy-phenyl; 4-carboxy-phenyl; 2-acetyl-phenyl; 3-acetyl-phenyl; 4-acetyl-phenyl; 2-(C=O)-O-CH_3-phenyl; 3-(C=O)-O-CH_3-phenyl; 4-(C=O)-O-CH_3-phenyl; 2-(CH_2)-(CH_2)-(C=O)-O-CH_3; 3-(CH_2)-(CH_2)-(C=O)-O-CH_3; 4-(CH_2)-(CH_2)-(C=O)-O-CH_3; 2-cyano-phenyl; 3-cyano-phenyl; 4-cyano-phenyl; 2-nitro-phenyl; 3-nitro-phenyl; 4-nitro-phenyl; 4-(4-bromophenoxy)-phenyl; 2-methylsulfonyl-phenyl; 3-methylsulfonyl-phenyl; 4-methylsulfonyl-phenyl; 2-phenyl-phenyl (biphenyl-2-yl); 3-phenyl-phenyl (biphenyl-3-yl); 4-phenyl-phenyl

137
136


(biphenyl-4-yl); 2-phenoxy-phenyl; 3-phenoxy-phenyl; 4-phenoxy-phenyl; 2,4-dimethyl-phenyl; 3,4-dimethyl-phenyl; 2,4,6-trimethyl-phenyl; 2,3,5,6-tetramethyl-phenyl; pentamethyl-phenyl; 2,5-dimethoxy-phenyl; 3,4-dimethoxy-phenyl; 2,3-dichloro-phenyl; 2,4-dichloro-phenyl; 2,5-dichloro-phenyl; 3,4-dichloro-phenyl; 3,5-dichloro-phenyl; 2,6-dichloro-phenyl; 2,4-difluoro-phenyl; 3,4-difluoro-phenyl; 2,5-difluoro-phenyl; 2,6-difluoro-phenyl; 3-chloro-2-fluoro-phenyl; 3-chloro-4-fluoro-phenyl; 5-chloro-2-fluoro-phenyl; 2,3,4-trichloro-phenyl; 2,4,5-trichloro-phenyl; 2,4,6-trichloro-phenyl; 2,4,5-trifluoro-phenyl; 2,3,4-trifluoro-phenyl-; 2-chloro-4,5-difluoro-phenyl; 2-bromo-4-fluoro-phenyl; 2-bromo-4,6-difluoro-phenyl; 4-chloro-2,5-difluoro-phenyl; 5-chloro-2,4-difluoro-phenyl; 4-bromo-2,5-difluoro-phenyl; 5-bromo-2,4-difluoro-phenyl; pentafluoro-phenyl; 2,4-dinitro-phenyl; 4-chloro-3-nitro-phenyl; 2-methyl-5-nitro-phenyl; 5-bromo-2-methoxy-phenyl; 3-chloro-2-methyl-phenyl; 4-bromo-3-methyl-phenyl; 4-chloro-2,5-dimethyl-phenyl; 4-fluoro-3-methyl-phenyl; 5-fluoro-2-methyl-phenyl; 2-nitro-4-trifluoromethyl-phenyl; 2-methoxy-4-methyl-phenyl; 3,5-dichloro-2-hydroxy-phenyl; 3,5-dichloro-4-hydroxy-phenyl; 5-chloro-2,4-difluoro-phenyl; 3-chloro-4-(NH)-(C=O)-CH_3-phenyl; 2-chloro-6-methyl-phenyl; 2-chloro-5-trifluoromethyl-phenyl; 2-chloro-5-trifluoromethoxy-phenyl; 4-bromo-2-trifluoromethoxy-phenyl; 4-bromo-2-trifluoromethyl-phenyl; 4-bromo-3-trifluoromethyl-phenyl; 3-carboxy-4-fluoro-phenyl; 3-carboxy-4-chloro-6-fluoro-phenyl; 4-methoxy-2,3,6-trimethyl-phenyl-; or one of the following groups:



X
HN
N
NH-(C=O)-CH3
O
S


139
138


X
(CH2)1-2X
X
X
F
X
Cl
X
N
X
Cl
X
NH-C(=O)-CH3
X
O
N
O
X
HO
HO
X
H3C-(O=C)-O
H3C-(O=C)-O
X
(CH2)1-2-X
X
X
Cl

140
139







whereby in each case X denotes the position by which the respective substituent W^b is bonded to the $-SO_2$ group of formula (Ib).

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively.

1-43
142

Most particularly preferred are compounds of general formula (Ib) selected from the following group given in list B:

List B:

N°	Compound
1	1-[1-(Naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
2	1-[1-(Toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
3	1-(1-Phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
4	1-(1-Benzenesulfonyl-piperidin-4-yl)-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
5	6-Chloro-1-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
6	6-Chloro-1-(1-phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
7	6-Chloro-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
8	6-Chloro-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
9	6-Chloro-1-[1-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
10	1-[1-(Thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
11	1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
12	2-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
13	1-[1-(2,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
14	1-[1-(4-Methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
15	1-[1-(2-Naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
16	8-Methyl-1-[1-(thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
17	1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
18	2-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
19	1-[1-(2,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
20	1-[1-(4-Methoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
21	8-Methyl-1-[1-(2-naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
22	4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonic acid dimethylamide
23	2-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid methyl ester
24	1-[1-(3-Trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
25	2-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid methyl ester
26	8-Methyl-1-[1-(3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
27	1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
28	2-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
29	6-Chloro-1-[1-(4-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
30	2-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid methyl ester
31	6-Chloro-1-[1-(2,4-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
32	6-Chloro-1-[1-(3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
33	1-[1-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
34	1-[1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
35	1-[1-(4-Fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one

144
143

36	8-Methyl-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
37	8-Methyl-1-(1-phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
38	1-[1-(4-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
39	6-Chloro-1-[1-(4-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
40	1-[1-(Butane-1-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
41	1-[1-(4-Bromo-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
42	1-[1-(4-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
43	1-[1-(Butane-1-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
44	6-Chloro-1-[1-(2-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
45	6-Chloro-1-[1-(3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
46	1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
47	8-Methyl-1-[1-(2-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
48	8-Methyl-1-[1-(3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
49	1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
50	8-Methyl-1-[1-(4-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
51	6-Chloro-1-[1-(4-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
52	1-(1-Ethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
53	1-[1-(Propane-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
54	1-[1-(Propane-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
55	6-Chloro-1-(1-ethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
56	6-Chloro-1-[1-(propane-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
57	6-Chloro-1-[1-(propane-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
58	6-Chloro-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
59	1-[1-(4-Nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
60	8-Methyl-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
61	8-Methyl-1-[1-(2-naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
62	8-Methyl-1-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
63	1-[1-(4-Fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
64	8-Methyl-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
65	8-Methyl-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
66	1-[1-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
67	8-Methyl-1-[1-(4-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
68	1-(1-Benzenesulfonyl-piperidin-4-yl)-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
69	1-[1-(4-Chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
70	1-[1-(5-Dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
71	1-[1-(4-Chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
72	1-[1-(4-Chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
73	6-Chloro-1-[1-(4-chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
74	6-Chloro-1-[1-(5-dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one

75	1-[1-(4-Methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
76	1-[1-(4-Methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
77	6-Chloro-1-[1-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
78	1-[1-(4-Methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
79	1-[1-(2-Bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
80	1-[1-(2-Bromo-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
81	1-[1-(2-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
82	1-[1-(2-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
83	6-Chloro-1-[1-(2,3-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
84	1-[1-(2,3-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
85	1-[1-(2,4,6-Trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
86	8-Methyl-1-[1-(2,4,6-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
87	6-Chloro-1-[1-(2,4,6-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
88	6-Methyl-1-[1-(2,4,6-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
89	1-[1-(5-Bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
90	1-[1-(5-Bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
91	1-[1-(5-Bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
92	1-[1-(5-Bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
93	1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
94	1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
95	6-Chloro-1-[1-(2,5-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
96	1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
97	1-(1-Pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
98	8-Methyl-1-(1-pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
99	6-Chloro-1-(1-pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
100	6-Methyl-1-(1-pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
101	1-[1-[2-(2,2,2-Trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
102	8-Methyl-1-(1-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
103	6-Chloro-1-(1-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
104	6-Methyl-1-(1-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
105	1-[1-(2-Methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
106	8-Methyl-1-[1-(2-methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one

146
145

107	6-Chloro-1-[1-(2-methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
108	6-Methyl-1-[1-(2-methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
109	1-[1-(4-Bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
110	1-[1-(4-Bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
111	1-[1-(4-Bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
112	1-[1-(4-Bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
113	1-[1-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
114	1-[1-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
115	6-Chloro-1-[1-(4-chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
116	1-[1-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
117	1-[1-(4-Methoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
118	1-[1-(4-Isopropyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
119	1-[1-(4-Isopropyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
120	6-Chloro-1-[1-(4-isopropyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
121	1-[1-(4-Isopropyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
122	1-[1-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
123	1-[1-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
124	6-Chloro-1-[1-(3-chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
125	1-[1-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
126	1-[1-(4-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
127	6-Methyl-1-[1-(3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
128	6-Methyl-1-[1-(3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
129	1-[1-(4-Trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
130	1-[1-(2-Nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
131	1-[1-(3-Fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
132	1-[1-(2,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
133	1-[1-(2,4,6-Trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
134	1-[1-(2-Trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
135	6-Methyl-1-[1-(4-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
136	6-Methyl-1-[1-(2-nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
137	1-[1-(3-Fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
138	1-[1-(2,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one

139	8-Methyl-1-[1-(2,4,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
140	8-Methyl-1-[1-(2-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
141	1-[1-(4-Fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
142	1-[1-(4-Bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
143	1-[1-(3-Nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
144	1-[1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
145	1-[1-(3-Methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
146	1-[1-(2-Nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
147	8-Methyl-1-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
148	1-(1-Benzenesulfonyl-piperidin-4-yl)-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
149	1-[1-(3-Methoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
150	1-[1-(2,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
151	1-[1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
152	8-Methyl-1-[1-(thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
153	1-[1-(Toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
154	1-[1-(5-Fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
155	1-[1-(4-Isopropoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
156	1-[1-(3-Chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
157	1-[1-(3,4-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
158	1-(1-Pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
159	8-Methyl-1-[1-(toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
160	1-[1-(5-Fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydrobenzo[d][1,3]oxazin-2-one
161	1-[1-(4-Isopropoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
162	1-[1-(3-Chloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
163	1-[1-(3,4-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
164	8-Methyl-1-(1-pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
165	8-Methyl-1-[1-(toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
166	1-[1-(5-Fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
167	1-[1-(4-Isopropoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
168	1-[1-(3-Chloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
169	1-[1-(3,4-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
170	8-Methyl-1-(1-pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
171	8-Methyl-1-[1-(4-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
172	8-Methyl-1-[1-(2-nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
173	1-[1-(3-Fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
174	1-[1-(2,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
175	8-Methyl-1-[1-(2,4,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
176	8-Methyl-1-[1-(2-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-

	benzo[d][1,3]oxazin-2-one
177	1-[1-(3-Methoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
178	6-Methyl-1-[1-(2-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
179	1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
180	1-[1-(4-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
181	6-Methyl-1-(1-phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
182	2-[4-(6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]benzoic acid methyl ester
183	6-Methyl-1-[1-(2-oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
184	6-Chloro-1-[1-(4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
185	6-Chloro-1-[1-(3,5-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
186	1-[1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
187	6-Chloro-1-[1-(thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
188	6-Chloro-1-[1-(3-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
189	6-Chloro-1-[1-(2-oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
190	6-Chloro-1-[1-(toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
191	6-Chloro-1-[1-(5-fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
192	6-Chloro-1-[1-(4-isopropoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
193	6-Chloro-1-[1-(3-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
194	6-Chloro-1-[1-(3,4-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
195	6-Chloro-1-(1-pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
196	6-Chloro-1-[1-(4-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
197	6-Chloro-1-[1-(2-nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
198	6-Chloro-1-[1-(3-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
199	6-Chloro-1-[1-(2,4-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
200	6-Chloro-1-[1-(2,4,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
201	6-Chloro-1-[1-(2-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
202	1-[1-(2-Oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
203	1-[1-(3,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
204	1-[1-(2,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
205	1-[1-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
206	1-[1-(4-Chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
207	1-[1-(2,6-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
208	8-Methyl-1-[1-(2-oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
209	1-[1-(3,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
210	1-[1-(2,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-

	benzo[d][1,3]oxazin-2-one
211	1-[1-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
212	1-[1-(4-Chloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
213	1-[1-(2,6-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
214	1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
215	6-Chloro-1-[1-(2,5-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
216	1-[1-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
217	6-Chloro-1-[1-(4-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
218	6-Chloro-1-[1-(2,6-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
219	1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
220	2-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
221	1-[1-(2,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
222	1-[1-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
223	1-[1-(4-Chloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
224	1-[1-(2,6-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
225	1-[1-(3,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
226	8-Methyl-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
227	1-[1-(5-Bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
228	1-[1-(4-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
229	1-[1-(1-Methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
230	1-[1-(5-Bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
231	1-[1-(6-Chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
232	1-[1-(4-Ethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
233	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
234	1-[1-(6-Chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
235	1-[1-(4-Ethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
236	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
237	6-Chloro-1-[1-(6-chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
238	6-Chloro-1-[1-(4-ethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
239	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
240	1-[1-(6-Chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
241	1-[1-(4-Ethyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
242	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one

243	1-[1-(7-Chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
244	1-[1-(2-Methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
245	3-{4-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl}-propionic acid methyl ester
246	1-[1-(2,4-Dinitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
247	1-[1-(7-Chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
248	1-[1-(2-Methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
249	3-{4-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl}-propionic acid methyl ester
250	1-[1-(2,4-Dinitro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
251	1-[1-(7-Chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
252	1-[1-(2-Methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
253	3-{4-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl}-propionic acid methyl ester
254	1-[1-(2,4-Dinitro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
255	6-Chloro-1-[1-(7-chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
256	6-Chloro-1-[1-(2-methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
257	3-{4-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl}-propionic acid methyl ester
258	6-Chloro-1-[1-(2,4-dinitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
259	6-Chloro-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
260	1-[1-(5-Bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
261	8-Methyl-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
262	1-[1-(5-Bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
263	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
264	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
265	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
266	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
267	1-[1-(2,5-Difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
268	1-[1-(2,5-Difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
269	6-Chloro-1-[1-(2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
270	1-[1-(2,5-Difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
271	1-[1-(4-Chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
272	1-[1-(4-Chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
273	6-Chloro-1-[1-(4-chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
274	1-[1-(4-Chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-

	benzo[d][1,3]oxazin-2-one
275	1-[1-(2,4,5-Trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
276	8-Methyl-1-[1-(2,4,5-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
277	6-Chloro-1-[1-(2,4,5-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
278	6-Methyl-1-[1-(2,4,5-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
279	1-[1-(3,5-Dichloro-2-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
280	1-[1-(2,6-Difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
281	1-[1-(2,6-Difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
282	6-Chloro-1-[1-(2,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
283	1-[1-(2,6-Difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
284	1-[1-(5-Chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
285	1-[1-(5-Chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
286	6-Chloro-1-[1-(5-chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
287	1-[1-(5-Chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
288	1-[1-(2-Chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
289	1-[1-(2-Chloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
290	6-Chloro-1-[1-(2-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
291	1-[1-(2-Chloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
292	6-Chloro-1-[1-(2-naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
293	6-Bromo-1-[1-(4-bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
294	6-Bromo-1-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
295	6-Bromo-1-[1-(2,4-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
296	6-Bromo-1-[1-(2-naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
297	6-Bromo-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
298	6-Bromo-1-[1-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
299	6-Bromo-1-[1-(3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
300	6-Bromo-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
301	6-Bromo-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
302	1-(1-Benzenesulfonyl-piperidin-4-yl)-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one
303	6-Bromo-1-{1-[4-(4-bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl}-1,4-dihydro-benzo[d][1,3]oxazin-2-one
304	6-Bromo-1-[1-(thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
305	6-Bromo-1-[1-(2-methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
306	6-Bromo-1-[1-(4-bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
307	6-Bromo-1-[1-(toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
308	6-Bromo-1-[1-(5-fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
309	6-Bromo-1-[1-(4-isopropoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-

	benzo[d][1,3]oxazin-2-one
310	6-Bromo-1-[1-(3-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
311	6-Bromo-1-[1-(3,4-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
312	6-Bromo-1-(1-pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
313	6-Bromo-1-[1-(4-chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
314	6-Bromo-1-[1-(3-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
315	6-Bromo-1-[1-(4-isopropyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
316	6-Bromo-1-[1-(4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
317	6-Bromo-1-[1-(3-chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
318	6-Bromo-1-(1-pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
319	6-Bromo-1-[1-(2-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
320	6-Bromo-1-[1-(4-chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
321	6-Bromo-1-[1-(5-dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
322	6-Bromo-1-[1-(4-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
323	1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one
324	6-Bromo-1-[1-(4-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
325	1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one
326	6-Bromo-1-(1-phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
327	6-Bromo-1-[1-(2,5-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
328	6-Bromo-1-{1-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl}-1,4-dihydro-benzo[d][1,3]oxazin-2-one
329	6-Bromo-1-[1-(2,3-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
330	6-Bromo-1-[1-(2,4,6-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
331	6-Bromo-1-[1-(5-bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
332	6-Bromo-1-[1-(4-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
333	6-Bromo-1-[1-(2-nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
334	6-Bromo-1-[1-(3-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
335	6-Bromo-1-[1-(2,4-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
336	6-Bromo-1-[1-(2,4,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
337	6-Bromo-1-[1-(2-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
338	6-Bromo-1-[1-(2-bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
339	6-Bromo-1-[1-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
340	1-[1-(3,5-Dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-

	benzo[d][1,3]oxazin-2-one
341	1-[1-(3,5-Dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
342	6-Chloro-1-[1-(3,5-dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
343	1-[1-(3,5-Dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
344	6-Bromo-1-[1-(3,5-dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
345	6-Chloro-1-[1-(3,5-dichloro-2-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
346	6-Bromo-1-[1-(3,5-dichloro-2-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
347	2-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
348	6-Bromo-1-[1-(4-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
349	2-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid methyl ester
350	6-Bromo-1-[1-(3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
351	6-Bromo-1-[1-(2-oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
352	6-Bromo-1-[1-(3,5-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
353	6-Bromo-1-[1-(2,5-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
354	6-Bromo-1-[1-(5-bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
355	6-Bromo-1-[1-(4-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
356	6-Bromo-1-[1-(2,6-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
357	6-Bromo-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
358	6-Bromo-1-[1-(5-bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
359	6-Bromo-1-[1-(4-ethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
360	6-Bromo-1-[1-(6-chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
361	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one
362	6-Bromo-1-[1-(7-chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
363	6-Bromo-1-[1-(2-methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
364	3-[4-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl]-propionic acid methyl ester
365	6-Bromo-1-[1-(2,4-dinitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
366	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one
367	6-Bromo-1-[1-(2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
368	6-Bromo-1-[1-(4-chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
369	6-Bromo-1-[1-(2,4,5-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
370	6-Bromo-1-[1-(2,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one

371	6-Bromo-1-[1-(5-chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
372	6-Bromo-1-[1-(2-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
373	6-Bromo-1-[1-(2,3,4-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
374	N-[4-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-2-chloro-phenyl]-acetamide
375	1-[1-(2,3,4-Trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
376	8-Methyl-1-[1-(2,3,4-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
377	6-Chloro-1-[1-(2,3,4-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
378	6-Methyl-1-[1-(2,3,4-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
379	N-[2-Chloro-4-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl]-acetamide
380	1-[1-(3,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
381	1-[1-(3,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
382	6-Chloro-1-[1-(3,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
383	1-[1-(3,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
384	6-Bromo-1-[1-(3,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
385	N-[2-Chloro-4-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl]-acetamide
386	1-[1-(2-Chloro-4,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
387	1-[1-(2-Chloro-4,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
388	6-Chloro-1-[1-(2-chloro-4,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
389	1-[1-(2-Chloro-4,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
390	6-Bromo-1-[1-(2-chloro-4,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
391	N-[2-Chloro-4-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl]-acetamide
392	1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
393	1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
394	1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
395	1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
396	1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one
397	N-[2-Chloro-4-[4-(6-chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl]-acetamide
398	1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
399	1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
400	1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
401	1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one

402	1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one
403	1-(1-Ethanesulfonyl-piperidin-4-yl)-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
404	1-[1-(2,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
405	1-[1-(2,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
406	6-Chloro-1-[1-(2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
407	1-[1-(2,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
408	6-Bromo-1-[1-(2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
409	6-Methyl-1-[1-(propane-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
410	1-[1-(3,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
411	1-[1-(3,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
412	6-Chloro-1-[1-(3,4-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
413	1-[1-(3,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
414	6-Bromo-1-[1-(3,4-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
415	6-Methyl-1-[1-(propane-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
416	1-[1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
417	1-[1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
418	6-Chloro-1-[1-(2-chloro-6-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
419	1-[1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
420	1-[1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
421	6-Methyl-1-[1-(2,3,5,6-tetramethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
422	1-[1-(2,3,4-Trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
423	6-Methyl-1-[1-(2,3,4-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
424	6-Chloro-1-[1-(2,3,4-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
425	6-Methyl-1-[1-(2,3,4-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
426	6-Bromo-1-[1-(2,3,4-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
427	1-[1-(2,3,5,6-Tetramethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
428	1-[1-(Thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
429	6-Methyl-1-[1-(thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
430	6-Chloro-1-[1-(thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
431	6-Methyl-1-[1-(thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
432	6-Bromo-1-[1-(thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
433	6-Chloro-1-[1-(2,3,5,6-tetramethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
434	1-[1-(2,4,6-Trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
435	6-Methyl-1-[1-(2,4,6-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
436	6-Chloro-1-[1-(2,4,6-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
437	6-Methyl-1-[1-(2,4,6-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one

438	6-Bromo-1-[1-(2,4,6-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
439	6-Methyl-1-[1-(2,3,5,6-tetramethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
440	1-[1-(2-Bromo-4,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
441	1-[1-(2-Bromo-4,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
442	1-[1-(2-Bromo-4,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
443	6-Bromo-1-[1-(2-bromo-4,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
444	6-Bromo-1-[1-(2,3,5,6-tetramethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
445	1-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
446	1-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
447	1-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
448	1-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
449	6-Bromo-1-[1-(4-bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
450	1-[1-(4-Phenoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
451	1-[1-(3-Bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
452	1-[1-(3-Bromo-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
453	1-[1-(3-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
454	1-[1-(3-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
455	6-Bromo-1-[1-(3-bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
456	8-Methyl-1-[1-(4-phenoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
457	1-[1-(4-tert-Butyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
458	1-[1-(4-tert-Butyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
459	1-[1-(4-tert-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
460	1-[1-(4-tert-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
461	6-Bromo-1-[1-(4-tert-butyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
462	6-Chloro-1-[1-(4-phenoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
463	1-[1-(2-Bromo-4,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
464	1-[1-(2-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
465	6-Chloro-1-[1-(2-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
466	1-[1-(2-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
467	6-Bromo-1-[1-(2-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
468	8-Methyl-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
469	6-Chloro-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-

A57
156

	one
470	6-Methyl-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
471	6-Bromo-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
472	1-[1-(3-Chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
473	6-Chloro-1-[1-(3-chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
474	1-[1-(3-Chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
475	6-Bromo-1-[1-(3-chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
476	1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
477	1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
478	1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
479	6-Bromo-1-[1-(4-butyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
480	1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
481	1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
482	1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
483	6-Bromo-1-[1-(4-bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
484	1-[1-[4-(1,1-Dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
485	6-Chloro-1-[1-[4-(1,1-dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
486	1-[1-[4-(1,1-Dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl)-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
487	6-Bromo-1-[1-[4-(1,1-dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
488	1-(1-Ethanesulfonyl-piperidin-4-yl)-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
489	3-[4-(6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
490	3-[4-(6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
491	3-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
492	1-[1-(3-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
493	6-Chloro-1-[1-(3-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
494	1-[1-(3-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
495	6-Bromo-1-[1-(3-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
496	N-[4-Methyl-5-[4-(6-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiazol-2-yl]-acetamide
497	N-[5-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-methyl-thiazol-2-yl]-acetamide
498	N-[4-Methyl-5-[4-(6-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiazol-2-yl]-acetamide
499	N-[5-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-methyl-thiazol-2-yl]-acetamide
500	1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
501	1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-

	benzo[d][1,3]oxazin-2-one
502	1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
503	6-Bromo-1-[1-(2-bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
504	1-[1-(5-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
505	6-Chloro-1-[1-(5-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
506	1-[1-(5-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
507	6-Bromo-1-[1-(5-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
508	1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
509	1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
510	1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
511	6-Bromo-1-[1-(4-bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
512	1-[1-(2-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
513	1-[1-(4-Propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
514	1-[1-(3-Chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
515	1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
516	1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
517	1-[1-[4-(1,1-Dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
518	N-[4-Methyl-5-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiazol-2-yl]-acetamide
519	1-[1-(3-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
520	1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
521	1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
522	1-[1-(5-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
523	1-[1-(Isoquinoline-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
524	6-Fluoro-1-[1-(2-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
525	6-Fluoro-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
526	1-[1-(3-Chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
527	1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
528	1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
529	1-[1-[4-(1,1-Dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
530	N-(5-[4-(6-Fluoro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-methyl-thiazol-2-yl)-acetamide
531	1-[1-(3-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
532	1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
533	1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-

	benzo[d][1,3]oxazin-2-one
534	1-[1-(5-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
535	6-Fluoro-1-[1-(isoquinoline-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
536	6-Fluoro-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
537	1-[1-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
538	6-Fluoro-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
539	6-Fluoro-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
540	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
541	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
542	8-Methoxy-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
543	1-[1-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
544	8-Methoxy-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
545	8-Methoxy-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
546	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
547	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
548	5-Chloro-1-[1-(2-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
549	5-Chloro-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
550	5-Chloro-1-[1-(3-chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
551	1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
552	1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
553	5-Chloro-1-[1-[4-(1,1-dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
554	N-[5-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-methyl-thiazol-2-yl]-acetamide
555	5-Chloro-1-[1-(3-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
556	1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
557	1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
558	5-Chloro-1-[1-(5-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
559	5-Chloro-1-[1-(isoquinoline-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
560	1-[1-(2-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
561	1-[1-(2-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
562	1-[1-(3-Chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
563	1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
564	1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
565	1-[1-[4-(1,1-Dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
566	N-[5-[4-(8-Methoxy-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-methyl-

160
159

	thiazol-2-yl)-acetamide
567	1-[1-(3-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
568	1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
569	1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
570	1-[1-(5-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
571	1-[1-(Isoquinoline-5-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one; hydrochloride
572	1-[1-(4-Methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
573	6-Chloro-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
574	6-Methyl-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
575	8-Methyl-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
576	6-Fluoro-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
577	8-Methoxy-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
578	5-Chloro-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
579	5-Chloro-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
580	5-Chloro-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
581	5-Chloro-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
582	5-Chloro-1-[1-(6-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
583	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
584	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
585	6-Bromo-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
586	2-Chloro-4-fluoro-5-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
587	2-Chloro-5-[4-(6-chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-fluoro-benzoic acid
588	2-Chloro-4-fluoro-5-[4-(6-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
589	2-Chloro-4-fluoro-5-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
590	2-Chloro-4-fluoro-5-[4-(8-methoxy-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
591	2-Chloro-5-[4-(6-chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-fluoro-benzoic acid
592	3-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
593	3-[4-(8-Methoxy-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
594	3-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
595	1-[1-(Isoquinoline-5-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; hydrochloride
596	6-Chloro-1-[1-(isoquinoline-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one; hydrochloride
597	-[1-(Isoquinoline-5-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one;hydrochloride
598	6,7-Difluoro-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
599	1-[1-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
600	6,7-Difluoro-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-

	one
601	6,7-Difluoro-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
602	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
603	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
604	1-[1-(5-Dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
605	1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
606	1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
607	1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
608	1-[1-(7-Chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
609	6,7-Difluoro-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
610	1-[1-(4-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
611	1-[1-(4-Fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
612	1-[1-(Dibenzofuran-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
613	1-[1-(2,3-Dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
614	1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
615	1-[1-(5-Isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
616	1-[1-(4-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
617	1-[1-(4-Fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
618	1-[1-(Dibenzofuran-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
619	1-[1-(2,3-Dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
620	1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
621	1-[1-(5-Isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
622	5-Chloro-1-[1-(4-chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
623	5-Chloro-1-[1-(4-fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
624	5-Chloro-1-[1-(dibenzofuran-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
625	5-Chloro-1-[1-(2,3-dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
626	1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
627	5-Chloro-1-[1-(5-isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
628	1-[1-(4-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
629	1-[1-(4-Fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
630	1-[1-(Dibenzofuran-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
631	1-[1-(2,3-Dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
632	1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
633	1-[1-(5-Isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
634	8-Chloro-1-[1-(4-chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-

	benzo[d][1,3]oxazin-2-one
635	6-Chloro-1-[1-(4-fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
636	6-Chloro-1-[1-(dibenzofuran-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
637	6-Chloro-1-[1-(2,3-dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
638	1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
639	6-Chloro-1-[1-(5-isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
640	1-[1-(4-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
641	1-[1-(4-Fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
642	1-[1-(Dibenzofuran-2-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
643	1-[1-(2,3-Dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
644	1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
645	1-[1-(5-Isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
646	1-[1-(4-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
647	6,7-Difluoro-1-[1-(4-fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
648	1-[1-(Dibenzofuran-2-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
649	1-[1-(2,3-Dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
650	1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
651	6,7-Difluoro-1-[1-(5-isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
652	1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
653	1-[1-(5-Methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
654	1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
655	1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
656	6-Methyl-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
657	1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
658	6-Chloro-1-[1-(1,2-dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
659	6-Chloro-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
660	6-Chloro-1-[1-(3,5-dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
661	1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
662	8-Methoxy-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
663	1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
664	5-Chloro-1-[1-(1,2-dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
665	5-Chloro-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one

666	5-Chloro-1-[1-(3,5-dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
667	1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
668	8-Methyl-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
669	1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
670	1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-8-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
671	8-Fluoro-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
672	1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-8-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
673	1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
674	6,7-Difluoro-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
675	1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
676	1-[1-(5-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
677	1-[1-(5-Chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
678	N-[5-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl]-acetamide
679	1-[1-(5-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
680	1-[1-(5-Chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
681	N-[5-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl]-acetamide
682	5-Chloro-1-[1-(5-chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
683	5-Chloro-1-[1-(5-chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
684	N-[5-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl]-acetamide
685	1-[1-(5-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
686	1-[1-(5-Chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
687	N-[5-[4-(8-Methoxy-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl]-acetamide
688	2,5-Dimethyl-4-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-furan-3-carboxylic acid methyl ester
689	8-Methyl-1-[1-(2-oxo-2,3-dihydro-benzothiazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
690	1-[1-(4-Fluoro-3-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
691	8-Methyl-1-[1-(2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
692	1-[1-(4-Cyclohexyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
693	2,5-Dimethyl-4-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-furan-3-carboxylic acid methyl ester
694	1-[1-(4-Fluoro-3-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
695	1-[1-(2-Oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
696	1-[1-(4-Cyclohexyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
697	2-Fluoro-6-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic

	acid
698	2-Fluoro-5-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
699	1-[1-(2-Oxo-2,3-dihydro-benzothiazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
700	1-[1-(5-Pyridin-2-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro -benzo[d][1,3]oxazin-2-one
701	3-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
702	3-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiophene-2-carboxylic acid methyl ester
703	1-[5-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl]-pyrrolidine-2,5-dione
704	1-[1-(2-Chloro-5-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
705	1-[1-(3,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
706	8-Methyl-1-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
707	3-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
708	3-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiophene-2-carboxylic acid methyl ester
709	1-[5-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl]-pyrrolidine-2,5-dione
710	1-[1-(2-Chloro-5-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
711	1-[1-(3,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
712	5-Chloro-1-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
713	3-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
714	3-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiophene-2-carboxylic acid methyl ester
715	1-[5-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl]-pyrrolidine-2,5-dione
716	5-Chloro-1-[1-(2-chloro-5-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
717	5-Chloro-1-[1-(3,4-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
718	8-Methyl-1-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
719	3-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
720	3-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiophene-2-carboxylic acid methyl ester
721	1-[5-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl]-pyrrolidine-2,5-dione
722	1-[1-(2-Chloro-5-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
723	1-[1-(3,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
724	8-Chloro-1-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
725	3-[4-(8-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
726	3-[4-(8-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiophene-2-carboxylic acid methyl ester
727	1-[5-[4-(8-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl]-pyrrolidine-2,5-dione
728	8-Chloro-1-[1-(2-chloro-5-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
729	8-Chloro-1-[1-(3,4-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
730	1-[1-(5-Methyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
731	1-[1-(2,2-Dimethyl-chromen-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one

165
164

732	1-[1-(4-Methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
733	1-[1-(2,3-Dihydro-benzo[1,4]dioxine-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
734	1-[1-(1,3,5-Trimethyl-1H-pyrazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
735	1-[1-(3-Methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
736	8-Methyl-1-[1-(6-methyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
737	1-[1-(2,2-Dimethyl-chroman-6-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
738	8-Methyl-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
739	1-[1-(2,3-Dihydro-benzo[1,4]dioxine-6-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
740	8-Methyl-1-[1-(1,3,5-trimethyl-1H-pyrazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
741	8-Methyl-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
742	8-Methoxy-1-[1-(1,3,5-trimethyl-1H-pyrazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
743	8-Methoxy-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
744	1-[1-(Benzo[d]isoxazol-3-ylmethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
745	1-[1-(2,2,4,6,7-Pentamethyl-2,3-dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
746	6-Methyl-5-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-1H-pyrimidine-2,4-dione
747	1-[1-(3-Methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
748	1-[1-(2,2,5,7,8-Pentamethyl-chroman-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
749	1,4-Dimethyl-6-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-1,4-dihydro-quinoxaline-2,3-dione
750	1-[1-(1H-Imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
751	1-[1-(2-Oxo-1,2,3,4-tetrahydro-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
752	7-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione
753	8-Methyl-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
754	6-Chloro-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
755	5-Chloro-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
756	8-Methoxy-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
757	1-[1-(Pyridine-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
758	1-[1-(6,7-Dihydroxy-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
759	Acetic acid 3-acetoxy-5-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-2-yl ester
760	1-[1-(1H-Benzoimidazole-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
761	1-[1-(1H-Benzoimidazole-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
762	1-[1-(1H-Benzoimidazole-2-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
763	1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one

165
166


764	1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
765	1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
766	6-Chloro-1-[1-(2,5-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
767	1-[1-(5-Dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
768	6-Chloro-1-[1-(5-dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
769	6-Chloro-1-[1-(5-chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
770	1-[1-(5-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
771	1-[1-(5-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
772	6-Chloro-1-[1-(5-chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
773	1-[1-(5-Chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
774	1-[1-(5-Chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-8-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
775	6-Methyl-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
776	6-Fluoro-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
777	6,7-Difluoro-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
778	6-Chloro-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
779	6-Methyl-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
780	6-Fluoro-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
781	6,7-Difluoro-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
782	5-Chloro-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
783	6-Chloro-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
784	6-Methyl-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
785	6-Fluoro-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
786	8-Methoxy-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
787	5-Chloro-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one.

166
467

Preferably, the compound 1-[[(7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methyl]sulfonyl]-4-(2-oxo-2H-3,1-benzoxazin-1(4H)-yl-piperidine may be excluded. More preferably, the compound 1-[[(7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methyl]sulfonyl]-4-(2-oxo-2H-3,1-benzoxazin-1(4H)-yl-piperidine, salts thereof and solvates thereof may be excluded.


The compounds of general formula (Ib), their stereoisomers, corresponding salts and corresponding solvates may be obtained analogously by the methods described above for compounds of general formula (I). For details of the process reference is made to the description given above for compounds of general formula (I).

Thus, in another aspect the present invention relates to a process for the preparation of benzoxazinone-derived sulfonamide compounds of general formula (Ib) given above, which comprises reacting at least one piperidine compound of general formula (IIb), wherein R^{1b} to R^{8b} have the meaning given above and/or a salt, preferably a hydrochloride salt, thereof,



(IIb)

with at least one compound of general formula (IIIb),



(IIIb)

wherein W^b has the meaning given above, in a suitable reaction medium, optionally in the presence of at least one base and/or at least one auxiliary agent.

In a further aspect the present invention relates to a process for the preparation of a physiologically acceptable salt of the benzoxazinone-derived sulphonamide compounds of general formula (Ib) given above or a corresponding stereoisomer thereof, characterized in that at least one compound of general formula (Ib) having at least one basic group is reacted with at least one acid, preferably an inorganic or organic acid, preferably in the presence of a suitable reaction medium.

In a further aspect the present invention relates to a process for the preparation of a physiologically acceptable salt of the benzoxazinone-derived sulphonamide compounds of general formula (Ib) given above or a corresponding stereoisomer thereof, characterized in that at least one compound of general formula (Ib) having at least one acidic group is reacted with at least one base, preferably in the presence of a suitable reaction medium.

In yet another aspect the present invention relates to a pharmaceutical composition comprising at least one benzoxazinone-derived sulphonamide compound of general formula (Ib) given above, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively, and optionally one or more pharmaceutically acceptable adjuvants.

168
A69

In yet another aspect the present invention provides for a medicament comprising at least one benzoxazinone-derived sulphonamide compound of general formula (Ib) given above, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively, and optionally one or more pharmaceutically acceptable adjuvants.

The medicament of the present invention is suitable for the prophylaxis and/or treatment of disorders that are at least partially mediated via 5-HT_6-receptors.

In particular, the medicament of the present invention is suitable for the prophylaxis and/or treatment of food intake disorders, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, for the prophylaxis and/or treatment of bulimia, for the prophylaxis and/or treatment of anorexia, for the prophylaxis and/or treatment of cachexia, for the prophylaxis and/or treatment type II diabetes (non-insulin dependent diabetes mellitus).

Also in particular, the medicament of the present invention is suitable for the prophylaxis and/or treatment of gastrointestinal disorders, preferably irritable colon syndrome; for the prophylaxis and/or treatment of disorders of the central nervous system; for the prophylaxis and/or treatment of anxiety; for the prophylaxis and/or treatment panic attacks; for the prophylaxis and/or treatment of depression; for the prophylaxis and/or treatment of bipolar disorders; for the prophylaxis and/or treatment cognitive disorders, preferably memory disorders; for improvement of cognition (for cognitive enhancement); for the prophylaxis and/or treatment of senile dementia; for the prophylaxis and/or treatment of psychosis; for the prophylaxis and/or treatment neurodegenerative disorders; preferably selected from the group consisting of Morbus Alzheimer, Morbus Parkinson, Morbus Huntington and Multiple Sclerosis; for the prophylaxis and/or treatment of schizophrenia or for the prophylaxis and/or treatment hyperactivity disorder (ADHD, attention deficit, hyperactivity disorder).

169
A70

Another aspect of the present invention is the use of at least one benzoxazinone-derived sulphonamide compound of general formula (Ib) given above, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively, for the manufacture of a medicament for 5-HT_6 receptor-regulation, in particular for the manufacture of a medicament for the prophylaxis and/or treatment of disorders that are at least partially mediated via 5-HT_6 receptors.

Preferred is the use of at least one benzoxazinone-derived sulphonamide compound of general formula (Ib) given above, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively, for the manufacture of a medicament for the prophylaxis and/or treatment of food intake disorders, preferably for the regulation of appetite, for the reduction, increase or maintenance of body weight; for the prophylaxis and/or treatment of obesity, for the prophylaxis and/or treatment of bulimia, for the prophylaxis and/or treatment of anorexia; for the prophylaxis and/or treatment of cachexia; or for the prophylaxis and/or treatment of type II diabetes.

Also preferred is the use of at least one benzoxazinone-derived sulphonamide compound of general formula (Ib) given above, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively, for the manufacture of a medicament for the prophylaxis and/or treatment of of gastrointestinal disorders, preferably irritable colon syndrome; for the prophylaxis and/or treatment of disorders of the central nervous system; for the prophylaxis and/or treatment of anxiety; for the prophylaxis and/or treatment panic attacks; for the prophylaxis and/or treatment of depression; for the prophylaxis and/or treatment of bipolar disorders; for the prophylaxis and/or treatment cognitive disorders, preferably memory disorders; for improvement of cognition (for cognitive

enhancement); for the prophylaxis and/or treatment of senile dementia; for the prophylaxis and/or treatment of psychosis; for the prophylaxis and/or treatment neurodegenerative disorders; preferably selected from the group consisting of Morbus Alzheimer, Morbus Parkinson, Morbus Huntington and Multiple Sclerosis; for the prophylaxis and/or treatment of schizophrenia; or for the prophylaxis and/or treatment hyperactivity disorder (ADHD, attention deficit, hyperactivity disorder).

The medicament according to the present invention may be in any form suitable for the application to humans and/or animals, particularly mammals, including humans, and can be produced by standard procedures known to those skilled in the art. The composition of the medicament may vary depending on the route of administration.

The preparation of corresponding pharmaceutical compositions as well as of the formulated medicaments may be carried out by conventional methods known to those skilled in the art, e.g. from the tables of contents from „Pharmaceutics: the Science of Dosage Forms", Second Edition, Aulton, M.E. (Ed.) Churchill Livingstone, Edinburgh (2002); „Encyclopedia of Pharmaceutical Technology", Second Edition, Swarbrick, J. and Boylan J.C. (Eds.), Marcel Dekker, Inc. New York (2002); „Modern Pharmaceutics", Fourth Edition, Banker G.S. and Rhodes C.T. (Eds.) Marcel Dekker, Inc. New York 2002 and „The Theory and Practice of Industrial Pharmacy", Lachman L., Lieberman H. and Kanig J. (Eds.), Lea & Febiger, Philadelphia (1986). The respective literature descriptions are incorporated by reference and are part of the disclosure.

The pharmaceutical compositions as well as the formulated medicaments prepared according to the present invention may in addition to at least one compound of general formula (I), (Ia) or (Ib), optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a corresponding physiologically acceptable salt or a corresponding solvate, comprise further conventional auxiliary substances known to those skilled in the art, such as carriers, fillers, solvents, diluents, colouring agents, coating agents, matrix agents and/or binders. As is also known to those skilled in the art, the choice of the auxiliary substances and the amounts thereof to be used are dependent on the intended route of

171
172

administration, e.g. oral, rectal, intravenous, intraperitoneal, intramuscular, intranasal, buccal or topical route.

Medicaments suitable for oral administration are for example, tablets, sugar-coated pills, capsules or multiparticulates, such as granules or pellets, optionally compressed into tablets, filled into capsules or suspended in a suitable liquid, solutions or suspensions.

Medicaments suitable for parenteral, topical or inhalatory administration may preferably be selected from the group consisting of solutions, suspensions, readily reconstitutable dry preparations and also sprays.

Suitable medicaments, e.g. medicaments for oral or percutaneous use may release the compounds of general formula (I), (Ia) or (Ib) and/or in each case stereoisomers thereof in a delayed manner, whereby the preparation of these delayed release medicaments is generally known to those skilled in the art.

Suitable delayed-release forms as well as materials and methods for their preparation are known to those skilled in the art, e.g. from the tables of contents from „Modified-Release Drug Delivery Technology", Rathbone, M.J. Hadgraft, J. and Roberts, M.S. (Eds.), Marcel Dekker, Inc., New York (2002); „Handbook of Pharmaceutical Controlled Release Technology", Wise, D.L. (Ed.), Marcel Dekker, Inc. New York, (2000);"Controlled Drug Delivery", Vol. I, Basic Concepts, Bruck, S.D. (Ed.), CRC Press Inc., Boca Raton (1983) and from Takada, K. and Yoshikawa, H., „Oral Drug delivery", Encyclopedia of Controlled Drug Delivery, Mathiowitz, E. (Ed.), John Wiley & Sons, Inc., New York (1999), Vol. 2, 728-742; Fix, J., „Oral drug delivery, small intestine and colon", Encylopedia of Controlled Drug Delivery, Mathiowitz, E. (Ed.), John Wiley & Sons, Inc., New York (1999), Vol. 2, 699-728. The respective descriptions are incorporated by reference and are part of the disclosure.

The medicament of the present invention may also have at least one enteric coating which dissolves as a function of pH. Because of this coating, the medicament can pass through the stomach undissolved and the compounds of general formula (I), (Ia) or (Ib) are only released in the intestinal tract. The enteric coating preferably dissolves at a pH

172
173

of between 5 and 7.5. Suitable materials and methods for the preparation of enteric coatings are also known to those skilled in the art

The compositions of the present invention may also be administered topically or via a suppository.

The above mentioned compositions include preferably 1 to 60 % by weight of one or more of the benzoxazinone-derived sulphonamide compounds of general formulas (I), (Ia) or (Ib), optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively, and 40 to 99 % by weight of the appropriate pharmaceutical vehicle(s).

The daily dosage for humans and animals may vary depending on factors that have their basis in the respective species or other factors, such as age, sex, weight or degree of illness and so forth. The daily dosage for humans usually ranges from 1 to 2000, preferably 1 to 1500, more preferably 1 to 1000 milligrams of substace to be administered during one or several intakes.

173
174

Pharmacological Methods:

BINDING TO SEROTONIN RECEPTOR $5HT_6$

Cell membranes of HEK-293 cells expressing the $5HT_6$-human recombinant receptor were supplied by Receptor Biology. In said membranes the receptor concentration is 2.18 pmol/mg protein and the protein concentration is 9.17 mg/ml. The experimental protocol follows the method of B. L. Roth et al. [B. L. Roth, S. C. Craigo, M. S. Choudhary, A. Uluer, F. J. Monsma, Y. Shen, H. Y. Meltzer, D. R. Sibley: Binding of Typical and Atypical Antipsychotic Agents to 5-Hydroxytryptamine-6 and Hydroxytriptamine-7 Receptors. *The Journal of Pharmacology and Experimental Therapeutics*, 1994, *268*, 1403] with the following slight changes. The respective part of the literature description is hereby incorporated by reference and forms part of the disclosure.

The commercial membrane is diluted (1:40 dilution) with the binding buffer: 50 mM Tris-HCl, 10 mM $MgCl_2$, 0.5 mM EDTA (pH 7.4). The radioligand used is [^{3}H]-LSD at a concentration of 2.7 nM with a final volume of 200 µl. Incubation is initiated by adding 100 µl of membrane suspension, (≈ 22.9 µg membrane protein), and is prolonged for 60 minutes at a temperature of 37 °C. The incubation is ended by fast filtration in a Brandel Cell Harvester through fiber glass filters made by Schleicher & Schuell GF 3362 pretreated with a solution of polyethylenimine at 0.5 %. The filters are washed three times with three milliliters of buffer Tris-HCl 50 mM pH 7.4. The filters are transferred to flasks and 5 ml of Ecoscint H liquid scintillation cocktail are added to each flask. The flasks are allowed to reach equilibrium for several hours before counting with a Wallac Winspectral 1414 scintillation counter. Non-specific binding is determined in the presence of 100 µM of serotonin. Tests were made in triplicate. The inhibition constants (K_i, nM) were calculated by non-linear regression analysis using the program EBDA/LIGAND described in Munson and Rodbard, *Analytical Biochemistry*, 1980, *107*, 220, which is hereby incorporated by reference and forms part of the disclosure.

174
175

FOOD INTAKE MEASUREMENT (BEHAVIOURAL MODEL):

Male W rats (200-270 g) obtained from Harlan, S.A. are used. The animals are acclimatized to the animal facility for at least 5 days before they are subjected to any treatment. During this period the animals are housed (in groups of five) in translucid cages and provided with food and water ad libitum. At least 24 hours before the treatment starts, the animals are adapted to single-housing conditions.

The acute effect of the inventively used sulphonamide derivatives of general formula (I) on food intake in fasted rats is then determined as follows:

The rats were fasted for 23 hours in their single homecages. After this period, the rats are orally or intraperitoneally dosed with a composition comprising a sulphonamide derivative of general formula (I) or a corresponding composition (vehicle) without said sulphonamide derivative. Immediately afterwards, the rat is left with preweighed food and cumulative food intake is measured after 1, 2, 4 and 6 hours.

Said method of measuring food intake is also described in the literature publications of Kask et al., European Journal of Pharmacology 414 (2001), 215-224 and of Turnbull et al., Diabetes, Vol. 51, August 2002. The respective parts of the descriptions are hereby incorporated by reference and form part of the disclosure.

The present invention is illustrated below with the aid of examples. These illustrations are given solely by way of example and do not limit the general spirit of the present invention.

175
196


Examples:

The intermediates of general formulas (II) and (III) were prepared by means of conventional organic chemistry methods known to those skilled in the art. The following example A shows the preparation of an intermediate of general formula (II):

Example A:

Synthesis of an intermediate compound of general formula (II)

Preparation of 6-Chloro-1-(piperidine-4-yl)-1,4-dihydro-2H-3,1-benzoxazin-2-one hydrochloride



a) 1-(*tert*-Butyloxycarbonyl)-4-[4-chloro-(2-hydroxymethylphenylamine)] piperidine

A solution of 1-(*tert*-butyloxycarbonyl)-4-piperidinone (20 g, 0.10 mol), 2-amino-5-chlorobenzylic alcohol (17.34 g, 0.11 mol) and acetic acid (14 mL, 0.22 mol) in dry toluene (600 mL) was heated at reflux temperature, with water elimination by means of azeotrope distillation with Dean-Stark, for 6 hours. The mixture was then cooled and vacuum concentrated up to half volume. $NaBH_3CN$ (20 g, 0.32 mol) and dry THF (300 mL) were added to the resulting solution. Acetic acid (10 mL, 0.17 mol) was then dripped for one hour. The reaction was stirred at room temperature for 24 hours. The mixture was vacuum concentrated and the residue was dissolved in ethyl acetate (750 mL), washed with a $NaHCO_3$-saturated solution (4 x 250 mL) and a NaCl-saturated solution (250 mL), dried and evaporated to dryness. The residue was purified by means of flash chromatography eluting with a mixture of ethyl acetate:

176
177

petroleum ether (1:3). The desired product was thus obtained as an oil (32.7 g, 96%). ^{1}H NMR ($CDCl_3$): 1.32 (d, *J*=11.2 Hz, 2H), 1.41 (s, 9H), 1.92 (d, *J*=11.2 Hz, 2H), 2.92 (t, *J*=12.0 Hz, 1H), 3.10 (s, 1H), 3.37 (m, 1H), 3.88 (d, *J*= 13.7 Hz, 2H), 4.49 (s, 2H), 4.75 (s, 1H), 6.52 (d, *J*= 8.6 Hz, 1H), 6.96 (s, 1H), 7.07 (d, *J*= 8.6 Hz, 1H).

b.) 1-(1-*tert*-Butyloxycarbonyl-4-piperidinyl)-6-chloro-1,4-dihydro-2H-3,1-benzoxazin-2-one

N, N-diisopropylethylamine (DIEA) (43 mL, 0.25 mol) and triphosgene (8.65 g, 29.2 mmol) were added to a solution of 1-(*tert*-Butyloxycarbonyl)-4-[(4-chloro-(2-hydroxymethyl) phenyl-amino)]piperidine (27.0 g, 79 mmol) in dry THF (250 mL) cooled at 0°C. The reaction was stirred at 0°C for 1 h and at room temperature for 72 h. Ethyl ether was added and the mixture was cooled at 0°C for 3 h and the DIEA hydrochloride was then filtered. The filtered solution was evaporated to dryness and the residue was dissolved in ethyl acetate (750 mL), washed with 5% solution of citric acid (2 x 500 mL), water (250 mL) and $NaHCO_3$-saturated solution (2 x 500 mL). The ethyl acetate solution was dried ($MgSO_4$), filtered and evaporated under reduced pressure. The residue was brought to the boil with ethyl ether until the whole solid was dissolved and then cooled overnight to yield the desired compound in crystalline form (28.9 g, 67%).
Melting point: 177-179 °C

^{1}H NMR ($CDCl_3$): 1.46 (s, 9H), 1.79 (d, *J*= 10.1 Hz, 1H), 2.54 (m, 2H), 2.78 (m, 2H), 3.96 (m, 1H), 4.28 (m, 2H), 5.02 (s, 2H), 6.96 (d, *J*= 8.7 Hz, 1H) 7.13 (d, *J*= 2.4 Hz, 1H), 7.28 (dd, *J*= 8.7 Hz, *J*= 2.4 Hz, 1H).

c.) 6-chloro-1-(piperidin-4-yl)-1,4-dihydro-2H-3,1-benzoxazin-2-one hydrochloride

A solution of 1-[(1-*tert*-Butyloxycarbonyl)-4-piperidinyl]-6-chloro-1,4-dihydro-2H-3,1-benzoxazin-2-one (24 g, 65 mmol) in ethyl acetate (500 mL) was cooled at 0°C. A 5 M solution of hydrogen chloride in ethyl ether (500 mL) was then added and the resulting mixture was stirred at 0°C for 4 h. The precipitate formed was collected by

177
178

filtration, washed with ether and vacuum dried to yield the desired product as a solid (16.95 g, 97%).
Melting point: 254-257 °C

^{1}H NMR (CD_3OD): 2.13 (d, J= 12.2 Hz, 2H), 2.88 (m, 2H), 3.20 (m, 2H), 3.53 (d, J= 12.8 Hz, 2H), 4.24 (m, 1H), 5.16 (s, 2H), 7.31 (m, 2H), 7.41 (dd, J= 8.8 Hz, J= 2.6 Hz, 1H).

Several substituted 3,1-benzoxazin-2-one compounds were prepared via the respectively substituted benzyl alcohols by reducing the respectively substituted anthranilic acids with lithium aluminium hydride and other known reducing agents by methods well known to those skilled in the art (see scheme 1), e.g. por ejemplo 6-methyl-1-(piperidin-4-yl)-1,4-dihydro-2H-3,1-benzoxazin-2-one, 7-methyl-1-(piperidin-4-yl)-1,4-dihydro-2H-3,1-benzoxazin-2-one, 8-methyl-1-(piperidin-4-yl)-1,4-dihydro-2H-3,1-benzoxazin-2-one , 5-methoxy-1-(piperidin-4-yl)-1,4-dihydro-2H-3,1-benzoxazin-2-one, 6-fluoro-1-(piperidin-4-yl)-1,4-dihydro-2H-3,1-benzoxazin-2-one, 8-methoxy-1-(piperidinyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one, 5-methyl-1-(piperidin-4-yl)-1,4-dihydro-2H-3,1-benzoxazin-2-one, 7-fluoro-1-(piperidin-4-yl)-1,4-dihydro-2H-3,1-benzoxazin-2-one, 5-fluoro-1-(piperidin-4-yl)-1,4-dihydro-2H-3,1-benzoxazin-2-one, 6-methoxy-1-(piperidinyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one, 5-chloro-1-(piperidinyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one, 7-chloro-1-(piperidinyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one, 8-chloro-1-(piperidinyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one and others. The reaction of the respective 5-methoxy-1-(piperidinyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one, 8-methoxy-1-(piperidinyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one and 6-methoxy-1-(piperidinyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one compounds according to conventional methods, e.g. BBr_3 in an inert organic solvent yields the respective 5-hydroxy-1-(piperidinyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one, 8-hydroxy-1-(piperidinyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one and 6-hydroxy-1-(piperidinyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one compounds. The unsubstituted benzoxazin-2-one 1-(piperidin-4-yl)-1,4-dihydro-2H-3,1-benzoxazin-2-one is prepared according the method described in J. Med. Chem. 1995, 38, 4634 and J.Med.Chem. 1998, 41, 2146, which are hereby incorporated by reference and form part of the disclosure.

178
179

The substituted anthranilic acids were reduced by conventional methods known to those skilled in the art, e.g. by the use of $LiAlH_4$ as reducing agent in anhydrous THF under an inert-gas atmosphere, e.g. argon or nitrogen. This process is very efficient and in most cases the respective 2-aminobenzylalcohols are obtained in very good yields.


General instruction for the reduction of substituted anthranilic acids:

To a three neck flask, equipped with a mechanical stirrer and an inlet for gaseous nitrogen, 100 mL anhydrous THF and 116,6 mmoles of $LiAlH_4$ were given and the resulting suspension cooled to 0 °C. After the addition of 58,3 mmoles of the respective substituted anthranilic acid in 150 mL anhydrous THF, the resulting reaction mixture is warmed to room temperature and stirred or about an hour. Under cooling to 0° C 4,7 mL water , 4,7 mL NaOH 15 wt.-%, and finally 14 mL water are carefully added to the mixture. The resulting suspension is filtered and washed with ethylacetate.

The organic phase is washed with water, dried and the solvent evaporated. In most cases the resulting product may be used without further purification.

Example 5:

Preparation of 1-[1-quinoline-8-sulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one



179
180

150 mg (0,66 mmol) quinoline-8-sulfonyl chloride are added to a mixture of 1-(4-piperidinyl)-1,4-dihydro-2H-3,1-benzoxazinone hydrochloride (161 mg, 0,60 mmol) and diisopropylethylamin (230 mg, 1,80 mmol) in dichloromethane (10 ml) and the resulting reaction mixture was stirred overnight at room temperature. The reaction mixture was then washed with water (3 x 15 mL) and the organic phase was separated, dryed and evaporated to dryness. A solid was obtained, which was recrystallized from ethanol. 152 mg of 1-[1-quinoline-8-sulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one were obtained as a white solid (yield 69 %).




IR (cm^{-1}) KBr: 1712, 1337, 1291, 1205, 1162, 1144, 1034, 717, 583

^{1}H-NMR(δ in ppm): 1.8 (d, *J*=9.5 Hz, 2 H) 2.6 (qd, *J*=12.6, 4.4 Hz, 2 H) 3.0 (td, *J*=12.8, 2.5 Hz, 2 H) 4.1 (tt, *J*=12.5, 3.8 Hz, 1 H) 4.3 (ddd, *J*=13.0, 2.3 Hz, 2 H) 5.0 (s, 2 H) 7.1 (m, 3 H) 7.3 (m, 1 H) 7.6 (dd, *J*=8.4, 4.2 Hz, 1 H) 7.8 (m, 1 H) 8.1 (dd, *J*=8.2, 1.3 Hz, 1 H) 8.3 (dd, *J*=8.3, 1.7 Hz, 1 H) 8.5 (dd, *J*=7.3, 1.5 Hz, 1 H) 9.1 (dd, *J*=4.2, 1.8 Hz, 1 H) (CDCl3-d).
Melting point: 170-172 °C.




The compounds according to examples 1-4 and 6-10 given in the following table I as well as the compounds according to lists A and B given above were prepared analogously to the methods described above.

180
181




Table I:

Ex. 1	1-[1-(Naphthyl-1-sulfonyl)-piperidine-4-yl] -1,4-dihydro-benzo[d][1,3]oxazine-2-one	
		1H-NMR: 1.8 (d, J=10.5 Hz, 2 H) 2.4 (m, 2 H) 2.7 (t, J=11.6 Hz, 2 H) 3.9 (m, 3 H) 5.1 (s, 2 H) 7.1 (m, 2 H) 7.2 (m, 2 H) 7.7 (m, 3 H) 8.1 (d, J=8.1 Hz, 1 H) 8.2 (d, J=7.8 Hz, 1 H) 8.3 (d, J=8.1 Hz, 1 H) 8.7 (d, J=8.3 Hz, 1 H) (DMSO-d6)
		IR (KBr) 1709, 1498, 1353, 1162, 1034, 770, 718, 579
		Melting point: 147-149°C
Ex. 2	1-(1-Phenylsulfonyl-piperidine-4-yl] -1,4-dihydro-benzo[d][1,3]oxazine-2-one	
		1H-NMR: 1.9 (dd, J=12.1, 2.1 Hz, 2 H) 2.4 (td, J=12.2, 2.4 Hz, 2 H) 2.7 (qd, J=12.6, 4.3 Hz, 2 H) 3.9 (tt, J=12.3, 3.9 Hz, 1 H) 4.0 (dt, J=11.9, 2.1 Hz, 2 H) 5.0 (s, 2 H) 7.0 (d, J=8.3 Hz, 1 H) 7.0 (t, J=7.3 Hz, 1 H) 7.1 (m, 1 H) 7.3 (m, 1 H) 7.6 (m, 3 H) 7.8 (m, 2 H) ($CDCl_3$-d)
		IR (KBr) 1705, 1497, 1340, 1293, 1205, 1160, 736, 691, 576
		Melting point: 172-174°C
Ex. 3	1-[1-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidine-4-yl] -1,4-dihydro-benzo[d][1,3]oxazine-2-one	
		1H-NMR: 1.8 (d, J=10.8 Hz, 2 H) 2.5 (m, 2 H) 2.7 (s, 3 H) 2.8 (t, J=11.4 Hz, 2 H) 3.8 (d, J=11.4 Hz, 2 H) 3.9 (m, 1 H) 5.1 (s, 2 H) 7.0 (t, J=7.2 Hz, 1 H) 7.2 (d, J=8.1 Hz, 1 H) 7.2 (m, 2 H) 7.6 (dd, J=8.6, 2.0 Hz, 1 H) 8.1 (d, J=2.0 Hz, 1 H) 8.2 (d, J=8.6 Hz, 1 H) (DMSO-d6)
		IR (KBr) 1717, 1358, 1248, 1201, 1160, 1035, 712, 554
		Melting point: 204-206°C
Ex. 4	8-Methyl-1-[1-(naphthyl-1-sulfonyl)-piperidine-4-yl] -1,4-dihydro-benzo[d][1,3]oxazine-2-one	
		1H-NMR: 1.9 (d, J=12.5 Hz, 2 H) 2.3 (s, 3 H) 2.7 (m, 4 H) 3.3 (m, 1 H) 4.0 (d, J=11.2 Hz, 2 H) 4.9 (s, 2 H) 7.0 (m, 2 H) 7.1 (d, J=7.0 Hz, 1 H) 7.6 (m, 3 H) 7.9 (m, 1 H) 8.1 (d, J=8.2 Hz, 1 H) 8.2 (dd, J=7.3, 1.1 Hz, 1 H) 8.7 (d, J=8.5 Hz, 1 H) (CDCl3-d)
		IR (KBr) 1712, 1316, 1279, 1222, 1160, 1135, 1025, 768, 607
		Melting point: 203-204°C

181
182

Ex. 5	1-[1-(Quinolinyl-8-sulfonyl)-piperidine-4-yl] -1,4-dihydro-benzo[d][1,3]oxazine-2-one	
		1H-NMR: 1.8 (d, J=9.5 Hz, 2 H) 2.6 (qd, J=12.6, 4.4 Hz, 2 H) 3.0 (td, J=12.8, 2.5 Hz, 2 H) 4.1 (ti, J=12.5, 3.8 Hz, 1 H) 4.3 (ddd, J=13.0, 2.3 Hz, 2 H) 5.0 (s, 2 H) 7.1 (m, 3 H) 7.3 (m, 1 H) 7.6 (dd, J=8.4, 4.2 Hz, 1 H) 7.8 (m, 1 H) 8.1 (dd, J=8.2, 1.3 Hz, 1 H) 8.3 (dd, J=8.3, 1.7 Hz, 1 H) 8.5 (dd, J=7.3, 1.5 Hz, 1 H) 9.1 (dd, J=4.2, 1.8 Hz, 1 H) (CDCl3-d)
		IR (KBr) 1712, 1337, 1291, 1205, 1162, 1144, 1034, 717, 583
		Melting point: 170-172°C
Ex. 6	6-Methyl-1-[1-(quinolinyl-8-sulfonyl)-piperidine-4-yl] -1,4-dihydro-benzo[d][1,3]oxazine-2-one	
		1H-NMR: 1.9 (d, J=12.6 Hz, 2 H) 2.3 (s, 3 H) 2.7 (qd, J=12.2, 3.9 Hz, 2 H) 2.9 (m, 2 H) 3.3 (tt, J=11.7, 3.4 Hz, 1 H) 4.3 (d, J=12.8 Hz, 2 H) 4.9 (s, 2 H) 7.0 (m, 2 H) 7.1 (d, J=7.3 Hz, 1 H) 7.5 (dd, J=8.3, 4.1 Hz, 1 H) 7.6 (m, 1 H) 8.0 (dd, J=8.2, 1.3 Hz, 1 H) 8.2 (dd, J=8.3, 1.7 Hz, 1 H) 8.5 (dd, J=7.3, 1.5 Hz, 1 H) 9.1 (dd, J=4.2, 1.8 Hz, 1 H) (CDCl3-d)
		IR (KBr) 1702, 1329, 1284, 1218, 1024, 785, 701, 582
		Melting point: 202-206°C
Ex. 7	1-[1-(5-Dimethylamino-naphthyl-1-sulfonyl)-piperidine-4-yl]-6-Methyl -1,4-dihydro-benzo[d][1,3]oxazine-2-one	
		1H-NMR: 1.9 (d, J=11.9 Hz, 2 H) 2.3 (s, 3 H) 2.7 (m, 4 H) 2.9 (s, 6 H) 3.3 (m, 1 H) 4.0 (d, J=9.9 Hz, 2 H) 4.9 (s, 2 H) 7.0 (m, 2 H) 7.2 (m, J=7.3 Hz, 2 H) 7.5 (m, 2 H) 8.2 (dd, J=7.3, 1.1 Hz, 1 H) 8.4 (d, J=8.6 Hz, 1 H) 8.6 (d, J=8.4 Hz, 1 H) (CDCl3-d)
		IR (KBr) 2981, 1711, 1336, 1221, 1149, 1025, 794, 709, 571
		Melting point: 202-203°C

182
A83

Ex. 8	1-[1-(5-Dimethylamino-naphthyl-1-sulfonyl)-piperidine-4-yl] -1,4-dihydro-benzo[d][1,3]oxazine-2-one	
		1H-NMR 1.8 (dd, J=12.3, 3.5 Hz, 2 H) 2.7 (m, 4 H) 2.9 (s, 6 H) 4.0 (m, 3 H) 5.0 (s, 2 H) 6.9 (d, J=8.2 Hz, 1 H) 7.1 (m, 2 H) 7.3 (m, 2 H) 7.6 (td, J=8.9, 7.4 Hz, 2 H) 8.3 (dd, J=7.3, 1.3 Hz, 1 H) 8.4 (d, J=8.8 Hz, 1 H) 8.6 (d, J=8.2 Hz, 1 H) (CDCl3-d)
		IR (KBr) 2935, 1720, 1319, 1242, 1144, 920, 791, 755, 642
		Melting point: 182-186°C
Ex. 9	1-[1-(2,3-Dichloro-phenylsulfonyl)-piperidine-4-yl] -1,4-dihydro-benzo[d][1,3]oxazine-2-one	
		1H-NMR 1.9 (d, J=10.1 Hz, 2 H) 2.7 (qd, J=12.6, 4.2 Hz, 2 H) 3.0 (td, J=12.7, 2.3 Hz, 2 H) 4.1 (m, 3 H) 5.1 (s, 2 H) 7.1 (m, 3 H) 7.3 (m, 2 H) 7.7 (dd, J=8.0, 1.6 Hz, 1 H) 8.0 (dd, J=8.0, 1.6 Hz, 1 H) (CDCl3-d)
		IR (KBr) 1697, 1395, 1244, 1165, 1045, 942, 710, 582
		Melting point: 185-187 °C
Ex. 10	1-[1-(2,3-Dichloro-phenylsulfonyl)-piperidine-4-yl]-8-Methyl-1,4-dihydro-benzo[d][1,3]oxazine-2-one	
		1H-NMR: 2.0 (d, J=11.5 Hz, 2 H) 2.4 (s, 3 H) 2.8 (m, 4 H) 3.4 (m, 1 H) 4.0 (d, J=9.9 Hz, 2 H) 5.0 (s, 2 H) 7.0 (m, 2 H) 7.2 (d, J=7.7 Hz, 1 H) 7.3 (t, J=8.0 Hz, 1 H) 7.7 (dd, J=8.1, 1.6 Hz, 1 H) 8.0 (dd, J=8.0, 1.6 Hz, 1 H) (CDCl3-d)
		IR (KBr) 1705, 1404, 1339, 1224, 1149, 939
		Melting point: 184-185°C

183
184

Pharmacological data:

The binding of the benzoxazinone derived sulphonamide compounds of general formulae (I), (Ia) and (Ib) was determined as described above.

The binding results of some these compounds are given in the following table 2:


Table 2:

Compound according to example:	% inhibition 10^{-6} M	K_i (nM)
1	98.1 ± 4.0	51.7
3		107.4
4		246
5		152
6		165.9
7	88	
8	88	

189
185

Claims:

1. Benzoxazinone-derived sulfonamide compounds of general formula (I)



(I),

wherein

R^1, R^2, R^3, R^4 are each independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano group, $-OR^{10}$, $-OC(=O)R^{11}$, $-(C=O)-OR^{11}$, $-SR^{12}$, $-SOR^{12}$, $-SO_2R^{12}$, $-NH-SO_2R^{12}$, $-SO_2NH_2$ and a $-NR^{13}R^{14}$ moiety,

185
186

R^5 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical,

R^6, R^7, R^8, R^9 are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano group and a -$COOR^{15}$ moiety,

W represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

an optionally at least mono-substituted heteroaryl radical, which may be bonded via an optionally mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

an optionally at least mono-substituted, monocyclic aryl radical, which is condensed with an optionally at least mono-substituted mono- or polycyclic ring-system and which may be bonded via an optionally at least mono-substituted alkylene group,

a -$NR^{16}R^{17}$-moiety,

a -COR^{18}-moiety,

or a phenyl radical, which is at least mono-substituted with one of the substituents selected from the group consisting of:

2,2,2,-Trifluoroethoxy-, C_{2-6}-Alkenyl-, 1,3-Dihydro-1-oxo-2H-isoindol-2-yl-, N-Phthalimidinyl-, [(2-chloro-1,3-thiazolyl-5-yl)-methoxy, Ethyl-5-yl-2-methyl-3-furoate, C_{11-20}-alkyl-, 1,3-Dioxo-2-azaspiro[4,4]non-2-yl-, pyrazolyl-, (1,3-oxazol-5-yl)-, (5-Methyl-1,3,4-oxadiazol-2-yl)-, difluoromethoxy, dichloromethoxy, 1-pyrrolidinylsulfonyl, morpholinosulfonyl, 2-methyl-4-pyrimidinyl-, a phenoxy group, which is at least mono-substituted with C_{1-6}-alkoxy, a phenyl group, which is at least mono-substituted with one of the substituents selected from the group consisting of nitro, C_{1-6}-alkoxy, F, Cl, Br, at least partially fluorinated C_{1-6}-alkyl, at least partially chlorinated C_{1-6}-alkyl, [(2-Chloro-1,3-thiazol-5-yl)-methoxy]-, -(C=O)-H and -(C=O)-C_{1-6}-alkyl, a pyridinyl group, which is at least mono-substituted with C_{1-6}-alkoxy, a pyridinyloxy group, which is at least mono-substituted with C_{1-6}-alkoxy, a phenoxy group, which is at least di-substituted and a pyridinyloxy group, which is at least di-substituted,

with the proviso that W does not represent unsubstituted furyl-, unsubstituted thienyl- or thienyl substituted with a substituent selected from the group consisting of C_{1-6}-alkoxycarbonyl, C_{1-6}-alkylcarbonyl, carboxyl and pyridyl, unsubstituted pyrrolyl-, unsubstituted naphthyl, unsubstituted indolyl, unsubstituted tetrahydronaphthyl, substituted or unsubstituted pyridyl, unsubstituted pyrazinyl, unsubstituted quinolinyl-, C_{1-6}-alkylsubstituted pyrrolyl-, and unsubstituted cyclohexyl or cyclohexyl substituted with one or two members selected from the group consisting of oxo, hydroxyl, C_{1-6}-alkoxyl, C_{1-6}-alkoxy-carbonylamino-C_{1-6} alkyl and amino-C_{1-6} alkyl,

R^{10} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may

be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{11} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{12} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{13} and R^{14} each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an

optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

or R^{13} and R^{14} together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member, ...

R^{15} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{16} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

R^{17} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, and

R^{18} represents an optionally at least mono-substituted aryl radical,

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate.

189
190

2. Compounds according to claim 1, characterized in that R^1, R^2, R^3, R^4 are each independently selected from the group consisting of H, F, Cl, Br, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano, $-OR^{10}$, $-OC(=O)R^{11}$, $-SR^{12}$, $-SOR^{12}$, $-SO_2R^{12}$, $-NH-SO_2R^{12}$, $-SO_2NH_2$ and a $-NR^{13}R^{14}$ moiety, preferably selected from the group consisting of H, F, Cl, Br, a saturated, branched or unbranched, optionally at least mono-substituted C_{1-5}-aliphatic radical, a saturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_6- or C_5- cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_1- or C_2-alkylene group, a nitro, cyano, $-OR^{10}$, $-OC(=O)R^{11}$, $-SR^{12}$ and $-NR^{13}R^{14}$ moiety, more preferably selected from the group consisting of H, F, Cl, $-CH_3$, $-CH_2CH_3$, $-CF_3$, $-CF_2CF_3$, cyclopentyl, cyclohexyl, a nitro group, a cyano group and $-OR^{10}$.

3. Compounds according to claim 1 or 2, characterized in that R^5 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, preferably represents H or a branched or unbranched C_{1-5}-alkyl radical, more preferably represents H, $-CH_3$ or $-CH_2CH_3$.

190
191

4. Compounds according to any one of claims 1 to 3, characterized in that R^6, R^7, R^8, R^9 are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, a cyano group and a $-COOR^{16}$ moiety, preferably selected from the group consisting of H, a branched or unbranched C_{1-6}-alkyl radical, a cyano group and a $-COOR^{15}$ group, more preferably from the group consisting of H, $-CH_3$, $-CH_2CH_3$ and a cyano moiety.

5. Compounds according to any one of claims 1 to 4, characterized in that W represents an unbranched or branched, optionally at least mono-substituted C_{11-20}-alkyl radical, a napthyl group, which is at least mono substituted, a quinolinyl group, which is at least mono-substituted, a pyrrolyl group, which is at least mono-substituted by a substituent other than C_{1-6}-alkyl, an optionally at least mono-substituted thiazolyl-, benzo[b]-thiophenyl-, benzo[b]-furanyl-, isoquinolinyl-, tetrahydroisoquinolinyl-, pyrazolyl-, isoazolyl-, chromanyl-, benzothiadiazolyl-, imidazolyl-, benzofurazanyl-, dibenzo[b,d]-furanyl-, benzoxadiazolyl-, Imidazo[2,1-b]-thiazolyl-, anthracenyl-, coumarinyl-, 2,3-Dihydro-1,4-benzodioxinyl-, 2,3-Dihydrobenzo[b]furanyl-, 3,4-Dihydro-2H-1,4-Benzoxazinyl-, 3,4-Dihydro-2H-1,5-Benzodioxepinyl-, Benzothiazolyl-, Imidazo[1,2-a]-pyridinyl-, a chromonyl- group, an isatinyl group, a pentamethyldihydrobenzofuranyl group, an optionally at least mono-substituted cyclopropyl- or cyclopentyl-group, a 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl-)-ethyl, a thienyl group, which is at least mono-substituted by one or more substituents independently selected from the group consisting of F, Cl, Br, C_{1-6}-alkoxy-, CF_3, $-SO_2-C_{1-6}$-alkyl and optionally at least mono substituted benzoylaminomethyl-, phenylsulfonyl-, isoxazolyl-, benzamidomethyl-, pyrimidyl-, thiazolyl-, pyrazolyl-, phenyl-, 1,2,4-thiadiazolyl-, 1,3-oxazolyl- or 1,2,4-oxadiazolyl-, a furyl group, which is at least mono-substituted by one or more substituents independently selected from the group consisting of a C_{1-6}-alkyl radical, which may be at least partially fluorinated or chlorinated, an optionally at least mono-substituted phenyl and a $-(C=O)-O-C_{1-6}$-alkyl group,

191
192

a $NR^{16}R^{17}$-moiety,

a COR^{18}-moiety,

or a phenyl radical, which is at least mono-substituted with one of the substituents selected from the group consisting of:

2,2,2,-Trifluoroethoxy-, C_{2-6}-Alkenyl-, 1,3-Dihydro-1-oxo-2H-isoindol-2-yl-, N-Phthalimidinyl-, [(2-chloro-1,3-thiazolyl-5-yl)-methoxy, Ethyl-5-yl-2-methyl-3-furoate, C_{11-22}-alkyl-, 1,3-Dioxo-2-azaspiro[4,4]non-2-yl-, pyrazolyl-, (1,3-oxazol-5-yl)-, (5-Methyl-1,3,4-oxadiazol-2-yl)-, difluoromethoxy, dichloromethoxy, 1-pyrrolidinylsulfonyl, morpholinosulfonyl, 2-methyl-4-pyrimidinyl-, a phenoxy group, which is at least mono-substituted with C_{1-6}-alkoxy, a phenyl group, which is at least mono-substituted with one of the substituents selected from the group consisting of nitro, C_{1-6}-alkoxy, F, Cl, Br, at least partially fluorinated C_{1-6}-alkyl, at least partially chlorinated C_{1-6}-alkyl, [(2-Chloro-1,3-thiazol-5-yl)-methoxy]-, -(C=O)-H and -(C=O)-C_{1-6}-alkyl, a pyridinyl group, which is at least mono-substituted with C_{1-6}-alkoxy, a pyridinyloxy group, which is at least mono-substituted with C_{1-6}-alkoxy, a phenoxy group, which is at least di-substituted and a pyridinyloxy group, which is at least di-substituted,

more preferably W represents a moiety selected from the group consisting of 5-Dimethylamino-napth-1-yl, 2-Acetamido-4-methyl-5-thiazolyl-, Trifluoromethyl-, Trichloromethyl-, Isopropyl-, Methyl-, 2,2,2-Trifluoroethyl-, Ethyl-, Hexadecyl-, 2-Chloroethyl-, n-Propyl-, 3-Chloro-propyl-, n-Butyl-, Dichloromethyl-, Chloromethyl-, Dodecyl-, 1-Octyl-, 6-(p-toluidino)-naphth-2-yl-, 4,5-Dibromo-thiophene-2-yl-, Benzoylchloride-3-yl-, 1-Octadecyl-, 4-Bromo-2,5-dichloro-thiophene-3-yl-, 2,5-Dichloro-thiophene-3-yl-, 5-Chloro-thiophene-2-yl-, 1-Decyl-, 3,5-Dichloro-4-(2-chloro-4-nitrophenoxy)-phenyl-, 2,3-Dichlorothiophene-5-yl-, 3-Bromo-2-chloro-thiophene-5-yl-, 3-Bromo-5-chloro-thiophene-2-yl-, 2-(Benzoylaminomethyl)-thiophene-5-yl-, 4-(Phenyl-sulphonyl)-thiophene-2-yl-, 2-Phenyl-sulphonyl-thiophene-5-yl-, 2-[1-Methyl-5-(trifluoromethyl)pyrazol-3-yl]-thiophene-5-yl-, 5-Chloro-1,3-dimethylpyrazole-4-

198
193

yl-, 3,5-Dimethylisoxazole-4-yl-, 2-(2,4-Dichlorophenoxy)-phenyl, 4-(2-Chloro-6-nitro-phenoxy)-phenyl-, 4-(3-chloro-2-cyanophenoxy)-phenyl, 2,4-Dimethyl-1,3-thiazole-5-yl-, Methyl-methane-sulfonyl-, 2,5-Bis-(2,2,2-Trifluoroethoxy)-phenyl-, 5-(Di-n-propylamino)-naphth-1-yl-, 2,2,5,7,8-Pentamethyl-chroman-6-yl-, 5-Chloro-4-nitro-thiophene-2-yl-, 2,1,3-Benzothiadiazole-4-yl-, 1-Methyl-imidazole-4-yl-, Benzofurazan-4-yl-, 5-(Isoxazol-3-yl)-thiophene-2-yl-, Vinyl-phenyl-4-yl-, 5-Dichloro-methyl-furan-2-yl-, 5-Bromo-thiophene-2-yl-, 5-(4-Chlorobenzamidomethyl)-thiophene-2-yl-, Dibenzo[b,d]-furan-2-yl-, 5-Chloro-3-methylbenzo[b]-thiophene-2-yl-, 3-Methoxy-4-(methoxycarbonyl)-thiophene-2-yl-, 5-[2-(Methylthio)-pyrimidin-4-yl-]-thiophene-2-yl-, 4-Chloro-2,1,3-Benzoxadiazole-7-yl-, 5-Chloro-2,1,3-Benzoxadiazole-4-yl-, 6-Chloro-Imidazo(2,1-b)-thiazole-5-yl-, 3-Methyl-benzo[b]-thiophene-2-yl-, 4-[[3-Chloro-5-(Trifluoromethyl)-2-pyridyl]oxy-phenyl-, 5-Chloro-naphth-1-yl-, 5-Chloro-naphth-2-yl-, 9,10-Dibromoanthracene-2-yl-, Isoquinoline-5-yl-, 4-Methoxy-2,3,6-trimethylbenzoyl-, 4'-Nitro-biphenyl-4-yl-, (1,3-Dihydro-1-oxo-2H-Isoindol-2-yl-)-4-phenyl-, 5-(2-Methyl-1,3-thiazole-4-yl)-thiophene-2-yl-, 5-(1-Methyl-3-(trifluoromethyl)pyrazol-5-yl-]-thiophene-2-yl-, 5-[5-Trifluoromethyl)-Isoxazol-3-yl]-thiophene-2-yl-, p-Dodecyl-phenyl-, 4-[(3-Cyano-4-methoxy-2-pyridinyl)oxy]-phenyl-, 4-(N-phthalimidinyl)-phenyl-, 1,2,3,4-Tetrahydro-2-(trifluoroacetyl)-isoquinoline-7-yl-, 1,2-Dimethylimidazole-4-yl-, 2,2,4,6,7-Pentamethyldihydrobenzofuran-5-yl-, 4-Chloro-naphth-1-yl-, 2,5-Dichloro-4-nitro-thiophene-3-yl-, 4-(4-Methoxy-phenoxy)-phenyl-, [4-(3,5-Dichlorophenoxy)phenyl]-, [4-(3,4-Dichlorophenoxy)phenyl]-, [4-(3,5)-Bis(trifluoromethylphenoxy)phenyl]-, 3-(2-Methoxy-phenoxy)-phenyl, 3-(4-Methoxy-phenyl)-phenyl-, 3-(4-Chloro-phenyl)-phenyl-, 3-(3,5-Dichloro-phenyl)-phenyl-, 3-(3,4-Dichloro-phenyl)-phenyl-, 3-(4-Fluorophenyl)-phenyl-, 3-[4-(Trifluoromethyl)-phenyl]-phenyl-, 3-[3,5-Bis-(Trifluoromethyl)-phenyl]-phenyl-, 4-(2-Methoxy-phenoxy)-phenyl-, 4-(2-Methyl-phenoxy)-phenyl-, 4-(4-Methoxy-phenoxy)-phenyl-, 4-(4-Chlorophenyl)-phenyl-, 4-(3,5-Dichlorophenyl)-phenyl-, 4-(3,4-Dichlorophenyl)-phenyl-, 4-(4-Fluorophenyl)-phenyl-, 4-[4-(Trifluormethyl)-phenyl]-phenyl-, 4-[3,5-Bis-(Trifluoromethyl)-phenyl]-phenyl-, Cyclopropyl-, 2-(2-Chlorophenyl)-2-Phenylethyl-, 2-(2-Trifluoromethylphenyl)-2-phenylethyl-, 5-[4-Cyano-1-methyl-5-(methylthio)-1H-pyrazol-3-yl-thiophene-2-yl-, 3-Cyano-2,4-bis-(2,2,2-Trifluorothoxy)-phenyl-, 4-

193
+96

[(2-Chloro-1,3-Thiazol-5-yl)-methoxy]-phenyl-, 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethyl-, 5-Iodo-naphth-1-yl-, Ethyl-2,5-dimethyl-1-phenylpyrrole-4-carboxylate-3-yl-, Ethyl-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxylate-4-yl-, Ethyl-5-(4-chlorophenyl)-2-methyl-3-furoate-4-yl, Ethyl-5-(4-chlorophenyl)-2-methyl-1-phenyl-3-carboxylate-4-yl-, Ethyl-2,5-dimethyl-3-furoate-4-yl-, 3-Chloro-4-(1,3-dioxo-2-Azaspiro[4,4]non-2-yl)-phenyl-, Coumarin-6-yl, 3-(4-Methoxy-phenoxy)-phenyl-, [3-(3,5-Dichlorophenoxy)]-phenyl-, [3-(3,4 Dichlorophenoxy)]-phenyl-, 3,5-Bis(Trifluoromethyl)phenoxyphenyl-, 2,2-Diphenylethyl-, 4-Phenyl-5-(trifluoromethyl)-thiophene-3-yl-, Methyl-4-Phenyl-5-(Trifluoromethyl)-thiophene-2-carboxylate-3-yl-, Methyl-1,2,5-trimethylpyrrole-3-Carboxylate-4-yl-, 4-Fluoro-naphth-1-yl-, 5-Fluoro-3-methylbenzo[b]-thiophene-2-yl-, Methyl-2,5-dimethyl-3-furoate-4-yl-, Methyl-2-furoate-5-yl-, Methyl-2-methyl-3-furoate-5-yl-, Methyl-1-methyl-1H-pyrrole-2-Carboxylate-5-yl-, 2-(5-Chloro-1,2,4-Thiadiazol-3-yl)-thiophene-5-yl-, 1,3,5-Trimethyl-1H-pyrazole-4-yl-, Pentafluoroethoxytetrafluoroethyl-, 5-(5-Isoxazyl)-thiophene-2-yl-, 5-(5-Isoxazol-yl)-2-furyl-, 5-Methyl-2,1,3-benzothiadiazole-4-yl-, 2,3-Dihydro-1,4-benzodioxine-6-yl-, 4-Methyl-Naphth-1-yl-, 5-Methyl-2-(Trifluormethyl)-3-Furyl-, 2,3-Dihydrobenzo[b]furan-5-yl-, 1-Benzothiophene-3-yl-, 4-Methyl-3,4-dihydro-2H-1,4-Benzoxazine-7-yl-, 5-Methyl-1-phenyl-1H-pyrazole-4-yl-, 6-Morpholino-3-Pyridinyl-, 4-(1H-Pyrazol-1-yl)-phenyl-, 6-Phenoxy-3-Pyridyl-, 3,4-Dihydro-2H-1,5-benzodioxapine-7-yl-, 5-(1,3-Oxazol-5-yl)-2-thienyl-, 4-(1,3-Oxazol-5-yl)-phenyl-, 5-Methyl-4-Isoxazolyl, 2,1,3-Benzothiadiazole-5-yl-, 5-Acetamido-naphth-1-yl-, 3-Methyl-8-Quinolinyl-, 1,3-Benzothiazole-6-yl-, 2-Morpholino-3-Pyridyl-, 2,5-Dimethyl-3-thienyl-, 5-[5-(Chloromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl-, Ethyl-3-[5-yl-2-thienyl-]1,2,4-oxadiazole-5-carboxylate-, 3-(5-Methyl-1,3,4-oxadiazol-2-yl)-phenyl-, 4-(Difluoromethoxy)-phenyl-, 3-(Difluoromethoxy)-phenyl-, 2,2-Dimethyl-6-Chromanyl-, Ethyl-3,5-dimethyl-1H-pyrrole-2-carboxylate-4-yl-, Imidazo[1,2-A]pyridine-3-yl-, 3-(1,3-Oxazol-5-yl)-phenyl-, Ethyl-5-[4-yl)-phenyl]-2-methyl-3-furoate, 1-Pyrrolidinylphenylsulfonyl-, Methyl-5-yl-4-methyl-2-thiophene-carboxylate, Methyl-3-yl-4-(isopropylsulfonyl)-2-thiophene, 7-Chlorochromone-3-yl-, 4'-Bromobiphenyl-4-yl-, 4'-Acetyl-biphenyl-4-yl-, 4'-Bromo-2'-fluoro-biphenyl-4-yl-, 1-Methyl-5-isatinyl-, 2-Chloro-3-thiophenecarboxylic-acid-5-yl-,

194
195

2-Methoxy-5-(N-phthalimidinyl)-phenyl-, 1-Benzothiophene-2-yl-, Morpholinophenylsulfonyl- and 3-(2-Methyl-4-pyrimidinyl)-phenyl-

6. Compounds according to any one of claims 1 to 5, characterized in that R^{10} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl.

7. Compounds according to any one of claims 1 to 6, characterized in that R^{11} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl.

195
196

8. Compounds according to any one of claims 1 to 7, characterized in that R^{12} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl.

9. Compounds according to any one of claims 1 to 8, characterized in that R^{13} and R^{14} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably are each independently selected from the group consisting of H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical and a phenyl radical, more preferably are each independently selected from the group consisting of H, $-CH_3$, $-C_2H_5$ and phenyl.

10. Compounds according to any one of claims 1 to 8, characterized in that R^{13} and R^{14} together with the bridging nitrogen atom form a saturated, unsaturated or aromatic, 5- or 6-membered heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member, preferably form an unsubstituted piperidin or morpholine group.

11. Compounds according to any one of claims 1 to 10, characterized in that R^{16} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-6}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably represents H, $-CH_3$, $-C_2H_5$ or phenyl.

12. Compounds according to any one of claims 1 to 11, characterized in that R^{16} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6} aliphatic radical, preferably an unbranched or branched, saturated, unsubstituted C_{1-3} alkyl radical, more preferably a methyl radical.

13. Compounds according to any one of claims 1 to 12, characterized in that R^{17} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6} aliphatic radical, preferably an unbranched or branched, saturated, unsubstituted C_{1-3} alkyl radical, more preferably a methyl radical.

197

14. Compounds according to one or more of claims 1 to 13:


1-[1-(5-Chloro-3-methyl-benzo[b]thiophenyl-2-sulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

1-[1-(5-Dimethylamino-naphthyl-1-sulfonyl)-piperidine-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

1-[1-(5-Dimethylamino-naphthyl-1-sulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

and corresponding salts thereof, and corresponding solvates.


15. Process for the preparation of benzoxazinone-derived sulfonamide compounds of general formula (I) according to one or more of claims 1 to 14, characterized in that it comprises reacting at least one piperidine compound of general formula (II), wherein R^1 to R^8 have the meaning according to claim 1, and/or a salt, preferably a hydrochloride salt, thereof,



(II)

198
199

with at least one compound of general formula (III),



(III)

wherein W has the meaning according to claim 1, in a suitable reaction medium, optionally in the presence of at least one base and/or at least one auxiliary agent.

16. Process for the preparation of a physiologically acceptable salt of the benzoxazinone-derived sulphonamide compounds according to claims 1-14, characterized in that at least one compound of general formula (I) having at least one basic group is reacted with at least one acid, preferably an inorganic or organic acid, preferably in the presence of a suitable reaction medium.

17. Process for the preparation of a physiologically acceptable salt of the benzoxazinone-derived sulphonamide compounds according to claims 1-14, characterized in that at least one compound of general formula (I) having at least one acidic group is reacted with at least one base, preferably in the presence of a suitable reaction medium.

18. Medicament comprising at least one benzoxazinone-derived sulphonamide compound according to any one of claims 1-14, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively, and optionally one or more pharmaceutically acceptable adjuvants.


199
200

19. Medicament according to claim 18 for 5-HT_6-receptor regulation, for cognitive enhancement, for the prophylaxis and/or treatment of food ingestion (food intake) disorders, particularly for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (Non-Insulin Dependent Diabetes Mellitus), preferably type II diabetes, which is caused by obesity, disorders of the central nervous system, disorders of the gastrointestinal tract, such as irritable intestine syndrom, anxiety, panic, depression, cognitive memory disorders, senile dementia disorders, such as Morbus Alzheimer, Morbus Parkinson and Morbus Huntington, schizophrenia, psychosis, infantile hyperkinesis or ADHC (attention deficit, hyperactivity disorders).

20. Use of at least one benzoxazinone-derived sulphonamide compound according to any one of claims 1-14, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, for the manufacture of a medicament for 5-HT_6-receptor regulation, for cognitive enhancement, for the prophylaxis and/or treatment of food ingestion (food intake) disorders, particularly for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (Non-Insulin Dependent Diabetes Mellitus), preferably type II diabetes, which is caused by obesity, disorders of the central nervous system, disorders of the gastrointestinal tract, such as irritable intestine syndrom, anxiety, panic, depression, cognitive memory disorders, senile dementia disorders, such as Morbus Alzheimer, Morbus Parkinson and Morbus Huntington, schizophrenia, psychosis, infantile hyperkinesis or ADHC (attention deficit, hyperactivity disorders).

200
201

21. Use of at least one benzoxazinone-derived sulfonamide compound of general formula (Ia),



(Ia)

wherein

R^{1a}, R^{2a}, R^{3a}, R^{4a} are each independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano group, $-OR^{10a}$, $-OC(=O)R^{11a}$, $-(C=O)-OR^{11a}$, $-SR^{12a}$, $-SOR^{12a}$, $-SO_2R^{12a}$, $-NH-SO_2R^{12a}$, $-SO_2NH_2$ and a $-NR^{13a}R^{14a}$ moiety,

R^{6a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical,

R^{6a}, R^{7a}, R^{8a}, R^{9a} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano group and a -$COOR^{15a}$ moiety,

W^a represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, a $NR^{16a}R^{17a}$-moiety or a COR^{18a}-moiety,

R^{10a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{11a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{12a} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{13a} and R^{14a} each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

or R^{13a} and R^{14a} together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member,

R^{15a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{16a} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

R^{17a} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

R^{18a} represents an optionally at least mono-substituted aryl radical,

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively,

for the manufacture of a medicament for 5-HT_6-receptor regulation.

204
205

22. Use according to claim 21, characterized in that R^{1a}, R^{2a}, R^{3a}, R^{4a} are each independently selected from the group consisting of H, F, Cl, Br, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano group, -OR^{10a}, -$OC(=O)R^{11a}$, -SR^{12a}, -SOR^{12a}, -SO_2R^{12a}, -NH-SO_2R^{12a}, -SO_2NH_2 and a -$NR^{13a}R^{14a}$ moiety, preferably selected from the group consisting of H, F, Cl, Br, a saturated, branched or unbranched, optionally at least mono-substituted C_{1-6}-aliphatic radical, a saturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_5- or C_6-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_1- or C_2-alkylene group, a nitro group, a cyano group, -OR^{10a}, -$OC(=O)R^{11a}$, -SR^{12a} and -$NR^{13a}R^{14a}$ moiety, more preferably selected from the group consisting of H, F, Cl, -CH_3, -CH_2CH_3, -CF_3, -CF_2CF_3, cyclopentyl, cyclohexyl, nitro, cyano and -OR^{10a}.

23. Use according to claim 21 or 22, characterized in that R^{4a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, preferably represents H or a branched or unbranched C_{1-8}-alkyl radical, more preferably H, -CH_3 or -CH_2CH_3.

24. Use according to any one of claims 21 to 23, characterized in that R^{6a}, R^{7a}, R^{8a}, R^{9a} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, a cyano group and a -$COOR^{15a}$ moiety, preferably selected from the group consisting of H, a branched or unbranched C_{1-3}-alkyl radical, a cyano group and a $COOR^{15a}$ group, more preferably from the group consisting of H, $-CH_3$, $-CH_2CH_3$ and a cyano moiety.

25. Use according to any one of claims 21 to 24, characterized in that W^a represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-20} aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8} cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}- alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, a $NR^{16a}R^{17a}$-moiety or a COR^{15a}-moiety,

preferably is selected from the group consisting of 1-Naphthyl-, 5-Dimethylamino-napth-1-yl, 2-Naphthyl-, 2-Acetamido-4-methyl-5-thiazolyl-, 2-Thienyl-, 8-Quinolinyl-, Phenyl-, Pentafluorophenyl-, 2,4,5-Trichloro-phenyl-, 2,5-Dichloro-phenyl-, 2-Nitrophenyl-, 2,4-Dinitro-phenyl-, 3,5-Dichloro-2-hydroxy-phenyl-, 2,4,6-Triisopropyl-phenyl-, 2-Mesityl-, 3-Nitro-phenyl-, 4-Bromo-phenyl-, 4-Fluoro-phenyl-, 4-Chlorophenyl-, 4-Chloro-3-nitro-phenyl-, 4-Iodo-phenyl-, N-Acetyl-sulfanilyl-, 4-Nitro-phenyl-, 4-Methoxy-phenyl-, Benzoic-acid-4-yl-, 4-tert-Butyl-phenyl-, p-Tolyl-, Trifluoromethyl-, Trichloromethyl-, Isopropyl-, Methyl-, Benzyl-, trans-styryl-, 2,2,2-Trifluoroethyl-, Ethyl-, Hexadecyl-, 2-Chloroethyl-, n-Propyl-, 3-Chloro-propyl-, n-Butyl-, Methyl-benzoate-2-yl-, 2-Nitro-4-(trifluoromethyl)-phenyl-, Pentamethyl-phenyl-

206
207

, 2,3,5,6-Tetramethyl-phenyl-, 3-(Trifluoromethyl)-phenyl-, 3,5-Bis-(Trifluoromethyl)-phenyl-, Dichloromethyl-, Chloromethyl-, Dodecyl-, 1-Octyl-, 2,3,4-Trichloro-phenyl-, 2,5-Dimethoxy-phenyl-, o-Tolyl-, p-xylyl-2-yl-, Benzoic-acid-3-yl-, 4-Chloro-3-(trifluoromethyl)-phenyl-, 4-Chloro-5-nitro-benzoic acid-3-yl-, 6-(p-toluidino)-naphth-2-yl-, 4-Methoxy-2,3,6-trimethylphenyl-, 3,4-Dichlorophenyl-, 4,5-Dibromo-thiophene-2-yl-, 3-Chloro-4-fluoro-phenyl-, 4-Ethyl-phenyl-, 4-n-Propyl-phenyl-, 4-(1,1-Dimethylpropyl)-phenyl-, 4-Isopropyl-phenyl-, 4-Bromo-2,5-difluoro-phenyl-, 2-Fluoro-phenyl-, 3-Fluoro-phenyl-, 4-(Trifluoromethoxy)-phenyl-, 4-(Trifluoromethyl)-phenyl-, 2,4-Difluoro-phenyl-, 2,4-Dichloro-5-methyl-phenyl-, 4-Chloro-2,5-dimethyl-phenyl-, 5-Diethylamino-napth-2-yl-, Benzoyl chloride-3-yl-, 2-Chloro-phenyl-, 1-Octadecyl-, 4-Bromo-2,5-dichloro-thiophene-3-yl-, 2,5-Dichloro-thiophene-3-yl-, 5-Chloro-thiophene-2-yl-, 2-Methyl-5-nitro-phenyl-, 2-(Trifluoromethyl)-phenyl-, 3-Chloro-phenyl-, 3,5-Dichloro-phenyl-, 1-Decyl-, 3-Methyl-phenyl-, 2-Chloro-6-methyl-, 5-Bromo-2-methoxy-phenyl-, 3,4-Dimethoxy-phenyl-, 2-3-Dichloro-phenyl-, 2-Bromo-phenyl-, 3,5-Dichloro-4-(2-chloro-4-nitrophenoxy)-phenyl-, 2,3-Dichloro-thiophene-5-yl-, 3-Bromo-2-chloro-thiophene-5-yl-, 3-Bromo-5-chloro-thiophene-2-yl-, 2-(Benzoylaminomethyl)-thiophene-5-yl-, 4-(Phenyl-sulphonyl)-thiophene-2-yl-, 2-Phenyl-sulphonyl-thiophene-5-yl-, 3-Chloro-2-methyl-phenyl-, 2-[1-Methyl-5-(trifluoromethyl)pyrazol-3-yl]-thiophene-5-yl-, 5-Pyrid-2-yl-thiophene-2-yl-, 2-Chloro-5-(trifluoromethyl)-phenyl-, 2,6-Dichloro-phenyl-, 3-Bromo-phenyl-, 2-(Trifluoromethoxy)-phenyl-, 4-Cyano-phenyl-, 2-Cyano-phenyl-, 4-n-Butoxy-phenyl-, 4-Acetamido-3-chloro-phenyl, 2,5-Dibromo-3,6-difluoro-phenyl-, 5-Chloro-1,3-dimethylpyrazole-4-yl-, 3,5-Dimethylisoxazole-4-yl-, 2-(2,4-Dichlorophenoxy)-phenyl-, 4-(2-Chloro-6-nitro-phenoxy)-phenyl-, 4-(3-Chloro-2-cyano-phenoxy)-phenyl-, 2,4-Dichloro-phenyl-, 2,4-Dimethyl-1,3-thiazole-5-yl-, Methyl-methane-sulfonyl-, 2,5-Bis-(2,2,2-Trifluoroethoxy)-phenyl-, 2-Chloro-4-(trifluoromethyl)-phenyl-, 2-Chloro-4-fluoro-phenyl-, 5-Fluoro-2-methyl-phenyl-, 5-Chloro-2-methoxy-phenyl-, 2,4,6-Trichloro-phenyl-, 2-Hydroxy-benzoic acid-5-yl-, 5-(Di-n-propylamino)-naphth-1-yl-, 6-Methoxy-m-tolyl-, 2,5-Difluoro-phenyl-, 2,4-Dimethoxy-phenyl-, 2,5-Dibromo-phenyl-, 3,4-Dibromo-phenyl-, 2,2,5,7,8-Pentamethyl-chroman-6-yl-, 2-Methoxy-benzoic-acid-5-yl-, 5-Chloro-4-nitro-thiophene-2-yl-, 2,1,3-Benzothiadiazole-4-yl-, 1-Methyl-Imidazole-4-yl-, Benzofurazan-4-yl-, 2-

(Methoxycarbonyl)-thiophene-3-yl-, 5-(Isoxazol-3-yl)-thiophene-2-yl-, 2,4,5-Trifluoro-phenyl-, Biphenyl-4-yl-, Vinyl-phenyl-4-yl-, 2-Nitro-benzyl-, 5-Dichloro-methyl-furan-2-yl-, 5-Bromo-thiophene-2-yl-, 5-(4-Chlorobenzamidomethyl)-thiophene-2-yl-, 2,6-Difluoro-phenyl-, 2,5-Dimethoxy-4-nitro-phenyl-, Dibenzo[b,d]-furan-2-yl-, 2,3,4-Trifluoro-phenyl-, 3-Nitro-p-tolyl-, 4-Methoxy-2-nitro-phenyl-, 3,4-Difluoro-phenyl-, 4-(Bromoethyl)-phenyl-, 3,5-Dichloro-4-hydroxy-phenyl-, 4-n-Amyl-phenyl-, 5-Chloro-3-methylbenzo[b]-thiophene-2-yl-, 3-Methoxy-4-(methoxycarbonyl)-thiophene-2-yl-, 4-n-Butyl-phenyl-, 2-Chloro-4-cyano-phenyl-, 5-[2-(Methylthio)-pyrimidin-4-yl-]-thiophene-2-yl-, 3,5-Dinitro-4-methoxy-phenyl-, 4-Bromo-2-(trifluoromethoxy)-phenyl-, 4-Chloro-2,1,3-Benzoxadiazole-7-yl-, 2-(1-Naphthyl)-ethyl-, 3-Cyano-phenyl-, 5-Chloro-2,1,3-Benzoxadiazole-4-yl-, 3-Chloro-4-methyl-phenyl-, 4-Bromo-2-ethyl-phenyl-, 2,4-Dichloro-6-methyl-phenyl-, 6-Chloro-imidazo(2,1-B)-thiazole-5-yl-, 3-Methyl-benzo[b]-thiophene-2-yl-, 4-Methyl-sulphonyl-phenyl-, 2-Methyl-sulphonyl-phenyl-, 4-Bromo-2-methyl-phenyl-, 2,6-Dichloro-4-(trifluoromethyl)-phenyl-, 4-[[3-Chloro-5-(trifluoromethyl)-2-pyridinyl]oxy]-phenyl-, 5-Chloro-naphth-1-yl-, 5-Chloro-naphth-2-yl-, 9,10-Dibromoanthracene-2-yl-, Isoquinoline-5-yl-, 4-Methoxy-2,3,6-trimethyl-phenyl-, 4'-Nitro-biphenyl-4-yl-, [(4-Phenoxy)-phenyl-, (1,3-Dihydro-1-oxo-2H-Isoindol-2-yl-)-4-phenyl-, 4-Acetyl-phenyl-, 5-(2-Methyl-1,3-thiazole-4-yl)-thiophene-2-yl-, 5-(1-Methyl-3-(trifluoromethyl)pyrazol-5-yl-]-thiophene-2-yl-, 5-[5-Trifluoromethyl)-isoxazol-3-yl]-thiophene-2-yl-, 2-Iodo-phenyl-, p-Dodecyl-phenyl-, 4-[(3-Cyano-4-methoxy-2-pyridinyl)oxy]-phenyl-, 4-(N-phthalimidinyl)-phenyl-, 1,2,3,4-Tetrahydro-2-(trifluoroacetyl)-isoquinoline-7-yl-, 4-Bromo-2-fluoro-phenyl-, 2-Fluoro-5-(trifluoromethyl)-phenyl-, 4-Fluoro-2-(trifluoromethyl)-phenyl-, 4-Fluoro-3-(trifluoromethyl)-phenyl-, 2,4,6-Trifluoro-phenyl-, 3-(Trifluoromethoxy)-phenyl-, 1,2-Dimethylimidazole-4-yl-, Ethyl-4-Carboxylate-3-yl-, 2,2,4,6,7-Pentamethyldihydrobenzofuran-5-yl-, 3-Bromo-2-chloropyridine-5-yl-, 3-Methoxy-phenyl-, 2-Methoxy-4-methyl-phenyl-, 2-Chloro-4-fluorobenzoic-acid-5-yl-, 4-Chloro-naphth-1-yl-, 2,5-Dichloro-4-nitro-thiophene-3-yl-, 4-(4-Methoxy-phenoxy)-phenyl-, 4-(4-Chloro-phenoxy)-phenyl-, 4-(3,5-Dichloro-phenoxy)-phenyl-, 4-(3,4-Dichloro-phenoxy)-phenyl-, 4-(4-Fluoro-phenoxy)-phenyl-, 4-(4-Methyl-phenoxy)-phenyl-, 4-[4-(Trifluormethyl)-phenoxy-phenyl-, 4-[3,5-Bis-(trifluoromethyl)-phenoxy]-phenyl-,

208
209

3-(2-Methoxy-phenoxy)-phenyl-, [3-(2-Chloro-phenoxy)-phenyl-, 3-(2-Methyl-phenoxy)-phenyl-, 4-[2-(Trifluoromethyl)-phenoxy]-phenyl-, 3-Phenyl-phenyl-, 3-(4-Methoxy-phenyl)-phenyl-, 3-(4-Chloro-phenyl)-phenyl-, 3-(3,5-Dichloro-phenyl)-phenyl-, 3-(3,4-Dichloro-phenyl)-phenyl-, 3-(4-Fluorophenyl)-phenyl-, 3-(4-Methylphenyl)-phenyl-, 3-[4-(Trifluoromethyl)-phenyl]-phenyl-, 3-[3,5-Bis-(Trifluoromethyl)-phenyl]-phenyl-, 4-(4-Pyridyloxy)-phenyl)-, 4-(2-Methoxy-phenoxy)-phenyl-, 4-(2-Chloro-phenoxy)-phenyl-, 4-(2-Methyl-phenoxy)-phenyl-, 4-(4-Methoxy-phenoxy)-phenyl-, 4-(4-Chlorophenyl)-phenyl-, 4-(3,5-Dichlorophenyl)-phenyl-, 4-(3,4-Dichlorophenyl)-phenyl-, 4-(4-Fluorophenyl)-phenyl-, 4-(4-Methylphenyl)-phenyl-, 4-[4-(Trifluormethyl)-phenyl]-phenyl-, 4-[3,5-Bis-(Trifluoromethyl)-phenyl]-phenyl-, [3-(Trifluoromethyl)-phenyl]-methyl-, (4-Chlorophenyl)-methyl-, (3,5-Dichlorophenyl)-methyl-, (3,5-Dichlorophenyl)-methyl-, (4-Fluorophenyl)-methyl-, 4-Methylphenylmethyl-, [4-(Trifluoromethyl)-phenyl]-methyl-, Cyclopropyl-, 2-(2-Chlorophenyl)-2-Phenylethyl-, 2-(2-Trifluoromethylphenyl)-2-phenylethyl-, 5-[4-Cyano-1-methyl-5-(methylthio)-1H-pyrazol-3-yl-thiophene-2-yl-, 3-Cyano-2,4-bis-(2,2,2-Trifluorothoxy)-phenyl-, 4-[(2-Chloro-1,3-Thiazol-5-yl)-methoxy]-phenyl-, 3-Nitro-phenylmethyl-, 4-Formylphenyl-, 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethyl-, [3,5-Bis-(Trifluoromethyl)-phenyl]-methyl-, (4-(2-Pyridyloxy)-phenyl)-, (4-(3-Pyridyloxy)-phenyl)-, 5-Iodo-naphth-1-yl-, Ethyl-2,5-dimethyl-1-phenylpyrrole-4-carboxylate-3-yl-, Ethyl-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxylate-4-yl-, Ethyl-5-(4-chlorophenyl)-2-methyl-3-furoate-4-yl, Ethyl-5-(4-chlorophenyl)-2-methyl-1-phenyl-3-carboxylate-4-yl-, Ethyl-2,5-dimethyl-3-furoate-4-yl-, 3-Chloro-4-(1,3-dioxo-2-Azaspiro[4,4]non-2-yl)-phenyl-, 5-Bromo-2,4-difluoro-phenyl-, 5-Chloro-2,4-difluorophenyl-, Coumarin-6-yl, 2-Methoxy-phenyl, (3-Phenoxy)-phenyl-, 3-(4-Methoxy-phenoxy)-phenyl-, 3-(4-Chlorophenoxy)-phenyl-, 3-(3,5-Dichlorophenoxy)-phenyl-, 3-(3,4-Dichlorophenoxy)-phenyl-, 3-(4-Fluorophenoxy)-phenyl-, 3-(4-Methylphenoxy)-phenyl-, 3-[4-(Trifluoromethyl)-phenoxy]-phenyl-, 3-[3,5-(Trifluoromethyl)-phenoxy]-phenyl-, 3-[2-(Trifluoromethyl)-phenoxy]-phenyl-, 2,2-Diphenylethyl-, 4-Phenyl-5-(trifluoromethyl)-thiophene-3-yl-, Methyl-4-Phenyl-5-(Trifluoromethyl)-thiophene-2-carboxylate-3-yl-, Methyl-1,2,5-trimethylpyrrole-3-Carboxylate-4-yl-, 4-Fluoro-naphth-1-yl-, 3,5-Difluorophenyl-, 3-Fluoro-4-methoxy-phenyl-, 4-Chloro-2,5-difluorophenyl-, 2-Chloro-4,5-difluoro-phenyl-, 5-Fluoro-3-

methylbenzo[b]-thiophene-2-yl-, Methyl-3-phenylpropionate-4-yl, Dihydrocinnamic Acid-4-yl-, Methyl-2,5-dimethyl-3-furoate-4-yl-, Methyl-2-furoate-5-yl-, Methyl-2-methyl-3-furoate-5-yl-, Methyl-1-methyl-1H-pyrrole-2-Carboxylate-5-yl-, 2-(5-Chloro-1,2,4-Thiadiazol-3-yl)-thiophene-5-yl-, 1,3,5-Trimethyl-1H-pyrazole-4-yl-, 3-Chloro-5-fluoro-2-methylphenyl-, Pentafluoroethoxytetrafluoroethyl-, 5-(5-Isoxazyl)-thiophene-2-yl-, 5-(5-Isoxazol-yl)-2-furyl-, 5-Methyl-2,1,3-benzothiadiazole-4-yl-, Biphenyl-2-yl-, 2,3-Dihydro-1,4-benzodioxine-6-yl-, 4-Methyl-Naphth-1-yl-, 5-Methyl-2-(Trifluormethyl)-3-Furyl-, 2,3-Dihydrobenzo[b]furan-5-yl-, 1-Benzothiophene-3-yl-, 4-Methyl-3,4-dihydro-2H-1,4-Benzoxazine-7-yl-, 5-Methyl-1-phenyl-1H-pyrazole-4-yl-, 6-Morpholino-3-Pyridinyl-, 4-(1H-Pyrazol-1-yl)-phenyl-, 6-Phenoxy-3-Pyridyl-, 3,4-Dihydro-2H-1,5-benzodioxepine-7-yl-, 5-(1,3-Oxazol-5-yl)-2-thienyl-, 4-(1,3-Oxazol-5-yl)-phenyl-, 5-Methyl-4-isoxazolyl, 2,1,3-Benzothiadiazole-5-yl-, 3-Thienyl-, 2-Methyl-benzyl-, 3-Chloro-benzyl-, 5-Acetamido-naphth-1-yl-, 3-Methyl-8-Quinolinyl-, 4-Chloro-2-nitrophenyl-, 6-Quinolinyl-, 1,3-Benzothiazole-6-yl-, 2-Morpholino-3-Pyridyl-, 2,5-Dimethyl-3-thienyl-, 5-[5-(Chloromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl-, Ethyl-3-[5-yl-2-thienyl-]1,2,4-oxadiazole-5-carboxylate-, 3-(5-Methyl-1,3,4-oxadiazol-2-yl)-phenyl-, 4-Isopropoxyphenyl-, 2,4-Dibromophenyl-, 3-Cyano-4-fluorophenyl-, 2,5-Bis-(Trifluoromethyl)-phenyl, 2-Bromo-4-fluorophenyl-, 4-Bromo-3-fluorophenyl-, 4-(Difluoromethoxy)-phenyl-, 3-(Difluoromethoxy)-phenyl-, 5-Chloro-2-fluoro-phenyl-, 3-Chloro-2-fluorophenyl-, 2-Fluoro-4-methylphenyl-, 4 Nitro-3-(trifluoromethyl)-phenyl-, 3-Fluoro-4-methylphenyl-, 4-Fluoro-2-methylphenyl-, 4-Bromo-3-(tifluoromethyl)-phenyl-, 4-Bromo-2-(trifluoromethyl)-phenyl-, 3-Bromo-5-(trifluoromethyl)-phenyl-, 2-Bromo-4-(trifluoromethyl)-phenyl-, 2-Bromo-5-(trifluoromethyl)-phenyl-, 2,4-Dichloro-5-fluorophenyl-, 4,5-Dichloro-2-fluorophenyl-, 3,4,5-Trifluorophenyl-, 4-Chloro-2-fluorophenyl-, 2-Bromo-4,6-Difluorophenyl-, 2-Ethylphenyl-, 4-Bromo-2-chlorophenyl-, 4-Bromo-2,6-dichlorophenyl-, 2-Bromo-4,6-dichloro-phenyl-, 4-Bromo-2,6-dimethylphenyl-, 3,5-Dimethylphenyl-, 4-Bromo-3-methylphenyl-, 2-Methoxy-4-nitrophenyl-, 2,2-Dimethyl-6-Chromanyl-, Ethyl-3,5-dimethyl-1H-pyrrole-2-carboxylate-4-yl-, Imidazo[1,2-A]pyridine-3-yl-, 3-(1,3-Oxazol-5-yl)-phenyl-, Ethyl-5-[4-yl)-phenyl]-2-methyl-3-furoate, Methyl-3-(yl)-4-methoxybenzoate, 1-Pyrrolidinylphenylsulfonyl-, Methyl-5-yl-4-methyl-2-

thiophene-carboxylate, Methyl-3-yl-4-(isopropylsulfonyl)-2-thiophene, 2-Pyridyl-, 3-Fluoro-4-nitrophenyl-, 7-Chlorochromone-3-yl-, 4'-Bromobiphenyl-4-yl-, 4'-Acetyl-biphenyl-4-yl-, 4'-Bromo-2'-fluoro-biphenyl-4-yl-, 2-Chloro-4-(3-propyl-Ureido)-phenyl-, 3-(-Bromoacetyl)-phenyl-, 2-Bromo-3-(trifluoromethyl)-phenyl-, 1-Methyl-5-isatinyl-, 4-Isopropyl-benzoic-acid-3-yl-, 2-Chloro-3-thiophenecarboxylic-acid-5-yl-, 3-Pyridyl-, Cyclohexylmethyl-, 2-Methoxy-5-(N-phthalimidinyl)-phenyl-, 1-Benzothiophene-2-yl-, Morpholinophenylsulfonyl-, 3-(2-Methyl-4-pyrimidinyl)-phenyl-, and 2-Cyano-5-methylphenyl-.

26. Use according to any one of claims 21 to 25, characterized in that R^{10a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl.

27. Use according to any one of claims 21 to 26, characterized in that R^{11a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

preferably H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl.

28. Use according to any one of claims 21 to 27, characterized in that R^{12a} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl.

29. Use according to any one of claims 21 to 28, characterized in that R^{13a} and R^{14a} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably are each independently selected from the group consisting of H, a linear or branched C_{1-4}-alkyl radical, cyclohexyl and a phenyl radical, more preferably are each independently selected from the group consisting of H, $-CH_3$, $-C_2H_5$ and phenyl.

212
213

30. Use according to any one of claims 21 to 29, characterized in that R^{13a} and R^{14a} together with the bridging nitrogen atom form a saturated, unsaturated or aromatic, 5- or 6-membered heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member, preferably form an unsubstituted piperidin or morpholine group.

31. Use according to any one of claims 21 to 30, characterized in that R^{15a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-6}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably represents H, $-CH_3$, $-C_2H_5$ or phenyl.

32. Use according to any one of claims 21 to 31, characterized in that R^{16a} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6} aliphatic radical, preferably an unbranched or branched, saturated, unsubstituted C_{1-3} alkyl radical, more preferably a methyl radical.

33. Use according to any one of claims 21 to 32 characterized in that R^{17a} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6} aliphatic radical, preferably an unbranched or branched, saturated, unsubstituted C_{1-3} alkyl radical, more preferably a methyl radical.

213
214

34. Use according to any one of claims 21 to 33, characterized in that one or more benzooxazinone-derived sulfonamide compounds of general formula (Ia) are selected from the group consisting of:

1-[1-(Naphthyl-1-sulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

1-(1-Phenylsulfonyl-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]-oxazin-2-one,

1-[1-(5-Chloro-3-methyl-benzo[b]thiophenyl-2-sulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

8-Methyl-1-[1-naphthyl-1-sulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

8-Methyl-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

1-[1-(5-Dimethylamino-naphthyl-1-sulfonyl)-piperidine-4-yl]-8-methyl-1,4-dihydrobenzo[d][1,3]oxazin-2-one,

1-[1-(5-Dimethylamino-naphthyl-1-sulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

1-[1-(2,3-Dichloro-phenylsulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

1-[1-(2,3-Dichloro-phenylsulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, and

corresponding salts thereof, or corresponding solvates thereof.

35. Use of at least one benzoxazinone-derived sulphonamide compound of general formula (Ia) according to any one of claims 21-34, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate, for the manufacture of a medicament for the prophylaxis and/or treatment of food intake disorders.

36. Use according to claim 35 for the regulation of appetite.

37. Use according to claim 35 for the reduction, increase or maintenance of body weight.

38. Use according to claim 35 for the prophylaxis and/or treatment of obesity.

39. Use according to claim 35 for the prophylaxis and/or treatment of bulimia.

40. Use according to claim 35 for the prophylaxis and/or treatment of anorexia.

41. Use according to claim 35 for the prophylaxis and/or treatment of cachexia.

42. Use according to claim 35 for the prophylaxis and/or treatment of type II diabetes.

43. Use of at least one benzoxazinone-derived sulphonamide compound of general formula (Ia) according to any one of claims 21-34, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate, for the manufacture of a medicament for the prophylaxis and/or treatment of anxiety.

44. Use of at least one benzoxazinone-derived sulphonamide compound of general formula (Ia) according to any one of claims 21-34, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate, for the manufacture of a medicament for the prophylaxis and/or treatment of panic.

45. Use of at least one benzoxazinone-derived sulphonamide compound of general formula (Ia) according to any one of claims 21-34, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate, for the manufacture of a medicament for the prophylaxis and/or treatment of depression.

46. Use of at least one benzoxazinone-derived sulphonamide compound of general formula (Ia) according to any one of claims 21-34, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate, for the manufacture of a medicament for the prophylaxis and/or treatment of cognitive disorders, preferably memory disorders.

47. Use of at least one benzoxazinone-derived sulphonamide compound of general formula (Ia) according to any one of claims 21-34, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate, for the manufacture of a medicament for the prophylaxis and/or treatment of senile dementia processes, preferably selected from the group consisting of Morbus Alzheimer, Morbus Parkinson, Morbus Huntington.

48. Use of at least one benzoxazinone-derived sulphonamide compound of general formula (Ia) according to any one of claims 21-34, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate, for the manufacture of a medicament for the prophylaxis and/or treatment of psychosis.

49. Use of at least one benzoxazinone-derived sulphonamide compound of general formula (Ia) according to any one of claims 21-34, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate, for the manufacture of a medicament for the prophylaxis and/or treatment of infantile hyperkinesis.

50. Use of at least one benzoxazinone-derived sulphonamide compound of general formula (Ia) according to any one of claims 21-34, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate, for the manufacture of a medicament for the prophylaxis and/or treatment of ADHC (attention deficit/hyperactivity disorder).


51. Use of at least one benzoxazinone-derived sulphonamide compound of general formula (Ia) according to any one of claims 21-34, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate, for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of the gastrointestinal tract, preferably irritable intestine syndrom.

217
218

52. Use of at least one benzoxazinone-derived sulphonamide compound of general formula (Ia) according to any one of claims 21-34, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate, for the manufacture of a medicament for the prophylaxis and/or treatment of schizophrenia.

53. Use of at least one benzoxazinone-derived sulphonamide compound of general formula (Ia) according to any one of claims 21-34, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate, for the manufacture of a medicament for cognitive enhancement.

54. Benzoxazinone-derived sulfonamide compounds of general formula (Ib),



(Ib)

wherein

R^{1b}, R^{2b}, R^{3b}, R^{4b} are each independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano group, $-OR^{10b}$, $-OC(=O)R^{11b}$, $-(C=O)-OR^{11b}$, $-SR^{12b}$, $-SOR^{12b}$, $-SO_2R^{12b}$, $-NH-SO_2R^{12b}$, $-SO_2NH_2$ and a $-NR^{13b}R^{14b}$ moiety,

R^{5b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical,

R^{6b}, R^{7b}, R^{8b}, R^{9b} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano group and a $-COOR^{15b}$ moiety,

W^b represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene

group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, a $NR^{16b}R^{17b}$-moiety or a COR^{16b}-moiety,

R^{10b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{11b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{12b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted

alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{13b} and R^{14b} each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

or R^{13b} and R^{14b} together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member,

R^{15b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{16b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

R^{17b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

R^{18b} represents an optionally at least mono-substituted aryl radical,

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively.

55. Compounds according to claim 54, characterized in that R^{1b}, R^{2b}, R^{3b}, R^{4b} are each independently selected from the group consisting of H, F, Cl, Br, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano group, -OR^{10b}, -$OC(=O)R^{11b}$, -SR^{12b}, -SOR^{12b}, -SO_2R^{12b}, -NH-SO_2R^{12b}, -SO_2NH_2 and a -$NR^{13b}R^{14b}$ moiety, preferably selected from the group consisting of H, F, Cl, Br, a saturated, branched or unbranched, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_5- or C_6-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_1- or C_2-alkylene group, a nitro group, a cyano group, -OR^{10b}, -$OC(=O)R^{11b}$, -SR^{12b} and -$NR^{13b}R^{14b}$ moiety, more preferably selected from the group consisting of H, F, Cl, Br, -CH_3, -CH_2CH_3, -CF_3, -CF_2CF_3, cyclopentyl, cyclohexyl, nitro, cyano and -OR^{10b}.

56. Compounds according to claim 54 or 55, characterized in that R^{5b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, preferably represents H or a branched or unbranched C_{1-3}-alkyl radical, more preferably H, $-CH_3$ or $-CH_2CH_3$, most preferably a hydrogen atom.

57. Compounds according to any one of claims 54 to 56, characterized in that R^{6b}, R^{7b}, R^{8b}, R^{9b} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, a cyano group and a $-COOR^{15b}$ moiety, preferably selected from the group consisting of H, a branched or unbranched C_{1-3}-alkyl radical, a cyano group and a $COOR^{15b}$ group, more preferably from the group consisting of H, $-CH_3$, $-CH_2CH_3$ and a cyano moiety, most preferably each of R^{6b}, R^{7b}, R^{8b} and R^{9b} represent a hydrogen atom.

58. Compounds according to any one of claims 54 to 57, characterized in that W^b represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-20} aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8} cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}- alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, a $NR^{16b}R^{17b}$-moiety or a COR^{18b}-moiety,

preferably W^b represents

a linear or branched C_{1-20}-alkyl radical, preferably an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl and 1,1-dimethyl-propyl; a linear or branched C_{2-20}-alkenyl radical; preferably a vinyl radical; $-CF_3$; $-CHF_2$; $-CH_2F$; $-CCl_3$; $-CHCl_2$; $-CH_2Cl$; $-CH_2-CF_3$; $-CH_2-CH_2-Cl$; $-CH_2-CH_2-CH_2-Cl$; $-CH_2-S(=O)_2-CH_3$; a cyclopropyl radical; a cyclobutyl radical; a cyclopentyl radical; a cyclohexyl radical; $-CH_2$-cyclopropyl; $-CH_2$-cyclobutyl; $-CH_2$-cyclopentyl; $-CH_2$-cyclohexyl; $-N(CH_3)_2$; $-N(C_2H_5)_2$; $-N(n-CH_2-CH_2-CH_3)_2$; phenyl; benzyl; naphthyl; -CH=CH-phenyl; $-(CF_2)-(CF_2)$-O-phenyl; $-(CH_2)$-naphtyl; $-(CH_2)-(CH_2)$-naphthyl; anthracenyl; -(C=O)-phenyl; thiophenyl; benzo[b]thiophenyl; furanyl; 2-oxo-2H-chromenyl; dibenzofuranyl; 2,3-dihydrobenzofuranyl; chromanyl; 2,3-dihydro-benzo[1,4]dioxinyl; 3,4-dihydro-2H-1,5-benzo-dioxapinyl; chromonyl; 1H-Imidazolyl; pyridinyl; pyrrolidine-2,5-dionyl; pyrrolyl; 1H-pyrazolyl; 1H-pyrimidine-2,4-dionyl; quinolinyl; isoquinolinyl; 1H-Benzoimidazolyl; 1,4-dihydro-quinoxaline-2,3-dionyl; 1,2,3,4-tetrahydro-isoquinolinyl; 1,4-dihydro-benzo[b][1,4]diazepine-2,4-dionyl; 1,3-dihydro-1-oxo-2H-isoindolyl; phthalimidinyl; 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethyl; Imidazo[1,2-a]pyridine; isatinyl; thiazolyl; 1,3-thiazolyl; 1,2,4-thiadiazolyl; Imidazo[2,1-b]thiazolyl; 1,3-benzothiazolyl; benzo[1,2,5]thiadiazolyl; 2-oxo-2,3-dihydro-benzothiazolyl; 2,1,3-benzothiadiazolyl; Imidazo[2,1-b]thiazolyl; isoxazolyl; benzo[1,2,5]oxadiazolyl; benzo[d]isoxazolyl; benzofurazanyl; 2-oxo-2,3-dihydro-benzooxazolyl; 3,4-dihydro-2H-benzo[1,4]oxazinyl; or 2,1,3-benzooxadiazolyl;

whereby each of these afore mentioned cyclic moieties may optionally be substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of methyl; ethyl; n-propyl; iso-propyl; n-butyl; iso-butyl; sec-butyl; tert-butyl; 1,1-dimethyl-propyl; n-pentyl; vinyl; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; morpholino; methoxy; ethoxy; n-propoxy; iso-propoxy; n-propoxy; F; Cl; Br; I; -CN; -OH; $-CF_3$; $-CF_2H$; $-CH_2F$; $-CCl_3$; $-CClH_2$; $-CHCl_2$; $-CH_2-F$; $-CH_2-Cl$;$-CH_2-Br$; -(C=O)-CH_2-Br; $-OCF_3$; $-O-CH_2-CF_3$; $-O-CHF_2$; $-NO_2$; $-NH_2$; $-N(CH_3)_2$; $-N(C_2H_5)_2$; -


$N(n\text{-}CH_2\text{-}CH_2\text{-}CH_3)_2$; $-N(n\text{-}CH_2\text{-}CH_2\text{-}CH_2\text{-}CH_3)_2$; $-NH\text{-}(C=O)\text{-}CH_3$; -NH-phenyl; $-(C=O)\text{-}CF_3$; $-(C=O)\text{-}OH$; =O (oxo); $-(C=O)\text{-}H$; $-S(=O)_2\text{-}CH_3$; $-S(=O)_2$-isopropyl; $-S(=O)_2$-phenyl; $-S(=O)_2$-pyrrolidinyl; $-S(=O)_2$-morpholino; $-(CH_2)\text{-}(CH_2)\text{-}(C=O)\text{-}O\text{-}CH_3$; $-NH\text{-}(C=O)\text{-}NH\text{-}CH_2\text{-}CH_2\text{-}CH_3$; $-(C=O)\text{-}CH_3$; $-(C=O)\text{-}O\text{-}CH_3$; $-(C=O)\text{-}O\text{-}C_2H_5$; $-(CH_2)\text{-}NH\text{-}(C=O)$-phenyl; $-CH_2\text{-}C(H)$(phenyl)(phenyl); $-O\text{-}CH_2$-thiazolyl; 1,3-dioxo-2-azaspiro[4.4]non-2-yl; phenyl; phenoxy; isoxazolyl; 1,3-oxazolyl; 1,2,4-oxadiazolyl; 1,3,4-oxadiazolyl; pyridinyl; pyridinyloxy; pyrazolyl; pyrimidinyl and phthalimidinyl; and


whereby each of the cyclic moieties of these afore mentioned substituents may optionally be substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of methyl; ethyl; n-propyl; iso-propyl; F; Cl; Br; I; CN; $-CH_2\text{-}F$; $-CH_2\text{-}Cl$; $-CH_2\text{-}Br$; $-CF_3$ and $-S\text{-}CH_3$,

more preferably W^b represents


an alkyl radical selected from the group consisting of methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec.butyl; iso-butyl and tert-butyl; vinyl (CH_2=CH-); $-N(CH_3)_2$; 1-naphthyl; benzyl; 2-naphtyl; phenyl; 2-methyl-phenyl; 3-methyl-phenyl; 4-methyl-phenyl; 2-ethyl-phenyl; 3-ethyl-phenyl; 4-ethyl-phenyl; 2-n-propyl-phenyl; 3-n-propyl-phenyl; 4-n-propyl-phenyl; 2-isopropyl-phenyl; 3-isopropyl-phenyl; 4-isopropyl-phenyl; 2-n-butyl-phenyl; 3-n-butyl-phenyl; 4-n-butyl-phenyl; 2-iso-butyl-phenyl; 3-iso-butyl-phenyl; 4-iso-butyl-phenyl; 2-tert-butyl-phenyl; 3-tert-butyl-phenyl; 4-tert-butyl-phenyl; 1,1-dimethylpropyl-phenyl; 2-cyclopentyl-phenyl; 3-cyclopentyl-phenyl; 4-cyclopentyl-phenyl 2-cyclohexyl-phenyl; 3-cyclohexyl-phenyl; 4-cyclohexyl-phenyl; 2-methoxy-phenyl; 3-methoxy-phenyl; 4-methoxy-phenyl; 2-ethoxy-phenyl; 3-ethoxy-phenyl; 4-ethoxy-phenyl; 2-n-propoxy-phenyl; 3-n-propoxy-phenyl; 4-n-propoxy-phenyl; 2-iso-propoxy-phenyl; 3-iso-propoxy-phenyl; 4-isopropoxy-phenyl;2-fluoro-phenyl; 3-fluoro-phenyl; 4-fluoro-phenyl; 2-chloro-phenyl; 3-chloro-phenyl; 4-chloro-phenyl; 2-bromo-phenyl; 3-bromo-phenyl; 4-bromo-phenyl; 2-trifluoromethyl-phenyl; 3-trifluoromethyl-phenyl; 4-trifluoromethyl-

phenyl; 2-trifluoromethoxy-phenyl; 3-trifluoromethoxy-phenyl; 4-trifluoromethoxy-phenyl; 2-carboxy-phenyl; 3-carboxy-phenyl; 4-carboxy-phenyl; 2-acetyl-phenyl; 3-acetyl-phenyl; 4-acetyl-phenyl; 2-(C=O)-O-CH_3-phenyl; 3-(C=O)-O-CH_3-phenyl; 4-(C=O)-O-CH_3-phenyl; 2-(CH_2)-(CH_2)-(C=O)-O-CH_3; 3-(CH_2)-(CH_2)-(C=O)-O-CH_3; 4-(CH_2)-(CH_2)-(C=O)-O-CH_3; 2-cyano-phenyl; 3-cyano-phenyl; 4-cyano-phenyl; 2-nitro-phenyl; 3-nitro-phenyl; 4-nitro-phenyl; 4-(4-bromophenoxy)-phenyl; 2-methylsulfonyl-phenyl; 3-methylsulfonyl-phenyl; 4-methylsulfonyl-phenyl; 2-phenyl-phenyl (biphenyl-2-yl); 3-phenyl-phenyl (biphenyl-3-yl); 4-phenyl-phenyl (biphenyl-4-yl); 2-phenoxy-phenyl; 3-phenoxy-phenyl; 4-phenoxy-phenyl; 2,4-dimethyl-phenyl; 3,4-dimethyl-phenyl; 2,4,6-trimethyl-phenyl; 2,3,5,6-tetramethyl-phenyl; pentamethyl-phenyl; 2,5-dimethoxy-phenyl; 3,4-dimethoxy-phenyl; 2,3-dichloro-phenyl; 2,4-dichloro-phenyl; 2,5-dichloro-phenyl; 3,4-dichloro-phenyl; 3,5-dichloro-phenyl; 2,6-dichloro-phenyl; 2,4-difluoro-phenyl; 3,4-difluoro-phenyl; 2,5-difluoro-phenyl; 2,6-difluoro-phenyl; 3-chloro-2-fluoro-phenyl; 3-chloro-4-fluoro-phenyl; 5-chloro-2-fluoro-phenyl; 2,3,4-trichloro-phenyl; 2,4,5-trichloro-phenyl; 2,4,6-trichloro-phenyl; 2,4,5-trifluoro-phenyl; 2,3,4-trifluoro-phenyl-; 2-chloro-4,5-difluoro-phenyl; 2-bromo-4-fluoro-phenyl; 2-bromo-4,6-difluoro-phenyl; 4-chloro-2,5-difluoro-phenyl; 5-chloro-2,4-difluoro-phenyl; 4-bromo-2,5-difluoro-phenyl; 5-bromo-2,4-difluoro-phenyl; pentafluoro-phenyl; 2,4-dinitro-phenyl; 4-chloro-3-nitro-phenyl; 2-methyl-5-nitro-phenyl; 5-bromo-2-methoxy-phenyl; 3-chloro-2-methyl-phenyl; 4-bromo-3-methyl-phenyl; 4-chloro-2,5-dimethyl-phenyl; 4-fluoro-3-methyl-phenyl; 5-fluoro-2-methyl-phenyl; 2-nitro-4-trifluoromethyl-phenyl; 2-methoxy-4-methyl-phenyl; 3,5-dichloro-2-hydroxy-phenyl; 3,5-dichloro-4-hydroxy-phenyl; 5-chloro-2,4-difluoro-phenyl; 3-chloro-4-(NH)-(C=O)-CH_3-phenyl; 2-chloro-6-methyl-phenyl; 2-chloro-5-trifluoromethyl-phenyl; 2-chloro-5-trifluoromethoxy-phenyl; 4-bromo-2-trifluoromethoxy-phenyl; 4-bromo-2-trifluoromethyl-phenyl; 4-bromo-3-trifluoromethyl-phenyl; 3-carboxy-4-fluoro-phenyl; 3-carboxy-4-chloro-6-fluoro-phenyl; 4-methoxy-2,3,6-trimethyl-phenyl-; or one of the following groups:



X
HN
N
NH-(C=O)-CH3
O
NH



X
(CH2)1-2X
F
Cl
N
NH-C(=O)-CH3
O
HO
H3C-(O=C)-O

228
229



250
229





whereby in each case X denotes the position by which the respective substituent W^b is bonded to the $-SO_2$ group of formula (Ib).

59. Compounds according to any one of claims 54 to 58, characterized in that R^{10b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl.

60. Compounds according to any one of claims 54 to 59, characterized in that R^{11b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl.

61. Compounds according to any one of claims 54 to 60, characterized in that R^{12b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be

condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl.

62. Compounds according to any one of claims 54 to 61, characterized in that R^{13b} and R^{14b} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably are each independently selected from the group consisting of H, a linear or branched C_{1-4}-alkyl radical, cyclohexyl and a phenyl radical, more preferably are each independently selected from the group consisting of H, $-CH_3$, $-C_2H_5$ and phenyl.

63. Compounds according to any one of claims 54 to 62, characterized in that R^{13b} and R^{14b} together with the bridging nitrogen atom form a saturated, unsaturated or aromatic, 5- or 6-membered heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member, preferably form an unsubstituted piperidin or morpholine group.

64. Compounds according to any one of claims 54 to 63, characterized in that R^{16b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably represents H, $-CH_3$, $-C_2H_5$ or phenyl.

65. Compounds according to any one of claims 54 to 64, characterized in that R^{16b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8} aliphatic radical, preferably an unbranched or branched, saturated, unsubstituted C_{1-3} alkyl radical, more preferably a methyl radical.

66. Compounds according to any one of claims 54 to 65 characterized in that R^{17b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8} aliphatic radical, preferably an unbranched or branched, saturated, unsubstituted C_{1-3} alkyl radical, more preferably a methyl radical.

67. Compounds according to any one of claims 54 to 66 characterized in that R^{18b} represents a phenyl radical, which is optionally at least mono-substituted by a C_{1-8} aliphatic radical, more preferably a phenyl radical, which is optionally at least mono-substituted by a methyl group.

235
23A

68. Compounds according to any one of claims 54 to 67, characterized in that

R^{1b}, R^{2b}, R^{3b}, R^{4b} are each independently selected from the group consisting of a hydrogen atom; a fluorine atom; a chlorine atom; a bromine atom; a methyl group and a methoxy group;


R^{5b} represents a hydrogen atom;


R^{6b}, R^{7b}, R^{8b}, R^{9b} each represent a hydrogen atom;


W^b represents

an alkyl radical selected from the group consisting of methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec.butyl; iso-butyl and tert-butyl; vinyl (CH_2=CH-); -$N(CH_3)_2$; 1-naphthyl; benzyl; 2-naphtyl; phenyl; 2-methyl-phenyl; 3-methyl-phenyl; 4-methyl-phenyl; 2-ethyl-phenyl; 3-ethyl-phenyl; 4-ethyl-phenyl; 2-n-propyl-phenyl; 3-n-propyl-phenyl; 4-n-propyl-phenyl; 2-isopropyl-phenyl; 3-isopropyl-phenyl; 4-isopropyl-phenyl; 2-n-butyl-phenyl; 3-n-butyl-phenyl; 4-n-butyl-phenyl; 2-iso-butyl-phenyl; 3-iso-butyl-phenyl; 4-iso-butyl-phenyl; 2-tert-butyl-phenyl; 3-tert-butyl-phenyl; 4-tert-butyl-phenyl; 1,1-dimethylpropyl-phenyl; 2-cyclopentyl-phenyl; 3-cyclopentyl-phenyl; 4-cyclopentyl-phenyl 2-cyclohexyl-phenyl; 3-cyclohexyl-phenyl; 4-cyclohexyl-phenyl; 2-methoxy-phenyl; 3-methoxy-phenyl; 4-methoxy-phenyl; 2-ethoxy-phenyl; 3-ethoxy-phenyl; 4-ethoxy-phenyl; 2-n-propoxy-phenyl; 3-n-propoxy-phenyl; 4-n-propoxy-phenyl; 2-iso-propoxy-phenyl; 3-iso-propoxy-phenyl; 4-isopropoxy-phenyl;2-fluoro-phenyl; 3-fluoro-phenyl; 4-fluoro-phenyl; 2-chloro-phenyl; 3-chloro-phenyl; 4-chloro-phenyl; 2-bromo-phenyl; 3-bromo-phenyl; 4-bromo-phenyl; 2-trifluoromethyl-phenyl; 3-trifluoromethyl-phenyl; 4-trifluoromethyl-phenyl; 2-trifluoromethoxy-phenyl; 3-trifluoromethoxy-phenyl; 4-trifluoromethoxy-phenyl; 2-carboxy-phenyl; 3-carboxy-phenyl; 4-carboxy-phenyl; 2-acetyl-phenyl; 3-acetyl-phenyl; 4-acetyl-phenyl; 2-(C=O)-O-CH_3-phenyl; 3-(C=O)-O-CH_3-phenyl; 4-(C=O)-O-CH_3-phenyl; 2-(CH_2)-(CH_2)-(C=O)-O-CH_3; 3-(CH_2)-(CH_2)-(C=O)-O-CH_3; 4-(CH_2)-(CH_2)-(C=O)-O-CH_3; 2-cyano-


phenyl; 3-cyano-phenyl; 4-cyano-phenyl; 2-nitro-phenyl; 3-nitro-phenyl; 4-nitro-phenyl; 4-(4-bromophenoxy)-phenyl; 2-methylsulfonyl-phenyl; 3-methylsulfonyl-phenyl; 4-methylsulfonyl-phenyl; 2-phenyl-phenyl (biphenyl-2-yl); 3-phenyl-phenyl (biphenyl-3-yl); 4-phenyl-phenyl (biphenyl-4-yl); 2-phenoxy-phenyl; 3-phenoxy-phenyl; 4-phenoxy-phenyl; 2,4-dimethyl-phenyl; 3,4-dimethyl-phenyl; 2,4,6-trimethyl-phenyl; 2,3,5,6-tetramethyl-phenyl; pentamethyl-phenyl; 2,5-dimethoxy-phenyl; 3,4-dimethoxy-phenyl; 2,3-dichloro-phenyl; 2,4-dichloro-phenyl; 2,5-dichloro-phenyl; 3,4-dichloro-phenyl; 3,5-dichloro-phenyl; 2,6-dichloro-phenyl; 2,4-difluoro-phenyl; 3,4-difluoro-phenyl; 2,5-difluoro-phenyl; 2,6-difluoro-phenyl; 3-chloro-2-fluoro-phenyl; 3-chloro-4-fluoro-phenyl; 5-chloro-2-fluoro-phenyl; 2,3,4-trichloro-phenyl; 2,4,5-trichloro-phenyl; 2,4,6-trichloro-phenyl; 2,4,5-trifluoro-phenyl; 2,3,4-trifluoro-phenyl-; 2-chloro-4,5-difluoro-phenyl; 2-bromo-4-fluoro-phenyl; 2-bromo-4,6-difluoro-phenyl; 4-chloro-2,5-difluoro-phenyl; 5-chloro-2,4-difluoro-phenyl; 4-bromo-2,5-difluoro-phenyl; 5-bromo-2,4-difluoro-phenyl; pentafluoro-phenyl; 2,4-dinitro-phenyl; 4-chloro-3-nitro-phenyl; 2-methyl-5-nitro-phenyl; 5-bromo-2-methoxy-phenyl; 3-chloro-2-methyl-phenyl; 4-bromo-3-methyl-phenyl; 4-chloro-2,5-dimethyl-phenyl; 4-fluoro-3-methyl-phenyl; 5-fluoro-2-methyl-phenyl; 2-nitro-4-trifluoromethyl-phenyl; 2-methoxy-4-methyl-phenyl; 3,5-dichloro-2-hydroxy-phenyl; 3,5-dichloro-4-hydroxy-phenyl; 5-chloro-2,4-difluoro-phenyl; 3-chloro-4-(NH)-(C=O)-CH_3-phenyl; 2-chloro-6-methyl-phenyl; 2-chloro-5-trifluoromethyl-phenyl; 2-chloro-5-trifluoromethoxy-phenyl; 4-bromo-2-trifluoromethoxy-phenyl; 4-bromo-2-trifluoromethyl-phenyl; 4-bromo-3-trifluoromethyl-phenyl; 3-carboxy-4-fluoro-phenyl; 3-carboxy-4-chloro-6-fluoro-phenyl; 4-methoxy-2,3,6-trimethyl-phenyl-; or one of the following groups:



X
HN
N
NH-(C=O)-CH3
O
NH


X
(CH2)1-2X
F
Cl
N
NH-C(=O)-CH3
O
HO
H3C-(O=C)-O



240
239





whereby in each case X denotes the position by which the respective substituent W^b is bonded to the $-SO_2$ group of formula (Ib).

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively.

242
241

69. Compounds according to any one of claims 54 to 68 selected from the following group:

N°	Compound
1	1-[1-(Naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
2	1-[1-(Toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
3	1-(1-Phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
4	1-(1-Benzenesulfonyl-piperidin-4-yl)-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
5	6-Chloro-1-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
6	6-Chloro-1-(1-phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
7	6-Chloro-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
8	6-Chloro-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
9	6-Chloro-1-[1-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
10	1-[1-(Thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
11	1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
12	2-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
13	1-[1-(2,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
14	1-[1-(4-Methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
15	1-[1-(2-Naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
16	8-Methyl-1-[1-(thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
17	1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
18	2-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
19	1-[1-(2,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
20	1-[1-(4-Methoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
21	8-Methyl-1-[1-(2-naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
22	4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonic acid dimethylamide
23	2-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid methyl ester
24	1-[1-(3-Trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
25	2-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid methyl ester
26	8-Methyl-1-[1-(3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
27	1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
28	2-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
29	6-Chloro-1-[1-(4-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
30	2-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid methyl ester
31	6-Chloro-1-[1-(2,4-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
32	6-Chloro-1-[1-(3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
33	1-[1-(6-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
34	1-[1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
35	1-[1-(4-Fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
36	8-Methyl-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
37	8-Methyl-1-(1-phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
38	1-[1-(4-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-

	one
39	6-Chloro-1-[1-(4-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
40	1-[1-(Butane-1-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
41	1-[1-(4-Bromo-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
42	1-[1-(4-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
43	1-[1-(Butane-1-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
44	6-Chloro-1-[1-(2-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
45	6-Chloro-1-[1-(3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
46	1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
47	8-Methyl-1-[1-(2-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
48	8-Methyl-1-[1-(3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
49	1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
50	8-Methyl-1-[1-(4-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
51	6-Chloro-1-[1-(4-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
52	1-(1-Ethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
53	1-[1-(Propane-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
54	1-[1-(Propane-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
55	6-Chloro-1-(1-ethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
56	6-Chloro-1-[1-(propane-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
57	6-Chloro-1-[1-(propane-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
58	6-Chloro-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
59	1-[1-(4-Nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
60	8-Methyl-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
61	8-Methyl-1-[1-(2-naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
62	8-Methyl-1-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
63	1-[1-(4-Fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
64	8-Methyl-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
65	8-Methyl-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
66	1-[1-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
67	8-Methyl-1-[1-(4-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
68	1-(1-Benzenesulfonyl-piperidin-4-yl)-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
69	1-[1-(4-Chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
70	1-[1-(5-Dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
71	1-[1-(4-Chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
72	1-[1-(4-Chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
73	6-Chloro-1-[1-(4-chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
74	6-Chloro-1-[1-(5-dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
75	1-[1-(4-Methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
76	1-[1-(4-Methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-

	benzo[d][1,3]oxazin-2-one
77	6-Chloro-1-[1-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
78	1-[1-(4-Methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
79	1-[1-(2-Bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
80	1-[1-(2-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
81	1-[1-(2-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
82	1-[1-(2-Bromo-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
83	6-Chloro-1-[1-(2,3-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
84	1-[1-(2,3-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
85	1-[1-(2,4,5-Trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
86	8-Methyl-1-[1-(2,4,5-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
87	6-Chloro-1-[1-(2,4,5-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
88	6-Methyl-1-[1-(2,4,5-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
89	1-[1-(5-Bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
90	1-[1-(5-Bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
91	1-[1-(5-Bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
92	1-[1-(5-Bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
93	1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
94	1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
95	6-Chloro-1-[1-(2,5-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
96	1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
97	1-(1-Pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
98	8-Methyl-1-(1-pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
99	6-Chloro-1-(1-pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
100	6-Methyl-1-(1-pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
101	1-(1-[2-(2,2,2-Trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
102	8-Methyl-1-[1-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
103	6-Chloro-1-[1-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
104	6-Methyl-1-[1-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
105	1-[1-(2-Methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
106	8-Methyl-1-[1-(2-methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
107	6-Chloro-1-[1-(2-methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
108	6-Methyl-1-[1-(2-methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-

243
244

	benzo[d][1,3]oxazin-2-one
109	1-[1-(4-Bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
110	1-[1-(4-Bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
111	1-[1-(4-Bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
112	1-[1-(4-Bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
113	1-[1-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
114	1-[1-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
115	6-Chloro-1-[1-(4-chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
116	1-[1-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
117	1-[1-(4-Methoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
118	1-[1-(4-Isopropyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
119	1-[1-(4-Isopropyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
120	6-Chloro-1-[1-(4-isopropyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
121	1-[1-(4-Isopropyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
122	1-[1-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
123	1-[1-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
124	6-Chloro-1-[1-(3-chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
125	1-[1-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
126	1-[1-(4-Bromo-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
127	8-Methyl-1-[1-(3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
128	8-Methyl-1-[1-(3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
129	1-[1-(4-Trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
130	1-[1-(2-Nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
131	1-[1-(3-Fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
132	1-[1-(2,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
133	1-[1-(2,4,6-Trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
134	1-[1-(2-Trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
135	8-Methyl-1-[1-(4-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
136	8-Methyl-1-[1-(2-nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
137	1-[1-(3-Fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
138	1-[1-(2,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
139	8-Methyl-1-[1-(2,4,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
140	8-Methyl-1-[1-(2-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-

.	benzo[d][1,3]oxazin-2-one
141	1-[1-(4-Fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
142	1-[1-(4-Bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
143	1-[1-(3-Nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
144	1-[1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
145	1-[1-(3-Methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
146	1-[1-(2-Nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
147	6-Methyl-1-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
148	1-(1-Benzenesulfonyl-piperidin-4-yl)-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
149	1-[1-(3-Methoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
150	1-[1-(2,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
151	1-[1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
152	6-Methyl-1-[1-(thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
153	1-[1-(Toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
154	1-[1-(5-Fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
155	1-[1-(4-Isopropoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
156	1-[1-(3-Chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
157	1-[1-(3,4-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
158	1-(1-Pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
159	6-Methyl-1-[1-(toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
160	1-[1-(5-Fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydrobenzo[d][1,3]oxazin-2-one
161	1-[1-(4-Isopropoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
162	1-[1-(3-Chloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
163	1-[1-(3,4-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
164	6-Methyl-1-(1-pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
165	6-Methyl-1-[1-(toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
166	1-[1-(5-Fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
167	1-[1-(4-Isopropoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
168	1-[1-(3-Chloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
169	1-[1-(3,4-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
170	6-Methyl-1-(1-pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
171	6-Methyl-1-[1-(4-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
172	6-Methyl-1-[1-(2-nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
173	1-[1-(3-Fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
174	1-[1-(2,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
175	6-Methyl-1-[1-(2,4,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
176	6-Methyl-1-[1-(2-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
177	1-[1-(3-Methoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one

246
247

178	6-Methyl-1-[1-(2-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
179	1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
180	1-[1-(4-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
181	6-Methyl-1-(1-phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
182	2-[4-(6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]benzoic acid methyl ester
183	6-Methyl-1-[1-(2-oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
184	6-Chloro-1-[1-(4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
185	6-Chloro-1-[1-(3,5-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
186	1-[1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
187	6-Chloro-1-[1-(thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
188	6-Chloro-1-[1-(3-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
189	6-Chloro-1-[1-(2-oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
190	6-Chloro-1-[1-(toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
191	6-Chloro-1-[1-(5-fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
192	6-Chloro-1-[1-(4-isopropoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
193	6-Chloro-1-[1-(3-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
194	6-Chloro-1-[1-(3,4-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
195	6-Chloro-1-(1-pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
196	6-Chloro-1-[1-(4-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
197	6-Chloro-1-[1-(2-nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
198	6-Chloro-1-[1-(3-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
199	6-Chloro-1-[1-(2,4-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
200	6-Chloro-1-[1-(2,4,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
201	6-Chloro-1-[1-(2-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
202	1-[1-(2-Oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
203	1-[1-(3,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
204	1-[1-(2,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
205	1-[1-(6-Bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
206	1-[1-(4-Chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
207	1-[1-(2,6-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
208	6-Methyl-1-[1-(2-oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
209	1-[1-(3,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
210	1-[1-(2,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
211	1-[1-(6-Bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one

247
248

212	1-[1-(4-Chloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
213	1-[1-(2,6-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
214	1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
215	6-Chloro-1-[1-(2,5-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
216	1-[1-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
217	6-Chloro-1-[1-(4-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
218	6-Chloro-1-[1-(2,5-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
219	1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
220	2-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
221	1-[1-(2,6-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
222	1-[1-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
223	1-[1-(4-Chloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
224	1-[1-(2,6-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
225	1-[1-(3,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
226	8-Methyl-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
227	1-[1-(5-Bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
228	1-[1-(4-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
229	1-[1-(1-Methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
230	1-[1-(5-Bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
231	1-[1-(6-Chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
232	1-[1-(4-Ethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
233	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
234	1-[1-(6-Chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
235	1-[1-(4-Ethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
236	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
237	6-Chloro-1-[1-(6-chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
238	6-Chloro-1-[1-(4-ethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
239	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
240	1-[1-(6-Chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
241	1-[1-(4-Ethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
242	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
243	1-[1-(7-Chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
244	1-[1-(2-Methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-

	2-one
245	3-[4-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl]-propionic acid methyl ester
246	1-[1-(2,4-Dinitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
247	1-[1-(7-Chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
248	1-[1-(2-Methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
249	3-[4-[4-(6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl]-propionic acid methyl ester
250	1-[1-(2,4-Dinitro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
251	1-[1-(7-Chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
252	1-[1-(2-Methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
253	3-[4-[4-(6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl]-propionic acid methyl ester
254	1-[1-(2,4-Dinitro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
255	6-Chloro-1-[1-(7-chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
256	6-Chloro-1-[1-(2-methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
257	3-[4-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl]-propionic acid methyl ester
258	6-Chloro-1-[1-(2,4-dinitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
259	6-Chloro-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
260	1-[1-(5-Bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
261	6-Methyl-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
262	1-[1-(5-Bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
263	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
264	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
265	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
266	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
267	1-[1-(2,5-Difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
268	1-[1-(2,5-Difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
269	6-Chloro-1-[1-(2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
270	1-[1-(2,5-Difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
271	1-[1-(4-Chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
272	1-[1-(4-Chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
273	6-Chloro-1-[1-(4-chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
274	1-[1-(4-Chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
275	1-[1-(2,4,5-Trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
276	6-Methyl-1-[1-(2,4,5-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-

	benzo[d][1,3]oxazin-2-one
277	6-Chloro-1-[1-(2,4,5-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
278	6-Methyl-1-[1-(2,4,5-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
279	1-[1-(3,5-Dichloro-2-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
280	1-[1-(2,6-Difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
281	1-[1-(2,6-Difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
282	6-Chloro-1-[1-(2,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
283	1-[1-(2,6-Difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
284	1-[1-(5-Chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
285	1-[1-(5-Chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
286	6-Chloro-1-[1-(5-chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
287	1-[1-(5-Chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
288	1-[1-(2-Chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
289	1-[1-(2-Chloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
290	6-Chloro-1-[1-(2-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
291	1-[1-(2-Chloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
292	6-Chloro-1-[1-(2-naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
293	6-Bromo-1-[1-(4-bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
294	6-Bromo-1-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
295	6-Bromo-1-[1-(2,4-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
296	6-Bromo-1-[1-(2-naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
297	6-Bromo-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
298	6-Bromo-1-[1-(6-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
299	6-Bromo-1-[1-(3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
300	6-Bromo-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
301	6-Bromo-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
302	1-(1-Benzenesulfonyl-piperidin-4-yl)-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one
303	6-Bromo-1-{1-[4-(4-bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl}-1,4-dihydro-benzo[d][1,3]oxazin-2-one
304	6-Bromo-1-[1-(thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
305	6-Bromo-1-[1-(2-methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
306	6-Bromo-1-[1-(4-bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
307	6-Bromo-1-[1-(toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
308	6-Bromo-1-[1-(5-fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
309	6-Bromo-1-[1-(4-isopropoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
310	6-Bromo-1-[1-(3-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one

311	6-Bromo-1-[1-(3,4-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
312	6-Bromo-1-(1-pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
313	6-Bromo-1-[1-(4-chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
314	6-Bromo-1-[1-(3-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
315	6-Bromo-1-[1-(4-isopropyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
316	6-Bromo-1-[1-(4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
317	6-Bromo-1-[1-(3-chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
318	6-Bromo-1-(1-pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
319	6-Bromo-1-[1-(2-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
320	6-Bromo-1-[1-(4-chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
321	6-Bromo-1-[1-(5-dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
322	6-Bromo-1-[1-(4-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
323	1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one
324	6-Bromo-1-[1-(4-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
325	1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one
326	6-Bromo-1-(1-phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
327	6-Bromo-1-[1-(2,5-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
328	6-Bromo-1-{1-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl}-1,4-dihydro-benzo[d][1,3]oxazin-2-one
329	6-Bromo-1-[1-(2,3-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
330	6-Bromo-1-[1-(2,4,5-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
331	6-Bromo-1-[1-(5-bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
332	6-Bromo-1-[1-(4-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
333	6-Bromo-1-[1-(2-nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
334	6-Bromo-1-[1-(3-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
335	6-Bromo-1-[1-(2,4-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
336	6-Bromo-1-[1-(2,4,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
337	6-Bromo-1-[1-(2-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
338	6-Bromo-1-[1-(2-bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
339	6-Bromo-1-[1-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
340	1-[1-(3,5-Dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
341	1-[1-(3,5-Dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one

342	6-Chloro-1-[1-(3,5-dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
343	1-[1-(3,5-Dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
344	6-Bromo-1-[1-(3,5-dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
345	6-Chloro-1-[1-(3,5-dichloro-2-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
346	6-Bromo-1-[1-(3,5-dichloro-2-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
347	2-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
348	6-Bromo-1-[1-(4-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
349	2-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid methyl ester
350	6-Bromo-1-[1-(3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
351	6-Bromo-1-[1-(2-oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
352	6-Bromo-1-[1-(3,5-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
353	6-Bromo-1-[1-(2,5-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
354	6-Bromo-1-[1-(5-bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
355	6-Bromo-1-[1-(4-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
356	6-Bromo-1-[1-(2,6-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
357	6-Bromo-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
358	6-Bromo-1-[1-(5-bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
359	6-Bromo-1-[1-(4-ethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
360	6-Bromo-1-[1-(6-chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
361	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one
362	6-Bromo-1-[1-(7-chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
363	6-Bromo-1-[1-(2-methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
364	3-[4-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl]-propionic acid methyl ester
365	6-Bromo-1-[1-(2,4-dinitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
366	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one
367	6-Bromo-1-[1-(2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
368	6-Bromo-1-[1-(4-chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
369	6-Bromo-1-[1-(2,4,5-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
370	6-Bromo-1-[1-(2,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
371	6-Bromo-1-[1-(5-chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
372	6-Bromo-1-[1-(2-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-

252
253

	one
373	6-Bromo-1-[1-(2,3,4-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
374	N-[4-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-2-chloro-phenyl]-acetamide
375	1-[1-(2,3,4-Trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
376	8-Methyl-1-[1-(2,3,4-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
377	6-Chloro-1-[1-(2,3,4-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
378	6-Methyl-1-[1-(2,3,4-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
379	N-[2-Chloro-4-[4-(6-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl]-acetamide
380	1-[1-(3,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
381	1-[1-(3,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
382	6-Chloro-1-[1-(3,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
383	1-[1-(3,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
384	6-Bromo-1-[1-(3,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
385	N-[2-Chloro-4-[4-(6-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl]-acetamide
386	1-[1-(2-Chloro-4,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
387	1-[1-(2-Chloro-4,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
388	6-Chloro-1-[1-(2-chloro-4,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
389	1-[1-(2-Chloro-4,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
390	6-Bromo-1-[1-(2-chloro-4,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
391	N-[2-Chloro-4-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl]-acetamide
392	1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
393	1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
394	1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
395	1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
396	1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one
397	N-[2-Chloro-4-[4-(6-chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl]-acetamide
398	1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
399	1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
400	1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
401	1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
402	1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-8-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one
403	1-(1-Ethanesulfonyl-piperidin-4-yl)-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one

404	1-[1-(2,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
405	1-[1-(2,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
406	6-Chloro-1-[1-(2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
407	1-[1-(2,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
408	6-Bromo-1-[1-(2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
409	8-Methyl-1-[1-(propane-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
410	1-[1-(3,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
411	1-[1-(3,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
412	6-Chloro-1-[1-(3,4-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
413	1-[1-(3,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
414	6-Bromo-1-[1-(3,4-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
415	8-Methyl-1-[1-(propane-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
416	1-[1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
417	1-[1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
418	6-Chloro-1-[1-(2-chloro-6-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
419	1-[1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
420	1-[1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
421	8-Methyl-1-[1-(2,3,5,6-tetramethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
422	1-[1-(2,3,4-Trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
423	8-Methyl-1-[1-(2,3,4-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
424	6-Chloro-1-[1-(2,3,4-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
425	6-Methyl-1-[1-(2,3,4-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
426	6-Bromo-1-[1-(2,3,4-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
427	1-[1-(2,3,5,6-Tetramethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
428	1-[1-(Thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
429	8-Methyl-1-[1-(thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
430	6-Chloro-1-[1-(thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
431	6-Methyl-1-[1-(thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
432	6-Bromo-1-[1-(thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
433	6-Chloro-1-[1-(2,3,5,6-tetramethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
434	1-[1-(2,4,6-Trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
435	8-Methyl-1-[1-(2,4,6-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
436	6-Chloro-1-[1-(2,4,6-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
437	6-Methyl-1-[1-(2,4,6-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
438	6-Bromo-1-[1-(2,4,6-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
439	6-Methyl-1-[1-(2,3,5,6-tetramethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-

	benzo[d][1,3]oxazin-2-one
440	1-[1-(2-Bromo-4,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
441	1-[1-(2-Bromo-4,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
442	1-[1-(2-Bromo-4,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
443	6-Bromo-1-[1-(2-bromo-4,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
444	6-Bromo-1-[1-(2,3,5,6-tetramethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
445	1-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
446	1-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
447	1-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
448	1-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
449	6-Bromo-1-[1-(4-bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
450	1-[1-(4-Phenoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
451	1-[1-(3-Bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
452	1-[1-(3-Bromo-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
453	1-[1-(3-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
454	1-[1-(3-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
455	6-Bromo-1-[1-(3-bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
456	8-Methyl-1-[1-(4-phenoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
457	1-[1-(4-tert-Butyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
458	1-[1-(4-tert-Butyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
459	1-[1-(4-tert-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
460	1-[1-(4-tert-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
461	6-Bromo-1-[1-(4-tert-butyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
462	6-Chloro-1-[1-(4-phenoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
463	1-[1-(2-Bromo-4,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
464	1-[1-(2-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
465	6-Chloro-1-[1-(2-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
466	1-[1-(2-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
467	6-Bromo-1-[1-(2-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
468	8-Methyl-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
469	6-Chloro-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
470	6-Methyl-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one

471	6-Bromo-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
472	1-[1-(3-Chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
473	6-Chloro-1-[1-(3-chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
474	1-[1-(3-Chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
475	6-Bromo-1-[1-(3-chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
476	1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
477	1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
478	1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
479	6-Bromo-1-[1-(4-butyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
480	1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
481	1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
482	1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
483	6-Bromo-1-[1-(4-bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
484	1-[1-[4-(1,1-Dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
485	6-Chloro-1-[1-[4-(1,1-dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
486	1-[1-[4-(1,1-Dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
487	6-Bromo-1-[1-[4-(1,1-dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
488	1-(1-Ethanesulfonyl-piperidin-4-yl)-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
489	3-[4-(6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
490	3-[4-(6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
491	3-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
492	1-[1-(3-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
493	6-Chloro-1-[1-(3-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
494	1-[1-(3-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
495	6-Bromo-1-[1-(3-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
496	N-[4-Methyl-5-[4-(6-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiazol-2-yl]-acetamide
497	N-[5-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-methyl-thiazol-2-yl]-acetamide
498	N-[4-Methyl-5-[4-(6-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiazol-2-yl]-acetamide
499	N-[5-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-methyl-thiazol-2-yl]-acetamide
500	1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
501	1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
502	1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one

256
257

503	6-Bromo-1-[1-(2-bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
504	1-[1-(5-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
505	6-Chloro-1-[1-(5-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
506	1-[1-(5-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
507	6-Bromo-1-[1-(5-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
508	1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
509	1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-8-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
510	1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
511	6-Bromo-1-[1-(4-bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
512	1-[1-(2-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
513	1-[1-(4-Propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
514	1-[1-(3-Chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
515	1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
516	1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
517	1-[1-[4-(1,1-Dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
518	N-(4-Methyl-5-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiazol-2-yl)-acetamide
519	1-[1-(3-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
520	1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
521	1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
522	1-[1-(5-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
523	1-[1-(Isoquinoline-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
524	6-Fluoro-1-[1-(2-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
525	6-Fluoro-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
526	1-[1-(3-Chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
527	1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
528	1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
529	1-[1-[4-(1,1-Dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
530	N-(5-[4-(6-Fluoro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-methyl-thiazol-2-yl)-acetamide
531	1-[1-(3-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
532	1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
533	1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
534	1-[1-(5-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one

257
258

535	6-Fluoro-1-[1-(isoquinoline-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
536	6-Fluoro-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
537	1-[1-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
538	6-Fluoro-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
539	6-Fluoro-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
540	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
541	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
542	8-Methoxy-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
543	1-[1-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
544	8-Methoxy-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
545	8-Methoxy-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
546	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
547	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
548	5-Chloro-1-[1-(2-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
549	5-Chloro-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
550	5-Chloro-1-[1-(3-chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
551	1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
552	1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
553	5-Chloro-1-[1-[4-(1,1-dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
554	N-[5-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-methyl-thiazol-2-yl]-acetamide
555	5-Chloro-1-[1-(3-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
556	1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
557	1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
558	5-Chloro-1-[1-(5-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
559	5-Chloro-1-[1-(isoquinoline-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
560	1-[1-(2-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
561	1-[1-(2-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
562	1-[1-(3-Chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
563	1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
564	1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
565	1-(1-[4-(1,1-Dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl)-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
566	N-[5-[4-(8-Methoxy-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-methyl-thiazol-2-yl]-acetamide
567	1-[1-(3-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one

568	1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
569	1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
570	1-[1-(5-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
571	1-[1-(Isoquinoline-5-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one; hydrochloride
572	1-[1-(4-Methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
573	8-Chloro-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
574	8-Methyl-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
575	8-Methyl-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
576	8-Fluoro-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
577	8-Methoxy-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
578	6-Chloro-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
579	6-Chloro-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
580	6-Chloro-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
581	6-Chloro-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
582	6-Chloro-1-[1-(6-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
583	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
584	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
585	6-Bromo-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
586	2-Chloro-4-fluoro-5-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
587	2-Chloro-5-[4-(6-chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-fluoro-benzoic acid
588	2-Chloro-4-fluoro-5-[4-(6-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
589	2-Chloro-4-fluoro-5-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
590	2-Chloro-4-fluoro-5-[4-(8-methoxy-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
591	2-Chloro-5-[4-(5-chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-fluoro-benzoic acid
592	3-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
593	3-[4-(8-Methoxy-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
594	3-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
595	1-[1-(Isoquinoline-5-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; hydrochloride
596	6-Chloro-1-[1-(isoquinoline-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one; hydrochloride
597	-[1-(Isoquinoline-5-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-onehydrochloride
598	6,7-Difluoro-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
599	1-[1-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
600	6,7-Difluoro-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
601	6,7-Difluoro-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one

260
259

602	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
603	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
604	1-[1-(5-Dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
605	1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
606	1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
607	1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
608	1-[1-(7-Chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
609	6,7-Difluoro-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
610	1-[1-(4-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
611	1-[1-(4-Fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
612	1-[1-(Dibenzofuran-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
613	1-[1-(2,3-Dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
614	1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
615	1-[1-(5-Isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
616	1-[1-(4-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
617	1-[1-(4-Fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
618	1-[1-(Dibenzofuran-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
619	1-[1-(2,3-Dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
620	1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
621	1-[1-(5-Isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
622	5-Chloro-1-[1-(4-chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
623	5-Chloro-1-[1-(4-fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
624	5-Chloro-1-[1-(dibenzofuran-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
625	5-Chloro-1-[1-(2,3-dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
626	1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
627	5-Chloro-1-[1-(5-isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
628	1-[1-(4-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
629	1-[1-(4-Fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
630	1-[1-(Dibenzofuran-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
631	1-[1-(2,3-Dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
632	1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
633	1-[1-(5-Isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
634	6-Chloro-1-[1-(4-chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
635	6-Chloro-1-[1-(4-fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one

636	6-Chloro-1-[1-(dibenzofuran-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
637	6-Chloro-1-[1-(2,3-dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
638	1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
639	6-Chloro-1-[1-(5-isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
640	1-[1-(4-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
641	1-[1-(4-Fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
642	1-[1-(Dibenzofuran-2-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
643	1-[1-(2,3-Dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
644	1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
645	1-[1-(5-Isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
646	1-[1-(4-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
647	6,7-Difluoro-1-[1-(4-fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
648	1-[1-(Dibenzofuran-2-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
649	1-[1-(2,3-Dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
650	1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
651	6,7-Difluoro-1-[1-(5-isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
652	1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
653	1-[1-(5-Methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
654	1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
655	1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
656	6-Methyl-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
657	1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
658	6-Chloro-1-[1-(1,2-dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
659	6-Chloro-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
660	6-Chloro-1-[1-(3,5-dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
661	1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-6-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
662	6-Methoxy-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
663	1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-6-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
664	5-Chloro-1-[1-(1,2-dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
665	5-Chloro-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
666	5-Chloro-1-[1-(3,5-dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
667	1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-

261

	benzo[d][1,3]oxazin-2-one
668	6-Methyl-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
669	1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
670	1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
671	6-Fluoro-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
672	1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
673	1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
674	6,7-Difluoro-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
675	1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
676	1-[1-(5-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
677	1-[1-(5-Chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
678	N-[5-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl]-acetamide
679	1-[1-(5-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
680	1-[1-(5-Chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
681	N-[5-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl]-acetamide
682	5-Chloro-1-[1-(5-chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
683	5-Chloro-1-[1-(5-chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
684	N-[5-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl]-acetamide
685	1-[1-(5-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
686	1-[1-(5-Chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
687	N-[5-[4-(8-Methoxy-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl]-acetamide
688	2,5-Dimethyl-4-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-furan-3-carboxylic acid methyl ester
689	8-Methyl-1-[1-(2-oxo-2,3-dihydro-benzothiazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
690	1-[1-(4-Fluoro-3-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
691	8-Methyl-1-[1-(2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
692	1-[1-(4-Cyclohexyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
693	2,5-Dimethyl-4-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-furan-3-carboxylic acid methyl ester
694	1-[1-(4-Fluoro-3-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
695	1-[1-(2-Oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
696	1-[1-(4-Cyclohexyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
697	2-Fluoro-5-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
698	2-Fluoro-5-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
699	1-[1-(2-Oxo-2,3-dihydro-benzothiazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-

	benzo[d][1,3]oxazin-2-one
700	1-[1-(5-Pyridin-2-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro -benzo[d][1,3]oxazin-2-one
701	3-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
702	3-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiophene-2-carboxylic acid methyl ester
703	1-(5-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl)-pyrrolidine-2,5-dione
704	1-[1-(2-Chloro-5-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
705	1-[1-(3,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
706	8-Methyl-1-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
707	3-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
708	3-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiophene-2-carboxylic acid methyl ester
709	1-(5-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl)-pyrrolidine-2,5-dione
710	1-[1-(2-Chloro-5-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
711	1-[1-(3,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
712	8-Chloro-1-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
713	3-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
714	3-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiophene-2-carboxylic acid methyl ester
715	1-(5-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl)-pyrrolidine-2,5-dione
716	5-Chloro-1-[1-(2-chloro-5-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
717	5-Chloro-1-[1-(3,4-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
718	8-Methyl-1-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
719	3-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
720	3-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiophene-2-carboxylic acid methyl ester
721	1-(5-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl)-pyrrolidine-2,5-dione
722	1-[1-(2-Chloro-5-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
723	1-[1-(3,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
724	6-Chloro-1-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
725	3-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
726	3-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiophene-2-carboxylic acid methyl ester
727	1-(5-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl)-pyrrolidine-2,5-dione
728	6-Chloro-1-[1-(2-chloro-5-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
729	6-Chloro-1-[1-(3,4-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
730	1-[1-(5-Methyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
731	1-[1-(2,2-Dimethyl-chroman-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
732	1-[1-(4-Methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
733	1-[1-(2,3-Dihydro-benzo[1,4]dioxine-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-


263

	benzo[d][1,3]oxazin-2-one
734	1-[1-(1,3,5-Trimethyl-1H-pyrazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
735	1-[1-(3-Methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
736	8-Methyl-1-[1-(5-methyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
737	1-[1-(2,2-Dimethyl-chroman-6-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
738	8-Methyl-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
739	1-[1-(2,3-Dihydro-benzo[1,4]dioxine-6-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
740	8-Methyl-1-[1-(1,3,5-trimethyl-1H-pyrazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
741	8-Methyl-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
742	8-Methoxy-1-[1-(1,3,5-trimethyl-1H-pyrazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
743	8-Methoxy-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
744	1-[1-(Benzo[d]isoxazol-3-ylmethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
745	1-[1-(2,2,4,6,7-Pentamethyl-2,3-dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
746	6-Methyl-5-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-1H-pyrimidine-2,4-dione
747	1-[1-(3-Methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
748	1-[1-(2,2,5,7,8-Pentamethyl-chroman-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
749	1,4-Dimethyl-6-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-1,4-dihydro-quinoxaline-2,3-dione
750	1-[1-(1H-Imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
751	1-[1-(2-Oxo-1,2,3,4-tetrahydro-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
752	7-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione
753	8-Methyl-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
754	6-Chloro-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
755	5-Chloro-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
756	8-Methoxy-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
757	1-[1-(Pyridine-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
758	1-[1-(6,7-Dihydroxy-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
759	Acetic acid 3-acetoxy-5-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-2-yl ester
760	1-[1-(1H-Benzoimidazole-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
761	1-[1-(1H-Benzoimidazole-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
762	1-[1-(1H-Benzoimidazole-2-sulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
763	1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
764	1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
765	1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-

	benzo[d][1,3]oxazin-2-one
766	5-Chloro-1-[1-(2,5-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
767	1-[1-(5-Dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
768	5-Chloro-1-[1-(5-dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
769	6-Chloro-1-[1-(5-chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
770	1-[1-(5-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
771	1-[1-(5-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
772	6-Chloro-1-[1-(5-chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
773	1-[1-(5-Chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
774	1-[1-(5-Chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-8-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
775	8-Methyl-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
776	8-Fluoro-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
777	6,7-Difluoro-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
778	6-Chloro-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
779	8-Methyl-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
780	8-Fluoro-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
781	6,7-Difluoro-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
782	5-Chloro-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
783	6-Chloro-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
784	8-Methyl-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
785	8-Fluoro-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
786	8-Methoxy-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
787	5-Chloro-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one


265

70. Process for the preparation of benzoxazinone-derived sulfonamide compounds of general formula (Ib) according to one or more of claims 54 to 69, characterized in that it comprises reacting at least one piperidine compound of general formula (IIb), wherein R^{1b} to R^{8b} have the meaning according to one or more of claims 54-69 and/or a salt, preferably a hydrochloride salt, thereof,



(IIb)

with at least one compound of general formula (IIIb),



(IIIb)

wherein W^b has the meaning according to one or more of claims 54-69, in a suitable reaction medium, optionally in the presence of at least one base and/or at least one auxiliary agent.

266

71. Process for the preparation of a physiologically acceptable salt of the benzoxazinone-derived sulphonamide compounds according to claims 54-69, characterized in that at least one compound of general formula (Ib) having at least one basic group is reacted with at least one acid, preferably an inorganic or organic acid, preferably in the presence of a suitable reaction medium.

72. Process for the preparation of a physiologically acceptable salt of the benzoxazinone-derived sulphonamide compounds according to claims 54-69, characterized in that at least one compound of general formula (Ib) having at least one acidic group is reacted with at least one base, preferably in the presence of a suitable reaction medium.

73. Medicament comprising at least one benzoxazinone-derived sulphonamide compound according to any one of claims 54-69 and optionally one or more pharmaceutically acceptable adjuvants.

74. Medicament according to claim 73 for the prophylaxis and/or treatment of disorders that are at least partially mediated via 5-HT_6-receptors.

75. Medicament according to claim 73 or 74 for the prophylaxis and/or treatment of food intake disorders, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, for the prophylaxis and/or treatment of bulimia, for the prophylaxis and/or treatment of anorexia, for the prophylaxis and/or treatment of cachexia, for the prophylaxis and/or treatment type II diabetes (non-insulin dependent diabetes mellitus).

76. Medicament according to claim 73 or 74 for the prophylaxis and/or treatment of gastrointestinal disorders, preferably irritable colon syndrome; for the prophylaxis and/or treatment of disorders of the central nervous system; for the prophylaxis and/or treatment of anxiety; for the prophylaxis and/or treatment panic attacks; for the prophylaxis and/or treatment of depression; for the prophylaxis and/or treatment of bipolar disorders; for the prophylaxis and/or treatment cognitive disorders, preferably memory disorders; for

267

Improvement of cognition (for cognitive enhancement); for the prophylaxis and/or treatment of senile dementia; for the prophylaxis and/or treatment of psychosis; for the prophylaxis and/or treatment neurodegenerative disorders; preferably selected from the group consisting of Morbus Alzheimer, Morbus Parkinson, Morbus Huntington and Multiple Sclerosis; for the prophylaxis and/or treatment of schizophrenia or for the prophylaxis and/or treatment hyperactivity disorder (ADHD, attention deficit, hyperactivity disorder).

77. Use of at least one benzoxazinone-derived sulphonamide compound according to any one of claims 54-69 for the manufacture of a medicament for 5-HT_6 receptor-regulation.

78. Use of at least one benzoxazinone-derived sulphonamide compound according to any one of claims 54-69 for the manufacture of a medicament for the prophylaxis and/or treatment of disorders that are at least partially mediated via 5-HT_6 receptors.

79. Use of at least one benzoxazinone-derived sulphonamide compound according to any one of claims 54-69 for the manufacture of a medicament for the prophylaxis and/or treatment of food intake disorders.

80. Use according to claim 79 for the regulation of appetite, for the reduction, increase or maintenance of body weight; for the prophylaxis and/or treatment of obesity, for the prophylaxis and/or treatment of bulimia, for the prophylaxis and/or treatment of anorexia; for the prophylaxis and/or treatment of cachexia; or for the prophylaxis and/or treatment of type II diabetes.

81. Use of at least one benzoxazinone-derived sulphonamide compound according to any one of claims 54-69 for the manufacture of a medicament for the prophylaxis and/or treatment of of gastrointestinal disorders, preferably irritable colon syndrome; for the prophylaxis and/or treatment of disorders of the central nervous system; for the prophylaxis and/or treatment of anxiety; for the prophylaxis and/or treatment panic attacks; for the prophylaxis and/or treatment of depression; for the prophylaxis and/or treatment of bipolar

268

disorders; for the prophylaxis and/or treatment cognitive disorders, preferably memory disorders; for improvement of cognition (for cognitive enhancement); for the prophylaxis and/or treatment of senile dementia; for the prophylaxis and/or treatment of psychoses; for the prophylaxis and/or treatment neurodegenerative disorders; preferably selected from the group consisting of Morbus Alzheimer, Morbus Parkinson, Morbus Huntington and Multiple Sclerosis; for the prophylaxis and/or treatment of schizophrenia; or for the prophylaxis and/or treatment hyperactivity disorder (ADHD, attention deficit, hyperactivity disorder).

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/008507

269

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D413/04 A61K31/535 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 665 719 A (PETTIBONE DOUGLAS J ET AL) 9 September 1997 (1997-09-09) the whole document column 30; example 10	1-81
A	WO 01/85725 A (FEENSTRA ROELOF W ; LONG STEPHEN K (NL); HEIJDEN JOHANNES A M V D (NL)) 15 November 2001 (2001-11-15) the whole document	1-81
A	WO 97/45419 A (WARNER LAMBERT CO ; WISE LAWRENCE DAVID (US); WUSTROW DAVID JUERGEN (U) 4 December 1997 (1997-12-04) the whole document	1-81
A	US 6 225 312 B1 (KRUSE CORNELIS GERRIT ET AL) 1 May 2001 (2001-05-01) the whole document	1-81

-/-

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents:

'A' document defining the general state of the art which is not considered to be of particular relevance

'E' earlier document but published on or after the international filing date

'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

'O' document referring to an oral disclosure, use, exhibition or other means

'P' document published prior to the international filing date but later than the priority date claimed

'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

'&' document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
15 October 2004	03/11/2004

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Deutsch, M

Form PCT/ISA/210 (second sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/008507

270

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category°	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 1 242 396 A (ASTRAZENECA AB) 25 September 2002 (2002-09-25) the whole document	1-81

x

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP2004/008507

271

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5665719 A	09-09-1997	AT 216580 T	15-05-2002
		AU 691829 B2	28-05-1998
		AU 7513294 A	13-02-1995
		CA 2166975 A1	26-01-1995
		DE 69430483 D1	29-05-2002
		EP 0714299 A1	05-06-1996
		JP 9500134 T	07-01-1997
		WO 9502405 A1	26-01-1995
WO 0185725 A	15-11-2001	EP 1153925 A1	14-11-2001
		AT 255578 T	15-12-2003
		AU 6392701 A	20-11-2001
		BR 0110592 A	01-04-2003
		CA 2405971 A1	15-11-2001
		CN 1429226 T	09-07-2003
		CZ 20023721 A3	12-02-2003
		DE 60101386 D1	15-01-2004
		DE 60101386 T2	27-05-2004
		DK 1283838 T3	22-03-2004
		WO 0185725 A1	15-11-2001
		EP 1283838 A1	19-02-2003
		ES 2211809 T3	16-07-2004
		HU 0302016 A2	29-09-2003
		JP 2003532729 T	05-11-2003
		NO 20025365 A	08-11-2002
		NZ 522116 A	30-04-2004
		PT 1283838 T	30-04-2004
		SK 15872002 A3	01-04-2003
		US 2003119849 A1	26-06-2003
		ZA 200208537 A	22-01-2004
WO 9745419 A	04-12-1997	AT 231846 T	15-02-2003
		AU 731104 B2	22-03-2001
		AU 3072797 A	05-01-1998
		BG 64049 B1	28-11-2003
		BG 102959 A	31-08-1999
		BR 9709630 A	10-08-1999
		CA 2253406 A1	04-12-1997
		CN 1219930 A ,B	16-06-1999
		CZ 9803846 A3	17-03-1999
		DE 69718786 D1	06-03-2003
		DE 69718786 T2	23-10-2003
		DK 906294 T3	05-05-2003
		EA 1486 B1	23-04-2001
		EE 9800417 A	15-06-1999
		EP 0906294 A1	07-04-1999
		ES 2191180 T3	01-09-2003
		HK 1019737 A1	05-07-2002
		HR 970301 A1	30-04-1998
		HU 9903758 A2	28-06-2000
		ID 17286 A	18-12-1997
		IL 126895 A	14-06-2001
		JP 2000511534 T	05-09-2000
		KR 2000016151 A	25-03-2000
		NO 985531 A	27-11-1998
		NZ 332737 A	23-06-2000
		PL 330195 A1	26-04-1999
		PT 906294 T	30-06-2003

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP2004/008507

272


Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9745419	A		SI	906294 T1	30-04-2003
			SK	162798 A3	11-06-1999
			TW	542833 B	21-07-2003
			WO	9745419 A1	04-12-1997
			US	6177422 B1	23-01-2001
			ZA	9704684 A	30-12-1997
US 6225312	B1	01-05-2001	AU	708053 B2	29-07-1999
			AU	2029497 A	22-10-1997
			BR	9708389 A	04-01-2000
			CA	2250347 A1	09-10-1997
			CN	1215400 A ,B	28-04-1999
			CZ	9803068 A3	13-01-1999
			WO	9736893 A1	09-10-1997
			EP	0889889 A1	13-01-1999
			HU	9902471 A2	28-03-2000
			JP	2000507949 T	27-06-2000
			KR	2000005412 A	25-01-2000
			NO	984533 A	02-11-1998
			NZ	331860 A	28-04-2000
			PL	329123 A1	15-03-1999
			RU	2178414 C2	20-01-2002
			SK	133198 A3	11-02-1999
			TR	9801942 T2	21-08-2000
			TW	422846 B	21-02-2001
			ZA	9702639 A	02-10-1997
EP 1242396	A	25-09-2002	AT	250590 T	15-10-2003
			AU	775741 B2	12-08-2004
			AU	2244301 A	25-06-2001
			BR	0016396 A	20-08-2002
			CA	2392894 A1	21-06-2001
			DE	60005560 D1	30-10-2003
			DE	60005560 T2	15-07-2004
			EP	1242396 A1	25-09-2002
			JP	2003516978 T	20-05-2003
			MX	PA02005788 A	18-09-2002
			NO	20022857 A	01-08-2002
			CN	1434811 T	06-08-2003
			WO	0144213 A1	21-06-2001
			US	2003040513 A1	27-02-2003
			ZA	200204429 A	03-09-2003

P.751.

273

COMPUESTOS DE SULFONAMIDAS DERIVADOS DE BENZOXAZINONA, SU PREPARACIÓN Y USO COMO MEDICAMENTOS

La presente invención se refiere a compuestos de sulfonamidas derivados de benzoxazinona de fórmula general (I),



(I)

a un procedimiento para su preparación, a un medicamento que comprende estos compuestos y al uso de compuestos de sulfonamida derivados de benzoxazinona para la preparación de medicamentos para la regulación del receptor 5-HT_6 así como para el tratamiento de trastornos relacionados al mismo.

La superfamilia de receptores de serotonina (5-HT) comprende 7 clases (5-HT_1-5-HT_7) que abarcan 14 subclases humanas [D. Hoyer, et al., Neuropharmacology, 1997, 36, 419]. El receptor 5-HT_6 ha sido el último receptor de serotonina identificado por clonación molecular tanto en ratas [F.J. Monsma, et al., Mol. Pharmacol., 1993, 43, 320; M. Ruat, et al., Biochem. Biophys. Res. Commun., 1993, 193, 268] como en humanos [R. Kohen, et al., J. Neurochem., 1996, 66, 47]. Los compuestos con afinidad al receptor 5-HT_6 son útiles en el tratamiento de diversos trastornos del sistema nervioso central y del aparato gastrointestinal, tales como el síndrome del intestino irritable. Los compuestos con afinidad al receptor 5-HT_6 son útiles para el tratamiento de la ansiedad, depresión y trastornos cognitivos de la memoria [M. Yoshioka, et al., *Ann. NY Acad. Sci.*, 1998, 861, 244; A. Bourson, et al., *Br. J. Pharmacol.*, 1998, 125, 1562; D.C. Rogers, et al., *Br. J. Pharmacol. Suppl.*, 1999, 127, 22P; A. Bourson, et al., *J. Pharmacol. Exp. Ther.*, 1995, 274, 173; A.J. Sleight, et al., *Behav.* Brain Res., 1996,

73, 245; T.A. Branchek, et al., *Annu. Rev. Pharmacol. Toxicol.*, 2000, 40, 319; C. Routledge, et al., *Br. J Pharmacol.*, 2000, 130, 1606]. Se ha demostrado que los antipsicóticos típicos y atípicos para el tratamiento de la esquizofrenia tienen una elevada afinidad por los receptores 5-HT_6 [B.L. Roth, et al., *J. Pharmacol. Exp.* Ther., 1994, 268, 1403; C.E. Glatt, et al., *Mol. Med.*, 1995, 1, 398; F.J. Moema, et al., *Mol. Pharmacol.*, 1993, 43, 320; T. Shinkai, et al., *Am. J. Med. Genet.*, 1999, 88, 120]. Los compuestos con una afinidad por el receptor 5-HT_6 son útiles para el tratamiento de la hiperquinesia infantil (ADHD, déficit de atención/ trastorno de hiperactividad) [W.D. Hirst, et al., *Br. J. Pharmacol.*, 2000, 130, 1597; C. Gérard, et al., *Brain Research*, 1997, 746, 207; M.R. Pranzatelli, *Drugs of Today*, 1997, 33, 379].

Además, se ha demostrado que el receptor 5-HT_6 desempeña un papel en la ingestión de alimentos [Neuropharmacology, 41, 2001, 210-219].


Los trastornos alimentarios, particularmente la obesidad, son una amenaza seria y creciente para la salud de las personas de todos los grupos de edad, ya que incrementan el riesgo de desarrollar otras enfermedades serias, incluso mortales, como la diabetes y las enfermedades coronarias.

Por consiguiente, un objeto de la presente invención era proporcionar nuevos compuestos que fueran particularmente adecuados como principios activos en medicamentos, preferiblemente en medicamentos para la regulación de receptores 5-HT_6, para la mejora de la cognición, para la profilaxis y/o el tratamiento de trastornos alimentarios, trastornos del sistema nervioso central, trastornos del tracto gastrointestinal, como el síndrome del intestino irritable, ansiedad, pánico, depresión, trastornos cognitivos de la memoria, trastornos de demencia senil, como enfermedad de Alzheimer, Enfermedad de Parkinson y Enfermedad de Huntington, esquizofrenia, psicosis, hiperquinesia infantil, ADHC (déficit de atención, trastornos de hiperactividad) y otros trastornos mediados por 5-HT_6 particularmente en mamíferos, incluido en humanos.

Se ha encontrado que los compuestos de sulfonamidas derivados de benzoxazinona de fórmulas generales (I) y (Ia) mostrados a continuación muestran afinidad por el receptor 5-HT_6. Estos compuestos también son por consiguiente adecuados para la fabricación de un medicamento para la mejora de la cognición, para la profilaxis y/o el tratamiento de trastornos relacionados con la ingestión alimenticia, particularmente para la regulación del apetito, para el mantenimiento, incremento o reducción del peso corporal, para la profilaxis y/o el tratamiento de obesidad, bulimia, anorexia, caquexia o diabetes tipo II (diabetes mellitus insulino independiente),

preferiblemente diabetes tipo II que sea causada por obesidad, trastornos del sistema nervioso central, trastornos del tracto gastrointestinal, como el síndrome del intestino irritable, ansiedad, pánico, depresión, trastornos cognitivos de la memoria, trastornos de demencia senil, como enfermedad de Alzheimer, enfermedad de Parkinson y enfermedad de Huntington, esquizofrenia, psicosis, hiperquinesia infantil, ADHC (déficit de atención, trastornos de hiperactividad) y otros trastornos mediados por 5-HT_6 particularmente en mamíferos, incluido el hombre.

Por consiguiente, un aspecto de la presente invención son compuestos de sulfonamidas derivados de benzoxazinona de fórmula general (I),



(I)

en la que

R^1, R^2, R^3, R^4 se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, halógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos

monosustituido, un grupo nitro, ciano, -OR^{10}, -$O(C=O)R^{11}$, -$(C=O)OR^{11}$, -SR^{12}, -SOR^{12}, -SO_2R^{12}, -NH-SO_2R^{12}, -SO_2NH_2 y un resto –$NR^{13}R^{14}$,

R^5 representa hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido o un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo,

R^6, R^7, R^8, R^9 se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, un grupo ciano y un resto –$COOR^{15}$,

W representa un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido,

un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

un radical heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

un radical arilo monocíclico, opcionalmente al menos monosustituido, que está condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido y que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido,

un resto $NR^{16}R^{17}$,

un resto -COR^{18},

o un radical fenilo, que está al menos monosustituido por uno de los sustituyentes seleccionados del grupo que consiste en:

2,2,2-trifluoroetoxi, alquenilo C_{2-6}, 1,3-dihidro-1-oxo-2H-isoindol-2-ilo, N-ftalimidinilo, [(2-cloro-1,3-tiazolil-5-il)-metoxi, etil-5-il-2-metil-3-furoato, alquilo C_{11-20}, 1,3-dioxo-2-azaspiro[4,4]non-2-ilo, pirazolilo, (1,3-oxazol-5-il)-, (5-metil-1,3,4-oxadiazol-2-il)-, difluorometoxi, diclorometoxi, 1-pirrolidinilsulfonilo, morfolinosulfonilo, 2-metil-4-pirimidinilo, un grupo fenoxi, que está al menos monosustituido por alcoxi C_{1-6}, un

grupo fenilo, que está al menos monosustituido por uno de los sustituyentes seleccionados del grupo que consiste en nitro, alcoxi C_{1-5}, F, Cl, Br, alquilo C_{1-5} al menos parcialmente fluorado, C_{1-5} alquilo al menos parcialmente clorado, [(2-cloro-1,3-tiazol-5-il)-metoxi]-, -(C=O)-H y alquilo (C=O)-C_{1-5}, un grupo piridinilo, que está al menos monosustituido por alcoxi C_{1-5}, un grupo piridiniloxi, que está al menos monosustituido por alcoxi C_{1-5}, un grupo fenoxi, que está al menos disustituido y un grupo piridiniloxi, que está al menos disustituido,

con la condición de que W no represente furilo no sustituido, tienilo no sustituido o tienilo sustituido por un sustituyente seleccionado del grupo que consiste en alcoxicarbonilo C_{1-5}, alquilcarbonilo C_{1-5}, carboxilo y piridilo, pirrolilo no sustituido, naftilo no sustituido, indolilo no sustituido, tetrahidronaftilo no sustituido, piridilo sustituido o no sustituido, pirazinilo no sustituido, quinolinilo no sustituido, pirrolilo sustituido por alquilo C_{1-5}, y ciclohexilo no sustituido o ciclohexilo sustituido por uno o dos miembros seleccionados del grupo que consiste en oxo, hidroxilo, alcoxilo C_{1-5}, alcoxi-carbonilamino C_{1-5}, alquilo C_{1-5} y aminoalquilo C_{1-5},

R^{10} representa hidrógeno, un radical alifático, lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{11} representa hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{12} representa un radical alifático, lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{13} y R^{14} se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, un radical alifático, lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

o R^{13} y R^{14} junto con el átomo puente de nitrógeno forman un anillo heterocíclico saturado, insaturado o aromático, que puede estar al menos monosustituido y/o contener al menos un heteroátomo más como miembro del anillo,

R^{16} representa hidrógeno, un radical alifático, lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{18} representa un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido,

R^{17} representa un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, y

R^{18} representa un radical arilo opcionalmente al menos monosustituido,

opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o una sal correspondiente de los mismos, o un solvato correspondiente de los mismos.

Según la presente invención, un sistema cíclico mono o policíclico significa un sistema cíclico hidrocarbonado mono o policíclico que puede estar saturado, insaturado o ser aromático. Si el sistema cíclico es policíclico, cada uno de sus diferentes anillos puede mostrar un grado de saturación distinto, es decir, puede estar saturado, insaturado o ser aromático. Opcionalmente, cada anillo del sistema cíclico mono o policíclico puede contener uno o más heteroátomos como miembros del anillo, que pueden ser idénticos o diferentes y que pueden seleccionarse preferiblemente del grupo que consiste en N, O, S y P, más preferiblemente se seleccionan del grupo que consiste en N, O y S. Preferiblemente el sistema cíclico policíclico puede comprender dos anillos que están condensados. Los anillos del sistema cíclico mono o policíclico tienen preferiblemente 5 ó 6 miembros.

Si uno o más de los residuos R^1-R^{17} y W representa un radical alifático, que está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, halógeno, alcoxi C_{1-4} lineal o ramificado, perfluoroalcoxi C_{1-4} lineal o ramificado, perfluoroalquilo C_{1-4} lineal o ramificado, amino, carboxilo, amido, ciano, nitro, $-SO_2NH_2$, alquilo $-CO-C_{1-4}$, alquilo $-SO-C_{1-4}$, alquilo SO_2-C_{1-4}, alquilo $-NH-SO_2-C_{1-4}$, en el que el alquilo C_{1-4} puede en cada caso ser lineal o ramificado, un radical fenilo o naftilo no sustituido o al menos monosustituido y un radical furanilo, tienilo, pirrolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, quinolinilo e isoquinolinilo no sustituido o al menos monosustituido, más preferiblemente se selecciona del grupo que consiste en hidroxilo, F, Cl, Br, metoxi, etoxi, $-CF_3$ y un radical fenilo no sustituido. Si cualquiera de los sustituyentes mencionados anteriormente está en sí al menos monosustituido, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en F, Cl, metilo y metoxi.

Si uno o más de los residuos R^1-R^{18} representa o comprende un radical cicloalifático, que está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, halógeno, alquilo C_{1-4} lineal o ramificado, alcoxi C_{1-4}

lineal o ramificado, perfluoroalcoxi C_{1-4} lineal o ramificado, fenoxi, benzoilo, ciclohexilo, perfluoroalquilo C_{1-4} lineal o ramificado, $-NR^AR^B$ en el que R^A, R^B se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, $-CH_2-CH_2-OH$ y fenilo, carboxilo, amido, ciano, nitro, $-SO_2NH_2$, alquilo $-CO-C_{1-4}$, alquilo $-CO-OC_{1-4}$, alquilo $-SO-C_{1-4}$, alquilo $-SO_2-C_{1-4}$, alquilo $-NH-SO_2-C_{1-4}$, en el que alquilo C_{1-4} puede en cada caso ser lineal o ramificado, fenilo o naftilo no sustituido o al menos monosustituido y radical furanilo, tienilo, pirrolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, quinolinilo e isoquinolinilo no sustituido o al menos monosustituido, más preferiblemente se selecciona del grupo que consiste en hidroxilo, F, Cl, Br, metilo, etilo, metoxi, etoxi, benzoilo, fenoxi, ciclohexilo, $-CF_3$, $-CO-CH_3$, $-CO-OCH_3$, $-NR^AR^B$ en el que R^A, R^B se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, $-CH_2-CH_2-OH$ y fenilo, y un radical fenilo no sustituido. Si cualquiera de los sustituyentes mencionados anteriormente está en sí al menos monosustituido, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en F, Cl, metilo y metoxi.

Si uno o más de los, residuos R^1-R^4, R^{10}-R^{15} y W comprende un grupo alquileno, que está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, halógeno, alcoxi C_{1-4} lineal o ramificado, perfluoroalcoxi C_{1-4} lineal o ramificado, perfluoroalquilo C_{1-4} lineal o ramificado, amino, carboxilo, amido, ciano, nitro, $-SO_2NH_2$, alquilo $-CO-C_{1-4}$, alquilo $-SO-C_{1-4}$, alquilo $-SO_2-C_{1-4}$, alquilo $-NH-SO_2-C_{1-4}$, en el que alquilo C_{1-4} puede ser lineal o ramificado, un radical fenilo o naftilo no sustituido o al menos monosustituido y un radical furanilo, tienilo, pirrolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, quinolinilo e isoquinolinilo no sustituido o al menos monosustituido, más preferiblemente se selecciona del grupo que consiste en hidroxilo, F, Cl, Br, metoxi, etoxi, $-CF_3$ y fenilo no sustituido. Si cualquiera de los sustituyentes mencionados anteriormente está en sí al menos monosustituido, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en F, Cl, metilo y metoxi.

Si uno o más de los residuos R^1-R^4, R^{10}-R^{15} comprende un sistema cíclico mono o policíclico, que está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, halógeno, alquilo C_{1-4} lineal o ramificado, alcoxi C_{1-4} lineal o ramificado, perfluoroalcoxi C_{1-4} lineal o ramificado,

perfluoroalquilo C_{1-4} lineal o ramificado, amino, carboxilo, amido, ciano, ceto, nitro, -SO_2NH_2, alquilo -CO-C_{1-4}, alquilo -SO-C_{1-4}, alquilo –SO_2-C_{1-4}, alquilo -NH-SO_2-C_{1-4}, en el que alquilo C_{1-4} puede ser lineal o ramificado, un radical fenilo o naftilo no sustituido o al menos monosustituido o un radical furanilo, tienilo, pirrolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, quinolinilo e isoquinolinilo no sustituido o al menos monosustituido, más preferiblemente del grupo que consiste en hidroxilo, F, Cl, Br, metilo, etilo, metoxi, etoxi, -CF_3, ceto, ciano y un radical fenilo no sustituido. Si cualquiera de los sustituyentes mencionados anteriormente está en sí al menos monosustituido, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en F, Cl, metilo y metoxi.

Si uno o más de los residuos R^1-R^4, R^{10}-R^{15} y R^8 representa o comprende un radical arilo, que está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, halógeno, alcoxi C_{1-4} lineal o ramificado, alquilo C_{1-4} lineal o ramificado, perfluoroalcoxi C_{1-4} lineal o ramificado, fenoxi no sustituido o al menos monosustituido, benzoilo no sustituido o al menos monosustituido, ciclohexilo, perfluoroalquilo C_{1-4} lineal o ramificado, NR^AR^B en el que R^A, R^B se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, -CH_2-CH_2-OH y fenilo, carboxilo, amido, ciano, -CH(OH)(fenil), nitro, -SO_2NH_2, alquilo -CO-C_{1-4}, alquilo -CO-OC_{1-4}, alquilo -SO-C_{1-4}, alquilo –SO_2-C_{1-4}, alquilo -NH-SO_2-C_{1-4}, en el que alquilo C_{1-4} puede ser lineal o ramificado, un radical fenilo o naftilo no sustituido o al menos monosustituido y radical furanilo, tienilo, pirrolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, quinolinilo e isoquinolinilo no sustituido o al menos monosustituido, más preferiblemente se seleccionan del grupo que consiste en hidroxilo, F, Cl, Br, metilo, etilo, ciano, -CH(OH)(fenil), metoxi, etoxi, benzoilo no sustituido o al menos monosustituido, fenoxi no sustituido o al menos monosustituido, ciclohexilo, -CF_3, -CO-CH_3, -CO-OCH_3, -NR^AR^B en el que R^A, R^B se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, -CH_2-CH_2-OH y fenilo, y un radical fenilo no sustituido. Si cualquiera de los sustituyentes mencionados anteriormente está en sí al menos monosustituido, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en F, Cl, metilo y metoxi.

Si uno o más de los residuos R^1-R^4, R^{10}-R^{15} representa o comprende un radical heteroarilo, que está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del

grupo que consiste en hidroxilo, halógeno, alcoxi C_{1-4} lineal o ramificado, alquilo C_{1-4} lineal o ramificado, perfluoroalcoxi C_{1-4} lineal o ramificado, fenoxi no sustituido o al menos monosustituido, benzoilo no sustituido o al menos monosustituido, ciclohexilo, perfluoroalquilo C_{1-4} lineal o ramificado, NR^AR^B en el que R^A, R^B se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, $-CH_2-CH_2-OH$ y fenilo, carboxilo, amido, ciano, nitro -CH(OH)(fenil), $-SO_2NH_2$, alquilo $-CO-C_{1-4}$, alquilo $-CO-OC_{1-4}$, alquilo $-SO-C_{1-4}$, alquilo $-SO_2-C_{1-4}$, alquilo $-NH-SO_2-C_{1-4}$, en el que alquilo C_{1-4} puede ser lineal o ramificado, un radical fenilo o naftilo no sustituido o al menos monosustituido y un radical furanilo, tienilo, pirrolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, quinolinilo e isoquinolinilo no sustituido o al menos monosustituido, más preferiblemente se seleccionan del grupo que consiste en hidroxilo, F, Cl, Br, metilo, etilo, ciano, metoxi, etoxi, benzoilo no sustituido o al menos monosustituido, fenoxi no sustituido o al menos monosustituido, ciclohexilo, $-CF_3$, -CH(OH)(fenil), $-CO-CH_3$, $-CO-OCH_3$, $-NR^AR^B$ en el que R^A, R^B se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, $-CH_2-CH_2-OH$ y fenilo, y un radical fenilo no sustituido. Si cualquiera de los sustituyentes mencionados anteriormente está en sí al menos monosustituido, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en F, Cl, metilo y metoxi.

Si R^{13} y R^{14} forman un anillo heterocíclico, que está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, halógeno, alcoxi C_{1-4} lineal o ramificado, alquilo C_{1-4} lineal o ramificado, perfluoroalcoxi C_{1-4} lineal o ramificado, perfluoroalquilo C_{1-4} lineal o ramificado, amino, carboxilo, amido, ciano, nitro, $-SO_2NH_2$, alquilo $-CO-C_{1-4}$, alquilo $-SO-C_{1-4}$, alquilo $-SO_2-C_{1-4}$, alquilo $-NH-SO_2-C_{1-4}$, en el que alquilo C_{1-4} puede ser lineal o ramificado, un radical fenilo o naftilo no sustituido o al menos monosustituido y un radical furanilo, tienilo, pirrolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, quinolinilo e isoquinolinilo no sustituido o al menos monosustituido, más preferiblemente se seleccionan del grupo que consiste en hidroxilo, F, Cl, Br, metoxi, etoxi, metilo, $-CF_3$ y un radical fenilo no sustituido. Si cualquiera de los sustituyentes mencionados anteriormente está en sí al menos monosustituido, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en F, Cl, metilo y metoxi.

Si R^{13} y R^{14} forman un anillo heterocíclico, que contiene uno o más heteroátomos adicionales como miembros del anillo, a menos que se defina lo

contrario, cada uno de estos heteroátomos puede seleccionarse preferiblemente del grupo que consiste en N, O y S, más preferiblemente del grupo que consiste en N y O.

Si uno o más de los residuos R^1-R^{15} y W representa o comprende un radical cicloalifático, que contiene uno o más heteroátomos como miembros del anillo, a menos que se defina lo contrario, cada uno de estos heteroátomos puede seleccionarse preferiblemente del grupo que consiste en N, O, S y P, más preferiblemente del grupo que consiste en N, O y S.

Si uno o más de los residuos R^1-R^4 y R^{10}-R^{15} y W representa o comprende un radical heteroarilo, que contiene uno o más heteroátomos como miembros del anillo, a menos que se defina lo contrario, cada uno de estos heteroátomos puede seleccionarse preferiblemente del grupo que consiste en N, O, S y P, más preferiblemente del grupo que consiste en N, O y S.

Si W representa o comprende un radical cicloalifático, un radical heteroarilo, un radical arilo y/o un sistema cíclico mono o policíclico, que está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, nitro, carboxilo, ciano, ceto, halógeno, alquilo C_{1-20}, alquilo C_{1-4} parcialmente fluorado, alquilo C_{1-4} parcialmente clorado, alquilo C_{1-4} parcialmente bromado, alcoxi C_{1-5}, alcoxi C_{1-4} parcialmente fluorado, alcoxi C_{1-4} parcialmente clorado, alcoxi C_{1-4} parcialmente bromado, alquenilo C_{2-6}, alquilo SO_2-C_{1-4}, alquilo -(C=O)-C_{1-5}, alquilo -(C=O)-O-C_{1-5}, -(C=O)-Cl, alquilo –S-C_{1-4}, -(C=O)-H, alquilo -NH-(C=O)-NH-C_{1-4}, perfluoroalquilo -(C=O)-C_{1-4}, -NR^AR^B, en el que R^A y R^B se seleccionan independientemente del grupo que consiste en H, alquilo C_{1-4} y fenilo, alquilo NH-(C=O)-C_{1-5}, alquilen C_{1-5} alquilo -(C=O)-C_{1-5}, (1,3-dihidro-1-oxo-2H-isoindol-2-il), N-ftalimidinilo, (1,3-dioxo-2-azaspiro[4,4]-non-2-il), fenilo sustituido o no sustituido, -SO_2-fenilo, fenoxi, piridinilo, piridiniloxi, pirazolilo, pirimidinilo, pirrolidinilo, -SO_2-pirrolidinilo, morfolinilo, SO_2-morfolinilo, tiadiazolilo, oxadiazolilo, oxazolilo, tiazolilo, isoxazolilo, O-CH_2-tiazolilo, NH-fenilo, y alquilen-NH-(C=O)-fenilo C_{1-4}, más preferiblemente del grupo que consiste en hidroxilo, nitro, carboxilo, ciano, ceto, F, Cl, Br, I, alquilo C_{1-12}, -CH_2F, -CHF_2, -CF_3, -CH_2Cl, -CH_2Cl_2, -CCl_3, -CH_2Br, -$CHBr_2$, -CBr_3, OCF_3, $OCHF_2$, OCH_2F, O-CH_2-CF_3, vinilo, SO_2-CH_3, -(C=O)-CH_3, -(C=O)-C_2H_5, -(C=O)-O-CH_3, -(C=O)-O-C_2CH_5, -(C=O)-Cl, -S-CH_3-, -(C=O)-H, -NH-(C=O)-NH-CH_3, -(C=O)-CF_3, dimetilamino, dietilamino, di-n-propilamino, di-iso-propilamino, di-n-butilamino, di-terc-butilamino, NH-(C=O)-CH_3, -CH_2-(C=O)-CH_3, -CH_2-(C=O)C_2H_5, (1,3-dihidro-1-oxo-2H-isoindol-2-il), N-ftalimidinilo, (1,3-dioxo-2-azaspiro[4,4]-non-2-il), fenilo sustituido o no sustituido, -SO_2-fenilo, fenoxi,

piridinilo, piridiniloxi, pirazolilo, pirimidinilo, pirrolidinilo, -SO_2-pirrolidinilo, morfolinilo, SO_2-morfolinilo, tiadiazolilo, oxadiazolilo, oxazolilo, tiazolilo, isoxazolilo, O-CH_2-tiazolilo, NH-fenilo, y -CH_2-NH-(C=O)-fenilo.

Si cualquiera de los sustituyentes mencionados en sí mismo está sustituido por uno o más sustituyentes, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en halógeno, nitro, ciano, hidroxilo, alquilo -(C=O)-C_{1-4}, alquilo C_{1-4}, alquilo C_{1-4} al menos parcialmente fluorado, alquilo C_{1-4} al menos parcialmente clorado, alquilo C_{1-4} al menos parcialmente bromado, alquilo -S-C_{1-4}, alquilo -C(=O)-O-C_{1-6}, -(C=O)CH_2-F, -(C=O)-CH_2-Cl, -(C=O)-CH_2-Br, preferiblemente del grupo que consiste en F, Cl, Br, -CH_2F, -CHF_2, -CF_3, -CH_2Cl, -$CHCl_2$, -CCl_3, -CH_2Br, -$CHBr_2$, -CBr_3, nitro, ciano, hidroxilo, -(C=O)-CH_3, -CH_3, -C_2H_5, -S-CH_3, -C(=O)-O-CH_3, -C(=O)-O-C_2H_5, -(C=O)-CH_2-F, -(C=O)-CH_2-Cl y -(C=O)-CH_2-Br.

Se prefieren aquellos compuestos de fórmula general (I) en la que R^1, R^2, R^3, R^4 se seleccionan cada uno independientemente del grupo que consiste en H, F, Cl, Br, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un radical arilo o heteroarilo de 5 ó 6 miembros opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un grupo nitro, un grupo ciano, -OR^{10}, -$O(C=O)R^{11}$, -SR^{12}, -SOR^{12}, -SO_2R^{12}, -NH-SO_2R^{12}, -SO_2NH_2 y un resto –$NR^{13}R^{14}$,

preferiblemente seleccionados del grupo que consiste en H, F, Cl, Br, un radical alifático C_{1-3} lineal o ramificado, saturado, opcionalmente al menos monosustituido, un radical cicloalifático C_5 o C_6 saturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_1 o C_2 opcionalmente al menos monosustituido, un grupo nitro, un grupo ciano, -OR^{10}, -$O(C=O)R^{11}$, -SR^{12}, y un resto –$NR^{13}R^{14}$,

más preferiblemente seleccionados del grupo que consiste en H, F, Cl, -CH_3, -CH_2CH_3, -CF_3, -CF_2CF_3, ciclopentilo, ciclohexilo, un grupo nitro, un grupo ciano y -OR^{10},

y R^5-R^{18} y W tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

También se prefieren compuestos de fórmula general (I), en la que R^5 representa hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido o un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo,

preferiblemente representa H o un radical alquilo C_{1-3} lineal o ramificado,

más preferiblemente H, $-CH_3$ o $-CH_2CH_3$,

y R^1-R^4, R^6-R^{18} y W tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

También se prefieren aquellos compuestos de fórmula general (I) en la que R^6, R^7, R^8, R^9 se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, un grupo ciano y un resto $COOR^{15}$,

preferiblemente seleccionados del grupo que consiste en H, un radical alquilo C_{1-3} lineal o ramificado, un grupo ciano y un grupo $COOR^{15}$,

más preferiblemente del grupo que consiste en H, $-CH_3$, $-CH_2CH_3$ y un resto ciano,

y R^1-R^5, R^{10}-R^{18} y W tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

También se prefieren compuestos de fórmula general (I), en la que W representa un radical alquilo C_{11-20} lineal o ramificado, opcionalmente al menos monosustituido, un grupo naftilo, que está al menos monosustituido, un grupo quinolinilo, que está al menos monosustituido, un grupo pirrolilo, que está al menos monosustituido por un sustituyente distinto de alquilo C_{1-5}, un tiazolilo opcionalmente al menos monosustituido, benzo[b]-tiofenilo, benzo[b]-furanilo, isoquinolinilo, tetrahidroisoquinolinilo, pirazolilo, isoazolilo, cromanilo, benzotiadiazolilo, imidazolilo, benzofurazanilo, dibenzo[b,d]-furanilo, benzoxadiazolilo, imidazo[2,1-b]-tiazolilo, antracenilo, coumarinilo, 2,3-dihidro-1,4-benzodioxinilo, 2,3-dihidrobenzo[b]furanilo, 3,4-dihidro-2H-1,4-benzoxazinilo, 3,4-dihidro-2H-1,5-benzodioxepinilo, benzotiazolilo, imidazo[1,2-a]-piridinilo, un grupo cromonilo, un grupo isatinilo, un grupo pentametildihidrobenzofuranilo, un grupo ciclopropilo o ciclopentilo opcionalmente al menos monosustituido, 2-(1,3-dioxo-1,3-dihidro-isoindol-2-il)-etilo, un grupo tienilo, que está al menos monosustituido por uno o más sustituyentes seleccionados independientemente del grupo que consiste en F, Cl, Br, alcoxi C_{1-5}, $-CF_3$, alquilo $-SO_2-C_{1-5}$ y benzoilaminometilo, fenilsulfonilo, isoxazolilo, benzoamidometilo, pirimidilo, tiazolilo, pirazolilo, fenilo, 1,2,4-tiadiazolilo, 1,3-oxazolilo o 1,2,4-oxadiazolilo, opcionalmente al menos monosustituidos, un grupo furilo, que está al menos monosustituido por uno o más sustituyentes seleccionados independientemente del grupo que consiste en un radical alquilo C_{1-5}, que puede estar al menos parcialmente fluorado o clorado, un fenilo opcionalmente al menos monosustituido y un grupo alquilo (C=O)-O- C_{1-5},

un resto $NR^{16}R^{17}$,

un resto COR^{16},

o un radical fenilo, que está al menos monosustituido por uno de los sustituyentes seleccionados del grupo que consiste en:

2,2,2-trifluoroetoxi, alquenilo C_{2-6}, 1,3-dihidro-1-oxo-2H-isoindol-2-ilo, N-ftalimidinilo, [(2-cloro-1,3-tiazolil-5-il)-metoxi, etil-5-il-2-metil-3-furoato, alquilo C_{11-20}, 1,3-dioxo-2-azaspiro[4,4]non-2-ilo, pirazolilo, (1,3-oxazol-5-il)-, (5-metil-1,3,4-oxadiazol-2-il)-, difluorometoxi, diclorometoxi, 1-pirrolidinilsulfonilo, morfolinosulfonilo, 2-metil-4-pirimidinilo, un grupo fenoxi, que está al menos monosustituido por alcoxi C_{1-5}, un grupo fenilo, que está al menos monosustituido por uno de los sustituyentes seleccionados del grupo que consiste en nitro, alcoxi C_{1-5}, F, Cl, Br, alquilo C_{1-5} al menos parcialmente fluorado, C_{1-5} alquilo al menos parcialmente clorado, [(2-cloro-1,3-tiazol-5-il)-metoxi]-, -(C=O)-H y alquilo (C=O)-C_{1-5}, un grupo piridinilo, que está al

menos monosustituido por alcoxi C_{1-5}, un grupo piridiniloxi, que está al menos monosustituido por alcoxi C_{1-5}, un grupo fenoxi, que está al menos disustituido y un grupo piridiniloxi, que está al menos disustituido,

más preferiblemente W representa un resto seleccionado del grupo que consiste en 5-dimetilamino-naft-1-ilo, 2-acetamido-4-metil-5-tiazolilo, trifluorometilo, triclorometilo, isopropilo, metilo, 2,2,2-trifluoroetilo, etilo, hexadecilo, 2-cloroetilo, n-propilo, 3-cloro-propilo, n-butilo, diclorometilo, clorometilo, dodecilo, 1-octilo, 6-(p-toluidino)-naft-2-ilo, 4,5-dibromo-tiofen-2-ilo, cloruro de benzoilo-2-ilo, 1-octadecilo, 4-bromo-2,5-dicloro-tiofen-3-ilo, 2,5-dicloro-tiofen-3-ilo, 5-cloro-tiofen-2-ilo, 1-decilo, 3,5-dicloro-4-(2-cloro-4-nitrofenoxi)-fenilo, 2,3-diclorotiofen-5-ilo, 3-bromo-2-cloro-tiofen-5-ilo, 3-bromo-5-cloro-tiofen-2-ilo, 2-(benzoilaminometil)-tiofen-5-ilo, 4-(fenil-sulfonil)-tiofen-2-ilo, 2-fenil-sulfonil-tiofen-5-ilo, 2-[1-metil-5-(trifluorometil)pirazol-3-il]-tiofen-5-ilo, 5-cloro-1,3-dimetilpirazol-4-ilo, 3,5-dimetilisoxazol-4-ilo, 2-(2,4-diclorofenoxi)fenilo, 4-(2-cloro-6-nitro-fenoxi)-fenilo, 4-(3-cloro-2-cianofenoxi)-fenilo, 2,4-dimetil-1,3-tiazol-5-ilo, metil-metano-sulfonilo, 2,5-bis-(2,2,2-trifluoroetoxi)-fenilo, 5-(di-n-propilamino)-naft-1-ilo, 2,2,5,7,8-pentametil-croman-6-ilo, 5-cloro-4-nitro-tiofen-2-ilo, 2,1,3-benzotiadiazol-4-ilo, 1-metil-imidazol-4-ilo, benzofurazan-4-ilo, 5-(isoxazol-3-il)-tiofen-2-ilo, vinil-fenil-4-ilo, 5-dicloro-metil-furan-2-ilo, 5-bromotiofen-2-ilo, 5-(4-clorobenzoamidometil)-tiofen-2-ilo, dibenzo[b,d]-furan-2-ilo, 5-cloro-3-metilbenzo[b]-tiofen-2-ilo, 3-metoxi-4-(metoxicarbonil)-tiofen-2-ilo, 5-[2-(metiltio)-pirimidin-4-il-]-tiofen-2-ilo, 4-cloro-2,1,3-benzoxadiazol-7-ilo, 5-cloro-2,1,3-benzoxadiazol-4-ilo, 6-cloro-imidazo(2,1-b)-tiazol-5-ilo, 3-metil-benzo[b]-tiofen-2-ilo, 4-[3-cloro-5-(trifluorometil)-2-piridil]oxi-fenilo, 5-cloro-naft-1-ilo, 5-cloro-naft-2-ilo, 9,10-dibromoantracen-2-ilo, isoquinolin-5-ilo, 4-metoxi-2,3,6-trimetilbenzoilo, 4'-nitro-bifenil-4-ilo, (1,3-dihidro-1-oxo-2H-isoindol-2-il)-4-fenilo, 5-(2-metil-1,3-tiazol-4-il)-tiofen-2-ilo, 5-(1-metil-3-(trifluorometil)pirazol-5-il]-tiofen-2-ilo, 5-[5-(trifluorometil)-isoxazol-3-il]-tiofen-2-ilo, p-dodecil-fenilo, 4-[(3-ciano-4-metoxi-2-piridinil)oxi]-fenilo, 4-(N-ftalimidinil)-fenilo, 1,2,3,4-tetrahidro-2-(trifluoroacetil)-isoquinolin-7-ilo, 1,2-dimetilimidazol-4-ilo, 2,2,4,6,7-pentametildihidrobenzofuran-5-ilo, 4-cloro-naft-1-ilo, 2,5-dicloro-4-nitro-tiofen-3-ilo, 4-(4-metoxi-fenoxi)-fenilo, [4-(3,5-diclorofenoxi)fenil]-, [4-(3,4-diclorofenoxi)-fenil], [4-(3,5)-bis(trifluorometilfenoxi)fenil], 3-(2-metoxi-fenoxi)-fenilo, 3-(4-metoxi-fenil)-fenilo, 3-(4-cloro-fenil)-fenilo, 3-(3,5-dicloro-fenil)-fenilo, 3-(3,4-dicloro-fenil)-fenilo, 3-(4-fluorofenil)-fenilo, 3-[4-(trifluorometil)-fenil]-fenilo, 3-[3,5-bis(trifluorometil)-fenil]-fenilo, 4-(2-metoxi-fenoxi)-fenilo, 4-(2-metil-fenoxi)-fenilo, 4-(4-metoxi-fenoxi)-fenilo, 4-(4-clorofenil)-fenilo, 4-(3,5-diclorofenil)-fenilo, 4-(3,4-diclorofenil)-fenilo, 4-(4-fluorofenil)-

fenilo, 4-[4-(trifluorometil)-fenil]-fenilo, 4-[3,5-bis(trifluorometil)-fenil]-fenilo, ciclopropilo, 2-(2-clorofenil)-2-feniletilo, 2-(2-trifluorometilfenil)-2-feniletilo, 5-[4-ciano-1-metil-5-(metiltio)-1H-pirazol-3-il-tiofen-2-ilo, 3-ciano-2,4-bis(2,2,2-trifluoroetoxi)-fenilo, 4-[(2-cloro-1,3-tiazol-5-il)-metoxi]-fenilo, 2-(1,3-dioxo-1,3-dihidro-isoindol-2-il)-etilo, 5-yodo-naft-1-ilo, etil-2,5-dimetil-1-fenilpirrol-4-carboxilato-3-ilo, etil-2-metil-1,5-difenil-1H-pirrol-3-carboxilato-4-ilo, etil-5-(4-clorofenil)-2-metil-3-furoato-4-ilo, etil-5-(4-clorofenil)-2-metil-1-fenil-3-carboxilato-4-ilo, etil-2,5-dimetil-3-furoato-4-ilo, 3-cloro-4-(1,3-dioxo-2-azaspiro[4,4]non-2-il)-fenilo, cumarin-6-ilo, 3-(4-metoxi-fenoxi)-fenilo, [3-(3,5-diclorofenoxi)]fenilo, [3-(3,4-diclorofenoxi)]-fenilo, 3,5-bis(trifluorometil)fenoxifenilo, 2,2-difeniletilo, 4-fenil-5-(trifluorometil)-tiofen-3-ilo, metil-4-fenil-5-(trifluorometil)-tiofen-2-carboxilato-3-ilo, metil-1,2,5-trimetilpirrol-3-carboxilato-4-ilo, 4-fluoro-naft-1-ilo, 5-fluoro-3-metilbenzo[b]-tiofen-2-ilo, metil-2,5-dimetil-3-furoato-4-ilo, metil-2-furoato-5-ilo, metil-2-metil-3-furoato-5-ilo, metil-1-metil-1H-pirrol-2-carboxilato-5-ilo, 2-(5-cloro-1,2,4-tiadiazol-3-il)-tiofen-5-ilo, 1,3,5-trimetil- 1H-pirazol-4-ilo, pentafluoroetoxitetrafluoroetilo, 5-(5-isoxacil)-tiofen-2-ilo, 5-(5-isoxazolil)-2-furilo, 5-metil-2,1,3-benzotiadiazol-4-ilo, 2,3-dihidro-1,4-benzodioxin-6-ilo, 4-metil-naft-1-ilo, 5-metil-2-(trifluorometil)-3-furilo, 2,3-dihidrobenzo[b]furan-5-ilo, 1-benzotiofen-3-ilo, 4-metil-3,4-dihidro-2H-1,4-benzoxazin-7-ilo, 5-metil-1-fenil-1H-pirazol-4-ilo, 6-morfolin-3-piridinilo, 4-(1H-pirazol-1-il)-fenilo, 6-fenoxi-3-piridilo, 3,4-dihidro-2H-1,5-benzodioxepin-7-ilo, 5-(1,3-oxazol-5-il)-2-tienilo, 4-(1,3-oxazol-5-il)-fenilo, 5-metil-4-isoxazolilo, 2,1,3-benzotiadiazol-5-ilo, 5-acetamido-naft-1-ilo, 3-metil-8-quinolinilo, 1,3-benzotiazol-6-ilo, 2-morfolin-3-piridilo, 2,5-dimetil-3-tienilo, 5-[5-(clorometil)-1,2,4-oxadiazol-3-il]-2-tienilo, etil-3-[5-il-2-tienil]-1,2,4-oxadiazol-5-carboxilato, 3-(5-metil-1,3,4-oxadiazol-2-il)-fenilo, 4-(difluorometoxi)-fenilo, 3-(difluorometoxi)-fenilo, 2,2-dimetil-6-cromanilo, etil-3,5-dimetil-1H-pirrol-2-carboxilato-4-ilo, imidazo[1,2-a]piridin-3-ilo, 3-(1,3-oxazol-5-il)-fenilo, etil-5-[4-il-fenil]-2-metil-3-furoato, 1-pirrolidinilfenilsulfonilo, metil-5-il-4-metil-2-tiofen-carboxilato, metil-3-il-4-(isopropilsulfonil)-2-tiofeno, 7-clorocromon-3-ilo, 4'-bromobifenil-4-ilo, 4'-acetilbifenil-4-ilo, 4'-bromo-2'-fluoro-bifenil-4-ilo, 1-metil-5-isatinilo, ácido 2-cloro-3-tiofencarboxilico-5-ilo, 2-metoxi-5-(N-ftalimidinil)fenilo, 1-benzotiofen-2-ilo, morfolinfenilsulfonilo y 3-(2-metil-4-pirimidinil)-fenilo y R^1-R^{18} tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

Además, se prefieren compuestos de fórmula general (I), en la que R^{10} representa hidrógeno, un radical alifático C_{1-8} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-8} opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo de 5 ó 6 miembros opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-8} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

preferiblemente H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo o un radical fenilo,

más preferiblemente H, $-CH_3$, $-C_2H_5$ o fenilo,

y R^1-R^9, R^{12}-R^{18} y W tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

Además, se prefieren compuestos de fórmula general (I), en la que R^{11} representa hidrógeno, un radical alifático C_{1-8} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-8} opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo de 5 ó 6 miembros opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-8} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

preferiblemente H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo o un radical fenilo, más preferiblemente H, $-CH_3$, $-C_2H_5$ o fenilo,

y R^1-R^{10}, R^{12}-R^{18} y W tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente

enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

También se da preferencia a compuestos de fórmula general (I), en la que R^{12} representa un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo de 5 ó 6 miembros, opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

preferiblemente representa H, un radical alquilo C_{1-4}, un radical ciclohexilo o un radical fenilo,

más preferiblemente H, $-CH_3$, $-C_2H_5$ o fenilo,

y R^1-R^{11}, R^{13}-R^{18} y W tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

También se prefieren compuestos de fórmula general (I), en la que R^{13} y R^{14} se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo de 5 ó 6 miembros, opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido

y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

preferiblemente se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo y un radical fenilo,

más preferiblemente se seleccionan cada uno independientemente del grupo que consiste en H, $-CH_3$, $-C_2H_5$ y fenilo,

y R^1-R^{12}, R^{15}-R^{18} y W tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

Además, se prefieren compuestos de fórmula general (I), en la que R^{13} y R^{14} junto con el átomo puente de nitrógeno forman un anillo heterocíclico de 5 ó 6 miembros saturado, insaturado o aromático, que puede estar al menos monosustituido y/o contener al menos un heteroátomo más como miembro del anillo,

preferiblemente forman un grupo piperidina o morfolina no sustituido,

y R^1-R^{12}, R^{15}-R^{18} y W tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos , o solvatos correspondientes.

También se prefieren compuestos de fórmula general (I), en la que R^{15} representa hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, o un radical arilo o heteroarilo de 5 ó 6 miembros opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

preferiblemente representa H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo o un radical fenilo,

más preferiblemente H, $-CH_3$, $-C_2H_5$ o fenilo,

y R^1-R^{14}, R^{16}, R^{17}, R^{18} y W tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

También se prefieren compuestos de fórmula general (I), en la que R^{16} representa un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido,

preferiblemente un radical alquilo C_{1-3} lineal o ramificado, saturado, no sustituido,

más preferiblemente un radical metilo,

y R^1-R^{15}, R^{17}, R^{18} y W tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

También se prefieren compuestos de fórmula general (I), en la que R^{17} representa un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido,

preferiblemente un radical alquilo C_{1-3} lineal o ramificado, saturado, no sustituido,

más preferiblemente un radical metilo,


y R^1-R^{16}, R^{18} y W tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

También se prefieren compuestos de fórmula general (I), en la que R^{18} representa un radical fenilo que está opcionalmente al menos monosustituido por un radical alifático C_{1-6}, más preferiblemente un radical fenilo que está opcionalmente al menos monosustituido por un grupo metilo,


y R^1-R^{17} y W tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

Se prefieren particularmente compuestos de fórmula general (I) seleccionados de la siguiente lista A:


Lista A:




1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(toluen-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-(1-fenilmetanosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-(1-bencenosulfonil-piperidin-4-il)-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(toluen-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-(1-fenilmetanosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(5-cloro-3-metil-benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(5-cloro-3-metil-benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-acetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




2-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo




1-[1-(2,4-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




Dimetilamida del ácido 4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfónico




1-[1-(2-naftalen-1-il-etanosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




8-metil-1-[1-(tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-acetil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




2-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo




1-[1-(2,4-dimetil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-metoxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




Dimetilamida del ácido 4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfónico




8-metil-1-[1-(2-naftalen-1-il-etanosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




Dimetilamida del ácido 4-(6-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfónico




Éster metílico del ácido 2-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico




1-[1-(3-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




Éster metílico del ácido 2-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il]-piperidina-1-sulfonil]-benzoico




8-metil-1-[1-(3-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-acetil-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




2-[4-(6-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo




6-cloro-1-[1-(4-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




Éster metílico del ácido 2-[4-(6-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico




6-cloro-1-[1-(2,4-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(3-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(5-cloro-3-metil-benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-{1-[4-(4-bromo-fenoxi)-bencenosulfonil]-piperidin-4-il}-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-fluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




8-metil-1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




8-metil-1-(1-fenilmetanosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-bromo-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(4-metanosulfonil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(butano-1-sulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-bromo-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-metanosulfonil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-butano-1-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(2-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(bifenil-4-sulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




8-metil-1-[1-(2-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




8-metil-1-[1-(3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona



1-[1-(bifenil-4-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




8-metil-1-[1-(4-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(4-nitro-bencenosulfonil]-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona


302




1-(1-etanosulfonil-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(propano-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(propano-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-(1-etanosulfonil-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(propano-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(propano-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-[1-(quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-[1-(2-naftalen-1-il-etanosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-[1-(tolueno-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-fluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-[1-(naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(5-cloro-3-metil-benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-[1-(4-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-(1-bencenosulfonil-piperidin-4-il)-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-cloro-3-nitro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(5-dimetilamino-naftaleno-1-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-cloro-3-nitro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-cloro-3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(4-cloro-3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(5-dimetilamino-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona



1-[1-(4-metoxi-2,3,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-metoxi-2,3,6-trimetil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(4-metoxi-2,3,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona


3.06




1-[1-(4-metoxi-2,3,6-trimetil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2-bromo-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2-bromo-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2-bromo-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2-bromo-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(2,3-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2,3-dicloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2,4,5-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




8-metil-1-[1-(2,4,5-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(2,4,5-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-[1-(2,4,5-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(5-bromo-2-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(5-bromo-2-metoxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(5-bromo-2-metoxi-bencenosulfonil)-piperidin-4-il]-8-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-[5-bromo-2-metoxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2,6-dimetoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2,6-dimetoxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(2,6-dimetoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2,6-dimetoxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-(1-pentametilbencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




8-metil-1-(1-pentametilbencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-(1-pentametilbencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-(1-pentametilbencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-[2-(2,2,2-trifluoro-acetil)-1,2,3,4-tetrahidro-isoquinolina-7-sulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




8-metil-1-{1-[2-(2,2,2-trifluoro-acetil)-1,2,3,4-tetrahidro-isoquinolina-7-sulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-{1-[2-(2,2,2-trifluoro-acetil)-1,2,3,4-tetrahidro-isoquinolina-7-sulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-{1-[2-(2,2,2-trifluoro-acetil)-1,2,3,4-tetrahidro-isoquinolina-7-sulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2-metil-5-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




8-metil-1-[1-(2-metil-5-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(2-metil-5-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-[1-(2-metil-5-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-bromo-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-bromo-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-bromo-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-bromo-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-cloro-2,5-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-cloro-2,5-dimetil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(4-cloro-2,5-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-cloro-2,5-dimetil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-metoxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-isopropil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-isopropil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(4-isopropil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-isopropil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3-cloro-4-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3-cloro-4-fluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(3-cloro-4-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3-cloro-4-fluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-bromo-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-[1-(3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-[1-(3-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2-nitro-4-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2,4-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2,4,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




8-metil-1-[1-(4-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




8-metil-1-[1-(2-nitro-4-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3-fluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2,4-dicloro-bencenosulfonil)-piperidin-4-il]-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




8-metil-1-[1-(2,4,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




8-metil-1-[1-(2-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-bromo-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-{1-[4-(4-bromo-fenoxi)-bencenosulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




8-metil-1-[1-(tolueno-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-(1-bencenosulfonil-piperidin-4-il)-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3-metoxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2,4-dimetil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-[4-(4-bromo-fenoxi)-bencenosulfonil]-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-[1-(tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(tolueno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(5-fluoro-2-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-isopropoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3,4-dimetoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-(1-pentafluorobencenosulfonil-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




8-metil-1-[1-tolueno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(5-fluoro-2-metil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-isopropoxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3-cloro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3,4-dimetoxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




8-metil-1-(1-pentafluorobencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-[1-(tolueno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(5-fluoro-2-metil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-isopropoxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3-cloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3,4-dimetoxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-(1-pentafluorobencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-[1-(4-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-[1-(2-nitro-4-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3-fluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2,4-dicloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-[1-(2,4,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-[1-(2-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3-metoxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-[1-(2-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-acetil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-metanosulfonil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-(1-fenilmetanosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




Éster metílico del ácido 2-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]benzoico




6-metil-1-[1-(2-oxo-2H-cromeno-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(4-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(3,5-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-{1-[4-(4-bromo-fenoxi)-bencenosulfonil]-piperidin-4-il}-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(3-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(2-oxo-2H-cromeno-6-sulfonil]-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(tolueno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(5-fluoro-2-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(4-isopropoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(3-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(3,4-dimetoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-(1-pentafluorobencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(4-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(2-nitro-4-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacina




6-cloro-1-[1-(3-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(2,4-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(2,4,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(2-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2-oxo-2H-cromeno-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3,5-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2,5-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(5-bromo-6-cloro-piridina-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2,6-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




8-metil-1-[1-(2-oxo-2H-cromeno-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3,5-dicloro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2,5-dicloro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(5-bromo-6-cloro-piridina-3-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-cloro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2,6-dicloro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(bifenil-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(2,5-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(5-bromo-6-cloro-piridina-3-sulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(4-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(2,6-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(bifenil-4-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




2-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo




1-[1-(2,5-dicloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(5-bromo-6-cloro-piridina-3-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-cloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2,6-dicloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3,5-dicloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-[1-(1-metil-1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(5-bromo-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-metanosulfonil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(1-metil-1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(5-bromo-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(6-cloro-imidazo[2,1-b]tiazol-5-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-etil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(benzo[b]tiofeno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(6-cloro-imidazo[2,1-b]tiazol-5-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-etil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(benzo[b]tiofeno-3-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(6-cloro-imidazo[2,1-b]tiazol-5-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(4-etil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(benzo[b]tiofeno-3-sulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(6-cloro-imidazo[2,1-b]tiazol-5-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-etil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(benzo[b]tiofeno-3-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(7-cloro-benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2-metoxi-4-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




Éster metílico del ácido 3-{4-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-fenil}-propiónico




1-[1-(2,4-dinitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(7-cloro-benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2-metoxi-4-metil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




Éster metílico del ácido 3-{4-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-fenil}-propiónico




1-[1-(2,4-dinitro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(7-cloro-benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2-metoxi-4-metil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




Éster metílico del ácido 3-{4-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-fenil}-propiónico




1-[1-(2,4-dinitro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(7-cloro-benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(2-metoxi-4-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




Éster metílico del ácido 3-{4-[4-(6-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-fenil}-propiónico




6-cloro-1-[1-(2,4-dinitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(1-metil-1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(5-bromo-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




8-metil-1-[1-(1-metil-1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(5-bromo-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2,5-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(2,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2,5-difluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-cloro-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-cloro-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(4-cloro-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-cloro-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2,4,5-trifluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




8-metil-1-[1-(2,4,5-trifluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(2,4,5-trifluoro-bencenosulfonil]-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-metil-1-[1-(2,4,5-trifluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3,5-dicloro-2-hidroxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2,6-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2,6-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(2,6-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2,6-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(5-cloro-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(5-cloro-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(5-cloro-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(5-cloro-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2-cloro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(2-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(2-cloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(2-naftalen-1-il-etanosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(4-bromo-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(tolueno-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(2,4-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(2-naftalen-1-il-etanosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(5-cloro-3-metil-benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-(1-bencenosulfonil-piperidin-4-il)-6-bromo-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-{1-[4-(4-bromo-fenoxi)-bencenosulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(2-metil-5-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(4-bromo-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(tolueno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(5-fluoro-2-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(4-isopropoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(3-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(3,4-dimetoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-(1-pentafluorobencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(4-cloro-2,5-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(3-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(4-isopropil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(4-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(3-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-(1-pentametilbencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(2-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(4-cloro-3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(5-dimetilamino-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(4-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(4-acetil-bencenosulfonil)-piperidin-4-il]-6-bromo-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(4-metanosulfonil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(bifenil-4-sulfonil)-piperidin-4-il]-6-bromo-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-(1-fenilmetanosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(2,5-dimetoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-{1-[2-(2,2,2-trifluoro-acetil)-1,2,3,4-tetrahidro-isoquinolina-7-sulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(2,3-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(2,4,5-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(5-bromo-2-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(4-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(2-nitro-4-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(3-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(2,4-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(2,4,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(2-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(2-bromo-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(4-metoxi-2,3,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3,5-dicloro-4-hidroxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3,5-dicloro-4-hidroxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(3,5-dicloro-4-hidroxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




1-[1-(3,5-dicloro-4-hidroxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(3,5-dicloro-4-hidroxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-cloro-1-[1-(3,5-dicloro-2-hidroxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(3,5-dicloro-2-hidroxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




2-[4-(6-bromo-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo




6-bromo-1-[1-(4-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




Éster metílico del ácido 2-[4-(6-bromo-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico




6-bromo-1-[1-(2-oxo-2H-cromeno-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(3,5-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(2,5-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(5-bromo-6-cloro-piridina-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona




6-bromo-1-[1-(4-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona



6-bromo-1-[1-(2,6-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona



6-bromo-1-[1-(1-metil-1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona



6-bromo-1-[1-(5-bromo-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

Se prefieren más particularmente compuestos de fórmula general (I) seleccionados del grupo que consiste en:


1-[1-(5-cloro-3-metil-benzo[b]tiofenil-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d] [1,3]oxazin-2-ona,

1-[1-(5-dimetilamino-naftil-1-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxazin-2-ona,

1-[1-(5-dimetilamino-naftil-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona,


y sales correspondientes de los mismos, y solvatos correspondientes.

En aspecto adicional, la presente invención también proporciona un procedimiento para la reparación de compuestos de sulfonamidas derivados de benzoxazinona de fórmula general (I), en la que R^1-R^9 y W tienen la significación definida anteriormente, que comprende hacer reaccionar al menos un compuesto de piperidina de fórmula general (II) y/o una sale correspondientes del mismo, preferiblemente una sal clorhidrato,



(II)

en la que R^1 a R^9 tienen la significación definida anteriormente, con al menos un compuesto de fórmula general (III),



(III)

en la que W tiene la significación definida anteriormente, en un medio de reacción adecuado, opcionalmente en presencia de al menos una base y/o al menos un agente auxiliar, para dar un compuesto de fórmula general (I).

Medios de reacción adecuados incluyen, por ejemplo disolventes orgánicos, tales como éteres, preferiblemente dietil éter, dioxano, tetrahidrofurano, dimetil glicol éter, o alcoholes, por ejemplo metanol, etanol, propanol, isopropanol, butanol, isobutanol, terc-butanol, o hidrocarburos preferiblemente benceno, tolueno, xileno, hexano, ciclohexano, éter de petróleo o hidrocarburos halogenados, por ejemplo diclorometano, triclorometano, tetraclorometano, dicloroetileno, tricloroetileno, clorobenceno o/y otros disolventes, preferiblemente acetato de etilo, trietilamina, piridina, dimetilsulfóxido, dimetilformamida, hexametilfosforamida, acetonitrilo, acetona o nitrometano. También pueden utilizarse mezclas basadas en uno o más de los disolventes mencionados anteriormente.

Las bases que pueden utilizarse en el procedimiento según la presente invención, son en general bases orgánicas o inorgánicas, preferiblemente hidróxidos de metales alcalinos, por ejemplo hidróxido de sodio o hidróxido de potasio, u obtenidas a partir de otros metales como el hidróxido de bario o diferentes carbonatos, preferiblemente carbonato de potasio, carbonato de sodio, carbonato de calcio, o alcóxidos, por ejemplo metóxido de sodio, metóxido de potasio, etóxido de sodio, metóxido de potasio, etóxido de potasio ó terc-butóxido de potasio, o aminas orgánicas, preferiblemente trietilamina, diisopropiletilamina o heterociclos, por ejemplo 1,4-diazabiciclo[2,2,2]octano, 1,8-diazabiciclo[5,4,0]undec-7-eno, piridina, diaminopiridina, dimetilaminopiridina, metilpiperidina o morfolina. También pueden utilizarse metales alcalinos tales como sodio o sus hidruros, por ejemplo, hidruro de sodio. También pueden utilizarse mezclas basadas en una o más de las bases mencionadas anteriormente.

Durante las reacciones sintéticas descritas anteriormente o durante la preparación de los compuestos de fórmulas generales (II) o (III), puede ser necesaria

y/o deseable la protección de grupos sensibles o de los reactivos. Esto puede realizarse utilizando grupos protectores convencionales como los descritos en la bibliografía [Protective Groups in Organic Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973; T. W. Greene & P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & sons, 1991]. Dicha descripción bibliográfica se incorpora aquí como referencia como parte la descripción. Los grupos protectores también pueden eliminarse según convenga mediante medios bien conocidos por aquellos expertos en la técnica.


Los compuestos de fórmulas generales (II) y (III) o bien están disponibles comercialmente o bien pueden producirse según métodos conocidos por aquellos expertos en la técnica. También puede facilitarse la reacción de compuestos de fórmulas generales (II) y (III) para dar compuestos de sulfonamidas derivados de benzoxazinona de fórmula general (I) con métodos conocidos por aquellos expertos en la técnica.

Los compuestos de benzoxazinonas sustituidos de fórmula general (II) donde R^8 representa H, se sintetizan preferiblemente a partir de ácido antranílico sustituido o un éster correspondiente mediante el alcohol bencílico correspondiente (véase el esquema 1, método A). Por aminación reductora con 1-boc-(terc-butilcarboniloxi)-4-piperidona, se introduce el resto boc-piperidina en el alcohol bencílico sustituido. El anillo de benzoxazinona se forma mediante ciclación con trifosgeno. La eliminación de grupo protector boc- se lleva a cabo mediante tratamiento en medio ácido según el método descrito en Williams et al., J. Med Chem., 1995, 38, 4634 y posteriormente en Bell et al., J. Med Chem., 1998, 41, 2146, que se incorporan aquí como referencias y forman parte de la descripción. Mediante la reacción de tales compuestos de benzoxazinonas sustituidos de fórmula general (II) con un cloruro de sulfurilo de fórmula general (III), se obtienen compuestos de fórmula general (I).

Por reducción de las cetonas correspondientes mediante métodos convencionales conocidos por aquellos expertos en la técnica, por ejemplo por reducción con borohidruro de sodio (véase esquema 1, método B, R5 = Z) pueden obtenerse compuestos de sulfonamidas derivados de benzoxazinona de fórmula general (I), en la que R^8 representa un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos mono sustituido, o un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo (denominado Z en el método B).

Los respectivos reactivos utilizados en dicho procedimiento para la preparación de compuestos de sulfonamidas derivados de benzoxazinona de fórmula general (I) o bien están disponibles comercialmente o bien pueden obtenerse por métodos bien conocidos por aquellos expertos la técnica.

Esquema 1:



En un aspecto adicional, la presente invención proporciona igualmente un procedimiento para la preparación de sales de compuestos de sulfonamidas derivados de benzoxazinona de fórmula general (I), en el que se hace reaccionar al menos un compuesto de fórmula general (I) que tiene al menos un grupo básico con al menos un ácido orgánico y/o inorgánico, preferiblemente en presencia de un medio de reacción adecuado. Medios de reacción adecuados son, por ejemplo, los facilitados anteriormente. Ácidos inorgánicos adecuados incluyen ácido clorhídrico, ácido bromhídrico, ácido fosfórico, ácido sulfúrico y ácido nítrico, ácidos orgánicos adecuados son por ejemplo ácido cítrico, ácido maleico, ácido fumárico, ácido tartárico o derivados de los mismos, ácido p-toluensulfónico, ácido metanosulfónico o ácido canforsulfónico.

Aún en un aspecto adicional, la presente invención proporciona también un procedimiento para la preparación de sales de compuestos de sulfonamidas derivados

de benzoxazinona de fórmula general (I), en el que se hace reaccionar al menos un compuesto de fórmula general (I) que tiene al menos un grupo ácido con una o más bases adecuadas, preferiblemente en presencia de un medio de reacción adecuado. Bases adecuadas son por ejemplo hidróxidos, carbonatos, bicarbonatos o alcóxidos, que incluyen cationes adecuados, derivados por ejemplo de metales alcalinos, metales alcalinotérreos o cationes orgánicos, por ejemplo $[NH_nR_{4-n}]^+$, en la que n es 0, 1, 2, 3 ó 4 y R representa un radical alquilo C_{1-4} lineal o ramificado. Medios de reacción adecuados son, por ejemplo, los definidos anteriormente.

Los solvatos, preferiblemente hidratos, de los compuestos de sulfonamidas derivados de benzoxazinona de fórmula general (I), o de sales de los mismos también pueden obtenerse por métodos convencionales conocidos por aquellos expertos en la técnica.

Si los compuestos derivados de benzoxazinona de fórmula general (I) se obtienen en forma de mezcla de estereoisómeros, particularmente enantiómeros o diasterómeros, dichas mezclas pueden separarse mediante procedimientos convencionales conocidos por aquellos expertos la técnica, por ejemplo métodos cromatográficos o de cristalización con agentes quirales.

La purificación y el aislamiento de los compuestos de sulfonamidas derivados de benzoxazinona de fórmula general (I) o un estereoisómero correspondiente, o sal, o solvato respectivamente, si es necesario, pueden realizarse mediante métodos convencionales conocidos por aquellos expertos la técnica, por ejemplo métodos cromatográficos o de recristalización.

Los compuestos de sulfonamidas derivados de benzoxazinona de fórmula general (I), sus estereoisómeros, las sales correspondientes y los solvatos correspondientes son toxicológicamente aceptables y por tanto son adecuados como principios activos farmacéuticos para la preparación de medicamentos.

Por tanto, la presente invención también proporciona un medicamento que comprende al menos un compuesto de sulfonamida derivado de benzoxazinona de fórmula general (I), opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato correspondiente, y opcionalmente uno o más adyuvantes farmacéuticamente aceptables.


Además, la presente invención también proporciona una composición farmacéutica que comprende al menos un compuesto de sulfonamida derivado de benzoxazinona de fórmula general (I), opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros en cualquier razón de mezcla, o una sal fisiológicamente aceptable del mismo, o un solvato correspondiente y opcionalmente uno o más adyuvantes farmacéuticamente aceptables, que aún no se ha formulado en un medicamento.

Preferiblemente el medicamento es adecuado para la regulación del receptor 5-HT_6, para la mejora de la cognición, para la profilaxis y/o el tratamiento de trastornos relacionados con la ingestión de alimentos (ingesta de alimentos), particularmente para la regulación del apetito, para el mantenimiento, incremento o reducción del peso corporal, para la profilaxis y/o el tratamiento de obesidad, bulimia, anorexia, caquexia o diabetes de tipo II (diabetes mellitus insulino independiente), preferiblemente diabetes tipo II que sea causada por obesidad, trastornos del sistema nervioso central, trastornos del tracto gastrointestinal, como el síndrome del intestino irritable, ansiedad, pánico, depresión, trastornos cognitivos de la memoria, trastornos de demencia senil, como enfermedad de Alzheimer, enfermedad de Parkinson y enfermedad de Huntington, esquizofrenia, psicosis, hiperquinesia infantil, ADHC (déficit de atención, trastornos de hiperactividad) y otros trastornos mediados por 5-HT_6 particularmente en mamíferos, incluido en humanos.

Un aspecto adicional de la presente invención es el uso de al menos un compuesto derivado de benzoxazinona de fórmula general (I) para la fabricación de un medicamento para la regulación del receptor 5-HT_6, para la mejora de la cognición, para la profilaxis y/o el tratamiento de trastornos relacionados con la ingestión de alimentos (ingesta de alimentos), particularmente para la regulación del apetito, para el mantenimiento, incremento o reducción del peso corporal, para la profilaxis y/o el tratamiento de obesidad, bulimia, anorexia, caquexia o diabetes tipo II (diabetes mellitus insulino independiente), preferiblemente diabetes de tipo II que sea causada por obesidad, trastornos del sistema nervioso central, trastornos del tracto gastrointestinal, como el síndrome del intestino irritable, ansiedad, pánico, depresión, trastornos cognitivos de la memoria, trastornos de demencia senil, como enfermedad de Alzheimer, enfermedad de Parkinson y enfermedad de Huntington, esquizofrenia, psicosis, hiperquinesia infantil, ADHC (déficit de atención, trastornos de hiperactividad)

y otros trastornos mediados por 5-HT_6 particularmente en mamíferos, incluido en humanos.

Aún en otro aspecto, la presente invención también proporciona el uso de al menos un compuesto de sulfonamida derivado de benzoxazinona de fórmula general (Ia)



(Ia)

en la que

R^{1a}, R^{2a}, R^{3a}, R^{4a} se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, halógeno, un radical alifático, lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un grupo nitro, un grupo ciano, $-OR^{10a}$, $-O(C=O)R^{11a}$, $-(C=O)OR^{11a}$, $-SR^{12a}$, $-SOR^{12a}$, $-SO_2R^{12a}$, $-NH-SO_2R^{12a}$, $-SO_2NH_2$ y un resto $-NR^{13a}R^{14a}$,

R^{5a} representa hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido o un radical cicloalifático saturado

o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo,

R^{6a}, R^{7a}, R^{8a}, R^{9a} se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, un grupo ciano y un resto $-COOR^{15a}$,

W^a representa un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un resto $NR^{16a}R^{17a}$, un resto COR^{18a},

R^{10a} representa hidrógeno, un radical alifático, lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{11a} representa hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede

estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{12a} representa un radical alifático, lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{13a} y R^{14a} se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, un radical alifático, lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

o R^{13a} y R^{14a} junto con el átomo puente de nitrógeno forman un anillo heterocíclico saturado, insaturado o aromático, que puede estar al menos monosustituido y/o contener al menos un heteroátomo más como miembro del anillo,

R^{15a} representa hidrógeno, un radical alifático, lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{16a} representa un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido,

R^{17a} representa un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, y

R^{18a} representa un radical arilo opcionalmente al menos monosustituido,

opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o una sal correspondiente de los mismos, o un solvato correspondiente de los mismos.

para la fabricación de un medicamento para la regulación del receptor 5-HT_6, para la mejora de la cognición, para la profilaxis y/o el tratamiento de trastornos relacionados con la ingestión de alimentos (ingesta de alimentos), particularmente para la regulación del apetito, para el mantenimiento, incremento o reducción del peso corporal, para la profilaxis y/o el tratamiento de obesidad, bulimia, anorexia, caquexia o diabetes tipo II (diabetes mellitus insulino independiente), preferiblemente diabetes tipo II que sea causada por obesidad, trastornos del tracto gastrointestinal, como el síndrome del intestino irritable, ansiedad, pánico, depresión, trastornos cognitivos de la memoria, trastornos de demencia senil, como enfermedad de Alzheimer, Enfermedad de Parkinson y enfermedad de Huntington, esquizofrenia, psicosis, hiperquinesia infantil, ADHC (déficit de atención, trastornos de hiperactividad) y otros trastornos mediados por el receptor 5-HT_6 particularmente en mamíferos, incluido en humanos.

Si uno o más de los residuos R^{1a}-R^{17a} y W^a representa un radical alifático, que está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, halógeno, alcoxi C_{1-4} lineal o ramificado, perfluoroalcoxi C_{1-4} lineal o ramificado, perfluoroalquilo C_{1-4} lineal o ramificado, amino, carboxilo, amido, ciano, nitro, $-SO_2NH_2$, alquilo $-CO-C_{1-4}$, alquilo $-SO-C_{1-4}$, alquilo SO_2-C_{1-4}, alquilo $-NH-SO_2-C_{1-4}$, en el que el alquilo C_{1-4} puede en cada caso ser lineal o ramificado, un radical fenilo o naftilo no sustituido o al menos monosustituido y un radical furanilo, tienilo, pirrolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, quinolinilo e isoquinolinilo no sustituido o al menos monosustituido, más preferiblemente se selecciona del grupo que consiste en hidroxilo, F, Cl, Br, metoxi, etoxi, $-CF_3$ y un radical fenilo no sustituido. Si cualquiera de los sustituyentes mencionados anteriormente está en sí al menos monosustituido, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en F, Cl, metilo y metoxi.

Si uno o más de los residuos R^{1a}-R^{16a} representa o comprende un radical cicloalifático, que está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, halógeno, alquilo C_{1-4} lineal o ramificado, alcoxi C_{1-4} lineal o ramificado, perfluoroalcoxi C_{1-4} lineal o ramificado, fenoxi, benzoilo, ciclohexilo, perfluoroalquilo C_{1-4} lineal o ramificado, $-NR^AR^B$ en el que R^A, R^B se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, $-CH_2-CH_2-OH$ y fenilo, carboxilo, ceto, amido, ciano, nitro, $-SO_2NH_2$, alquilo $-CO-C_{1-4}$, alquilo $-CO-OC_{1-4}$, alquilo $-SO-C_{1-4}$, alquilo $-SO_2-C_{1-4}$, alquilo $-NH-SO_2-C_{1-4}$, en el que alquilo C_{1-4} puede en cada caso ser lineal o ramificado, fenilo o naftilo no sustituido o al menos monosustituido y radical furanilo, tienilo, pirrolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, quinolinilo e isoquinolinilo no sustituido o al menos monosustituido, más preferiblemente se selecciona del grupo que consiste en hidroxilo, F, Cl, Br, metilo, etilo, metoxi, etoxi, ceto, benzoilo, fenoxi, ciclohexilo, $-CF_3$, $-CO-CH_3$, $-CO-OCH_3$, $-NR^AR^B$ en el que R^A, R^B se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, $-CH_2-CH_2-OH$ y fenilo, y un radical fenilo no sustituido. Si cualquiera de los sustituyentes mencionados anteriormente está en sí al menos monosustituido, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en F, Cl, metilo y metoxi.

Si uno o más de los, residuos R^{1a}-R^{4a}, R^{10a}-R^{15a} y W^a comprende un grupo alquileno, que está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, halógeno, alcoxi C_{1-4} lineal o ramificado, alquilo C_{1-4} lineal o ramificado, perfluoroalcoxi C_{1-4} lineal o ramificado, perfluoroalquilo C_{1-4} lineal o ramificado, amino, carboxilo, amido, ciano, nitro, $-SO_2NH_2$, alquilo $-CO-C_{1-4}$, alquilo $-SO-C_{1-4}$, alquilo $-SO_2-C_{1-4}$, alquilo $-NH-SO_2-C_{1-4}$, en el que alquilo C_{1-4} puede ser lineal o ramificado, un radical fenilo o naftilo no sustituido o al menos monosustituido y un radical furanilo, tienilo, pirrolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, quinolinilo e isoquinolinilo no sustituido o al menos monosustituido, más preferiblemente se selecciona del grupo que consiste en hidroxilo, F, Cl, Br, metoxi, etoxi, $-CF_3$ y fenilo no sustituido. Si cualquiera de los sustituyentes mencionados anteriormente está en sí al menos monosustituido, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en F, Cl, metilo y metoxi.

Si uno o más de los residuos R^{1a}-R^{4a}, R^{10a}-R^{15a} comprende un sistema cíclico mono o policíclico, que está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, halógeno, alquilo C_{1-4} lineal o ramificado, alcoxi C_{1-4} lineal o ramificado, perfluoroalcoxi C_{1-4} lineal o ramificado, perfluorocarbonilo C_{1-4} lineal o ramificado, perfluoroalquilo C_{1-4} lineal o ramificado, amino, carboxilo, amido, ciano, ceto, nitro, $-SO_2NH_2$, alquilo -CO-C_{1-4}, alquilo -SO-C_{1-4}, alquilo $-SO_2-C_{1-4}$, alquilo -NH-SO_2-C_{1-4}, en el que alquilo C_{1-4} puede ser lineal o ramificado, un radical fenilo o naftilo no sustituido o al menos monosustituido o un radical furanilo, tienilo, pirrolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, quinolinilo e isoquinolinilo no sustituido o al menos monosustituido, más preferiblemente del grupo que consiste en hidroxilo, F, Cl, Br, metilo, etilo, metoxi, etoxi, $-CF_3$, -(C=O)-CF_3, ceto, ciano y un radical fenilo no sustituido. Si cualquiera de los sustituyentes mencionados anteriormente está en sí al menos monosustituido, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en F, Cl, metilo y metoxi.

Si uno o más de los residuos R^{1a}-R^{4a}, R^{10a}-R^{15a} y R^{8a} representa o comprende un radical arilo, que está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, halógeno, alcoxi C_{1-4} lineal o ramificado, alquilo C_{1-4} lineal o ramificado, perfluoroalcoxi C_{1-4} lineal o ramificado, fenoxi no sustituido o al menos monosustituido, benzoilo no sustituido o al menos monosustituido, ciclohexilo, perfluoroalquilo C_{1-4} lineal o ramificado, NR^AR^B en el que R^A, R^B se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, $-CH_2-CH_2-OH$ y fenilo, carboxilo, amido, ciano, -CH(OH)(fenil), nitro, $-SO_2NH_2$, alquilo -CO-C_{1-4}, alquilo -CO-OC_{1-4}, alquilo -SO-C_{1-4}, alquilo $-SO_2-C_{1-4}$, alquilo -NH-SO_2-C_{1-4}, en el que alquilo C_{1-4} puede ser lineal o ramificado, un radical fenilo o naftilo no sustituido o al menos monosustituido y radical furanilo, tienilo, pirrolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, quinolinilo e isoquinolinilo no sustituido o al menos monosustituido, más preferiblemente se seleccionan del grupo que consiste en hidroxilo, F, Cl, Br, metilo, etilo, ciano, nitro, -CH(OH)(fenil), metoxi, etoxi, benzoilo no sustituido o al menos monosustituido, fenoxi no sustituido o al menos monosustituido, ciclohexilo, $-CF_3$, OCF_3, $-CO-CH_3$, $-CO-OCH_3$, SO_2-CH_3, $-NR^AR^B$ en el que R^A, R^B se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, $-CH_2-CH_2-OH$ y fenilo, y un radical fenilo no sustituido. Si cualquiera de los sustituyéntes mencionados

anteriormente está en sí al menos monosustituido, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en F, Cl, Br, $-CF_3$, OCF_3, metilo y metoxi.

Si uno o más de los residuos R^{1a}-R^{4a}, R^{10a}-R^{15a} representa o comprende un radical heteroarilo, que está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, halógeno, alcoxi C_{1-4} lineal o ramificado, alquilo C_{1-4} lineal o ramificado, perfluoroalcoxi C_{1-4} lineal o ramificado, fenoxi no sustituido o al menos monosustituido, benzoilo no sustituido o al menos monosustituido, ciclohexilo, perfluoroalquilo C_{1-4} lineal o ramificado, NR^AR^B en el que R^A, R^B se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, $-CH_2-CH_2-OH$ y fenilo, carboxilo, amido, ciano, nitro -CH(OH)(fenil), $-SO_2NH_2$, alquilo $-CO-C_{1-4}$, alquilo $-CO-OC_{1-4}$, alquilo $-SO-C_{1-4}$, alquilo $-SO_2-C_{1-4}$, alquilo $-NH-SO_2-C_{1-4}$, en el que alquilo C_{1-4} puede ser lineal o ramificado, un radical fenilo o naftilo no sustituido o al menos monosustituido y un radical furanilo, tienilo, pirrolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, quinolinilo e isoquinolinilo no sustituido o al menos monosustituido, más preferiblemente se seleccionan del grupo que consiste en hidroxilo, F, Cl, Br, metilo, etilo, ciano, nitro, -CH(OH)(fenil), metoxi, etoxi, benzoilo no sustituido o al menos monosustituido, fenoxi no sustituido o al menos monosustituido, ciclohexilo, $-CF_3$, $-OCF_3$, $-CO-CH_3$, $-CO-OCH_3$, $-SO_2-CH_3$, $-NR^AR^B$ en el que R^A, R^B se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, $-CH_2-CH_2-OH$ y fenilo, y un radical fenilo no sustituido. Si cualquiera de los sustituyentes mencionados anteriormente está en sí al menos monosustituido, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en F, Cl, Br, $-CF_3$, OCF_3, metilo y metoxi.

Si R^{13a} y R^{14a} forman un anillo heterocíclico, que está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, halógeno, alcoxi C_{1-4} lineal o ramificado, alquilo C_{1-4} lineal o ramificado, perfluoroalcoxi C_{1-4} lineal o ramificado, perfluoroalquilo C_{1-4} lineal o ramificado, amino, carboxilo, amido, ciano, nitro, $-SO_2NH_2$, alquilo $-CO-C_{1-4}$, alquilo $-SO-C_{1-4}$, alquilo $-SO_2-C_{1-4}$, alquilo $-NH-SO_2-C_{1-4}$, en el que alquilo C_{1-4} puede ser lineal o ramificado, un radical fenilo o naftilo no sustituido o al menos monosustituido y un radical furanilo, tienilo, pirrolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, quinolinilo e isoquinolinilo no sustituido o al menos

monosustituido, más preferiblemente se seleccionan del grupo que consiste en hidroxilo, F, Cl, Br, metoxi, etoxi, metilo, $-CF_3$ y un radical fenilo no sustituido. Si cualquiera de los sustituyentes mencionados anteriormente está en sí al menos monosustituido, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en F, Cl, metilo y metoxi.

Si R^{13a} y R^{14a} forman un anillo heterocíclico, que contiene uno o más heteroátomos adicionales como miembros del anillo, a menos que se defina lo contrario, cada uno de estos heteroátomos puede seleccionarse preferiblemente del grupo que consiste en N, O y S, más preferiblemente del grupo que consiste en N y O.

Si uno o más de los residuos R^{1a}-R^{15a} y W^a representa o comprende un radical cicloalifático, que contiene uno o más heteroátomos como miembros del anillo, a menos que se defina lo contrario, cada uno de estos heteroátomos puede seleccionarse preferiblemente del grupo que consiste en N, O, S y P, más preferiblemente del grupo que consiste en N, O y S.

Si uno o más de los residuos R^{1a}-R^{4a} y R^{10a}-R^{15a} y W^a representa o comprende un radical heteroarilo, que contiene uno o más heteroátomos como miembros del anillo, a menos que se defina lo contrario, cada uno de estos heteroátomos puede seleccionarse preferiblemente del grupo que consiste en N, O, S y P, más preferiblemente del grupo que consiste en N, O y S.

Si W^a representa o comprende un radical cicloalifático, un radical heteroarilo, un radical arilo y/o un sistema cíclico mono o policíclico, que está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, nitro, carboxilo, ciano, ceto, halógeno, alquilo C_{1-20}, alquilo C_{1-4} parcialmente fluorado, alquilo C_{1-4} parcialmente clorado, alquilo C_{1-4} parcialmente bromado, alcoxi C_{1-5}, alcoxi C_{1-4} parcialmente fluorado, alcoxi C_{1-4} parcialmente clorado, alcoxi C_{1-4} parcialmente bromado, alquenilo C_{2-6}, alquilo SO_2-C_{1-4}, alquilo -(C=O)-C_{1-5}, alquilo -(C=O)-O-C_{1-5}, -(C=O)-Cl, alquilo –S-C_{1-4}, -(C=O)-H, alquilo -NH-(C=O)-NH-C_{1-4}, perfluoroalquilo -(C=O)-C_{1-4}, $-NR^AR^B$, en el que R^A y R^B se seleccionan independientemente del grupo que consiste en H, alquilo C_{1-4} y fenilo, alquilo NH-(C=O)-C_{1-5}, alquilen C_{1-5} alquilo -(C=O)-C_{1-5}, (1,3-dihidro-1-oxo-2H-isoindol-2-il), N-ftalimidinilo, (1,3-dioxo-2-azaspiro[4,4]-non-2-il), fenilo sustituido o no sustituido, -SO_2-fenilo, fenoxi, piridinilo, piridiniloxi, pirazolilo, pirimidinilo, pirrolidinilo, -SO_2-pirrolidinilo, morfolinilo, SO_2-morfolinilo, tiadiazolilo, oxadiazolilo, oxazolilo, tiazolilo, isoxazolilo, O-CH_2-tiazolilo, NH-fenilo, y alquilen-NH-(C=O)-fenilo C_{1-4}, más preferiblemente del grupo que consiste en

hidroxilo, nitro, carboxilo, ciano, ceto, F, Cl, Br, I, alquilo C_{1-12}, $-CH_2F$, $-CHF_2$, $-CF_3$, $-CH_2Cl$, $-CH_2Cl_2$, $-CCl_3$, $-CH_2Br$, $-CHBr_2$, $-CBr_3$, OCF_3, $OCHF_2$, OCH_2F, $O-CH_2-CF_3$, vinilo, SO_2-CH_3, $-(C=O)-CH_3$, $-(C=O)-C_2H_5$, $-(C=O)-O-CH_3$, $-(C=O)-O-C_2CH_5$, $-(C=O)-Cl$, $-S-CH_3-$, $-(C=O)-H$, $-NH-(C=O)-NH-CH_3$, $-(C=O)-CF_3$, dimetilamino, dietilamino, di-n-propilamino, di-iso-propilamino, di-n-butilamino, di-terc-butilamino, $NH-(C=O)-CH_3$, $-CH_2-(C=O)-CH_3$, $-CH_2-(C=O)C_2H_5$, (1,3-dihidro-1-oxo-2H-isoindol-2-il), N-ftalimidinilo, (1,3-dioxo-2-azaspiro[4,4]-non-2-il), fenilo sustituido o no sustituido, $-SO_2$-fenilo, fenoxi, piridinilo, piridiniloxi, pirazolilo, pirimidinilo, pirrolidinilo, $-SO_2$-pirrolidinilo, morfolinilo, SO_2-morfolinilo, tiadiazolilo, oxadiazolilo, oxazolilo, tiazolilo, isoxazolilo, $O-CH_2$-tiazolilo, NH-fenilo, y $-CH_2-NH-(C=O)$-fenilo.

Si cualquiera de los sustituyentes mencionados en sí mismo está sustituido por uno o más sustituyentes, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en halógeno, nitro, ciano, hidroxilo, alquilo $-(C=O)-C_{1-4}$, alquilo C_{1-4}, alquilo C_{1-4} al menos parcialmente fluorado, alquilo C_{1-4} al menos parcialmente clorado, alquilo C_{1-4} al menos parcialmente bromado, alquilo $-S-C_{1-4}$, alquilo $-C(=O)-O-C_{1-6}$, $-(C=O)CH_2-F$, $-(C=O)-CH_2-Cl$, $-(C=O)-CH_2-Br$, preferiblemente del grupo que consiste en F, Cl, Br, $-CH_2F$, $-CHF_2$, $-CF_3$, $-CH_2Cl$, $-CHCl_2$, $-CCl_3$, $-CH_2Br$, $-CHBr_2$, $-CBr_3$, nitro, ciano, hidroxilo, $-(C=O)-CH_3$, $-CH_3$, $-C_2H_5$, $-S-CH_3$, $-C(=O)-O-CH_3$, $-C(=O)-O-C_2H_5$, $-(C=O)-CH_2-F$, $-(C=O)-CH_2-Cl$ y $-(C=O)-CH_2-Br$.

Se prefiere el uso de compuestos de fórmula general (Ia) en la que R^{1a}, R^{2a}, R^{3a}, R^{4a} se seleccionan cada uno independientemente del grupo que consiste en H, F, Cl, Br, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un radical arilo o heteroarilo de 5 ó 6 miembros opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un grupo nitro, un grupo ciano, $-OR^{10a}$, $-O(C=O)R^{11a}$, $-SR^{12a}$, $-SOR^{12a}$, $-SO_2R^{12a}$, $-NH-SO_2R^{12a}$, $-SO_2NH_2$ y un resto $-NR^{13a}R^{14a}$,

preferiblemente seleccionados del grupo que consiste en H, F, Cl, Br, un radical alifático C_{1-3} lineal o ramificado, saturado, opcionalmente al menos monosustituido, un radical cicloalifático C_5 o C_6 saturado, opcionalmente al menos

monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_1 o C_2 opcionalmente al menos monosustituido, un resto nitro, ciano, $-OR^{10a}$, $-O(C=O)R^{11a}$, $-SR^{12a}$, y $-NR^{13a}R^{14a}$,

más preferiblemente seleccionados del grupo que consiste en H, F, Cl, $-CH_3$, $-CH_2CH_3$, $-CF_3$, $-CF_2CF_3$, ciclopentilo, ciclohexilo, un grupo nitro, un grupo ciano y $-OR^{10a}$,

y R^{5a}-R^{15a} y W^a tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

También se prefieren compuestos de fórmula general (Ia), en la que R^{5a} representa hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido o un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo,

preferiblemente representa H o un radical alquilo C_{1-3} lineal o ramificado,

más preferiblemente H, $-CH_3$ o $-CH_2CH_3$,

y R^{1a}-R^{4a}, R^{6a}-R^{15a} y W^a tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

También se prefieren aquellos compuestos de fórmula general (Ia) en la que R^{6a}, R^{7a}, R^{8a}, R^{9a} se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, un grupo ciano y un resto $COOR^{15a}$,

preferiblemente seleccionados del grupo que consiste en H, un radical alquilo C_{1-3} lineal o ramificado, un grupo ciano y un grupo $COOR^{15a}$,

más preferiblemente del grupo que consiste en H, $-CH_3$, $-CH_2CH_3$ y un resto ciano,

y R^{1a}-R^{6a}, R^{10a}-R^{18a} y W^a tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

También se prefieren compuestos de fórmula general (Ia), en la que W^a representa un radical alquilo C_{1-20} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico, opcionalmente al menos monosustituido, un radical arilo o heteroarilo de 5 ó 6 miembros opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico, opcionalmente al menos monosustituido, un resto $NR^{16a}R^{17a}$ o un resto COR^{18a},

preferiblemente se selecciona del grupo que consiste en 1-naftilo, 5-dimetilamino-naft-1-ilo, 2-acetamido-4-metil-5-tiazolilo, 2-tienilo, 8-quinolinilo, fenilo, pentafluorofenilo, 2,4,5-triclorofenilo, 2,5-diclorofenilo, 2-nitrofenilo, 2,4-dinitrofenilo, 3,5-dicloro-2-hidroxi-fenilo, 2,4,6-trisisopropil-fenilo, 2-mesitilo, 3-nitro-fenilo, 4-bromo-fenilo, 4-fluoro-fenilo, 4-clorofenilo, 4-cloro-3-nitro-fenilo, 4-yodo-fenilo, N-acetil-sulfanililo, 4-nitro-fenilo, 4-metoxi-fenilo, ácido benzoico-4-ilo, 4-terc-butil-bencilo, p-tolilo, trifluorometilo, triclorometilo, isopropilo, metilo, bencilo, trans-estirilo, 2,2,2-trifluoroetilo, etilo, hexadecilo, 2-cloroetilo, n-propilo, 3-cloro-propilo, n-butilo, metil-benzoato-2-ilo, 2-nitro-4-(trifluorometil)-fenilo, pentametil-fenilo, 2,3,5,6-tetrametil-fenilo, 3-(trifluorometil)-fenilo, 3,5-bis-(trifluorometil)-fenilo, diclorometilo, clorometilo, dodecilo, 1-octilo, 2,3,4-tricloro-fenilo, 2,5-dimetoxi-fenilo, o-tolilo, p-xilil-2-ilo, ácido benzoico-3-ilo, 4-cloro)-3-(trifluorometil)-fenilo, ácido 4-cloro-5-nitro-benzoico-3-ilo, 6-(p-toluidino)-naft-2-ilo, 4-metoxi-2,3,6-trimetilfenilo, 3,4-diclorofenilo, 4,5-dibromo-tiofen-2-ilo, 3-cloro-4-fluorofenilo, 4-etil-fenilo, 4-n-propil-fenilo, 4-(1,1-dimetilopropil)-fenilo, 4-isopropil-fenilo, 4-bromo-2,5-difluoro-fenilo, 2-fluoro-fenilo, 3-fluoro-fenilo, 4-(trifluorometoxi)-fenilo, 4-(trifluorometil)-fenilo, 2,4-difluoro-fenilo, 2,4-dicloro-5-metil-fenilo, 4-cloro-2,5-dimetil-fenilo, 5-dietilamino-naft-2-ilo, cloruro de benzoil-3-ilo, 2-

cloro-fenilo, 1-octadecilo, 4-bromo-2,5-dicloro-tiofen-3-ilo, 2,5-dicloro-tiofen-3-ilo, 5-cloro-tiofen-2-ilo, 2-metil-5-nitro-fenilo, 2-(trifluorometil)-fenilo, 3-cloro-fenilo, 3,5-dicloro-fenilo, 1-decilo, 3-metil-fenilo, 2-cloro-6-metilo, 5-bromo-2-metoxi-fenilo, 3,4-dimetoxi-fenilo, 2-3-dicloro-fenilo, 2-bromo-fenilo, 3,5-dicloro-4-(2-cloro-4-nitrofenoxi)-fenilo, 2,3-dicloro-tiofen-5-ilo, 3-bromo-2-cloro-tiofen-5-ilo, 3-bromo-5-cloro-tiofen-2-ilo, 2-(benzoilaminometil)-tiofen-5-ilo, 4-(fenilsulfonil)-tiofen-2-ilo, 2-fenilsulfoniltiofen-5-ilo, 3-cloro-2-metil-fenilo, 2-[1-metil-5-(trifluorometil)pirazol-3-il]-tiofen-5-ilo, 5-pirid-2-il-tiofen-2-ilo, 2-cloro-5-(trifluorometil)-fenilo, 2,6-dicloro-fenilo, 3-bromo-fenilo, 2-(trifluorometoxi)-fenilo, 4-ciano-fenilo, 2-ciano-fenilo, 4-n-butoxi-fenilo, 4-acetamido-3-cloro-fenilo, 2,5-dibromo-3,6-difluorofenilo, 5-cloro-1,3-dimetilpirazol-4-ilo, 3,5-dimetilisoxazol-4-ilo, 2-(2,4-diclorofenoxi)-fenilo, 4-(2-cloro-6-nitro-fenoxi)-fenilo, 4-(3-cloro-2-ciano-fenoxi)-fenilo, 2,4-dicloro-fenilo, 2,4-dimetil-1,3-tiazol-5-ilo, metil-metano-sulfonilo, 2,5-bis-(2,2,2-trifluoroetoxi)-fenilo, 2-cloro-4-(trifluorometil)-fenilo, 2-cloro-4-fluoro-fenilo, 5-fluoro-2-metil-fenilo, 5-cloro-2-metoxi-fenilo, 2,4,6-tricloro-fenilo, ácido 2-hidroxi-benzoico-5-ilo, 5-(di-n-propilamino)-naft-1-ilo, 6-metoxi-m-tolilo, 2,5-difluoro-fenilo, 2,4-dimetoxi-fenilo, 2,5-dibromo-fenilo, 3,4-dibromo-fenilo, 2,2,5,7,8-pentametil-croman-6-ilo, ácido 2-metoxi-benzoico-5-ilo, 5-cloro-4-nitro-tiofen-2-ilo, 2,1,3-benzotiadiazol-4-ilo, 1-metil-imidazol-4-ilo, benzofurazan-4-ilo, 2-(metoxicarbonil)-tiofen-3-ilo, 5-(isoxazol-3-il)-tiofen-2-ilo, 2,4,5-trifluorofenilo, bifenil-4-ilo, Vinil-fenil-4-ilo, 2-nitro-bencilo, 5-dicloro-metil-furan-2-ilo, 5-bromo-tiofen-2-ilo, 5-(4-clorobenzamidometil)-tiofen-2-ilo, 2,6-difluoro-fenilo, 2,5-dimetoxi-4-nitro-fenilo, dibenzo[b,d]-furan-2-ilo, 2,3,4-trifluoro-fenilo, 3-nitro-p-tolilo, 4-metoxi-2-nitro-fenilo, 3,4-difluoro-fenilo, 4-(bromoetil)-fenilo, 3,5-dicloro-4-hidroxi-fenilo, 4-n-amil-fenilo, 5-cloro-3-metilbenzo[b]-tiofen-2-ilo, 3-metoxi-4-(metoxicarbonil)-tiofen-2-ilo, 4-n-butilfenilo, 2-cloro-4-ciano-fenilo, 5-[2-(metiltio)-pirimidin-4-il-]-tiofen-2-ilo, 3,5-dinitro-4-metoxi-fenilo, 4-bromo-2-(trifluorometoxi)-fenilo, 4-cloro-2,1,3-benzoxadiazol-7-ilo, 2-(1-naftil)-etilo, 3-ciano-fenilo, 5-cloro-2,1,3-benzoxadiazol-4-ilo, 3-cloro-4-metil-fenilo, 4-bromo-2-etil-fenilo, 2,4-dicloro-6-metil-fenilo, 6-cloro-imidazo(2,1-b)-tiazol-5-ilo, 3-metil-benzo[b]-tiofen-2-ilo, 4-metil-sulfonil-fenilo, 2-metil-sulfonil-fenilo, 4-bromo-2-metil-fenilo, 2,6-dicloro-4-(trifluorometil)-fenilo, 4-[[3-cloro-5-(trifluorometil)-2-piridinil]oxi]-fenilo, 5-cloro-naft-1-ilo, 5-cloro-naft-2-ilo, 9,10-dibromoantracen-2-ilo, isoquinolin-5-ilo, 4-metoxi-2,3,6-trimetil-fenilo, 4'-nitro-bifenil-4-ilo, [(4-fenoxi)-fenilo, (1,3-dihidro-1-oxo-2H-isoindol-2-il)-4-fenilo, 4-acetil-fenilo, 5-(2-metil-1,3-tiazol-4-il)-tiofen-2-ilo, 5-(1-metil-3-(trifluorometil)pirazol-5-il-]-tiofen-2-ilo, 5-[5-trifluorometil)-isoxazol-3-il]-tiofen-2-ilo, 2-yodo-fenilo, p-dodecil-fenilo, 4-[(3-ciano-4-metoxi-2-piridinil)oxi]-fenilo, 4-(N-ftalimidinil)-

fenilo, 1,2,3,4-tetrahidro-2-(trifluoroacetil)-isoquinolin-7-ilo, 4-bromo-2-fluoro-fenilo, 2-fluoro-5-(trifluorometil)-fenilo, 4-fluoro-2-(trifluorometil)-fenilo, 4-fluoro-3-(trifluorometil)-fenilo, 2,4,6-trifluoro-fenilo, 3-(trifluorometoxi)-fenilo, 1,2-dimetilimidazol-4-ilo, etil-4-carboxilato-3-ilo, 2,2,4,6,7-pentametildihidrobenzofuran-5-ilo, 3-bromo-2-cloropiridin-5-ilo, 3-metoxi-fenilo, 2-metoxi-4-metil-fenilo, ácido 2-cloro-4-fluorobenzoico-5-ilo, 4-cloro-naft-1-ilo, 2,5-dicloro-4-nitro-tiofen-3-ilo, 4-(4-metoxi-fenoxi)-fenilo, 4-(4-cloro-fenoxi)-fenilo, 4-(3,5-dicloro-fenoxi)-fenilo, 4-(3,4-dicloro-fenoxi)-fenilo, 4-(4-fluoro-fenoxi)-fenilo, 4-(4-metil-fenoxi)-fenilo, 4-[4-(trifluorometil)-fenoxi-fenilo, 4-[3,5-bis-(trifluorometil)-fenoxi]-fenilo, 3-(2-metoxi-fenoxi)-fenilo, [3-(2-cloro-fenoxi)-fenilo, 3-(2-metil-fenoxi)-fenilo, 4-[2-(trifluorometil)-fenoxi]-fenilo, 3-fenil-fenilo, 3-(4-metoxi-fenil)-fenilo, 3-(4-cloro-fenil)-fenilo, 3-(3,5-dicloro-fenil)-fenilo, 3-(3,4-dicloro-fenil)-fenilo, 3-(4-fluorofenil)-fenilo, 3-(4-metilfenil)-fenilo, 3-[4-(trifluorometil)-fenil]-fenilo, 3-[3,5-bis-(trifluorometil)-fenil]-fenilo, 4-(4-piridiloxi)-fenil)-, 4-(2-metoxi-fenoxi)-fenilo, 4-(2-cloro-fenoxi)-fenilo, 4-(2-metil-fenoxi)-fenilo, 4-(4-metoxi-fenoxi)-fenilo, 4-(4-clorofenil)-fenilo, 4-(3,5-diclorofenil)-fenilo, 4-(3,4-diclorofenil)-fenilo, 4-(4-fluorofenil)-fenilo, 4-(4-metilfenil)-fenilo, 4-[4-(trifluorometil)-fenil]-fenilo, 4-[3,5-bis-(trifluorometil)-fenil]fenilo, [3-(trifluorometil)-fenil]-metilo, (4-clorofenil)-metilo, (3,5-diclorofenil)-metilo, (3,5-diclorofenil)-metilo, (4-fluorofenil)-metilo, 4-metilfenilmetilo, [4-(trifluorometil)-fenil]-metilo, ciclopropilo, 2-(2-clorofenil)-2-feniletilo, 2-(2-trifluorometilfenil)-2-feniletilo, 5-[4-ciano-1-metil-5-(metiltio)-1H-pirazol-3-il-tiofen-2-ilo, 3-ciano-2,4-bis-(2,2,2-trifluorotoxi)-fenilo, 4-[(2-cloro-1,3-tiazol-5-il)-metoxi]-fenilo, 3-nitro-fenilmetilo, 4-formilfenilo, 2-(1,3-dioxo-1,3-dihidro-isoindol-2-il)-etilo, [3,5-bis-(trifluorometil)-fenil]-metilo, (4-(2-piridiloxi)-fenil)-, (4-(3-piridiloxi)-fenil)-, 5-yodo-naft-1-ilo, etil-2,5-dimetil-1-fenilopirrol-4-carboxilato-3-ilo, etil-2-metil-1,5-difenil-1H-pirrol-3-carboxilato-4-ilo, etil-5-(4-clorofenil)-2-metil-3-furoato-4-ilo, etil-5-(4-clorofenil)-2-metil-1-fenil-3-carboxilato-4-ilo, etil-2,5-dimetil-3-furoato-4-ilo, 3-cloro-4-(1,3-dioxo-2-azaspiro[4,4]non-2-il)-fenilo, 5-bromo-2,4-difluoro-fenilo, 5-cloro-2,4-difluorofenilo, coumarin-6-ilo, 2-metoxi-fenilo, (3-fenoxi)-fenilo, 3-(4-metoxi-fenoxi)-fenilo, 3-(4-clorofenoxi)-fenilo, 3-(3,5-diclorofenoxi)-fenilo, 3-(3,4-diclorofenoxi)-fenilo, 3-(4-fluorofenoxi)-fenilo, 3-(4-metilfenoxi)-fenilo, 3-[4-(trifluorometil)-fenoxi]-fenilo, 3-[3,5-(trifluorometil)-fenoxi]-fenilo, 3-[2-(trifluorometil)-fenoxi]-fenilo, 2,2-difeniletilo, 4-fenil-5-(trifluorometil)-tiofen-3-ilo, metil-4-fenil-5-(trifluorometil)-tiofen-2-carboxilato-3-ilo, metil-1,2,5-trimetilpirrol-3-carboxilato-4-ilo, 4-fluoro-naft-1-ilo, 3,5-difluorofenilo, 3-fluoro-4-metoxi-fenilo, 4-cloro-2,5-difluorofenilo, 2-cloro-4,5-difluoro-fenilo, 5-fluoro-3-metilbenzo[b]-tiofen-2-ilo, metil-3-fenilpropionato-4-ilo, acido dihidrocinámico-4-ilo, metil-2,5-dimetil-3-furoato-4-ilo, metil-2-furoato-5-ilo,

metil-2-metil-3-furoato-5-ilo, metil-1-metil-1H-pirrol-2-carboxilato-5-ilo, 2-(5-cloro-1,2,4-tiadiazol-3-il)-tiofen-5-ilo, 1,3,5-trimetil-1H-pirazol-4-ilo, 3-cloro-5-fluoro-2-metilfenilo, pentafluoroetoxitetrafluoroetilo, 5-(5-isoxacil)-tiofen-2-ilo, 5-(5-isoxazolil)-2-furilo, 5-metil-2,1,3-benzotiadiazol-4-ilo, bifenil-2-ilo, 2,3-dihidro-1,4-benzodioxin-6-ilo, 4-metil-naft-1-ilo, 5-metil-2-(trifluorometil)-3-furilo, 2,3-dihidrobenzo[b]furan-5-ilo, 1-benzotiofen-3-ilo, 4-metil-3,4-dihidro-2H-1,4-benzoxazin-7-ilo, 5-metil-1-fenil-1H-pirazol-4-ilo, 6-morfolin-3-piridinilo, 4-(1H-pirazol-1-il)-fenilo, 6-fenoxi-3-piridilo, 3,4-dihidro-2H-1,5-benzodioxepin-7-ilo, 5-(1,3-oxazol-5-il)-2-tienilo, 4-(1,3-oxazol-5-il)-fenilo, 5-metil-4-isoxazolilo, 2,1,3-benzotiadiazol-5-ilo, 3-tienilo, 2-metil-bencilo, 3-cloro-bencilo, 5-acetamido-naft-1-ilo, 3-metil-8-quinolinilo, 4-cloro-2-nitrofenilo, 6-quinolinilo, 1,3-benzotiazol-6-ilo, 2-morfolin-3-piridilo, 2,5-dimetil-3-tienilo, 5-[5-(clorometil)-1,2,4-oxadiazol-3-il]-2-tienilo, etil-3-[5-il-2-tienil]-1,2,4-oxadiazol-5-carboxilato, 3-(5-metil-1,3,4-oxadiazol-2-il)-fenilo, 4-isopropoxifenilo, 2,4-dibromofenilo, 3-ciano-4-fluorofenilo, 2,5-bis-(trifluorometil)-fenilo, 2-bromo-4-fluorofenilo, 4-bromo-3-fluorofenilo, 4-(difluorometoxi)-fenilo, 3-(difluorometoxi)-fenilo, 5-cloro-2-fluorofenilo, 3-cloro-2-fluorofenilo, 2-fluoro-4-metilfenilo, 4-nitro-3-(trifluorometil)-fenilo, 3-fluoro-4-metilfenilo, 4-fluoro-2-metilfenilo, 4-bromo-3-(tifluorometil)-fenilo, 4-bromo-2-(trifluorometil)-fenilo, 3-bromo-5-(trifluorometil)-fenilo, 2-bromo-4-(trifluorometil)-fenilo, 2-bromo-5-(trifluorometil)-fenilo, 2,4-dicloro-5-fluorofenilo, 4,5-dicloro-2-fluorofenilo, 3,4,5-trifluorofenilo, 4-cloro-2-fluorofenilo, 2-bromo-4,6-difluorofenilo, 2-etilfenilo, 4-bromo-2-clorofenilo, 4-bromo-2,6-diclorofenilo, 2-bromo-4,6-dicloro-fenilo, 4-bromo-2,6-dimetilfenilo, 3,5-dimetilfenilo, 4-bromo-3-metilfenilo, 2-metoxi-4-nitrofenilo, 2,2-dimetil-6-cromanilo, etil-3,5-dimetil-1H-pirrol-2-carboxilato-4-ilo, Imidazo[1,2-a]piridin-3-ilo, 3-(1,3-oxazol-5-il)-fenilo, etil-5-[4-il)-fenil]-2-metil-3-furoato, metil-3-(il)-4-metoxibenzoato, 1-pirrolidinilfenilsulfonilo, metil-5-il-4-metil-2-tiofen-carboxilato, metil-3-il-4-(isopropilsulfonil)-2-tiofeno, 2-piridilo, 3-fluoro-4-nitrofenilo, 7-clorocromon-3-ilo, 4'-bromobifenil-4-ilo, 4'-acetil-bifenil-4-ilo, 4'-bromo-2'-fluoro-bifenil-4-ilo, 2-cloro-4-(3-propil-ureido)-fenilo, 3-(-bromoacetil)-fenilo, 2-bromo-3-(trifluorometil)-fenilo, 1-metil-5-isatinilo, ácido 4-isopropil-benzoico-3-ilo, ácido 2-cloro-3-tiofenocarboxílico-5-ilo, 3-piridilo, ciclohexilmetilo, 2-metoxi-5-(N-ftalimidinil)-fenilo, 1-benzotiofen-2-ilo, morfolinfenilsulfonilo, 3-(2-metil-4-pirimidinil)-fenilo, y 2-ciano-5-metilfenilo, y R^{1a}-R^{18a} tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente

enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

Además, se prefiere el uso de compuestos de fórmula general (Ia), en la que R^{10a} representa hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo de 5 ó 6 miembros opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

preferiblemente H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo o un radical fenilo,

más preferiblemente H, $-CH_3$, $-C_2H_5$ o fenilo,

y R^{1a}-R^{9a}, R^{12a}-R^{15a} y W^a tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

Además, se prefiere el uso de compuestos de fórmula general (Ia), en la que R^{11a} representa hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo de 5 ó 6 miembros opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

preferiblemente H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo o un radical fenilo, más preferiblemente H, $-CH_3$, $-C_2H_5$ o fenilo,

y R^{1a}-R^{10a}, R^{12a}-R^{16a} y W^a tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

También se da preferencia al uso de compuestos de fórmula general (Ia), en la que R^{12a} representa un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo de 5 ó 6 miembros, opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

preferiblemente representa H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo o un radical fenilo,

más preferiblemente H, $-CH_3$, $-C_2H_5$ o fenilo,

y R^{1a}-R^{11a}, R^{13a}-R^{16a} y W^a tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

También se prefieren compuestos de fórmula general (Ia), en la que R^{13a} y R^{14a} se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo de 5 ó 6 miembros, opcionalmente al menos monosustituido, que puede

estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

preferiblemente se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo y un radical fenilo,

más preferiblemente se seleccionan cada uno independientemente del grupo que consiste en H, $-CH_3$, $-C_2H_5$ y fenilo,

y R^{1a}-R^{12a}, R^{15a}-R^{18a} y W^a tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

Además, se prefiere el uso de compuestos de fórmula general (Ia), en la que R^{13a} y R^{14a} junto con el átomo puente de nitrógeno forman un anillo heterocíclico de 5 ó 6 miembros saturado, insaturado o aromático, que puede estar al menos monosustituido y/o contener al menos un heteroátomo más como miembro del anillo,

preferiblemente forman un grupo piperidina o morfolina no sustituido,

y R^{1a}-R^{12a}, R^{15a}-R^{18a} y W^a tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos , o solvatos correspondientes.

También se prefieren compuestos de fórmula general (Ia), en la que R^{15a} representa hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, o un radical arilo o heteroarilo de 5 ó 6 miembros opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

preferiblemente representa H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo o un radical fenilo,

más preferiblemente H, $-CH_3$, $-C_2H_5$ o fenilo,

y R^{1a}-R^{14a}, R^{16a}-R^{18a} y W^a tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

También se prefieren compuestos de fórmula general (Ia), en la que R^{16a} representa un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido,

preferiblemente un radical alquilo C_{1-3} lineal o ramificado, saturado, no sustituido,

más preferiblemente un radical metilo,

y R^{1a}-R^{15a}, R^{17a}, R^{18a} y W^a tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

También se prefieren compuestos de fórmula general (Ia), en la que R^{17a} representa un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido,

preferiblemente un radical alquilo C_{1-3} lineal o ramificado, saturado, no sustituido,

más preferiblemente un radical metilo,

y R^{1a}-R^{16a}, R^{18a} y W^a tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

También se prefieren compuestos de fórmula general (Ia), en la que R^{18a} representa un radical fenilo que está opcionalmente al menos monosustituido por un

radical alifático C_{1-6}, más preferiblemente un radical fenilo que está opcionalmente al menos monosustituido por un grupo metilo, y R^{1a}-R^{17a} y W^a tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

Se prefiere particularmente el uso de compuestos de sulfonamidas derivados de benzoxazinona de fórmula general (Ia) seleccionados de la lista A definida anteriormente.

Se prefiere más particularmente el uso de uno o más compuestos de fórmula general (Ia) seleccionados del grupo que consiste en:

1-[1-(naftil-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona,

1-(1-fenilsulfonilpiperidin-4-il]-1,4-dihidro-benzo[d][1,3]-oxazin-2-ona,

1-[1-(5-cloro-3-metil-benzo[b]tiofenil-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona,

8-metil-1-[1-naftil-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona,

1-[1-(quinolin-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona,

8-metil-1-[1-(quinolin-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona,

1-[1-(5-dimetilamino-naftil-1-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidrobenzo[d][1,3]oxazin-2-ona,

1-[1-(5-dimetilamino-naftil-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona,


1-[1-(2,3-dicloro-fenilsulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona,

1-[1-(2,3-dicloro-fenilsulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxazin-2-ona, y

sales correspondientes de los mismos, o solvatos correspondientes de los mismos.

Los compuestos de fórmula general (Ia), sus estereoisómeros, sales correspondientes y solvatos correspondientes pueden obtenerse de manera análoga mediante los métodos descritos anteriormente para compuestos de fórmula general (I).

En otro aspecto la presente invención se refiere a compuestos de sulfonamidas derivados de la benzoxazinona de fórmula general (Ib)



(Ib)

en la que

R^{1b}, R^{2b}, R^{3b}, R^{4b} se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, halógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un grupo nitro, un grupo ciano, $-OR^{10b}$, $-OC(=O)R^{11b}$, $-(C=O)-OR^{11b}$, $-SR^{12b}$, $-SOR^{12b}$, $-SO_2R^{12b}$, $-NH-SO_2R^{12b}$, $-SO_2NH_2$ y un resto $-NR^{13b}R^{14b}$,

R^{5b} representa hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, o un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo,

R^{6b}, R^{7b}, R^{8b}, R^{9b} se seleccionan cada uno independientemente del grupo que consisten en hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado,

opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, un grupo ciano y un resto $-COOR^{15b}$,

W^b representa un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un resto $NR^{16b}R^{17b}$ o un resto COR^{15b},

R^{10b} representa hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{11b} representa hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{12b} representa un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado,

opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{13b} y R^{14b} se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

o R^{13b} R^{14b} junto con el átomo puente de nitrógeno forman un anillo heterocíclico saturado, insaturado o aromático, que puede estar al menos monosustituido y/o contener al menos un heteroátomo más como miembro del anillo,

R^{15b} representa hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{16b} representa un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido,

R^{17b} representa un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido,

R^{18b} representa un radical arilo opcionalmente al menos monosustituido,

opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato, respectivamente.

Si uno o más de los residuos R^{1b}-R^{17b} y W^b representan un radical alifático, el cual está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, halógeno, alcoxi C_{1-4} lineal o ramificado, perfluoroalcoxi C_{1-4} lineal o ramificado, perfluoroalquilo C_{1-4} lineal o ramificado, amino, carboxi, amido, ciano, nitro, $-SO_2NH_2$, alquilo $-CO-C_{1-4}$, alquilo $-SO-C_{1-4}$, alquilo $-SO_2-C_{1-4}$, alquilo $-NH-SO_2-C_{1-4}$, en los que el alquilo C_{1-4} puede ser en cada caso lineal o ramificado, un radical fenilo o naftilo no sustituido o al menos monosustituido y un radical furanilo, tienilo, pirrolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, quinolinilo e isoquinolinilo no sustituido o al menos monosustituido, más preferiblemente seleccionarse del grupo que consiste en hidroxilo, F, Cl, Br, metoxi, etoxi, $-CF_3$ y un radical fenilo no sustituido. Si uno cualquiera de los sustituyentes mencionados anteriormente está en sí al menos monosustituido, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en F, Cl, metilo y metoxi.

Si uno o más de los residuos R^{1b}-R^{18b} representa o comprenden un radical cicloalifático, que está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, halógeno, alquilo C_{1-4} lineal o ramificado, alcoxi C_{1-4} lineal o ramificado, perfluoroalcoxi C_{1-4} lineal o ramificado, fenoxi, benzoilo, ciclohexilo, perfluoroalquilo C_{1-4} lineal o ramificado, $-NR^AR^B$ en el que R^A, R^B se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, $-CH_2-CH_2-OH$ y fenilo, carboxi, ceto, amido, ciano, nitro, $-SO_2NH_2$, alquilo $-CO-C_{1-4}$, alquilo $-CO-O-C_{1-4}$, alquilo $-SO-C_{1-4}$, alquilo $-SO_2-C_{1-4}$, alquilo $-NH-SO_2-C_{1-4}$, en los que el alquilo C_{1-4} puede ser en cada caso lineal o ramificado, un radical fenilo o naftilo no sustituido o al menos monosustituido y un radical furanilo, tienilo, pirrolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, quinolinilo e isoquinolinilo no sustituido o al menos monosustituido, más preferiblemente seleccionarse del grupo que consiste en hidroxilo, F, Cl, Br, metilo, etilo, metoxi, etoxi, ceto, benzoilo, fenoxi, ciclohexilo, $-CF_3$, $-CO-CH_3$, $-CO-OCH_3$, $-NR^AR^B$ en el que R^A, R^B se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o

ramificado, $-CH_2-CH_2-OH$ y fenilo, y un radical fenilo no sustituido. Si uno cualquiera de los sustituyentes mencionados anteriormente está en sí al menos monosustituido, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en F, Cl, metilo y metoxi.

Si uno o más de los residuos R^{1b}-R^{4b} y R^{10b}-R^{18b} y W^b comprenden un grupo alquileno, que está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, halógeno, alcoxi C_{1-4} lineal o ramificado, alquilo C_{1-4} lineal o ramificado, perfluoroalcoxi C_{1-4} lineal o ramificado, perfluoroalquilo C_{1-4} lineal o ramificado, amino, carboxi, amido, ciano, nitro, $-SO_2NH_2$, alquilo $-CO-C_{1-4}$, alquilo $-SO-C_{1-4}$, alquilo $-SO_2-C_{1-4}$, alquilo $-NH-SO_2-C_{1-4}$, en los que el alquilo C_{1-4} puede ser lineal o ramificado, un radical fenilo o naftilo no sustituido o al menos monosustituido y un radical furanilo, tienilo, pirrolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, quinolinilo e isoquinolinilo no sustituido o al menos monosustituido, más preferiblemente seleccionarse del grupo que consiste en hidroxilo, F, Cl, Br, metilo, metoxi, etoxi, $-CF_3$ y fenilo no sustituido. Si uno cualquiera de los sustituyentes mencionados anteriormente está en sí al menos monosustituido, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en F, Cl, metilo y metoxi.

Si uno o más de los residuos R^{1b}-R^{4b} y R^{10b}-R^{18b} comprenden un sistema cíclico mono o policíclico, que está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, halógeno, alquilo C_{1-4} lineal o ramificado, alcoxi C_{1-4} lineal o ramificado, perfluoroalcoxi C_{1-4} lineal o ramificado, perfluorocarbonilo C_{1-4} lineal o ramificado, perfluoroalquilo C_{1-4} lineal o ramificado, amino, carboxi, amido, ciano, ceto, nitro, $-SO_2NH_2$, alquilo $-CO-C_{1-4}$, alquilo $-SO-C_{1-4}$, alquilo $-SO_2-C_{1-4}$, alquilo $-NH-SO_2-C_{1-4}$, en los que el alquilo C_{1-4} puede ser lineal o ramificado, un radical fenilo o naftilo no sustituido o al menos monosustituido y un radical furanilo, tienilo, pirrolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, quinolinilo e isoquinolinilo no sustituido o al menos monosustituido, más preferiblemente del grupo que consiste en hidroxilo, F, Cl, Br, metilo, etilo, metoxi, etoxi, $-CF_3$, $-(C=O)-CF_3$, ceto, ciano y un radical fenilo no sustituido. Si uno cualquiera de los sustituyentes mencionados anteriormente está en sí al menos monosustituido, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en F, Cl, metilo y metoxi.

Si uno o más de los residuos R^{1b}-R^{4b}, R^{10b}-R^{18b} y R^{18b} representa o comprende un radical arilo, que está sustituido por uno o más sustituyentes, a menos que se

defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, halógeno, alcoxi C_{1-4} lineal o ramificado, alquilo C_{1-4} lineal o ramificado, perfluoroalcoxi C_{1-4} lineal o ramificado, fenoxi no sustituido o al menos monosustituido, benzoilo no sustituido o al menos monosustituido, ciclohexilo, perfluoroalquilo C_{1-4} lineal o ramificado, NR^AR^B en el que R^A, R^B se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, $-CH_2-CH_2-OH$ y fenilo, carboxi, amido, ciano, -CH(OH)(fenil), nitro, $-SO_2NH_2$, alquilo $-CO-C_{1-4}$, alquilo $-CO-O-C_{1-4}$, alquilo $-SO-C_{1-4}$, alquilo $-SO_2-C_{1-4}$, $-NH-SO_2-$alquilo C_{1-4}, en los que el alquilo C_{1-4} puede ser lineal o ramificado, un radical fenilo o naftilo no sustituido o al menos monosustituido y un radical furanilo, tienilo, pirrolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, quinolinilo e isoquinolinilo no sustituido o al menos monosustituido, más preferiblemente seleccionarse del grupo que consiste en hidroxilo, F, Cl, Br, metilo, etilo, ciano, nitro, -CH(OH)(fenil), metoxi, etoxi, benzoilo no sustituido o al menos monosustituido, fenoxi no sustituido o al menos monosustituido, ciclohexilo, $-CF_3$, $-OCF_3$, $-CO-CH_3$, $-CO-OCH_3$, SO_2-CH_3, $-NR^AR^B$ en el que R^A, R^B se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, $-CH_2-CH_2-OH$ y fenilo, y un radical fenilo no sustituido. Si uno cualquiera de los sustituyentes mencionados anteriormente está en sí al menos monosustituido, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en F, Cl, Br, $-CF_3$, $-OCF_3$, metilo y metoxi.

Si uno o más de los residuos R^{1b}-R^{4b} y R^{10b}-R^{15b} representa o comprende un radical heteroarilo, que está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, halógeno, alcoxi C_{1-4} lineal o ramificado, alquilo C_{1-4} lineal o ramificado, perfluoroalcoxi C_{1-4} lineal o ramificado, fenoxi no sustituido o al menos monosustituido, benzoilo no sustituido o al menos monosustituido, ciclohexilo, perfluoroalquilo C_{1-4} lineal o ramificado, NR^AR^B en el que R^A, R^B se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, $-CH_2-CH_2-OH$ y fenilo, carboxi, amido, ciano, -CH(OH)(fenil), nitro, $-SO_2NH_2$, alquilo $-CO-C_{1-4}$, alquilo $-CO-O-C_{1-4}$, alquilo $-SO-C_{1-4}$, alquilo $-SO_2-C_{1-4}$, alquilo $-NH-SO_2-C_{1-4}$, en los que el alquilo C_{1-4} puede ser lineal o ramificado, un radical fenilo o naftilo no sustituido o al menos monosustituido y un radical furanilo, tienilo, pirrolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, quinolinilo e isoquinolinilo no sustituido o al menos monosustituido, más preferiblemente

seleccionarse del grupo que consiste en hidroxilo, F, Cl, Br, metilo, etilo, ciano, nitro, -CH(OH)(fenil), metoxi, etoxi, benzoilo no sustituido o al menos monosustituido, fenoxi no sustituido o al menos monosustituido, ciclohexilo, $-CF_3$, $-OCF_3$, $-CO-CH_3$, $-CO-OCH_3$, SO_2-CH_3, $-NR^AR^B$ en el que R^A, R^B se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, $-CH_2-CH_2-OH$ y fenilo, y un radical fenilo no sustituido. Si uno cualquiera de los sustituyentes mencionados anteriormente está en sí al menos monosustituido, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en F, Cl, Br, $-CF_3$, $-OCF_3$, metilo y metoxi.

Si R^{13b} y R^{14b} forman un anillo heterocíclico, que está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, halógeno, alcoxi C_{1-4} lineal o ramificado, alquilo C_{1-4} lineal o ramificado, perfluoroalcoxi C_{1-4} lineal o ramificado, perfluoroalquilo C_{1-4} lineal o ramificado, amino, carboxi, amido, ciano, nitro, $-SO_2NH_2$, alquilo $-CO-C_{1-4}$, alquilo $-SO-C_{1-4}$, alquilo $-SO_2-C_{1-4}$, alquilo $-NH-SO_2-C_{1-4}$, en los que el alquilo C_{1-4} puede ser lineal o ramificado, un radical fenilo o naftilo no sustituido o al menos monosustituido y un radical furanilo, tienilo, pirrolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, quinolinilo e isoquinolinilo no sustituido o al menos monosustituido, más preferiblemente seleccionarse del grupo que consiste en hidroxilo, F, Cl, Br, metoxi, etoxi, metilo, $-CF_3$ y un radical fenilo no sustituido. Si uno cualquiera de los sustituyentes mencionados anteriormente está en sí al menos monosustituido, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en F, Cl, metilo y metoxi.

Si R^{13b} y R^{14b} forman un anillo heterocíclico, que contiene uno o más heteroátomos adicionales como miembros del anillo, a menos que se defina lo contrario, cada uno de estos heteroátomos puede seleccionarse preferiblemente del grupo que consiste en N, O y S, más preferiblemente del grupo que consiste en N y O.

Si uno o más de los residuos R^{1b}-R^{15b} y W^b representa o comprende un radical cicloalifático, que contiene uno o más heteroátomos como miembros del anillo, a menos que se defina lo contrario, cada uno de estos heteroátomos puede seleccionarse preferiblemente del grupo que consiste en N, O, S y P, más preferiblemente del grupo que consiste en N, O y S.

Si uno o más de los residuos R^{1b}-R^{4b}, R^{10b}-R^{15b} y W^b representa o comprende un radical heteroarilo, que contiene uno o más heteroátomos como miembros del anillo, a menos que se defina lo contrario, cada uno de estos heteroátomos puede

seleccionarse preferiblemente del grupo que consiste en N, O, S y P, más preferiblemente del grupo que consiste en N, O y S.

Si W^b representa o comprende un radical cicloalifático, un radical heteroarilo, un radical arilo y/o un sistema cíclico mono o policíclico, que está sustituido por uno o más sustituyentes, a menos que se defina lo contrario, cada uno de estos sustituyentes puede seleccionarse preferiblemente del grupo que consiste en hidroxilo, nitro, carboxi, ciano, ceto, halógeno, alquilo C_{1-20}, alquilo C_{1-4} parcialmente fluorado, alquilo C_{1-4} parcialmente clorado, alquilo C_{1-4} parcialmente bromado, alcoxi C_{1-5}, alcoxi C_{1-4} parcialmente fluorado, alcoxi C_{1-4} parcialmente clorado, alcoxi C_{1-4} parcialmente bromado, alquenilo C_{2-6}, alquilo -SO_2-C_{1-4}, alquilo -(C=O)-C_{1-5} alquilo , -(C=O)-O-C_{1-5}, -(C=O)-Cl, alquilo -S-C_{1-4}, -(C=O)-H, alquilo -NH-(C=O)-NH-C_{1-5}, perfluoroalquilo -(C=O)-C_{1-4}, -NR^AR^B en el que R^A, R^B se seleccionan cada uno independientemente del grupo que consiste en H, alquilo C_{1-4} y fenilo, alquilo NH-(C=O)-C_{1-5}, alquilen C_{1-5} alquilo (C=O)-C_{1-5}, (1,3-dihidro-1-oxo-2H-isoindol-2-il), N-ftalimidinilo, (1,3-dioxo-2-azaspiro[4,4]-non-2-il), fenilo sustituido o no sustituido, -SO_2-fenilo, fenoxi, piridinilo, piridiniloxi, pirazolilo, pirimidinilo, pirrolidinilo, -SO_2-pirrolidinilo, morfolinilo, -SO_2-morfolinilo, tiadiazolilo, oxadiazolilo, oxazolilo, tiazolilo, isoxazolilo, -O-CH_2-tiazolilo, -NH-fenilo, y alquilen C_{1-4} NH-(C=O)-fenilo, más preferiblemente del grupo que consiste en hidroxilo, nitro, carboxi, ciano, ceto, F, Cl, Br, I, alquilo C_{1-12}, CH_2F, CHF_2, CF_3, CH_2Cl, CH_2Cl_2, CCl_3, CH_2Br, $CHBr_2$, CBr_3, OCF_3, $OCHF_2$, OCH_2F, O-CH_2-CF_3, vinilo, SO_2-CH_3, -(C=O)-CH_3, -(C=O)-C_2H_5, -(C=O)-O-CH_3, -(C=O)-O-C_2CH_5, -(C=O)-Cl, -S-CH_3, -(C=O)-H, -NH-(C=O)-NH-CH_3, -(C=O)-CF_3, dimetilamino, dietilamino, di-n-propilamino, di-iso-propilamino, di-n-butilamino, di-terc-butilamino, NH-(C=O)-CH_3, -CH_2-(C=O)-CH_3, -CH_2-(C=O)-C_2H_5, (1,3-dihidro-1-oxo-2H-isoindol-2-il), N-ftalimidinilo, (1,3-dioxo-2-azaspiro[4,4]-non-2-il), fenilo sustituido o no sustituido, -SO_2-fenilo, fenoxi, piridinilo, piridiniloxi, pirazolilo, pirimidinilo, pirrolidinilo, -SO_2-pirrolidinilo, morfolinilo, -SO_2-morfolinilo, tiadiazolilo, oxadiazolilo, oxazolilo, tiazolilo, isoxazolilo, O-CH_2-tiazolilo, NH-fenilo, y -CH_2-NH-(C=O)-fenilo.

Si uno cualquiera de los sustituyentes antes mencionado está en sí sustituido por uno o más sustituyentes, dichos sustituyentes pueden seleccionarse preferiblemente del grupo que consiste en halógeno, nitro, ciano, hidroxilo, alquilo -(C=O)-C_{1-4}, alquilo C_{1-4}, alquilo C_{1-4} al menos parcialmente fluorado, alquilo C_{1-4} al menos parcialmente clorado, alquilo C_{1-4} al menos parcialmente bromado, alquilo -S-C_{1-4}, alquilo -C(=O)-O-C_{1-5}, -(C=O)-CH_2-F, -(C=O)-CH_2-Cl, -(C=O)-CH_2-Br, preferiblemente del grupo que consiste en F, Cl, Br, CH_2F, CHF_2, CF_3, CH_2Cl, $CHCl_2$,

CCl_3, CH_2Br, $CHBr_2$, CBr_3, nitro, ciano, hidroxilo, -(C=O)-CH_3, CH_3, C_2H_5, -S-CH_3, -C(=O)-O-CH_3, -C(=O)-O-C_2H_5, -(C=O)-CH_2-F, -(C=O)-CH_2-Cl y -(C=O)-CH_2-Br.

Se prefieren compuestos de fórmula general (Ib) dada anteriormente, en la que R^{1b}, R^{2b}, R^{3b}, R^{4b} se seleccionan cada uno independientemente del grupo que consiste en H, F, Cl, Br, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un radical arilo o heteroarilo de 5 ó 6 miembros, opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un grupo nitro, un grupo ciano, $-OR^{10b}$, $-OC(=O)R^{11b}$, $-SR^{12b}$, $-SOR^{12b}$, $-SO_2R^{12b}$, $-NH-SO_2R^{12b}$, $-SO_2NH_2$ y un resto $-NR^{13b}R^{14b}$, preferiblemente seleccionados del grupo que consiste en H, F, Cl, Br, un radical alifático C_{1-3} saturado, lineal o ramificado, opcionalmente al menos monosustituido, un radical cicloalifático C_5 o C_6 saturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_1 o C_2 opcionalmente al menos monosustituido, un grupo nitro, un grupo ciano, $-OR^{10b}$, $-OC(=O)R^{11b}$, $-SR^{12b}$ y un resto $-NR^{13b}R^{14b}$, más preferiblemente seleccionados del grupo que consiste en H, F, Cl, Br, $-CH_3$, $-CH_2CH_3$, $-CF_3$, $-CF_2CF_3$, ciclopentilo, ciclohexilo, nitro, ciano y $-OR^{10b}$, y R^{5b}-R^{18b} y W^b tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

También se prefieren compuestos de fórmula general (Ib) dada anteriormente, en la que R^{5b} representa hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido o un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, preferiblemente representa H o un radical alquilo C_{1-3} lineal o ramificado, más

preferiblemente H, $-CH_3$, o $-CH_2CH_3$, lo más preferiblemente un átomo de hidrógeno, y R^{1b}-R^{4b}, R^{6b}-R^{18b} y W^b tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

También se prefieren compuestos de fórmula general (Ib) dada anteriormente, en la que R^{6b}, R^{7b}, R^{8b}, R^{9b} se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, un grupo ciano y un resto $-COOR^{15b}$, preferiblemente seleccionados del grupo que consiste en H, un radical alquilo C_{1-3} lineal o ramificado, un grupo ciano y un grupo $COOR^{15b}$, más preferiblemente del grupo que consiste en H, $-CH_3$, $-CH_2CH_3$ y un resto ciano, lo más preferiblemente cada uno de R^{6b}, R^{7b}, R^{8b} y R^{9b} representa un átomo de hidrógeno, y R^{1b}-R^{5b}, R^{10b}-R^{18b} y W^b tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o sales correspondientes de los mismos, o solvatos correspondientes.

También se prefieren compuestos de fórmula general (Ib) dada anteriormente, en la que W^b representa un radical alifático C_{1-20} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un radical arilo o heteroarilo de 5 ó 6 miembros, opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un resto $NR^{16b}R^{17b}$ o un resto COR^{16b},

preferiblemente W^b representa

un radical alquilo C_{1-20} lineal o ramificado, preferiblemente un radical alquilo seleccionado del grupo que consiste en metilo, etilo, n-propilo, iso-propilo, n-butilo, iso-butilo, sec-butilo, terc-butilo y 1,1-dimetil-propilo; un radical alquenilo C_{2-20} lineal o ramificado; preferiblemente un radical vinilo; $-CF_3$; $-CHF_2$; $-CH_2F$; $-CCl_3$; $-CHCl_2$; $-CH_2Cl$; $-CH_2-CF_3$; $-CH_2-CH_2-Cl$; $-CH_2-CH_2-CH_2-Cl$; $-CH_2-S(=O)_2-CH_3$; un radical ciclopropilo; un radical ciclobutilo; un radical ciclopentilo; un radical ciclohexilo; $-CH_2$-ciclopropilo; $-CH_2$-ciclobutilo; - CH_2-ciclopentilo; - CH_2-ciclohexilo; $-N(CH_3)_2$; $-N(C_2H_5)_2$; $-N(n\text{-}CH_2\text{-}CH_2\text{-}CH_3)_2$; fenilo; bencilo; naftilo; -CH=CH-fenilo; $-(CF_2)$-(CF_2)-O-fenilo; $-(CH_2)$-naftilo; $-(CH_2)$-(CH_2)-naftilo; antracenilo; -(C=O)-fenilo; tiofenilo; benzo[b]tiofenilo; furanilo; 2-oxo-2H-cromenilo; dibenzofuranilo; 2,3-dihidrobenzofuranilo; cromanilo; 2,3-dihidro-benzo[1,4]dioxinilo; 3,4-dihidro-2H-1,5-benzo-dioxepinilo; cromonilo; 1H-imidazolilo; piridinilo; pirrolidin-2,5-dionilo; pirrolilo; 1H-pirazolilo; 1H-pirimidin-2,4-dionilo; quinolinilo; isoquinolinilo; 1H-benzoimidazolilo; 1,4-dihidro-quinoxalin-2,3-dionilo; 1,2,3,4-tetrahidro-isoquinolinilo; 1,4-dihidro-benzo[b][1,4]diazepin-2,4-dionilo; 1,3-dihidro-1-oxo-2H-isoindolilo; ftalimidinilo; 2-(1,3-dioxo-1,3-dihidro-isoindol-2-il)-etilo; imidazo[1,2-a]piridina; isatinilo; tiazolilo; 1,3-tiazolilo; 1,2,4-tiadiazolilo; imidazo[2,1-b]tiazolilo; 1,3-benzotiazolilo; benzo[1,2,5]tiadiazolilo; 2-oxo-2,3-dihidro-benzotiazolilo; 2,1,3-benzotiadiazolilo; imidazo[2,1-b]tiazolilo; isoxazolilo; benzo[1,2,5]oxadiazolilo; benzo[d]isoxazolilo; benzofurazanilo; 2-oxo-2,3-dihidro-benzooxazolilo; 3,4-dihidro-2H-benzo[1,4]oxazinilo; o 2,1,3-benzooxadiazolilo;


en los que cada uno de los restos cíclicos mencionados anteriormente puede sustituirse opcionalmente con 1, 2, 3, 4 ó 5 sustituyentes seleccionados independientemente del grupo que consiste en metilo; etilo; n-propilo; iso-propilo; n-butilo; iso-butilo; sec-butilo; terc-butilo; 1,1-dimetil-propilo; n-pentilo; vinilo; ciclopropilo; ciclobutilo; ciclopentilo; ciclohexilo; morfolino; metoxi; etoxi; n-propoxi; isopropoxi; n-propoxi; F; Cl; Br; I; -CN; -OH; $-CF_3$; $-CF_2H$; $-CH_2F$; $-CCl_3$; $-CClH_2$; $-CHCl_2$; $-CH_2$-F; $-CH_2$-Cl; $-CH_2$-Br; -(C=O)-CH_2-Br; $-OCF_3$; $-O\text{-}CH_2\text{-}CF_3$; $-O\text{-}CHF_2$; $-NO_2$; $-NH_2$; $-N(CH_3)_2$; $-N(C_2H_5)_2$; $-N(n\text{-}CH_2\text{-}CH_2\text{-}CH_3)_2$; $-N(n\text{-}CH_2\text{-}CH_2\text{-}CH_2\text{-}CH_3)_2$; -NH-(C=O)-$CH_3$; -NH-fenilo; -(C=O)-$CF_3$; -(C=O)-OH; =O (oxo); -(C=O)-H; $-S(=O)_2-CH_3$; $-S(=O)_2$-isopropilo; $-S(=O)_2$-fenilo; $-S(=O)_2$-pirrolidinilo; $-S(=O)_2$-morfolino; $-(CH_2)$-(CH_2)-(C=O)-O-CH_3; -NH-(C=O)-NH-CH_2-CH_2-CH_3; -(C=O)-CH_3; -(C=O)-O-CH_3; -(C=O)-O-C_2H_5; $-(CH_2)$-NH-(C=O)-fenilo; $-CH_2$-C(H)(fenil)(fenil); $-O\text{-}CH_2$-tiazolilo; 1,3-dioxo-2-azaspiro[4,4]non-2-ilo; fenilo; fenoxi; isoxazolilo; 1,3-oxazolilo; 1,2,4-oxadiazolilo; 1,3,4-oxadiazolilo; piridinilo; piridiniloxi; pirazolilo; pirimidinilo y ftalimidinilo; y

en los que cada uno de los restos cíclicos de estos sustituyentes mencionados anteriormente puede sustituirse con 1, 2, 3, 4 ó 5 sustituyentes que se seleccionan independientemente del grupo que consiste en metilo; etilo; n-propilo; isopropilo; F; Cl; Br; I; CN, $-CH_2-F$; $-CH_2-Cl$; $-CH_2-Br$; $-CF_3$ y $-S-CH_3$,


más preferiblemente W^b representa


un radical alquilo seleccionado del grupo que consiste en metilo; etilo; n-propilo; iso-propilo; n-butilo; sec-butilo; iso-butilo y terc-butilo; vinilo (CH_2=CH-); $-N(CH_3)_2$; 1-naftilo; bencilo; 2-naftilo; fenilo; 2-metil-fenilo; 3-metil-fenilo; 4-metil-fenilo; 2-etil-fenilo; 3-etil-fenilo; 4-etil-fenilo; 2-n-propil-fenilo; 3-n-propil-fenilo; 4-n-propil-fenilo; 2-isopropil-fenilo; 3-isopropil-fenilo: 4-isopropil-fenilo; 2-n-butil-fenilo; 3-n-butil-fenilo; 4-n-butil-fenilo; 2-iso-butil-fenilo; 3-iso-butil-fenilo; 4-iso-butil-fenilo; 2-terc-butil-fenilo; 3-terc-butil-fenilo; 4-terc-butil-fenilo; 1,1-dimetilpropil-fenilo; 2-ciclopentil-fenilo; 3-ciclopentil-fenilo; 4-ciclopentil-fenilo; 2-ciclohexil-fenilo; 3-ciclohexil-fenilo; 4-ciclohexil-fenilo; 2-metoxi-fenilo; 3-metoxi-fenilo; 4-metoxi-fenilo; 2-etoxi-fenilo; 3-etoxi-fenilo; 4-etoxi-fenilo; 2-n-propoxi-fenilo; 3-n-propoxi-fenilo; 4-n-propoxi-fenilo; 2-iso-propoxi-fenilo; 3-iso-propoxi-fenilo; 4-iso-propoxi-fenilo; 2-fluoro-fenilo; 3-fluoro-fenilo; 4-fluoro-fenilo; 2-cloro-fenilo; 3-cloro-fenilo; 4-cloro-fenilo; 2-bromo-fenilo; 3-bromo-fenilo; 4-bromo-fenilo; 2-trifluorometil-fenilo; 3-trifluorometil-fenilo; 4-trifluorometil-fenilo; 2-trifluorometoxi-fenilo; 3-trifluorometoxi-fenilo; 4-trifluorometoxi-fenilo; 2-carboxi-fenilo; 3-carboxi-fenilo; 4-carboxi-fenilo; 2-acetil-fenilo; 3-acetil-fenilo; 4-acetil-fenilo; 2-(C=O)-O-CH_3-fenilo; 3-(C=O)-O-CH_3-fenilo; 4-(C=O)-O-CH_3-fenilo; 2-(CH_2)-(CH_2)-(C=O)-O-CH_3; 3-(CH_2)-(CH_2)-(C=O)-O-CH_3; 4-(CH_2)-(CH_2)-(C=O)-O-CH_3; 2-ciano-fenilo; 3-ciano-fenilo; 4-ciano-fenilo; 2-nitro-fenilo; 3-nitro-fenilo; 4-nitro-fenilo; 4-(4-bromofenoxi)-fenilo; 2-metilsulfonil-fenilo; 3-metilsulfonil-fenilo; 4-metilsulfonil-fenilo; 2-fenil-fenil-(bifenil-2-il); 3-fenil-fenil-(bifenil-3-il); 4-fenil-fenil-(bifenil-4-il); 2-fenoxi-fenilo; 3-fenoxi-fenilo; 4-fenoxi-fenilo; 2,4-dimetil-fenilo; 3,4-dimetil-fenilo; 2,4,6-trimetil-fenilo; 2,3,5,6-tetrametil-fenilo; pentametil-fenilo; 2,5-dimetoxi-fenilo; 3,4-dimetoxi-fenilo; 2,3-dicloro-fenilo; 2,4-dicloro-fenilo; 2,5-dicloro-fenilo; 3,4-dicloro-fenilo; 3,5-dicloro-fenilo; 2,6-dicloro-fenilo; 2,4-difluoro-fenilo; 3,4-difluoro-fenilo; 2,5-difluoro-fenilo; 2,6-difluoro-fenilo; 3-cloro-2-fluoro-fenilo; 3-cloro-4-fluoro-fenilo; 5-cloro-2-fluoro-fenilo; 2,3,4-tricloro-fenilo; 2,4,5-tricloro-fenilo; 2,4,6-tricloro-fenilo; 2,4,5-trifluoro-fenilo; 2,3,4-trifluoro-fenilo; 2-cloro-4,5-difluoro-fenilo; 2-bromo-4-fluoro-fenilo; 2-bromo-4,6-difluoro-fenilo; 4-cloro-2,5-difluoro-fenilo; 5-cloro-2,4-difluoro-fenilo; 4-bromo-2,5-difluoro-fenilo; 5-bromo-2,4-difluoro-fenilo; pentafluoro-fenilo; 2,4-dinitro-fenilo; 4-cloro-3-nitro-fenilo; 2-metil-5-nitro-fenilo; 5-bromo-2-metoxi-fenilo; 3-cloro-2-metil-fenilo; 4-bromo-3-metil-


fenilo; 4-cloro-2,5-dimetil-fenilo; 4-fluoro-3-metil-fenilo; 5-fluoro-2-metil-fenilo; 2-nitro-4-trifluorometil-fenilo; 2-metoxi-4-metil-fenilo; 3,5-dicloro-2-hidroxil-fenilo; 3,5-dicloro-4-hidroxil-fenilo; 5-cloro-2,4-difluoro-fenilo; 3-cloro-4-(NH)-(C=O)-CH_3-fenilo; 2-cloro-6-metil-fenilo; 2-cloro-5-trifluorometil-fenilo; 2-cloro-5-trifluorometoxi-fenilo; 4-bromo-2-trifluorometoxi-fenilo; 4-bromo-2-trifluorometil-fenilo; 4-bromo-3-trifluorometil-fenilo; 3-carboxi-4-fluoro-fenilo; 3-carboxi-4-cloro-6-fluoro-fenilo; 4-metoxi-2,3,6-trimetil-fenilo; o uno de los grupos siguientes:




~~384~~
384


X
(CH2)1-2X
X
X
F
X
Cl
X
N
X
Cl
X
NH-C(=O)-CH3
X
N
O
O
X
HO
HO
X
H3C-(O=C)-O
H3C-(O=C)-O
(CH2)1-2-X
X
X
Cl


X
S
Cl
O
N
H
F3C
NH


X
O
O
X
O
X
O
X
O
X
O
X
O
X
O
N
X
O
H
X
O
N
X
O
X
N
H
O
X
O
N
X
O
N
X
(CH2)
X
N
O
X
N
O
Cl
X
N
O
N



en los que en cada caso X indica la posición por la cual se une el sustituyente W^b respectivo al grupo $-SO_2$ de la fórmula (Ib),

y R^{1b}-R^{18b} tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o las sales correspondientes de los mismos, o los solvatos correspondientes.

También se prefieren compuestos de fórmula general (Ib) dada anteriormente, en la que R^{10b} representa hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar

unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido o un radical arilo o heteroarilo de 5 ó 6 miembros, opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, preferiblemente H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo o un radical fenilo, más preferiblemente H, $-CH_3$, $-C_2H_5$ o fenilo, y R^{1b}-R^{9b}, R^{11b}-R^{15b} y W^b tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o las sales correspondientes de los mismos, o los solvatos correspondientes.

También se prefieren compuestos de fórmula general (Ib) dada anteriormente, en la que R^{11b} representa hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo de 5 ó 6 miembros, opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, preferiblemente H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo o un radical fenilo, más preferiblemente H, $-CH_3$, $-C_2H_5$ o fenilo, y R^{1b}-R^{10b}, R^{12b}-R^{15b} y W^b tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o las sales correspondientes de los mismos, o los solvatos correspondientes.

También se prefieren compuestos de fórmula general (Ib) dada anteriormente, en la que R^{12b} representa un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene

opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo de 5 ó 6 miembros, opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, preferiblemente representa H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo o un radical fenilo, más preferiblemente H, $-CH_3$, $-C_2H_5$ o fenilo, y R^{1b}-R^{11b}, R^{13b}-R^{18b} y W^b tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o las sales correspondientes de los mismos, o los solvatos correspondientes.

También se prefieren compuestos de fórmula general (Ib) dada anteriormente, en la que R^{13b} y R^{14b} se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo de 5 ó 6 miembros, opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, preferiblemente se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, ciclohexilo y un radical fenilo, más preferiblemente se seleccionan cada uno independientemente del grupo que consiste en H, $-CH_3$, $-C_2H_5$ y fenilo, y R^{1b}-R^{12b}, R^{15b}-R^{18b} y W^b tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente

enantiómeros o diasterómeros, en cualquier razón de mezcla, o las sales correspondientes de los mismos, o los solvatos correspondientes.

También se prefieren compuestos de fórmula general (Ib) dada anteriormente, en la que R^{13b} y R^{14b} junto con el átomo puente de nitrógeno forman un anillo heterocíclico de 5 ó 6 miembros, saturado, insaturado o aromático, que puede estar al menos monosustituido y/o contener al menos un heteroátomo más como miembro del anillo, preferiblemente forman un grupo piperidina o morfolina no sustituido, y R^{1b}-R^{12b}, R^{15b}-R^{18b} y W^b tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o las sales correspondientes de los mismos, o los solvatos correspondientes.

También se prefieren compuestos de fórmula general (Ib) dada anteriormente, en la que R^{15b} representa hidrógeno, un radical alifático C_{1-8} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo o un radical arilo o heteroarilo de 5 ó 6 miembros, opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-8} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, preferiblemente representa H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo o un radical fenilo, más preferiblemente representa H, $-CH_3$, $-C_2H_5$ o fenilo, y R^{1b}-R^{14b}, R^{16b}-R^{18b} y W^b tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o las sales correspondientes de los mismos, o los solvatos correspondientes.

También se prefieren compuestos de fórmula general (Ib) dada anteriormente, en la que R^{16b} representa un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, preferiblemente un radical alquilo C_{1-3} lineal o ramificado, saturado, no sustituido, más preferiblemente un radical metilo, y R^{1b}-R^{15b}, R^{17b} y R^{18b} y W^b tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos

dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o las sales correspondientes de los mismos, o los solvatos correspondientes.

También se prefieren compuestos de fórmula general (Ib) dada anteriormente, en la que R^{17b} representa un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, preferiblemente un radical alquilo C_{1-3} lineal o ramificado, saturado, no sustituido, más preferiblemente un radical metilo, y R^{1b}-R^{16b}, R^{18b} y W^b tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o las sales correspondientes de los mismos, o los solvatos correspondientes.

También se prefieren compuestos de fórmula general (Ib) dada anteriormente, en la que R^{18b} representa un radical fenilo, que está opcionalmente al menos monosustituido por un radical alifático C_{1-6}, más preferiblemente un radical fenilo, que está opcionalmente al menos monosustituido por un grupo metilo, y R^{1b}-R^{17b} y W^b tienen la significación definida anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, sus racematos o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o las sales correspondientes de los mismos, o los solvatos correspondientes.

Se prefieren más los compuestos de fórmula general (Ib) dada anteriormente, en la que

R^{1b}, R^{2b}, R^{3b}, R^{4b} se seleccionan cada uno independientemente del grupo que consiste en un átomo de hidrógeno; un átomo de flúor; un átomo de cloro; un átomo de bromo; un grupo metilo y un grupo metoxi;


R^{5b} representa un átomo de hidrógeno;

R^{6b}, R^{7b}, R^{8b}, R^{9b} representan cada uno un átomo de hidrógeno;


W^b representa


un radical alquilo seleccionado del grupo que consiste en metilo; etilo; n-propilo; iso-propilo; n-butilo; sec-butilo; iso-butilo y terc-butilo; vinilo (CH_2=CH-); -N(CH_3)$_2$; 1-naftilo; bencilo; 2-naftilo; fenilo; 2-metil-fenilo; 3-metil-fenilo; 4-metil-fenilo; 2-etil-fenilo; 3-etil-fenilo; 4-etil-fenilo; 2-n-propil-fenilo; 3-n-propil-fenilo; 4-n-propil-fenilo; 2-isopropil-fenilo; 3-isopropil-fenilo: 4-isopropil-fenilo; 2-n-butil-fenilo; 3-n-butil-fenilo; 4-n-butil-fenilo; 2-iso-butil-fenilo; 3-iso-butil-fenilo; 4-iso-butil-fenilo; 2-terc-butil-fenilo; 3-terc-


butil-fenilo; 4-terc-butil-fenilo; 1,1-dimetilpropil-fenilo; 2-ciclopentil-fenilo; 3-ciclopentil-fenilo; 4-ciclopentil-fenilo; 2-ciclohexil-fenilo; 3-ciclohexil-fenilo; 4-ciclohexil-fenilo; 2-metoxi-fenilo; 3-metoxi-fenilo; 4-metoxi-fenilo; 2-etoxi-fenilo; 3-etoxi-fenilo; 4-etoxi-fenilo; 2-n-propoxi-fenilo; 3-n-propoxi-fenilo; 4-n-propoxi-fenilo; 2-iso-propoxi-fenilo; 3-iso-propoxi-fenilo; 4-iso-propoxi-fenilo; 2-fluoro-fenilo; 3-fluoro-fenilo; 4-fluoro-fenilo; 2-cloro-fenilo; 3-cloro-fenilo; 4-cloro-fenilo; 2-bromo-fenilo; 3-bromo-fenilo; 4-bromo-fenilo; 2-trifluorometil-fenilo; 3-trifluorometil-fenilo; 4-trifluorometil-fenilo; 2-trifluorometoxi-fenilo; 3-trifluorometoxi-fenilo; 4-trifluorometoxi-fenilo; 2-carboxi-fenilo; 3-carboxi-fenilo; 4-carboxi-fenilo; 2-acetil-fenilo; 3-acetil-fenilo; 4-acetil-fenilo; 2-(C=O)-O-CH_3-fenilo; 3-(C=O)-O-CH_3-fenilo; 4-(C=O)-O-CH_3-fenilo; 2-(CH_2)-(CH_2)-(C=O)-O-CH_3; 3-(CH_2)-(CH_2)-(C=O)-O-CH_3; 4-(CH_2)-(CH_2)-(C=O)-O-CH_3; 2-ciano-fenilo; 3-ciano-fenilo; 4-ciano-fenilo; 2-nitro-fenilo; 3-nitro-fenilo; 4-nitro-fenilo; 4-(4-bromofenoxi)-fenilo; 2-metilsulfonil-fenilo; 3-metilsulfonil-fenilo; 4-metilsulfonil-fenilo; 2-fenil-fenil-(bifenil-2-il); 3-fenil-fenil-(bifenil-3-il); 4-fenil-fenil-(bifenil-4-il); 2-fenoxi-fenilo; 3-fenoxi-fenilo; 4-fenoxi-fenilo; 2,4-dimetil-fenilo; 3,4-dimetil-fenilo; 2,4,6-trimetil-fenilo; 2,3,5,6-tetrametil-fenilo; pentametil-fenilo; 2,5-dimetoxi-fenilo; 3,4-dimetoxi-fenilo; 2,3-dicloro-fenilo; 2,4-dicloro-fenilo; 2,5-dicloro-fenilo; 3,4-dicloro-fenilo; 3,5-dicloro-fenilo; 2,6-dicloro-fenilo; 2,4-difluoro-fenilo; 3,4-difluoro-fenilo; 2,5-difluoro-fenilo; 2,6-difluoro-fenilo; 3-cloro-2-fluoro-fenilo; 3-cloro-4-fluoro-fenilo; 5-cloro-2-fluoro-fenilo; 2,3,4-tricloro-fenilo; 2,4,5-tricloro-fenilo; 2,4,6-tricloro-fenilo; 2,4,5-trifluoro-fenilo; 2,3,4-trifluoro-fenilo; 2-cloro-4,5-difluoro-fenilo; 2-bromo-4-fluoro-fenilo; 2-bromo-4,6-difluoro-fenilo; 4-cloro-2,5-difluoro-fenilo; 5-cloro-2,4-difluoro-fenilo; 4-bromo-2,5-difluoro-fenilo; 5-bromo-2,4-difluoro-fenilo; pentafluoro-fenilo; 2,4-dinitro-fenilo; 4-cloro-3-nitro-fenilo; 2-metil-5-nitro-fenilo; 5-bromo-2-metoxi-fenilo; 3-cloro-2-metil-fenilo; 4-bromo-3-metil-fenilo; 4-cloro-2,5-dimetil-fenilo; 4-fluoro-3-metil-fenilo; 5-fluoro-2-metil-fenilo; 2-nitro-4-trifluorometil-fenilo; 2-metoxi-4-metil-fenilo; 3,5-dicloro-2-hidroxi-fenilo; 3,5-dicloro-4-hidroxi-fenilo; 5-cloro-2,4-difluoro-fenilo; 3-cloro-4-(NH)-(C=O)-CH_3-fenilo; 2-cloro-6-metil-fenilo; 2-cloro-5-trifluorometil-fenilo; 2-cloro-5-trifluorometoxi-fenilo; 4-bromo-2-trifluorometoxi-fenilo; 4-bromo-2-trifluorometil-fenilo; 4-bromo-3-trifluorometil-fenilo; 3-carboxi-4-fluoro-fenilo; 3-carboxi-4-cloro-6-fluoro-fenilo; 4-metoxi-2,3,6-trimetil-fenilo; o uno de los grupos siguientes:



X
HN
N
NH-(C=O)-CH3
O
S

/


X
(CH2)1-2X
X
X
F
X
Cl
X
N
X
Cl
X
NH-C(=O)-CH3
X
N
O
O
X
HO
HO
X
H3C-(O=C)-O
H3C-(O=C)-O
(CH2)1-2-X
X
X
Cl




X
O
O
X
O
X
O
X
O
X
O
X
O
X
O
X
O
X
O
X
O
X
N
H
O
X
N
O
X
N
O
X
(CH2)—X
N
O
X
N
O
N
Cl
X
N
O
N



en los que en cada caso X indica la posición por la que se une el sustituyente W^b respectivo al grupo $-SO_2$ de la fórmula (Ib),

opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato, respectivamente.

Los compuestos preferidos más particularmente son los de fórmula general (Ib) seleccionados del grupo siguiente dado en la lista B:

Lista B:

Nº	Compuesto
1	1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
2	1-[1-(tolueno-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
3	1-(1-fenilmetanosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
4	1-(1-bencenosulfonil-piperidin-4-il)-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
5	6-cloro-1-[1-(tolueno-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
6	6-cloro-1-(1-fenilmetanosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
7	6-cloro-1-[1-(naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
8	6-cloro-1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
9	6-cloro-1-[1-(5-cloro-3-metil-benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
10	1-[1-(tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
11	1-[1-(4-acetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
12	2-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo
13	1-[1-(2,4-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
14	1-[1-(4-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
15	1-[1-(2-naftalen-1-il-etanosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
16	8-metil-1-[1-(tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
17	1-[1-(4-acetil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
18	2-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo
19	1-[1-(2,4-dimetil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
20	1-[1-(4-metoxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
21	8-metil-1-[1-(2-naftalen-1-il-etanosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
22	Dimetilamida del ácido 4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfónico
23	Éster metílico del ácido 2-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
24	1-[1-(3-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
25	Éster metílico del ácido 2-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il]-piperidina-1-sulfonil]-benzoico
26	8-metil-1-[1-(3-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
27	1-[1-(4-acetil-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
28	2-[4-(6-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo
29	6-cloro-1-[1-(4-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-

	benzo[d][1,3]oxacin-2-ona
30	Éster metílico del ácido 2-[4-(6-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
31	6-cloro-1-[1-(2,4-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
32	6-cloro-1-[1-(3-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
33	1-[1-(5-cloro-3-metil-benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
34	1-[1-[4-(4-bromo-fenoxi)-bencenosulfonil]-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
35	1-[1-(4-fluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
36	8-metil-1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
37	8-metil-1-(1-fenilmetanosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
38	1-[1-(4-bromo-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
39	6-cloro-1-[1-(4-metanosulfonil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
40	1-[1-(butano-1-sulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
41	1-[1-(4-bromo-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
42	1-[1-(4-metanosulfonil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
43	1-[1-butano-1-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
44	6-cloro-1-[1-(2-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
45	6-cloro-1-[1-(3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
46	1-[1-(bifenil-4-sulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
47	8-metil-1-[1-(2-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
48	8-metil-1-[1-(3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
49	1-[1-(bifenil-4-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
50	8-metil-1-[1-(4-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
51	6-cloro-1-[1-(4-nitro-bencenosulfonil]-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
52	1-(1-etanosulfonil-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
53	1-[1-(propano-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
54	1-[1-(propano-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
55	6-cloro-1-(1-etanosulfonil-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
56	6-cloro-1-[1-(propano-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

57	6-cloro-1-[1-(propano-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
58	6-cloro-1-[1-(quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
59	1-[1-(4-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
60	6-metil-1-[1-(quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
61	6-metil-1-[1-(2-naftalen-1-il-etanosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
62	6-metil-1-[1-(tolueno-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
63	1-[1-(4-fluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
64	6-metil-1-[1-(naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
65	6-metil-1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
66	1-[1-(5-cloro-3-metil-benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
67	6-metil-1-[1-(4-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
68	1-(1-bencenosulfonil-piperidin-4-il)-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
69	1-[1-(4-cloro-3-nitro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
70	1-[1-(5-dimetilamino-naftaleno-1-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
71	1-[1-(4-cloro-3-nitro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
72	1-[1-(4-cloro-3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
73	6-cloro-1-[1-(4-cloro-3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
74	6-cloro-1-[1-(5-dimetilamino-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
75	1-[1-(4-metoxi-2,3,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
76	1-[1-(4-metoxi-2,3,6-trimetil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
77	6-cloro-1-[1-(4-metoxi-2,3,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
78	1-[1-(4-metoxi-2,3,6-trimetil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
79	1-[1-(2-bromo-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
80	1-[1-(2-bromo-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
81	1-[1-(2-bromo-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
82	1-[1-(2-bromo-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
83	6-cloro-1-[1-(2,3-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

84	1-[1-(2,3-dicloro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
85	1-[1-(2,4,5-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
86	8-metil-1-[1-(2,4,5-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
87	6-cloro-1-[1-(2,4,5-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
88	6-metil-1-[1-(2,4,5-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
89	1-[1-(5-bromo-2-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
90	1-[1-(5-bromo-2-metoxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
91	1-[1-(5-bromo-2-metoxi-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
92	1-[1-[5-bromo-2-metoxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
93	1-[1-(2,5-dimetoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
94	1-[1-(2,5-dimetoxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
95	6-cloro-1-[1-(2,5-dimetoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
96	1-[1-(2,5-dimetoxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
97	1-(1-pentametilbencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
98	8-metil-1-(1-pentametilbencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
99	6-cloro-1-(1-pentametilbencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
100	6-metil-1-(1-pentametilbencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
101	1-{1-[2-(2,2,2-trifluoro-acetil)-1,2,3,4-tetrahidro-isoquinolina-7-sulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
102	8-metil-1-{1-[2-(2,2,2-trifluoro-acetil)-1,2,3,4-tetrahidro-isoquinolina-7-sulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
103	6-cloro-1-{1-[2-(2,2,2-trifluoro-acetil)-1,2,3,4-tetrahidro-isoquinolina-7-sulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
104	6-metil-1-{1-[2-(2,2,2-trifluoro-acetil)-1,2,3,4-tetrahidro-isoquinolina-7-sulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
105	1-[1-(2-metil-5-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
106	8-metil-1-[1-(2-metil-5-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
107	6-cloro-1-[1-(2-metil-5-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
108	6-metil-1-[1-(2-metil-5-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
109	1-[1-(4-bromo-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

110	1-[1-(4-bromo-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
111	1-[1-(4-bromo-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
112	1-[1-(4-bromo-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
113	1-[1-(4-cloro-2,5-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
114	1-[1-(4-cloro-2,5-dimetil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
115	6-cloro-1-[1-(4-cloro-2,5-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
116	1-[1-(4-cloro-2,5-dimetil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
117	1-[1-(4-metoxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
118	1-[1-(4-isopropil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
119	1-[1-(4-isopropil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
120	6-cloro-1-[1-(4-isopropil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
121	1-[1-(4-isopropil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
122	1-[1-(3-cloro-4-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
123	1-[1-(3-cloro-4-fluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
124	6-cloro-1-[1-(3-cloro-4-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
125	1-[1-(3-cloro-4-fluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
126	1-[1-(4-bromo-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
127	6-metil-1-[1-(3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
128	8-metil-1-[1-(3-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
129	1-[1-(4-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
130	1-[1-(2-nitro-4-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
131	1-[1-(3-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
132	1-[1-(2,4-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
133	1-[1-(2,4,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
134	1-[1-(2-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
135	8-metil-1-[1-(4-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

136	8-metil-1-[1-(2-nitro-4-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
137	1-[1-(3-fluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
138	1-[1-(2,4-dicloro-bencenosulfonil)-piperidin-4-il]-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
139	8-metil-1-[1-(2,4,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
140	8-metil-1-[1-(2-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
141	1-[1-(4-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
142	1-[1-(4-bromo-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
143	1-[1-(3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
144	1-[1-[4-(4-bromo-fenoxi)-bencenosulfonil]-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
145	1-[1-(3-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
146	1-[1-(2-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
147	8-metil-1-[1-(tolueno-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
148	1-(1-bencenosulfonil-piperidin-4-il)-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
149	1-[1-(3-metoxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
150	1-[1-(2,4-dimetil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
151	1-[1-[4-(4-bromo-fenoxi)-bencenosulfonil]-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
152	8-metil-1-[1-(tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
153	1-[1-(tolueno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
154	1-[1-(5-fluoro-2-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
155	1-[1-(4-isopropoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
156	1-[1-(3-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
157	1-[1-3,4-dimetoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
158	1-(1-pentafluorobencenosulfonil-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
159	8-metil-1-[1-tolueno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
160	1-[1-(5-fluoro-2-metil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
161	1-[1-(4-isopropoxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
162	1-[1-(3-cloro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
163	1-[1-(3,4-dimetoxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-

	benzo[d][1,3]oxacin-2-ona
164	8-metil-1-(1-pentafluorobencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
165	6-metil-1-[1-(tolueno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
166	1-[1-(5-fluoro-2-metil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
167	1-[1-(4-isopropoxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
168	1-[1-(3-cloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
169	1-[1-(3,4-dimetoxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
170	6-metil-1-(1-pentafluorobencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
171	6-metil-1-[1-(4-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
172	6-metil-1-[1-(2-nitro-4-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
173	1-[1-(3-fluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
174	1-[1-(2,4-dicloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
175	6-metil-1-[1-(2,4,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
176	6-metil-1-[1-(2-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
177	1-[1-(3-metoxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
178	6-metil-1-[1-(2-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
179	1-[1-(4-acetil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
180	1-[1-(4-metanosulfonil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
181	6-metil-1-(1-fenilmetanosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
182	Éster metílico del ácido 2-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]benzoico
183	6-metil-1-[1-(2-oxo-2H-cromeno-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
184	6-cloro-1-[1-(4-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
185	6-cloro-1-[1-(3,5-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
186	1-{1-[4-(4-bromo-fenoxi)-bencenosulfonil]-piperidin-4-il}-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
187	6-cloro-1-(1-tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
188	6-cloro-1-[1-(3-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
189	6-cloro-1-[1-(2-oxo-2H-cromeno-6-sulfonil]-piperidin-4-il]-1,4-dihidro-

	benzo[d][1,3]oxacin-2-ona
190	6-cloro-1-[1-(tolueno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
191	6-cloro-1-[1-(5-fluoro-2-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
192	6-cloro-1-[1-(4-isopropoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
193	6-cloro-1-[1-(3-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
194	6-cloro-1-[1-(3,4-dimetoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
195	6-cloro-1-(1-pentafluorobencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
196	6-cloro-1-[1-(4-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
197	6-cloro-1-[1-(2-nitro-4-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
198	6-cloro-1-[1-(3-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
199	6-cloro-1-[1-(2,4-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
200	6-cloro-1-[1-(2,4,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
201	6-cloro-1-[1-(2-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
202	1-[1-(2-oxo-2H-cromeno-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
203	1-[1-(3,5-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
204	1-[1-(2,5-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
205	1-[1-(5-bromo-6-cloro-piridina-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
206	1-[1-(4-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
207	1-[1-(2,6-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
208	8-metil-1-[1-(2-oxo-2H-cromeno-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
209	1-[1-(3,5-dicloro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
210	1-[1-(2,5-dicloro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
211	1-[1-(5-bromo-6-cloro-piridina-3-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
212	1-[1-(4-cloro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
213	1-[1-(2,6-dicloro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
214	1-[1-(bifenil-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
215	6-cloro-1-[1-(2,5-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

216	1-[1-(5-bromo-6-cloro-piridina-3-sulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
217	6-cloro-1-[1-(4-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
218	6-cloro-1-[1-(2,6-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
219	1-[1-(bifenil-4-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
220	2-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo
221	1-[1-(2,5-dicloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
222	1-[1-(5-bromo-6-cloro-piridina-3-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
223	1-[1-(4-cloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
224	1-[1-(2,6-dicloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
225	1-[1-(3,5-dicloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
226	6-metil-1-[1-(1-metil-1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
227	1-[1-(5-bromo-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
228	1-[1-(4-metanosulfonil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
229	1-[1-(1-metil-1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
230	1-[1-(5-bromo-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
231	1-[1-(6-cloro-imidazo[2,1-b]tiazol-5-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
232	1-[1-(4-etil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
233	1-[1-(benzo[b]tiofeno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
234	1-[1-(6-cloro-imidazo[2,1-b]tiazol-5-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
235	1-[1-(4-etil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
236	1-[1-(benzo[b]tiofeno-3-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
237	6-cloro-1-[1-(6-cloro-imidazo[2,1-b]tiazol-5-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
238	6-cloro-1-[1-(4-etil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
239	1-[1-(benzo[b]tiofeno-3-sulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
240	1-[1-(6-cloro-imidazo[2,1-b]tiazol-5-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
241	1-[1-(4-etil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
242	1-[1-(benzo[b]tiofeno-3-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

243	1-[1-(7-cloro-benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
244	1-[1-(2-metoxi-4-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
245	Éster metílico del ácido 3-{4-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-fenil}-propiónico
246	1-[1-(2,4-dinitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
247	1-[1-(7-cloro-benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
248	1-[1-(2-metoxi-4-metil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
249	Éster metílico del ácido 3-{4-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-fenil}-propiónico
250	1-[1-(2,4-dinitro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
251	1-[1-(7-cloro-benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
252	1-[1-(2-metoxi-4-metil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
253	Éster metílico del ácido 3-{4-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-fenil}-propiónico
254	1-[1-(2,4-dinitro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
255	6-cloro-1-[1-(7-cloro-benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
256	6-cloro-1-[1-(2-metoxi-4-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
257	Éster metílico del ácido 3-{4-[4-(6-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-fenil}-propiónico
258	6-cloro-1-[1-(2,4-dinitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
259	6-cloro-1-[1-(1-metil-1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
260	1-[1-(5-bromo-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
261	8-metil-1-[1-(1-metil-1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
262	1-[1-(5-bromo-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
263	1-[1-(benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
264	1-[1-(benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
265	1-[1-(benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
266	1-[1-(benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
267	1-[1-(2,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
268	1-[1-(2,5-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

269	6-cloro-1-[1-(2,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
270	1-[1-(2,5-difluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
271	1-[1-(4-cloro-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
272	1-[1-(4-cloro-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
273	6-cloro-1-[1-(4-cloro-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
274	1-[1-(4-cloro-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
275	1-[1-(2,4,5-trifluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
276	8-metil-1-[1-(2,4,5-trifluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
277	6-cloro-1-[1-(2,4,5-trifluoro-bencenosulfonil]-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
278	6-metil-1-[1-(2,4,5-trifluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
279	1-[1-(3,5-dicloro-2-hidroxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
280	1-[1-(2,6-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
281	1-[1-(2,6-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
282	6-cloro-1-[1-(2,6-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
283	1-[1-(2,6-difluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
284	1-[1-(5-cloro-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
285	1-[1-(5-cloro-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
286	6-cloro-1-[1-(5-cloro-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
287	1-[1-(5-cloro-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
288	1-[1-(2-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
289	1-[1-(2-cloro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
290	6-cloro-1-[1-(2-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
291	1-[1-(2-cloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
292	6-cloro-1-[1-(2-naftalen-1-il-etanosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
293	6-bromo-1-[1-(4-bromo-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
294	6-bromo-1-[1-(tolueno-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

295	6-bromo-1-[1-(2,4-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
296	6-bromo-1-[1-(2-naftalen-1-il-etanosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
297	6-bromo-1-[1-(quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
298	6-bromo-1-[1-(5-cloro-3-metil-benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
299	6-bromo-1-[1-(3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
300	6-bromo-1-[1-(naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
301	6-bromo-1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
302	1-(1-bencenosulfonil-piperidin-4-il)-6-bromo-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
303	6-bromo-1-{1-[4-(4-bromo-fenoxi)-bencenosulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
304	6-bromo-1-[1-(tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
305	6-bromo-1-[1-(2-metil-5-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
306	6-bromo-1-[1-(4-bromo-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
307	6-bromo-1-[1-(tolueno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
308	6-bromo-1-[1-(5-fluoro-2-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
309	6-bromo-1-[1-(4-isopropoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
310	6-bromo-1-[1-(3-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
311	6-bromo-1-[1-(3,4-dimetoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
312	6-bromo-1-(1-pentafluorobencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
313	6-bromo-1-[1-(4-cloro-2,5-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
314	6-bromo-1-[1-(3-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
315	6-bromo-1-[1-(4-isopropil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
316	6-bromo-1-[1-(4-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
317	6-bromo-1-[1-(3-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
318	6-bromo-1-(1-pentametilbencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
319	6-bromo-1-[1-(2-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
320	6-bromo-1-[1-(4-cloro-3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

321	6-bromo-1-[1-(5-dimetilamino-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
322	6-bromo-1-[1-(4-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
323	1-[1-(4-acetil-bencenosulfonil)-piperidin-4-il]-6-bromo-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
324	6-bromo-1-[1-(4-metanosulfonil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
325	1-[1-(bifenil-4-sulfonil)-piperidin-4-il]-6-bromo-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
326	6-bromo-1-(1-fenilmetanosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
327	6-bromo-1-[1-(2,5-dimetoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
328	6-bromo-1-{1-[2-(2,2,2-trifluoro-acetil)-1,2,3,4-tetrahidro-isoquinolina-7-sulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
329	6-bromo-1-[1-(2,3-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
330	6-bromo-1-[1-(2,4,5-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
331	6-bromo-1-[1-(5-bromo-2-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
332	6-bromo-1-[1-(4-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
333	6-bromo-1-[1-(2-nitro-4-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
334	6-bromo-1-[1-(3-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
335	6-bromo-1-[1-(2,4-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
336	6-bromo-1-[1-(2,4,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
337	6-bromo-1-[1-(2-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
338	6-bromo-1-[1-(2-bromo-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
339	6-bromo-1-[1-(4-metoxi-2,3,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
340	1-[1-(3,5-dicloro-4-hidroxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
341	1-[1-(3,5-dicloro-4-hidroxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
342	6-cloro-1-[1-(3,5-dicloro-4-hidroxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
343	1-[1-(3,5-dicloro-4-hidroxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
344	6-bromo-1-[1-(3,5-dicloro-4-hidroxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
345	6-cloro-1-[1-(3,5-dicloro-2-hidroxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
346	6-bromo-1-[1-(3,5-dicloro-2-hidroxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

347	2-[4-(6-bromo-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo
348	6-bromo-1-[1-(4-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
349	Éster metílico del ácido 2-[4-(6-bromo-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
350	6-bromo-1-[1-(3-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
351	6-bromo-1-[1-(2-oxo-2H-cromeno-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
352	6-bromo-1-[1-(3,5-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
353	6-bromo-1-[1-(2,5-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
354	6-bromo-1-[1-(5-bromo-6-cloro-piridina-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
355	6-bromo-1-[1-(4-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
356	6-bromo-1-[1-(2,6-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
357	6-bromo-1-[1-(1-metil-1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
358	6-bromo-1-[1-(5-bromo-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
359	6-bromo-1-[1-(4-etil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
360	6-bromo-1-[1-(6-cloro-imidazo[2,1-b]tiazol-5-sulfonil)-piperedin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
361	1-[1-(benzo[b]tiofeno-3-sulfonil)-piperidin-4-il]-6-bromo-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
362	6-bromo-1-[1-(7-cloro-benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
363	6-bromo-1-[1-(2-metoxi-4-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
364	Éster metílico del ácido 3-{4-[4-(6-bromo-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-fenil}-propiónico
365	6-bromo-1-[1-(2,4-dinitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
366	1-[1-(benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-6-bromo-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
367	6-bromo-1-[1-(2,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
368	6-bromo-1-[1-(4-cloro-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
369	6-bromo-1-[1-(2,4,5-trifluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
370	6-bromo-1-[1-(2,6-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
371	6-bromo-1-[1-(5-cloro-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
372	6-bromo-1-[1-(2-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

373	6-bromo-1-[1-(2,3,4-trifluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
374	N-{4-[4-(6-bromo-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-2-cloro-fenil}-acetamida
375	1-[1-(2,3,4-trifluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
376	8-metil-1-[1-(2,3,4-trifluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
377	6-cloro-1-[1-(2,3,4-trifluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
378	6-metil-1-[1-(2,3,4-trifluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
379	N-{2-cloro-4-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-fenil}-acetamida
380	1-[1-(3,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
381	1-[1-(3,4-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
382	6-cloro-1-[1-(3,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
383	1-[1-(3,4-difluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
384	6-bromo-1-[1-(3,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
385	N-{2-cloro-4-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-fenil}-acetamida
386	1-[1-(2-cloro-4,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
387	1-[1-(2-cloro-4,5-difluoro-bencenosulfonil]-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
388	6-cloro-1-[1-(2-cloro-4,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
389	1-[1-(2-cloro-4,5-difluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
390	6-bromo-1-[1-(2-cloro-4,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
391	N-{2-cloro-4-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-fenil}-acetamida
392	1-[1-(benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
393	1-[1-(benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
394	1-[1-(benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
395	1-[1-(benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
396	1-[1-(benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-6-bromo-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
397	N-{2-cloro-4-[4-(6-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-fenil}-acetamida
398	1-[1-(benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

399	1-[1-(benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
400	1-[1-(benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
401	1-[1-(benzo[1,2,5]tiadiazol-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
402	1-[1-(benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-6-bromo-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
403	1-(1-etanosulfonil-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
404	1-[1-(2,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
405	1-[1-(2,4-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
406	6-cloro-1-[1-(2,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
407	1-[1-(2,4-difluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
408	6-bromo-1-[1-(2,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
409	8-metil-1-[propano-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
410	1-[1-(3,4-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
411	1-[1-(3,4-dicloro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
412	6-cloro-1-[1-(3,4-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
413	1-[1-(3,4-dicloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
414	6-bromo-1-[1-(3,4-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
415	8-metil-1-[1-(propano-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
416	1-[1-(2-cloro-6-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
417	1-[1-(2-cloro-6-metil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
418	6-cloro-1-[1-(2-cloro-6-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
419	1-[1-(2-cloro-6-metil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
420	1-[1-(2-cloro-6-metil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
421	8-metil-1-[1-(2,3,5,6-tetrametil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
422	1-[1-2,3,4-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
423	8-metil-1-[1-(2,3,4-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
424	6-cloro-1-[1-(2,3,4-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
425	6-metil-1-[1-(2,3,4-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

426	6-bromo-1-[1-(2,3,4-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
427	1-[1-(2,3,5,6-tetrametil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
428	1-[1-(tiofeno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
429	8-metil-1-[1-(tiofeno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
430	6-cloro-1-[1-(tiofeno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
431	6-metil-1-[1-(tiofeno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
432	6-bromo-1-[1-(tiofeno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
433	6-cloro-1-[1-(2,3,5,6-tetrametil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
434	1-[1-(2,4,6-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
435	8-metil-1-[1-(2,4,6-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
436	6-cloro-1-[1-(2,4,6-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
437	6-metil-1-[1-(2,4,6-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
438	6-bromo-1-[1-(2,4,6-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
439	6-metil-1-[1-(2,3,5,6-tetrametil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
440	1-[1-(2-bromo-4,6-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
441	1-[1-(2-bromo-4,6-difluoro-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
442	1-[1-(2-bromo-4,6-difluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
443	6-bromo-1-[1-(2-bromo-4,6-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
444	6-bromo-1-[1-(2,3,5,6-tetrametil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
445	1-[1-(4-bromo-2-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
446	1-[1-(4-bromo-2-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
447	1-[1-(4-bromo-2-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
448	1-[1-(4-bromo-2-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
449	6-bromo-1-[1-(4-bromo-2-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
450	1-[1-(4-fenoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
451	1-[1-(3-bromo-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
452	1-[1-(3-bromo-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-

	benzo[d][1,3]oxacin-2-ona
453	1-[1-(3-bromo-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
454	1-[1-(3-bromo-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
455	6-bromo-1-[1-[3-bromo-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
456	8-metil-1-[1-(4-fenoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
457	1-[1-(4-terc-butil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
458	1-[1-(4-terc-butil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
459	1-[1-(4-terc-butil-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
460	1-[1-(4-terc-butil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
461	6-bromo-1-[1-(4-terc-butil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
462	6-cloro-1-[1-(4-fenoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
463	1-[1-(2-bromo-4,6-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
464	1-[1-(2-metanosulfonil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
465	6-cloro-1-[1-(2-metanosulfonil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
466	1-[1-(2-metanosulfonil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
467	6-bromo-1-[1-(2-metanosulfonil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
468	8-metil-1-[1-(4-propil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
469	6-cloro-1-[1-(4-propil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
470	6-metil-1-[1-(4-propil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
471	6-bromo-1-[1-(4-propil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
472	1-[1-(3-cloro-2-metil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
473	6-cloro-1-[1-(3-cloro-2-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
474	1-[1-[3-cloro-2-metil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
475	6-bromo-1-[1-(3-cloro-2-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
476	1-[1-(4-butil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
477	1-[1-(4-butil-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
478	1-[1-(4-butil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-

	benzo[d][1,3]oxacin-2-ona
479	6-bromo-1-[1-(4-butil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
480	1-[1-(4-bromo-3-metil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
481	1-[1-(4-bromo-3-metil-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
482	1-[1-(4-bromo-3-metil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
483	6-bromo-1-[1-(4-bromo-3-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
484	1-{1-[4-(1,1-dimetil-propil)-bencenosulfonil]-piperidin-4-il}-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
485	6-cloro-1-{1-[4-(1,1-dimetil-propil)-bencenosulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
486	1-{1-[4-(1,1-dimetil-propil)-bencenosulfonil]-piperidin-4-il}-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
487	6-bromo-1-{1-[4-(1,1-dimetil-propil)-bencenosulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
488	1-(1-etanosulfonil-piperidin-4-il)-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
489	Ácido 3-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il]-piperina-1-sulfonil]-benzoico
490	Ácido 3-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il]-piperina-1-sulfonil]-benzoico
491	Ácido 3-[4-(6-bromo-2-oxo-4H-benzo[d][1,3]oxacin-1-il]-piperina-1-sulfonil]-benzoico
492	1-[1-(3-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
493	6-cloro-1-[1-(3-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
494	1-[1-(3-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
495	6-bromo-1-[1-(3-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
496	N-(4-metil-5-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-tiazol-2-il)-acetamida
497	N-(5-[4-(6-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-4-metil-tiazol-2-il)-acetamida
498	N-(4-metil-5-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-tiazol-2-il)-acetamida
499	N-(5-[4-(6-bromo-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-4-metil-tiazol-2-il)-acetamida
500	1-[1-(2-bromo-4-fluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
501	1-[1-(2-bromo-4-fluoro-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
502	1-[1-(2-bromo-4-fluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
503	6-bromo-1-[1-(2-bromo-4-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
504	1-[1-5-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

505	6-cloro-1-[1-(5-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
506	1-[1-(5-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
507	6-bromo-1-[1-(5-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
508	1-[1-(4-bromo-3-trifluorometil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
509	1-[1-(4-bromo-3-trifluorometil-bencenosulfonil)-piperidin-4-il]-8-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
510	1-[1-(4-bromo-3-trifluorometil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
511	6-bromo-1-[1-(4-bromo-3-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
512	1-[1-(2-metanosulfonil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
513	1-[1-(4-propil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
514	1-[1-(3-cloro-2-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
515	1-[1-(4-butil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
516	1-[1-(4-bromo-3-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
517	1-{1-[4-(1,1-dimetil-propil)-bencenosulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
518	N-{4-metil-5-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-tiazol-2-il}-acetamida
519	1-[1-(3-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
520	1-[1-(2-bromo-4-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
521	1-[1-(4-bromo-3-trifluorometil-bencenosulfonil]-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
522	1-[1-(5-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
523	1-[1-(isoquinolina-5-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
524	6-fluoro-1-[1-(2-metanosulfonil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
525	6-fluoro-1-[1-(4-propil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
526	1-[1-(3-cloro-2-metil-bencenosulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
527	1-[1-(4-butil-bencenosulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
528	1-[1-(4-bromo-3-metil-bencenosulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
529	1-{1-[4-(1,1-dimetil-propil)-bencenosulfonil]-piperidin-4-il}-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
530	N-{5-[4-(6-fluoro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-4-metil-tiazol-2-il}-acetamida
531	1-[1-(3-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

532	1-[1-(2-bromo-4-fluoro-bencenosulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
533	1-[1-(4-bromo-3-trifluorometil-bencenosulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
534	1-[1-(5-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
535	6-fluoro-1-[1-(isoquinolina-5-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
536	6-fluoro-1-[1-(quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
537	1-[1-(5-cloro-3-metil-benzo[b]tiofeno-2-sulfonil]-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
538	6-fluoro-1-[1-(naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
539	6-fluoro-1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
540	1-[1-(benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
541	1-[1-(benzo[b]tiofeno-3-sulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
542	8-metoxi-1-[1-(quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
543	1-[1-(5-cloro-3-metil-benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
544	8-metoxi-1-[1-(naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
545	8-metoxi-1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
546	1-[1-(benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
547	1-[1-(benzo[b]tiofeno-3-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
548	5-cloro-1-[1-(2-metanosulfonil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
549	5-cloro-1-[1-(4-propil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
550	5-cloro-1-[1-(3-cloro-2-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
551	1-[1-(4-butil-bencenosulfonil)-piperidin-4-il]-5-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
552	1-[1-(4-bromo-3-metil-bencenosulfonil)-piperidin-4-il]-5-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
553	5-cloro-1-{1-[4-(1,1-dimetil-propil)-bencenosulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
554	N-{5-[4-(5-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-4-metil-tiazol-2-il}-acetamida
555	5-cloro-1-[1-(3-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
556	1-[1-(2-bromo-4-fluoro-bencenosulfonil)-piperidin-4-il]-5-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
557	1-[1-(4-bromo-3-trifluorometil-bencenosulfonil)-piperidin-4-il]-5-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

558	5-cloro-1-[1-(5-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
559	5-cloro-1-[1-(isoquinolina-5-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
560	1-[1-(2-metanosulfonil-bencenosulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
561	1-[1-(2-metanosulfonil-bencenosulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
562	1-[1-(3-cloro-2-metil-bencenosulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
563	1-[1-(4-butil-bencenosulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
564	1-[1-(4-bromo-3-metil-bencenosulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
565	1-{1-[4-(1,1-dimetil-propil)-bencenosulfonil]-piperidin-4-il}-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
566	N-{5-[4-(8-metoxi-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-4-metil-tiazol-2-il}-acetamida
567	1-[1-(3-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
568	1-[1-(2-bromo-4-fluoro-bencenosulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
569	1-[1-(4-bromo-3-trifluorometil-bencenosulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
570	1-[1-(5-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
571	Clorhidrato de 1-[1-(isoquinolina-5-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
572	1-[1-(4-metil-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
573	6-cloro-1-[1-(4-metil-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
574	6-metil-1-[1-(4-metil-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
575	8-metil-1-[1-(4-metil-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
576	6-fluoro-1-[1-(4-metil-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
577	8-metoxi-1-[1-(4-metil-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
578	5-cloro-1-[1-(4-metil-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
579	5-cloro-1-[1-(naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
580	5-cloro-1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
581	5-cloro-1-[1-(quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
582	5-cloro-1-[1-(5-cloro-3-metil-benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
583	1-[1-(benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-5-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

584	1-[1-(benzo[b]tiofeno-3-sulfonil)-piperidin-4-il]-5-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
585	6-bromo-1-[1-(4-metil-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
586	Ácido 2-cloro-4-fluoro-5-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
587	Ácido 2-cloro-5-[4-(6-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-4-fluoro-benzoico
588	Ácido 2-cloro-4-fluoro-5-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
589	Ácido 2-cloro-4-fluoro-5-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
590	Ácido 2-cloro-4-fluoro-5-[4-(8-metoxi-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
591	Ácido 2-cloro-5-[4-(5-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-4-fluoro-benzoico
592	Ácido 3-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
593	Ácido 3-[4-(8-metoxi-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
594	Ácido 3-[4-(5-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
595	Clorhidrato de 1-[1-(isoquinolina-5-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
596	Clorhidrato de 6-cloro-1-[1-(isoquinolina-5-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
597	Clorhidrato de [1-(isoquinolina-5-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
598	6,7-difluoro-1-[1-(quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
599	1-[1-(5-cloro-3-metil-benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
600	6,7-difluoro-1-[1-(naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
601	6,7-difluoro-1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
602	1-[1-[benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
603	1-[1-[benzo[b]tiofeno-3-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
604	1-[1-(5-dimetilamino-naftaleno-1-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
605	1-[1-(bifenil-4-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
606	1-[1-(benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
607	1-[1-(benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
608	1-[1-(7-cloro-benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
609	6,7-difluoro-1-[1-(4-metil-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
610	1-[1-(4-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-

	ona
611	1-[1-(4-fluoro-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
612	1-[1-(dibenzofuran-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
613	1-[1-(2,3-dihidro-benzofuran-5-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
614	1-[1-(bifenil-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
615	1-[1-(5-isoxazol-5-il-tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
616	1-[1-(4-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
617	1-[1-(4-fluoro-naftaleno-1-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
618	1-[1-(dibenzofuran-2-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
619	1-[1-(2,3-dihidro-benzofuran-5-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
620	1-[1-(bifenil-2-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
621	1-[1-(5-isoxazol-5-il-tiofeno-2-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
622	5-cloro-1-[1-(4-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
623	5-cloro-1-[1-(4-fluoro-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
624	5-cloro-1-[1-(dibenzofuran-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
625	5-cloro-1-[1-(2,3-dihidro-benzofuran-5-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
626	1-[1-(bifenil-2-sulfonil)-piperidin-4-il]-5-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
627	5-cloro-1-[1-(5-isoxazol-5-il-tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
628	1-[1-(4-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
629	1-[1-(4-fluoro-naftaleno-1-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
630	1-[1-(dibenzofuran-2-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
631	1-[1-(2,3-dihidro-benzofuran-5-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
632	1-[1-(bifenil-2-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
633	1-[1-(5-isoxazol-5-il-tiofeno-2-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
634	6-cloro-1-[1-(4-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
635	6-cloro-1-[1-(4-fluoro-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
636	6-cloro-1-[1-(dibenzofuran-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

637	6-cloro-1-[1-(2,3-dihidro-benzofuran-5-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
638	1-[1-bifenil-2-sulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
639	6-cloro-1-[1-(5-isoxazol-5-il-tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
640	1-[1-(4-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
641	1-[1-(4-fluoro-naftaleno-1-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
642	1-[1-(dibenzofuran-2-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
643	1-[1-(2,3-dihidro-benzofuran-5-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
644	1-[1-(bifenil-2-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
645	1-[1-(5-isoxazol-5-il-tiofeno-2-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
646	1-[1-(4-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
647	6,7-difluoro-1-[1-(4-fluoro-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
648	1-[1-(dibenzofuran-2-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
649	1-[1-(2,3-dihidro-benzofuran-5-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
650	1-[1-(bifenil-2-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
651	6,7-difluoro-1-[1-(5-isoxazol-5-il-tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
652	1-[1-(1,2-dimetil-1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
653	1-[1-(5-metil-benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
654	1-[1-(3,5-dimetil-isoxazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
655	1-[1-(1,2-dimetil-1H-imidazol-4-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
656	8-metil-1-[1-(5-metil-benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
657	1-[1-(3,5-dimetil-isoxazol-4-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
658	6-cloro-1-[1-(1,2-dimetil-1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
659	6-cloro-1-[1-(5-metil-benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
660	6-cloro-1-[1-(3,5-dimetil-isoxazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
661	1-[1-(1,2-dimetil-1H-imidazol-4-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
662	8-metoxi-1-[1-(5-metil-benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
663	1-[1-(3,5-dimetil-isoxazol-4-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-

	benzo[d][1,3]oxacin-2-ona
664	5-cloro-1-[1-(1,2-dimetil-1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
665	5-cloro-1-[1-(5-metil-benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
666	5-cloro-1-[1-(3,5-dimetil-isoxazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
667	1-[1-(1,2-dimetil-1H-imidazol-4-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
668	6-metil-1-[1-(5-metil-benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
669	1-[1-(3,5-dimetil-isoxazol-4-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
670	1-[1-(1,2-dimetil-1H-imidazol-sulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
671	6-fluoro-1-[1-(5-metil-benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
672	1-[1-(3,5-dimetil-isoxazol-4-sulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
673	1-[1-(1,2-dimetil-1H-imidazol-4-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
674	6,7-difluoro-1-[1-(5-metil-benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
675	1-[1-(3,5-dimetil-isoxazol-4-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
676	1-[1-(5-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
677	1-[1-(5-cloro-naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
678	N-{5-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-naftalen-1-il}-acetamida
679	1-[1-(5-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
680	1-[1-(5-cloro-naftaleno-2-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
681	N-{5-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-naftalen-1-il}-acetamida
682	5-cloro-1-[1-(5-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
683	5-cloro-1-[1-(5-cloro-naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
684	N-{5-[4-(5-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-naftalen-1-il}-acetamida
685	1-[1-(5-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
686	1-[1-(5-cloro-naftaleno-2-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
687	N-{5-[4-(8-metoxi-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-naftalen-1-il}-acetamida
688	Éster metílico del ácido 2,5-dimetil-4-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-furan-3-carboxílico
689	8-metil-1-[1-(2-oxo-2,3-dihidro-benzotiazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-

	benzo[d][1,3]oxacin-2-ona
690	1-[1-(4-fluoro-3-metil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
691	8-metil-1-[1-(2-oxo-2,3-dihidro-benzooxazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
692	1-[1-(4-ciclohexil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
693	Éster metílico del ácido 2,5-dimetil-4-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-furan-3-carboxílico
694	1-[1-(4-fluoro-3-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
695	1-[1-(2-oxo-2,3-dihidro-benzooxazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
696	1-[1-(4-ciclohexil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
697	Ácido 2-fluoro-5-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
698	Ácido 2-fluoro-5-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
699	1-[1-(2-oxo-2,3-dihidro-benzotiazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
700	1-[1-(5-piridin-2-il-tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
701	3-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo
702	Éster metílico del ácido 3-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-tiofeno-2-carboxílico
703	1-{5-[4-(2-oxo-4H-benzo[d](1,3]oxacin-1-il)-piperidina-1-sulfonil]-naftalen-1-il}-pirrolidin-2,5-diona
704	1-[1-(2-cloro-5-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
705	1-[1-(3,4-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
706	8-metil-1-[1-(5-piridin-2-il-tiofeno-2-sulfonil)-piperidin-4-il]1,4-dihidro-benzo[d][1,3]oxacin-2-ona
707	3-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo
708	Éster metílico del ácido 3-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-tiofeno-2-carboxílico
709	1-{5-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-naftalen-1-il}-pirrolidin-2,5-diona
710	1-[1-(2-cloro-5-trifluorometil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
711	1-[1-(3,4-dimetil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
712	5-cloro-1-[1-(5-piridin-2-il-tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
713	3-[4-(5-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo
714	Éster metílico del ácido 3-[4-(5-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-tiofeno-2-carboxílico
715	1-{5-[4-(5-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-naftalen-1-il}-pirrolidin-2,5-diona
716	5-cloro-1-[1-(2-cloro-5-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-

	benzo[d][1,3]oxacin-2-ona
717	5-cloro-1-[1-(3,4-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
718	6-metil-1-[1-(5-piridin-2-il-tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
719	3-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo
720	Éster metílico del ácido 3-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-tiofeno-2-carboxílico
721	1-{5-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-naftalen-1-il}-pirrolidin-2,5-diona
722	1-[1-(2-cloro-5-trifluorometil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
723	1-[1-(3,4-dimetil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
723	6-cloro-1-[1-(5-piridin-2-il-tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
725	3-[4-(6-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo
726	Éster metílico del ácido 3-[4-(6-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-tiofeno-2-carboxílico
727	1-{5-[4-(6-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-naftalen-1-il}-pirrolidin-2,5-diona
728	6-cloro-1-[1-(2-cloro-5-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
729	6-cloro-1-[1-(3,4-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
730	1-[1-(5-metil-isoxazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
731	1-[1-(2,2-dimetil-croman-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
732	1-[1-(4-metil-3,4-dihidro-2H-benzo[1,4]oxacin-7-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
733	1-[1-(2,3-dihidro-benzo[1,4]dioxina-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
734	1-[1-(1,3,5-trimetil-1H-pirazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
735	1-[1-(3-metil-2-oxo-2,3-dihidro-benzooxazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
736	8-metil-1-[1-(5-metil-isoxazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
737	1-[1-(2,2-dimetil-croman-6-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
738	8-metil-1-[1-(4-metil-3,4-dihidro-2H-benzo[1,4]oxacina-7-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
739	1-[1-(2,3-dihidro-benzo[1,4]dioxina-6-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
740	8-metil-1-[1-(1,3,5-trimetil-1H-pirazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
741	8-metil-1-[1-(3-metil-2-oxo-2,3-dihidro-benzooxazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
742	8-metoxi-1-[1-(1,3,5-trimetil-1H-pirazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona


743	8-metoxi-1-[1-(3-metil-2-oxo-2,3-dihidro-benzooxazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
744	1-[1-(benzo[d]isoxazol-3-il-metanosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
745	1-[1-(2,2,4,6,7-pentametil-2,3-dihidro-benzofuran-5-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
746	6-metil-5-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-1H-pirimidin-2,4-diona
747	1-[1-(3-metil-quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
748	1-[1-(2,2,5,7,8-pentametil-croman-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
749	1,4-dimetil-6-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-1,4-dihidro-quinoxalina-2,3-diona
750	1-[1-(1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
751	1-[1-(2-oxo-1,2,3,4-tetrahidro-quinolina-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
752	7-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-1,5-dihidro-benzo[b][1,4]diacepin-2,4-diona
753	8-metil-1-[1-(3-metil-quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
754	6-cloro-1-[1-(3-metil-quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
755	5-cloro-1-[1-(3-metil-quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
756	8-metoxi-1-[1-(3-metil-quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
757	1-[1-(piridina-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
758	1-[1-(6,7-dihidroxi-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
759	Éster 3-acetoxi-5-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-naftalen-2-ílico del ácido acético
760	1-[1-(1H-benzoimidazol-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
761	1-[1-(1H-benzoimidazol-2-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
762	1-[1-(1H-benzoimidazol-2-sulfonil)-piperidin-4-il]-5-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
763	1-[1-(2,5-dimetoxi-bencenosulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
764	1-[1-(2,5-dimetoxi-bencenosulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
765	1-[1-(2,5-dimetoxi-bencenosulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
766	5-cloro-1-[1-(2,5-dimetoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
767	1-[1-(5-dimetilamino-naftaleno-1-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
768	5-cloro-1-[1-(5-dimetilamino-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
769	6-cloro-1-[1-(5-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

770	1-[1-(5-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
771	1-[1-(5-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
772	6-cloro-1-[1-(5-cloro-naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
773	1-[1-(5-cloro-naftaleno-2-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
774	1-[1-(5-cloro-naftaleno-2-sulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
775	6-metil-1-[1-(3-metil-quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
776	6-fluoro-1-[1-(3-metil-quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
777	6,7-difluoro-1-[1-(3-metil-quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
778	6-cloro-1-[1-(3-metil-2-oxo-2,3-dihidro-benzooxazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
779	6-metil-1-[1-(3-metil-2-oxo-2,3-dihidro-benzooxazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
780	6-fluoro-1-[1-(3-metil-2-oxo-2,3-dihidro-benzooxazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
781	6,7-difluoro-1-[1-(3-metil-2-oxo-2,3-dihidro-benzooxazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
782	5-cloro-1-[1-(3-metil-2-oxo-2,3-dihidro-benzooxazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
783	6-cloro-1-[1-(4-metil-3,4-dihidro-2H-benzo[1,4]oxacina-7-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
784	6-metil-1-[1-(4-metil-3,4-dihidro-2H-benzo[1,4]oxacina-7-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo il]oxacin-2-ona
785	6-fluoro-1-[1-(4-metil-3,4-dihidro-2H-benzo[1,4]oxacina-7-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo il]oxacin-2-ona
786	8-metoxi-1-[1-(4-metil-3,4-dihidro-2H-benzo[1,4]oxacina-7-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo il]oxacin-2-ona
787	5-cloro-1-[1-(4-metil-3,4-dihidro-2H-benzo[1,4]oxacina-7-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

Preferiblemente, puede excluirse el compuesto 1-[[(7,7-dimetil-2-oxobiciclo[2,2,1]hept-1-il)metil]sulfonil]-4-(2-oxo-2H-3,1-benzoxazin-1(4H)-il-piperidina. Más preferiblemente, pueden excluirse el compuesto 1-[[(7,7-dimetil-2-oxobiciclo[2,2,1]hept-1-il)metil]sulfonil]-4-(2-oxo-2H-3,1-benzoxazin-1(4H)-il-piperidina, las sales del mismo y los solvatos del mismo.


Los compuestos de fórmula general (Ib), sus estereoisómeros, las sales correspondientes y los solvatos correspondientes pueden obtenerse análogamente mediante los métodos descritos anteriormente para los compuestos de fórmula general (I). Para detalles del procedimiento, se hace referencia a la descripción dada anteriormente para los compuestos de fórmula general (I).

De este modo, en otro aspecto la presente invención se refiere al procedimiento para la preparación de compuestos de sulfonamidas derivados de la benzoxazinona de fórmula general (Ib) dada anteriormente, que comprende hacer reaccionar al menos un compuesto de piperidina de fórmula general (IIb), en la que R^{1b} a R^{9b} tienen la significación definida anteriormente y/o una sal, preferiblemente un sal de clorhidrato, de los mismos,



(IIb)

con al menos un compuesto de fórmula general (IIIb),



(IIIb)

en la que W^b tiene la significación definida anteriormente, en un medio de reacción adecuado, opcionalmente en presencia de al menos una base y/o al menos un agente auxiliar.

En un objeto más la presente invención se refiere al procedimiento para la preparación de una sal fisiológicamente aceptable de los compuestos de sulfonamidas derivados de la benzoxazinona de fórmula general (Ib) dada anteriormente o un estereoisómero correspondiente de los mismos, caracterizado porque se hace reaccionar al menos un compuesto de fórmula general (Ib) que tiene al menos un grupo básico con al menos un ácido, preferiblemente un ácido orgánico o inorgánico, preferiblemente en presencia de un medio de reacción adecuado.

En un objeto más la presente invención se refiere al procedimiento para la preparación de una sal fisiológicamente aceptable de los compuestos de sulfonamidas derivados de la benzoxazinona de fórmula general (Ib) dada anteriormente o un estereoisómero correspondiente de los mismos, caracterizado porque se hace reaccionar al menos un compuesto de fórmula general (Ib) que tiene al menos un grupo ácido con al menos una base, preferiblemente en presencia de un medio de reacción adecuado.

Aún en otro objeto la presente invención se refiere a una composición farmacéutica que comprende al menos un compuesto de sulfonamida derivado de la benzoxazinona de fórmula general (Ib) dada anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato, respectivamente, y opcionalmente uno o más adyuvantes farmacéuticamente aceptables.

Aún en otro objeto la presente invención proporciona un medicamento que comprende al menos un compuesto de sulfonamida derivado de la benzoxazinona de fórmula general (Ib) dada anteriormente, opcionalmente en forma de uno de sus

estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato, respectivamente, y opcionalmente uno o más adyuvantes farmacéuticamente aceptables.

El medicamento de la presente invención es adecuado para la profilaxis y/o el tratamiento de trastornos que son mediados al menos parcialmente mediante receptores 5-HT_6.

En particular, el medicamento de la presente invención es adecuado para la profilaxis y/o el tratamiento de trastornos relacionados con la ingestión de alimentos, preferiblemente para la regulación del apetito, para el mantenimiento, incremento o reducción del peso corporal, para la profilaxis y/o el tratamiento de la obesidad, para la profilaxis y/o el tratamiento de la bulimia, para la profilaxis y/o el tratamiento de la anorexia, para la profilaxis y/o el tratamiento de la caquexia, para la profilaxis y/o el tratamiento de la diabetes de tipo II (diabetes mellitus insulino independiente).

También en particular, el medicamento de la presente invención es adecuado para la profilaxis y/o el tratamiento de trastornos gastrointestinales, preferiblemente el síndrome del colon irritable; para la profilaxis y/o el tratamiento de trastornos del sistema nervioso central; para la profilaxis y/o el tratamiento de la ansiedad; para la profilaxis y/o el tratamiento de ataques de pánico; para la profilaxis y/o el tratamiento de la depresión; para la profilaxis y/o el tratamiento de trastornos bipolares; para la profilaxis y/o el tratamiento de trastornos cognitivos, preferiblemente trastornos de la memoria; para el desarrollo de la cognición (para mejora de la cognición); para la profilaxis y/o el tratamiento de la demencia senil; para la profilaxis y/o el tratamiento de la psicosis; para la profilaxis y/o el tratamiento de trastornos neurodegenerativos; preferiblemente seleccionados del grupo que consiste en la enfermedad de Alzheimer, enfermedad de Parkinson, enfermedad de Huntington y esclerosis múltiple; para la profilaxis y/o el tratamiento de la esquizofrenia o para la profilaxis y/o el tratamiento del trastorno de hiperactividad (ADHD, déficit de atención, trastorno de hiperactividad).

Otro objeto de la presente invención es el uso de al menos un compuesto de sulfonamida derivado de la benzoxazinona de fórmula general (Ib) dada anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un

solvato, respectivamente, para la preparación de un medicamento para la regulación del receptor 5-HT_6, en particular para la preparación de un medicamento para la profilaxis y/o el tratamiento de trastornos que están mediados al menos parcialmente mediante los receptores 5-HT_6.

Se prefiere el uso de al menos un compuesto de sulfonamida derivado de la benzoxazinona de fórmula general (Ib) dada anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato, respectivamente, para la preparación de un medicamento para la profilaxis y/o el tratamiento de trastornos relacionados con la ingestión de alimentos, preferiblemente para la regulación del apetito, para la reducción, incremento o mantenimiento del peso corporal; para la profilaxis y/o el tratamiento de la obesidad, para la profilaxis y/o el tratamiento de la bulimia, para la profilaxis y/o el tratamiento de la anorexia, para la profilaxis y/o el tratamiento de la caquexia, para la profilaxis y/o el tratamiento de la diabetes de tipo II.

También se prefiere el uso de al menos un compuesto de sulfonamida derivado de la benzoxazinona de fórmula general (Ib) dada anteriormente, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato, respectivamente, para la preparación de un medicamento para la profilaxis y/o el tratamiento de trastornos gastrointestinales, preferiblemente el síndrome del colon irritable; para la profilaxis y/o el tratamiento de trastornos del sistema nervioso central; para la profilaxis y/o el tratamiento de la ansiedad; para la profilaxis y/o el tratamiento de ataques de pánico; para la profilaxis y/o el tratamiento de la depresión; para la profilaxis y/o el tratamiento de trastornos bipolares; para la profilaxis y/o el tratamiento de trastornos cognitivos; preferiblemente trastornos de la memoria; para el desarrollo de la cognición (para mejora de la cognición); para la profilaxis y/o el tratamiento de la demencia senil; para la profilaxis y/o el tratamiento de la psicosis; para la profilaxis y/o el tratamiento de trastornos neurodegenerativos; preferiblemente seleccionados del grupo que consiste en la enfermedad de Alzheimer, enfermedad de Parkinson, enfermedad de Huntington y esclerosis múltiple; para la profilaxis y/o el tratamiento de la esquizofrenia; o para la

profilaxis y/o el tratamiento del trastorno de hiperactividad (ADHD, déficit de atención, trastorno de hiperactividad).

El medicamento según la presente invención puede estar en cualquier forma adecuada para su aplicación en humanos y/o animales, particularmente mamíferos, incluido en humanos, y puede fabricarse mediante procedimientos convencionales conocidos por aquellos expertos en la técnica. La composición del medicamento puede variar en función de la vía de administración.

La preparación de las composiciones farmacéuticas correspondientes así como de los medicamentos formulados puede llevarse a cabo mediante métodos convencionales conocidos por aquellos expertos en la técnica, por ejemplo a partir de los índices de "Pharmaceutics: The Science of Dosage Forms", segunda edición, Aulton, M.E. (Ed. Churchill Livingstone, Edimburgo (2002); "Encyclopedia of Pharmaceutical Technology", segunda edición, Swarbrick, J. y Boylan J.C. (Eds.), Marcel Dekker, Inc. Nueva York(2002); "Modern Pharmaceutics", cuarta edición, Banker G.S. y Rhodes C.T. (Eds.) Marcel Dekker, Inc. Nueva York 2002 y "The Theory and Practice of Industrial Pharmacy", Lachman L., Lieberman H. y Kanig J. (Eds.), Lea & Febiger, Filadelfia (1986). Las respectivas descripciones bibliográficas se incorporan como referencia y son parte de la descripción.

Las composiciones farmacéuticas, así como los medicamentos formulados preparados según la presente invención, pueden comprender adicionalmente, además de al menos un compuesto de fórmula general (I), (Ia) o (Ib), opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o una sal fisiológicamente aceptable correspondiente o un solvato correspondiente, otras sustancias auxiliares convencionales conocidas por aquellos expertos en la técnica, tales como excipientes, cargas, disolventes, diluyentes, agentes colorantes, agentes de recubrimiento, agentes para formar una matriz y/o aglutinantes. Como también saben los expertos en la técnica, la elección de las sustancias auxiliares y las cantidades de las mismas dependen de la vía de administración prevista, por ejemplo vía oral, rectal, intravenosa, intraperitoneal, intramuscular, intranasal, bucal o tópica.

Medicamentos adecuados para administración oral son, por ejemplo, comprimidos, grageas, cápsulas o multiparticulados, como gránulos o microgránulos, sometidos opcionalmente a compresión en comprimidos, cargados en cápsulas o suspendidos en disoluciones, suspensiones o líquidos adecuados.

Medicamentos adecuados para administración parenteral, tópica o inhalada pueden seleccionarse preferiblemente del grupo que consiste en disoluciones, suspensiones, preparaciones anhidras de rápida reconstitución y también aerosoles.

Medicamentos adecuados, por ejemplo para uso oral o percutáneo pueden liberar los compuestos de fórmula general (I), (Ia) o (Ib) y/o en cada caso estereoisómeros de los mismos de forma retardada, generalmente se conoce la preparación de estos medicamentos de liberación retardada por aquellos expertos en la técnica.

Las formas adecuadas de liberación retardada, así como los materiales y métodos para su preparación, se conocen por aquellos expertos en la técnica, por ejemplo a partir de los índices de "Modified-Release Drug Delivery Technology", Rathbone, M.J. Hadgraft, J. y Roberts, M.S. (Eds.), Marcel Dekker, Inc., Nueva York (2002); "Handbook of Pharmaceutical Controlled Release Technology", Wise, D.L. (Ed.), Marcel Dekker, Inc. Nueva York, (2000); "Controlled Drug Delivery", Vol. 1, Basic Concepts, Bruck, S.D. (Ed.), CRD Press Inc., Boca Raton (1983) y de Takada, K. y Yoshikawa, H., "Oral Drug Delivery", Encyclopedia of Controlled Drug Delivery, Mathiowitz, E. (Ed.), John Wiley & Sons, Inc., Nueva York (1999), Vol. 2, 728-742; Fix, J., "Oral drug delivery, small intestine and colon", EncyclopeOia of Controlled Drug Delivery, Mathiowitz, E. (Ed.), John Wiley & Sons, Inc., Nueva York (1999), Vol. 2, 698-728. Las descripciones respectivas se incorporan por referencia y forman parte de la descripción.

El medicamento de la presente invención también puede tener al menos un recubrimiento entérico que se disuelve en función del pH. Debido a dicho recubrimiento, el medicamento puede pasar por el estómago sin disolverse y los compuestos de fórmula general (I), (Ia) o (Ib) se liberan sólo en el tracto intestinal. El recubrimiento entérico se disuelve preferiblemente a un pH de entre 5 y 7,5. También se conocen por aquellos expertos en la técnica los materiales y métodos adecuados para preparar recubrimientos entéricos.

Los compuestos de la presente invención también pueden administrarse por vía tópica o mediante supositorio.

Las composiciones mencionadas anteriormente incluyen preferiblemente de un 1 a un 60% en peso de uno o más compuestos de sulfonamidas derivados de benzoxazinona de fórmulas generales (I), (Ia) o (Ib), opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diastarómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros, en cualquier

razón de mezcla, o una sale fisiológicamente aceptable de los mismos, o un solvato, respectivamente, y de un 40 a un 99% en peso del(de los) vehículo(s) farmacéuticamente apropiado(s).

La dosis diaria para seres humanos y animales puede variar dependiendo de factores basados en las respectivas especies o en otros factores, tales como edad, sexo, peso o grado de enfermedad, etc. Normalmente, la dosis diaria para seres humanos oscila desde 1 hasta 2.000, preferiblemente de 1 a 1.500, más preferiblemente de 1 a 1.000 miligramos de sustancia que debe administrarse en una o varias ingestas.

Métodos Farmacéuticos

I) UNIÓN AL RECEPTOR DE LA SEROTONINA 5-HT$_6$

La membranas celulares de células HEK-293 que expresan el receptor recombinante humano 5HT$_6$ fueron suministradas por Receptor Biology. En dichas membranas la concentración de receptor es de 2,18 pmol/mg de proteína y la concentración de proteína es de 9,17 mg/ml. El protocolo experimental sigue el método de B. L. Roth et al. [B. L. Roth, S. C. Craigo, M. S. Choudhary, A. Uluer, F. J. Monsma, Y. Shen, H. Y. Meltzer, D. R. Sibley: Binding of Typical and Atypical Antipsychotic Agents to 5-Hydroxytryptamine-6 and Hydroxytryptamine-7 Receptors. *The Journal of Farmacology and Experimental Therapeutics*, 1994, 268, 1403] con las siguientes ligeras modificaciones. La parte respectiva de la descripción bibliográfica se incorpora aquí como referencia y forma parte de la descripción.

Se diluye la membrana comercial (dilución 1:40) con el tampón de unión: Tris-HCl 50 mM, $MgCl_2$ 10 mM, EDTA 0,5 mM (pH 7,4). El radioligando usado es [^{3}H]-LSD a una concentración de 2,7 nM con un volumen final de 200 µl se inicia la incubación añadiendo 100 µl de suspensión de membrana, (≈ 22,9 µg de proteína de membrana), y se prolonga durante 60 minutos a una temperatura de 37 ºC. Se finaliza la incubación por filtración rápida en un colector de células de Brandel a través de filtros de fibra de vidrio fabricados por Schleicher & Schuell GF 3362 tratados previamente con una disolución de polietilenimina al 0,5 %. Se lavan los filtros tres veces con tres mililitros de tampón Tris-HCl 50 mM, pH 7,4. Se transfieren los filtros a frascos y se añaden a cada frasco 5 ml de la mezcla de centelleo líquido Ecoscint H. Se deja que los viales alcancen el equilibrio durante varias horas antes del recuento con un contador de centelleo Wallac Winspectral 1414. Se determina la unión no específica

en presencia de serotonina 100 µM. Se realizan las pruebas por triplicado. Se calcularon las constantes de inhibición (K_i, nM) por un análisis de regresión no lineal usando el programa EBDA/LIGAND descrito en Munson y Rodbard, *Analytical Biochemistry*, 1980, 107, 220, que se incorpora aquí como referencia y forma parte de la descripción.

II.) MEDIDAS DE LA INGESTIÓN DE COMIDA (MODELO DE COMPORTAMIENTO):

Se usan ratas macho W (200-270 g) obtenidas de Harlan, S.A. Los animales se aclimataron a los alojamientos durante al menos 5 días antes de que se sometan a cualquier tratamiento. Durante este periodo los animales se alojan (en grupos de cinco) en jaulas traslúcidas, y se les da agua y comida a voluntad. Al menos 24 horas antes de que comience el tratamiento, los animales se adaptan a condiciones individuales de alojamiento.

Entonces, se determina el efecto agudo de los derivados de sulfonamida de fórmula (I) usados de manera inventiva sobre la ingesta de comida en ratas en ayunas según se indica a continuación:

Las ratas se mantienen en ayunas durante 23 horas en sus jaulas individuales. Después de este periodo, se trata a las ratas por vía oral o intraperitoneal con una dosis de una composición que comprende un derivado de sulfonamida de fórmula general (I) o una composición correspondiente (vehículo) sin dicho derivado de sulfonamida. Inmediatamente después de esto, se deja a la rata con alimentos pesados previamente y se mide la ingesta de comida acumulada después de 1, 2, 4 y 6 horas.

Este método de medida de la ingesta de comida se describe también en las publicaciones bibliográficas de Kask et al., *European Journal of Farmacology* 414 (2001), 215-224 y de Tumbull et al., *Diabetes*, Vol. 51, Agosto 2002. Las partes respectivas de las descripciones se incorporan aquí como referencia y forman parte de la descripción.

La presente invención se ilustra a continuación con la ayuda de ejemplos. Estas ilustraciones se dan solamente a modo de ejemplo y no limitan el espíritu general de la invención.


Ejemplos

Los compuestos intermedios de fórmulas generales (II) y (III) se prepararon por medio de métodos de química orgánica convencionales conocidos por aquellos expertos en la técnica. El siguiente ejemplo A muestra la preparación de un compuesto intermedio de fórmula general (II):

Ejemplo A

Síntesis de un compuesto intermedio de fórmula general (II)

Preparación de clorhidrato de 6-cloro-1-(piperidin-4-il)-1,4-dihidro-2H-3,1-benzoxazin-2-ona



a) 1-(terc-butiloxicarbonil)-4-[4-cloro-(2-hidroximetilfenilamino)]piperidina

Se calentó a la temperatura de reflujo una disolución de 1-(terc-butiloxicarbonil)-4-piperidina (20 g, 0,10 mol), alcohol 2-amino-5-clorobencílico (17,34 g, 0,11 mol) y ácido acético (14 ml, 0,22 mol) en tolueno anhidro (500 ml), con eliminación de agua mediante destilación azeotrópica con un Dean-Stark, durante 6 horas. Entonces, se enfrió la mezcla y se concentró a vacío hasta la mitad de volumen. Se añadió $NaBH_3CN$ (20 g, 0,32 mol) y THF anhidro (300 ml) a la disolución resultante. Entonces, se añadió ácido acético (10 ml, 0,17 mol) gota a gota durante una hora. Se agitó la reacción a temperatura ambiente durante 24 horas. Se concentró a vacío la mezcla se y se disolvió el residuo en acetato de etilo (750 ml), se lavó con una disolución saturada de $NaHCO_3$ (4 x 250 ml) y con una disolución saturada de NaCl (250 ml), se secó y evaporó hasta sequedad. Se purificó el residuo mediante cromatografía ultrarrápida eluyendo con una mezcla de acetato de etilo : éter de petróleo (1:3). Dé esta forma se obtuvo el producto deseado como un aceite (32,7 g, 96%).

^{1}H RMN ($CDCl_3$): 1,32 (d, *J* = 11,2 Hz, 2H), 1,41(s, 9H), 1,92 (d, *J* = 11,2 Hz, 2H), 2,92 (t, *J* = 12,0 Hz, 1H), 3,10 (s, 1H), 3,37 (m, 1H), 3,88 (d, *J* = 13,7 Hz, 2H), 4,49 (s, 2H), 4,75 (s, 1H), 6,52 (d, *J* = 8,6 Hz, 1H), 6,96 (s, 1H), 7,07 (d, *J* = 8,6 Hz, 1 H).

b) 1-(1-terc-butiloxicarbonil-4-piperidinil)-6-cloro-1,4-dihidro-2H-3,1-benzoxazin-2-ona

Se añadió N,N-diisopropiletilamina (DIEA) (43 ML 025 mol) y trifosgeno (8,65 g, 29,2 mmol) a una disolución de 1-(terc-butiloxicarbonil)-4-[(4-cloro-(2-hidroximetil)fenil-amino)]piperidina (27,0 g, 79 mmol) en THF anhidro (250 ml) enfriada a 0°C. Se agitó la reacción a 0°C durante 1 h y a temperatura ambiente durante 72 h. Se añadió etil éter y se enfrió la mezcla a 0°C durante 3 h y entonces se filtró el clorhidrato de DIEA. Se evaporó la disolución filtrada hasta sequedad y se disolvió el residuo en acetato de etilo (750 ml), se lavó con una disolución al 5% de ácido cítrico (2 x 500 ml), agua (250 ml) y disolución saturada de $NaHCO_3$ (2 x 500 ml). Se secó la disolución de acetato de etilo ($MgSO_4$), se filtró y se evaporó a presión reducida. Se llevó el residuo a ebullición con etil éter hasta que se disolvió todo el sólido y se enfrió durante la noche para dar el compuesto deseado en forma cristalina (28,9 g, 67%).

Punto de fusión: 177-179°C

^{1}H RMN ($CDCl_3$): 1,48 (s, 9H), 1,79 (d, J = 10,1 Hz, 1H), 2,54 (m, 2H), 2,78 (m, 2H), 3,96 (m, 1H), 4,28 (m, 2H), 5,02 (s, 2H), 6,98 (d, J = 8,7 Hz, 1H), 7,13 (d, J = 2,4 Hz, 1H), 7,28 (dd, J = 8,7 Hz, J = 2,4 Hz, 1H).

c) Clorhidrato de 6-cloro-1-(piperidin-4-il)-1,4-dihidro-2H-3,1-benzoxazin-2-ona

Se enfrió una disolución de 1-[(1-terc-butiloxicarbonil)-4-piperidinil]-6-cloro-1,4-dihidro-2H-3,1-benzoxazin-2-ona (24 g, 65 mmol) en acetato de etilo (500 ml) a 0°C. Entonces se añadió una disolución de cloruro de hidrógeno en etil éter 5 M (500 ml) y se agitó la mezcla resultante agitación a 0°C durante 4 horas. Se recogió el precipitado formado por filtración, se lavó con éter y se secó a vacío para dar el producto deseado como un sólido (16,95 g, 97%).

Punto de fusión: 254-257°C

^{1}H RMN (CD_3OD): 2,13 (d, J = 12,2 Hz, 2H), 2,88 (m, 2H), 3,20 (m, 2H), 3,53 (d, J = 12,8 Hz, 2H), 4,24 (m, 1H), 5,16 (s, 2H), 7,31 (m, 2H), 7,41 (dd, J = 8,8 Hz, J = 2,6 Hz, 1 H).

Se prepararon varios compuestos de 3,1-benzoxazin-2-ona sustituidos mediante sus respectivos alcoholes bencílicos sustituidos obtenidos por reducción de los correspondientes ácidos antranílicos sustituidos con hidruro de litio y aluminio y otros agentes reductores conocidos mediante métodos bien conocidos por aquellos expertos en la técnica (véase esquema 1), por ejemplo 6-metil-1-(piperidin-4-il)-1,4-dihidro-2H-3,1-benzoxazin-2-ona, 7-metil-1-(piperidin-4-il)-1,4-dihidro-2H-3,1-benzoxazin-2-ona, 8-metil-1-(piperidin-4-il)-1,4-dihidro-2H-3,1-benzoxazin-2-ona, 5-

metoxi-1-(piperidin-4-il)-1,4-dihidro-2H-3,1-benzoxazin-2-ona, 6-fluoro-1-(piperidin-4-il)-1,4-dihidro-2H-3,1-benzoxazin-2-ona, 8-metoxi-1-(piperidinil)-1,4-dihidro-2H-3,1-benzoxazin-2-ona, 5-metil-1-(piperidin-4-il)-1,4-dihidro-2H-3,1-benzoxazin-2-ona, 7-fluoro-1-(piperidin-4-il)-1,4-dihidro-2H-3,1-benzoxazin-2-ona, 5-fluoro-1-(piperidin-4-il)-1,4-dihidro-2H-3,1-benzoxazin-2-ona, 6-metoxi-1-(piperidinil)-1,4-dihidro-2H-3,1-benzoxazin-2-ona, 5-cloro-1-(piperidinil)-1,4-dihidro-2H-3,1-benzoxazin-2-ona, 7-cloro-1-(piperidinil)-1,4-dihidro-2H-3,1-benzoxazin-2-ona, 8-cloro-1-(piperidinil)-1,4-dihidro-2H-3,1-benzoxazin-2-ona, y otras. La reacción de los compuestos 5-metoxi-1-(piperidinil)-1,4-dihidro-2H-3,1-benzoxazin-2-ona, 8-metoxi-1-(piperidinil)-1,4-dihidro-2H-3,1-benzoxazin-2-ona y 6-metoxi-1-(piperidinil)-1,4-dihidro-2H-3,1-benzoxazin-2-ona respectivos según métodos convencionales, por ejemplo BBr_3 en un disolvente orgánico inerte da los compuestos 5-hidroxi-1-(piperidinil)-1,4-dihidro-2H-3,1-benzoxazin-2-ona, 8-hidroxi-1-(piperidinil)-1,4-dihidro-2H-3,1-benzoxazin-2-ona y 6-hidroxi-1-(piperidinil)-1,4-dihidro-2H-3,1-benzoxazin-2-ona respectivos. Se prepara la benzoxazin-2-ona sin sustituir, 1-(piperidin-4-il)-1,4-dihidro-2H-3,1-benzoxazin-2-ona, según el método descrito en J. Med. Chem. 1995, 38, 4634 y J. Med.Chem. 1998, 41,2146, que se incorporan aquí como referencia y forman parte de la descripción.

Se redujeron los ácidos antranílicos sustituidos por métodos convencionales conocidos por aquellos expertos en la técnica, por ejemplo mediante el uso de $LiAlH_4$ como agente reductor en THF anhidro y bajo atmósfera de un gas inerte, por ejemplo argón o nitrógeno. El procedimiento es muy eficaz y se obtienen en la mayoría de los casos los 2-aminobencilalcoholes respectivos con muy buenos rendimientos.


Método general para la reducción de ácidos antranílicos sustituidos:

En un matraz de tres bocas, equipado con un agitador mecánico y una entrada de gas nitrógeno, se introducen 100 ml de THF anhidro y 116,6 mmoles de $LiAlH_4$ y se enfría la suspensión resultante a 0°C. Después de la adición de 58,3 mmoles del ácido antranílico sustituido respectivo en 150 ml de THF anhidro, se calienta la mezcla de reacción hasta temperatura ambiente y se agita durante aproximadamente una hora. Enfriando la mezcla a 0°C se añade con precaución 4,7 ml de agua, 4,7 ml de NaOH al 15% y finalmente 14 ml de agua. Se filtra la suspensión resultante y se lava con acetato de etilo.

Se lava la fase orgánica con agua, se seca y se evapora el disolvente. En la mayoría de los casos puede utilizarse el producto resultante sin purificación adicional.

Ejemplo 5

Preparación de 1-[1-quinolin-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona



Se añaden 150 mg (0,66 mmol) de cloruro de quinolin-8-sulfonilo a una mezcla de clorhidrato de 1-(4-piperidinil)-1,4-dihidro-2H-3,1-benzoxazinona (161 mg, 0,60 mmol) y diisopropiletilamina (230 mg, 1,80 mmol) en diclorometano (10 ml) y se agitó la mezcla de reacción resultante durante la noche a temperatura ambiente. Entonces se lavó la mezcla de reacción con agua (3 x 15 ml) y se separó la fase orgánica, se secó y se evaporó hasta sequedad. Se obtuvo un sólido, que se recristalizó en etanol. Se obtuvieron 182 mg de 1-[1-quinolin-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona como un sólido blanco (rendimiento del 69%).





IR (cm^{-1}) KBr: 1712, 1337, 1291, 1205, 1162, 1144, 1034, 717, 583




^{1}H RMN (δ en ppm): 1,8 (d, *J* = 9,5 Hz, 2 H) 2,6 (qd, *J* = 12,6, 4,4 Hz, 2 H) 3,0 (td, *J* = 12,8, 2,5 Hz, 2H) 4,1(tt, *J* = 12,5, 3,8 Hz, 1H) 4,3 (ddd, *J* = 13,0, 2,3 Hz, 2H) 5,0 (s, 2 H) 7,1 (m, 3 H) 7,3 (m, 1H) 7,6 (dd, *J* = 8,4, 4,2 Hz, 1H) 7,6 (m, 1H) 8,1 (dd, *J* = 8,2, 1,3 Hz, 1H) 8,3 (dd, *J* = 8,3, 1,7 Hz, 1H) 8,5 (dd, *J* = 7,3, 1,5 Hz, 1H) 9,1 (dd, *J* = 4,2, 1,8 Hz, 1H) ($CDCl_3$-d).




Punto de fusión: 170-172°C.

Los compuestos según los ejemplos 1-4 y 6-10 facilitados en la siguiente tabla 1 así como los compuestos según las listas A y B facilitadas anteriormente se prepararon de forma análoga a los métodos descritos anteriormente.

Tabla I:

Ej 1	1-[1-(naftil-1-sulfonil)-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxazin-2-ona	
		1H-RMN: 1.8 (d, J=10.5 Hz, 2 H) 2.4 (m, 2 H) 2.7 (t, J=11.6 Hz, 2 H) 3.9 (m, 3 H) 5.1 (s, 2 H) 7.1 (m, 2 H) 7.2 (m, 2 H) 7.7 (m, 3 H) 8.1 (d, J=8.1 Hz, 1 H) 8.2 (d, J=7.8 Hz, 1 H) 8.3 (d, J=8.1 Hz, 1 H) 8.7 (d, J=8.3 Hz, 1 H) (DMSO-d6) IR (KBr) 1709, 1498, 1353, 1162, 1034, 770, 718, 579 Punto de fusión: 147-148°C
Ej 2	1-(1-fenilsulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxazin-2-ona	
		1H-RMN: 1.9 (dd, J=12.1, 2.1 Hz, 2 H) 2.4 (td, J=12.2, 2.4 Hz, 2 H) 2.7 (qd, J=12.6, 4.3 Hz, 2 H) 3.9 (tt, J=12.3, 3.9 Hz, 1 H) 4.0 (dt, J=11.9, 2.1 Hz, 2 H) 5.0 (s, 2 H) 7.0 (d, J=8.3 Hz, 1 H) 7.0 (t, J=7.3 Hz, 1 H) 7.1 (m, 1 H) 7.3 (m, 1 H) 7.6 (m, 3 H) 7.8 (m, 2 H) (CDCl3-d) IR (KBr) 1705, 1497, 1340, 1293, 1205, 1160, 736, 691, 576 Punto de fusión: 172-174°C
Ej 3	1-[1-(5-cloro-3-metil-benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona	
		1H-RMN: 1.8 (d, J=10.8 Hz, 2 H) 2.5 (m, 2 H) 2.7 (s, 3 H) 2.8 (t, J=11.4 Hz, 2 H) 3.8 (d, J=11.4 Hz, 2 H) 3.9 (m, 1 H) 5.1 (s, 2 H) 7.0 (t, J=7.2 Hz, 1 H) 7.2 (d, J=8.1 Hz, 1 H) 7.2 (m, 2 H) 7.8 (dd, J=8.6, 2.0 Hz, 1 H) 8.1 (d, J=2.0 Hz, 1 H) 8.2 (d, J=8.6 Hz, 1 H) (DMSO-d6) IR (KBr) 1717, 1358, 1248, 1201, 1160, 1035, 712, 554 Punto de fusión: 204-206°C
Ej 4	6-metil-1-[1-(naftil-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona	
		1H-RMN: 1.9 (d, J=12.5 Hz, 2 H) 2.3 (s, 3 H) 2.7 (m, 4 H) 3.8 (m, 1 H) 4.0 (d, J=11.2 Hz, 2 H) 4.9 (s, 2 H) 7.0 (m, 2 H) 7.1 (d, J=7.0 Hz, 1 H) 7.5 (m, 3 H) 7.9 (m, 1 H) 8.1 (d, J=8.2 Hz, 1 H) 8.2 (dd, J=7.3, 1.1 Hz, 1 H) 8.7 (d, J=8.8 Hz, 1 H) (CDCl3-d) IR (KBr) 1712, 1316, 1279, 1222, 1160, 1135, 1025, 768, 607 Punto de fusión: 203-204°C

Ej 5	1-[1-(quinolinil-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona	
		1H-RMN: 1.8 (d, J=9.5 Hz, 2 H) 2.6 (qd, J=12.5, 4.4 Hz, 2 H) 3.0 (td, J=12.8, 2.5 Hz, 2 H) 4.1 (tt, J=12.5, 3.8 Hz, 1 H) 4.3 (ddd, J=13.0, 2.3 Hz, 2 H) 5.0 (s, 2 H) 7.1 (m, 3 H) 7.3 (m, 1 H) 7.6 (dd, J=8.4, 4.2 Hz, 1 H) 7.8 (m, 1 H) 8.1 (dd, J=8.2, 1.3 Hz, 1 H) 8.3 (dd, J=8.3, 1.7 Hz, 1 H) 8.5 (dd, J=7.3, 1.5 Hz, 1 H) 9.1 (dd, J=4.2, 1.8 Hz, 1 H) (CDCl3-d)
		IR (KBr) 1712, 1337, 1291, 1205, 1162, 1144, 1034, 717, 583
		Punto de fusión: 170-172°C
Ej 6	8-metil-1-[1-(quinolinil-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona	
		1H-RMN: 1.9 (d, J=12.6 Hz, 2 H) 2.3 (s, 3 H) 2.7 (qd, J=12.2, 3.9 Hz, 2 H) 2.9 (m, 2 H) 3.3 (tt, J=11.7, 3.4 Hz, 1 H) 4.3 (d, J=12.8 Hz, 2 H) 4.9 (s, 2 H) 7.0 (m, 2 H) 7.1 (d, J=7.3 Hz, 1 H) 7.5 (dd, J=8.3, 4.1 Hz, 1 H) 7.6 (m, 1 H) 8.0 (dd, J=8.2, 1.3 Hz, 1 H) 8.2 (dd, J=8.3, 1.7 Hz, 1 H) 8.5 (dd, J=7.3, 1.5 Hz, 1 H) 9.1 (dd, J=4.2, 1.8 Hz, 1 H) (CDCl3-d)
		IR (KBr) 1702, 1329, 1284, 1218, 1024, 785, 701, 582
		Punto de fusión: 202-206°C
Ej 7	1-[1-(5-dimetilamino-naftil-1-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxazin-2-ona	
		1H-RMN: 1.9 (d, J=11.9 Hz, 2 H) 2.3 (s, 3 H) 2.7 (m, 4 H) 2.9 (s, 6 H) 3.3 (m, 1 H) 4.0 (d, J=8.9 Hz, 2 H) 4.9 (s, 2 H) 7.0 (m, 2 H) 7.2 (m, J=7.3 Hz, 2 H) 7.5 (m, 2 H) 8.2 (dd, J=7.3, 1.1 Hz, 1 H) 8.4 (d, J=8.6 Hz, 1 H) 8.6 (d, J=8.4 Hz, 1 H) (CDCl3-d)
		IR (KBr) 2951, 1711, 1336, 1221, 1149, 1025, 794, 709, 571
		Punto de fusión: 202-203°C

Ej. 8	1-[1-(5-dimetilamino-naftil-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona	
		1H-RMN 1.8 (dd, J=12.3, 3.5 Hz, 2 H) 2.7 (m, 4 H) 2.9 (s, 6 H) 4.0 (m, 3 H) 5.0 (s, 2 H) 6.9 (d, J=8.2 Hz, 1 H) 7.1 (m, 2 H) 7.3 (m, 2 H) 7.6 (td, J=8.9, 7.4 Hz, 2 H) 8.3 (dd, J=7.3, 1.3 Hz, 1 H) 8.4 (d, J=8.8 Hz, 1 H) 8.6 (d, J=8.2 Hz, 1 H) (CDCl3-d) IR (KBr) 2935, 1720, 1319, 1242, 1144, 920, 791, 755, 642 Punto de fusión: 182-186°C
Ej 9	1-[1-(2,3-dicloro-fenilsulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona	
		1H-RMN 1.9 (d, J=10.1 Hz, 2 H) 2.7 (qd, J=12.8, 4.2 Hz, 2 H) 3.0 (td, J=12.7, 2.3 Hz, 2 H) 4.1 (m, 3 H) 5.1 (s, 2 H) 7.1 (m, 3 H) 7.3 (m, 2 H) 7.7 (dd, J=8.0, 1.6 Hz, 1 H) 8.0 (dd, J=8.0, 1.6 Hz, 1 H) (CDCl3-d) IR (KBr) 1697, 1395, 1244, 1165, 1045, 942, 710, 582 Punto de fusión: 185-187 °C
Ej 10	1-[1-(2,3-dicloro-fenilsulfonil)-piperidin-4-il]-8-metil-i,4-dihidro-benzo[d][1,3]oxazin-2-ona	
		1H-RMN : 2.0 (d, J=11.5 Hz, 2 H) 2.4 (s, 3 H) 2.8 (m, 4 H) 3.4 (m, 1 H) 4.0 (d, J=9.9 Hz, 2 H) 5.0 (s, 2 H) 7.0 (m, 2 H) 7.2 (d, J=7.7 Hz, 1 H) 7.3 (t, J=8.0 Hz, 1 H) 7.7 (dd, J=8.1, 1.5 Hz, 1 H) 8.0 (dd, J=8.0, 1.6 Hz, 1 H) (CDCl3-d) IR (KBr) 1705, 1404, 1339, 1224, 1149, 939 Punto de fusión: 184-185°C

Datos farmacéuticos:

La unión de los nuevos compuestos de sulfonamidas derivados de benzoxazinona fórmulas generales (I), (Ia) y (Ib) se determinó como se describe anteriormente.


Los resultados de unión para algunos de estos compuestos se indican a continuación en la tabla 2:

Tabla 2:

Compuesto según el ejemplo:	% de inhibición 10^{-6} M	K_i(nM)
1	98,1 ± 4,0	51,7
3		107,4
4		246
5		152
6		165,9
7	88	
8	68	

REIVINDICACIONES

1. Compuesto de sulfonamidas derivado de benzoxazinona de fórmula general (I)



(I),

en la que

R^1, R^2, R^3, R^4 se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, halógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un grupo nitro, un grupo ciano, $-OR^{10}$, $-O(C=O)R^{11}$, $-(C=O)OR^{11}$, $-SR^{12}$, $-SOR^{12}$, $-SO_2R^{12}$, $-NH-SO_2R^{12}$, $-SO_2NH_2$ y un resto $-NR^{13}R^{14}$,

R^5 representa hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido o un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo,

R^6, R^7, R^8, R^9 se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado,

opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, un grupo ciano y un resto $-COOR^{15}$,

W representa un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido,

un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

un radical heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

un radical arilo monocíclico, opcionalmente al menos monosustituido, que está condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido y que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido,

un resto $NR^{16}R^{17}$,

un resto COR^{18},

o un radical fenilo, que está al menos monosustituido por uno de los sustituyentes seleccionados del grupo que consiste en:

2,2,2-trifluoroetoxi, alquenilo C_{2-6}, 1,3-dihidro-1-oxo-2H-isoindol-2-ilo, N-ftalimidinilo, [(2-cloro-1,3-tiazolil-5-il)-metoxi, etil-5-il-2-metil-3-furoato, alquilo C_{11-20}, 1,3-dioxo-2-azaspiro[4,4]non-2-ilo, pirazolilo, (1,3-oxazol-5-il)-, (5-metil-1,3,4-oxadiazol-2-il)-, difluorometoxi, diclorometoxi, 1-pirrolidinilsulfonilo, morfolinosulfonilo, 2-metil-4-pirimidinilo, un grupo fenoxi, que está al menos monosustituido por alcoxi C_{1-6}, un grupo fenilo, que está al menos monosustituido por uno de los sustituyentes seleccionados del grupo que consiste en nitro, alcoxi C_{1-6}, F, Cl, Br, alquilo C_{1-6} al menos parcialmente fluorado, C_{1-6} alquilo al menos parcialmente clorado, [(2-cloro-1,3-tiazol-5-il)-metoxi]-, -(C=O)-H y alquilo (C=O)-C_{1-6}, un grupo piridinilo, que está al menos monosustituido por alcoxi C_{1-6}, un grupo piridiniloxi, que está al menos monosustituido por alcoxi C_{1-6}, un grupo fenoxi, que está al menos disustituido y un grupo piridiniloxi, que está al menos disustituido,

con la condición de que W no represente furilo no sustituido, tienilo no sustituido o tienilo sustituido por un sustituyente seleccionado del grupo que consiste

en alcoxicarbonilo C_{1-5}, alquilcarbonilo C_{1-5}, carboxilo y piridilo, pirrolilo no sustituido, naftilo no sustituido, indolilo no sustituido, tetrahidronaftilo no sustituido, piridilo sustituido o no sustituido, pirazinilo no sustituido, quinolinilo no sustituido, pirrolilo sustituido por alquilo C_{1-5}, y ciclohexilo no sustituido o ciclohexilo sustituido por uno o dos miembros seleccionados del grupo que consiste en oxo, hidroxilo, alcoxilo C_{1-5}, alcoxi-carboniloamino C_{1-5}, alquilo C_{1-5} y aminoalquilo C_{1-5},

R^{10} representa hidrógeno, un radical alifático, lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{11} representa hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{12} representa un radical alifático, lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar

condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{13} y R^{14} se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, un radical alifático, lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

o R^{13} y R^{14} junto con el átomo puente de nitrógeno forman un anillo heterocíclico saturado, insaturado o aromático, que puede estar al menos monosustituido y/o contener al menos un heteroátomo más como miembro del anillo,

R^{15} representa hidrógeno, un radical alifático, lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{16} representa un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido,

R^{17} representa un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, y

R^{18} representa un radical arilo opcionalmente al menos monosustituido,

opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o una sal correspondiente de los mismos, o un solvato correspondiente de los mismos.

2. Compuesto según la reivindicación 1, caracterizado porque R^1, R^2, R^3, R^4 se seleccionan cada uno independientemente del grupo que consiste en H, F, Cl, Br, un

radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un radical arilo o heteroarilo de 5 ó 6 miembros opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un grupo nitro, un ciano, $-OR^{10}$, $-O(C=O)R^{11}$, $-SR^{12}$, $-SOR^{12}$, $-SO_2R^{12}$, $-NH-SO_2R^{12}$, $-SO_2NH_2$ y un resto $-NR^{13}R^{14}$, preferiblemente seleccionados del grupo que consiste en H, F, Cl, Br, un radical alifático C_{1-3} lineal o ramificado, saturado, opcionalmente al menos monosustituido, un radical cicloalifático C_5 o C_6 saturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_1 o C_2 opcionalmente al menos monosustituido, un nitro, un ciano, $-OR^{10}$, $-O(C=O)R^{11}$, $-SR^{12}$, y un resto $-NR^{13}R^{14}$, más preferiblemente seleccionados del grupo que consiste en H, F, Cl, $-CH_3$, $-CH_2CH_3$, $-CF_3$, $-CF_2CF_3$, ciclopentilo, ciclohexilo, un grupo nitro, un grupo ciano y $-OR^{10}$.

3. Compuestos según la reivindicación 1 ó 2, caracterizado porque R^6 representa hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido o un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, preferiblemente representa H o un radical alquilo C_{1-3} lineal o ramificado, más preferiblemente representa H, $-CH_3$ o $-CH_2CH_3$.

4. Compuesto según una cualquiera de las reivindicaciones 1 a 3, caracterizado porque R^6, R^7, R^8, R^9 se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, un grupo ciano y un resto $COOR^{15}$, preferiblemente seleccionados del grupo que consiste en H, un radical alquilo C_{1-3} lineal o ramificado, un grupo ciano y un grupo $COOR^{15}$, más preferiblemente del grupo que consiste en H, $-CH_3$, $-CH_2CH_3$ y un resto ciano.

5. Compuesto según una cualquiera de las reivindicaciones 1 a 4, caracterizado porque W representa un radical alquilo C_{11-20} lineal o ramificado, opcionalmente al menos monosustituido, un grupo naftilo, que está al menos monosustituido, un grupo quinolinilo, que está al menos monosustituido, un grupo pirrolilo, que está al menos monosustituido por un sustituyente distinto de alquilo C_{1-5}, un tiazolilo opcionalmente al menos monosustituido, benzo[b]-tiofenilo, benzo[b]-furanilo, isoquinolinilo, tetrahidroisoquinolinilo, pirazolilo, isoxazolilo, cromanilo, benzotiadiazolilo, imidazolilo, benzofurazanilo, dibenzo[b,d]-furanilo, benzoxadiazolilo, imidazo[2,1-b]-tiazolilo, antracenilo, coumarinilo, 2,3-dihidro-1,4-benzodioxinilo, 2,3-dihidrobenzo[b]furanilo, 3,4-dihidro-2H-1,4-benzoxazinilo, 3,4-dihidro-2H-1,5-benzodioxepinilo, benzotiazolilo, imidazo[1,2-a]-piridinilo, un grupo cromonilo, un grupo isatinilo, un grupo pentametildihidrobenzofuranilo, un grupo ciclopropilo o ciclopentilo opcionalmente al menos monosustituido, 2-(1,3-dioxo-1,3-dihidro-isoindol-2-il)-etilo, un grupo tienilo, que está al menos monosustituido por uno o más sustituyentes seleccionados independientemente del grupo que consiste en F, Cl, Br, alcoxi C_{1-5}, $-CF_3$, alquilo $-SO_2-C_{1-5}$ y benzoilaminometilo, fenilsulfonilo, isoxazolilo, benzoamidometilo, pirimidilo, tiazolilo, pirazolilo, fenilo, 1,2,4-tiadiazolilo, 1,3-oxazolilo o 1,2,4-oxadiazolilo, opcionalmente al menos monosustituidos, un grupo furilo, que está al menos monosustituido por uno o más sustituyentes seleccionados independientemente del grupo que consiste en un radical alquilo C_{1-5}, que puede estar al menos parcialmente fluorado o clorado, un fenilo opcionalmente al menos monosustituido y un grupo alquilo (C=O)-O- C_{1-5},

un resto $NR^{16}R^{17}$,

un resto COR^{18},

o un radical fenilo, que está al menos monosustituido por uno de los sustituyentes seleccionados del grupo que consiste en:

2,2,2-trifluoroetoxi, alquenilo C_{2-6}, 1,3-dihidro-1-oxo-2H-isoindol-2-ilo, N-ftalimidinilo, [(2-cloro-1,3-tiazolil-5-il)-metoxi, etil-5-il-2-metil-3-furoato, alquilo C_{11-20}, 1,3-dioxo-2-azaspiro[4,4]non-2-ilo, pirazolilo, (1,3-oxazol-5-il)-, (5-metil-1,3,4-oxadiazol-2-il)-, difluorometoxi, diclorometoxi, 1-pirrolidinilsulfonilo, morfolinosulfonilo, 2-metil-4-pirimidinilo, un grupo fenoxi, que está al menos monosustituido por alcoxi C_{1-5}, un grupo fenilo, que está al menos monosustituido por uno de los sustituyentes seleccionados del grupo que consiste en nitro, alcoxi C_{1-5}, F, Cl, Br, alquilo C_{1-5} al menos parcialmente fluorado, C_{1-5} alquilo al menos parcialmente clorado, [(2-cloro-1,3-tiazol-5-il)-metoxi]-, -(C=O)-H y alquilo (C=O)-C_{1-5}, un grupo piridinilo, que está al

menos monosustituido por alcoxi C_{1-6}, un grupo piridiniloxi, que está al menos monosustituido por alcoxi C_{1-6}, un grupo fenoxi, que está al menos disustituido y un grupo piridiniloxi, que está al menos disustituido,

más preferiblemente W representa un resto seleccionado del grupo que consiste en 5-dimetilamino-naft-1-ilo, 2-acetamido-4-metil-5-tiazolilo, trifluorometilo, triclorometilo, isopropilo, metilo, 2,2,2-trifluoroetilo, etilo, hexadecilo, 2-cloroetilo, n-propilo, 3-cloro-propilo, n-butilo, diclorometilo, clorometilo, dodecilo, 1-octilo, 6-(p-toluidino)-naft-2-ilo, 4,5-dibromo-tiofen-2-ilo, cloruro de benzoilo-3-ilo, 1-octadecilo, 4-bromo-2,5-dicloro-tiofen-3-ilo, 2,5-dicloro-tiofen-3-ilo, 5-cloro-tiofen-2-ilo, 1-decilo, 3,5-dicloro-4-(2-cloro-4-nitrofenoxi)-fenilo, 2,3-diclorotiofen-5-ilo, 3-bromo-2-cloro-tiofen-5-ilo, 3-bromo-5-cloro-tiofen-2-ilo, 2-(benzoilaminometil)-tiofen-5-ilo, 4-(fenil-sulfonil)-tiofen-2-ilo, 2-fenil-sulfonil-tiofen-5-ilo, 2-[1-metil-5-(trifluorometil)pirazol-3-il]-tiofen-5-ilo, 5-cloro-1,3-dimetilpirazol-4-ilo, 3,5-dimetilisoxazol-4-ilo, 2-(2,4-diclorofenoxi)fenilo, 4-(2-cloro-6-nitro-fenoxi)-fenilo, 4-(3-cloro-2-cianofenoxi)-fenilo, 2,4-dimetil-1,3-tiazol-5-ilo, metil-metano-sulfonilo, 2,5-bis-(2,2,2-trifluoroetoxi)-fenilo, 5-(di-n-propilamino)-naft-1-ilo, 2,2,5,7,8-pentametil-croman-6-ilo, 5-cloro-4-nitro-tiofen-2-ilo, 2,1,3-benzotiadiazol-4-ilo, 1-metil-imidazol-4-ilo, benzofurazan-4-ilo, 5-(isoxazol-3-il)-tiofen-2-ilo, vinil-fenil-4-ilo, 5-dicloro-metil-furan-2-ilo, 5-bromotiofen-2-ilo, 5-(4-clorobenzoamidometil)-tiofen-2-ilo, dibenzo[b,d]-furan-2-ilo, 5-cloro-3-metilbenzo[b]-tiofen-2-ilo, 3-metoxi-4-(metoxicarbonil)-tiofen-2-ilo, 5-[2-(metiltio)-pirimidin-4-il-]-tiofen-2-ilo, 4-cloro-2,1,3-benzoxadiazol-7-ilo, 5-cloro-2,1,3-benzoxadiazol-4-ilo, 6-cloro-imidazo(2,1-b)-tiazol-5-ilo, 3-metil-benzo[b]-tiofen-2-ilo, 4-[3-cloro-5-(trifluorometil)-2-piridil]oxi-fenilo, 5-cloro-naft-1-ilo, 5-cloro-naft-2-ilo, 9,10-dibromoantracen-2-ilo, isoquinolin-5-ilo, 4-metoxi-2,3,6-trimetilbenzoilo, 4'-nitro-bifenil-4-ilo, (1,3-dihidro-1-oxo-2H-isoindol-2-il)-4-fenilo, 5-(2-metil-1,3-tiazol-4-il)-tiofen-2-ilo, 5-(1-metil-3-(trifluorometil)pirazol-5-il]-tiofen-2-ilo, 5-[5-(trifluorometil)-isoxazol-3-il]-tiofen-2-ilo, p-dodecil-fenilo, 4-[(3-ciano-4-metoxi-2-piridinil)oxi]-fenilo, 4-(N-ftalimidinil)-fenilo, 1,2,3,4-tetrahidro-2-(trifluoroacetil)-isoquinolin-7-ilo, 1,2-dimetilimidazol-4-ilo, 2,2,4,6,7-pentametildihidrobenzofuran-5-ilo, 4-cloro-naft-1-ilo, 2,5-dicloro-4-nitro-tiofen-3-ilo, 4-(4-metoxi-fenoxi)-fenilo, [4-(3,5-diclorofenoxi)fenil]-, [4-(3,4-diclorofenoxi)-fenil], [4-(3,5)-bis(trifluorometilfenoxi)fenil], 3-(2-metoxi-fenoxi)-fenilo, 3-(4-metoxi-fenil)-fenilo, 3-(4-cloro-fenil)-fenilo, 3-(3,5-dicloro-fenil)-fenilo, 3-(3,4-dicloro-fenil)-fenilo, 3-(4-fluorofenil)-fenilo, 3-[4-(trifluorometil)-fenil]-fenilo, 3-[3,5-bis(trifluorometil)-fenil]-fenilo, 4-(2-metoxi-fenoxi)-fenilo, 4-(2-metil-fenoxi)-fenilo, 4-(4-metoxi-fenoxi)-fenilo, 4-(4-clorofenil)-fenilo, 4-(3,5-diclorofenil)-fenilo, 4-(3,4-diclorofenil)-fenilo, 4-(4-fluorofenil)-

fenilo, 4-[4-(trifluorometil)-fenil]-fenilo, 4-[3,5-bis(trifluorometil)-fenil]-fenilo, ciclopropilo, 2-(2-clorofenil)-2-feniletilo, 2-(2-trifluorometilfenil)-2-feniletilo, 5-[4-ciano-1-metil-5-(metiltio)-1H-pirazol-3-il-tiofen-2-ilo, 3-ciano-2,4-bis(2,2,2-trifluoroetoxi)-fenilo, 4-[(2-cloro-1,3-tiazol-5-il)-metoxi]-fenilo, 2-(1,3-dioxo-1,3-dihidro-isoindol-2-il)-etilo, 5-yodo-naft-1-ilo, etil-2,5-dimetil-1-fenilpirrol-4-carboxilato-3-ilo, etil-2-metil-1,5-difenil-1H-pirrol-3-carboxilato-4-ilo, etil-5-(4-clorofenil)-2-metil-3-furoato-4-ilo, etil-5-(4-clorofenil)-2-metil-1-fenil-3-carboxilato-4-ilo, etil-2,5-dimetil-3-furoato-4-ilo, 3-cloro-4-(1,3-dioxo-2-azaspiro[4,4]non-2-il)-fenilo, cumarin-6-ilo, 3-(4-metoxi-fenoxi)-fenilo, [3-(3,5-dicloro-fenoxi)]fenilo, [3-(3,4-dicloro-fenoxi)]-fenilo, 3,5-bis(trifluorometil)fenoxifenilo, 2,2-difeniletilo, 4-fenil-5-(trifluorometil)-tiofen-3-ilo, metil-4-fenil-5-(trifluorometil)-tiofen-2-carboxilato-3-ilo, metil-1,2,5-trimetilpirrol-3-carboxilato-4-ilo, 4-fluoro-naft-1-ilo, 5-fluoro-3-metilbenzo[b]-tiofen-2-ilo, metil-2,5-dimetil-3-furoato-4-ilo, metil-2-furoato-5-ilo, metil-2-metil-3-furoato-5-ilo, metil-1-metil-1H-pirrol-2-carboxilato-5-ilo, 2-(5-cloro-1,2,4-tiadiazol-3-il)-tiofen-5-ilo, 1,3,5-trimetil- 1H-pirazol-4-ilo, pentafluoroetoxitetrafluoroetilo, 5-(5-isoxacil)-tiofen-2-ilo, 5-(5-isoxazolil)-2-furilo, 5-metil-2,1,3-benzotiadiazol-4-ilo, 2,3-dihidro-1,4-benzodioxin-6-ilo, 4-metil-naft-1-ilo, 5-metil-2-(trifluorometil)-3-furilo, 2,3-dihidrobenzo[b]furan-5-ilo, 1-benzotiofen-3-ilo, 4-metil-3,4-dihidro-2H-1,4-benzoxazin-7-ilo, 5-metil-1-fenil-1H-pirazol-4-ilo, 6-morfolin-3-piridinilo, 4-(1H-pirazol-1-il)-fenilo, 6-fenoxi-3-piridilo, 3,4-dihidro-2H-1,5-benzodioxepin-7-ilo, 5-(1,3-oxazol-5-il)-2-tienilo, 4-(1,3-oxazol-5-il)-fenilo, 5-metil-4-isoxazolilo, 2,1,3-benzotiadiazol-5-ilo, 5-acetamido-naft-1-ilo, 3-metil-8-quinolinilo, 1,3-benzotiazol-6-ilo, 2-morfolin-3-piridilo, 2,5-dimetil-3-tienilo, 5-[5-(clorometil)-1,2,4-oxadiazol-3-il]-2-tienilo, etil-3-[5-il-2-tienil]-1,2,4-oxadiazol-5-carboxilato, 3-(5-metil-1,3,4-oxadiazol-2-il)-fenilo, 4-(difluorometoxi)-fenilo, 3-(difluorometoxi)-fenilo, 2,2-dimetil-6-cromanilo, etil-3,5-dimetil-1H-pirrol-2-carboxilato-4-ilo, imidazo[1,2-a]piridin-3-ilo, 3-(1,3-oxazol-5-il)-fenilo, etil-5-[4-il-fenil]-2-metil-3-furoato, 1-pirrolidinilfenilsulfonilo, metil-5-il-4-metil-2-tiofen-carboxilato, metil-3-il-4-(isopropilsulfonil)-2-tiofeno, 7-clorocromon-3-ilo, 4'-bromobifenil-4-ilo, 4'-acetil-bifenil-4-ilo, 4'-bromo-2'-fluoro-bifenil-4-ilo, 1-metil-5-isatinilo, ácido 2-cloro-3-tiofencarboxílico-5-ilo, 2-metoxi-5-(N-ftalimidinil)fenilo, 1-benzotiofen-2-ilo, morfolinfenilsulfonilo y 3-(2-metil-4-pirimidinil)-fenilo.

6. Compuesto según una cualquiera de las reivindicaciones 1 a 5, caracterizado porque R^{10} representa hidrógeno, un radical alifático C_{1-8} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar

unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo de 5 ó 6 miembros opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, preferiblemente H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo o un radical fenilo, más preferiblemente H, $-CH_3$, $-C_2H_5$ o fenilo.

7. Compuesto según una cualquiera de las reivindicaciones 1 a 6, caracterizado porque R^{11} representa hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo de 5 ó 6 miembros opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, preferiblemente H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo o un radical fenilo, más preferiblemente H, $-CH_3$, $-C_2H_5$ o fenilo.

8. Compuesto según una cualquiera de las reivindicaciones 1 a 7, caracterizado porque R^{12} representa un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo de 5 ó 6 miembros, opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, preferiblemente representa H, un radical alquilo C_{1-4}, un radical ciclohexilo o un radical fenilo, más preferiblemente H, $-CH_3$, $-C_2H_5$ o fenilo.

9. Compuesto según una cualquiera de las reivindicaciones 1 a 8, caracterizado porque R^{13} y R^{14} se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo de 5 ó 6 miembros, opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, preferiblemente se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo y un radical fenilo, más preferiblemente se seleccionan cada uno independientemente del grupo que consiste en H, $-CH_3$, $-C_2H_5$ y fenilo.

10. Compuesto según una cualquiera de las reivindicaciones 1 a 9, caracterizado porque R^{13} y R^{14} junto con el átomo puente de nitrógeno forman un anillo heterocíclico de 5 ó 6 miembros saturado, insaturado o aromático, que puede estar al menos monosustituido y/o contener al menos un heteroátomo más como miembro del anillo, preferiblemente forman un grupo piperidina o morfolina no sustituido.

11. Compuesto según una cualquiera de las reivindicaciones 1 a 10, caracterizado porque R^{15} representa hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, o un radical arilo o heteroarilo de 5 ó 6 miembros opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, preferiblemente representa H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo o un radical fenilo, más preferiblemente H, $-CH_3$, $-C_2H_5$ o fenilo.

12. Compuesto según una cualquiera de las reivindicaciones 1 a 11, caracterizado porque R^{16} representa un radical alifático C_{1-6} lineal o ramificado, saturado o

insaturado, opcionalmente al menos monosustituido, preferiblemente un radical alquilo C_{1-3} lineal o ramificado, saturado, no sustituido, más preferiblemente un radical metilo.

13. Compuesto según una cualquiera de las reivindicaciones 1 a 12, caracterizado porque R^{17} representa un radical alifático C_{1-8} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, preferiblemente un radical alquilo C_{1-3} lineal o ramificado, saturado, no sustituido, más preferiblemente un radical metilo.

14. Compuesto según una cualquiera de las reivindicaciones 1 a 13:


1-[1-(5-cloro-3-metil-benzo[b]tiofenil-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d] [1,3]oxazin-2-ona,

1-[1-(5-dimetilamino-naftil-1-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxazin-2-ona,

1-[1-(5-dimetilamino-naftil-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona,


y sales correspondientes de los mismos, y solvatos correspondientes.

15. Procedimiento para la preparación de compuestos de sulfonamidas derivados de benzoxazinona de fórmula general (I) según una o más de las reivindicaciones 1 a 14, caracterizado porque comprende hacer reaccionar al menos un compuesto de piperidina de fórmula general (II), en la que de R^1 a R^9 tienen la significación según la reivindicación 1, y/o una sal, preferiblemente sal clorhidrato, del mismo,



(II)

con al menos un compuesto de fórmula general (III),



(III)

en la que W tiene la significación según la reivindicación 1, en un medio de reacción adecuado, opcionalmente en presencia de al menos una base y/o al menos un agente auxiliar.

16. Procedimiento para la preparación de una sal fisiológicamente aceptable de compuestos de sulfonamidas derivados de benzoxazinona según las reivindicaciones 1-14, caracterizado porque se hace reaccionar al menos un compuesto de fórmula general (I) que tiene al menos un grupo básico con al menos un ácido, preferiblemente un ácido orgánico o inorgánico, preferiblemente en presencia de un medio de reacción adecuado.

17. Procedimiento para la preparación de una sal fisiológicamente aceptable de compuestos de sulfonamidas derivados de benzoxazinona según las reivindicaciones 1-14, caracterizado porque se hace reaccionar al menos un compuesto de fórmula general (I) que tiene al menos un grupo ácido con al menos una base, preferiblemente en presencia de un medio de reacción adecuado.


18. Medicamento que comprende al menos un compuesto de sulfonamidas derivado de benzoxazinona según una cualquiera de las reivindicaciones 1-14, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato , respectivamente, y opcionalmente uno o más adyuvantes farmacéuticamente aceptables.

19. Medicamento según la reivindicación 18 para la regulación del receptor 5-HT_6, para la mejora de la cognición, la profilaxis y/o el tratamiento de un trastorno relacionado con la ingestión de alimentos (ingesta de alimentos), particularmente para la regulación del apetito, para el mantenimiento, incremento o reducción del peso corporal, para la profilaxis y/o el tratamiento de la obesidad, bulimia, anorexia, caquexia o diabetes de tipo II (diabetes mellitus insulino independiente), preferiblemente diabetes de tipo II que es causada por la obesidad, trastornos del sistema nervioso central, trastornos del tracto gastrointestinal, tales como síndrome del

intestino irritable, ansiedad, pánico, depresión, trastornos cognitivos de la memoria, procesos de demencia senil, tales como enfermedad de Alzheimer, enfermedad de Parkinson y enfermedad de Huntington, esquizofrenia, psicosis, hiperquinesia infantil o ADHD (déficit de atención, trastorno de hiperactividad).

20. Uso de al menos un compuesto de sulfonamidas derivado de benzoxazinona según una cualquiera de las reivindicaciones 1-14, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato, para la preparación de un medicamento para la regulación del receptor 5-HT_6, para la mejora de la cognición, la profilaxis y/o el tratamiento de un trastorno relacionado con la ingestión de alimentos (ingesta de alimentos), particularmente para la regulación del apetito, para el mantenimiento, incremento o reducción del peso corporal, para la profilaxis y/o el tratamiento de la obesidad, bulimia, anorexia, caquexia o diabetes de tipo II (diabetes mellitus insulino independiente), preferiblemente diabetes de tipo II que es causada por la obesidad, trastornos del sistema nervioso central, trastornos del tracto gastrointestinal, tales como síndrome del intestino irritable, ansiedad, pánico, depresión, trastornos cognitivos de la memoria, procesos de demencia senil, tales como enfermedad de Alzheimer, enfermedad de Parkinson y enfermedad de Huntington, esquizofrenia, psicosis, hiperquinesia infantil o ADHD (déficit de atención, trastorno de hiperactividad).

21. Uso de al menos un compuesto de sulfonamidas derivado de benzoxazinona de fórmula general (Ia),



(Ia)

en la que,

R^{1a}, R^{2a}, R^{3a}, R^{4a} se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, halógeno, un radical alifático, lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un grupo nitro, un grupo ciano, $-OR^{10a}$, $-O(C=O)R^{11a}$, $-(C=O)OR^{11a}$, $-SR^{12a}$, $-SOR^{12a}$, $-SO_2R^{12a}$, $-NH-SO_2R^{12a}$, $-SO_2NH_2$ y un resto $-NR^{13a}R^{14a}$,

R^{5a} representa hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido o un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo,

R^{6a}, R^{7a}, R^{8a}, R^{9a} se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, un grupo ciano y un resto $-COOR^{15a}$,

W^a representa un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un resto $NR^{18a}R^{17a}$, un resto COR^{18a},

R^{10a} representa hidrógeno, un radical alifático, lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{11a} representa hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{12a} representa un radical alifático, lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido, y/o puede estar condensado con un

sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{13a} y R^{14a} se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, un radical alifático, lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíctico opcionalmente al menos monosustituido,

o R^{13a} y R^{14a} junto con el átomo puente de nitrógeno forman un anillo heterocíclico saturado, insaturado o aromático, que puede estar al menos monosustituido y/o contener al menos un heteroátomo más como miembro del anillo,

R^{15a} representa hidrógeno, un radical alifático, lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{16a} representa un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido,

R^{17a} representa un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, y

R^{18a} representa un radical arilo opcionalmente al menos monosustituido,

opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en

cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato, respectivamente,

para la preparación de un medicamento para la regulación del receptor 5-HT_6.

22. Uso según la reivindicación 21, caracterizado porque R^{1a}, R^{2a}, R^{3a}, R^{4a} se seleccionan cada uno independientemente del grupo que consiste en H, F, Cl, Br, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un radical arilo o heteroarilo de 5 ó 6 miembros opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un grupo nitro, un grupo ciano, $-OR^{10a}$, $-O(C=O)R^{11a}$, $-SR^{12a}$, $-SOR^{12a}$, $-SO_2R^{12a}$, $-NH-SO_2R^{12a}$, $-SO_2NH_2$ y un resto $-NR^{13a}R^{14a}$, preferiblemente seleccionados del grupo que consiste en H, F, Cl, Br, un radical alifático C_{1-3} lineal o ramificado, saturado, opcionalmente al menos monosustituido, un radical cicloalifático C_5 o C_6 saturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_1 o C_2 opcionalmente al menos monosustituido, un grupo nitro, un grupo ciano, $-OR^{10a}$, $-O(C=O)R^{11a}$, $-SR^{12a}$, y resto $-NR^{13a}R^{14a}$, más preferiblemente seleccionados del grupo que consiste en H, F, Cl, $-CH_3$, $-CH_2CH_3$, $-CF_3$, $-CF_2CF_3$, ciclopentilo, ciclohexilo, nitro, ciano y $-OR^{10a}$.

23. Uso según la reivindicación 21 ó 22, caracterizado porque R^{5a} representa hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido o un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, preferiblemente representa H o un radical alquilo C_{1-3} lineal o ramificado, más preferiblemente H, $-CH_3$ o $-CH_2CH_3$.

24. Uso según una cualquiera de las reivindicaciones 21 a 23, caracterizado porque R^{6a}, R^{7a}, R^{8a}, R^{9a} se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene

opcionalmente al menos un heteroátomo como miembro del anillo, un grupo ciano y un resto $COOR^{15a}$, preferiblemente seleccionados del grupo que consiste en H, un radical alquilo C_{1-3} lineal o ramificado, un grupo ciano y un grupo $COOR^{15a}$, más preferiblemente del grupo que consiste en H, $-CH_3$, $-CH_2CH_3$ y un resto ciano.

25. Uso según una cualquiera de las reivindicaciones 21 a 24, caracterizado porque W^a representa un radical alquilo C_{1-20} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico, opcionalmente al menos monosustituido, un radical arilo o heteroarilo de 5 ó 6 miembros opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico, opcionalmente al menos monosustituido, un resto $NR^{16a}R^{17a}$ o un resto COR^{15a},

preferiblemente se selecciona del grupo que consiste en 1-naftilo, 5-dimetilamino-naft-1-ilo, 2-acetamido-4-metil-5-tiazolilo, 2-tienilo, 8-quinolinilo, fenilo, pentafluorofenilo, 2,4,5-triclorofenilo, 2,5-diclorofenilo, 2-nitrofenilo, 2,4-dinitrofenilo, 3,5-dicloro-2-hidroxi-fenilo, 2,4,6-trisisopropil-fenilo, 2-mesitilo, 3-nitro-fenilo, 4-bromo-fenilo, 4-fluoro-fenilo, 4-clorofenilo, 4-cloro-3-nitro-fenilo, 4-yodo-fenilo, N-acetil-sulfanililo, 4-nitro-fenilo, 4-metoxi-fenilo, ácido benzoico-4-ilo, 4-terc-butil-bencilo, p-tolilo, trifluorometilo, triclorometilo, isopropilo, metilo, bencilo, trans-estirilo, 2,2,2-trifluoroetilo, etilo, hexadecilo, 2-cloroetilo, n-propilo, 3-cloro-propilo, n-butilo, metil-benzoato-2-ilo, 2-nitro-4-(trifluorometil)-fenilo, pentametil-fenilo, 2,3,5,6-tetrametil-fenilo, 3-(trifluorometil)-fenilo, 3,5-bis-(trifluorometil)-fenilo, diclorometilo, clorometilo, dodecilo, 1-octilo, 2,3,4-tricloro-fenilo, 2,5-dimetoxi-fenilo, o-tolilo, p-xilil-2-ilo, ácido benzoico-3-ilo, 4-cloro-3-(trifluorometil)-fenilo, ácido 4-cloro-5-nitro-benzoico-3-ilo, 6-(p-toluidino)-naft-2-ilo, 4-metoxi-2,3,6-trimetilfenilo, 3,4-diclorofenilo, 4,5-dibromo-tiofen-2-ilo, 3-cloro-4-fluorofenilo, 4-etil-fenilo, 4-n-propil-fenilo, 4-(1,1-dimetilopropil)-fenilo, 4-isopropil-fenilo, 4-bromo-2,5-difluoro-fenilo, 2-fluoro-fenilo, 3-fluoro-fenilo, 4-(trifluorometoxi)-fenilo, 4-(trifluorometil)-fenilo, 2,4-difluoro-fenilo, 2,4-dicloro-5-metil-fenilo, 4-cloro-2,5-dimetil-fenilo, 5-dietilamino-naft-2-ilo, cloruro de benzoil-3-ilo, 2-cloro-fenilo, 1-octadecilo, 4-bromo-2,5-dicloro-tiofen-3-ilo, 2,5-dicloro-tiofen-3-ilo, 5-cloro-tiofen-2-ilo, 2-metil-5-nitro-fenilo, 2-(trifluorometil)-fenilo, 3-cloro-fenilo, 3,5-

diclorо-fenilo, 1-decilo, 3-metil-fenilo, 2-cloro-6-metilo, 5-bromo-2-metoxi-fenilo, 3,4-dimetoxi-fenilo, 2-3-diclorо-fenilo, 2-bromo-fenilo, 3,5-diclorо-4-(2-cloro-4-nitrofenoxi)-fenilo, 2,3-diclorо-tiofen-5-ilo, 3-bromo-2-cloro-tiofen-5-ilo, 3-bromo-5-cloro-tiofen-2-ilo, 2-(benzoilaminometil)-tiofen-5-ilo, 4-(fenilsulfonil)-tiofen-2-ilo, 2-fenilsulfoniltiofen-5-ilo, 3-cloro-2-metil-fenilo, 2-[1-metil-5-(trifluorometil)pirazol-3-il]-tiofen-5-ilo, 5-pirid-2-il-tiofen-2-ilo, 2-cloro-5-(trifluorometil)-fenilo, 2,6-diclorо-fenilo, 3-bromo-fenilo, 2-(trifluorometoxi)-fenilo, 4-ciano-fenilo, 2-ciano-fenilo, 4-n-butoxi-fenilo, 4-acetamido-3-cloro-fenilo, 2,5-dibromo-3,6-difluorofenilo, 5-cloro-1,3-dimetilpirazol-4-ilo, 3,5-dimetilisoxazol-4-ilo, 2-(2,4-diclorofenoxi)-fenilo, 4-(2-cloro-6-nitro-fenoxi)-fenilo, 4-(3-cloro-2-ciano-fenoxi)-fenilo, 2,4-diclorо-fenilo, 2,4-dimetil-1,3-tiazol-5-ilo, metil-metano-sulfonilo, 2,5-bis-(2,2,2-trifluoroetoxi)-fenilo, 2-cloro-4-(trifluorometil)-fenilo, 2-cloro-4-fluoro-fenilo, 5-fluoro-2-metil-fenilo, 5-cloro-2-metoxi-fenilo, 2,4,6-tricloro-fenilo, ácido 2-hidroxi-benzoico-5-ilo, 5-(di-n-propilamino)-naft-1-ilo, 6-metoxi-m-tolilo, 2,5-difluoro-fenilo, 2,4-dimetoxi-fenilo, 2,5-dibromo-fenilo, 3,4-dibromo-fenilo, 2,2,5,7,8-pentametil-croman-6-ilo, ácido 2-metoxi-benzoico-5-ilo, 5-cloro-4-nitro-tiofen-2-ilo, 2,1,3-benzotiadiazol-4-ilo, 1-metil-imidazol-4-ilo, benzofurazan-4-ilo, 2-(metoxicarbonil)-tiofen-3-ilo, 5-(isoxazol-3-il)-tiofen-2-ilo, 2,4,5-trifluorofenilo, bifenil-4-ilo, Vinil-fenil-4-ilo, 2-nitro-bencilo, 5-diclorо-metil-furan-2-ilo, 5-bromo-tiofen-2-ilo, 5-(4-clorobenzamidometil)-tiofen-2-ilo, 2,6-difluoro-fenilo, 2,5-dimetoxi-4-nitro-fenilo, dibenzo[b,d]-furan-2-ilo, 2,3,4-trifluoro-fenilo, 3-nitro-p-tolilo, 4-metoxi-2-nitro-fenilo, 3,4-difluoro-fenilo, 4-(bromoetil)-fenilo, 3,5-diclorо-4-hidroxi-fenilo, 4-n-amil-fenilo, 5-cloro-3-metilbenzo[b]-tiofen-2-ilo, 3-metoxi-4-(metoxicarbonil)-tiofen-2-ilo, 4-n-butilfenilo, 2-cloro-4-ciano-fenilo, 5-[2-(metiltio)-pirimidin-4-il-]-tiofen-2-ilo, 3,5-dinitro-4-metoxi-fenilo, 4-bromo-2-(trifluorometoxi)-fenilo, 4-cloro-2,1,3-benzoxadiazol-7-ilo, 2-(1-naftil)-etilo, 3-ciano-fenilo, 5-cloro-2,1,3-benzoxadiazol-4-ilo, 3-cloro-4-metil-fenilo, 4-bromo-2-etil-fenilo, 2,4-diclorо-6-metil-fenilo, 6-cloro-imidazo(2,1-b)-tiazol-5-ilo, 3-metil-benzo[b]-tiofen-2-ilo, 4-metil-sulfonil-fenilo, 2-metil-sulfonil-fenilo, 4-bromo-2-metil-fenilo, 2,6-diclorо-4-(trifluorometil)-fenilo, 4-[[3-cloro-5-(trifluorometil)-2-piridinil]oxi]-fenilo, 5-cloro-naft-1-ilo, 5-cloro-naft-2-ilo, 9,10-dibromoantracen-2-ilo, isoquinolin-5-ilo, 4-metoxi-2,3,6-trimetil-fenilo, 4'-nitro-bifenil-4-ilo, [(4-fenoxi)-fenilo, (1,3-dihidro-1-oxo-2H-isoindol-2-il)-4-fenilo, 4-acetil-fenilo, 5-(2-metil-1,3-tiazol-4-il)-tiofen-2-ilo, 5-(1-metil-3-(trifluorometil)pirazol-5-il-]-tiofen-2-ilo, 5-[5-trifluorometil)-isoxazol-3-il]-tiofen-2-ilo, 2-yodo-fenilo, p-dodecil-fenilo, 4-[(3-ciano-4-metoxi-2-piridinil)oxi]-fenilo, 4-(N-ftalimidinil)-fenilo, 1,2,3,4-tetrahidro-2-(trifluoroacetil)-isoquinolin-7-ilo, 4-bromo-2-fluoro-fenilo, 2-fluoro-5-(trifluorometil)-fenilo, 4-fluoro-2-(trifluorometil)-fenilo, 4-fluoro-3-(trifluorometil)-

fenilo, 2,4,6-trifluoro-fenilo, 3-(trifluorometoxi)-fenilo, 1,2-dimetilimidazol-4-ilo, etil-4-carboxilato-3-ilo, 2,2,4,6,7-pentametildihidrobenzofuran-5-ilo, 3-bromo-2-cloropiridin-5-ilo, 3-metoxi-fenilo, 2-metoxi-4-metil-fenilo, ácido 2-cloro-4-fluorobenzoico-5-ilo, 4-cloro-naft-1-ilo, 2,5-dicloro-4-nitro-tiofen-3-ilo, 4-(4-metoxi-fenoxi)-fenilo, 4-(4-cloro-fenoxi)-fenilo, 4-(3,5-dicloro-fenoxi)-fenilo, 4-(3,4-dicloro-fenoxi)-fenilo, 4-(4-fluoro-fenoxi)-fenilo, 4-(4-metil-fenoxi)-fenilo, 4-[4-(trifluorometil)-fenoxi-fenilo, 4-[3,5-bis-(trifluorometil)-fenoxi]-fenilo, 3-(2-metoxi-fenoxi)-fenilo, [3-(2-cloro-fenoxi)-fenilo, 3-(2-metil-fenoxi)-fenilo, 4-[2-(trifluorometil)-fenoxi]-fenilo, 3-fenil-fenilo, 3-(4-metoxi-fenil)-fenilo, 3-(4-cloro-fenil)-fenilo, 3-(3,5-dicloro-fenil)-fenilo, 3-(3,4-dicloro-fenil)-fenilo, 3-(4-fluorofenil)-fenilo, 3-(4-metilfenil)-fenilo, 3-[4-(trifluorometil)-fenil]-fenilo, 3-[3,5-bis-(trifluorometil)-fenil]-fenilo, 4-(4-piridiloxi)-fenil)-, 4-(2-metoxi-fenoxi)-fenilo, 4-(2-cloro-fenoxi)-fenilo, 4-(2-metil-fenoxi)-fenilo, 4-(4-metoxi-fenoxi)-fenilo, 4-(4-clorofenil)-fenilo, 4-(3,5-diclorofenil)-fenilo, 4-(3,4-diclorofenil)-fenilo, 4-(4-fluorofenil)-fenilo, 4-(4-metilfenil)-fenilo, 4-[4-(trifluorometil)-fenil]-fenilo, 4-[3,5-bis-(trifluorometil)-fenil]fenilo, [3-(trifluorometil)-fenil]-metilo, (4-clorofenil)-metilo, (3,5-diclorofenil)-metilo, (3,5-diclorofenil)-metilo, (4-fluorofenil)-metilo, 4-metilfenilmetilo, [4-(trifluorometil)-fenil]-metilo, ciclopropilo, 2-(2-clorofenil)-2-feniletilo, 2-(2-trifluorometilfenil)-2-feniletilo, 5-[4-ciano-1-metil-5-(metiltio)-1H-pirazol-3-il-tiofen-2-ilo, 3-ciano-2,4-bis-(2,2,2-trifluorotoxi)-fenilo, 4-[(2-cloro-1,3-tiazol-5-il)-metoxi]-fenilo, 3-nitro-fenilmetilo, 4-formilfenilo, 2-(1,3-dioxo-1,3-dihidro-isoindol-2-il)-etilo, [3,5-bis-(trifluorometil)-fenil]-metilo, (4-(2-piridiloxi)-fenil)-, (4-(3-piridiloxi)-fenil)-, 5-yodo-naft-1-ilo, etil-2,5-dimetil-1-fenilopirrol-4-carboxilato-3-ilo, etil-2-metil-1,5-difenil-1H-pirrol-3-carboxilato-4-ilo, etil-5-(4-clorofenil)-2-metil-3-furoato-4-ilo, etil-5-(4-clorofenil)-2-metil-1-fenil-3-carboxilato-4-ilo, etil-2,5-dimetil-3-furoato-4-ilo, 3-cloro-4-(1,3-dioxo-2-azaspiro[4,4]non-2-il)-fenilo, 5-bromo-2,4-difluoro-fenilo, 5-cloro-2,4-difluorofenilo, cumarin-6-ilo, 2-metoxi-fenilo, (3-fenoxi)-fenilo, 3-(4-metoxi-fenoxi)-fenilo, 3-(4-clorofenoxi)-fenilo, 3-(3,5-diclorofenoxi)-fenilo, 3-(3,4-diclorofenoxi)-fenilo, 3-(4-fluorofenoxi)-fenilo, 3-(4-metilfenoxi)-fenilo, 3-[4-(trifluorometil)-fenoxi]-fenilo, 3-[3,5-(trifluorometil)-fenoxi]-fenilo, 3-[2-(trifluorometil)-fenoxi]-fenilo, 2,2-difeniletilo, 4-fenil-5-(trifluorometil)-tiofen-3-ilo, metil-4-fenil-5-(trifluorometil)-tiofen-2-carboxilato-3-ilo, metil-1,2,5-trimetilpirrol-3-carboxilato-4-ilo, 4-fluoro-naft-1-ilo, 3,5-difluorofenilo, 3-fluoro-4-metoxi-fenilo, 4-cloro-2,5-difluorofenilo, 2-cloro-4,5-difluoro-fenilo, 5-fluoro-3-metilbenzo[b]-tiofen-2-ilo, metil-3-fenilopropionato-4-ilo, acido dihidrocinámico-4-ilo, metil-2,5-dimetil-3-furoato-4-ilo, metil-2-furoato-5-ilo, metil-2-metil-3-furoato-5-ilo, metil-1-metil-1H-pirrol-2-carboxilato-5-ilo, 2-(5-cloro-1,2,4-tiadiazol-3-il)-tiofen-5-ilo, 1,3,5-trimetil-1H-pirazol-4-ilo, 3-cloro-5-fluoro-2-metilfenilo,

pentafluoroetoxitetrafluoroetilo, 5-(5-isoxacil)-tiofen-2-ilo, 5-(5-isoxazolil)-2-furilo, 5-metil-2,1,3-benzotiadiazol-4-ilo, bifenil-2-ilo, 2,3-dihidro-1,4-benzodioxin-6-ilo, 4-metil-naft-1-ilo, 5-metil-2-(trifluorometil)-3-furilo, 2,3-dihidrobenzo[b]furan-5-ilo, 1-benzotiofen-3-ilo, 4-metil-3,4-dihidro-2H-1,4-benzoxazin-7-ilo, 5-metil-1-fenil-1H-pirazol-4-ilo, 6-morfolin-3-piridinilo, 4-(1H-pirazol-1-il)-fenilo, 6-fenoxi-3-piridilo, 3,4-dihidro-2H-1,5-benzodioxepin-7-ilo, 5-(1,3-oxazol-5-il)-2-tienilo, 4-(1,3-oxazol-5-il)-fenilo, 5-metil-4-isoxazolilo, 2,1,3-benzotiadiazol-5-ilo, 3-tienilo, 2-metil-bencilo, 3-cloro-bencilo, 5-acetamido-naft-1-ilo, 3-metil-8-quinolinilo, 4-cloro-2-nitrofenilo, 6-quinolinilo, 1,3-benzotiazol-6-ilo, 2-morfolin-3-piridilo, 2,5-dimetil-3-tienilo, 5-[5-(clorometil)-1,2,4-oxadiazol-3-il]-2-tienilo, etil-3-[5-il-2-tienil]-1,2,4-oxadiazol-5-carboxilato, 3-(5-metil-1,3,4-oxadiazol-2-il)-fenilo, 4-isopropoxifenilo, 2,4-dibromofenilo, 3-ciano-4-fluorofenilo, 2,5-bis-(trifluorometil)-fenilo, 2-bromo-4-fluorofenilo, 4-bromo-3-fluorofenilo, 4-(difluorometoxi)-fenilo, 3-(difluorometoxi)-fenilo, 5-cloro-2-fluorofenilo, 3-cloro-2-fluorofenilo, 2-fluoro-4-metilfenilo, 4-nitro-3-(trifluorometil)-fenilo, 3-fluoro-4-metilfenilo, 4-fluoro-2-metilfenilo, 4-bromo-3-(tifluorometil)-fenilo, 4-bromo-2-(trifluorometil)-fenilo, 3-bromo-5-(trifluorometil)-fenilo, 2-bromo-4-(trifluorometil)-fenilo, 2-bromo-5-(trifluorometil)-fenilo, 2,4-dicloro-5-fluorofenilo, 4,5-dicloro-2-fluorofenilo, 3,4,5-trifluorofenilo, 4-cloro-2-fluorofenilo, 2-bromo-4,6-difluorofenilo, 2-etilfenilo, 4-bromo-2-clorofenilo, 4-bromo-2,6-diclorofenilo, 2-bromo-4,6-dicloro-fenilo, 4-bromo-2,6-dimetilfenilo, 3,5-dimetilfenilo, 4-bromo-3-metilfenilo, 2-metoxi-4-nitrofenilo, 2,2-dimetil-6-cromanilo, etil-3,5-dimetil-1H-pirrol-2-carboxilato-4-ilo, imidazo[1,2-a]pridin-3-ilo, 3-(1,3-oxazol-5-il)-fenilo, etil-5-[4-il)-fenil]-2-metil-3-furoato, metil-3-(il)-4-metoxibenzoato, 1-pirrolidinilfenilsulfonilo, metil-5-il-4-metil-2-tiofen-carboxilato, metil-3-il-4-(isopropilsulfonil)-2-tiofeno, 2-piridilo, 3-fluoro-4-nitrofenilo, 7-clorocromon-3-ilo, 4'-bromobifenil-4-ilo, 4'-acetil-bifenil-4-ilo, 4'-bromo-2'-fluoro-bifenil-4-ilo, 2-cloro-4-(3-propil-ureido)-fenilo, 3-(-bromoacetil)-fenilo, 2-bromo-3-(trifluorometil)-fenilo, 1-metil-5-isatinilo, ácido 4-isopropil-benzoico-3-ilo, ácido 2-cloro-3-tiofenocarboxílico-5-ilo, 3-piridilo, ciclohexilmetilo, 2-metoxi-5-(N-ftalimidinil)-fenilo, 1-benzotiofen-2-ilo, morfolinofenilsulfonilo, 3-(2-metil-4-pirimidinil)-fenilo, y 2-ciano-5-metilfenilo.

26. Uso según una cualquiera de las reivindicaciones 21 a 25, caracterizado porque R^{10a} representa hidrógeno, un radical alifático C_{1-8} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-8} opcionalmente al menos monosustituido, y/o

puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo de 5 ó 6 miembros opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, preferiblemente H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo o un radical fenilo, más preferiblemente H, $-CH_3$, $-C_2H_5$ o fenilo.

27. Uso según una cualquiera de las reivindicaciones 21 a 26, caracterizado porque R^{11a} representa hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo de 5 ó 6 miembros opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, preferiblemente H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo o un radical fenilo, más preferiblemente H, $-CH_3$, $-C_2H_5$ o fenilo.

28. Uso según una cualquiera de las reivindicaciones 21 a 27, caracterizado porque R^{12a} representa un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo de 5 ó 6 miembros, opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, preferiblemente representa H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo o un radical fenilo, más preferiblemente H, $-CH_3$, $-C_2H_5$ o fenilo.

29. Uso según una cualquiera de las reivindicaciones 21 a 28, caracterizado porque R^{13a} y R^{14a} se seleccionan cada uno independientemente del grupo que

consiste en hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido, y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo de 5 ó 6 miembros, opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, preferiblemente se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, ciclohexilo y un radical fenilo, más preferiblemente se seleccionan cada uno independientemente del grupo que consiste en H, $-CH_3$, $-C_2H_5$ y fenilo.

30. Uso según una cualquiera de las reivindicaciones 21 a 29, caracterizado porque R^{13a} y R^{14a} junto con el átomo puente de nitrógeno forman un anillo heterocíclico de 5 ó 6 miembros saturado, insaturado o aromático, que puede estar al menos monosustituido y/o contener al menos un heteroátomo más como miembro del anillo, preferiblemente forman un grupo piperidina o morfolina no sustituido.

31. Uso según una cualquiera de las reivindicaciones 21 a 30, caracterizado porque R^{15a} representa hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, o un radical arilo o heteroarilo de 5 ó 6 miembros opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, preferiblemente representa H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo o un radical fenilo, más preferiblemente H, $-CH_3$, $-C_2H_5$ o fenilo.

32. Uso según una cualquiera de las reivindicaciones 21 a 31, caracterizado porque R^{16a} representa un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, preferiblemente un radical alquilo C_{1-3} lineal o ramificado, saturado, no sustituido, más preferiblemente un radical metilo.

33. Uso según una cualquiera de las reivindicaciones 21 a 32, caracterizado porque R^{17a} representa un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, preferiblemente un radical alquilo C_{1-3} lineal o ramificado, saturado, no sustituido, más preferiblemente un radical metilo.

34. Uso según una cualquiera de las reivindicaciones 21 a 33, caracterizado porque uno o más de los compuestos de sulfonamidas derivados de benzoxazinona de fórmula general (Ia) se seleccionan del grupo que consiste en:

1-[1-(naftil-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona,

1-(1-fenilsulfonilpiperidin-4-il]-1,4-dihidro-benzo[d][1,3]-oxazin-2-ona,

1-[1-(5-cloro-3-metil-benzo[b]tiofenil-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona,

8-metil-1-[1-naftil-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona,

1-[1-(quinolin-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona,

8-metil-1-[1-(quinolin-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona,

1-[1-(5-dimetilamino-naftil-1-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidrobenzo[d][1,3]oxazin-2-ona,

1-[1-(5-dimetilamino-naftil-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona,

1-[1-(2,3-dicloro-fenilsulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxazin-2-ona,

1-[1-(2,3-dicloro-fenilsulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxazin-2-ona, y

sales correspondientes de los mismos, o solvatos correspondientes de los mismos.

35. Uso de al menos un compuesto de sulfonamidas derivado de benzoxazinona de fórmula general (Ia) según una cualquiera de las reivindicaciones 21-34, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato correspondiente, para la preparación de un medicamento para la profilaxis y/o el tratamiento de trastornos relacionados con la ingestión de alimentos.

36. Uso según la reivindicación 35 para la regulación del apetito.

37. Uso según la reivindicación 35 para la reducción, incremento o mantenimiento del peso corporal.

38. Uso según la reivindicación 35 para la profilaxis y/o el tratamiento de la obesidad.

39. Uso según la reivindicación 35 para la profilaxis y/o el tratamiento de la bulimia.

40. Uso según la reivindicación 35 para la profilaxis y/o el tratamiento de la anorexia.

41. Uso según la reivindicación 35 para la profilaxis y/o el tratamiento de la caquexia.

42. Uso según la reivindicación 35 para la profilaxis y/o el tratamiento de la diabetes de tipo II.

43. Uso de al menos un compuesto de sulfonamidas derivado de benzoxazinona de fórmula general (Ia) según una cualquiera de las reivindicaciones 21-34, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato correspondiente, para la preparación de un medicamento para la profilaxis y/o el tratamiento de la ansiedad.

44. Uso de al menos un compuesto de sulfonamidas derivado de benzoxazinona de fórmula general (Ia) según una cualquiera de las reivindicaciones 21-34, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato correspondiente, para la preparación de un medicamento para la profilaxis y/o el tratamiento del pánico.

45. Uso de al menos un compuesto de sulfonamidas derivado de benzoxazinona de fórmula general (Ia) según una cualquiera de las reivindicaciones 21-34, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato correspondiente, para la preparación de un medicamento para la profilaxis y/o el tratamiento de trastornos de la depresión.

46. Uso de al menos un compuesto de sulfonamidas derivado de benzoxazinona de fórmula general (Ia) según una cualquiera de las reivindicaciones 21-34, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente

enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato correspondiente, para la preparación de un medicamento para la profilaxis y/o el tratamiento de trastornos cognitivos, preferiblemente trastornos de la memoria.

47. Uso de al menos un compuesto de sulfonamidas derivado de benzoxazinona de fórmula general (Ia) según una cualquiera de las reivindicaciones 21-34, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato correspondiente, para la preparación de un medicamento para la profilaxis y/o el tratamiento de procesos de demencia senil, preferiblemente seleccionados del grupo que consiste en enfermedad de Alzheimer, enfermedad de Parkinson, enfermedad de Huntington.

48. Uso de al menos un compuesto de sulfonamidas derivado de benzoxazinona de fórmula general (Ia) según una cualquiera de las reivindicaciones 21-34, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato correspondiente, para la preparación de un medicamento para la profilaxis y/o el tratamiento de la psicosis.

49. Uso de al menos un compuesto de sulfonamidas derivado de benzoxazinona de fórmula general (Ia) según una cualquiera de las reivindicaciones 21-34, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato correspondiente, para la preparación de un medicamento para la profilaxis y/o el tratamiento de la hiperquinesia infantil.

50. Uso de al menos un compuesto de sulfonamidas derivado de benzoxazinona de fórmula general (Ia) según una cualquiera de las reivindicaciones 21-34, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato correspondiente, para la preparación de un


medicamento para la profilaxis y/o el tratamiento de ADHC (déficit de atención, trastornos de hiperactividad).

51. Uso de al menos un compuesto de sulfonamidas derivado de benzoxazinona de fórmula general (Ia) según una cualquiera de las reivindicaciones 21-34, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato correspondiente, para la preparación de un medicamento para la profilaxis y/o el tratamiento de trastornos del tracto gastrointestinal, preferiblemente síndrome del intestino irritable.

52. Uso de al menos un compuesto de sulfonamidas derivado de benzoxazinona de fórmula general (Ia) según una cualquiera de las reivindicaciones 21-34, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato correspondiente, para la preparación de un medicamento para la profilaxis y/o el tratamiento de la esquizofrenia.

53. Uso de al menos un compuesto de sulfonamidas derivado de benzoxazinona de fórmula general (Ia) según una cualquiera de las reivindicaciones 21-34, opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato correspondiente, para la preparación de un medicamento para la mejora de la cognición.

54. Compuesto de sulfonamidas derivado de benzoxazinona de fórmula general (Ib),



(Ib)

en la que

R^{1b}, R^{2b}, R^{3b}, R^{4b} se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, halógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un grupo nitro, un grupo ciano, $-OR^{10b}$, $-OC(=O)R^{11b}$, $-(C=O)-OR^{11b}$, $-SR^{12b}$, $-SOR^{12b}$, $-SO_2R^{12b}$, $-NH-SO_2R^{12b}$, $-SO_2NH_2$ y un resto $-NR^{13b}R^{14b}$,

R^{5b} representa hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, o un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo,

R^{6b}, R^{7b}, R^{8b}, R^{9b} se seleccionan cada uno independientemente del grupo que consisten en hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, un grupo ciano y un resto $-COOR^{15b}$,

W^b representa un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un resto $NR^{16b}R^{17b}$ o un resto COR^{18b},

R^{10b} representa hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{11b} representa hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{12b} representa un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un

sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{13b} y R^{14b} se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

o R^{13b} R^{14b} junto con el átomo puente de nitrógeno forman un anillo heterocíclico saturado, insaturado o aromático, que puede estar al menos monosustituido y/o contener al menos un heteroátomo más como miembro del anillo,

R^{16b} representa hidrógeno, un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo o un radical arilo o heteroarilo opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno opcionalmente al menos monosustituido y/o puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido,

R^{16b} representa un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido,

R^{17b} representa un radical alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido,

R^{18b} representa un radical arilo opcionalmente al menos monosustituido,

opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en

cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato, respectivamente.

55. Compuesto según la reivindicación 54, caracterizado porque R^{1b}, R^{2b}, R^{3b}, R^{4b} se seleccionan cada uno independientemente del grupo que consiste en H, F, Cl, Br, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un radical arilo o heteroarilo de 5 ó 6 miembros, opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un grupo nitro, un grupo ciano, $-OR^{10b}$, $-OC(=O)R^{11b}$, $-SR^{12b}$, $-SOR^{12b}$, $-SO_2R^{12b}$, $-NH-SO_2R^{12b}$, $-SO_2NH_2$ y un resto $-NR^{13b}R^{14b}$, preferiblemente seleccionados del grupo que consiste en H, F, Cl, Br, un radical alifático C_{1-3} saturado, lineal o ramificado, opcionalmente al menos monosustituido, un radical cicloalifático C_5 o C_6 saturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_1 o C_2 opcionalmente al menos monosustituido, un grupo nitro, un grupo ciano, $-OR^{10b}$, $-OC(=O)R^{11b}$, $-SR^{12b}$ y un resto $-NR^{13b}R^{14b}$, más preferiblemente seleccionados del grupo que consiste en H, F, Cl, Br, $-CH_3$, $-CH_2CH_3$, $-CF_3$, $-CF_2CF_3$, ciclopentilo, ciclohexilo, nitro, ciano y $-OR^{10b}$.

56. Compuesto según la reivindicación 54 ó 55, caracterizado porque R^{5b} representa hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido o un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, preferiblemente representa H o un radical alquilo C_{1-3} lineal o ramificado, más preferiblemente H, $-CH_3$, o $-CH_2CH_3$, lo más preferiblemente un átomo de hidrógeno.

57. Compuesto según una cualquiera de las reivindicaciones 54 a 56, caracterizado porque R^{6b}, R^{7b}, R^{8b}, R^{9b} se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático

C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, un grupo ciano y un resto $-COOR^{16b}$, preferiblemente seleccionados del grupo que consiste en H, un radical alquilo C_{1-3} lineal o ramificado, un grupo ciano y un grupo $COOR^{16b}$, más preferiblemente del grupo que consiste en H, $-CH_3$, $-CH_2CH_3$ y un resto ciano, lo más preferiblemente cada uno de R^{6b}, R^{7b}, R^{8b} y R^{9b} representa un átomo de hidrógeno.

58. Compuesto según una cualquiera de las reivindicaciones 54 a 57, caracterizado porque W^b representa un radical alifático C_{1-20} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un radical arilo o heteroarilo de 5 ó 6 miembros, opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, un resto $NR^{16b}R^{17b}$ o un resto COR^{16b},

preferiblemente W^b representa

un radical alquilo C_{1-20} lineal o ramificado, preferiblemente un radical alquilo seleccionado del grupo que consiste en metilo, etilo, n-propilo, iso-propilo, n-butilo, iso-butilo, sec-butilo, terc-butilo y 1,1-dimetil-propilo; un radical alquenilo C_{2-20} lineal o ramificado; preferiblemente un radical vinilo; $-CF_3$; $-CHF_2$; $-CH_2F$; $-CCl_3$; $-CHCl_2$; $-CH_2Cl$; $-CH_2-CF_3$; $-CH_2-CH_2-Cl$; $-CH_2-CH_2-CH_2-Cl$; $-CH_2-S(=O)_2-CH_3$; un radical ciclopropilo; un radical ciclobutilo; un radical ciclopentilo; un radical ciclohexilo; $-CH_2$-ciclopropilo; $-CH_2$-ciclobutilo; $-CH_2$-ciclopentilo; $-CH_2$-ciclohexilo; $-N(CH_3)_2$; $-N(C_2H_5)_2$; $-N(n\text{-}CH_2\text{-}CH_2\text{-}CH_3)_2$; fenilo; bencilo; naftilo; -CH=CH-fenilo; $-(CF_2)$-(CF_2)-O-fenilo; $-(CH_2)$-naftilo; $-(CH_2)$-(CH_2)-naftilo; antracenilo; -(C=O)-fenilo; tiofenilo; benzo[b]tiofenilo; furanilo; 2-oxo-2H-cromenilo; dibenzofuranilo; 2,3-dihidrobenzofuranilo; cromanilo; 2,3-dihidro-benzo[1,4]dioxinilo; 3,4-dihidro-2H-1,5-benzo-dioxepinilo; cromonilo; 1H-imidazolilo; piridinilo; pirrolidin-2,5-dionilo; pirrolilo; 1H-pirazolilo; 1H-pirimidin-2,4-dionilo; quinolinilo; isoquinolinilo; 1H-benzoimidazolilo; 1,4-dihidro-quinoxalin-2,3-dionilo; 1,2,3,4-tetrahidro-isoquinolinilo; 1,4-dihidro-benzo[b][1,4]diazepin-2,4-dionilo; 1,3-dihidro-1-oxo-2H-isoindolilo; ftalimidinilo; 2-(1,3-dioxo-1,3-dihidro-isoindol-2-il)-etilo; imidazo[1,2-a]piridina; isatinilo; tiazolilo; 1,3-tiazolilo; 1,2,4-tiadiazolilo; imidazo[2,1-

b]tiazolilo; 1,3-benzotiazolilo; benzo[1,2,5]tiadiazolilo; 2-oxo-2,3-dihidro-benzotiazolilo; 2,1,3-benzotiadiazolilo; imidazo[2,1-b]tiazolilo; isoxazolilo; benzo[1,2,5]oxadiazolilo; benzo[d]isoxazolilo; benzofurazanilo; 2-oxo-2,3-dihidro-benzooxazolilo; 3,4-dihidro-2H-benzo[1,4]oxazinilo; o 2,1,3-benzooxadiazolilo;

en los que cada uno de los restos cíclicos mencionados anteriormente puede sustituirse opcionalmente con 1, 2, 3, 4 ó 5 sustituyentes seleccionados independientemente del grupo que consiste en metilo; etilo; n-propilo; iso-propilo; n-butilo; iso-butilo; sec-butilo; terc-butilo; 1,1-dimetil-propilo; n-pentilo; vinilo; ciclopropilo; ciclobutilo; ciclopentilo; ciclohexilo; morfolino; metoxi; etoxi; n-propoxi; isopropoxi; n-propoxi; F; Cl; Br; I; -CN; -OH; $-CF_3$; $-CF_2H$; $-CH_2F$; $-CCl_3$; $-CClH_2$; $-CHCl_2$; $-CH_2-F$; $-CH_2-Cl$; $-CH_2-Br$; $-(C=O)-CH_2-Br$; $-OCF_3$; $-O-CH_2-CF_3$; $-O-CHF_2$; $-NO_2$; $-NH_2$; $-N(CH_3)_2$; $-N(C_2H_5)_2$; $-N(n\text{-}CH_2\text{-}CH_2\text{-}CH_3)_2$; $-N(n\text{-}CH_2\text{-}CH_2\text{-}CH_2\text{-}CH_3)_2$; $-NH-(C=O)-CH_3$; -NH-fenilo; $-(C=O)-CF_3$; -(C=O)-OH; =O (oxo); -(C=O)-H; $-S(=O)_2-CH_3$; $-S(=O)_2$-isopropilo; $-S(=O)_2$-fenilo; $-S(=O)_2$-pirrolidinilo; $-S(=O)_2$-morfolino; $-(CH_2)-(CH_2)-(C=O)-O-CH_3$; $-NH-(C=O)-NH-CH_2-CH_2-CH_3$; $-(C=O)-CH_3$; $-(C=O)-O-CH_3$; $-(C=O)-O-C_2H_5$; $-(CH_2)-NH-(C=O)$-fenilo; $-CH_2-C(H)(fenil)(fenil)$; $-O-CH_2$-tiazolilo; 1,3-dioxo-2-azaspiro[4,4]non-2-ilo; fenilo; fenoxi; isoxazolilo; 1,3-oxazolilo; 1,2,4-oxadiazolilo; 1,3,4-oxadiazolilo; piridinilo; piridiniloxi; pirazolilo; pirimidinilo y ftalimidinilo; y


en los que cada uno de los restos cíclicos de estos sustituyentes mencionados anteriormente puede sustituirse con 1, 2, 3, 4 ó 5 sustituyentes seleccionados independientemente del grupo que consiste en metilo; etilo; n-propilo; isopropilo; F; Cl; Br; I; CN, $-CH_2-F$; $-CH_2-Cl$; $-CH_2-Br$; $-CF_3$ y $-S-CH_3$,


más preferiblemente W^b representa


un radical alquilo seleccionado del grupo que consiste en metilo; etilo; n-propilo; iso-propilo; n-butilo; sec-butilo; iso-butilo y terc-butilo; vinilo ($CH_2=CH-$); $-N(CH_3)_2$; 1-naftilo; bencilo; 2-naftilo; fenilo; 2-metil-fenilo; 3-metil-fenilo; 4-metil-fenilo; 2-etil-fenilo; 3-etil-fenilo; 4-etil-fenilo; 2-n-propil-fenilo; 3-n-propil-fenilo; 4-n-propil-fenilo; 2-isopropil-fenilo; 3-isopropil-fenilo: 4-isopropil-fenilo; 2-n-butil-fenilo; 3-n-butil-fenilo; 4-n-butil-fenilo; 2-iso-butil-fenilo; 3-iso-butil-fenilo; 4-iso-butil-fenilo; 2-terc-butil-fenilo; 3-terc-butil-fenilo; 4-terc-butil-fenilo; 1,1-dimetilpropil-fenilo; 2-ciclopentil-fenilo; 3-ciclopentil-fenilo; 4-ciclopentil-fenilo; 2-ciclohexil-fenilo; 3-ciclohexil-fenilo; 4-ciclohexil-fenilo; 2-metoxi-fenilo; 3-metoxi-fenilo; 4-metoxi-fenilo; 2-etoxi-fenilo; 3-etoxi-fenilo; 4-etoxi-fenilo; 2-n-propoxi-fenilo; 3-n-propoxi-fenilo; 4-n-propoxi-fenilo; 2-iso-propoxi-fenilo; 3-iso-propoxi-fenilo; 4-iso-propoxi-fenilo; 2-fluoro-fenilo; 3-fluoro-fenilo; 4-fluoro-fenilo; 2-cloro-fenilo; 3-cloro-fenilo; 4-cloro-fenilo; 2-bromo-fenilo; 3-bromo-fenilo; 4-bromo-


fenilo; 2-trifluorometil-fenilo; 3-trifluorometil-fenilo; 4-trifluorometil-fenilo; 2-trifluorometoxi-fenilo; 3-trifluorometoxi-fenilo; 4-trifluorometoxi-fenilo; 2-carboxi-fenilo; 3-carboxi-fenilo; 4-carboxi-fenilo; 2-acetil-fenilo; 3-acetil-fenilo; 4-acetil-fenilo; 2-(C=O)-O-CH_3-fenilo; 3-(C=O)-O-CH_3-fenilo; 4-(C=O)-O-CH_3-fenilo; 2-(CH_2)-(CH_2)-(C=O)-O-CH_3; 3-(CH_2)-(CH_2)-(C=O)-O-CH_3; 4-(CH_2)-(CH_2)-(C=O)-O-CH_3; 2-ciano-fenilo; 3-ciano-fenilo; 4-ciano-fenilo; 2-nitro-fenilo; 3-nitro-fenilo; 4-nitro-fenilo; 4-(4-bromofenoxi)-fenilo; 2-metilsulfonil-fenilo; 3-metilsulfonil-fenilo; 4-metilsulfonil-fenilo; 2-fenil-fenil-(bifenil-2-il); 3-fenil-fenil-(bifenil-3-il); 4-fenil-fenil-(bifenil-4-il); 2-fenoxi-fenilo; 3-fenoxi-fenilo; 4-fenoxi-fenilo; 2,4-dimetil-fenilo; 3,4-dimetil-fenilo; 2,4,6-trimetil-fenilo; 2,3,5,6-tetrametil-fenilo; pentametil-fenilo; 2,5-dimetoxi-fenilo; 3,4-dimetoxi-fenilo; 2,3-dicloro-fenilo; 2,4-dicloro-fenilo; 2,5-dicloro-fenilo; 3,4-dicloro-fenilo; 3,5-dicloro-fenilo; 2,6-dicloro-fenilo; 2,4-difluoro-fenilo; 3,4-difluoro-fenilo; 2,5-difluoro-fenilo; 2,6-difluoro-fenilo; 3-cloro-2-fluoro-fenilo; 3-cloro-4-fluoro-fenilo; 5-cloro-2-fluoro-fenilo; 2,3,4-tricloro-fenilo; 2,4,5-tricloro-fenilo; 2,4,6-tricloro-fenilo; 2,4,5-trifluoro-fenilo; 2,3,4-trifluoro-fenilo; 2-cloro-4,5-difluoro-fenilo; 2-bromo-4-fluoro-fenilo; 2-bromo-4,6-difluoro-fenilo; 4-cloro-2,5-difluoro-fenilo; 5-cloro-2,4-difluoro-fenilo; 4-bromo-2,5-difluoro-fenilo; 5-bromo-2,4-difluoro-fenilo; pentafluoro-fenilo; 2,4-dinitro-fenilo; 4-cloro-3-nitro-fenilo; 2-metil-5-nitro-fenilo; 5-bromo-2-metoxi-fenilo; 3-cloro-2-metil-fenilo; 4-bromo-3-metil-fenilo; 4-cloro-2,5-dimetil-fenilo; 4-fluoro-3-metil-fenilo; 5-fluoro-2-metil-fenilo; 2-nitro-4-trifluorometil-fenilo; 2-metoxi-4-metil-fenilo; 3,5-dicloro-2-hidroxi-fenilo; 3,5-dicloro-4-hidroxi-fenilo; 5-cloro-2,4-difluoro-fenilo; 3-cloro-4-(NH)-(C=O)-CH_3-fenilo; 2-cloro-6-metil-fenilo; 2-cloro-5-trifluorometil-fenilo; 2-cloro-5-trifluorometoxi-fenilo; 4-bromo-2-trifluorometoxi-fenilo; 4-bromo-2-trifluorometil-fenilo; 4-bromo-3-trifluorometil-fenilo; 3-carboxi-4-fluoro-fenilo; 3-carboxi-4-cloro-6-fluoro-fenilo; 4-metoxi-2,3,6-trimetil-fenilo; o uno de los grupos siguientes:


(57)


X
HN
N
NH-(C=O)-CH3
O
NH


X
(CH2)1-2X
F
Cl
N
NH-C(=O)-CH3
O
HO
H3C-(O=C)-O


X
S
X
S
X
Cl
S
X
O
S
N
H
X
N
X
N
X
N
X
F3C
O
N
X
X
N
Cl
S
N
N
X
N
H
O
H
N
X
O
NH
X
N
S
N
X
N
S
N


X
O
N
H
(CH2)—X
Cl



en los que en cada caso X indica la posición por la cual se une el sustituyente W^b respectivo al grupo $-SO_2-$ de la fórmula (Ib).

59. Compuesto según una cualquiera de las reivindicaciones 54 a 58, caracterizado porque R^{10b} representa hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido o un radical arilo o heteroarilo de 5 ó 6 miembros, opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o que puede estar

condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, preferiblemente H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo o un radical fenilo, más preferiblemente H, $-CH_3$, $-C_2H_5$ o fenilo.

60. Compuesto según una cualquiera de las reivindicaciones 54 a 59, caracterizado porque R^{11b} representa hidrógeno, un radical alifático C_{1-8} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-8} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo de 5 ó 6 miembros, opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-8} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, preferiblemente H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo o un radical fenilo, más preferiblemente H, $-CH_3$, $-C_2H_5$ o fenilo.

61. Compuesto según una cualquiera de las reivindicaciones 54 a 60, caracterizado porque R^{12b} representa un radical alifático C_{1-8} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-8} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo de 5 ó 6 miembros, opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-8} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, preferiblemente representa H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo o un radical fenilo, más preferiblemente H, $-CH_3$, $-C_2H_5$ o fenilo.

62. Compuesto según una cualquiera de las reivindicaciones 54 a 61, caracterizado porque R^{13b} y R^{14b} se seleccionan cada uno independientemente del grupo que consiste en hidrógeno, un radical alifático C_{1-8} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-8} saturado o insaturado, opcionalmente al menos monosustituido, que contiene

opcionalmente al menos un heteroátomo como miembro del anillo, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, o un radical arilo o heteroarilo de 5 ó 6 miembros, opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, preferiblemente se seleccionan cada uno independientemente del grupo que consiste en H, un radical alquilo C_{1-4} lineal o ramificado, ciclohexilo y un radical fenilo, más preferiblemente se seleccionan cada uno independientemente del grupo que consiste en H, $-CH_3$, $-C_2H_5$ y fenilo.

63. Compuesto según una cualquiera de las reivindicaciones 54 a 62, caracterizado porque R^{13b} y R^{14b} junto con el átomo puente de nitrógeno forman un anillo heterocíclico de 5 ó 6 miembros, saturado, insaturado o aromático, que puede estar al menos monosustituido y/o contener al menos un heteroátomo más como miembro del anillo, preferiblemente forman un grupo piperidina o morfolina no sustituido.

64. Compuesto según una cualquiera de las reivindicaciones 54 a 63, caracterizado porque R^{15b} representa hidrógeno, un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, un radical cicloalifático C_{3-6} saturado o insaturado, opcionalmente al menos monosustituido, que contiene opcionalmente al menos un heteroátomo como miembro del anillo o un radical arilo o heteroarilo de 5 ó 6 miembros, opcionalmente al menos monosustituido, que puede estar unido mediante un grupo alquileno C_{1-6} opcionalmente al menos monosustituido y/o que puede estar condensado con un sistema cíclico mono o policíclico opcionalmente al menos monosustituido, preferiblemente representa H, un radical alquilo C_{1-4} lineal o ramificado, un radical ciclohexilo o un radical fenilo, más preferiblemente representa H, $-CH_3$, $-C_2H_5$ o fenilo.

65. Compuesto según una cualquiera de las reivindicaciones 54 a 64, caracterizado porque R^{16b} representa un radical alifático C_{1-6} lineal o ramificado, saturado o insaturado, opcionalmente al menos monosustituido, preferiblemente un radical alquilo C_{1-3} lineal o ramificado, saturado, no sustituido, más preferiblemente un radical metilo.

66. Compuesto según una cualquiera de las reivindicaciones 54 a 65, caracterizado porque R^{17b} representa un radical alifático C_{1-6} lineal o ramificado,

saturado o insaturado, opcionalmente al menos monosustituido, preferiblemente un radical alquilo C_{1-3} lineal o ramificado, saturado, no sustituido, más preferiblemente un radical metilo.

67. Compuesto según una cualquiera de las reivindicaciones 54 a 66, caracterizado porque R^{1b} representa un radical fenilo, que está opcionalmente al menos monosustituido por un radical alifático C_{1-6}, más preferiblemente un radical fenilo, que está opcionalmente al menos monosustituido por un grupo metilo.

68. Compuesto según una cualquiera de las reivindicaciones 54 a 67, caracterizado porque R^{1b}, R^{2b}, R^{3b}, R^{4b} se seleccionan cada uno independientemente del grupo que consiste en un átomo de hidrógeno; un átomo de flúor; un átomo de cloro; un átomo de bromo; un grupo metilo y un grupo metoxi;

R^{5b} representa un átomo de hidrógeno;


R^{6b}, R^{7b}, R^{8b}, R^{9b} representan cada uno un átomo de hidrógeno;


W^b representa


un radical alquilo seleccionado del grupo que consiste en metilo; etilo; n-propilo; iso-propilo; n-butilo; sec-butilo; iso-butilo y terc-butilo; vinilo (CH_2=CH-); -$N(CH_3)_2$; 1-naftilo; bencilo; 2-naftilo; fenilo; 2-metil-fenilo; 3-metil-fenilo; 4-metil-fenilo; 2-etil-fenilo; 3-etil-fenilo; 4-etil-fenilo; 2-n-propil-fenilo; 3-n-propil-fenilo; 4-n-propil-fenilo; 2-isopropil-fenilo; 3-isopropil-fenilo: 4-isopropil-fenilo; 2-n-butil-fenilo; 3-n-butil-fenilo; 4-n-butil-fenilo; 2-iso-butil-fenilo; 3-iso-butil-fenilo; 4-iso-butil-fenilo; 2-terc-butil-fenilo; 3-terc-butil-fenilo; 4-terc-butil-fenilo; 1,1-dimetilpropil-fenilo; 2-ciclopentil-fenilo; 3-ciclopentil-fenilo; 4-ciclopentil-fenilo; 2-ciclohexil-fenilo; 3-ciclohexil-fenilo; 4-ciclohexil-fenilo; 2-metoxi-fenilo; 3-metoxi-fenilo; 4-metoxi-fenilo; 2-etoxi-fenilo; 3-etoxi-fenilo; 4-etoxi-fenilo; 2-n-propoxi-fenilo; 3-n-propoxi-fenilo; 4-n-propoxi-fenilo; 2-iso-propoxi-fenilo; 3-iso-propoxi-fenilo; 4-iso-propoxi-fenilo; 2-fluoro-fenilo; 3-fluoro-fenilo; 4-fluoro-fenilo; 2-cloro-fenilo; 3-cloro-fenilo; 4-cloro-fenilo; 2-bromo-fenilo; 3-bromo-fenilo; 4-bromo-fenilo; 2-trifluorometil-fenilo; 3-trifluorometil-fenilo; 4-trifluorometil-fenilo; 2-trifluorometoxi-fenilo; 3-trifluorometoxi-fenilo; 4-trifluorometoxi-fenilo; 2-carboxi-fenilo; 3-carboxi-fenilo; 4-carboxi-fenilo; 2-acetil-fenilo; 3-acetil-fenilo; 4-acetil-fenilo; 2-(C=O)-O-CH_3-fenilo; 3-(C=O)-O-CH_3-fenilo; 4-(C=O)-O-CH_3-fenilo; 2-(CH_2)-(CH_2)-(C=O)-O-CH_3; 3-(CH_2)-(CH_2)-(C=O)-O-CH_3; 4-(CH_2)-(CH_2)-(C=O)-O-CH_3; 2-ciano-fenilo; 3-ciano-fenilo; 4-ciano-fenilo; 2-nitro-fenilo; 3-nitro-fenilo; 4-nitro-fenilo; 4-(4-bromofenoxi)-fenilo; 2-metilsulfonil-fenilo; 3-metilsulfonil-fenilo; 4-metilsulfonil-fenilo; 2-fenil-fenil-(bifenil-2-il); 3-fenil-fenil-(bifenil-3-il); 4-fenil-fenil-(bifenil-4-il); 2-fenoxi-fenilo; 3-fenoxi-fenilo; 4-fenoxi-fenilo; 2,4-dimetil-fenilo; 3,4-dimetil-fenilo; 2,4,6-trimetil-fenilo; 2,3,5,6-


tetrametil-fenilo; pentametil-fenilo; 2,5-dimetoxi-fenilo; 3,4-dimetoxi-fenilo; 2,3-dicloro-fenilo; 2,4-dicloro-fenilo; 2,5-dicloro-fenilo; 3,4-dicloro-fenilo; 3,5-dicloro-fenilo; 2,6-dicloro-fenilo; 2,4-difluoro-fenilo; 3,4-difluoro-fenilo; 2,5-difluoro-fenilo; 2,6-difluoro-fenilo; 3-cloro-2-fluoro-fenilo; 3-cloro-4-fluoro-fenilo; 5-cloro-2-fluoro-fenilo; 2,3,4-tricloro-fenilo; 2,4,5-tricloro-fenilo; 2,4,6-tricloro-fenilo; 2,4,5-trifluoro-fenilo; 2,3,4-trifluoro-fenilo; 2-cloro-4,5-difluoro-fenilo; 2-bromo-4-fluoro-fenilo; 2-bromo-4,6-difluoro-fenilo; 4-cloro-2,5-difluoro-fenilo; 5-cloro-2,4-difluoro-fenilo; 4-bromo-2,5-difluoro-fenilo; 5-bromo-2,4-difluoro-fenilo; pentafluoro-fenilo; 2,4-dinitro-fenilo; 4-cloro-3-nitro-fenilo; 2-metil-5-nitro-fenilo; 5-bromo-2-metoxi-fenilo; 3-cloro-2-metil-fenilo; 4-bromo-3-metil-fenilo; 4-cloro-2,5-dimetil-fenilo; 4-fluoro-3-metil-fenilo; 5-fluoro-2-metil-fenilo; 2-nitro-4-trifluorometil-fenilo; 2-metoxi-4-metil-fenilo; 3,5-dicloro-2-hidroxi-fenilo; 3,5-dicloro-4-hidroxi-fenilo; 5-cloro-2,4-difluoro-fenilo; 3-cloro-4-(NH)-(C=O)-CH_3-fenilo; 2-cloro-6-metil-fenilo; 2-cloro-5-trifluorometil-fenilo; 2-cloro-5-trifluorometoxi-fenilo; 4-bromo-2-trifluorometoxi-fenilo; 4-bromo-2-trifluorometil-fenilo; 4-bromo-3-trifluorometil-fenilo; 3-carboxi-4-fluoro-fenilo; 3-carboxi-4-cloro-6-fluoro-fenilo; 4-metoxi-2,3,6-trimetil-fenilo; o uno de los grupos siguientes:


4.87




X
(CH2)n-2X
X
X
F
X
Cl
X
N
X
Cl
X
NH-C(=O)-CH3
X
N
O
O
X
HO
HO
X
H3C-(O=C)-O
H3C-(O=C)-O
(CH2)n-2-X
X
X
Cl


X
S
X
S
Cl
X
S
X
O
N
H
X
N
X
N
X
N
X
F3C
O
N
X
X
N
Cl
S
N
N
X
N
H
O
N
H
NH
O
X
X
N
S
N
X
N
S
N


X
O
O
X
O
X
O
X
O
X
O
X
O
X
O
X
O
X
O
X
O
X
N
X
O
X
N
H
X
O
X
N
X
O
X
N
H
X
O
X
N
X
(CH2)—X
N
O
X
N
O
N
Cl
X
N
O
N



en los que en cada caso X indica la posición por la que se une el sustituyente W^b respectivo al grupo $-SO_2$ de la fórmula (Ib),

opcionalmente en forma de uno de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisómeros, preferiblemente enantiómeros o diasterómeros, en cualquier razón de mezcla, o una sal fisiológicamente aceptable de los mismos, o un solvato, respectivamente.

69. Compuesto según una cualquiera de las reivindicaciones 54 a 68 seleccionado del siguiente grupo:

Nº	Compuesto
1	1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
2	1-[1-(tolueno-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

3	1-(1-fenilmetanosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
4	1-(1-bencenosulfonil-piperidin-4-il)-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
5	6-cloro-1-[1-(tolueno-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
6	6-cloro-1-(1-fenilmetanosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
7	6-cloro-1-[1-(naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
8	6-cloro-1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
9	6-cloro-1-[1-(5-cloro-3-metil-benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
10	1-[1-(tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
11	1-[1-(4-acetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
12	2-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo
13	1-[1-(2,4-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
14	1-[1-(4-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
15	1-[1-(2-naftalen-1-il-etanosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
16	8-metil-1-[1-(tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
17	1-[1-(4-acetil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
18	2-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo
19	1-[1-(2,4-dimetil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
20	1-[1-(4-metoxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
21	8-metil-1-[1-(2-naftalen-1-il-etanosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
22	Dimetilamida del ácido 4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfónico
23	Éster metílico del ácido 2-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
24	1-[1-(3-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
25	Éster metílico del ácido 2-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il]-piperidina-1-sulfonil]-benzoico
26	8-metil-1-[1-(3-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
27	1-[1-(4-acetil-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
28	2-[4-(6-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo
29	6-cloro-1-[1-(4-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
30	Éster metílico del ácido 2-[4-(6-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
31	6-cloro-1-[1-(2,4-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-

	benzo[d][1,3]oxacin-2-ona
32	6-cloro-1-[1-(3-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
33	1-[1-(5-cloro-3-metil-benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
34	1-[1-[4-(4-bromo-fenoxi)-bencenosulfonil]-piperidin-4-il)-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
35	1-[1-(4-fluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
36	8-metil-1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
37	8-metil-1-(1-fenilmetanosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
38	1-[1-(4-bromo-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
39	6-cloro-1-[1-(4-metanosulfonil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
40	1-[1-(butano-1-sulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
41	1-[1-(4-bromo-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
42	1-[1-(4-metanosulfonil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
43	1-[1-butano-1-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
44	6-cloro-1-[1-(2-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
45	6-cloro-1-[1-(3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
46	1-[1-(bifenil-4-sulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
47	8-metil-1-[1-(2-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
48	8-metil-1-[1-(3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
49	1-[1-(bifenil-4-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
50	8-metil-1-[1-(4-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
51	6-cloro-1-[1-(4-nitro-bencenosulfonil]-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
52	1-(1-etanosulfonil-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
53	1-[1-(propano-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
54	1-[1-(propano-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
55	6-cloro-1-(1-etanosulfonil-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
56	6-cloro-1-[1-(propano-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
57	6-cloro-1-[1-(propano-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
58	6-cloro-1-[1-(quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

59	1-[1-(4-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
60	6-metil-1-[1-(quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
61	6-metil-1-[1-(2-naftalen-1-il-etanosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
62	6-metil-1-[1-(tolueno-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
63	1-[1-(4-fluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
64	6-metil-1-[1-(naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
65	6-metil-1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
66	1-[1-(5-cloro-3-metil-benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
67	6-metil-1-[1-(4-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
68	1-(1-bencenosulfonil-piperidin-4-il)-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
69	1-[1-(4-cloro-3-nitro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
70	1-[1-(5-dimetilamino-naftaleno-1-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
71	1-[1-(4-cloro-3-nitro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
72	1-[1-(4-cloro-3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
73	6-cloro-1-[1-(4-cloro-3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
74	6-cloro-1-[1-(5-dimetilamino-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
75	1-[1-(4-metoxi-2,3,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
76	1-[1-(4-metoxi-2,3,6-trimetil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
77	6-cloro-1-[1-(4-metoxi-2,3,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
78	1-[1-(4-metoxi-2,3,6-trimetil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
79	1-[1-(2-bromo-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
80	1-[1-(2-bromo-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
81	1-[1-(2-bromo-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
82	1-[1-(2-bromo-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
83	6-cloro-1-[1-(2,3-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
84	1-[1-(2,3-dicloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
85	1-[1-(2,4,5-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

86	8-metil-1-[1-(2,4,5-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
87	6-cloro-1-[1-(2,4,5-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
88	6-metil-1-[1-(2,4,5-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
89	1-[1-(5-bromo-2-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
90	1-[1-(5-bromo-2-metoxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
91	1-[1-(5-bromo-2-metoxi-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
92	1-[1-[5-bromo-2-metoxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
93	1-[1-(2,5-dimetoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
94	1-[1-(2,5-dimetoxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
95	6-cloro-1-[1-(2,5-dimetoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
96	1-[1-(2,5-dimetoxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
97	1-(1-pentametilbencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
98	8-metil-1-(1-pentametilbencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
99	6-cloro-1-(1-pentametilbencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
100	6-metil-1-(1-pentametilbencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
101	1-[1-[2-(2,2,2-trifluoro-acetil)-1,2,3,4-tetrahidro-isoquinolina-7-sulfonil]-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
102	8-metil-1-[1-[2-(2,2,2-trifluoro-acetil)-1,2,3,4-tetrahidro-isoquinolina-7-sulfonil]-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
103	6-cloro-1-[1-[2-(2,2,2-trifluoro-acetil)-1,2,3,4-tetrahidro-isoquinolina-7-sulfonil]-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
104	6-metil-1-[1-[2-(2,2,2-trifluoro-acetil)-1,2,3,4-tetrahidro-isoquinolina-7-sulfonil]-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
105	1-[1-(2-metil-5-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
106	8-metil-1-[1-(2-metil-5-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
107	6-cloro-1-[1-(2-metil-5-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
108	6-metil-1-[1-(2-metil-5-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
109	1-[1-(4-bromo-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
110	1-[1-(4-bromo-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
111	1-[1-(4-bromo-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

112	1-[1-(4-bromo-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
113	1-[1-(4-cloro-2,5-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
114	1-[1-(4-cloro-2,5-dimetil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
115	6-cloro-1-[1-(4-cloro-2,5-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
116	1-[1-(4-cloro-2,5-dimetil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
117	1-[1-(4-metoxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
118	1-[1-(4-isopropil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
119	1-[1-(4-isopropil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
120	6-cloro-1-[1-(4-isopropil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
121	1-[1-(4-isopropil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
122	1-[1-(3-cloro-4-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
123	1-[1-(3-cloro-4-fluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
124	6-cloro-1-[1-(3-cloro-4-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
125	1-[1-(3-cloro-4-fluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
126	1-[1-(4-bromo-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
127	6-metil-1-[1-(3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
128	6-metil-1-[1-(3-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
129	1-[1-(4-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
130	1-[1-(2-nitro-4-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
131	1-[1-(3-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
132	1-[1-(2,4-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
133	1-[1-(2,4,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
134	1-[1-(2-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
135	8-metil-1-[1-(4-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
136	8-metil-1-[1-(2-nitro-4-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
137	1-[1-(3-fluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

138	1-[1-(2,4-dicloro-bencenosulfonil)-piperidin-4-il]-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
139	8-metil-1-[1-(2,4,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
140	8-metil-1-[1-(2-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
141	1-[1-(4-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
142	1-[1-(4-bromo-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
143	1-[1-(3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
144	1-[1-[4-(4-bromo-fenoxi)-bencenosulfonil]-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
145	1-[1-(3-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
146	1-[1-(2-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
147	8-metil-1-[1-(tolueno-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
148	1-(1-bencenosulfonil-piperidin-4-il)-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
149	1-[1-(3-metoxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
150	1-[1-(2,4-dimetil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
151	1-[1-[4-(4-bromo-fenoxi)-bencenosulfonil]-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
152	8-metil-1-[1-(tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
153	1-[1-(tolueno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
154	1-[1-(5-fluoro-2-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
155	1-[1-(4-isopropoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
156	1-[1-(3-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
157	1-[1-3,4-dimetoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
158	1-(1-pentafluorobencenosulfonil-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
159	8-metil-1-[1-tolueno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
160	1-[1-(5-fluoro-2-metil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
161	1-[1-(4-isopropoxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
162	1-[1-(3-cloro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
163	1-[1-(3,4-dimetoxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
164	8-metil-1-(1-pentafluorobencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
165	8-metil-1-[1-(tolueno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-

	ona
166	1-[1-(5-fluoro-2-metil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
167	1-[1-(4-isopropoxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
168	1-[1-(3-cloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
169	1-[1-(3,4-dimetoxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
170	6-metil-1-(1-pentafluorobencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
171	6-metil-1-[1-(4-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
172	6-metil-1-[1-(2-nitro-4-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
173	1-[1-(3-fluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
174	1-[1-(2,4-dicloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
175	6-metil-1-[1-(2,4,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
176	6-metil-1-[1-(2-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
177	1-[1-(3-metoxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
178	6-metil-1-[1-(2-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
179	1-[1-(4-acetil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
180	1-[1-(4-metanosulfonil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
181	6-metil-1-(1-fenilmetanosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
182	Éster metílico del ácido 2-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]benzoico
183	6-metil-1-[1-(2-oxo-2H-cromeno-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
184	6-cloro-1-[1-(4-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
185	6-cloro-1-[1-(3,5-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
186	1-{1-[4-(4-bromo-fenoxi)-bencenosulfonil]-piperidin-4-il}-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
187	6-cloro-1-(1-tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
188	6-cloro-1-[1-(3-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
189	6-cloro-1-[1-(2-oxo-2H-cromeno-6-sulfonil]-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
190	6-cloro-1-[1-(tolueno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
191	6-cloro-1-[1-(5-fluoro-2-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-

	benzo[d][1,3]oxacin-2-ona
192	6-cloro-1-[1-(4-isopropoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
193	6-cloro-1-[1-(3-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
194	6-cloro-1-[1-(3,4-dimetoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
195	6-cloro-1-(1-pentafluorobencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
196	6-cloro-1-[1-(4-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
197	6-cloro-1-[1-(2-nitro-4-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
198	6-cloro-1-[1-(3-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
199	6-cloro-1-[1-(2,4-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
200	6-cloro-1-[1-(2,4,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
201	6-cloro-1-[1-(2-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
202	1-[1-(2-oxo-2H-cromeno-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
203	1-[1-(3,5-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
204	1-[1-(2,5-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
205	1-[1-(5-bromo-6-cloro-piridina-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
206	1-[1-(4-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
207	1-[1-(2,6-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
208	8-metil-1-[1-(2-oxo-2H-cromeno-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
209	1-[1-(3,5-dicloro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
210	1-[1-(2,5-dicloro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
211	1-[1-(5-bromo-6-cloro-piridina-3-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
212	1-[1-(4-cloro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
213	1-[1-(2,6-dicloro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
214	1-[1-(bifenil-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
215	6-cloro-1-[1-(2,5-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
216	1-[1-(5-bromo-6-cloro-piridina-3-sulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
217	6-cloro-1-[1-(4-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

218	6-cloro-1-[1-(2,6-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
219	1-[1-(bifenil-4-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
220	2-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo
221	1-[1-(2,5-dicloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
222	1-[1-(5-bromo-6-cloro-piridina-3-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
223	1-[1-(4-cloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
224	1-[1-(2,6-dicloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
225	1-[1-(3,5-dicloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
226	6-metil-1-[1-(1-metil-1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
227	1-[1-(5-bromo-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
228	1-[1-(4-metanosulfonil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
229	1-[1-(1-metil-1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
230	1-[1-(5-bromo-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
231	1-[1-(6-cloro-imidazo[2,1-b]tiazol-5-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
232	1-[1-(4-etil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
233	1-[1-(benzo[b]tiofeno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
234	1-[1-(6-cloro-imidazo[2,1-b]tiazol-5-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
235	1-[1-(4-etil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
236	1-[1-(benzo[b]tiofeno-3-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
237	6-cloro-1-[1-(6-cloro-imidazo[2,1-b]tiazol-5-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
238	6-cloro-1-[1-(4-etil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
239	1-[1-(benzo[b]tiofeno-3-sulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
240	1-[1-(6-cloro-imidazo[2,1-b]tiazol-5-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
241	1-[1-(4-etil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
242	1-[1-(benzo[b]tiofeno-3-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
243	1-[1-(7-cloro-benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
244	1-[1-(2-metoxi-4-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

245	Éster metílico del ácido 3-{4-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-fenil}-propiónico
246	1-[1-(2,4-dinitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
247	1-[1-(7-cloro-benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
248	1-[1-(2-metoxi-4-metil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
249	Éster metílico del ácido 3-{4-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-fenil}-propiónico
250	1-[1-(2,4-dinitro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
251	1-[1-(7-cloro-benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
252	1-[1-(2-metoxi-4-metil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
253	Éster metílico del ácido 3-{4-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-fenil}-propiónico
254	1-[1-(2,4-dinitro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
255	6-cloro-1-[1-(7-cloro-benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
256	6-cloro-1-[1-(2-metoxi-4-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
257	Éster metílico del ácido 3-{4-[4-(6-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-fenil}-propiónico
258	6-cloro-1-[1-(2,4-dinitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
259	6-cloro-1-[1-(1-metil-1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
260	1-[1-(5-bromo-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
261	8-metil-1-[1-(1-metil-1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
262	1-[1-(5-bromo-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
263	1-[1-(benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
264	1-[1-(benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
265	1-[1-(benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
266	1-[1-(benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
267	1-[1-(2,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
268	1-[1-(2,5-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
269	6-cloro-1-[1-(2,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
270	1-[1-(2,5-difluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

271	1-[1-(4-cloro-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
272	1-[1-(4-cloro-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
273	6-cloro-1-[1-(4-cloro-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
274	1-[1-(4-cloro-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
275	1-[1-(2,4,5-trifluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
276	8-metil-1-[1-(2,4,5-trifluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
277	6-cloro-1-[1-(2,4,5-trifluoro-bencenosulfonil]-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
278	6-metil-1-[1-(2,4,5-trifluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
279	1-[1-(3,5-dicloro-2-hidroxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
280	1-[1-(2,6-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
281	1-[1-(2,6-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
282	6-cloro-1-[1-(2,6-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
283	1-[1-(2,6-difluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
284	1-[1-(5-cloro-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
285	1-[1-(5-cloro-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
286	6-cloro-1-[1-(5-cloro-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
287	1-[1-(5-cloro-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
288	1-[1-(2-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
289	1-[1-(2-cloro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
290	6-cloro-1-[1-(2-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
291	1-[1-(2-cloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
292	6-cloro-1-[1-(2-naftalen-1-il-etanosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
293	6-bromo-1-[1-(4-bromo-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
294	6-bromo-1-[1-(tolueno-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
295	6-bromo-1-[1-(2,4-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
296	6-bromo-1-[1-(2-naftalen-1-il-etanosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

297	6-bromo-1-[1-(quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
298	6-bromo-1-[1-(5-cloro-3-metil-benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
299	6-bromo-1-[1-(3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
300	6-bromo-1-[1-(naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
301	6-bromo-1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
302	1-(1-bencenosulfonil-piperidin-4-il)-6-bromo-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
303	6-bromo-1-[1-[4-(4-bromo-fenoxi)-bencenosulfonil]-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
304	6-bromo-1-[1-(tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
305	6-bromo-1-[1-(2-metil-5-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
306	6-bromo-1-[1-(4-bromo-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
307	6-bromo-1-[1-(tolueno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
308	6-bromo-1-[1-(5-fluoro-2-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
309	6-bromo-1-[1-(4-isopropoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
310	6-bromo-1-[1-(3-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
311	6-bromo-1-[1-(3,4-dimetoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
312	6-bromo-1-(1-pentafluorobencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
313	6-bromo-1-[1-(4-cloro-2,5-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
314	6-bromo-1-[1-(3-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
315	6-bromo-1-[1-(4-isopropil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
316	6-bromo-1-[1-(4-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
317	6-bromo-1-[1-(3-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
318	6-bromo-1-(1-pentametilbencenosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
319	6-bromo-1-[1-(2-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
320	6-bromo-1-[1-(4-cloro-3-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
321	6-bromo-1-[1-(5-dimetilamino-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
322	6-bromo-1-[1-(4-nitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

323	1-[1-(4-acetil-bencenosulfonil)-piperidin-4-il]-6-bromo-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
324	6-bromo-1-[1-(4-metanosulfonil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
325	1-[1-(bifenil-4-sulfonil)-piperidin-4-il]-6-bromo-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
326	6-bromo-1-(1-fenilmetanosulfonil-piperidin-4-il)-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
327	6-bromo-1-[1-(2,5-dimetoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
328	6-bromo-1-{1-[2-(2,2,2-trifluoro-acetil)-1,2,3,4-tetrahidro-isoquinolina-7-sulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
329	6-bromo-1-[1-(2,3-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
330	6-bromo-1-[1-(2,4,5-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
331	6-bromo-1-[1-(5-bromo-2-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
332	6-bromo-1-[1-(4-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
333	6-bromo-1-[1-(2-nitro-4-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
334	6-bromo-1-[1-(3-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
335	6-bromo-1-[1-(2,4-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
336	6-bromo-1-[1-(2,4,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
337	6-bromo-1-[1-(2-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
338	6-bromo-1-[1-(2-bromo-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
339	6-bromo-1-[1-(4-metoxi-2,3,6-trimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
340	1-[1-(3,5-dicloro-4-hidroxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
341	1-[1-(3,5-dicloro-4-hidroxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
342	6-cloro-1-[1-(3,5-dicloro-4-hidroxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
343	1-[1-(3,5-dicloro-4-hidroxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
344	6-bromo-1-[1-(3,5-dicloro-4-hidroxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
345	6-cloro-1-[1-(3,5-dicloro-2-hidroxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
346	6-bromo-1-[1-(3,5-dicloro-2-hidroxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
347	2-[4-(6-bromo-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo
348	6-bromo-1-[1-(4-metoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

349	Éster metílico del ácido 2-[4-(6-bromo-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
350	6-bromo-1-[1-(3-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
351	6-bromo-1-[1-(2-oxo-2H-cromeno-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
352	6-bromo-1-[1-(3,5-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
353	6-bromo-1-[1-(2,5-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
354	6-bromo-1-[1-(5-bromo-6-cloro-piridina-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
355	6-bromo-1-[1-(4-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
356	6-bromo-1-[1-(2,6-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
357	6-bromo-1-[1-(1-metil-1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
358	6-bromo-1-[1-(5-bromo-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
359	6-bromo-1-[1-(4-etil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
360	6-bromo-1-[1-(6-cloro-imidazo[2,1-b]tiazol-5-sulfonil)-piperedin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
361	1-[1-(benzo[b]tiofeno-3-sulfonil)-piperidin-4-il]-6-bromo-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
362	6-bromo-1-[1-(7-cloro-benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
363	6-bromo-1-[1-(2-metoxi-4-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
364	Éster metílico del ácido 3-{4-[4-(6-bromo-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-fenil}-propiónico
365	6-bromo-1-[1-(2,4-dinitro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
366	1-[1-(benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-6-bromo-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
367	6-bromo-1-[1-(2,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
368	6-bromo-1-[1-(4-cloro-2,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
369	6-bromo-1-[1-(2,4,5-trifluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
370	6-bromo-1-[1-(2,6-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
371	6-bromo-1-[1-(5-cloro-2,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
372	6-bromo-1-[1-(2-cloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
373	6-bromo-1-[1-(2,3,4-trifluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
374	N-{4-[4-(6-bromo-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-2-cloro-fenil}-acetamida

375	1-[1-(2,3,4-trifluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
376	8-metil-1-[1-(2,3,4-trifluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
377	6-cloro-1-[1-(2,3,4-trifluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
378	6-metil-1-[1-(2,3,4-trifluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
379	N-{2-cloro-4-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-fenil}-acetamida
380	1-[1-(3,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
381	1-[1-(3,4-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
382	6-cloro-1-[1-(3,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
383	1-[1-(3,4-difluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
384	6-bromo-1-[1-(3,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
385	N-{2-cloro-4-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-fenil}-acetamida
386	1-[1-(2-cloro-4,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
387	1-[1-(2-cloro-4,5-difluoro-bencenosulfonil]-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
388	6-cloro-1-[1-(2-cloro-4,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
389	1-[1-(2-cloro-4,5-difluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
390	6-bromo-1-[1-(2-cloro-4,5-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
391	N-{2-cloro-4-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-fenil}-acetamida
392	1-[1-(benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
393	1-[1-(benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
394	1-[1-(benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
395	1-[1-(benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
396	1-[1-(benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-6-bromo-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
397	N-{2-cloro-4-[4-(6-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-fenil}-acetamida
398	1-[1-(benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
399	1-[1-(benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
400	1-[1-(benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

401	1-[1-(benzo[1,2,5]tiadiazol-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
402	1-[1-(benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-6-bromo-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
403	1-(1-etanosulfonil-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
404	1-[1-(2,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
405	1-[1-(2,4-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
406	6-cloro-1-[1-(2,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
407	1-[1-(2,4-difluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
408	6-bromo-1-[1-(2,4-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
409	8-metil-1-[propano-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
410	1-[1-(3,4-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
411	1-[1-(3,4-dicloro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
412	6-cloro-1-[1-(3,4-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
413	1-[1-(3,4-dicloro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
414	6-bromo-1-[1-(3,4-dicloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
415	8-metil-1-[1-(propano-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
416	1-[1-(2-cloro-6-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
417	1-[1-(2-cloro-6-metil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
418	6-cloro-1-[1-(2-cloro-6-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
419	1-[1-(2-cloro-6-metil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
420	1-[1-(2-cloro-6-metil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
421	8-metil-1-[1-(2,3,5,6-tetrametil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
422	1-[1-2,3,4-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
423	8-metil-1-[1-(2,3,4-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
424	6-cloro-1-[1-(2,3,4-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
425	6-metil-1-[1-(2,3,4-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
426	6-bromo-1-[1-(2,3,4-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
427	1-[1-(2,3,5,6-tetrametil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

428	1-[1-(tiofeno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
429	8-metil-1-[1-(tiofeno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
430	6-cloro-1-[1-(tiofeno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
431	6-metil-1-[1-(tiofeno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
432	6-bromo-1-[1-(tiofeno-3-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
433	6-cloro-1-[1-(2,3,5,6-tetrametil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
434	1-[1-(2,4,6-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
435	8-metil-1-[1-(2,4,6-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
436	6-cloro-1-[1-(2,4,6-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
437	6-metil-1-[1-(2,4,6-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
438	6-bromo-1-[1-(2,4,6-tricloro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
439	6-metil-1-[1-(2,3,5,6-tetrametil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
440	1-[1-(2-bromo-4,6-difluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
441	1-[1-(2-bromo-4,6-difluoro-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
442	1-[1-(2-bromo-4,6-difluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
443	6-bromo-1-[1-(2-bromo-4,6-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
444	6-bromo-1-[1-(2,3,5,6-tetrametil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
445	1-[1-(4-bromo-2-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
446	1-[1-(4-bromo-2-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
447	1-[1-(4-bromo-2-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
448	1-[1-(4-bromo-2-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
449	6-bromo-1-[1-(4-bromo-2-trifluorometoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
450	1-[1-(4-fenoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
451	1-[1-(3-bromo-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
452	1-[1-(3-bromo-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
453	1-[1-(3-bromo-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
454	1-[1-(3-bromo-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-

	benzo[d][1,3]oxacin-2-ona
455	6-bromo-1-[1-[3-bromo-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
456	8-metil-1-[1-(4-fenoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
457	1-[1-(4-terc-butil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
458	1-[1-(4-terc-butil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
459	1-[1-(4-terc-butil-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
460	1-[1-(4-terc-butil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
461	6-bromo-1-[1-(4-terc-butil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
462	6-cloro-1-[1-(4-fenoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
463	1-[1-(2-bromo-4,6-difluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
464	1-[1-(2-metanosulfonil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
465	6-cloro-1-[1-(2-metanosulfonil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
466	1-[1-(2-metanosulfonil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
467	6-bromo-1-[1-(2-metanosulfonil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
468	8-metil-1-[1-(4-propil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
469	6-cloro-1-[1-(4-propil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
470	6-metil-1-[1-(4-propil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
471	6-bromo-1-[1-(4-propil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
472	1-[1-(3-cloro-2-metil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
473	6-cloro-1-[1-(3-cloro-2-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
474	1-[1-[3-cloro-2-metil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
475	6-bromo-1-[1-(3-cloro-2-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
476	1-[1-(4-butil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
477	1-[1-(4-butil-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
478	1-[1-(4-butil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
479	6-bromo-1-[1-(4-butil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
480	1-[1-(4-bromo-3-metil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-

	benzo[d][1,3]oxacin-2-ona
481	1-[1-(4-bromo-3-metil-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
482	1-[1-(4-bromo-3-metil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
483	6-bromo-1-[1-(4-bromo-3-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
484	1-{1-[4-(1,1-dimetil-propil)-bencenosulfonil]-piperidin-4-il}-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
485	6-cloro-1-{1-[4-(1,1-dimetil-propil)-bencenosulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
486	1-{1-[4-(1,1-dimetil-propil)-bencenosulfonil]-piperidin-4-il}-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
487	6-bromo-1-{1-[4-(1,1-dimetil-propil)-bencenosulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
488	1-(1-etanosulfonil-piperidin-4-il)-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
489	Ácido 3-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il]-piperina-1-sulfonil]-benzoico
490	Ácido 3-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il]-piperina-1-sulfonil]-benzoico
491	Ácido 3-[4-(6-bromo-2-oxo-4H-benzo[d][1,3]oxacin-1-il]-piperina-1-sulfonil]-benzoico
492	1-[1-(3-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
493	6-cloro-1-[1-(3-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
494	1-[1-(3-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
495	6-bromo-1-[1-(3-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
496	N-{4-metil-5-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-tiazol-2-il}-acetamida
497	N-{5-[4-(6-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-4-metil-tiazol-2-il}-acetamida
498	N-{4-metil-5-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-tiazol-2-il}-acetamida
499	N-{5-[4-(6-bromo-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-4-metil-tiazol-2-il}-acetamida
500	1-[1-(2-bromo-4-fluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
501	1-[1-(2-bromo-4-fluoro-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
502	1-[1-(2-bromo-4-fluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
503	6-bromo-1-[1-(2-bromo-4-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
504	1-[1-5-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
505	6-cloro-1-[1-(5-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
506	1-[1-(5-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

507	6-bromo-1-[1-(5-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
508	1-[1-(4-bromo-3-trifluorometil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
509	1-[1-(4-bromo-3-trifluorometil-bencenosulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
510	1-[1-(4-bromo-3-trifluorometil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
511	6-bromo-1-[1-(4-bromo-3-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
512	1-[1-(2-metanosulfonil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
513	1-[1-(4-propil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
514	1-[1-(3-cloro-2-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
515	1-[1-(4-butil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
516	1-[1-(4-bromo-3-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
517	1-{1-[4-(1,1-dimetil-propil)-bencenosulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
518	N-{4-metil-5-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-tiazol-2-il}-acetamida
519	1-[1-(3-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
520	1-[1-(2-bromo-4-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
521	1-[1-(4-bromo-3-trifluorometil-bencenosulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
522	1-[1-(5-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
523	1-[1-(isoquinolina-5-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
524	6-fluoro-1-[1-(2-metanosulfonil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
525	6-fluoro-1-[1-(4-propil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
526	1-[1-(3-cloro-2-metil-bencenosulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
527	1-[1-(4-butil-bencenosulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
528	1-[1-(4-bromo-3-metil-bencenosulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
529	1-{1-[4-(1,1-dimetil-propil)-bencenosulfonil]-piperidin-4-il}-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
530	N-{5-[4-(6-fluoro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-4-metil-tiazol-2-il}-acetamida
531	1-[1-(3-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
532	1-[1-(2-bromo-4-fluoro-bencenosulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
533	1-[1-(4-bromo-3-trifluorometil-bencenosulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

534	1-[1-(5-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
535	6-fluoro-1-[1-(isoquinolina-5-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
536	6-fluoro-1-[1-(quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
537	1-[1-(5-cloro-3-metil-benzo[b]tiofeno-2-sulfonil]-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
538	6-fluoro-1-[1-(naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
539	6-fluoro-1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
540	1-[1-(benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
541	1-[1-(benzo[b]tiofeno-3-sulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
542	8-metoxi-1-[1-(quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
543	1-[1-(5-cloro-3-metil-benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
544	8-metoxi-1-[1-(naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
545	8-metoxi-1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
546	1-[1-(benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
547	1-[1-(benzo[b]tiofeno-3-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
548	5-cloro-1-[1-(2-metanosulfonil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
549	5-cloro-1-[1-(4-propil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
550	5-cloro-1-[1-(3-cloro-2-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
551	1-[1-(4-butil-bencenosulfonil)-piperidin-4-il]-5-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
552	1-[1-(4-bromo-3-metil-bencenosulfonil)-piperidin-4-il]-5-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
553	5-cloro-1-{1-[4-(1,1-dimetil-propil)-bencenosulfonil]-piperidin-4-il}-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
554	N-{5-[4-(5-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-4-metil-tiazol-2-il}-acetamida
555	5-cloro-1-[1-(3-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
556	1-[1-(2-bromo-4-fluoro-bencenosulfonil)-piperidin-4-il]-5-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
557	1-[1-(4-bromo-3-trifluorometil-bencenosulfonil)-piperidin-4-il]-5-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
558	5-cloro-1-[1-(5-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
559	5-cloro-1-[1-(isoquinolina-5-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

560	1-[1-(2-metanosulfonil-bencenosulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
561	1-[1-(2-metanosulfonil-bencenosulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
562	1-[1-(3-cloro-2-metil-bencenosulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
563	1-[1-(4-butil-bencenosulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
564	1-[1-(4-bromo-3-metil-bencenosulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
565	1-[1-[4-(1,1-dimetil-propil)-bencenosulfonil]-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
566	N-[5-[4-(8-metoxi-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-4-metil-tiazol-2-il]-acetamida
567	1-[1-[3-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
568	1-[1-[2-bromo-4-fluoro-bencenosulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
569	1-[1-(4-bromo-3-trifluorometil-bencenosulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
570	1-[1-(5-cloro-2-fluoro-bencenosulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
571	Clorhidrato de 1-[1-(isoquinolina-5-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
572	1-[1-(4-metil-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
573	6-cloro-1-[1-(4-metil-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
574	6-metil-1-[1-(4-metil-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
575	8-metil-1-[1-(4-metil-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
576	6-fluoro-1-[1-(4-metil-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
577	8-metoxi-1-[1-(4-metil-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
578	5-cloro-1-[1-(4-metil-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
579	5-cloro-1-[1-(naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
580	5-cloro-1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
581	5-cloro-1-[1-(quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
582	5-cloro-1-[1-(5-cloro-3-metil-benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
583	1-[1-(benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-5-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
584	1-[1-(benzo[b]tiofeno-3-sulfonil)-piperidin-4-il]-5-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
585	6-bromo-1-[1-(4-metil-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

586	Ácido 2-cloro-4-fluoro-5-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
587	Ácido 2-cloro-5-[4-(6-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-4-fluoro-benzoico
588	Ácido 2-cloro-4-fluoro-5-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
589	Ácido 2-cloro-4-fluoro-5-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
590	Ácido 2-cloro-4-fluoro-5-[4-(8-metoxi-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
591	Ácido 2-cloro-5-[4-(5-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-4-fluoro-benzoico
592	Ácido 3-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
593	Ácido 3-[4-(8-metoxi-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
594	Ácido 3-[4-(5-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
595	Clorhidrato de 1-[1-(isoquinolina-5-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
596	Clorhidrato de 6-cloro-1-[1-(isoquinolina-5-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
597	Clorhidrato de [1-(isoquinolina-5-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
598	6,7-difluoro-1-[1-(quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
599	1-[1-(5-cloro-3-metil-benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
600	6,7-difluoro-1-[1-(naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
601	6,7-difluoro-1-[1-(naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
602	1-[1-[benzo[b]tiofeno-2-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
603	1-[1-[benzo[b]tiofeno-3-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
604	1-[1-(5-dimetilamino-naftaleno-1-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
605	1-[1-(bifenil-4-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
606	1-[1-(benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
607	1-[1-(benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
608	1-[1-(7-cloro-benzo[1,2,5]oxadiazol-4-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
609	6,7-difluoro-1-[1-(4-metil-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
610	1-[1-(4-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
611	1-[1-(4-fluoro-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
612	1-[1-(dibenzofuran-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

613	1-[1-(2,3-dihidro-benzofuran-5-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
614	1-[1-(bifenil-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
615	1-[1-(5-isoxazol-5-il-tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
616	1-[1-(4-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
617	1-[1-(4-fluoro-naftaleno-1-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
618	1-[1-(dibenzofuran-2-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
619	1-[1-(2,3-dihidro-benzofuran-5-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
620	1-[1-(bifenil-2-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
621	1-[1-(5-isoxazol-5-il-tiofeno-2-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
622	5-cloro-1-[1-(4-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
623	5-cloro-1-[1-(4-fluoro-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
624	5-cloro-1-[1-(dibenzofuran-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
625	5-cloro-1-[1-(2,3-dihidro-benzofuran-5-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
626	1-[1-(bifenil-2-sulfonil)-piperidin-4-il]-5-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
627	5-cloro-1-[1-(5-isoxazol-5-il-tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
628	1-[1-(4-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
629	1-[1-(4-fluoro-naftaleno-1-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
630	1-[1-(dibenzofuran-2-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
631	1-[1-(2,3-dihidro-benzofuran-5-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
632	1-[1-(bifenil-2-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
633	1-[1-(5-isoxazol-5-il-tiofeno-2-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
634	6-cloro-1-[1-(4-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
635	6-cloro-1-[1-(4-fluoro-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
636	6-cloro-1-[1-(dibenzofuran-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
637	6-cloro-1-[1-(2,3-dihidro-benzofuran-5-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
638	1-[1-bifenil-2-sulfonil)-piperidin-4-il]-6-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
639	6-cloro-1-[1-(5-isoxazol-5-il-tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

640	1-[1-(4-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
641	1-[1-(4-fluoro-naftaleno-1-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
642	1-[1-(dibenzofuran-2-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
643	1-[1-(2,3-dihidro-benzofuran-5-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
644	1-[1-(bifenil-2-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
645	1-[1-(5-isoxazol-5-il-tiofeno-2-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
646	1-[1-(4-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
647	6,7-difluoro-1-[1-(4-fluoro-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
648	1-[1-(dibenzofuran-2-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
649	1-[1-(2,3-dihidro-benzofuran-5-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
650	1-[1-(bifenil-2-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
651	6,7-difluoro-1-[1-(5-isoxazol-5-il-tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
652	1-[1-(1,2-dimetil-1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
653	1-[1-(5-metil-benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
654	1-[1-(3,5-dimetil-isoxazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
655	1-[1-(1,2-dimetil-1H-imidazol-4-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
656	8-metil-1-[1-(5-metil-benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
657	1-[1-(3,5-dimetil-isoxazol-4-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
658	6-cloro-1-[1-(1,2-dimetil-1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
659	6-cloro-1-[1-(5-metil-benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
660	6-cloro-1-[1-(3,5-dimetil-isoxazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
661	1-[1-(1,2-dimetil-1H-imidazol-4-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
662	8-metoxi-1-[1-(5-metil-benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
663	1-[1-(3,5-dimetil-isoxazol-4-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
664	5-cloro-1-[1-(1,2-dimetil-1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
665	5-cloro-1-[1-(5-metil-benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

666	5-cloro-1-[1-(3,5-dimetil-isoxazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
667	1-[1-(1,2-dimetil-1H-imidazol-4-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
668	6-metil-1-[1-(5-metil-benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
669	1-[1-(3,5-dimetil-isoxazol-4-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
670	1-[1-(1,2-dimetil-1H-imidazol-sulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
671	6-fluoro-1-[1-(5-metil-benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
672	1-[1-(3,5-dimetil-isoxazol-4-sulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
673	1-[1-(1,2-dimetil-1H-imidazol-4-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
674	6,7-difluoro-1-[1-(5-metil-benzo[1,2,5]tiadiazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
675	1-[1-(3,5-dimetil-isoxazol-4-sulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
676	1-[1-(5-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
677	1-[1-(5-cloro-naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
678	N-{5-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-naftalen-1-il}-acetamida
679	1-[1-(5-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
680	1-[1-(5-cloro-naftaleno-2-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
681	N-{5-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-naftalen-1-il}-acetamida
682	5-cloro-1-[1-(5-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
683	5-cloro-1-[1-(5-cloro-naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
684	N-{5-[4-(5-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-naftalen-1-il}-acetamida
685	1-[1-(5-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
686	1-[1-(5-cloro-naftaleno-2-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
687	N-{5-[4-(8-metoxi-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-naftalen-1-il}-acetamida
688	Éster metílico del ácido 2,5-dimetil-4-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-furan-3-carboxílico
689	8-metil-1-[1-(2-oxo-2,3-dihidro-benzotiazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
690	1-[1-(4-fluoro-3-metil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
691	8-metil-1-[1-(2-oxo-2,3-dihidro-benzooxazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona


692	1-[1-(4-ciclohexil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
693	Éster metílico del ácido 2,5-dimetil-4-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-furan-3-carboxílico
694	1-[1-(4-fluoro-3-metil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
695	1-[1-(2-oxo-2,3-dihidro-benzooxazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
696	1-[1-(4-ciclohexil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
697	Ácido 2-fluoro-5-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
698	Ácido 2-fluoro-5-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzoico
699	1-[1-(2-oxo-2,3-dihidro-benzotiazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
700	1-[1-(5-piridin-2-il-tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
701	3-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo
702	Éster metílico del ácido 3-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-tiofeno-2-carboxílico
703	1-{5-[4-(2-oxo-4H-benzo[d](1,3]oxacin-1-il)-piperidina-1-sulfonil]-naftalen-1-il}-pirrolidin-2,5-diona
704	1-[1-(2-cloro-5-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
705	1-[1-(3,4-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
706	8-metil-1-[1-(5-piridin-2-il-tiofeno-2-sulfonil)-piperidin-4-il]1,4-dihidro-benzo[d][1,3]oxacin-2-ona
707	3-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo
708	Éster metílico del ácido 3-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-tiofeno-2-carboxílico
709	1-{5-[4-(8-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-naftalen-1-il}-pirrolidin-2,5-diona
710	1-[1-(2-cloro-5-trifluorometil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
711	1-[1-(3,4-dimetil-bencenosulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
712	5-cloro-1-[1-(5-piridin-2-il-tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
713	3-[4-(5-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo
714	Éster metílico del ácido 3-[4-(5-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-tiofeno-2-carboxílico
715	1-{5-[4-(5-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-naftalen-1-il}-pirrolidin-2,5-diona
716	5-cloro-1-[1-(2-cloro-5-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
717	5-cloro-1-[1-(3,4-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
718	6-metil-1-[1-(5-piridin-2-il-tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

719	3-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo
720	Éster metílico del ácido 3-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-tiofeno-2-carboxílico
721	1-{5-[4-(6-metil-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-naftalen-1-il}-pirrolidin-2,5-diona
722	1-[1-(2-cloro-5-trifluorometil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
723	1-[1-(3,4-dimetil-bencenosulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
723	6-cloro-1-[1-(5-piridin-2-il-tiofeno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
725	3-[4-(6-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-benzonitrilo
726	Éster metílico del ácido 3-[4-(6-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-tiofeno-2-carboxílico
727	1-{5-[4-(6-cloro-2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-naftalen-1-il}-pirrolidin-2,5-diona
728	6-cloro-1-[1-(2-cloro-5-trifluorometil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
729	6-cloro-1-[1-(3,4-dimetil-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
730	1-[1-(5-metil-isoxazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
731	1-[1-(2,2-dimetil-croman-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
732	1-[1-(4-metil-3,4-dihidro-2H-benzo[1,4]oxacin-7-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
733	1-[1-(2,3-dihidro-benzo[1,4]dioxina-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
734	1-[1-(1,3,5-trimetil-1H-pirazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
735	1-[1-(3-metil-2-oxo-2,3-dihidro-benzooxazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
736	8-metil-1-[1-(5-metil-isoxazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
737	1-[1-(2,2-dimetil-croman-6-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
738	8-metil-1-[1-(4-metil-3,4-dihidro-2H-benzo[1,4]oxacina-7-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
739	1-[1-(2,3-dihidro-benzo[1,4]dioxina-6-sulfonil)-piperidin-4-il]-8-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
740	8-metil-1-[1-(1,3,5-trimetil-1H-pirazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
741	8-metil-1-[1-(3-metil-2-oxo-2,3-dihidro-benzooxazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
742	8-metoxi-1-[1-(1,3,5-trimetil-1H-pirazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
743	8-metoxi-1-[1-(3-metil-2-oxo-2,3-dihidro-benzooxazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
744	1-[1-(benzo[d]isoxazol-3-il-metanosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
745	1-[1-(2,2,4,6,7-pentametil-2,3-dihidro-benzofuran-5-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

746	6-metil-5-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-1H-pirimidin-2,4-diona
747	1-[1-(3-metil-quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
748	1-[1-(2,2,5,7,8-pentametil-croman-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
749	1,4-dimetil-6-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-1,4-dihidro-quinoxalina-2,3-diona
750	1-[1-(1H-imidazol-4-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
751	1-[1-(2-oxo-1,2,3,4-tetrahidro-quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
752	7-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-1,5-dihidro-benzo[b][1,4]diacepin-2,4-diona
753	8-metil-1-[1-(3-metil-quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
754	6-cloro-1-[1-(3-metil-quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
755	5-cloro-1-[1-(3-metil-quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
756	8-metoxi-1-[1-(3-metil-quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
757	1-[1-(piridina-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
758	1-[1-(6,7-dihidroxi-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
759	Éster 3-acetoxi-5-[4-(2-oxo-4H-benzo[d][1,3]oxacin-1-il)-piperidina-1-sulfonil]-naftalen-2-ílico del ácido acético
760	1-[1-(1H-benzoimidazol-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
761	1-[1-(1H-benzoimidazol-2-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
762	1-[1-(1H-benzoimidazol-2-sulfonil)-piperidin-4-il]-5-cloro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
763	1-[1-(2,5-dimetoxi-bencenosulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
764	1-[1-(2,5-dimetoxi-bencenosulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
765	1-[1-(2,5-dimetoxi-bencenosulfonil)-piperidin-4-il]-6,7-difluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
766	5-cloro-1-[1-(2,5-dimetoxi-bencenosulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
767	1-[1-(5-dimetilamino-naftaleno-1-sulfonil)-piperidin-4-il]-8-metoxi-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
768	5-cloro-1-[1-(5-dimetilamino-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
769	6-cloro-1-[1-(5-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
770	1-[1-(5-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
771	1-[1-(5-cloro-naftaleno-1-sulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
772	6-cloro-1-[1-(5-cloro-naftaleno-2-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona


773	1-[1-(5-cloro-naftaleno-2-sulfonil)-piperidin-4-il]-6-metil-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
774	1-[1-(5-cloro-naftaleno-2-sulfonil)-piperidin-4-il]-6-fluoro-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
775	6-metil-1-[1-(3-metil-quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
776	6-fluoro-1-[1-(3-metil-quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
777	6,7-difluoro-1-[1-(3-metil-quinolina-8-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
778	6-cloro-1-[1-(3-metil-2-oxo-2,3-dihidro-benzooxazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
779	6-metil-1-[1-(3-metil-2-oxo-2,3-dihidro-benzooxazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
780	6-fluoro-1-[1-(3-metil-2-oxo-2,3-dihidro-benzooxazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
781	6,7-difluoro-1-[1-(3-metil-2-oxo-2,3-dihidro-benzooxazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
782	5-cloro-1-[1-(3-metil-2-oxo-2,3-dihidro-benzooxazol-6-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
783	6-cloro-1-[1-(4-metil-3,4-dihidro-2H-benzo[1,4]oxacina-7-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona
784	6-metil-1-[1-(4-metil-3,4-dihidro-2H-benzo[1,4]oxacina-7-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo il]oxacin-2-ona
785	6-fluoro-1-[1-(4-metil-3,4-dihidro-2H-benzo[1,4]oxacina-7-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo il]oxacin-2-ona
786	6-metoxi-1-[1-(4-metil-3,4-dihidro-2H-benzo[1,4]oxacina-7-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo il]oxacin-2-ona
787	5-cloro-1-[1-(4-metil-3,4-dihidro-2H-benzo[1,4]oxacina-7-sulfonil)-piperidin-4-il]-1,4-dihidro-benzo[d][1,3]oxacin-2-ona

70. Procedimiento para la preparación de compuestos de sulfonamidas derivados de benzoxazinona de fórmula general (Ib) según una o más de las reivindicaciones 54 a 69, caracterizado porque comprende hacer reaccionar al menos un compuesto de piperidina de fórmula general (IIb), en la que de R^{1b} a R^{9b} tienen la significación según una o más de las reivindicaciones 54-69 y/o una sal, preferiblemente sal clorhidrato, del mismo,



(IIb)

con al menos un compuesto de fórmula general (IIIb),



(IIIb)

en la que W^b tiene la significación según una o más de las reivindicaciones 54-69, en un medio de reacción adecuado, opcionalmente en presencia de al menos una base y/o al menos un agente auxiliar.

71. Procedimiento para la preparación de una sal fisiológicamente aceptable de compuestos de sulfonamidas derivados de benzoxazinona según las reivindicaciones 54-69, caracterizado porque se hace reaccionar al menos un compuesto de fórmula general (Ib) que tiene al menos un grupo básico con al menos un ácido, preferiblemente un ácido orgánico o inorgánico, preferiblemente en presencia de un medio de reacción adecuado.

72. Procedimiento para la preparación de una sal fisiológicamente aceptable de compuestos de sulfonamidas derivados de benzoxazinona según las reivindicaciones 54-69, caracterizado porque se hace reaccionar al menos un compuesto de fórmula general (Ib) que tiene al menos un grupo ácido con al menos una base, preferiblemente en presencia de un medio de reacción adecuado.

73. Medicamento que comprende al menos un compuesto de sulfonamidas derivado de benzoxazinona según una cualquiera de las reivindicaciones 54-69 y opcionalmente uno o más adyuvantes farmacéuticamente aceptables.

74. Medicamento según la reivindicación 73 para la profilaxis y/o el tratamiento de trastornos que están al menos parcialmente mediados mediante los receptores 5-HT_6.

75. Medicamento según la reivindicación 73 ó 74 par la profilaxis y/o el tratamiento de trastornos relacionados con la ingestión de alimentos, preferiblemente para la regulación del apetito, para el mantenimiento, incremento o reducción del peso corporal, para la profilaxis y/o el tratamiento de la obesidad, para la profilaxis y/o el tratamiento de la bulimia, para la profilaxis y/o el tratamiento de la anorexia, para la profilaxis y/o el tratamiento de la caquexia, para la profilaxis y/o el tratamiento de la diabetes de tipo II (diabetes mellitus insulino independiente).

76. Medicamento según la reivindicación 73 ó 74 par la profilaxis y/o el tratamiento de trastornos gastrointestinales, preferiblemente el síndrome del colon irritable; para la profilaxis y/o el tratamiento de trastornos del sistema nervioso central; para la profilaxis y/o el tratamiento de la ansiedad; para la profilaxis y/o el tratamiento de ataques de pánico; para la profilaxis y/o el tratamiento de la depresión; para la profilaxis y/o el tratamiento de trastornos bipolares; para la profilaxis y/o el tratamiento de trastornos cognitivos, preferiblemente trastornos de la memoria; para el desarrollo de la cognición (para mejora de la cognición); para la profilaxis y/o el tratamiento de la demencia senil; para la profilaxis y/o el tratamiento de la psicosis; para la profilaxis y/o el tratamiento de trastornos neurodegenerativos; preferiblemente seleccionados del grupo que consiste en enfermedad de Alzheimer, enfermedad de Parkinson, enfermedad de Huntington y esclerosis múltiple; para la profilaxis y/o el tratamiento de la esquizofrenia o para la profilaxis y/o el tratamiento del trastorno de hiperactividad (ADHD, déficit de atención / trastorno de hiperactividad).

77. Uso de al menos un compuesto de sulfonamidas derivado de benzoxazinona según una cualquiera de las reivindicaciones 54-69 para la preparación de un medicamento para la regulación del receptor 5-HT_6.

78. Uso de al menos un compuesto de sulfonamidas derivado de benzoxazinona según una cualquiera de las reivindicaciones 54-69 para la preparación de un medicamento para la profilaxis y/o el tratamiento de trastornos que están al menos parcialmente mediados mediante los receptores 5-HT_6.

79. Uso de al menos un compuesto de sulfonamidas derivado de benzoxazinona según una cualquiera de las reivindicaciones 54-69 para la preparación de un

medicamento para la profilaxis y/o el tratamiento de trastornos relacionados con la ingestión de alimentos.

80. Uso según la reivindicación 79 para la regulación del apetito, para la reducción, incremento o mantenimiento del peso corporal; para la profilaxis y/o el tratamiento de la obesidad, para la profilaxis y/o el tratamiento de la bulimia, para la profilaxis y/o el tratamiento de la anorexia, para la profilaxis y/o el tratamiento de la caquexia; o para la profilaxis y/o el tratamiento de la diabetes de tipo II.

81. Uso de al menos un compuesto de sulfonamidas derivado de benzoxazinona según una cualquiera de las reivindicaciones 54-69 para la preparación de un medicamento para la profilaxis y/o el tratamiento de trastornos gastrointestinales, preferiblemente el síndrome del colon irritable; para la profilaxis y/o el tratamiento de trastornos del sistema nervioso central; para la profilaxis y/o el tratamiento de la ansiedad; para la profilaxis y/o el tratamiento de ataques de pánico; para la profilaxis y/o el tratamiento de la depresión; para la profilaxis y/o el tratamiento de trastornos bipolares; para la profilaxis y/o el tratamiento de trastornos cognitivos, preferiblemente trastornos de la memoria; para el desarrollo de la cognición (para mejora de la cognición); para la profilaxis y/o el tratamiento de la demencia senil; para la profilaxis y/o el tratamiento de la psicosis; para la profilaxis y/o el tratamiento de trastornos neurodegenerativos; preferiblemente seleccionados del grupo que consiste en enfermedad de Alzheimer, enfermedad de Parkinson, enfermedad de Huntington y esclerosis múltiple; para la profilaxis y/o el tratamiento de la esquizofrenia o para la profilaxis y/o el tratamiento del trastorno de hiperactividad (ADHD, déficit de atención / trastorno de hiperactividad).

RESUMEN

La presente invención se refiere a compuestos de sulfonamidas derivados de benzoxazinona de fórmula general (I), a un procedimiento para su preparación, a un medicamento que comprende estos compuestos y al uso de compuestos de sulfonamidas derivados de benzoxazinona para la preparación de medicamentos para la regulación del receptor 5-HT_6 así como para el tratamiento de trastornos relacionados al mismo.

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

DAVILA BAZ, A.
Clarke, Modet & Co.
C/Goya, 11
28001 Madrid
ESPAGNE

22 DIC. 2005

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(PCT Rule 71.1)

Date of mailing *(day/month/year)*	15.12.2005
Applicant's or agent's file reference: P-INCI-X-04-0270	IMPORTANT NOTIFICATION

International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/EP2004/008507	29.07.2004	30.07.2003

Applicant
LABORATORIOS DEL DR. ESTEVE S.A. et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary report on patentability and its annexes, if any, established on the international application.

2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.

3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed invention is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international preliminary examining authority:	Authorized Officer
European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Hebert, W Tel. +49 89 2399-2152

Form PCT/IPEA/416 (January 2004)

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference P-INCI-X-04-0270	FOR FURTHER ACTION	See Form PCT/IPEA/416
International application No. PCT/EP2004/008507	International filing date *(day/month/year)* 29.07.2004	Priority date *(day/month/year)* 30.07.2003

International Patent Classification (IPC) or national classification and IPC
C07D413/04, A61K31/535, A61P25/00

Applicant
LABORATORIOS DEL DR. ESTEVE S.A. et al.

1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 5 sheets, including this cover sheet.
3. This report is also accompanied by ANNEXES, comprising:
   a. ☒ *sent to the applicant and to the International Bureau)* a total of 1-84 sheets, as follows:
      ☐ sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).
      ☐ sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.
   b. ☐ *(sent to the International Bureau only)* a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).

4. This report contains indications relating to the following items:

☒	Box No. I	Basis of the opinion
☐	Box No. II	Priority
☐	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
☐	Box No. IV	Lack of unity of invention
☒	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
☐	Box No. VI	Certain documents cited
☒	Box No. VII	Certain defects in the international application
☒	Box No. VIII	Certain observations on the international application

Date of submission of the demand	Date of completion of this report
28.02.2005	15.12.2005

Name and mailing address of the international preliminary examining authority:
European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized Officer
Deutsch, W
Telephone No. +49 89 2399-8281

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/EP2004/008507

Box No. I Basis of the report

1. With regard to the **language**, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.

   ☐ This report is based on translations from the original language into the following language , which is the language of a translation furnished for the purposes of:
   - ☐ international search (under Rules 12.3 and 23.1(b))
   - ☐ publication of the international application (under Rule 12.4)
   - ☐ international preliminary examination (under Rules 55.2 and/or 55.3)

2. With regard to the **elements*** of the international application, this report is based on *(replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report)*:

   Description, Pages

   1-260 as originally filed

   Claims, Numbers

   1-66 filed with telefax on 30.05.2005

   ☐ a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing

3. ☐ The amendments have resulted in the cancellation of:
   - ☐ the description, pages
   - ☐ the claims, Nos.
   - ☐ the drawings, sheets/figs
   - ☐ the sequence listing *(specify)*:
   - ☐ any table(s) related to sequence listing *(specify)*:

4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).
   - ☐ the description, pages
   - ☐ the claims, Nos.
   - ☐ the drawings, sheets/figs
   - ☐ the sequence listing *(specify)*:
   - ☐ any table(s) related to sequence listing *(specify)*:

* *If item 4 applies, some or all of these sheets may be marked "superseded."*

INTERNATI NAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/EP2004/008507

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-81
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-81
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-81
	No:	Claims	

2. Citations and explanations (Rule 70.7):

see separate sheet

Box No. VII Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

Re Item V.

1 The following document is referred to in this communication:

D1: US-A-5 665 719 (PETTIBONE DOUGLAS J ET AL) 9 September 1997 (1997-09-09)

D2: WO 01/85725 A (FEENSTRA ROELOF W ; LONG STEPHEN K (NL); HEIJDEN JOHANNES A M V D (NL)) 15 November 2001 (2001-11-15)

D3: WO 97/45419 A (WARNER LAMBERT CO ; WISE LAWRENCE DAVID (US); WUSTROW DAVID JUERGEN (U) 4 December 1997 (1997-12-04)

D4: US-B-6 225 3121 (KRUSE CORNELIS GERRIT ET AL) 1 May 2001 (2001-05-01)

D5: EP-A-1 242 396 (ASTRAZENECA AB) 25 September 2002 (2002-09-25)

Novelty

The compounds of the present claim 1, 42 differ from those of the amended claims through the possible substituents of the aliphatic group in the definition of W, Wb.

The subject matter of the present claim 1 and 42 is regarded as a novel selection from the general disclosures of D1.

The compounds of the present claims differ those of D2 to D5 through the presence of the SO_2 moiety at the 1 position of the piperidine ring.

The "subsequent medical use claim 21" is novel vis-avis D1 through the pathological condsitions listed

Inventive Step

The closest prior art is considered to be D4, since this discloses benzoxazinone compounds, which may be substituted inter alia by piperidine moieties and which are indicated as being active as 5-HT_{1A} receptors.

The problem underlying the present application is the provision of compounds which are

useful in the treatment of certain disorders related to $5HT_6$ receptor regulation.

The skilled person could not have arrived at the claimed subject matter from D4 in view of the structural differences between the claimed compounds and those of D4 (cf point of attachment of piperidine to the nitrogen of the benzoxazine ring and presence of the SO_2 group).

An inventive step can therefore be acknowledged

VII.

Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the documents D1 to D5 is not mentioned in the description, nor are these documents identified therein.

VIII

The term "preferably" used in the claims has no limiting effects on the claims.


The description is not adapted to the present claims.

****

The reasons for the provisos in the present claim 1 are at present unclear, and it may be necessary for the Applicant to explain these at the regional stage of examination.

Amended Claims:

1. Benzoxazinone-derived sulfonamide compounds of general formula (I)



(I),

wherein

R^1, R^2, R^3, R^4 are each independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano group, $-OR^{10}$, $-OC(=O)R^{11}$, $-(C=O)-OR^{11}$, $-SR^{12}$, $-SOR^{12}$, $-SO_2R^{12}$, $-NH-SO_2R^{12}$, $-SO_2NH_2$ and a $-NR^{13}R^{14}$ moiety,

R^5 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical,

R^6, R^7, R^8, R^9 are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano group and a $-COOR^{15}$ moiety,

W represents an unbranched or branched, saturated or unsaturated aliphatic radical, which may be substituted by one or more substituents selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-6}-alkoxy, branched or unbranched C_{1-6}-perfluoroalkoxy, branched or unbranched C_{1-6}-perfluoroalkyl, amino, carboxy, amido, cyano, nitro, $-SO_2NH_2$, $-CO-C_{1-6}$-alkyl, $-SO-C_{1-6}$-alkyl, $-SO_2-C_{1-6}$-alkyl, $-NH-SO_2-C_{1-6}$-alkyl , wherein the C_{1-6}-alkyl may in each case be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and an unsubstituted or at least mono-substituted furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl and isoquinolinyl radical,
whereby said substituents may be at least mono-substituted with F, Cl, methyl and methoxy,

a saturated or unsaturated, optionally at least one heteroatom as ring member containing cycloaliphatic radical, whereby said cycloaliphatic radical may be substituted by one or more substituents selected from the group consisting of hydroxy, nitro, carboxy, cyano, keto, halogen, C_{1-20}-alkyl, partially fluorinated C_{1-4} alkyl, partially chlorinated C_{1-4} alkyl, partially brominated C_{1-4} alkyl, C_{1-5}-alkoxy, partially fluorinated C_{1-4} alkoxy, partially chlorinated C_{1-4} alkoxy, partially brominated C_{1-4} alkoxy, C_{2-5}-alkenyl, SO_2-C_{1-4}-alkyl, $-(C=O)-C_{1-5}$-alkyl, $-(C=O)-O-C_{1-5}$-alkyl, $-(C=O)-Cl$, $-S-C_{1-4}$-alkyl-, $-(C=O)-H$, $-NH-(C=O)-NH-C_{1-5}$-alkyl, $-(C=O)-C_{1-4}$-perfluoroalkyl, $-NR^AR^B$, wherein R^A and R^B are independently selected from the group consisting of H, C_{1-4}-alkyl and phenyl,

NH-(C=O)-C_{1-8}-alkyl, -C_{1-8}-alkylen-(C=O)-C_{1-8}-alkyl, (1,3-Dihydro-1-oxo-2H-isoindol-2-yl), N-Phthalimidinyl-, (1,3-Dioxo-2-azaspiro[4,4]-non-2-yl, substituted or unsubstituted phenyl, -SO_2-phenyl, phenoxy, pyridinyl, pyridinyloxy, pyrazolyl, pyrimidinyl, pyrrolidinyl-, -SO_2-pyrrolidinyl, morpholinyl, SO_2-morpholinyl-, thiadiazolyl, oxadiazolyl, oxazolyl, thiazolyl, isoxazolyl, O-CH_2-thiazolyl, -NH-phenyl, and -C_{1-4}-Alkylen-NH-(C=O)-phenyl,
whereby said substituents may be substituted by one or more substituents selected from the group consisting of halogen, nitro, cyano, hydroxy, -(C=O)-C_{1-4}-alkyl, C_{1-4}-alkyl, at least partially fluorinated C_{1-4}-alkyl, at least partially chlorinated C_{1-4}-alkyl, at least partially brominated C_{1-4}-alkyl, -S-C_{1-4}-alkyl, -C(=O)-O-C_{1-8}-alkyl, -(C=O)-CH_2-F, -(C=O)-CH_2-Cl and -(C=O)-CH_2-Br,
and whereby said cycloaliphatic radical may be bonded via an optionally mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted aromatic mono- or polycyclic ring-system,

an optionally at least mono-substituted heteroaryl radical, which may be bonded via an optionally mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

an optionally at least mono-substituted, monocyclic aryl radical, which is condensed with an optionally at least mono-substituted mono- or polycyclic ring-system and which may be bonded via an optionally at least mono-substituted alkylene group,

a -$NR^{16}R^{17}$-moiety,

a -COR^{18}-moiety,

or a phenyl radical, which is at least mono-substituted with one of the substituents selected from the group consisting of:

2,2,2,-Trifluoroethoxy-, C_{2-6}-Alkenyl-, 1,3-Dihydro-1-oxo-2H-isoindol-2-yl-, N-Phthalimidinyl-, [(2-chloro-1,3-thiazolyl-5-yl)-methoxy, Ethyl-5-yl-2-methyl-3-furoate, C_{11-20}-alkyl-, 1,3-Dioxo-2-azaspiro[4,4]non-2-yl-, pyrazolyl-, (1,3-oxazol-5-yl)-, (5-Methyl-1,3,4-oxadiazol-2-yl)-, difluoromethoxy, dichloromethoxy, 1-pyrrolidinylsulfonyl, morpholinosulfonyl, 2-methyl-4-pyrimidinyl-, a phenoxy group, which is at least mono-substituted with C_{1-6}-alkoxy, a phenyl group, which is at least mono-substituted with one of the substituents selected from the group consisting of nitro, C_{1-6}-alkoxy, F, Cl, Br, at least partially fluorinated C_{1-6}-alkyl, at least partially chlorinated C_{1-6}-alkyl, [(2-Chloro-1,3-thiazol-5-yl)-methoxy]-, -(C=O)-H and -(C=O)-C_{1-6}-alkyl, a pyridinyl group, which is at least mono-substituted with C_{1-6}-alkoxy, a pyridinyloxy group, which is at least mono-substituted with C_{1-6}-alkoxy, a phenoxy group, which is at least di-substituted and a pyridinyloxy group, which is at least di-substituted,

with the proviso that W does not represent unsubstituted furyl-, unsubstituted thienyl- or thienyl substituted with a substituent selected from the group consisting of C_{1-6}-alkoxycarbonyl, C_{1-6}-alkylcarbonyl, carboxyl and pyridyl, unsubstituted pyrrolyl-, unsubstituted naphthyl, unsubstituted indolyl, unsubstituted tetrahydronaphthyl, substituted or unsubstituted pyridyl, unsubstituted pyrazinyl, unsubstituted quinolinyl-, C_{1-6}-alkylsubstituted pyrrolyl-, and unsubstituted cyclohexyl or cyclohexyl substituted with one or two members selected from the group consisting of oxo, hydroxyl, C_{1-6}-alkoxyl, C_{1-6}-alkoxy-carbonylamino-C_{1-6} alkyl and amino-C_{1-6} alkyl,

R^{10} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted

alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{11} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{12} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{13} and R^{14} each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may

be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

or R^{13} and R^{14} together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member,

R^{15} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{16} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

R^{17} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, and

R^{18} represents an optionally at least mono-substituted aryl radical,

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate.

2. Compounds according to claim 1, characterized in that R^1, R^2, R^3, R^4 are each independently selected from the group consisting of H, F, Cl, Br, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally

at least mono-substituted C_{1-6}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-6}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano, $-OR^{10}$, $-C(=O)R^{11}$, $-SR^{12}$, $-SOR^{12}$, $-SO_2R^{12}$, $-NH-SO_2R^{12}$, $-SO_2NH_2$ and a $-NR^{13}R^{14}$ moiety, preferably selected from the group consisting of H, F, Cl, Br, a saturated, branched or unbranched, optionally at least mono-substituted C_{1-3}-aliphatic radical, a saturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_3- or C_6- cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_1- or C_2-alkylene group, a nitro, cyano, $-OR^{10}$, $-OC(=O)R^{11}$, $-SR^{12}$ and $-NR^{13}R^{14}$ moiety, more preferably selected from the group consisting of H, F, Cl, $-CH_3$, $-CH_2CH_3$, $-CF_3$, $-CF_2CF_3$, cyclopentyl, cyclohexyl, a nitro group, a cyano group and $-OR^{10}$.

3. Compounds according to claim 1 or 2, characterized in that R^5 represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6}-aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-6}-cycloaliphatic radical, preferably represents H or a branched or unbranched C_{1-3}-alkyl radical, more preferably represents H, $-CH_3$ or $-CH_2CH_3$.

4. Compounds according to any one of claims 1 to 3, characterized in that R^6, R^7, R^8, R^9 are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-6}-cycloaliphatic radical, a cyano group and a $-COOR^{15}$ moiety, preferably selected from the group consisting of H, a branched or unbranched C_{1-3}-alkyl radical, a cyano group and a $-COOR^{15}$ group, more preferably from the group consisting of H, $-CH_3$, $-CH_2CH_3$ and a cyano moiety.

5. Compounds according to any one of claims 1 to 4, characterized in that W represents an unbranched or branched C_{11-20}-alkyl radical, which may be substituted by one or more substituents selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-6}-alkoxy, branched or unbranched C_{1-6}-perfluoroalkoxy, branched or unbranched C_{1-6}-perfluoroalkyl, amino, carboxy, amido, cyano, nitro, $-SO_2NH_2$, $-CO-C_{1-6}$-alkyl, $-SO-C_{1-6}$-alkyl, $-SO_2-C_{1-6}$-alkyl, $-NH-SO_2-C_{1-6}$-alkyl , wherein the C_{1-6}-alkyl may in each case be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and an unsubstituted or at least mono-substituted furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl and isoquinolinyl radical, whereby said substituents may be at least mono-substituted with F, Cl, methyl and methoxy; a napthyl group, which is at least mono substituted, a quinolinyl group, which is at least mono-substituted, a pyrrolyl group, which is at least mono-substituted by a substituent other than C_{1-5}-alkyl, an optionally at least mono-substituted thiazolyl-, benzo[b]-thiophenyl-, benzo[b]-furanyl-, isoquinolinyl-, tetrahydroisoquinolinyl-, pyrazolyl-, isoazolyl-, chromanyl-, benzothiadiazolyl-, imidazolyl-, benzofurazanyl-, dibenzo[b,d]-furanyl-, benzoxadiazolyl-, imidazo[2,1-b]-thiazolyl-, anthracenyl-, coumarinyl-, 2,3-Dihydro-1,4-benzodioxinyl-, 2,3-Dihydrobenzo[b]furanyl-, 3,4-Dihydro-2H-1,4-Benzoxazinyl-, 3,4-Dihydro-2H-1,5-Benzodioxepinyl-, Benzothiazolyl-, Imidazo[1,2-a]-pyridinyl-, a chromonyl-group, an Isatinyl group, a pentamethyldihydrobenzofuranyl group, a cyclopropyl- or cyclopentyl-group whereby said cyclopropyl or cyclopentyl group may be substituted by one or more substituents selected selected from the group consisting of hydroxy, nitro, carboxy, cyano, keto, halogen, C_{1-20}-alkyl, partially fluorinated C_{1-4} alkyl, partially chlorinated C_{1-4} alkyl, partially brominated C_{1-4} alkyl, C_{1-5}-alkoxy, partially fluorinated C_{1-4} alkoxy, partially chlorinated C_{1-4} alkoxy, partially brominated C_{1-4} alkoxy, C_{2-5}-alkenyl, SO_2-C_{1-4}-alkyl, $-(C=O)-C_{1-5}$-alkyl, $-(C=O)-O-C_{1-5}$-alkyl, $-(C=O)-Cl$, $-S-C_{1-4}$-alkyl-, $-(C=O)-H$, $-NH-(C=O)-NH-C_{1-5}$-alkyl, $-(C=O)-C_{1-4}$-perfluoroalkyl, $-NR^AR^B$, wherein R^A and R^B are independently selected from the group consisting of H, C_{1-4}-alkyl and phenyl, $NH-(C=O)-C_{1-5}$-alkyl, $-C_{1-5}$-alkylen-$(C=O)-C_{1-5}$-alkyl, (1,3-Dihydro-1-oxo-2H-Isoindol-2-yl), N-Phthalimidinyl-, (1,3-Dioxo-2-azaspiro[4,4]-non-2-yl,

S40

substituted or unsubstituted phenyl, -SO_2-phenyl, phenoxy, pyridinyl, pyridinyloxy, pyrazolyl, pyrimidinyl, pyrrolidinyl-, -SO_2-pyrrolidinyl, morpholinyl, SO_2-morpholinyl-, thiadiazolyl, oxadiazolyl, oxazolyl, thiazolyl, isoxazolyl, O-CH_2-thiazolyl, -NH-phenyl, and -C_{1-4}-Alkylen-NH-(C=O)-phenyl,
whereby said substituents may be substituted by one or more substituents selected from the group consisting of halogen, nitro, cyano, hydroxy, -(C=O)-C_{1-4}-alkyl, C_{1-4}-alkyl, at least partially fluorinated C_{1-4}-alkyl, at least partially chlorinated C_{1-4}-alkyl, at least partially brominated C_{1-4}-alkyl, -S-C_{1-4}-alkyl, -C(=O)-O-C_{1-5}-alkyl, -(C=O)-CH_2-F, -(C=O)-CH_2-Cl and -(C=O)-CH_2-Br,
a 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl-)-ethyl, a thienyl group, which is at least mono-substituted by one or more substituents independently selected from the group consisting of F, Cl, Br, C_{1-5}-alkoxy-, CF_3, -SO_2-C_{1-5}-alkyl and optionally at least mono substituted benzoylaminomethyl-, phenylsulfonyl-, isoxazolyl-, benzamidomethyl-, pyrimidyl-, thiazolyl-, pyrazolyl-, phenyl-, 1,2,4-thiadiazolyl-, 1,3-oxazolyl- or 1,2,4-oxadiazolyl-, a furyl group, which is at least mono-substituted by one or more substituents independently selected from the group consisting of a C_{1-5}-alkyl radical, which may be at least partially fluorinated or chlorinated, an optionally at least mono-substituted phenyl and a -(C=O)-O-C_{1-5}-alkyl group,

a $NR^{16}R^{17}$-moiety,

a COR^{18}-moiety,

or a phenyl radical, which is at least mono-substituted with one of the substituents selected from the group consisting of:

2,2,2,-Trifluoroethoxy-, C_{2-6}-Alkanyl-, 1,3-Dihydro-1-oxo-2H-isoindol-2-yl-, N-Phthalimidinyl-, [(2-chloro-1,3-thiazolyl-5-yl)-methoxy, Ethyl-5-yl-2-methyl-3-furoate, C_{11-20}-alkyl-, 1,3-Dioxo-2-azaspiro[4,4]non-2-yl-, pyrazolyl-, (1,3-oxazol-5-yl)-, (5-Methyl-1,3,4-oxadiazol-2-yl)-, difluoromethoxy, dichloromethoxy, 1-pyrrolidinylsulfonyl, morpholinosulfonyl, 2-methyl-4-pyrimidinyl-, a phenoxy group, which is at least mono-substituted with C_{1-5}-alkoxy, a phenyl group, which is at least mono-substituted with one of the

Empf.zeit:30/05/2005 15:35 :496 P.012

substituents selected from the group consisting of nitro, C_{1-5}-alkoxy, F, Cl, Br, at least partially fluorinated C_{1-5}-alkyl, at least partially chlorinated C_{1-5}-alkyl, [(2-Chloro-1,3-thiazol-5-yl)-methoxy]-, -(C=O)-H and -(C=O)-C_{1-5}-alkyl, a pyridinyl group, which is at least mono-substituted with C_{1-5}-alkoxy, a pyridinyloxy group, which is at least mono-substituted with C_{1-5}-alkoxy, a phenoxy group, which is at least di-substituted and a pyridinyloxy group, which is at least di-subsituted,

more preferably W represents a moiety selected from the group consisting of 5-Dimethylamino-napth-1-yl, 2-Acetamido-4-methyl-5-thiazolyl-, Trifluoromethyl-, Trichloromethyl-, Isopropyl-, Methyl-, 2,2,2-Trifluoroethyl-, Ethyl-, Hexadecyl-, 2-Chloroethyl-, n-Propyl-, 3-Chloro-propyl-, n-Butyl-, Dichloromethyl-, Chloromethyl-, Dodecyl-, 1-Octyl-, 6-(p-toluidino)-naphth-2-yl-, 4,5-Dibromo-thiophene-2-yl-, Benzoylchloride-3-yl-, 1-Octadecyl-, 4-Bromo-2,5-dichloro-thiophene-3-yl-, 2,5-Dichloro-thiophene-3-yl-, 5-Chloro-thiophene-2-yl-, 1-Decyl-, 3,5-Dichloro-4-(2-chloro-4-nitrophenoxy)-phenyl-, 2,3-Dichlorothiophene-5-yl-, 3-Bromo-2-chloro-thiophene-5-yl-, 3-Bromo-5-chloro-thiophene-2-yl-, 2-(Benzoylaminomethyl)-thiophene-5-yl-, 4-(Phenyl-sulphonyl)-thiophene-2-yl-, 2-Phenyl-sulphonyl-thiophene-5-yl-, 2-[1-Methyl-5-(trifluoromethyl)pyrazol-3-yl]-thiophene-5-yl-, 5-Chloro-1,3-dimethylpyrazole-4-yl-, 3,5-Dimethylisoxazole-4-yl-, 2-(2,4-Dichlorophenoxy)-phenyl, 4-(2-Chloro-6-nitro-phenoxy)-phenyl-, 4-(3-chloro-2-cyanophenoxy)-phenyl, 2,4-Dimethyl-1,3-thiazole-5-yl-, Methyl-methane-sulfonyl-, 2,5-Bis-(2,2,2-Trifluoroethoxy)-phenyl-, 5-(Di-n-propylamino)-naphth-1-yl-, 2,2,5,7,8-Pentamethyl-chroman-6-yl-, 5-Chloro-4-nitro-thiophene-2-yl-, 2,1,3-Benzothiadiazole-4-yl-, 1-Methyl-imidazole-4-yl-, Benzofurazan-4-yl-, 5-(Isoxazol-3-yl)-thiophene-2-yl-, Vinyl-phenyl-4-yl-, 5-Dichloro-methyl-furan-2-yl-, 5-Bromo-thiophene-2-yl-, 5-(4-Chlorobenzamidomethyl)-thiophene-2-yl-, Dibenzo[b,d]-furan-2-yl-, 5-Chloro-3-methylbenzo[b]-thiophene-2-yl-, 3-Methoxy-4-(methoxycarbonyl)-thiophene-2-yl-, 5-[2-(Methylthio)-pyrimidin-4-yl-]-thiophene-2-yl-, 4-Chloro-2,1,3-Benzoxadiazole-7-yl-, 5-Chloro-2,1,3-Benzoxadiazole-4-yl-, 6-Chloro-Imidazo(2,1-b)-thiazole-5-yl-, 3-Methyl-benzo[b]-thiophene-2-yl-, 4-[[3-Chloro-5-(Trifluoromethyl)-2-pyridy[]oxy-phenyl-, 5-Chloro-naphth-1-yl-, 5-Chloro-naphth-2-yl-, 9,10-Dibromoanthracene-2-yl-,

Isoquinoline-5-yl-, 4-Methoxy-2,3,6-trimethylbenzoyl-, 4'-Nitro-biphenyl-4-yl-, (1,3-Dihydro-1-oxo-2H-isoindol-2-yl-)-4-phenyl-, 5-(2-Methyl-1,3-thiazole-4-yl)-thiophene-2-yl-, 5-(1-Methyl-3-(trifluoromethyl)pyrazol-5-yl-]-thiophene-2-yl-, 5-[5-Trifluoromethyl)-isoxazol-3-yl]-thiophene-2-yl-, p-Dodecyl-phenyl-, 4-[(3-Cyano-4-methoxy-2-pyridinyl)oxy]-phenyl-, 4-(N-phthalimidinyl)-phenyl-, 1,2,3,4-Tetrahydro-2-(trifluoroacetyl)-isoquinoline-7-yl-, 1,2-Dimethylimidazole-4-yl-, 2,2,4,6,7-Pentamethyldihydrobenzofuran-5-yl-, 4-Chloro-naphth-1-yl-, 2,5-Dichloro-4-nitro-thiophene-3-yl-, 4-(4-Methoxy-phenoxy)-phenyl-, [4-(3,5-Dichlorophenoxy)phenyl]-, [4-(3,4-Dichlorophenoxy)phenyl]-, [4-(3,5)-Bis(trifluoromethylphenoxy)phenyl]-, 3-(2-Methoxy-phenoxy)-phenyl, 3-(4-Methoxy-phenyl)-phenyl-, 3-(4-Chloro-phenyl)-phenyl-, 3-(3,5-Dichloro-phenyl)-phenyl-, 3-(3,4-Dichloro-phenyl)-phenyl-, 3-(4-Fluorophenyl)-phenyl-, 3-[4-(Trifluoromethyl)-phenyl]-phenyl-, 3-[3,5-Bis-(Trifluoromethyl)-phenyl]-phenyl-, 4-(2-Methoxy-phenoxy)-phenyl-, 4-(2-Methyl-phenoxy)-phenyl-, 4-(4-Methoxy-phenoxy)-phenyl-, 4-(4-Chlorophenyl)-phenyl-, 4-(3,5-Dichlorophenyl)-phenyl-, 4-(3,4-Dichlorophenyl)-phenyl-, 4-(4-Fluorophenyl)-phenyl-, 4-[4-(Trifluormethyl)-phenyl]-phenyl-, 4-[3,5-Bis-(Trifluoromethyl)-phenyl]-phenyl-, Cyclopropyl-, 2-(2-Chlorophenyl)-2-Phenylethyl-, 2-(2-Trifluoromethylphenyl)-2-phenylethyl-, 5-[4-Cyano-1-methyl-5-(methylthio)-1H-pyrazol-3-yl-thiophene-2-yl-, 3-Cyano-2,4-bis-(2,2,2-Trifluorothoxy)-phenyl-, 4-[(2-Chloro-1,3-Thiazol-5-yl)-methoxy]-phenyl-, 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethyl-, 5-Iodo-naphth-1-yl-, Ethyl-2,5-dimethyl-1-phenylpyrrole-4-carboxylate-3-yl-, Ethyl-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxylate-4-yl-, Ethyl-5-(4-chlorophenyl)-2-methyl-3-furoate-4-yl, Ethyl-5-(4-chlorophenyl)-2-methyl-1-phenyl-3-carboxylate-4-yl-, Ethyl-2,5-dimethyl-3-furoate-4-yl-, 3-Chloro-4-(1,3-dioxo-2-Azaspiro[4,4]non-2-yl)-phenyl-, Coumarin-8-yl, 3-(4-Methoxy-phenoxy)-phenyl-, [3-(3,5-Dichlorophenoxy)]-phenyl-, [3-(3,4 Dichlorophenoxy)]-phenyl-, 3,5-Bis(Trifluoromethyl)phenoxyphenyl-, 2,2-Diphenylethyl-, 4-Phenyl-5-(trifluoromethyl)-thiophene-3-yl-, Methyl-4-Phenyl-5-(Trifluoromethyl)-thiophene-2-carboxylate-3-yl-, Methyl-1,2,5-trimethylpyrrole-3-Carboxylate-4-yl-, 4-Fluoro-naphth-1-yl-, 5-Fluoro-3-methylbenzo[b]-thiophene-2-yl-, Methyl-2,5-dimethyl-3-furoate-4-yl-, Methyl-2-furoate-5-yl-, Methyl-2-methyl-3-furoate-5-yl-, Methyl-1-methyl-1H-pyrrole-2-Carboxylate-5-yl-, 2-(5-Chloro-1,2,4-Thiadiazol-3-yl)-thiophene-5-yl-, 1,3,5-

Trimethyl-1H-pyrazole-4-yl-, Pentafluoroethoxytetrafluoroethyl-, 5-(5-Isoxazyl)-thiophene-2-yl-, 5-(5-Isoxazol-yl)-2-furyl-, 5-Methyl-2,1,3-benzothiadiazole-4-yl-, 2,3-Dihydro-1,4-benzodioxine-6-yl-, 4-Methyl-Naphth-1-yl-, 5-Methyl-2-(Trifluormethyl)-3-Furyl-, 2,3-Dihydrobenzo[b]furan-5-yl-, 1-Benzothiophene-3-yl-, 4-Methyl-3,4-dihydro-2H-1,4-Benzoxazine-7-yl-, 5-Methyl-1-phenyl-1H-pyrazole-4-yl-, 6-Morpholino-3-Pyridinyl-, 4-(1H-Pyrazol-1-yl)-phenyl-, 6-Phenoxy-3-Pyridyl-, 3,4-Dihydro-2H-1,5-benzodioxepine-7-yl-, 5-(1,3-Oxazol-5-yl)-2-thienyl-, 4-(1,3-Oxazol-5-yl)-phenyl-, 5-Methyl-4-Isoxazolyl, 2,1,3-Benzothiadiazole-5-yl-, 5-Acetamido-naphth-1-yl-, 3-Methyl-8-Quinolinyl-, 1,3-Benzothiazole-6-yl-, 2-Morpholino-3-Pyridyl-, 2,5-Dimethyl-3-thienyl-, 5-[5-(Chloromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl-, Ethyl-3-[5-yl-2-thienyl-]1,2,4-oxadiazole-5-carboxylate-, 3-(5-Methyl-1,3,4-oxadiazol-2-yl)-phenyl-, 4-(Difluoromethoxy)-phenyl-, 3-(Difluoromethoxy)-phenyl-, 2,2-Dimethyl-6-Chromanyl-, Ethyl-3,5-dimethyl-1H-pyrrole-2-carboxylate-4-yl-, Imidazo[1,2-A]pyridine-3-yl-, 3-(1,3-Oxazol-5-yl)-phenyl-, Ethyl-5-[4-yl)-phenyl]-2-methyl-3-furoate, 1-Pyrrolidinylphenylsulfonyl-, Methyl-5-yl-4-methyl-2-thiophene-carboxylate, Methyl-3-yl-4-(isopropylsulfonyl)-2-thiophene, 7-Chlorochromone-3-yl-, 4'-Bromobiphenyl-4-yl-, 4'-Acetyl-biphenyl-4-yl-, 4'-Bromo-2'-fluoro-biphenyl-4-yl-, 1-Methyl-5-Isatinyl-, 2-Chloro-3-thiophenecarboxylic-acid-5-yl-, 2-Methoxy-5-(N-phthalimidinyl)-phenyl-, 1-Benzothiophene-2-yl-, Morpholinophenylsulfonyl- and 3-(2-Methyl-4-pyrimidinyl)-phenyl-

6. Compounds according to any one of claims 1 to 5, characterized in that R^{10} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

preferably H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl.

7. Compounds according to any one of claims 1 to 6, characterized in that R^{11} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl.

8. Compounds according to any one of claims 1 to 7, characterized in that R^{12} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl.

9. Compounds according to any one of claims 1 to 8, characterized in that R^{13} and R^{14} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably are each independently selected from the group consisting of H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical and a phenyl radical, more preferably are each independently selected from the group consisting of H, $-CH_3$, $-C_2H_5$ and phenyl.

10. Compounds according to any one of claims 1 to 8, characterized in that R^{13} and R^{14} together with the bridging nitrogen atom form a saturated, unsaturated or aromatic, 5- or 6-membered heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member, preferably form an unsubstituted piperidin or morpholine group.

11. Compounds according to any one of claims 1 to 10, characterized in that R^{15} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear

or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably represents H, $-CH_3$, $-C_2H_5$ or phenyl.

12. Compounds according to any one of claims 1 to 11, characterized in that R^{16} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6} aliphatic radical, preferably an unbranched or branched, saturated, unsubstituted C_{1-3} alkyl radical, more preferably a methyl radical.

13. Compounds according to any one of claims 1 to 12, characterized in that R^{17} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6} aliphatic radical, preferably an unbranched or branched, saturated, unsubstituted C_{1-3} alkyl radical, more preferably a methyl radical.

14. Compounds according to one or more of claims 1 to 13:

1-[1-(5-Chloro-3-methyl-benzo[b]thiophenyl-2-sulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,


1-[1-(5-Dimethylamino-naphthyl-1-sulfonyl)-piperidine-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

1-[1-(5-Dimethylamino-naphthyl-1-sulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

and corresponding salts thereof, and corresponding solvates.


15. Process for the preparation of benzoxazinone-derived sulfonamide compounds of general formula (I) according to one or more of claims 1 to 14, characterized in that it comprises reacting at least one piperidine compound of general formula (II), wherein R^1 to R^9 have the meaning according to claim 1, and/or a salt, preferably a hydrochloride salt, thereof,

547



(II)

with at least one compound of general formula (III),



(III)

wherein W has the meaning according to claim 1, in a suitable reaction medium, optionally in the presence of at least one base and/or at least one auxiliary agent.

16. Process for the preparation of a physiologically acceptable salt of the benzoxazinone-derived sulphonamide compounds according to claims 1-14, characterized in that at least one compound of general formula (I) having at least one basic group is reacted with at least one acid, preferably an inorganic or organic acid, preferably in the presence of a suitable reaction medium.

548

17. Process for the preparation of a physiologically acceptable salt of the benzoxazinone-derived sulphonamide compounds according to claims 1-14, characterized in that at least one compound of general formula (I) having at least one acidic group is reacted with at least one base, preferably in the presence of a suitable reaction medium.


18. Medicament comprising at least one benzoxazinone-derived sulphonamide compound according to any one of claims 1-14, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively, and optionally one or more pharmaceutically acceptable adjuvants.

19. Medicament according to claim 18 for cognitive enhancement, for the prophylaxis and/or treatment of food ingestion (food intake) disorders, particularly for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (Non-Insulin Dependent Diabetes Mellitus), preferably type II diabetes, which is caused by obesity, disorders of the central nervous system, disorders of the gastrointestinal tract, such as irritable intestine syndrom, anxiety, panic, depression, cognitive memory disorders, senile dementia disorders, such as Morbus Alzheimer, Morbus Parkinson and Morbus Huntington, schizophrenia, psychosis, infantile hyperkinesia or ADHC (attention deficit, hyperactivity disorders).

20. Use of at least one benzoxazinone-derived sulphonamide compound according to any one of claims 1-14, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, for the manufacture of a medicament for cognitive enhancement, for the prophylaxis and/or treatment of food ingestion (food intake) disorders, particularly for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II

diabetes (Non-Insulin Dependent Diabetes Mellitus), preferably type II diabetes, which is caused by obesity, disorders of the central nervous system, disorders of the gastrointestinal tract, such as irritable intestine syndrom, anxiety, panic, depression, cognitive memory disorders, senile dementia disorders, such as Morbus Alzheimer, Morbus Parkinson and Morbus Huntington, schizophrenia, psychosis, infantile hyperkinesia or ADHC (attention deficit, hyperactivity disorders).

21. Use of at least one benzoxazinone-derived sulfonamide compound of general formula (Ia),



(Ia)

wherein

R^{1a}, R^{2a}, R^{3a}, R^{4a} are each independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic

ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano group, $-OR^{10a}$, $-OC(=O)R^{11a}$, $-(C=O)-OR^{11a}$, $-SR^{12a}$, $-SOR^{12a}$, $-SO_2R^{12a}$, $-NH-SO_2R^{12a}$, $-SO_2NH_2$ and a $-NR^{13a}R^{14a}$ moiety,

R^{5a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical,

R^{6a}, R^{7a}, R^{8a}, R^{9a} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano group and a $-COOR^{15a}$ moiety,

W^a represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, a $NR^{16a}R^{17a}$-moiety or a COR^{18a}-moiety,

R^{10a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may

be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{11a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{12a} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{13a} and R^{14a} each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an

optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

or R^{13a} and R^{14a} together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member,

R^{15a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{16a} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

R^{17a} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

R^{18a} represents an optionally at least mono-substituted aryl radical,

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively,

for the manufacture of a medicament for the prophylaxis and/or treatment of food intake disorders; anxiety; panic; depression; cognitive disorders; preferably memory disorders; senile dementia processes, preferably selected

from the group consisting of Morbus Alzheimer, Morbus Parkinson, Morbus Huntington; psychosis; infantile hyperkinesia; ADHC (attention deficit/hyperactivity disorder); disorders of the gastrointestinal tract, preferably intestine syndrom; schizophrenia or for cognitive enhancement.

22. Use according to claim 21, characterized in that R^{1a}, R^{2a}, R^{3a}, R^{4a} are each independently selected from the group consisting of H, F, Cl, Br, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano group, -OR^{10a}, -$OC(=O)R^{11a}$, -SR^{12a}, -SOR^{12a}, -SO_2R^{12a}, -NH-SO_2R^{12a}, -SO_2NH_2 and a -$NR^{13a}R^{14a}$ moiety, preferably selected from the group consisting of H, F, Cl, Br, a saturated, branched or unbranched, optionally at least mono-substituted C_{1-3}-aliphatic radical, a saturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_5- or C_6-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_1- or C_2-alkylene group, a nitro group, a cyano group, -OR^{10a}, -$OC(=O)R^{11a}$, -SR^{12a} and -$NR^{13a}R^{14a}$ moiety, more preferably selected from the group consisting of H, F, Cl, -CH_3, -CH_2CH_3, -CF_3, -CF_2CF_3, cyclopentyl, cyclohexyl, nitro, cyano and -OR^{10a}.

23. Use according to claim 21 or 22, characterized in that R^{5a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, preferably represents H or a

branched or unbranched C_{1-3}-alkyl radical, more preferably H, $-CH_3$ or $-CH_2CH_3$.

24. Use according to any one of claims 21 to 23, characterized in that R^{6a}, R^{7a}, R^{8a}, R^{9a} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, a cyano group and a $-COOR^{15a}$ moiety, preferably selected from the group consisting of H, a branched or unbranched C_{1-3}-alkyl radical, a cyano group and a $COOR^{15a}$ group, more preferably from the group consisting of H, $-CH_3$, $-CH_2CH_3$ and a cyano moiety.

25. Use according to any one of claims 21 to 24, characterized in that W^a represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-20} aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8} cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-6}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-6}- alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, a $NR^{16a}R^{17a}$-moiety or a COR^{16a}-moiety,

preferably is selected from the group consisting of 1-Naphthyl-, 5-Dimethylamino-napth-1-yl, 2-Naphthyl-, 2-Acetamido-4-methyl-6-thiazolyl-, 2-Thienyl-, 8-Quinolinyl-, Phenyl-, Pentafluorophenyl-, 2,4,5-Trichloro-phenyl-, 2,5-Dichloro-phenyl-, 2-Nitrophenyl-, 2,4-Dinitro-phenyl-, 3,5-Dichloro-2-hydroxy-phenyl-, 2,4,6-Trisisopropyl-phenyl-, 2-Mesityl-, 3-Nitro-phenyl-, 4-Bromo-phenyl-, 4-Fluoro-phenyl-, 4-Chlorophenyl-, 4-Chloro-3-nitro-phenyl-, 4-Iodo-phenyl-, N-Acetyl-sulfanilyl-, 4-Nitro-phenyl-, 4-Methoxy-phenyl-, Benzoic-acid-4-yl-, 4-tert-Butyl-phenyl-, p-Tolyl-, Trifluoromethyl-,

Trichloromethyl-, Isopropyl-, Methyl-, Benzyl-, trans-styryl-, 2,2,2-Trifluoroethyl-, Ethyl-, Hexadecyl-, 2-Chloroethyl-, n-Propyl-, 3-Chloro-propyl-, n-Butyl-, Methyl-benzoate-2-yl-, 2-Nitro-4-(trifluoromethyl)-phenyl-, Pentamethyl-phenyl-, 2,3,5,6-Tetramethyl-phenyl-, 3-(Trifluoromethyl)-phenyl-, 3,5-Bis-(Trifluoromethyl)-phenyl-, Dichloromethyl-, Chloromethyl-, Dodecyl-, 1-Octyl-, 2,3,4-Trichloro-phenyl-, 2,5-Dimethoxy-phenyl-, o-Tolyl-, p-xylyl-2-yl-, Benzoic-acid-3-yl-, 4-Chloro-3-(trifluoromethyl)-phenyl-, 4-Chloro-5-nitro-benzoic acid-3-yl-, 6-(p-toluidino)-naphth-2-yl-, 4-Methoxy-2,3,6-trimethylphenyl-, 3,4-Dichlorophenyl-, 4,5-Dibromo-thiophene-2-yl-, 3-Chloro-4-fluoro-phenyl-, 4-Ethyl-phenyl-, 4-n-Propyl-phenyl-, 4-(1,1-Dimethylpropyl)-phenyl-, 4-Isopropyl-phenyl-, 4-Bromo-2,5-difluoro-phenyl-, 2-Fluoro-phenyl-, 3-Fluoro-phenyl-, 4-(Trifluoromethoxy)-phenyl-, 4-(Trifluoromethyl)-phenyl-, 2,4-Difluoro-phenyl-, 2,4-Dichloro-5-methyl-phenyl-, 4-Chloro-2,5-dimethyl-phenyl-, 5-Diethylamino-napth-2-yl-, Benzoyl chloride-3-yl-, 2-Chloro-phenyl-, 1-Octadecyl-, 4-Bromo-2,5-dichloro-thiophene-3-yl-, 2,5-Dichloro-thiophene-3-yl-, 5-Chloro-thiophene-2-yl-, 2-Methyl-5-nitro-phenyl-, 2-(Trifluoromethyl)-phenyl-, 3-Chloro-phenyl-, 3,5-Dichloro-phenyl-, 1-Decyl-, 3-Methyl-phenyl-, 2-Chloro-6-methyl-, 5-Bromo-2-methoxy-phenyl-, 3,4-Dimethoxy-phenyl-, 2-3-Dichloro-phenyl-, 2-Bromo-phenyl-, 3,5-Dichloro-4-(2-chloro-4-nitrophenoxy)-phenyl-, 2,3-Dichloro-thiophene-5-yl-, 3-Bromo-2-chloro-thiophene-5-yl-, 3-Bromo-5-chloro-thiophene-2-yl-, 2-(Benzoylaminomethyl)-thiophene-5-yl-, 4-(Phenyl-sulphonyl)-thiophene-2-yl-, 2-Phenyl-sulphonyl-thiophene-5-yl-, 3-Chloro-2-methyl-phenyl-, 2-[1-Methyl-5-(trifluoromethyl)pyrazol-3-yl]-thiophene-5-yl-, 5-Pyrid-2-yl-thiophene-2-yl-, 2-Chloro-5-(trifluoromethyl)-phenyl-, 2,6-Dichloro-phenyl-, 3-Bromo-phenyl-, 2-(Trifluoromethoxy)-phenyl-, 4-Cyano-phenyl-, 2-Cyano-phenyl-, 4-n-Butoxy-phenyl-, 4-Acetamido-3-chloro-phenyl, 2,5-Dibromo-3,6-difluoro-phenyl-, 5-Chloro-1,3-dimethylpyrazole-4-yl-, 3,5-Dimethylisoxazole-4-yl-, 2-(2,4-Dichlorophenoxy)-phenyl-, 4-(2-Chloro-6-nitro-phenoxy)-phenyl-, 4-(3-Chloro-2-cyano-phenoxy)-phenyl-, 2,4-Dichloro-phenyl-, 2,4-Dimethyl-1,3-thiazole-5-yl-, Methyl-methane-sulfonyl-, 2,5-Bis-(2,2,2-Trifluoroethoxy)-phenyl-, 2-Chloro-4-(trifluoromethyl)-phenyl-, 2-Chloro-4-fluoro-phenyl-, 5-Fluoro-2-methyl-phenyl-, 5-Chloro-2-methoxy-phenyl-, 2,4,6-Trichloro-phenyl-, 2-Hydroxy-benzoic acid-5-yl-, 5-(Di-n-propylamino)-naphth-1-yl-, 6-Methoxy-m-tolyl-, 2,5-Difluoro-phenyl-, 2,4-Dimethoxy-phenyl-,

2,5-Dibromo-phenyl-, 3,4-Dibromo-phenyl-, 2,2,5,7,8-Pentamethyl-chroman-6-yl-, 2-Methoxy-benzoic-acid-5-yl-, 5-Chloro-4-nitro-thiophene-2-yl-, 2,1,3-Benzothiadiazole-4-yl-, 1-Methyl-imidazole-4-yl-, Benzofurazan-4-yl-, 2-(Methoxycarbonyl)-thiophene-3-yl-, 5-(Isoxazol-3-yl)-thiophene-2-yl-, 2,4,5-Trifluoro-phenyl-, Biphenyl-4-yl-, Vinyl-phenyl-4-yl-, 2-Nitro-benzyl-, 5-Dichloro-methyl-furan-2-yl-, 5-Bromo-thiophene-2-yl-, 5-(4-Chlorobenzamidomethyl)-thiophene-2-yl-, 2,6-Difluoro-phenyl-, 2,5-Dimethoxy-4-nitro-phenyl-, Dibenzo[b,d]-furan-2-yl-, 2,3,4-Trifluoro-phenyl-, 3-Nitro-p-tolyl-, 4-Methoxy-2-nitro-phenyl-, 3,4-Difluoro-phenyl-, 4-(Bromoethyl)-phenyl-, 3,5-Dichloro-4-hydroxy-phenyl-, 4-n-Amyl-phenyl-, 5-Chloro-3-methylbenzo[b]-thiophene-2-yl-, 3-Methoxy-4-(methoxycarbonyl)-thiophene-2-yl-, 4-n-Butyl-phenyl-, 2-Chloro-4-cyano-phenyl-, 5-[2-(Methylthio)-pyrimidin-4-yl-]-thiophene-2-yl-, 3,5-Dinitro-4-methoxy-phenyl-, 4-Bromo-2-(trifluoromethoxy)-phenyl-, 4-Chloro-2,1,3-Benzoxadiazole-7-yl-, 2-(1-Naphthyl)-ethyl-, 3-Cyano-phenyl-, 5-Chloro-2,1,3-Benzoxadiazole-4-yl-, 3-Chloro-4-methyl-phenyl-, 4-Bromo-2-ethyl-phenyl-, 2,4-Dichloro-6-methyl-phenyl-, 6-Chloro-Imidazo(2,1-B)-thiazole-5-yl-, 3-Methyl-benzo[b]-thiophene-2-yl-, 4-Methyl-sulphonyl-phenyl-, 2-Methyl-sulphonyl-phenyl-, 4-Bromo-2-methyl-phenyl-, 2,6-Dichloro-4-(trifluoromethyl)-phenyl-, 4-[[3-Chloro-5-(trifluoromethyl)-2-pyridinyl]oxy]-phenyl-, 5-Chloro-naphth-1-yl-, 5-Chloro-naphth-2-yl-, 9,10-Dibromoanthracene-2-yl-, Isoquinoline-5-yl-, 4-Methoxy-2,3,6-trimethyl-phenyl-, 4'-Nitro-biphenyl-4-yl-, [(4-Phenoxy)-phenyl-, (1,3-Dihydro-1-oxo-2H-isoindol-2-yl-)-4-phenyl-, 4-Acetyl-phenyl-, 5-(2-Methyl-1,3-thiazole-4-yl)-thiophene-2-yl-, 5-(1-Methyl-3-(trifluoromethyl)pyrazol-5-yl-]-thiophene-2-yl-, 5-[5-Trifluoromethyl)-Isoxazol-3-yl]-thiophene-2-yl-, 2-Iodo-phenyl-, p-Dodecyl-phenyl-, 4-[(3-Cyano-4-methoxy-2-pyridinyl)oxy]-phenyl-, 4-(N-phthalimidinyl)-phenyl-, 1,2,3,4-Tetrahydro-2-(trifluoroacetyl)-Isoquinoline-7-yl-, 4-Bromo-2-fluoro-phenyl-, 2-Fluoro-5-(trifluoromethyl)-phenyl-, 4-Fluoro-2-(trifluoromethyl)-phenyl-, 4-Fluoro-3-(trifluoromethyl)-phenyl-, 2,4,6-Trifluoro-phenyl-, 3-(Trifluoromethoxy)-phenyl-, 1,2-Dimethylimidazole-4-yl-, Ethyl-4-Carboxylate-3-yl-, 2,2,4,6,7-Pentamethyldihydrobenzofuran-5-yl-, 3-Bromo-2-chloropyridine-5-yl-, 3-Methoxy-phenyl-, 2-Methoxy-4-methyl-phenyl-, 2-Chloro-4-fluorobenzoic-acid-5-yl-, 4-Chloro-naphth-1-yl-, 2,5-Dichloro-4-nitro-thiophene-3-yl-, 4-(4-Methoxy-phenoxy)-phenyl-, 4-(4-Chloro-phenoxy)-

phenyl-, 4-(3,5-Dichloro-phenoxy)-phenyl-, 4-(3,4-Dichloro-phenoxy)-phenyl-, 4-(4-Fluoro-phenoxy)-phenyl-, 4-(4-Methyl-phenoxy)-phenyl-, 4-[4-(Trifluormethyl)-phenoxy-phenyl-, 4-[3,5-Bis-(trifluoromethyl)-phenoxy]-phenyl-, 3-(2-Methoxy-phenoxy)-phenyl-, [3-(2-Chloro-phenoxy)-phenyl-, 3-(2-Methyl-phenoxy)-phenyl-, 4-[2-(Trifluoromethyl)-phenoxy]-phenyl-, 3-Phenyl-phenyl-, 3-(4-Methoxy-phenyl)-phenyl-, 3-(4-Chloro-phenyl)-phenyl-, 3-(3,5-Dichloro-phenyl)-phenyl-, 3-(3,4-Dichloro-phenyl)-phenyl-, 3-(4-Fluorophenyl)-phenyl-, 3-(4-Methylphenyl)-phenyl-, 3-[4-(Trifluoromethyl)-phenyl]-phenyl-, 3-[3,5-Bis-(Trifluoromethyl)-phenyl]-phenyl-, 4-(4-Pyridyloxy)-phenyl)-, 4-(2-Methoxy-phenoxy)-phenyl-, 4-(2-Chloro-phenoxy)-phanyl-, 4-(2-Methyl-phenoxy)-phenyl-, 4-(4-Methoxy-phenoxy)-phenyl-, 4-(4-Chlorophenyl)-phenyl-, 4-(3,5-Dichlorophenyl)-phenyl-, 4-(3,4-Dichlorophenyl)-phenyl-, 4-(4-Fluorophenyl)-phenyl-, 4-(4-Methylphenyl)-phenyl-, 4-[4-(Trifluormethyl)-phenyl]-phenyl-, 4-[3,5-Bis-(Trifluoromethyl)-phenyl]-phenyl-, [3-(Trifluoromethyl)-phenyl]-methyl-, (4-Chlorophenyl)-methyl-, (3,5-Dichlorophanyl)-methyl-, (3,5-Dichlorophenyl)-methyl-, (4-Fluorophenyl)-methyl-, 4-Methylphenylmethyl-, [4-(Trifluoromethyl)-phenyl]-methyl-, Cyclopropyl-, 2-(2-Chlorophenyl)-2-Phenylethyl-, 2-(2-Trifluoromethylphenyl)-2-phenylethyl-, 5-[4-Cyano-1-methyl-5-(methylthio)-1H-pyrazol-3-yl-thiophene-2-yl-, 3-Cyano-2,4-bis-(2,2,2-Trifluorothoxy)-phenyl-, 4-[(2-Chloro-1,3-Thiazol-5-yl)-methoxy]-phenyl-, 3-Nitro-phenylmethyl-, 4-Formylphenyl-, 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethyl-, [3,5-Bis-(Trifluoromethyl)-phenyl]-methyl-, (4-(2-Pyridyloxy)-phenyl)-, (4-(3-Pyridyloxy)-phenyl)-, 5-Iodo-naphth-1-yl-, Ethyl-2,5-dimethyl-1-phenylpyrrole-4-carboxylate-3-yl-, Ethyl-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxylate-4-yl-, Ethyl-5-(4-chlorophenyl)-2-methyl-3-furoate-4-yl, Ethyl-5-(4-chlorophenyl)-2-methyl-1-phenyl-3-carboxylate-4-yl-, Ethyl-2,5-dimethyl-3-furoate-4-yl-, 3-Chloro-4-(1,3-dioxo-2-Azaspiro[4,4]non-2-yl)-phenyl-, 5-Bromo-2,4-difluoro-phenyl-, 5-Chloro-2,4-difluorophenyl-, Coumarin-6-yl, 2-Methoxy-phenyl, (3-Phenoxy)-phenyl-, 3-(4-Methoxy-phenoxy)-phenyl-, 3-(4-Chlorophenoxy)-phenyl-, 3-(3,5-Dichlorophenoxy)-phenyl-, 3-(3,4-Dichlorophenoxy)-phenyl-, 3-(4-Fluorophenoxy)-phenyl-, 3-(4-Methylphenoxy)-phenyl-, 3-[4-(Trifluoromethyl)-phenoxy]-phenyl-, 3-[3,5-(Trifluoromethyl)-phenoxy]-phenyl-, 3-[2-(Trifluoromethyl)-phenoxy]-phenyl-, 2,2-Diphenylethyl-, 4-Phenyl-5-(trifluoromethyl)-thiophene-3-yl-, Methyl-4-Phenyl-5-(Trifluoromethyl)-

thiophene-2-carboxylate-3-yl-, Methyl-1,2,5-trimethylpyrrole-3-Carboxylate-4-yl-, 4-Fluoro-naphth-1-yl-, 3,5-Difluorophenyl-, 3-Fluoro-4-methoxy-phenyl-, 4-Chloro-2,5-difluorophenyl-, 2-Chloro-4,5-difluoro-phenyl-, 5-Fluoro-3-methylbenzo[b]-thiophene-2-yl-, Methyl-3-phenylpropionate-4-yl, Dihydrocinnamic Acid-4-yl-, Methyl-2,5-dimethyl-3-furoate-4-yl-, Methyl-2-furoate-5-yl-, Methyl-2-methyl-3-furoate-5-yl-, Methyl-1-methyl-1H-pyrrole-2-Carboxylate-5-yl-, 2-(5-Chloro-1,2,4-Thiadiazol-3-yl)-thiophene-5-yl-, 1,3,5-Trimethyl-1H-pyrazole-4-yl-, 3-Chloro-5-fluoro-2-methylphenyl-, Pentafluoroethoxytetrafluoroethyl-, 5-(5-Isoxazyl)-thiophene-2-yl-, 5-(5-Isoxazol-yl)-2-furyl-, 5-Methyl-2,1,3-benzothiadiazole-4-yl-, Biphenyl-2-yl-, 2,3-Dihydro-1,4-benzodioxine-6-yl-, 4-Methyl-Naphth-1-yl-, 5-Methyl-2-(Trifluormethyl)-3-Furyl-, 2,3-Dihydrobenzo[b]furan-5-yl-, 1-Benzothiophene-3-yl-, 4-Methyl-3,4-dihydro-2H-1,4-Benzoxazine-7-yl-, 5-Methyl-1-phenyl-1H-pyrazole-4-yl-, 6-Morpholino-3-Pyridinyl-, 4-(1H-Pyrazol-1-yl)-phenyl-, 6-Phenoxy-3-Pyridyl-, 3,4-Dihydro-2H-1,5-benzodioxepine-7-yl-, 5-(1,3-Oxazol-5-yl)-2-thienyl-, 4-(1,3-Oxazol-5-yl)-phenyl-, 5-Methyl-4-Isoxazolyl, 2,1,3-Benzothiadiazole-5-yl-, 3-Thienyl-, 2-Methyl-benzyl-, 3-Chloro-benzyl-, 5-Acetamido-naphth-1-yl-, 3-Methyl-8-Quinolinyl-, 4-Chloro-2-nitrophenyl-, 6-Quinolinyl-, 1,3-Benzothiazole-6-yl-, 2-Morpholino-3-Pyridyl-, 2,5-Dimethyl-3-thienyl-, 5-[5-(Chloromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl-, Ethyl-3-[5-yl-2-thienyl-]1,2,4-oxadiazole-5-carboxylate-, 3-(5-Methyl-1,3,4-oxadiazol-2-yl)-phenyl-, 4-Isopropoxyphenyl-, 2,4-Dibromophenyl-, 3-Cyano-4-fluorophenyl-, 2,5-Bis-(Trifluoromethyl)-phenyl, 2-Bromo-4-fluorophenyl-, 4-Bromo-3-fluorophenyl-, 4-(Difluoromethoxy)-phenyl-, 3-(Difluoromethoxy)-phenyl-, 5-Chloro-2-fluoro-phenyl-, 3-Chloro-2-fluorophenyl-, 2-Fluoro-4-methylphenyl-, 4 Nitro-3-(trifluoromethyl)-phenyl-, 3-Fluoro-4-methylphenyl-, 4-Fluoro-2-methylphenyl-, 4-Bromo-3-(trifluoromethyl)-phenyl-, 4-Bromo-2-(trifluoromethyl)-phenyl-, 3-Bromo-5-(trifluoromethyl)-phenyl-, 2-Bromo-4-(trifluoromethyl)-phenyl-, 2-Bromo-5-(trifluoromethyl)-phenyl-, 2,4-Dichloro-5-fluorophenyl-, 4,5-Dichloro-2-fluorophenyl-, 3,4,5-Trifluorophenyl-, 4-Chloro-2-fluorophenyl-, 2-Bromo-4,6-Difluorophenyl-, 2-Ethylphenyl-, 4-Bromo-2-chlorophenyl-, 4-Bromo-2,6-dichlorophenyl-, 2-Bromo-4,6-dichloro-phenyl-, 4-Bromo-2,6-dimethylphenyl-, 3,5-Dimethylphenyl-, 4-Bromo-3-methylphenyl-, 2-Methoxy-4-nitrophenyl-, 2,2-Dimethyl-6-Chromanyl-, Ethyl-3,5-dimethyl-1H-

pyrrole-2-carboxylate-4-yl-, Imidazo[1,2-A]pyridine-3-yl-, 3-(1,3-Oxazol-5-yl)-phenyl-, Ethyl-5-[4-yl)-phenyl]-2-methyl-3-furoate, Methyl-3-(yl)-4-methoxybenzoate, 1-Pyrrolidinylphenylsulfonyl-, Methyl-5-yl-4-methyl-2-thiophene-carboxylate, Methyl-3-yl-4-(isopropylsulfonyl)-2-thiophene, 2-Pyridyl-, 3-Fluoro-4-nitrophenyl-, 7-Chlorochromone-3-yl-, 4'-Bromobiphenyl-4-yl-, 4'-Acetyl-biphenyl-4-yl-, 4'-Bromo-2'-fluoro-biphenyl-4-yl-, 2-Chloro-4-(3-propyl-Ureido)-phenyl-, 3-(-Bromoacetyl)-phenyl-, 2-Bromo-3-(trifluoromethyl)-phenyl-, 1-Methyl-5-isatinyl-, 4-Isopropyl-benzoic-acid-3-yl-, 2-Chloro-3-thiophenecarboxylic-acid-5-yl-, 3-Pyridyl-, Cyclohexylmethyl-, 2-Methoxy-5-(N-phthalimidinyl)-phenyl-, 1-Benzothiophene-2-yl-, Morpholinophenylsulfonyl-, 3-(2-Methyl-4-pyrimidinyl)-phenyl-, and 2-Cyano-5-methylphenyl-.

28. Use according to any one of claims 21 to 25, characterized in that R^{10a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl.

27. Use according to any one of claims 21 to 26, characterized in that R^{11a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-

membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-6}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl.

28. Use according to any one of claims 21 to 27, characterized in that R^{12a} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-6}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-6}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-6}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl.

29. Use according to any one of claims 21 to 28, characterized in that R^{13a} and R^{14a} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-6}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-6}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-6}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably are each independently selected from the group consisting of H, a linear or branched C_{1-4}-alkyl radical,

cyclohexyl and a phenyl radical, more preferably are each independently selected from the group consisting of H, $-CH_3$, $-C_2H_5$ and phenyl.

30. Use according to any one of claims 21 to 29, characterized in that R^{13a} and R^{14a} together with the bridging nitrogen atom form a saturated, unsaturated or aromatic, 5- or 6-membered heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member, preferably form an unsubstituted piperidin or morpholine group.

31. Use according to any one of claims 21 to 30, characterized in that R^{15a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched C_{1-6}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably represents H, $-CH_3$, $-C_2H_5$ or phenyl.

32. Use according to any one of claims 21 to 31, characterized in that R^{16a} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8} aliphatic radical, preferably an unbranched or branched, saturated, unsubstituted C_{1-3} alkyl radical, more preferably a methyl radical.

33. Use according to any one of claims 21 to 32 characterized in that R^{17a} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8} aliphatic radical, preferably an unbranched or branched, saturated, unsubstituted C_{1-3} alkyl radical, more preferably a methyl radical.

34. Use according to any one of claims 21 to 33, characterized in that one or more benzoxazinone-derived sulfonamide compounds of general formula (Ia) are selected from the group consisting of:

1-[1-(Naphthyl-1-sulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

1-(1-Phenylsulfonyl-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]-oxazin-2-one,

1-[1-(5-Chloro-3-methyl-benzo[b]thiophenyl-2-sulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

8-Methyl-1-[1-naphthyl-1-sulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

8-Methyl-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

1-[1-(5-Dimethylamino-naphthyl-1-sulfonyl)-piperidine-4-yl]-8-methyl-1,4-dihydrobenzo[d][1,3]oxazin-2-one,

1-[1-(5-Dimethylamino-naphthyl-1-sulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

1-[1-(2,3-Dichloro-phenylsulfonyl)-piperidine-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one,

1-[1-(2,3-Dichloro-phenylsulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, and

corresponding salts thereof, or corresponding solvates thereof.

35. Use according to any one of claims 21-34 for the regulation of appetite.

36. Use according to any one of claims 21-34 for the reduction, increase or maintenance of body weight.

37. Use according to any one of claims 21-34 for the prophylaxis and/or treatment of obesity.


38. Use according to any one of claims 21-34 for the prophylaxis and/or treatment of bulimia.

39. Use according to any one of claims 21-34 for the prophylaxis and/or treatment of anorexia.

40. Use according to any one of claims 21-34 for the prophylaxis and/or treatment of cachexia.

41. Use according to any one of claims 21-34 for the prophylaxis and/or treatment of type II diabetes.

42. Benzoxazinone-derived sulfonamide compounds of general formula (Ib),



(Ib)

wherein

R^{1b}, R^{2b}, R^{3b}, R^{4b} are each independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano group, $-OR^{10b}$, $-OC(=O)R^{11b}$, $-(C=O)-OR^{11b}$, $-SR^{12b}$, $-SOR^{12b}$, $-SO_2R^{12b}$, $-NH-SO_2R^{12b}$, $-SO_2NH_2$ and a $-NR^{13b}R^{14b}$ moiety,

R^{6b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical,

R^{6b}, R^{7b}, R^{8b}, R^{9b} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano group and a $-COOR^{15b}$ moiety,

W^b represents an unbranched or branched, saturated or unsaturated, aliphatic radical, which may be substituted by one or more substituents selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkoxy, branched or unbranched C_{1-4}-perfluoroalkoxy, branched or unbranched C_{1-4}-perfluoroalkyl, amino, carboxy, amido, cyano, nitro, $-SO_2NH_2$, $-CO-C_{1-4}$-alkyl, $-SO-C_{1-4}$-alkyl, $-SO_2-C_{1-4}$-alkyl, $-NH-SO_2-C_{1-4}$-alkyl , wherein the C_{1-4}-alkyl may in each case be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and an unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical,
whereby said substituents may be at least mono-substituted with F, Cl, methyl and methoxy,

a saturated or unsaturated, optionally at least one heteroatom as ring member containing cycloaliphatic radical,
whereby said cycloaliphatic radical may be substituted by one or more substituents selected from the group selected from the group consisting of hydroxy, nitro, carboxy, cyano, keto, halogen, C_{1-20}-alkyl, partially fluorinated C_{1-4} alkyl, partially chlorinated C_{1-4} alkyl, partially brominated C_{1-4} alkyl, C_{1-5}-alkoxy, partially fluorinated C_{1-4} alkoxy, partially chlorinated C_{1-4} alkoxy, partially brominated C_{1-4} alkoxy, C_{2-5}-alkenyl, SO_2-C_{1-4}-alkyl, $-(C=O)-C_{1-5}$-alkyl, $-(C=O)-O-C_{1-5}$-alkyl, $-(C=O)-Cl$, $-S-C_{1-4}$-alkyl-, $-(C=O)-H$, $-NH-(C=O)-NH-C_{1-5}$-alkyl, $-(C=O)-C_{1-4}$-perfluoroalkyl, $-NR^AR^B$, wherein R^A and R^B are

independently selected from the group consisting of H, C_{1-4}-alkyl and phenyl, NH-(C=O)-C_{1-5}-alkyl, -C_{1-5}-alkylen-(C=O)-C_{1-5}-alkyl, (1,3-Dihydro-1-oxo-2H-isoindol-2-yl), N-Phthalimidinyl-, (1,3-Dioxo-2-azaspiro[4,4]-non-2-yl, substituted or unsubstituted phenyl, -SO_2-phenyl, phenoxy, pyridinyl, pyridinyloxy, pyrazolyl, pyrimidinyl, pyrrolidinyl-, -SO_2-pyrrolidinyl, morpholinyl, SO_2-morpholinyl-, thiadiazolyl, oxadiazolyl, oxazolyl, thiazolyl, isoxazolyl, O-CH_2-thiazolyl, -NH-phenyl, and -C_{1-4}-Alkylen-NH-(C=O)-phenyl, whereby said substituents may be substituted by one or more substituents selected from the group consisting of halogen, nitro, cyano, hydroxy, -(C=O)-C_{1-4}-alkyl, C_{1-4}-alkyl, at least partially fluorinated C_{1-4}-alkyl, at least partially chlorinated C_{1-4}-alkyl, at least partially brominated C_{1-4}-alkyl, -S-C_{1-4}-alkyl, -C(=O)-O-C_{1-5}-alkyl, -(C=O)-CH_2-F, -(C=O)-CH_2-Cl and -(C=O)-CH_2-Br, and whereby said cycloaliphatic radical may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted aromatic mono- or polycyclic ring-system,

an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, a $NR^{16b}R^{17b}$-molety or a COR^{16b}-molety,

R^{16b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{11b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{12b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{13b} and R^{14b} each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

or R^{13b} and R^{14b} together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member,

R^{15b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{16b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

R^{17b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

R^{18b} represents an optionally at least mono-subsituted aryl radical,

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively.

43. Compounds according to claim 42, characterized in that R^{1b}, R^{2b}, R^{3b}, R^{4b} are each independently selected from the group consisting of H, F, Cl, Br, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl

radical, which may be bonded via an optionally at least mono-substituted C_{1-6}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro group, a cyano group, -OR^{10b}, -$OC(=O)R^{11b}$, -SR^{12b}, -SOR^{12b}, -SO_2R^{12b}, -NH-SO_2R^{12b}, -SO_2NH_2 and a -$NR^{13b}R^{14b}$ moiety, preferably selected from the group consisting of H, F, Cl, Br, a saturated, branched or unbranched, optionally at least mono-substituted C_{1-3}-aliphatic radical, a saturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_3- or C_6-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_1- or C_2-alkylene group, a nitro group, a cyano group, -OR^{10b}, -$OC(=O)R^{11b}$, -SR^{12b} and -$NR^{13b}R^{14b}$ moiety, more preferably selected from the group consisting of H, F, Cl, Br, -CH_3, -CH_2CH_3, -CF_3, -CF_2CF_3, cyclopentyl, cyclohexyl, nitro, cyano and -OR^{10b}.

44. Compounds according to claim 42 or 43, characterized in that R^{8b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6}-aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-6}-cycloaliphatic radical, preferably represents H or a branched or unbranched C_{1-3}-alkyl radical, more preferably H, -CH_3 or -CH_2CH_3, most preferably a hydrogen atom.

45. Compounds according to any one of claims 42 to 44, characterized in that R^{6b}, R^{7b}, R^{8b}, R^{9b} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-6}-cycloaliphatic radical, a cyano group and a -$COOR^{15b}$ moiety, preferably selected from the group consisting of H, a branched or unbranched C_{1-3}-alkyl radical, a cyano group and a $COOR^{15b}$ group, more preferably from the group consisting of H, -CH_3, -CH_2CH_3 and a cyano moiety, most preferably each of R^{6b}, R^{7b}, R^{8b} and R^{9b} represent a hydrogen atom.

46. Compounds according to any one of claims 42 to 45, characterized in that W^5 represents an unbranched or branched, saturated or unsaturated, C_{1-20} aliphatic radical, which may be substituted by one or more substituents selected from the group consisting of hydroxy, halogen, branched or unbranched C_{1-4}-alkoxy, branched or unbranched C_{1-4}-perfluoroalkoxy, branched or unbranched C_{1-4}-perfluoroalkyl, amino, carboxy, amido, cyano, nitro, $-SO_2NH_2$, $-CO-C_{1-4}$-alkyl, $-SO-C_{1-4}$-alkyl, $-SO_2-C_{1-4}$-alkyl, $-NH-SO_2-C_{1-4}$-alkyl , wherein the C_{1-4}-alkyl may in each case be branched or unbranched, an unsubstituted or at least mono-substituted phenyl or naphthyl radical and an unsubstituted or at least mono-substituted furanyl-, thienyl-, pyrrolyl-, imidazolyl-, pyrazolyl-, pyridinyl-, pyrimidinyl-, quinolinyl- and isoquinolinyl radical, whereby said substituents may be at least mono-substituted with F, Cl, methyl and methoxy; a saturated or unsaturated, optionally at least one heteroatom as ring member containing C_{3-8} cycloaliphatic radical, whereby said C_{3-8} cycloaliphatic radical may be substituted by one or more substituents selected from the group selected from the group consisting of hydroxy, nitro, carboxy, cyano, keto, halogen, C_{1-20}-alkyl, partially fluorinated C_{1-4} alkyl, partially chlorinated C_{1-4} alkyl, partially brominated C_{1-4} alkyl, C_{1-5}-alkoxy, partially fluorinated C_{1-4} alkoxy, partially chlorinated C_{1-4} alkoxy, partially brominated C_{1-4} alkoxy, C_{2-6}-alkenyl, SO_2-C_{1-4}-alkyl, $-(C=O)-C_{1-5}$-alkyl, $-(C=O)-O-C_{1-6}$-alkyl, -(C=O)-Cl, $-S-C_{1-6}$-alkyl-, -(C=O)-H, $-NH-(C=O)-NH-C_{1-5}$-alkyl, $-(C=O)-C_{1-4}$-perfluoroalkyl, $-NR^AR^B$, wherein R^A and R^B are independently selected from the group consisting of H, C_{1-4}-alkyl and phenyl, $NH-(C=O)-C_{1-5}$-alkyl, $-C_{1-5}$-alkylen-$(C=O)-C_{1-5}$-alkyl, (1,3-Dihydro-1-oxo-2H-isoindol-2-yl), N-Phthalimidinyl-, (1,3-Dioxo-2-azaspiro[4,4]-non-2-yl, substituted or unsubstituted phenyl, $-SO_2$-phenyl, phenoxy, pyridinyl, pyridinyloxy, pyrazolyl, pyrimidinyl, pyrrolidinyl-, $-SO_2$-pyrrolidinyl, morpholinyl, SO_2-morpholinyl-, thiadiazolyl, oxadiazolyl, oxazolyl, thiazolyl, isoxazolyl, O-CH_2-thiazolyl, -NH-phenyl, and $-C_{1-4}$-Alkylen-NH-(C=O)-phenyl, whereby said substituents may be substituted by one or more substituents selected from the group consisting of halogen, nitro, cyano, hydroxy, $-(C=O)-C_{1-4}$-alkyl, C_{1-4}-alkyl, at least partially fluorinated C_{1-4}-alkyl, at least partially chlorinated C_{1-4}-alkyl, at least partially brominated C_{1-4}-alkyl, $-S-C_{1-4}$-alkyl, $-C(=O)-O-C_{1-6}$-alkyl, $-(C=O)-CH_2-F$, $-(C=O)-CH_2-Cl$ and $-(C=O)-CH_2-Br$,

and whereby said C_{3-8} cycloaliphatic radical may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted aromatic mono- or polycyclic ring-system,

an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, a $NR^{16b}R^{17b}$-moiety or a COR^{16b}-moiety,

preferably W^b represents

a linear or branched C_{1-20}-alkyl radical, preferably an alkyl radical selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl and 1,1-dimethyl-propyl; a linear or branched C_{2-20}-alkenyl radical; preferably a vinyl radical; $-CF_3$; $-CHF_2$; $-CH_2F$; $-CCl_3$; $-CHCl_2$; $-CH_2Cl$; $-CH_2-CF_3$; $-CH_2-CH_2-Cl$; $-CH_2-CH_2-CH_2-Cl$; $-CH_2-S(=O)_2-CH_3$; a cyclopropyl radical; a cyclobutyl radical; a cyclopentyl radical; a cyclohexyl radical; $-CH_2$-cyclopropyl; $-CH_2$-cyclobutyl; $-CH_2$-cyclopentyl; $-CH_2$-cyclohexyl; $-N(CH_3)_2$; $-N(C_2H_5)_2$; $-N(n\text{-}CH_2-CH_2-CH_3)_2$; phenyl; benzyl; naphthyl; $-CH=CH$-phenyl; $-(CF_2)-(CF_2)-O$-phenyl; $-(CH_2)$-naphtyl; $-(CH_2)-(CH_2)$-naphthyl; anthracenyl; $-(C=O)$-phenyl; thiophenyl; benzo[b]thiophenyl; furanyl; 2-oxo-2H-chromenyl; dibenzofuranyl; 2,3-dihydrobenzofuranyl; chromanyl; 2,3-dihydro-benzo[1,4]dioxinyl; 3,4-dihydro-2H-1,5-benzo-dioxepinyl; chromonyl; 1H-imidazolyl; pyridinyl; pyrrolidine-2,5-dionyl; pyrrolyl; 1H-pyrazolyl; 1H-pyrimidine-2,4-dionyl; quinolinyl; isoquinolinyl; 1H-Benzoimidazolyl; 1,4-dihydro-quinoxaline-2,3-dionyl; 1,2,3,4-tetrahydro-isoquinolinyl; 1,4-dihydro-benzo[b][1,4]diazepine-2,4-dionyl; 1,3-dihydro-1-oxo-2H-isoindolyl; phthalimidinyl; 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethyl; imidazo[1,2-a]pyridine; isatinyl; thiazolyl; 1,3-thiazolyl; 1,2,4-thiadiazolyl; imidazo[2,1-b]thiazolyl; 1,3-benzothiazolyl; benzo[1,2,5]thiadiazolyl; 2-oxo-2,3-dihydro-benzothiazolyl; 2,1,3-benzothiadiazolyl; imidazo[2,1-b]thiazolyl; isoxazolyl; benzo[1,2,5]oxadiazolyl; benzo[d]isoxazolyl; benzofurazanyl;

2-oxo-2,3-dihydro-benzooxazolyl; 3,4-dihydro-2H-benzo[1,4]oxazinyl; or 2,1,3-benzoxadiazolyl;

whereby each of these afore mentioned cyclic moieties may optionally be substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of methyl; ethyl; n-propyl; iso-propyl; n-butyl; iso-butyl; sec-butyl; tert-butyl; 1,1-dimethyl-propyl; n-pentyl; vinyl; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; morpholino; methoxy; ethoxy; n-propoxy; iso-propoxy; n-propoxy; F; Cl; Br; I; -CN; -OH; $-CF_3$; $-CF_2H$; $-CH_2F$; $-CCl_3$; $-CClH_2$; $-CHCl_2$; $-CH_2-F$; $-CH_2-Cl$; $-CH_2-Br$; $-(C=O)-CH_2-Br$; $-OCF_3$; $-O-CH_2-CF_3$; $-O-CHF_2$; $-NO_2$; $-NH_2$; $-N(CH_3)_2$; $-N(C_2H_5)_2$; $-N(n-CH_2-CH_2-CH_3)_2$; $-N(n-CH_2-CH_2-CH_2-CH_3)_2$; $-NH-(C=O)-CH_3$; -NH-phenyl; $-(C=O)-CF_3$; $-(C=O)-OH$; =O (oxo); $-(C=O)-H$; $-S(=O)_2-CH_3$; $-S(=O)_2$-isopropyl; $-S(=O)_2$-phenyl; $-S(=O)_2$-pyrrolidinyl; $-S(=O)_2$-morpholino; $-(CH_2)-(CH_2)-(C=O)-O-CH_3$; $-NH-(C=O)-NH-CH_2-CH_2-CH_3$; $-(C=O)-CH_3$; $-(C=O)-O-CH_3$; $-(C=O)-O-C_2H_5$; $-(CH_2)-NH-(C=O)$-phenyl; $-CH_2-C(H)$(phenyl)(phenyl); $-O-CH_2$-thiazolyl; 1,3-dioxo-2-azaspiro[4.4]non-2-yl; phenyl; phenoxy; isoxazolyl; 1,3-oxazolyl; 1,2,4-oxadiazolyl; 1,3,4-oxadiazolyl; pyridinyl; pyridinyloxy; pyrazolyl; pyrimidinyl and phthalimidinyl; and


whereby each of the cyclic moieties of these afore mentioned substituents may optionally be substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of methyl; ethyl; n-propyl; iso-propyl; F; Cl; Br; I; CN; $-CH_2-F$; $-CH_2-Cl$; $-CH_2-Br$; $-CF_3$ and $-S-CH_3$.


more preferably W^5 represents


an alkyl radical selected from the group consisting of methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec.butyl; iso-butyl and tert-butyl; vinyl ($CH_2=CH-$); $-N(CH_3)_2$; 1-naphthyl; benzyl; 2-naphtyl; phenyl; 2-methyl-phenyl; 3-methyl-phenyl; 4-methyl-phenyl; 2-ethyl-phenyl; 3-ethyl-phenyl; 4-ethyl-phenyl; 2-n-propyl-phenyl; 3-n-propyl-phenyl; 4-n-propyl-phenyl; 2-isopropyl-phenyl; 3-

isopropyl-phenyl; 4-isopropyl-phenyl; 2-n-butyl-phenyl; 3-n-butyl-phenyl; 4-n-butyl-phenyl; 2-iso-butyl-phenyl; 3-iso-butyl-phenyl; 4-iso-butyl-phenyl; 2-tert-butyl-phenyl; 3-tert-butyl-phenyl; 4-tert-butyl-phenyl; 1,1-dimethylpropyl-phenyl; 2-cyclopentyl-phenyl; 3-cyclopentyl-phenyl; 4-cyclopentyl-phenyl 2-cyclohexyl-phenyl; 3-cyclohexyl-phenyl; 4-cyclohexyl-phenyl; 2-methoxy-phenyl; 3-methoxy-phenyl; 4-methoxy-phenyl; 2-ethoxy-phenyl; 3-ethoxy-phenyl; 4-ethoxy-phenyl; 2-n-propoxy-phenyl; 3-n-propoxy-phenyl; 4-n-propoxy-phenyl; 2-iso-propoxy-phenyl; 3-iso-propoxy-phenyl; 4-isopropoxy-phenyl;2-fluoro-phenyl; 3-fluoro-phenyl; 4-fluoro-phenyl; 2-chloro-phenyl; 3-chloro-phenyl; 4-chloro-phenyl; 2-bromo-phenyl; 3-bromo-phenyl; 4-bromo-phenyl; 2-trifluoromethyl-phenyl; 3-trifluoromethyl-phenyl; 4-trifluoromethyl-phenyl; 2-trifluoromethoxy-phenyl; 3-trifluoromethoxy-phenyl; 4-trifluoromethoxy-phenyl; 2-carboxy-phenyl; 3-carboxy-phenyl; 4-carboxy-phenyl; 2-acetyl-phenyl; 3-acetyl-phenyl; 4-acetyl-phenyl; 2-(C=O)-O-CH_3-phenyl; 3-(C=O)-O-CH_3-phenyl; 4-(C=O)-O-CH_3-phenyl; 2-(CH_2)-(CH_2)-(C=O)-O-CH_3; 3-(CH_2)-(CH_2)-(C=O)-O-CH_3; 4-(CH_2)-(CH_2)-(C=O)-O-CH_3; 2-cyano-phenyl; 3-cyano-phenyl; 4-cyano-phenyl; 2-nitro-phenyl; 3-nitro-phenyl; 4-nitro-phenyl; 4-(4-bromophenoxy)-phenyl; 2-methylsulfonyl-phenyl; 3-methylsulfonyl-phenyl; 4-methylsulfonyl-phenyl; 2-phenyl-phenyl (biphenyl-2-yl); 3-phenyl-phenyl (biphenyl-3-yl); 4-phenyl-phenyl (biphenyl-4-yl); 2-phenoxy-phenyl; 3-phenoxy-phenyl; 4-phenoxy-phenyl; 2,4-dimethyl-phenyl; 3,4-dimethyl-phenyl; 2,4,6-trimethyl-phenyl; 2,3,5,6-tetramethyl-phenyl; pentamethyl-phenyl; 2,5-dimethoxy-phenyl; 3,4-dimethoxy-phenyl; 2,3-dichloro-phenyl; 2,4-dichloro-phenyl; 2,5-dichloro-phenyl; 3,4-dichloro-phenyl; 3,5-dichloro-phenyl; 2,6-dichloro-phenyl; 2,4-difluoro-phenyl; 3,4-difluoro-phenyl; 2,5-difluoro-phenyl; 2,6-difluoro-phenyl; 3-chloro-2-fluoro-phenyl; 3-chloro-4-fluoro-phenyl; 5-chloro-2-fluoro-phenyl; 2,3,4-trichloro-phenyl; 2,4,5-trichloro-phenyl; 2,4,6-trichloro-phenyl; 2,4,5-trifluoro-phenyl; 2,3,4-trifluoro-phenyl-; 2-chloro-4,5-difluoro-phenyl; 2-bromo-4-fluoro-phenyl; 2-bromo-4,6-difluoro-phenyl; 4-chloro-2,5-difluoro-phenyl; 5-chloro-2,4-difluoro-phenyl; 4-bromo-2,5-difluoro-phenyl; 5-bromo-2,4-difluoro-phenyl; pentafluoro-phenyl; 2,4-dinitro-phenyl; 4-chloro-3-nitro-phenyl; 2-methyl-5-nitro-phenyl; 5-bromo-2-methoxy-phenyl; 3-chloro-2-methyl-phenyl; 4-bromo-3-methyl-phenyl; 4-chloro-2,5-dimethyl-phenyl; 4-fluoro-3-methyl-phenyl; 5-fluoro-2-methyl-

phenyl; 2-nitro-4-trifluoromethyl-phenyl; 2-methoxy-4-methyl-phenyl; 3,5-dichloro-2-hydroxy-phenyl; 3,5-dichloro-4-hydroxy-phenyl; 5-chloro-2,4-difluoro-phenyl; 3-chloro-4-(NH)-(C=O)-CH_3-phenyl; 2-chloro-6-methyl-phenyl; 2-chloro-5-trifluoromethyl-phenyl; 2-chloro-5-trifluoromethoxy-phenyl; 4-bromo-2-trifluoromethoxy-phenyl; 4-bromo-2-trifluoromethyl-phenyl; 4-bromo-3-trifluoromethyl-phenyl; 3-carboxy-4-fluoro-phenyl; 3-carboxy-4-chloro-6-fluoro-phenyl; 4-methoxy-2,3,6-trimethyl-phenyl-; or one of the following groups:





X
(CH2)1-2X
F
Cl
N
NH-C(=O)-CH3
O
HO
H3C-(O=C)-O




Empf.zeit:30/05/2005 15:40 .496 P.048

577



5

10



whereby in each case X denotes the position by which the respective substituent W^b is bonded to the $-SO_2$ group of formula (Ib).

SX9

47. Compounds according to any one of claims 42 to 46, characterized in that R^{10b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably H, a linear or branched C_{1-6}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl.

48. Compounds according to any one of claims 42 to 47, characterized in that R^{11b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably H, a linear or branched C_{1-6}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl.

49. Compounds according to any one of claims 42 to 48, characterized in that R^{12b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be

condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-5}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably H, $-CH_3$, $-C_2H_5$ or phenyl.

50. Compounds according to any one of claims 42 to 49, characterized in that R^{13b} and R^{14b} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6-membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-8}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably are each independently selected from the group consisting of H, a linear or branched C_{1-4}-alkyl radical, cyclohexyl and a phenyl radical, more preferably are each independently selected from the group consisting of H, $-CH_3$, $-C_2H_5$ and phenyl.

51. Compounds according to any one of claims 42 to 50, characterized in that R^{13b} and R^{14b} together with the bridging nitrogen atom form a saturated, unsaturated or aromatic, 5- or 6-membered heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member, preferably form an unsubstituted piperidin or morpholine group.

52. Compounds according to any one of claims 42 to 51, characterized in that R^{16b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-8}-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_{3-8}-cycloaliphatic radical or an optionally at least mono-substituted, 5- or 6- membered aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted C_{1-6}-alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, preferably represents H, a linear or branched C_{1-4}-alkyl radical, a cyclohexyl radical or a phenyl radical, more preferably represents H, $-CH_3$, $-C_2H_5$ or phenyl.

53. Compounds according to any one of claims 42 to 52, characterized in that R^{16b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6} aliphatic radical, preferably an unbranched or branched, saturated, unsubstituted C_{1-3} alkyl radical, more preferably a methyl radical.

54. Compounds according to any one of claims 42 to 53 characterized in that R^{17b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted C_{1-6} aliphatic radical, preferably an unbranched or branched, saturated, unsubstituted C_{1-3} alkyl radical, more preferably a methyl radical.

55. Compounds according to any one of claims 42 to 54 characterized in that R^{18b} represents a phenyl radical, which is optionally at least mono-substituted by a C_{1-6} aliphatic radical, more preferably a phenyl radical, which is optionally at least mono-substituted by a methyl group.

582

56. Compounds according to any one of claims 42 to 55, characterized in that

R^{1b}, R^{2b}, R^{3b}, R^{4b} are each independently selected from the group consisting of a hydrogen atom; a fluorine atom; a chlorine atom; a bromine atom; a methyl group and a methoxy group;


R^{5b} represents a hydrogen atom;


R^{6b}, R^{7b}, R^{8b}, R^{9b} each represent a hydrogen atom;

W^b represents


an alkyl radical selected from the group consisting of methyl; ethyl; n-propyl; iso-propyl; n-butyl; sec.butyl; iso-butyl and tert-butyl; vinyl (CH_2=CH-); -$N(CH_3)_2$; 1-naphthyl; benzyl; 2-naphtyl; phenyl; 2-methyl-phenyl; 3-methyl-phenyl; 4-methyl-phenyl; 2-ethyl-phenyl; 3-ethyl-phenyl; 4-ethyl-phenyl; 2-n-propyl-phenyl; 3-n-propyl-phenyl; 4-n-propyl-phenyl; 2-isopropyl-phenyl; 3-isopropyl-phenyl; 4-isopropyl-phenyl; 2-n-butyl-phenyl; 3-n-butyl-phenyl; 4-n-butyl-phenyl; 2-iso-butyl-phenyl; 3-iso-butyl-phenyl; 4-iso-butyl-phenyl; 2-tert-butyl-phenyl; 3-tert-butyl-phenyl; 4-tert-butyl-phenyl; 1,1-dimethylpropyl-phenyl; 2-cyclopentyl-phenyl; 3-cyclopentyl-phenyl; 4-cyclopentyl-phenyl 2-cyclohexyl-phenyl; 3-cyclohexyl-phenyl; 4-cyclohexyl-phenyl; 2-methoxy-phenyl; 3-methoxy-phenyl; 4-methoxy-phenyl; 2-ethoxy-phenyl; 3-ethoxy-phenyl; 4-ethoxy-phenyl; 2-n-propoxy-phenyl; 3-n-propoxy-phenyl; 4-n-propoxy-phenyl; 2-iso-propoxy-phenyl; 3-iso-propoxy-phenyl; 4-isopropoxy-phenyl;2-fluoro-phenyl; 3-fluoro-phenyl; 4-fluoro-phenyl; 2-chloro-phenyl; 3-chloro-phenyl; 4-chloro-phenyl; 2-bromo-phenyl; 3-bromo-phenyl; 4-bromo-phenyl; 2-trifluoromethyl-phenyl; 3-trifluoromethyl-phenyl; 4-trifluoromethyl-phenyl; 2-trifluoromethoxy-phenyl; 3-trifluoromethoxy-phenyl; 4-trifluoromethoxy-phenyl; 2-carboxy-phenyl; 3-carboxy-phenyl; 4-carboxy-phenyl; 2-acetyl-phenyl; 3-acetyl-phenyl; 4-acetyl-phenyl; 2-(C=O)-O-CH_3-phenyl; 3-(C=O)-O-CH_3-phenyl; 4-(C=O)-O-CH_3-phenyl; 2-(CH_2)-(CH_2)-(C=O)-O-CH_3; 3-(CH_2)-(CH_2)-(C=O)-O-CH_3; 4-(CH_2)-(CH_2)-(C=O)-O-CH_3; 2-cyano-

phenyl; 3-cyano-phenyl; 4-cyano-phenyl; 2-nitro-phenyl; 3-nitro-phenyl; 4-nitro-phenyl; 4-(4-bromophenoxy)-phenyl; 2-methylsulfonyl-phenyl; 3-methylsulfonyl-phenyl; 4-methylsulfonyl-phenyl; 2-phenyl-phenyl (biphenyl-2-yl); 3-phenyl-phenyl (biphenyl-3-yl); 4-phenyl-phenyl (biphenyl-4-yl); 2-phenoxy-phenyl; 3-phenoxy-phenyl; 4-phenoxy-phenyl; 2,4-dimethyl-phenyl; 3,4-dimethyl-phenyl; 2,4,6-trimethyl-phenyl; 2,3,5,6-tetramethyl-phenyl; pentamethyl-phenyl; 2,5-dimethoxy-phenyl; 3,4-dimethoxy-phenyl; 2,3-dichloro-phenyl; 2,4-dichloro-phenyl; 2,5-dichloro-phenyl; 3,4-dichloro-phenyl; 3,5-dichloro-phenyl; 2,6-dichloro-phenyl; 2,4-difluoro-phenyl; 3,4-difluoro-phenyl; 2,5-difluoro-phenyl; 2,6-difluoro-phenyl; 3-chloro-2-fluoro-phenyl; 3-chloro-4-fluoro-phenyl; 5-chloro-2-fluoro-phenyl; 2,3,4-trichloro-phenyl; 2,4,5-trichloro-phenyl; 2,4,6-trichloro-phenyl; 2,4,5-trifluoro-phenyl; 2,3,4-trifluoro-phenyl-; 2-chloro-4,5-difluoro-phenyl; 2-bromo-4-fluoro-phenyl; 2-bromo-4,6-difluoro-phenyl; 4-chloro-2,5-difluoro-phenyl; 5-chloro-2,4-difluoro-phenyl; 4-bromo-2,5-difluoro-phenyl; 5-bromo-2,4-difluoro-phenyl; pentafluoro-phenyl; 2,4-dinitro-phenyl; 4-chloro-3-nitro-phenyl; 2-methyl-5-nitro-phenyl; 5-bromo-2-methoxy-phenyl; 3-chloro-2-methyl-phenyl; 4-bromo-3-methyl-phenyl; 4-chloro-2,5-dimethyl-phenyl; 4-fluoro-3-methyl-phenyl; 5-fluoro-2-methyl-phenyl; 2-nitro-4-trifluoromethyl-phenyl; 2-methoxy-4-methyl-phenyl; 3,5-dichloro-2-hydroxy-phenyl; 3,5-dichloro-4-hydroxy-phenyl; 5-chloro-2,4-difluoro-phenyl; 3-chloro-4-(NH)-(C=O)-CH_3-phenyl; 2-chloro-6-methyl-phenyl; 2-chloro-5-trifluoromethyl-phenyl; 2-chloro-5-trifluoromethoxy-phenyl; 4-bromo-2-trifluoromethoxy-phenyl; 4-bromo-2-trifluoromethyl-phenyl; 4-bromo-3-trifluoromethyl-phenyl; 3-carboxy-4-fluoro-phenyl; 3-carboxy-4-chloro-6-fluoro-phenyl; 4-methoxy-2,3,6-trimethyl-phenyl-; or one of the following groups:



X
HN
N
NH
O
S
NH-(C=O)-CH3


X
(CH2)1-2-X
X
X
F
X
Cl
X
N
X
Cl
X
NH-C(=O)-CH3
X
O
N
O
X
HO
HO
X
H3C-(O=C)-O
H3C-(O=C)-O
(CH2)1-2-X
X
X
Cl

586




587



5

10



whereby in each case X denotes the position by which the respective substituent W^b is bonded to the $-SO_2$ group of formula (Ib).

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate, respectively.

57. Compounds according to any one of claims 42 to 56 selected from the following group:

N°	Compound
1	1-[1-(Naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
2	1-[1-(Toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
3	1-(1-Phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
4	1-(1-Benzenesulfonyl-piperidin-4-yl)-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
5	6-Chloro-1-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
6	6-Chloro-1-(1-phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
7	6-Chloro-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
8	6-Chloro-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
9	6-Chloro-1-[1-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
10	1-[1-(Thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
11	1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
12	2-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
13	1-[1-(2,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
14	1-[1-(4-Methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
15	1-[1-(2-Naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
16	8-Methyl-1-[1-(thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
17	1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
18	2-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
19	1-[1-(2,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
20	1-[1-(4-Methoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
21	8-Methyl-1-[1-(2-naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
22	4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonic acid dimethylamide
23	2-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid methyl ester
24	1-[1-(3-Trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
25	2-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid methyl ester
26	8-Methyl-1-[1-(3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
27	1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
28	2-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
29	6-Chloro-1-[1-(4-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
30	2-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid methyl ester
31	6-Chloro-1-[1-(2,4-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
32	6-Chloro-1-[1-(3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
33	1-[1-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
34	1-[1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
35	1-[1-(4-Fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
36	8-Methyl-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
37	8-Methyl-1-(1-phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
38	1-[1-(4-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-

	one
39	6-Chloro-1-[1-(4-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
40	1-[1-(Butane-1-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
41	1-[1-(4-Bromo-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
42	1-[1-(4-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
43	1-[1-(Butane-1-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
44	6-Chloro-1-[1-(2-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
45	6-Chloro-1-[1-(3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
46	1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
47	8-Methyl-1-[1-(2-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
48	8-Methyl-1-[1-(3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
49	1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
50	8-Methyl-1-[1-(4-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
51	6-Chloro-1-[1-(4-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
52	1-(1-Ethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
53	1-[1-(Propane-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
54	1-[1-(Propane-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
55	6-Chloro-1-(1-ethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
56	6-Chloro-1-[1-(propane-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
57	6-Chloro-1-[1-(propane-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
58	6-Chloro-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
59	1-[1-(4-Nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
60	8-Methyl-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
61	8-Methyl-1-[1-(2-naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
62	8-Methyl-1-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
63	1-[1-(4-Fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
64	8-Methyl-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
65	8-Methyl-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
66	1-[1-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
67	8-Methyl-1-[1-(4-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
68	1-(1-Benzenesulfonyl-piperidin-4-yl)-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
69	1-[1-(4-Chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
70	1-[1-(5-Dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
71	1-[1-(4-Chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
72	1-[1-(4-Chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
73	6-Chloro-1-[1-(4-chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
74	6-Chloro-1-[1-(5-dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
75	1-[1-(4-Methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
76	1-[1-(4-Methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-

	benzo[d][1,3]oxazin-2-one
77	6-Chloro-1-[1-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
78	1-[1-(4-Methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
79	1-[1-(2-Bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
80	1-[1-(2-Bromo-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
81	1-[1-(2-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
82	1-[1-(2-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
83	6-Chloro-1-[1-(2,3-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
84	1-[1-(2,3-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
85	1-[1-(2,4,5-Trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
86	8-Methyl-1-[1-(2,4,5-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
87	6-Chloro-1-[1-(2,4,5-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
88	8-Methyl-1-[1-(2,4,5-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
89	1-[1-(5-Bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
90	1-[1-(5-Bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
91	1-[1-(5-Bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
92	1-[1-(5-Bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
93	1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
94	1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
95	6-Chloro-1-[1-(2,5-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
96	1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
97	1-(1-Pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
98	8-Methyl-1-(1-pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
99	6-Chloro-1-(1-pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
100	6-Methyl-1-(1-pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
101	1-[1-[2-(2,2,2-Trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
102	8-Methyl-1-[1-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
103	6-Chloro-1-[1-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
104	6-Methyl-1-[1-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
105	1-[1-(2-Methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
106	8-Methyl-1-[1-(2-methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
107	6-Chloro-1-[1-(2-methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
108	6-Methyl-1-[1-(2-methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-

	benzo[d][1,3]oxazin-2-one
109	1-[1-(4-Bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
110	1-[1-(4-Bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
111	1-[1-(4-Bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
112	1-[1-(4-Bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
113	1-[1-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
114	1-[1-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
115	6-Chloro-1-[1-(4-chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
116	1-[1-(4-Chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
117	1-[1-(4-Methoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
118	1-[1-(4-Isopropyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
119	1-[1-(4-Isopropyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
120	6-Chloro-1-[1-(4-isopropyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
121	1-[1-(4-Isopropyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
122	1-[1-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
123	1-[1-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
124	6-Chloro-1-[1-(3-chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
125	1-[1-(3-Chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
126	1-[1-(4-Bromo-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
127	8-Methyl-1-[1-(3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
128	6-Methyl-1-[1-(3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
129	1-[1-(4-Trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
130	1-[1-(2-Nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
131	1-[1-(3-Fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
132	1-[1-(2,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
133	1-[1-(2,4,6-Trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
134	1-[1-(2-Trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
135	8-Methyl-1-[1-(4-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
136	8-Methyl-1-[1-(2-nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
137	1-[1-(3-Fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
138	1-[1-(2,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
139	8-Methyl-1-[1-(2,4,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
140	8-Methyl-1-[1-(2-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-

	benzo[d][1,3]oxazin-2-one
141	1-[1-(4-Fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
142	1-[1-(4-Bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
143	1-[1-(3-Nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
144	1-(1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
145	1-[1-(3-Methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
146	1-[1-(2-Nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
147	8-Methyl-1-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
148	1-(1-Benzenesulfonyl-piperidin-4-yl)-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
149	1-[1-(3-Methoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
150	1-[1-(2,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
151	1-(1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl)-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
152	8-Methyl-1-[1-(thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
153	1-[1-(Toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
154	1-[1-(5-Fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
155	1-[1-(4-Isopropoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
156	1-[1-(3-Chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
157	1-[1-(3,4-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
158	1-(1-Pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
159	8-Methyl-1-[1-(toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
160	1-[1-(5-Fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydrobenzo[d][1,3]oxazin-2-one
161	1-[1-(4-Isopropoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
162	1-[1-(3-Chloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
163	1-[1-(3,4-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
164	8-Methyl-1-(1-pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
165	8-Methyl-1-[1-(toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
166	1-[1-(5-Fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
167	1-[1-(4-Isopropoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
168	1-[1-(3-Chloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
169	1-[1-(3,4-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
170	8-Methyl-1-(1-pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
171	8-Methyl-1-[1-(4-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
172	8-Methyl-1-[1-(2-nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
173	1-[1-(3-Fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
174	1-[1-(2,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
175	8-Methyl-1-[1-(2,4,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
176	8-Methyl-1-[1-(2-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
177	1-[1-(3-Methoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one

178	6-Methyl-1-[1-(2-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
179	1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
180	1-[1-(4-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
181	6-Methyl-1-(1-phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
182	2-[4-(6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]benzoic acid methyl ester
183	6-Methyl-1-[1-(2-oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
184	6-Chloro-1-[1-(4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
185	6-Chloro-1-[1-(3,5-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
186	1-[1-[4-(4-Bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl)-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
187	6-Chloro-1-[1-(thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
188	6-Chloro-1-[1-(3-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
189	6-Chloro-1-[1-(2-oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
190	6-Chloro-1-[1-(toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
191	6-Chloro-1-[1-(5-fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
192	6-Chloro-1-[1-(4-isopropoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
193	6-Chloro-1-[1-(3-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
194	6-Chloro-1-[1-(3,4-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
195	6-Chloro-1-(1-pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
196	6-Chloro-1-[1-(4-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
197	6-Chloro-1-[1-(2-nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
198	6-Chloro-1-[1-(3-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
199	6-Chloro-1-[1-(2,4-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
200	6-Chloro-1-[1-(2,4,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
201	6-Chloro-1-[1-(2-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
202	1-[1-(2-Oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
203	1-[1-(3,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
204	1-[1-(2,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
205	1-[1-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
206	1-[1-(4-Chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
207	1-[1-(2,6-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
208	8-Methyl-1-[1-(2-oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
209	1-[1-(3,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
210	1-[1-(2,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
211	1-[1-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one

212	1-[1-(4-Chloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
213	1-[1-(2,6-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
214	1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
215	6-Chloro-1-[1-(2,5-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
216	1-[1-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
217	6-Chloro-1-[1-(4-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
218	6-Chloro-1-[1-(2,6-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
219	1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
220	2-[4-(6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
221	1-[1-(2,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
222	1-[1-(5-Bromo-6-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
223	1-[1-(4-Chloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
224	1-[1-(2,6-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
225	1-[1-(3,5-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
226	8-Methyl-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
227	1-[1-(5-Bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
228	1-[1-(4-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
229	1-[1-(1-Methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
230	1-[1-(5-Bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
231	1-[1-(6-Chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
232	1-[1-(4-Ethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
233	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
234	1-[1-(6-Chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
235	1-[1-(4-Ethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
236	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
237	6-Chloro-1-[1-(6-chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
238	6-Chloro-1-[1-(4-ethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
239	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
240	1-[1-(6-Chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
241	1-[1-(4-Ethyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
242	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
243	1-[1-(7-Chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
244	1-[1-(2-Methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-

	2-one
245	3-(4-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl)-propionic acid methyl ester
246	1-[1-(2,4-Dinitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
247	1-[1-(7-Chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
248	1-[1-(2-Methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
249	3-(4-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl)-propionic acid methyl ester
250	1-[1-(2,4-Dinitro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
251	1-[1-(7-Chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
252	1-[1-(2-Methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
253	3-(4-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl)-propionic acid methyl ester
254	1-[1-(2,4-Dinitro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
255	6-Chloro-1-[1-(7-chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
256	6-Chloro-1-[1-(2-methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
257	3-(4-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl)-propionic acid methyl ester
258	6-Chloro-1-[1-(2,4-dinitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
259	6-Chloro-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
260	1-[1-(5-Bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
261	8-Methyl-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
262	1-[1-(5-Bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
263	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
264	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
265	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
266	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
267	1-[1-(2,5-Difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
268	1-[1-(2,5-Difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
269	6-Chloro-1-[1-(2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
270	1-[1-(2,5-Difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
271	1-[1-(4-Chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
272	1-[1-(4-Chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
273	6-Chloro-1-[1-(4-chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
274	1-[1-(4-Chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
275	1-[1-(2,4,5-Trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
276	8-Methyl-1-[1-(2,4,5-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-

	benzo[d][1,3]oxazin-2-one
277	6-Chloro-1-[1-(2,4,5-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
278	6-Methyl-1-[1-(2,4,5-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
279	1-[1-(3,5-Dichloro-2-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
280	1-[1-(2,6-Difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
281	1-[1-(2,6-Difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
282	6-Chloro-1-[1-(2,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
283	1-[1-(2,6-Difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
284	1-[1-(5-Chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
285	1-[1-(5-Chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
286	6-Chloro-1-[1-(5-chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
287	1-[1-(5-Chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
288	1-[1-(2-Chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
289	1-[1-(2-Chloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
290	6-Chloro-1-[1-(2-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
291	1-[1-(2-Chloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
292	6-Chloro-1-[1-(2-naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
293	6-Bromo-1-[1-(4-bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
294	6-Bromo-1-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
295	6-Bromo-1-[1-(2,4-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
296	6-Bromo-1-[1-(2-naphthalen-1-yl-ethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
297	6-Bromo-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
298	6-Bromo-1-[1-(6-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
299	6-Bromo-1-[1-(3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
300	6-Bromo-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
301	6-Bromo-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
302	1-(1-Benzenesulfonyl-piperidin-4-yl)-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one
303	6-Bromo-1-[1-[4-(4-bromo-phenoxy)-benzenesulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
304	6-Bromo-1-[1-(thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
305	6-Bromo-1-[1-(2-methyl-5-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
306	6-Bromo-1-[1-(4-bromo-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
307	6-Bromo-1-[1-(toluene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
308	6-Bromo-1-[1-(5-fluoro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
309	6-Bromo-1-[1-(4-isopropoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
310	6-Bromo-1-[1-(3-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one

311	6-Bromo-1-[1-(3,4-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
312	6-Bromo-1-(1-pentafluorobenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
313	6-Bromo-1-[1-(4-chloro-2,5-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
314	6-Bromo-1-[1-(3-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
315	6-Bromo-1-[1-(4-isopropyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
316	6-Bromo-1-[1-(4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
317	6-Bromo-1-[1-(3-chloro-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
318	6-Bromo-1-(1-pentamethylbenzenesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
319	6-Bromo-1-[1-(2-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
320	6-Bromo-1-[1-(4-chloro-3-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
321	6-Bromo-1-[1-(5-dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
322	6-Bromo-1-[1-(4-nitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
323	1-[1-(4-Acetyl-benzenesulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one
324	6-Bromo-1-[1-(4-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
325	1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one
326	6-Bromo-1-(1-phenylmethanesulfonyl-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
327	6-Bromo-1-[1-(2,5-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
328	6-Bromo-1-[1-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
329	6-Bromo-1-[1-(2,3-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
330	6-Bromo-1-[1-(2,4,6-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
331	6-Bromo-1-[1-(5-bromo-2-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
332	6-Bromo-1-[1-(4-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
333	6-Bromo-1-[1-(2-nitro-4-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
334	6-Bromo-1-[1-(3-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
335	6-Bromo-1-[1-(2,4-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
336	6-Bromo-1-[1-(2,4,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
337	6-Bromo-1-[1-(2-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
338	6-Bromo-1-[1-(2-bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
339	6-Bromo-1-[1-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
340	1-[1-(3,5-Dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
341	1-[1-(3,5-Dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one

342	6-Chloro-1-[1-(3,5-dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
343	1-[1-(3,5-Dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
344	6-Bromo-1-[1-(3,5-dichloro-4-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
345	6-Chloro-1-[1-(3,6-dichloro-2-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
346	6-Bromo-1-[1-(3,6-dichloro-2-hydroxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
347	2-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
348	6-Bromo-1-[1-(4-methoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
349	2-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid methyl ester
350	6-Bromo-1-[1-(3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
351	6-Bromo-1-[1-(2-oxo-2H-chromene-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
352	6-Bromo-1-[1-(3,5-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
353	6-Bromo-1-[1-(2,5-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
354	6-Bromo-1-[1-(6-bromo-5-chloro-pyridine-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
355	6-Bromo-1-[1-(4-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
356	6-Bromo-1-[1-(2,6-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
357	6-Bromo-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
358	6-Bromo-1-[1-(5-bromo-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
359	6-Bromo-1-[1-(4-ethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
360	6-Bromo-1-[1-(6-chloro-imidazo[2,1-b]thiazole-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
361	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one
362	6-Bromo-1-[1-(7-chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
363	6-Bromo-1-[1-(2-methoxy-4-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
364	3-[4-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl]-propionic acid methyl ester
365	6-Bromo-1-[1-(2,4-dinitro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
366	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one
367	6-Bromo-1-[1-(2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
368	6-Bromo-1-[1-(4-chloro-2,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
369	6-Bromo-1-[1-(2,4,5-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
370	6-Bromo-1-[1-(2,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
371	6-Bromo-1-[1-(5-chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
372	6-Bromo-1-[1-(2-chloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-

600

	one
373	6-Bromo-1-[1-(2,3,4-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
374	N-(4-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-2-chloro-phenyl)-acetamide
375	1-[1-(2,3,4-Trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
376	8-Methyl-1-[1-(2,3,4-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
377	6-Chloro-1-[1-(2,3,4-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
378	6-Methyl-1-[1-(2,3,4-trifluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
379	N-(2-Chloro-4-[4-(6-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl)-acetamide
380	1-[1-(3,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
381	1-[1-(3,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
382	6-Chloro-1-[1-(3,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
383	1-[1-(3,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
384	6-Bromo-1-[1-(3,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
385	N-[2-Chloro-4-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl]-acetamide
386	1-[1-(2-Chloro-4,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
387	1-[1-(2-Chloro-4,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
388	6-Chloro-1-[1-(2-chloro-4,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
389	1-[1-(2-Chloro-4,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
390	6-Bromo-1-[1-(2-chloro-4,5-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
391	N-[2-Chloro-4-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl]-acetamide
392	1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
393	1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
394	1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
395	1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
396	1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one
397	N-(2-Chloro-4-[4-(6-chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-phenyl)-acetamide
398	1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
399	1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
400	1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
401	1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
402	1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-6-bromo-1,4-dihydro-benzo[d][1,3]oxazin-2-one
403	1-(1-Ethanesulfonyl-piperidin-4-yl)-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one

404	1-[1-(2,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
405	1-[1-(2,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
406	6-Chloro-1-[1-(2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
407	1-[1-(2,4-Difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
408	6-Bromo-1-[1-(2,4-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
409	8-Methyl-1-[1-(propane-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
410	1-[1-(3,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
411	1-[1-(3,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
412	6-Chloro-1-[1-(3,4-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
413	1-[1-(3,4-Dichloro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
414	6-Bromo-1-[1-(3,4-dichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
415	8-Methyl-1-[1-(propane-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
416	1-[1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
417	1-[1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
418	6-Chloro-1-[1-(2-chloro-6-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
419	1-[1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
420	1-[1-(2-Chloro-6-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
421	8-Methyl-1-[1-(2,3,5,6-tetramethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
422	1-[1-(2,3,4-Trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
423	8-Methyl-1-[1-(2,3,4-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
424	6-Chloro-1-[1-(2,3,4-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
425	6-Methyl-1-[1-(2,3,4-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
426	6-Bromo-1-[1-(2,3,4-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
427	1-[1-(2,3,5,6-Tetramethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
428	1-[1-(Thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
429	8-Methyl-1-[1-(thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
430	6-Chloro-1-[1-(thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
431	6-Methyl-1-[1-(thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
432	6-Bromo-1-[1-(thiophene-3-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
433	6-Chloro-1-[1-(2,3,5,6-tetramethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
434	1-[1-(2,4,6-Trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
435	8-Methyl-1-[1-(2,4,6-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
436	6-Chloro-1-[1-(2,4,6-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
437	6-Methyl-1-[1-(2,4,6-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
438	6-Bromo-1-[1-(2,4,6-trichloro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
439	8-Methyl-1-[1-(2,3,5,6-tetramethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-

	benzo[d][1,3]oxazin-2-one
440	1-[1-(2-Bromo-4,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
441	1-[1-(2-Bromo-4,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
442	1-[1-(2-Bromo-4,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
443	6-Bromo-1-[1-(2-bromo-4,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
444	6-Bromo-1-[1-(2,3,5,6-tetramethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
445	1-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
446	1-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
447	1-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
448	1-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
449	6-Bromo-1-[1-(4-bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
450	1-[1-(4-Phenoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
451	1-[1-(3-Bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
452	1-[1-(3-Bromo-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
453	1-[1-(3-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
454	1-[1-(3-Bromo-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
455	6-Bromo-1-[1-(3-bromo-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
456	8-Methyl-1-[1-(4-phenoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
457	1-[1-(4-tert-Butyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
458	1-[1-(4-tert-Butyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
459	1-[1-(4-tert-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
460	1-[1-(4-tert-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
461	6-Bromo-1-[1-(4-tert-butyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
462	6-Chloro-1-[1-(4-phenoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
463	1-[1-(2-Bromo-4,6-difluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
464	1-[1-(2-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
465	6-Chloro-1-[1-(2-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
466	1-[1-(2-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
467	6-Bromo-1-[1-(2-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
468	8-Methyl-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
469	6-Chloro-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
470	8-Methyl-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one

471	6-Bromo-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
472	1-[1-(3-Chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
473	6-Chloro-1-[1-(3-chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
474	1-[1-(3-Chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
475	6-Bromo-1-[1-(3-chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
476	1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
477	1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
478	1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
479	6-Bromo-1-[1-(4-butyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
480	1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
481	1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
482	1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
483	6-Bromo-1-[1-(4-bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
484	1-[1-[4-(1,1-Dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
485	6-Chloro-1-[1-[4-(1,1-dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
486	1-[1-[4-(1,1-Dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
487	6-Bromo-1-[1-[4-(1,1-dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
488	1-(1-Ethanesulfonyl-piperidin-4-yl)-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
489	3-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
490	3-[4-(6-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
491	3-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
492	1-[1-(3-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
493	6-Chloro-1-[1-(3-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
494	1-[1-(3-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
495	6-Bromo-1-[1-(3-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
496	N-[4-Methyl-5-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiazol-2-yl]-acetamide
497	N-[5-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-methyl-thiazol-2-yl]-acetamide
498	N-[4-Methyl-5-[4-(6-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiazol-2-yl]-acetamide
499	N-[5-[4-(6-Bromo-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-methyl-thiazol-2-yl]-acetamide
500	1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
501	1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
502	1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one

503	6-Bromo-1-[1-(2-bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
504	1-[1-(5-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
505	6-Chloro-1-[1-(5-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
506	1-[1-(5-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
507	6-Bromo-1-[1-(5-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
508	1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
509	1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
510	1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
511	6-Bromo-1-[1-(4-bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
512	1-[1-(2-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
513	1-[1-(4-Propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
514	1-[1-(3-Chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
515	1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
516	1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
517	1-[1-[4-(1,1-Dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
518	N-(4-Methyl-5-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiazol-2-yl)-acetamide
519	1-[1-(3-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
520	1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
521	1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
522	1-[1-(5-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
523	1-[1-(Isoquinoline-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
524	6-Fluoro-1-[1-(2-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
525	6-Fluoro-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
526	1-[1-(3-Chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
527	1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
528	1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
529	1-[1-[4-(1,1-Dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
530	N-[5-[4-(6-Fluoro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-methyl-thiazol-2-yl]-acetamide
531	1-[1-(3-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
532	1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
533	1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
534	1-[1-(5-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one

535	6-Fluoro-1-[1-(isoquinoline-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
536	6-Fluoro-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
537	1-[1-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
538	6-Fluoro-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
539	6-Fluoro-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
540	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
541	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
542	8-Methoxy-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
543	1-[1-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
544	8-Methoxy-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
545	8-Methoxy-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
546	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
547	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
548	5-Chloro-1-[1-(2-methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
549	5-Chloro-1-[1-(4-propyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
550	5-Chloro-1-[1-(3-chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
551	1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
552	1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
553	5-Chloro-1-[1-[4-(1,1-dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
554	N-(5-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-methyl-thiazol-2-yl)-acetamide
555	5-Chloro-1-[1-(3-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
556	1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
557	1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
558	5-Chloro-1-[1-(5-chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
559	5-Chloro-1-[1-(isoquinoline-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
560	1-[1-(2-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
561	1-[1-(2-Methanesulfonyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
562	1-[1-(3-Chloro-2-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
563	1-[1-(4-Butyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
564	1-[1-(4-Bromo-3-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
565	1-[1-[4-(1,1-Dimethyl-propyl)-benzenesulfonyl]-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
566	N-(5-[4-(8-Methoxy-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-methyl-thiazol-2-yl)-acetamide
567	1-[1-(3-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one

568	1-[1-(2-Bromo-4-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
569	1-[1-(4-Bromo-3-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
570	1-[1-(5-Chloro-2-fluoro-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
571	1-[1-(Isoquinoline-5-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one; hydrochloride
572	1-[1-(4-Methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
573	8-Chloro-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
574	8-Methyl-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
575	8-Methyl-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
576	8-Fluoro-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
577	8-Methoxy-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
578	5-Chloro-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
579	5-Chloro-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
580	5-Chloro-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
581	5-Chloro-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
582	5-Chloro-1-[1-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
583	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
584	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
585	8-Bromo-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
586	2-Chloro-4-fluoro-5-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
587	2-Chloro-5-[4-(8-chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-fluoro-benzoic acid
588	2-Chloro-4-fluoro-5-[4-(6-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
589	2-Chloro-4-fluoro-5-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
590	2-Chloro-4-fluoro-5-[4-(8-methoxy-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
591	2-Chloro-5-[4-(5-chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-4-fluoro-benzoic acid
592	3-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
593	3-[4-(8-Methoxy-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
594	3-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
595	1-[1-(Isoquinoline-5-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; hydrochloride
596	6-Chloro-1-[1-(isoquinoline-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one; hydrochloride
597	-[1-(Isoquinoline-5-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one;hydrochloride
598	6,7-Difluoro-1-[1-(quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
599	1-[1-(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
600	6,7-Difluoro-1-[1-(naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
601	6,7-Difluoro-1-[1-(naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one

602	1-[1-(Benzo[b]thiophene-2-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
603	1-[1-(Benzo[b]thiophene-3-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
604	1-[1-(5-Dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
605	1-[1-(Biphenyl-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
606	1-[1-(Benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
607	1-[1-(Benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
608	1-[1-(7-Chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
609	6,7-Difluoro-1-[1-(4-methyl-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
610	1-[1-(4-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
611	1-[1-(4-Fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
612	1-[1-(Dibenzofuran-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
613	1-[1-(2,3-Dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
614	1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
615	1-[1-(5-Isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
616	1-[1-(4-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
617	1-[1-(4-Fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
618	1-[1-(Dibenzofuran-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
619	1-[1-(2,3-Dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
620	1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
621	1-[1-(5-Isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
622	5-Chloro-1-[1-(4-chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
623	5-Chloro-1-[1-(4-fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
624	5-Chloro-1-[1-(dibenzofuran-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
625	5-Chloro-1-[1-(2,3-dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
626	1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-5-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
627	5-Chloro-1-[1-(5-isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
628	1-[1-(4-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
629	1-[1-(4-Fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
630	1-[1-(Dibenzofuran-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
631	1-[1-(2,3-Dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
632	1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
633	1-[1-(5-Isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
634	6-Chloro-1-[1-(4-chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
635	6-Chloro-1-[1-(4-fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one

636	6-Chloro-1-[1-(dibenzofuran-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
637	6-Chloro-1-[1-(2,3-dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
638	1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-6-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
639	6-Chloro-1-[1-(5-isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
640	1-[1-(4-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
641	1-[1-(4-Fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
642	1-[1-(Dibenzofuran-2-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
643	1-[1-(2,3-Dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
644	1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
645	1-[1-(5-Isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
646	1-[1-(4-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
647	6,7-Difluoro-1-[1-(4-fluoro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
648	1-[1-(Dibenzofuran-2-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
649	1-[1-(2,3-Dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
650	1-[1-(Biphenyl-2-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
651	6,7-Difluoro-1-[1-(5-isoxazol-5-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
652	1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
653	1-[1-(5-Methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
654	1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
655	1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
656	8-Methyl-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
657	1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
658	6-Chloro-1-[1-(1,2-dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
659	6-Chloro-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
660	6-Chloro-1-[1-(3,5-dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
661	1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
662	8-Methoxy-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
663	1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
664	5-Chloro-1-[1-(1,2-dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
665	5-Chloro-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
666	5-Chloro-1-[1-(3,5-dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
667	1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-

608
609


	benzo[d][1,3]oxazin-2-one
668	6-Methyl-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
669	1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
670	1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
671	6-Fluoro-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
672	1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
673	1-[1-(1,2-Dimethyl-1H-imidazole-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
674	6,7-Difluoro-1-[1-(5-methyl-benzo[1,2,5]thiadiazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
675	1-[1-(3,5-Dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
676	1-[1-(6-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
677	1-[1-(5-Chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
678	N-[5-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl]-acetamide
679	1-[1-(5-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
680	1-[1-(5-Chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
681	N-[5-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl]-acetamide
682	5-Chloro-1-[1-(5-chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
683	5-Chloro-1-[1-(5-chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
684	N-[5-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl]-acetamide
685	1-[1-(5-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
686	1-[1-(5-Chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
687	N-(5-[4-(8-Methoxy-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl)-acetamide
688	2,5-Dimethyl-4-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-furan-3-carboxylic acid methyl ester
689	8-Methyl-1-[1-(2-oxo-2,3-dihydro-benzothiazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
690	1-[1-(4-Fluoro-3-methyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
691	8-Methyl-1-[1-(2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
692	1-[1-(4-Cyclohexyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
693	2,5-Dimethyl-4-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-furan-3-carboxylic acid methyl ester
694	1-[1-(4-Fluoro-3-methyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
695	1-[1-(2-Oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
696	1-[1-(4-Cyclohexyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
697	2-Fluoro-5-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
698	2-Fluoro-5-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzoic acid
699	1-[1-(2-Oxo-2,3-dihydro-benzothiazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-

	benzo[d][1,3]oxazin-2-one
700	1-[1-(5-Pyridin-2-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
701	3-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
702	3-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiophene-2-carboxylic acid methyl ester
703	1-(5-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl)-pyrrolidine-2,5-dione
704	1-[1-(2-Chloro-5-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
705	1-[1-(3,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
706	8-Methyl-1-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
707	3-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
708	3-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiophene-2-carboxylic acid methyl ester
709	1-(5-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl)-pyrrolidine-2,5-dione
710	1-[1-(2-Chloro-5-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
711	1-[1-(3,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
712	5-Chloro-1-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
713	3-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
714	3-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiophene-2-carboxylic acid methyl ester
715	1-(5-[4-(5-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl)-pyrrolidine-2,5-dione
716	5-Chloro-1-[1-(2-chloro-5-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
717	5-Chloro-1-[1-(3,4-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
718	8-Methyl-1-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
719	3-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
720	3-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiophene-2-carboxylic acid methyl ester
721	1-(5-[4-(8-Methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl)-pyrrolidine-2,5-dione
722	1-[1-(2-Chloro-5-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
723	1-[1-(3,4-Dimethyl-benzenesulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
724	6-Chloro-1-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
725	3-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-benzonitrile
726	3-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-thiophene-2-carboxylic acid methyl ester
727	1-(5-[4-(6-Chloro-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-1-yl)-pyrrolidine-2,5-dione
728	6-Chloro-1-[1-(2-chloro-5-trifluoromethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
729	6-Chloro-1-[1-(3,4-dimethyl-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
730	1-[1-(5-Methyl-benzoxazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
731	1-[1-(2,2-Dimethyl-chroman-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
732	1-[1-(4-Methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
733	1-[1-(2,3-Dihydro-benzo[1,4]dioxine-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-

	benzo[d][1,3]oxazin-2-one
734	1-[1-(1,3,5-Trimethyl-1H-pyrazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
735	1-[1-(3-Methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
736	8-Methyl-1-[1-(5-methyl-isoxazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
737	1-[1-(2,2-Dimethyl-chroman-6-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
738	8-Methyl-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
739	1-[1-(2,3-Dihydro-benzo[1,4]dioxine-6-sulfonyl)-piperidin-4-yl]-8-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
740	8-Methyl-1-[1-(1,3,5-trimethyl-1H-pyrazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
741	8-Methyl-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
742	8-Methoxy-1-[1-(1,3,5-trimethyl-1H-pyrazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
743	8-Methoxy-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
744	1-[1-(Benzo[d]isoxazol-3-ylmethanesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
745	1-[1-(2,2,4,6,7-Pentamethyl-2,3-dihydro-benzofuran-5-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
746	6-Methyl-5-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-1H-pyrimidine-2,4-dione
747	1-[1-(3-Methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
748	1-[1-(2,2,5,7,8-Pentamethyl-chroman-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
749	1,4-Dimethyl-6-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-1,4-dihydro-quinoxaline-2,3-dione
750	1-[1-(1H-Imidazole-4-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
751	1-[1-(2-Oxo-1,2,3,4-tetrahydro-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
752	7-[4-(2-Oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione
753	8-Methyl-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
754	6-Chloro-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
755	5-Chloro-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
756	8-Methoxy-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
757	1-[1-(Pyridine-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
758	1-[1-(6,7-Dihydroxy-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
759	Acetic acid 3-acetoxy-5-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidine-1-sulfonyl]-naphthalen-2-yl ester
760	1-[1-(1H-Benzoimidazole-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
761	1-[1-(1H-Benzoimidazole-2-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
762	1-[1-(1H-Benzoimidazole-2-sulfonyl)-piperidin-4-yl]-8-chloro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
763	1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-8-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
764	1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
765	1-[1-(2,5-Dimethoxy-benzenesulfonyl)-piperidin-4-yl]-6,7-difluoro-1,4-dihydro-


	benzo[d][1,3]oxazin-2-one
766	5-Chloro-1-[1-(2,5-dimethoxy-benzenesulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
767	1-[1-(5-Dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-8-methoxy-1,4-dihydro-benzo[d][1,3]oxazin-2-one
768	5-Chloro-1-[1-(5-dimethylamino-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
769	6-Chloro-1-[1-(5-chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
770	1-[1-(5-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
771	1-[1-(5-Chloro-naphthalene-1-sulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
772	6-Chloro-1-[1-(6-chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
773	1-[1-(6-Chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
774	1-[1-(6-Chloro-naphthalene-2-sulfonyl)-piperidin-4-yl]-6-fluoro-1,4-dihydro-benzo[d][1,3]oxazin-2-one
775	6-Methyl-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
776	6-Fluoro-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
777	6,7-Difluoro-1-[1-(3-methyl-quinoline-8-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
778	6-Chloro-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
779	6-Methyl-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
780	6-Fluoro-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
781	6,7-Difluoro-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
782	5-Chloro-1-[1-(3-methyl-2-oxo-2,3-dihydro-benzooxazole-6-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
783	6-Chloro-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
784	6-Methyl-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
785	6-Fluoro-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
786	8-Methoxy-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one
787	5-Chloro-1-[1-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one

58. Process for the preparation of benzoxazinone-derived sulfonamide compounds of general formula (Ib) according to one or more of claims 42 to 57, characterized in that it comprises reacting at least one piperidine compound of general formula (IIb), wherein R^{1b} to R^{9b} have the meaning according to one or more of claims 42-57 and/or a salt, preferably a hydrochloride salt, thereof,



(IIb)

with at least one compound of general formula (IIIb),



(IIIb)

wherein W^b has the meaning according to one or more of claims 42-57, in a suitable reaction medium, optionally in the presence of at least one base and/or at least one auxiliary agent.

59. Process for the preparation of a physiologically acceptable salt of the benzoxazinone-derived sulphonamide compounds according to claims 42-57, characterized in that at least one compound of general formula (Ib) having at least one basic group is reacted with at least one acid, preferably an inorganic or organic acid, preferably in the presence of a suitable reaction medium.

60. Process for the preparation of a physiologically acceptable salt of the benzoxazinone-derived sulphonamide compounds according to claims 42-57, characterized in that at least one compound of general formula (Ib) having at least one acidic group is reacted with at least one base, preferably in the presence of a suitable reaction medium.

61. Medicament comprising at least one benzoxazinone-derived sulphonamide compound according to any one of claims 42-57 and optionally one or more pharmaceutically acceptable adjuvants.

62. Medicament according to claim 61 for the prophylaxis and/or treatment of food intake disorders, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, for the prophylaxis and/or treatment of bulimia, for the prophylaxis and/or treatment of anorexia, for the prophylaxis and/or treatment of cachexia, for the prophylaxis and/or treatment type II diabetes (non-insulin dependent diabetes mellitus).

63. Medicament according to claim 61 for the prophylaxis and/or treatment of gastrointestinal disorders, preferably irritable colon syndrome; for the prophylaxis and/or treatment of disorders of the central nervous system; for the prophylaxis and/or treatment of anxiety; for the prophylaxis and/or treatment panic attacks; for the prophylaxis and/or treatment of depression; for the prophylaxis and/or treatment of bipolar disorders; for the prophylaxis and/or treatment cognitive disorders, preferably memory disorders; for improvement of cognition (for cognitive enhancement); for the prophylaxis and/or treatment of senile dementia; for the prophylaxis and/or treatment of psychosis; for the prophylaxis and/or treatment neurodegenerative disorders;

preferably selected from the group consisting of Morbus Alzheimer, Morbus Parkinson, Morbus Huntington and Multiple Sclerosis; for the prophylaxis and/or treatment of schizophrenia or for the prophylaxis and/or treatment hyperactivity disorder (ADHD, attention deficit, hyperactivity disorder).

64. Use of at least one benzoxazinone-derived sulphonamide compound according to any one of claims 42-57 for the manufacture of a medicament for the prophylaxis and/or treatment of food intake disorders.

65. Use according to claim 64 for the regulation of appetite, for the reduction, increase or maintenance of body weight; for the prophylaxis and/or treatment of obesity, for the prophylaxis and/or treatment of bulimia, for the prophylaxis and/or treatment of anorexia; for the prophylaxis and/or treatment of cachexia; or for the prophylaxis and/or treatment of type II diabetes.

68. Use of at least one benzoxazinone-derived sulphonamide compound according to any one of claims 42-57 for the manufacture of a medicament for the prophylaxis and/or treatment of of gastrointestinal disorders, preferably irritable colon syndrome; for the prophylaxis and/or treatment of disorders of the central nervous system; for the prophylaxis and/or treatment of anxiety; for the prophylaxis and/or treatment panic attacks; for the prophylaxis and/or treatment of depression; for the prophylaxis and/or treatment of bipolar disorders; for the prophylaxis and/or treatment cognitive disorders, preferably memory disorders; for improvement of cognition (for cognitive enhancement); for the prophylaxis and/or treatment of senile dementia; for the prophylaxis and/or treatment of psychosis; for the prophylaxis and/or treatment neurodegenerative disorders; preferably selected from the group consisting of Morbus Alzheimer, Morbus Parkinson, Morbus Huntington and Multiple Sclerosis; for the prophylaxis and/or treatment of schizophrenia; or for the prophylaxis and/or treatment hyperactivity disorder (ADHD, attention deficit, hyperactivity disorder).

PATENT COOPERATI N TREATY

PCT

615
616.

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER ACTION	see Form PCT/ISA/220 as well as, where applicable, item 5 below.
ET0005PCT		
International application No.	International filing date *(day/month/year)*	(Earliest) Priority Date *(day/month/year)*
PCT/EP2004/008507	29/07/2004	30/07/2003
Applicant		
LABORATORIOS DEL DR. ESTEVE S.A.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.

[X] It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report
   a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
      [ ] The international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
   b. [ ] With regard to any nucleotide and/or amino acid sequence disclosed in the international application, see Box No. I.
2. [ ] Certain claims were found unsearchable (See Box II).
3. [ ] Unity of invention is lacking (see Box III).
4. With regard to the title,
   [ ] the text is approved as submitted by the applicant.
   [X] the text has been established by this Authority to read as follows:

   BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICA MENTS

5. With regard to the abstract,
   [X] the text is approved as submitted by the applicant.
   [ ] the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. With regards to the drawings,
   a. the figure of the drawings to be published with the abstract is Figure No. _____
      [ ] as suggested by the applicant.
      [ ] as selected by this Authority, because the applicant failed to suggest a figure.
      [ ] as selected by this Authority, because this figure better characterizes the invention.
   b. [ ] none of the figures is to be published with the abstract.

INTERNATI NAL SEARCH REPORT

International Application No
PCT/EP2004/008507

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D413/04 A61K31/535 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 665 719 A (PETTIBONE DOUGLAS J ET AL) 9 September 1997 (1997-09-09) the whole document column 30; example 10	1-81
A	WO 01/85725 A (FEENSTRA ROELOF W ; LONG STEPHEN K (NL); HEIJDEN JOHANNES A M V D (NL)) 15 November 2001 (2001-11-15) the whole document	1-81
A	WO 97/45419 A (WARNER LAMBERT CO ; WISE LAWRENCE DAVID (US); WUSTROW DAVID JUERGEN (U) 4 December 1997 (1997-12-04) the whole document	1-81
A	US 6 225 312 B1 (KRUSE CORNELIS GERRIT ET AL) 1 May 2001 (2001-05-01) the whole document	1-81

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
15 October 2004	03/11/2004

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Deutsch, W

Form PCT/ISA/210 (second sheet) (January 2004)

International Application No
PCT/EP2004/008507

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 1 242 396 A (ASTRAZENECA AB) 25 September 2002 (2002-09-25) the whole document	1-81

INTERNATI NAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP2004/008507

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5665719 A	09-09-1997	AT 216580 T	15-05-2002
		AU 691829 B2	28-05-1998
		AU 7513294 A	13-02-1995
		CA 2166975 A1	26-01-1995
		DE 69430483 D1	29-05-2002
		EP 0714299 A1	05-06-1996
		JP 9500134 T	07-01-1997
		WO 9502405 A1	26-01-1995
WO 0185725 A	15-11-2001	EP 1153925 A1	14-11-2001
		AT 255578 T	15-12-2003
		AU 6392701 A	20-11-2001
		BR 0110592 A	01-04-2003
		CA 2405971 A1	15-11-2001
		CN 1429226 T	09-07-2003
		CZ 20023721 A3	12-02-2003
		DE 60101386 D1	15-01-2004
		DE 60101386 T2	27-05-2004
		DK 1283838 T3	22-03-2004
		WO 0185725 A1	15-11-2001
		EP 1283838 A1	19-02-2003
		ES 2211809 T3	16-07-2004
		HU 0302016 A2	29-09-2003
		JP 2003532729 T	05-11-2003
		NO 20025365 A	08-11-2002
		NZ 522116 A	30-04-2004
		PT 1283838 T	30-04-2004
		SK 15872002 A3	01-04-2003
		US 2003119849 A1	26-06-2003
		ZA 200208537 A	22-01-2004
WO 9745419 A	04-12-1997	AT 231846 T	15-02-2003
		AU 731104 B2	22-03-2001
		AU 3072797 A	05-01-1998
		BG 64049 B1	28-11-2003
		BG 102959 A	31-08-1999
		BR 9709630 A	10-08-1999
		CA 2253406 A1	04-12-1997
		CN 1219930 A ,B	16-06-1999
		CZ 9803846 A3	17-03-1999
		DE 69718786 D1	06-03-2003
		DE 69718786 T2	23-10-2003
		DK 906294 T3	05-05-2003
		EA 1486 B1	23-04-2001
		EE 9800417 A	15-06-1999
		EP 0906294 A1	07-04-1999
		ES 2191180 T3	01-09-2003
		HK 1019737 A1	05-07-2002
		HR 970301 A1	30-04-1998
		HU 9903758 A2	28-06-2000
		ID 17266 A	18-12-1997
		IL 126895 A	14-06-2001
		JP 2000511534 T	05-09-2000
		KR 2000016151 A	25-03-2000
		NO 985531 A	27-11-1998
		NZ 332737 A	23-06-2000
		PL 330195 A1	26-04-1999
		PT 906294 T	30-06-2003

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP2004/008507

619

620

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9745419	A		SI	906294 T1	30-04-2003
			SK	162798 A3	11-06-1999
			TW	542833 B	21-07-2003
			WO	9745419 A1	04-12-1997
			US	6177422 B1	23-01-2001
			ZA	9704684 A	30-12-1997
US 6225312	B1	01-05-2001	AU	708053 B2	29-07-1999
			AU	2029497 A	22-10-1997
			BR	9708389 A	04-01-2000
			CA	2250347 A1	09-10-1997
			CN	1215400 A ,B	28-04-1999
			CZ	9803068 A3	13-01-1999
			WO	9736893 A1	09-10-1997
			EP	0889889 A1	13-01-1999
			HU	9902471 A2	28-03-2000
			JP	2000507949 T	27-06-2000
			KR	2000005412 A	25-01-2000
			NO	984533 A	02-11-1998
			NZ	331860 A	28-04-2000
			PL	329123 A1	15-03-1999
			RU	2178414 C2	20-01-2002
			SK	133198 A3	11-02-1999
			TR	9801942 T2	21-08-2000
			TW	422846 B	21-02-2001
			ZA	9702639 A	02-10-1997
EP 1242396	A	25-09-2002	AT	250590 T	15-10-2003
			AU	775741 B2	12-08-2004
			AU	2244301 A	25-06-2001
			BR	0016396 A	20-08-2002
			CA	2392894 A1	21-06-2001
			DE	60005560 D1	30-10-2003
			DE	60005560 T2	15-07-2004
			EP	1242396 A1	25-09-2002
			JP	2003516978 T	20-05-2003
			MX	PA02005788 A	18-09-2002
			NO	20022857 A	01-08-2002
			CN	1434811 T	06-08-2003
			WO	0144213 A1	21-06-2001
			US	2003040513 A1	27-02-2003
			ZA	200204429 A	03-09-2003

6-30
621

PCT

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only

International Application No.

International Filing Date

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference *(if desired) (12 characters maximum)* ET0005PCT

Box No. I TITLE OF INVENTION

Benzoazinone-derived sulfonamide compounds, their preparation and use as medicaments

Box No. II APPLICANT ☐ This person is also inventor

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)*

Laboratorios del Dr. Esteve S. A.
Av. Mare de Déu de Montserrat, 221
E-08041 Barcelona
SPAIN

Telephone No. +34-934466058
Facsimile No. +34-934501611
Teleprinter No.
Applicant's registration No. with the Office

State *(that is, country)* of nationality: ES

State *(that is, country)* of residence: ES

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)*

TORRENS JOVER, Antoni
C/Racó 8, 2° 2a
E-08221 Terrase (Barcelona)
SPAIN

This person is:
☐ applicant only
☒ applicant and inventor
☐ inventor only *(If this check-box is marked, do not fill in below.)*

Applicant's registration No. with the Office

State *(that is, country)* of nationality: ES

State *(that is, country)* of residence: ES

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

☒ Further applicants and/or (further) inventors are indicated on a continuation sheet.

Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as: ☒ agent ☐ common representative

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

DAVILA BAZ, A.,
Clarke, Modet & Co.
C/Goya, 11
E-28001 Madrid
SPAIN

Telephone No. +34-918065600
Facsimile No. +34-918065607
Teleprinter No.
Agent's registration No. with the Office

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

624/
622

Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

If none of the following sub-boxes is used, this sheet should not be included in the request.

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)*

MAS PRIÓ, Josep
C/Cal Princep, 39
E-08191 Rubí (Barcelona)
SPAIN

This person is:
- ☐ applicant only
- ☒ applicant and inventor
- ☐ inventor only *(If this check-box is marked, do not fill in below.)*

Applicant's registration No. with the Office

State *(that is, country)* of nationality: ES

State *(that is, country)* of residence: ES

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)*

DORDAL ZUERAS, Alberto
C/Maladeta 26, 3° 3a
E-08016 Barcelona
SPAIN

This person is:
- ☐ applicant only
- ☒ applicant and inventor
- ☐ inventor only *(If this check-box is marked, do not fill in below.)*

Applicant's registration No. with the Office

State *(that is, country)* of nationality: ES

State *(that is, country)* of residence: ES

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)*

FISAS ESCASANY, Maria Angeles
C/Hipólito Lázaro 19 3° 1a Izq.
E-08025 Barcelona
SPAIN

This person is:
- ☐ applicant only
- ☒ applicant and inventor
- ☐ inventor only *(If this check-box is marked, do not fill in below.)*

Applicant's registration No. with the Office

State *(that is, country)* of nationality: ES

State *(that is, country)* of residence: ES

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)*

This person is:
- ☐ applicant only
- ☐ applicant and inventor
- ☐ inventor only *(If this check-box is marked, do not fill in below.)*

Applicant's registration No. with the Office

State *(that is, country)* of nationality:

State *(that is, country)* of residence:

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on another continuation sheet.

622

623

Box No. V DESIGNATIONS

The filing of this request constitutes under Rule 4.9(a), the designation of all Contracting States bound by the PCT on the international filing date, for the grant of every kind of protection available and, where applicable, for the grant of both regional and national patents.

However,

☐ DE Germany is not designated for any kind of national protection

☐ KR Republic of Korea is not designated for any kind of national protection

☐ RU Russian Federation is not designated for any kind of national protection

(The check-boxes above may be used to exclude (irrevocably) the designations concerned in order to avoid the causing of the effect, under the national law, of an earlier national application from which priority is claimed. See the Notes to Box No. V as to the consequences of such national law provisions in these and certain other States.)

Box No. VI PRIORITY CLAIM

The priority of the following earlier application(s) is hereby claimed:

Filing date of earlier application *(day/month/year)*	Number of earlier application	Where earlier application is:		
		national application: country or Member of WTO	regional application:* regional Office	international application: receiving Office
item (1) July 30, 2003 (30/07/2003)	P200301812	ES		
item (2)				
item (3)				

☐ Further priority claims are indicated in the Supplemental Box.

The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) *(only if the earlier application was filed with the Office which for the purposes of this international application is the receiving Office)* identified above as:

☐ all items ☐ item (1) ☐ item (2) ☐ item (3) ☐ other, see Supplemental Box

** Where the earlier application is an ARIPO application, indicate at least one country party to the Paris Convention for the Protection of Industrial Property or one Member of the World Trade Organization for which that earlier application was filed (Rule 4.10(b)(ii)):* ....

.....

Box No. VII INTERNATIONAL SEARCHING AUTHORITY

Choice of International Searching Authority (ISA) *(if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used)*:

ISA / .....

Request to use results of earlier search; reference to that search *(if an earlier search has been carried out by or requested from the International Searching Authority)*:

Date *(day/month/year)* Number Country *(or regional Office)*

Box No. VIII DECLARATIONS

The following declarations are contained in Boxes Nos. VIII (i) to (v) *(mark the applicable check-boxes below and indicate in the right column the number of each type of declaration)*:		Number of declarations
☐ Box No. VIII (i)	Declaration as to the identity of the inventor :	
☐ Box No. VIII (ii)	Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent :	
☐ Box No. VIII (iii)	Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application :	
☐ Box No. VIII (iv)	Declaration of inventorship (only for the purposes of the designation of the United States of America) :	
☐ Box No. VIII (v)	Declaration as to non-prejudicial disclosures or exceptions to lack of novelty :	

623

624

Sheet No. 4

Box No. IX CHECK LIST; LANGUAGE OF FILING

This international application contains:

(a) in paper form, the following number of sheets:

request (including declaration sheets)	:	4
description (excluding sequence listing and/or tables related thereto)	:	176
claims	:	85
abstract	:	1
drawings	:	
Sub-total number of sheets	:	266
sequence listing	:	
tables related thereto	:	
(for both, actual number of sheets if filed in paper form, whether or not also filed in computer readable form; see (c) below)		
Total number of sheets	:	266

(b) ☐ only in computer readable form (Section 801(a)(i))
- (i) ☐ sequence listing
- (ii) ☐ tables related thereto

(c) ☐ also in computer readable form (Section 801(a)(ii))
- (i) ☐ sequence listing
- (ii) ☐ tables related thereto

Type and number of carriers (diskette, CD-ROM, CD-R or other) on which are contained the
- ☐ sequence listing: .....
- ☐ tables related thereto: .....

(additional copies to be indicated under items 9(ii) and/or 10(ii), in right column)

This international application is accompanied by the following item(s) *(mark the applicable check-boxes below and indicate in right column the number of each item)*:

		Number of items
1. ☒	fee calculation sheet	1
2. ☐	original separate power of attorney	
3. ☐	original general power of attorney	
4. ☒	copy of general power of attorney; reference number, if any:	1
5. ☐	statement explaining lack of signature	
6. ☐	priority document(s) identified in Box No. VI as item(s):	
7. ☐	translation of international application into *(language)*:	
8. ☐	separate indications concerning deposited microorganism or other biological material	
9. ☐	sequence listing in computer readable form *(indicate type and number of carriers)*	
(i) ☐	copy submitted for the purposes of international search under Rule 13*ter* only (and not as part of the international application)	
(ii) ☐	*(only where check-box (b)(i) or (c)(i) is marked in left column)* additional copies including, where applicable, the copy for the purposes of international search under Rule 13*ter*	
(iii) ☐	together with relevant statement as to the identity of the copy or copies with the sequence listing mentioned in left column	
10. ☐	tables in computer readable form related to sequence listing *(indicate type and number of carriers)*	
(i) ☐	copy submitted for the purposes of international search under Section 802(b-*quater*) only (and not as part of the international application)	
(ii) ☐	*(only where check-box (b)(ii) or (c)(ii) is marked in left column)* additional copies including, where applicable, the copy for the purposes of international search under Section 802(b-*quater*)	
(iii) ☐	together with relevant statement as to the identity of the copy or copies with the tables mentioned in left column	
11. ☐	other *(specify)*:	

Figure of the drawings which should accompany the abstract:

Language of filing of the international application: English

Box No. X SIGNATURE OF APPLICANT, AGENT OR COMMON REPRESENTATIVE

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).

Madrid, 21.07.2004

X

A. Dávila Baz

For receiving Office use only

1. Date of actual receipt of the purported international application:	2. Drawings: ☐ received: ☐ not received:
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:	
4. Date of timely receipt of the required corrections under PCT Article 11(2):	
5. International Searching Authority (if two or more are competent): ISA /	6. ☐ Transmittal of search copy delayed until search fee is paid

For International Bureau use only

Date of receipt of the record copy by the International Bureau:

625
624

SUPERINDUSTRIA Y COMERCIO
Radicacion : 06007787 00000000 Folios: 623
Fecha (AMD): 2006-01-27 17:51:45
Tramite : 011 PCT-PATENT 379 FASE NACI 411 PRESENTAC
Dependencia: 0020 DIVISION DE NUEVAS CREACIONES

REQUISITOS NECESARIOS PARA PRESENTACION Y AGILIZACION DE TRAMITE

	USUARIO	RADICADOR
PATENTE DE INVENCIÓN ✓ MODELO DE UTILIDAD	( )	( )
- Indicación de que se solicita la concesión de una patente ✓	( )	( )
- Datos de identificación del solicitante o de la persona que se presenta la solicitud ✓	( )	( )
- Descripción de la invención. ✓	( )	( )
- Dibujos de ser estos pertinentes ✓	( )	( )
- Comprobante de Pago de las tasas establecidas. ✓	( )	( )
COMPLETA ( ) INCOMPLETA	( )	( )
DISEÑO INDUSTRIAL ( )		
- Indicación de que se solicita el registro de Diseño Industrial	( )	( )
- Datos de identificación del solicitante o de la persona que presenta	( )	( )
- la solicitud.		
- Representación gráfica o fotográfica del Diseño Industrial o muestra del Material que incorpora el diseño.	( )	( )
Comprobante de pago de las tasas establecidas	( )	( )
COMPLETA ( ) INCOMPLETA	( )	( )
ESQUEMA DE TRAZADO ( )		
- Indicación de que solicita el registro de un Esquema de trazado.	( )	( )
- Datos de identificación del solicitante o de la persona que presenta La solicitud.	( )	( )
Representación gráfica del esquema de trazado	( )	( )
Comprobante de pago de las tasas establecidas.	( )	( )
COMPLETA ( ) INCOMPLETA	( )	( )

Firma Responsable:

Fecha: Enero 27 de 2006

625
626

REPUBLICA DE COLOMBIA
SUPERINTENDENCIA DE INDUSTRIA Y COMERCI

Bogotá,
2020

Doctor(a)
RODRIGUEZ DILIA MARIA
Apoderado(a) y/o Representante de
LABORATORIOS DEL DR ESTEVE S.A

P-751

REFERENCIA	Radicación No.	6 7787
	Solicitud internacional	EP2004/008507
	Fecha inicio fase nacional	28/02/2006
	Trámite	11
	Evento	379
	Actuación	430
	Oficio No.	3169

Como resultado del examen de forma, realizado con fundamento en el artículo 38 de la Decisión 486 de la Comisión de la Comunidad Andina, artículo 27 del Tratado de Cooperación en Materia de Patentes (PCT), regla 51 bis del Reglamento y Circular Única de la Superintendencia de Industria y Comercio, se le comunica que:

1. La solicitud no contiene la copia del documento en que consta la cesión del derecho a la patente del inventor al solicitante o a su causante. (Art. 26-k) Decisión 486.

En cumplimiento de lo dispuesto por el artículo 39 de la Decisión 486, se le requiere para que dentro del término de dos meses siguientes a la fecha de notificación del presente oficio, complete los requisitos anteriormente enunciados. En caso de no dar cumplimiento al presente requerimiento, la solicitud se considerará abandonada y perderá su prelación.

Notifíquese el presente oficio conforme a lo dispuesto en el numeral 5.2, literal e), del capítulo quinto del título primero de la Circular Unica No.10 de 2001.

ALIX CARMENZA CRESPEDES DE VERGEL
Jefe de la división de Nuevas Creaciones

El anterior requerimiento fue notificado por fijación en lista de fecha 17 MAR. 2006
jramos